{
  "vaccines": [
    {
      "id": "hepb_recombivax",
      "name": "Recombivax HB",
      "type": "HepB",
      "manufacturer": "Merck",
      "description": "Hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus. Approved for all ages. 3-dose series.",
      "sources": [
        "hepb_recombivax_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One referenced study (Beasley et al., 1983) was a 'Randomized Double-Blind, Placebo-Controlled Trial' for HBIG efficacy. However, the primary vaccine efficacy study in neonates (Section 14.1) used 'untreated historical controls' rather than a concurrent placebo group. The adolescent regimen comparison (Section 14.3) was an 'open, randomized, multicenter study' without placebo control.",
            "level_description": "While one referenced study used placebo control (for HBIG), the main vaccine efficacy data relied on historical controls rather than concurrent placebo groups. Immunogenicity studies were open-label without placebo comparators."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One referenced study (Beasley et al., 1983) was described as 'Double-Blind.' However, the key adolescent comparison study (Section 14.3) is explicitly described as 'an open, randomized, multicenter study.' Other immunogenicity studies do not specify blinding.",
            "level_description": "Double-blinding was used in one referenced HBIG study but not in the primary vaccine trials. The adolescent regimen comparison was explicitly open-label, which introduces potential observer and participant bias."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The adolescent two-dose vs. three-dose study (Section 14.3) was described as 'an open, randomized, multicenter study.' One referenced study (Beasley et al., 1983) was also randomized. However, no details on randomization methods are provided.",
            "level_description": "Randomization was used in at least one key study and one referenced trial, but no description of randomization methodology (e.g., allocation concealment, sequence generation) is provided in the document."
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.1: '434 doses of RECOMBIVAX HB, 5 mcg, were administered to 147 healthy infants and children (up to 10 years of age).' Section 14.1: '130 infants after nine months of follow-up.' Section 14.2: 'protective level of antibody in 100% of 92 infants, 99% of 129 children, and in 99% of 112 adolescents.' Section 14.3: 255 adolescents in two-dose arm, 121 in three-dose arm.",
            "level_description": "Pediatric sample sizes ranged from 92 to 255 subjects per age group. While adequate for immunogenicity assessment, these are relatively modest sample sizes for detecting rare adverse events. The safety monitoring study (147 children for 434 doses) is small."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Section 6.1: 'monitored for 5 days after each dose.' Section 14.1: 'after nine months of follow-up.' Section 2.4: 'The duration of the protective effect of RECOMBIVAX HB in healthy vaccinees is unknown at present.'",
            "level_description": "Active safety monitoring was limited to only 5 days post-dose, which is inadequate for detecting delayed adverse events. The 9-month efficacy follow-up in neonates is reasonable for infection prevention but inadequate for long-term safety assessment. The document explicitly acknowledges that long-term protective duration is unknown."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Clinical studies reported results separately for: infants and children up to 10 years of age (Section 6.1, 14.2); neonates born to HBsAg/HBeAg positive mothers (Section 14.1); adolescents 11-15 years (Section 14.3); young adults 20-29 years, adults 30-39 years, and adults >=40 years (Section 14.4); predialysis/dialysis patients (Section 14.5).",
            "level_description": "The document provides separate immunogenicity and safety data for multiple age groups including infants, children, adolescents, and adult age brackets, allowing assessment of age-specific responses."
          },
          "inclusion_exclusion_criteria": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Studies included 'healthy infants and children' and 'healthy adults.' Section 14.1 specified neonates 'born of mothers positive for both HBsAg and HBeAg.' Section 14.5 addresses chronic HCV patients and dialysis patients. No detailed inclusion/exclusion criteria are provided.",
            "level_description": "The document describes study populations in general terms (e.g., 'healthy') but does not provide specific inclusion/exclusion criteria, making it impossible to assess the rigor of participant selection or generalizability."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.1 reports adverse reactions by system organ class (General Disorders, Gastrointestinal, Respiratory, Nervous System, Skin, Musculoskeletal, etc.) with frequency thresholds (>1% vs <1%). Specific reactions are listed including injection site reactions, fever (defined as >=101F or >=100F), and systemic complaints.",
            "level_description": "Adverse events are reported by system organ class with frequency categories, suggesting some standardization. However, the document does not describe the use of standardized grading scales or definitions for severity assessment."
          },
          "active_monitoring_serious": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Section 6.1: 'monitored for 5 days after each dose.' Section 6.2 (Post-Marketing Experience) lists serious events reported voluntarily, including Guillain-Barre syndrome, multiple sclerosis, seizures, Stevens-Johnson syndrome, thrombocytopenia, encephalitis, etc., but states 'it is not possible to reliably estimate their frequency or establish a causal relationship.'",
            "level_description": "Active monitoring was limited to 5 days post-vaccination, which is grossly inadequate for detecting serious adverse events that may have delayed onset. Serious events are only captured through passive post-marketing surveillance with acknowledged limitations in establishing causality and frequency."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.2 (Post-Marketing Experience) lists: 'Autoimmune diseases including systemic lupus erythematosus (SLE), lupus-like syndrome, vasculitis, and polyarteritis nodosa.' Neurological: 'Guillain-Barre syndrome; multiple sclerosis; exacerbation of multiple sclerosis; myelitis including transverse myelitis; seizure; febrile seizure; peripheral neuropathy including Bell's Palsy; radiculopathy; encephalitis.' These are passive reports only.",
            "level_description": "Autoimmune and neurological events are documented in post-marketing surveillance, but these were not systematically monitored in clinical trials. The document explicitly states a causal relationship cannot be established for these post-marketing reports."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 5.2-5.3 addresses premature infants and infants <2000g. Section 8.1 reports pregnancy data (26 women in clinical studies, 105 in post-approval reports). Section 8.5 notes geriatric populations showed 'diminished antibody response' in subjects >60 years. Section 14.5 covers chronic HCV patients (~70% seroprotection) and predialysis/dialysis patients (lower response rates).",
            "level_description": "Some vulnerable subgroups are addressed (premature infants, pregnancy, elderly, immunocompromised dialysis patients, HCV patients), but data are limited and often from post-marketing or observational sources rather than controlled trials designed to assess these populations."
          },
          "statistical_analysis": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Results are presented as percentages of seroprotection (e.g., '100% of 92 infants,' '96% of 1213 healthy adults,' '99% of 255 subjects'). Section 14.1 states 'estimated efficacy in prevention of chronic hepatitis B infection was 95%.' No confidence intervals, p-values, or statistical methodology is described.",
            "level_description": "The document reports only point estimates without confidence intervals, p-values, or description of statistical methods. The claim that two-dose regimen 'appears similar' to three-dose regimen lacks formal statistical comparison."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 15 provides 9 references to published studies and CDC recommendations. Some numerical data are provided (sample sizes, seroconversion rates). However, individual patient data, complete safety databases, and detailed study protocols are not available in this document.",
            "level_description": "The prescribing information references published studies and provides summary statistics, but detailed raw data, complete safety databases, and full study protocols are not included. Access to underlying data would require retrieval of cited references."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 provides extensive post-marketing experience including hypersensitivity reactions, autoimmune diseases, neurological disorders, and other serious events. Section 17 instructs reporting to VAERS. The document states the vaccine has been marketed since 1986 with ongoing surveillance through 2018 (revision date).",
            "level_description": "The document includes a comprehensive list of post-marketing adverse events and provides mechanisms for ongoing surveillance (VAERS, manufacturer reporting). Over 30 years of post-marketing data collection is reflected."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document identifies Merck Sharp & Dohme Corp. as manufacturer and distributor. No disclosure of conflicts of interest, funding sources for clinical trials, or investigator relationships is provided.",
            "level_description": "The prescribing information does not include any conflict of interest disclosures or information about trial funding. The manufacturer conducted the studies but no financial relationships or potential biases are addressed."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No mortality data or death rates are reported in the clinical trials section or adverse events section. The document does not provide information on all-cause mortality in vaccinated vs. control groups.",
            "level_description": "The document contains no information about deaths in clinical trials or all-cause mortality comparisons. This critical safety endpoint is not addressed."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB prescribing information reflects trials from the 1980s era with methodological limitations by current standards. Strengths include separate age group analysis, adequate immunogenicity data, and extensive post-marketing surveillance over 30+ years. Significant limitations include: reliance on historical rather than concurrent placebo controls for efficacy, open-label design in key trials, very short active safety monitoring (5 days), absence of statistical rigor in reporting (no confidence intervals or p-values), no mortality data, and no conflict of interest disclosure. The document adequately demonstrates immunogenicity but provides limited evidence for comprehensive safety assessment, particularly for rare or delayed adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um estudo referenciado (Beasley et al., 1983) foi um 'Ensaio Randomizado Duplo-Cego Controlado por Placebo' para efic√°cia de HBIG. No entanto, o estudo prim√°rio de efic√°cia da vacina em neonatos (Se√ß√£o 14.1) utilizou 'controles hist√≥ricos n√£o tratados' em vez de um grupo placebo concorrente. A compara√ß√£o de regime em adolescentes (Se√ß√£o 14.3) foi um 'estudo aberto, randomizado e multic√™ntrico' sem controle placebo.",
            "level_description": "Embora um estudo referenciado tenha usado controle placebo (para HBIG), os principais dados de efic√°cia da vacina basearam-se em controles hist√≥ricos em vez de grupos placebo concorrentes. Os estudos de imunogenicidade foram abertos, sem comparadores placebo."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um estudo referenciado (Beasley et al., 1983) foi descrito como 'Duplo-Cego'. No entanto, o principal estudo comparativo em adolescentes (Se√ß√£o 14.3) √© explicitamente descrito como 'um estudo aberto, randomizado e multic√™ntrico'. Outros estudos de imunogenicidade n√£o especificam o cegamento.",
            "level_description": "O duplo-cegamento foi utilizado em um estudo referenciado de HBIG, mas n√£o nos ensaios prim√°rios da vacina. A compara√ß√£o de regime em adolescentes foi explicitamente aberta, o que introduz potencial vi√©s do observador e do participante."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo de duas doses versus tr√™s doses em adolescentes (Se√ß√£o 14.3) foi descrito como 'um estudo aberto, randomizado e multic√™ntrico'. Um estudo referenciado (Beasley et al., 1983) tamb√©m foi randomizado. No entanto, nenhum detalhe sobre os m√©todos de randomiza√ß√£o √© fornecido.",
            "level_description": "A randomiza√ß√£o foi utilizada em pelo menos um estudo principal e um ensaio referenciado, mas nenhuma descri√ß√£o da metodologia de randomiza√ß√£o (por exemplo, oculta√ß√£o de aloca√ß√£o, gera√ß√£o de sequ√™ncia) √© fornecida no documento."
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Se√ß√£o 6.1: '434 doses de RECOMBIVAX HB, 5 mcg, foram administradas a 147 beb√™s e crian√ßas saud√°veis (at√© 10 anos de idade).' Se√ß√£o 14.1: '130 beb√™s ap√≥s nove meses de acompanhamento.' Se√ß√£o 14.2: 'n√≠vel protetor de anticorpos em 100% de 92 beb√™s, 99% de 129 crian√ßas e em 99% de 112 adolescentes.' Se√ß√£o 14.3: 255 adolescentes no bra√ßo de duas doses, 121 no bra√ßo de tr√™s doses.",
            "level_description": "Os tamanhos de amostra pedi√°trica variaram de 92 a 255 indiv√≠duos por faixa et√°ria. Embora adequados para avalia√ß√£o de imunogenicidade, s√£o tamanhos de amostra relativamente modestos para detectar eventos adversos raros. O estudo de monitoramento de seguran√ßa (147 crian√ßas para 434 doses) √© pequeno."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Se√ß√£o 6.1: 'monitorados por 5 dias ap√≥s cada dose.' Se√ß√£o 14.1: 'ap√≥s nove meses de acompanhamento.' Se√ß√£o 2.4: 'A dura√ß√£o do efeito protetor de RECOMBIVAX HB em vacinados saud√°veis √© desconhecida no momento.'",
            "level_description": "O monitoramento ativo de seguran√ßa foi limitado a apenas 5 dias p√≥s-dose, o que √© inadequado para detectar eventos adversos tardios. O acompanhamento de efic√°cia de 9 meses em neonatos √© razo√°vel para preven√ß√£o de infec√ß√£o, mas inadequado para avalia√ß√£o de seguran√ßa a longo prazo. O documento reconhece explicitamente que a dura√ß√£o da prote√ß√£o a longo prazo √© desconhecida."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos cl√≠nicos relataram resultados separadamente para: beb√™s e crian√ßas at√© 10 anos de idade (Se√ß√£o 6.1, 14.2); neonatos nascidos de m√£es positivas para HBsAg/HBeAg (Se√ß√£o 14.1); adolescentes de 11-15 anos (Se√ß√£o 14.3); adultos jovens de 20-29 anos, adultos de 30-39 anos e adultos >=40 anos (Se√ß√£o 14.4); pacientes em pr√©-di√°lise/di√°lise (Se√ß√£o 14.5).",
            "level_description": "O documento fornece dados separados de imunogenicidade e seguran√ßa para m√∫ltiplas faixas et√°rias, incluindo beb√™s, crian√ßas, adolescentes e faixas et√°rias adultas, permitindo avalia√ß√£o de respostas espec√≠ficas por idade."
          },
          "inclusion_exclusion_criteria": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os estudos inclu√≠ram 'beb√™s e crian√ßas saud√°veis' e 'adultos saud√°veis'. A Se√ß√£o 14.1 especificou neonatos 'nascidos de m√£es positivas tanto para HBsAg quanto para HBeAg'. A Se√ß√£o 14.5 aborda pacientes com HCV cr√¥nico e pacientes em di√°lise. Nenhum crit√©rio detalhado de inclus√£o/exclus√£o √© fornecido.",
            "level_description": "O documento descreve as popula√ß√µes do estudo em termos gerais (por exemplo, 'saud√°veis'), mas n√£o fornece crit√©rios espec√≠ficos de inclus√£o/exclus√£o, tornando imposs√≠vel avaliar o rigor da sele√ß√£o de participantes ou a generaliza√ß√£o dos resultados."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.1 relata rea√ß√µes adversas por classe de sistema org√¢nico (Dist√∫rbios Gerais, Gastrointestinais, Respirat√≥rios, Sistema Nervoso, Pele, Musculoesquel√©ticos, etc.) com limites de frequ√™ncia (>1% vs <1%). Rea√ß√µes espec√≠ficas s√£o listadas, incluindo rea√ß√µes no local da inje√ß√£o, febre (definida como >=101F ou >=100F) e queixas sist√™micas.",
            "level_description": "Os eventos adversos s√£o relatados por classe de sistema org√¢nico com categorias de frequ√™ncia, sugerindo alguma padroniza√ß√£o. No entanto, o documento n√£o descreve o uso de escalas padronizadas de gradua√ß√£o ou defini√ß√µes para avalia√ß√£o de gravidade."
          },
          "active_monitoring_serious": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Se√ß√£o 6.1: 'monitorados por 5 dias ap√≥s cada dose.' A Se√ß√£o 6.2 (Experi√™ncia P√≥s-Comercializa√ß√£o) lista eventos graves relatados voluntariamente, incluindo s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla, convuls√µes, s√≠ndrome de Stevens-Johnson, trombocitopenia, encefalite, etc., mas afirma que 'n√£o √© poss√≠vel estimar com confiabilidade sua frequ√™ncia ou estabelecer uma rela√ß√£o causal.'",
            "level_description": "O monitoramento ativo foi limitado a 5 dias p√≥s-vacina√ß√£o, o que √© grosseiramente inadequado para detectar eventos adversos graves que podem ter in√≠cio tardio. Eventos graves s√£o capturados apenas por meio de vigil√¢ncia passiva p√≥s-comercializa√ß√£o com limita√ß√µes reconhecidas no estabelecimento de causalidade e frequ√™ncia."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.2 (Experi√™ncia P√≥s-Comercializa√ß√£o) lista: 'Doen√ßas autoimunes incluindo l√∫pus eritematoso sist√™mico (LES), s√≠ndrome tipo l√∫pus, vasculite e poliarterite nodosa.' Neurol√≥gico: 'S√≠ndrome de Guillain-Barr√©; esclerose m√∫ltipla; exacerba√ß√£o de esclerose m√∫ltipla; mielite incluindo mielite transversa; convuls√£o; convuls√£o febril; neuropatia perif√©rica incluindo paralisia de Bell; radiculopatia; encefalite.' Estes s√£o apenas relatos passivos.",
            "level_description": "Eventos autoimunes e neurol√≥gicos s√£o documentados na vigil√¢ncia p√≥s-comercializa√ß√£o, mas n√£o foram monitorados sistematicamente nos ensaios cl√≠nicos. O documento afirma explicitamente que uma rela√ß√£o causal n√£o pode ser estabelecida para esses relatos p√≥s-comercializa√ß√£o."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As Se√ß√µes 5.2-5.3 abordam beb√™s prematuros e beb√™s <2000g. A Se√ß√£o 8.1 relata dados de gravidez (26 mulheres em estudos cl√≠nicos, 105 em relatos p√≥s-aprova√ß√£o). A Se√ß√£o 8.5 observa que popula√ß√µes geri√°tricas apresentaram 'resposta de anticorpos diminu√≠da' em indiv√≠duos >60 anos. A Se√ß√£o 14.5 abrange pacientes com HCV cr√¥nico (~70% de soroprote√ß√£o) e pacientes em pr√©-di√°lise/di√°lise (taxas de resposta mais baixas).",
            "level_description": "Alguns subgrupos vulner√°veis s√£o abordados (beb√™s prematuros, gravidez, idosos, pacientes em di√°lise imunocomprometidos, pacientes com HCV), mas os dados s√£o limitados e frequentemente provenientes de fontes p√≥s-comercializa√ß√£o ou observacionais, em vez de ensaios controlados projetados para avaliar essas popula√ß√µes."
          },
          "statistical_analysis": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os resultados s√£o apresentados como porcentagens de soroprote√ß√£o (por exemplo, '100% de 92 beb√™s', '96% de 1213 adultos saud√°veis', '99% de 255 indiv√≠duos'). A Se√ß√£o 14.1 afirma que 'a efic√°cia estimada na preven√ß√£o de infec√ß√£o cr√¥nica por hepatite B foi de 95%.' Nenhum intervalo de confian√ßa, valores-p ou metodologia estat√≠stica √© descrita.",
            "level_description": "O documento relata apenas estimativas pontuais sem intervalos de confian√ßa, valores-p ou descri√ß√£o de m√©todos estat√≠sticos. A afirma√ß√£o de que o regime de duas doses 'parece similar' ao regime de tr√™s doses carece de compara√ß√£o estat√≠stica formal."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 15 fornece 9 refer√™ncias a estudos publicados e recomenda√ß√µes do CDC. Alguns dados num√©ricos s√£o fornecidos (tamanhos de amostra, taxas de soroconvers√£o). No entanto, dados individuais de pacientes, bancos de dados completos de seguran√ßa e protocolos detalhados dos estudos n√£o est√£o dispon√≠veis neste documento.",
            "level_description": "As informa√ß√µes de prescri√ß√£o fazem refer√™ncia a estudos publicados e fornecem estat√≠sticas resumidas, mas dados brutos detalhados, bancos de dados completos de seguran√ßa e protocolos completos dos estudos n√£o est√£o inclu√≠dos. O acesso aos dados subjacentes exigiria a recupera√ß√£o das refer√™ncias citadas."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 fornece extensa experi√™ncia p√≥s-comercializa√ß√£o, incluindo rea√ß√µes de hipersensibilidade, doen√ßas autoimunes, dist√∫rbios neurol√≥gicos e outros eventos graves. A Se√ß√£o 17 instrui a reportar ao VAERS. O documento afirma que a vacina est√° no mercado desde 1986 com vigil√¢ncia cont√≠nua at√© 2018 (data de revis√£o).",
            "level_description": "O documento inclui uma lista abrangente de eventos adversos p√≥s-comercializa√ß√£o e fornece mecanismos para vigil√¢ncia cont√≠nua (VAERS, relatos ao fabricante). Mais de 30 anos de coleta de dados p√≥s-comercializa√ß√£o est√£o refletidos."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento identifica Merck Sharp & Dohme Corp. como fabricante e distribuidor. Nenhuma divulga√ß√£o de conflitos de interesse, fontes de financiamento para ensaios cl√≠nicos ou relacionamentos de investigadores √© fornecida.",
            "level_description": "As informa√ß√µes de prescri√ß√£o n√£o incluem nenhuma divulga√ß√£o de conflito de interesse ou informa√ß√£o sobre financiamento dos ensaios. O fabricante conduziu os estudos, mas nenhuma rela√ß√£o financeira ou potenciais vieses s√£o abordados."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum dado de mortalidade ou taxas de √≥bito s√£o relatados na se√ß√£o de ensaios cl√≠nicos ou se√ß√£o de eventos adversos. O documento n√£o fornece informa√ß√µes sobre mortalidade por todas as causas em grupos vacinados versus grupos controle.",
            "level_description": "O documento n√£o cont√©m informa√ß√µes sobre √≥bitos em ensaios cl√≠nicos ou compara√ß√µes de mortalidade por todas as causas. Este desfecho cr√≠tico de seguran√ßa n√£o √© abordado."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "As informa√ß√µes de prescri√ß√£o do RECOMBIVAX HB refletem ensaios da d√©cada de 1980 com limita√ß√µes metodol√≥gicas pelos padr√µes atuais. Os pontos fortes incluem an√°lise separada por faixa et√°ria, dados adequados de imunogenicidade e extensa vigil√¢ncia p√≥s-comercializa√ß√£o por mais de 30 anos. Limita√ß√µes significativas incluem: depend√™ncia de controles hist√≥ricos em vez de controles placebo concorrentes para efic√°cia, desenho aberto em ensaios-chave, monitoramento ativo de seguran√ßa muito curto (5 dias), aus√™ncia de rigor estat√≠stico nos relatos (sem intervalos de confian√ßa ou valores-p), aus√™ncia de dados de mortalidade e nenhuma divulga√ß√£o de conflito de interesse. O documento demonstra adequadamente a imunogenicidade, mas fornece evid√™ncias limitadas para avalia√ß√£o abrangente de seguran√ßa, particularmente para eventos adversos raros ou tardios."
        }
      },
      "safety_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The pediatric clinical trial data is limited. Only 147 healthy infants and children (up to 10 years of age) received 434 doses across three clinical studies. For adolescents, the two-dose vs three-dose regimen comparison included 255 and 121 subjects respectively. While safety was established across all pediatric age groups, the sample sizes are relatively small for detecting rare adverse events in a vaccine approved since 1986 and administered to millions of children."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Follow-up was extremely limited. In the pediatric studies, subjects were monitored for only 5 days after each dose. In adult studies, monitoring was similarly limited to 5 days after each dose. For neonates with peripartum exposure, follow-up extended to 9 months, but this was primarily to assess efficacy (prevention of chronic infection) rather than comprehensive safety monitoring. No long-term safety follow-up data is presented in the prescribing information."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document references 'historical controls' for efficacy comparisons in neonates (untreated historical controls and those receiving only HBIG). The adolescent two-dose vs three-dose study was randomized and open-label. However, the document does not describe placebo-controlled trials or true randomized safety comparisons for the primary clinical studies. The comparison methodology for safety assessment is not well documented."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials used active monitoring for 5 days after each dose, capturing injection site reactions and systemic adverse reactions. However, the short duration limits the ability to detect delayed-onset adverse events. The document mentions that adverse reactions were 'monitored' but does not detail the surveillance methodology (e.g., diaries, follow-up calls, clinic visits). Post-marketing surveillance relies on voluntary VAERS reporting rather than active surveillance."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials captured some neurological symptoms including vertigo/dizziness and paresthesia at <1% incidence. Post-marketing reports include serious neurological events: Guillain-Barre syndrome, multiple sclerosis and its exacerbation, transverse myelitis, seizures, febrile seizures, peripheral neuropathy (including Bell's Palsy), radiculopathy, encephalitis, optic neuritis, and muscle weakness. However, no systematic neurological monitoring protocol is described in the pre-licensure trials."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The document addresses several vulnerable populations: premature infants (warning about apnea risk), infants weighing <2000g (vaccination delay recommendations), dialysis/predialysis patients (separate formulation and dosing), pregnant women (post-approval data from 26 clinical study pregnancies and 105 post-approval reports showing background-rate outcomes), and elderly (noted diminished antibody response in >60 years). Chronic hepatitis C patients and immunocompromised populations are also discussed regarding immunogenicity."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document provides aggregate adverse reaction rates (e.g., 17% injection site reactions, 15% systemic reactions in adults; 0.2% and 10.4% in children) and lists adverse events by incidence category (>1% vs <1%). However, detailed study designs, statistical analyses, confidence intervals, and raw data tables are not included. Individual study protocols are not described. The document acknowledges that post-marketing events cannot establish causality due to voluntary reporting from uncertain population sizes."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 provides a comprehensive list of post-marketing adverse events organized by system organ class, including serious events like anaphylaxis, autoimmune diseases (SLE, vasculitis, polyarteritis nodosa), neurological disorders, and skin reactions (Stevens-Johnson syndrome). The document references VAERS reporting system with contact information. Post-approval pregnancy data spans 1986-2018 with 105 pregnancies tracked. However, the document notes inability to establish causality or reliable frequency estimates from voluntary reports."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB, approved in 1986, has limited pre-licensure safety documentation by modern standards. Pediatric trials included only 147 children with just 5-day follow-up periods, which is insufficient to detect rare or delayed adverse events. The document lacks placebo-controlled trial data and detailed study methodologies. However, some strengths exist: vulnerable subgroups (premature infants, dialysis patients, pregnant women) are reasonably addressed, and post-marketing surveillance has accumulated decades of data identifying serious but rare events including neurological and autoimmune conditions. The overall safety profile relies heavily on post-marketing experience rather than robust pre-licensure evidence, reflecting the regulatory standards of the 1980s rather than current requirements."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Os dados de ensaios cl√≠nicos pedi√°tricos s√£o limitados. Apenas 147 beb√™s e crian√ßas saud√°veis (at√© 10 anos de idade) receberam 434 doses em tr√™s estudos cl√≠nicos. Para adolescentes, a compara√ß√£o entre o regime de duas doses versus tr√™s doses incluiu 255 e 121 participantes, respectivamente. Embora a seguran√ßa tenha sido estabelecida em todos os grupos et√°rios pedi√°tricos, os tamanhos das amostras s√£o relativamente pequenos para detectar eventos adversos raros em uma vacina aprovada desde 1986 e administrada a milh√µes de crian√ßas."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento foi extremamente limitado. Nos estudos pedi√°tricos, os participantes foram monitorados por apenas 5 dias ap√≥s cada dose. Nos estudos com adultos, o monitoramento foi igualmente limitado a 5 dias ap√≥s cada dose. Para neonatos com exposi√ß√£o periparto, o acompanhamento estendeu-se at√© 9 meses, mas isso foi principalmente para avaliar a efic√°cia (preven√ß√£o de infec√ß√£o cr√¥nica) em vez de monitoramento abrangente de seguran√ßa. Nenhum dado de acompanhamento de seguran√ßa a longo prazo √© apresentado nas informa√ß√µes de prescri√ß√£o."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento faz refer√™ncia a 'controles hist√≥ricos' para compara√ß√µes de efic√°cia em neonatos (controles hist√≥ricos n√£o tratados e aqueles que receberam apenas HBIG). O estudo comparativo de duas doses versus tr√™s doses em adolescentes foi randomizado e aberto. No entanto, o documento n√£o descreve ensaios controlados por placebo ou compara√ß√µes de seguran√ßa verdadeiramente randomizadas para os estudos cl√≠nicos prim√°rios. A metodologia de compara√ß√£o para avalia√ß√£o de seguran√ßa n√£o est√° bem documentada."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os ensaios cl√≠nicos utilizaram monitoramento ativo por 5 dias ap√≥s cada dose, registrando rea√ß√µes no local da inje√ß√£o e rea√ß√µes sist√™micas adversas. No entanto, a curta dura√ß√£o limita a capacidade de detectar eventos adversos de in√≠cio tardio. O documento menciona que as rea√ß√µes adversas foram 'monitoradas', mas n√£o detalha a metodologia de vigil√¢ncia (por exemplo, di√°rios, liga√ß√µes de acompanhamento, visitas cl√≠nicas). A vigil√¢ncia p√≥s-comercializa√ß√£o depende de relatos volunt√°rios ao VAERS em vez de vigil√¢ncia ativa."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os ensaios cl√≠nicos registraram alguns sintomas neurol√≥gicos, incluindo vertigem/tontura e parestesia com incid√™ncia <1%. Os relatos p√≥s-comercializa√ß√£o incluem eventos neurol√≥gicos graves: s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla e sua exacerba√ß√£o, mielite transversa, convuls√µes, convuls√µes febris, neuropatia perif√©rica (incluindo paralisia de Bell), radiculopatia, encefalite, neurite √≥ptica e fraqueza muscular. No entanto, nenhum protocolo sistem√°tico de monitoramento neurol√≥gico √© descrito nos ensaios pr√©-licenciamento."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O documento aborda v√°rias popula√ß√µes vulner√°veis: beb√™s prematuros (advert√™ncia sobre risco de apneia), beb√™s com peso <2000g (recomenda√ß√µes de adiamento da vacina√ß√£o), pacientes em di√°lise/pr√©-di√°lise (formula√ß√£o e dosagem separadas), gestantes (dados p√≥s-aprova√ß√£o de 26 gesta√ß√µes em estudos cl√≠nicos e 105 relatos p√≥s-aprova√ß√£o mostrando resultados dentro das taxas basais) e idosos (resposta diminu√≠da de anticorpos observada em >60 anos). Pacientes com hepatite C cr√¥nica e popula√ß√µes imunocomprometidas tamb√©m s√£o discutidos em rela√ß√£o √† imunogenicidade."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento fornece taxas agregadas de rea√ß√µes adversas (por exemplo, 17% de rea√ß√µes no local da inje√ß√£o, 15% de rea√ß√µes sist√™micas em adultos; 0,2% e 10,4% em crian√ßas) e lista eventos adversos por categoria de incid√™ncia (>1% vs <1%). No entanto, desenhos detalhados dos estudos, an√°lises estat√≠sticas, intervalos de confian√ßa e tabelas de dados brutos n√£o est√£o inclu√≠dos. Os protocolos individuais dos estudos n√£o s√£o descritos. O documento reconhece que os eventos p√≥s-comercializa√ß√£o n√£o podem estabelecer causalidade devido a relatos volunt√°rios de tamanhos populacionais incertos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 fornece uma lista abrangente de eventos adversos p√≥s-comercializa√ß√£o organizados por classe de sistema de √≥rg√£os, incluindo eventos graves como anafilaxia, doen√ßas autoimunes (LES, vasculite, poliarterite nodosa), dist√∫rbios neurol√≥gicos e rea√ß√µes cut√¢neas (s√≠ndrome de Stevens-Johnson). O documento faz refer√™ncia ao sistema de notifica√ß√£o VAERS com informa√ß√µes de contato. Os dados de gravidez p√≥s-aprova√ß√£o abrangem 1986-2018 com 105 gesta√ß√µes acompanhadas. No entanto, o documento observa a incapacidade de estabelecer causalidade ou estimativas de frequ√™ncia confi√°veis a partir de relatos volunt√°rios."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB, aprovada em 1986, possui documenta√ß√£o de seguran√ßa pr√©-licenciamento limitada pelos padr√µes modernos. Os ensaios pedi√°tricos inclu√≠ram apenas 147 crian√ßas com per√≠odos de acompanhamento de apenas 5 dias, o que √© insuficiente para detectar eventos adversos raros ou tardios. O documento carece de dados de ensaios controlados por placebo e metodologias detalhadas dos estudos. No entanto, existem alguns pontos fortes: subgrupos vulner√°veis (beb√™s prematuros, pacientes em di√°lise, gestantes) s√£o razoavelmente abordados, e a vigil√¢ncia p√≥s-comercializa√ß√£o acumulou d√©cadas de dados identificando eventos graves, por√©m raros, incluindo condi√ß√µes neurol√≥gicas e autoimunes. O perfil geral de seguran√ßa depende fortemente da experi√™ncia p√≥s-comercializa√ß√£o em vez de evid√™ncias pr√©-licenciamento robustas, refletindo os padr√µes regulat√≥rios da d√©cada de 1980 em vez dos requisitos atuais."
        }
      }
    },
    {
      "id": "hepb_engerix",
      "name": "Engerix-B",
      "type": "HepB",
      "manufacturer": "GlaxoSmithKline",
      "description": "Hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus.",
      "sources": [
        "hepb_engerix_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hepb_engerix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document describes clinical studies but does not mention use of placebo controls. Studies compared vaccine groups, diabetic vs non-diabetic subjects, or different dosing schedules, but no inert placebo comparator group is described.",
            "level_description": "No placebo-controlled trials are mentioned in the prescribing information."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not mention blinding procedures in any of the clinical trials described. There is no reference to double-blind, single-blind, or open-label study designs.",
            "level_description": "No information about blinding methodology is provided."
          },
          "randomization": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document describes various clinical studies but does not explicitly mention randomization procedures. Studies are described as clinical trials without specification of randomization methods.",
            "level_description": "No explicit mention of randomization in the clinical trial descriptions."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "In 36 clinical studies, 13,495 doses were administered to 5,071 healthy adults, children, and neonates. Specific pediatric studies: 58 high-risk neonates in efficacy study; 381 infants in immunogenicity study at 0,1,2 months schedule; 52 infants at 0,1,6 months schedule; 242 children aged 6 months through 10 years; 181 children/adolescents aged 5-16 years on 0,1,6 month schedule; 161 on 0,12,24 month schedule.",
            "level_description": "Adequate pediatric sample sizes across multiple age groups, though some individual studies have modest numbers."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Adverse reaction monitoring was 4 days post-administration. In the diabetes study, serious adverse events were monitored through 30 days following the last vaccination. Neonatal efficacy study had 12-month follow-up. Homosexual men study had 18-month follow-up after immunization completion.",
            "level_description": "Short-term safety follow-up (4 days for adverse reactions, 30 days for SAEs) with longer immunogenicity follow-up in some studies. Long-term safety follow-up is limited."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Studies clearly separate: neonates, infants, children (birth through 10 years, 6 months through 10 years, 5-10 years), adolescents (11-16 years, 11-19 years), adults (16-65 years, 20+ years, 40+ years, 60+ years), and special populations (diabetics, hemodialysis patients). Different dosing schedules provided by age group.",
            "level_description": "Comprehensive stratification by age groups with specific immunogenicity data for each."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Studies enrolled subjects who were 'initially seronegative for hepatitis B markers' and 'healthy.' Specific population criteria mentioned for diabetes study (type 2 diabetes diagnosed within 5 years, stratified by age and BMI). No detailed inclusion/exclusion criteria provided.",
            "level_description": "Basic eligibility criteria mentioned but detailed inclusion/exclusion criteria not provided in the prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Adverse events categorized using symptom checklist by system organ class: Nervous System Disorders, General Disorders, Infections, Blood/Lymphatic, Metabolism, Psychiatric, Vascular, GI, Skin, Musculoskeletal. Incidence reported as percentages (<1%, 1-10%) for different reaction categories.",
            "level_description": "Standardized reporting by organ system class with frequency categories, though limited detail on grading severity."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "In the diabetes study, 'Serious adverse events were monitored through 30 days following the last vaccination. Serious adverse events (SAEs) occurred in 3.8% of diabetic subjects and 1.6% of controls. No SAEs were deemed related to ENGERIX-B.' General monitoring was 4 days post-administration using symptom checklists.",
            "level_description": "Active monitoring described for one study with 30-day SAE follow-up; most studies used 4-day post-dose monitoring."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 5.7 states 'Results from 2 clinical studies indicate that there is no association between hepatitis B vaccination and the development of multiple sclerosis, and that vaccination with hepatitis B vaccine does not appear to increase the short-term risk of relapse in multiple sclerosis.' Postmarketing section lists neurological events: encephalitis, encephalopathy, Guillain-Barre syndrome, Bell's palsy, transverse myelitis, optic neuritis.",
            "level_description": "MS association studied; neurological events reported in postmarketing but not systematically evaluated in pre-licensure trials."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies included: premature infants (<2000g), infants born to HBsAg-positive mothers, immunocompromised persons, hemodialysis patients (n=56), adults with type 2 diabetes (n=416 diabetics, n=258 controls), persons with chronic hepatitis C (n=67), elderly (>60 years with noted diminished response).",
            "level_description": "Multiple vulnerable populations studied with specific data, though sample sizes vary."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Some statistical measures provided: GMTs with 95% confidence intervals, P-values for some comparisons (e.g., P=0.18, P=0.02), seroprotection rates as percentages. Protective efficacy calculated as 95% in neonatal study. However, detailed statistical methodology not described.",
            "level_description": "Basic statistical results reported (GMT, CI, percentages) but methodology not detailed."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Summary results provided for multiple studies with sample sizes, seroprotection rates, and GMTs. References to 8 published studies provided. However, individual patient data, complete adverse event tables, and detailed methodology not included in prescribing information.",
            "level_description": "Summary-level data available with references to published literature; full study details not in prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 provides extensive postmarketing adverse event reporting including rare events: thrombocytopenia, anaphylaxis, encephalitis, Guillain-Barre syndrome, Stevens-Johnson syndrome. States 'reported voluntarily from a population of uncertain size.' VAERS reporting encouraged: 'contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967.'",
            "level_description": "Comprehensive postmarketing surveillance system with VAERS reporting and detailed adverse event categories."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not address conflicts of interest, funding sources for clinical trials, or investigator disclosures. Manufacturer is GlaxoSmithKline Biologicals.",
            "level_description": "No disclosure of conflicts of interest or funding sources in the prescribing information."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report all-cause mortality data from clinical trials. Deaths are not mentioned in the adverse events sections, neither in clinical trials nor postmarketing.",
            "level_description": "No mortality data reported in the prescribing information."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ENGERIX-B has substantial clinical data across multiple age groups and populations with 36 clinical studies and over 5,000 subjects. Strengths include excellent age stratification, inclusion of vulnerable subgroups, standardized adverse event reporting, and active postmarketing surveillance. However, significant methodological limitations exist: no documented placebo controls, blinding, or randomization in the prescribing information. Safety follow-up was primarily short-term (4 days post-dose). The document lacks mortality data, conflict of interest disclosures, and detailed statistical methodology. Initial FDA approval was 1989 when trial design standards differed from current expectations."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepb_engerix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento descreve estudos cl√≠nicos, mas n√£o menciona o uso de controles placebo. Os estudos compararam grupos vacinados, indiv√≠duos diab√©ticos versus n√£o diab√©ticos, ou diferentes esquemas de dosagem, mas nenhum grupo comparador placebo inerte √© descrito.",
            "level_description": "Nenhum ensaio controlado por placebo √© mencionado na bula."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o menciona procedimentos de cegamento em nenhum dos ensaios cl√≠nicos descritos. N√£o h√° refer√™ncia a designs de estudo duplo-cego, simples-cego ou aberto.",
            "level_description": "Nenhuma informa√ß√£o sobre metodologia de cegamento √© fornecida."
          },
          "randomization": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento descreve v√°rios estudos cl√≠nicos, mas n√£o menciona explicitamente procedimentos de randomiza√ß√£o. Os estudos s√£o descritos como ensaios cl√≠nicos sem especifica√ß√£o de m√©todos de randomiza√ß√£o.",
            "level_description": "Nenhuma men√ß√£o expl√≠cita de randomiza√ß√£o nas descri√ß√µes dos ensaios cl√≠nicos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Em 36 estudos cl√≠nicos, 13.495 doses foram administradas a 5.071 adultos, crian√ßas e neonatos saud√°veis. Estudos pedi√°tricos espec√≠ficos: 58 neonatos de alto risco em estudo de efic√°cia; 381 beb√™s em estudo de imunogenicidade no esquema 0,1,2 meses; 52 beb√™s no esquema 0,1,6 meses; 242 crian√ßas de 6 meses a 10 anos; 181 crian√ßas/adolescentes de 5-16 anos no esquema 0,1,6 meses; 161 no esquema 0,12,24 meses.",
            "level_description": "Tamanhos de amostra pedi√°trica adequados em m√∫ltiplas faixas et√°rias, embora alguns estudos individuais tenham n√∫meros modestos."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O monitoramento de rea√ß√µes adversas foi de 4 dias p√≥s-administra√ß√£o. No estudo de diabetes, eventos adversos graves foram monitorados por at√© 30 dias ap√≥s a √∫ltima vacina√ß√£o. O estudo de efic√°cia neonatal teve acompanhamento de 12 meses. O estudo em homens homossexuais teve acompanhamento de 18 meses ap√≥s a conclus√£o da imuniza√ß√£o.",
            "level_description": "Acompanhamento de seguran√ßa de curto prazo (4 dias para rea√ß√µes adversas, 30 dias para EAGs) com acompanhamento de imunogenicidade mais longo em alguns estudos. O acompanhamento de seguran√ßa a longo prazo √© limitado."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Os estudos separam claramente: neonatos, beb√™s, crian√ßas (do nascimento at√© 10 anos, 6 meses a 10 anos, 5-10 anos), adolescentes (11-16 anos, 11-19 anos), adultos (16-65 anos, 20+ anos, 40+ anos, 60+ anos) e popula√ß√µes especiais (diab√©ticos, pacientes em hemodi√°lise). Diferentes esquemas de dosagem fornecidos por faixa et√°ria.",
            "level_description": "Estratifica√ß√£o abrangente por faixas et√°rias com dados de imunogenicidade espec√≠ficos para cada uma."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os estudos inclu√≠ram indiv√≠duos que eram 'inicialmente soronegativos para marcadores de hepatite B' e 'saud√°veis'. Crit√©rios populacionais espec√≠ficos mencionados para estudo de diabetes (diabetes tipo 2 diagnosticado nos √∫ltimos 5 anos, estratificado por idade e IMC). Nenhum crit√©rio detalhado de inclus√£o/exclus√£o √© fornecido.",
            "level_description": "Crit√©rios b√°sicos de elegibilidade mencionados, mas crit√©rios detalhados de inclus√£o/exclus√£o n√£o fornecidos na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os eventos adversos foram categorizados usando lista de verifica√ß√£o de sintomas por classe de sistema org√¢nico: Dist√∫rbios do Sistema Nervoso, Dist√∫rbios Gerais, Infec√ß√µes, Sangue/Linf√°tico, Metabolismo, Psiqui√°tricos, Vasculares, Gastrointestinais, Pele, Musculoesquel√©ticos. Incid√™ncia relatada como porcentagens (<1%, 1-10%) para diferentes categorias de rea√ß√£o.",
            "level_description": "Relato padronizado por classe de sistema org√¢nico com categorias de frequ√™ncia, embora com detalhes limitados sobre gradua√ß√£o de gravidade."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "No estudo de diabetes, 'Eventos adversos graves foram monitorados por at√© 30 dias ap√≥s a √∫ltima vacina√ß√£o. Eventos adversos graves (EAGs) ocorreram em 3,8% dos indiv√≠duos diab√©ticos e 1,6% dos controles. Nenhum EAG foi considerado relacionado a ENGERIX-B.' O monitoramento geral foi de 4 dias p√≥s-administra√ß√£o usando listas de verifica√ß√£o de sintomas.",
            "level_description": "Monitoramento ativo descrito para um estudo com acompanhamento de EAGs por 30 dias; a maioria dos estudos usou monitoramento de 4 dias p√≥s-dose."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 5.7 afirma 'Resultados de 2 estudos cl√≠nicos indicam que n√£o h√° associa√ß√£o entre vacina√ß√£o contra hepatite B e o desenvolvimento de esclerose m√∫ltipla, e que a vacina√ß√£o com vacina contra hepatite B n√£o parece aumentar o risco de curto prazo de reca√≠da na esclerose m√∫ltipla.' A se√ß√£o p√≥s-comercializa√ß√£o lista eventos neurol√≥gicos: encefalite, encefalopatia, s√≠ndrome de Guillain-Barr√©, paralisia de Bell, mielite transversa, neurite √≥ptica.",
            "level_description": "Associa√ß√£o com EM estudada; eventos neurol√≥gicos relatados em p√≥s-comercializa√ß√£o, mas n√£o avaliados sistematicamente em ensaios pr√©-licenciamento."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos inclu√≠ram: beb√™s prematuros (<2000g), beb√™s nascidos de m√£es HBsAg-positivas, pessoas imunocomprometidas, pacientes em hemodi√°lise (n=56), adultos com diabetes tipo 2 (n=416 diab√©ticos, n=258 controles), pessoas com hepatite C cr√¥nica (n=67), idosos (>60 anos com resposta diminu√≠da observada).",
            "level_description": "M√∫ltiplas popula√ß√µes vulner√°veis estudadas com dados espec√≠ficos, embora os tamanhos de amostra variem."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Algumas medidas estat√≠sticas fornecidas: TMGs com intervalos de confian√ßa de 95%, valores-p para algumas compara√ß√µes (por exemplo, P=0,18, P=0,02), taxas de soroprote√ß√£o como porcentagens. Efic√°cia protetora calculada como 95% no estudo neonatal. No entanto, metodologia estat√≠stica detalhada n√£o descrita.",
            "level_description": "Resultados estat√≠sticos b√°sicos relatados (TMG, IC, porcentagens), mas metodologia n√£o detalhada."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Resultados resumidos fornecidos para m√∫ltiplos estudos com tamanhos de amostra, taxas de soroprote√ß√£o e TMGs. Refer√™ncias a 8 estudos publicados fornecidas. No entanto, dados individuais de pacientes, tabelas completas de eventos adversos e metodologia detalhada n√£o inclu√≠dos na bula.",
            "level_description": "Dados de n√≠vel resumido dispon√≠veis com refer√™ncias √† literatura publicada; detalhes completos dos estudos n√£o est√£o na bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 fornece extenso relato de eventos adversos p√≥s-comercializa√ß√£o incluindo eventos raros: trombocitopenia, anafilaxia, encefalite, s√≠ndrome de Guillain-Barr√©, s√≠ndrome de Stevens-Johnson. Afirma 'relatados voluntariamente de uma popula√ß√£o de tamanho incerto.' Relato ao VAERS encorajado: 'contatar GlaxoSmithKline em 1-888-825-5249 ou VAERS em 1-800-822-7967.'",
            "level_description": "Sistema abrangente de vigil√¢ncia p√≥s-comercializa√ß√£o com relato ao VAERS e categorias detalhadas de eventos adversos."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o aborda conflitos de interesse, fontes de financiamento para ensaios cl√≠nicos ou divulga√ß√µes de investigadores. O fabricante √© GlaxoSmithKline Biologicals.",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse ou fontes de financiamento na bula."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas dos ensaios cl√≠nicos. Mortes n√£o s√£o mencionadas nas se√ß√µes de eventos adversos, nem em ensaios cl√≠nicos nem em p√≥s-comercializa√ß√£o.",
            "level_description": "Nenhum dado de mortalidade relatado na bula."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ENGERIX-B possui dados cl√≠nicos substanciais em m√∫ltiplas faixas et√°rias e popula√ß√µes com 36 estudos cl√≠nicos e mais de 5.000 indiv√≠duos. Os pontos fortes incluem excelente estratifica√ß√£o por idade, inclus√£o de subgrupos vulner√°veis, relato padronizado de eventos adversos e vigil√¢ncia p√≥s-comercializa√ß√£o ativa. No entanto, existem limita√ß√µes metodol√≥gicas significativas: nenhum controle placebo documentado, cegamento ou randomiza√ß√£o na bula. O acompanhamento de seguran√ßa foi principalmente de curto prazo (4 dias p√≥s-dose). O documento carece de dados de mortalidade, divulga√ß√µes de conflitos de interesse e metodologia estat√≠stica detalhada. A aprova√ß√£o inicial da FDA foi em 1989, quando os padr√µes de design de ensaios diferiam das expectativas atuais."
        }
      },
      "safety_en": {
        "vaccine_id": "hepb_engerix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Across 36 clinical studies, 13,495 doses were administered to 5,071 subjects including healthy adults, children, and neonates. Specific pediatric data: 58 high-risk neonates in efficacy study; 381 infants receiving 0,1,2 month schedule; 52 infants on 0,1,6 month schedule; 242 children aged 6 months to 10 years; 181+161 children/adolescents aged 5-16 years on different schedules. While total pediatric numbers are reasonable, individual study sizes are modest."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Primary safety monitoring was only 4 days post-administration for adverse reactions. In the diabetes study, serious adverse events were monitored for 30 days after last vaccination. The document states 'All subjects were monitored for 4 days post-administration.' This short duration is inadequate for detecting delayed adverse events, autoimmune conditions, or long-term safety signals. The neonatal efficacy study had 12-month follow-up for efficacy but safety follow-up duration unclear."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "No placebo control group is documented. The diabetes study included matched control subjects (258 non-diabetics vs 416 diabetics), but both groups received the vaccine. The document describes comparisons between different dosing schedules and populations (e.g., diabetic vs non-diabetic, different age groups) but no unvaccinated or placebo control for direct safety comparison. Interchangeability study compared with RECOMBIVAX HB (another Hep B vaccine), not placebo."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance used symptom checklists completed by subjects or parents/guardians for 4 days post-administration. In diabetes study, serious adverse events were actively monitored through 30 days. The document states 'Using a symptom checklist, the most frequently reported adverse reactions were injection site soreness (22%) and fatigue (14%).' However, active surveillance was limited to short-term follow-up. Postmarketing surveillance relies on voluntary VAERS reporting."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Two clinical studies specifically evaluated multiple sclerosis association (Section 5.7), finding no association with MS development or increased relapse risk. Clinical trial adverse events included nervous system disorders (dizziness, headache, somnolence, tingling) at 1-10% or <1% incidence. However, systematic neurological monitoring protocols not described. Postmarketing reports include serious neurological events: encephalitis, encephalopathy, Guillain-Barre syndrome, Bell's palsy, transverse myelitis, optic neuritis, seizures, paresthesia."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Multiple vulnerable populations studied: premature infants (<2000g at birth) with specific dosing guidance; immunocompromised persons (Section 5.6 notes diminished immune response); hemodialysis patients (n=56, with 4-dose schedule); adults with type 2 diabetes (n=416 with SAE rate of 3.8% vs 1.6% in controls, no SAEs deemed vaccine-related); chronic hepatitis C patients (n=67); elderly persons over 60 years with documented diminished antibody response. Pregnancy data from 58 inadvertent exposures and TWINRIX registry (245 women)."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Summary statistics provided: adverse event frequencies by category (<1%, 1-10%, 22% injection site soreness), seroprotection rates, GMTs with 95% confidence intervals. SAE rates in diabetes study (3.8% diabetics, 1.6% controls). Eight published references cited. However, individual patient data not available, complete adverse event tables not included, and postmarketing states 'not always possible to reliably estimate their frequency or establish a causal relationship.' No mortality data provided."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 provides comprehensive postmarketing adverse event reporting organized by system organ class. Reports VAERS contact information (1-800-822-7967) and manufacturer reporting (1-888-825-5249). Events include rare but serious conditions: thrombocytopenia, anaphylaxis, serum sickness-like syndrome, encephalitis, Guillain-Barre syndrome, Stevens-Johnson syndrome, transverse myelitis. Appropriately notes that voluntary reporting cannot establish frequency or causality. Long track record since 1989 approval."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ENGERIX-B safety documentation shows adequate pediatric sample sizes and good coverage of vulnerable subgroups including premature infants, hemodialysis patients, diabetics, and the elderly. Postmarketing surveillance is established with detailed adverse event cataloging. However, significant safety assessment limitations exist: the primary follow-up duration of only 4 days post-dose is insufficient for detecting delayed reactions; no true placebo comparison group was used; active surveillance was short-term. The MS association studies provide some neurological safety data, but systematic neurological monitoring was not described. The vaccine has been in use since 1989 providing extensive real-world safety data through VAERS, though voluntary reporting has inherent limitations."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepb_engerix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Em 36 estudos cl√≠nicos, 13.495 doses foram administradas a 5.071 indiv√≠duos, incluindo adultos, crian√ßas e neonatos saud√°veis. Dados pedi√°tricos espec√≠ficos: 58 neonatos de alto risco em estudo de efic√°cia; 381 beb√™s recebendo esquema 0,1,2 meses; 52 beb√™s no esquema 0,1,6 meses; 242 crian√ßas de 6 meses a 10 anos; 181+161 crian√ßas/adolescentes de 5-16 anos em diferentes esquemas. Embora os n√∫meros pedi√°tricos totais sejam razo√°veis, os tamanhos individuais dos estudos s√£o modestos."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O monitoramento de seguran√ßa prim√°rio foi de apenas 4 dias p√≥s-administra√ß√£o para rea√ß√µes adversas. No estudo de diabetes, eventos adversos graves foram monitorados por 30 dias ap√≥s a √∫ltima vacina√ß√£o. O documento afirma 'Todos os indiv√≠duos foram monitorados por 4 dias p√≥s-administra√ß√£o.' Esta curta dura√ß√£o √© inadequada para detectar eventos adversos tardios, condi√ß√µes autoimunes ou sinais de seguran√ßa a longo prazo. O estudo de efic√°cia neonatal teve acompanhamento de 12 meses para efic√°cia, mas a dura√ß√£o do acompanhamento de seguran√ßa n√£o √© clara."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Nenhum grupo controle placebo √© documentado. O estudo de diabetes incluiu indiv√≠duos controle pareados (258 n√£o diab√©ticos versus 416 diab√©ticos), mas ambos os grupos receberam a vacina. O documento descreve compara√ß√µes entre diferentes esquemas de dosagem e popula√ß√µes (por exemplo, diab√©ticos versus n√£o diab√©ticos, diferentes faixas et√°rias), mas sem controle n√£o vacinado ou placebo para compara√ß√£o direta de seguran√ßa. O estudo de intercambialidade comparou com RECOMBIVAX HB (outra vacina contra Hep B), n√£o placebo."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A vigil√¢ncia ativa usou listas de verifica√ß√£o de sintomas preenchidas pelos indiv√≠duos ou pais/respons√°veis por 4 dias p√≥s-administra√ß√£o. No estudo de diabetes, eventos adversos graves foram ativamente monitorados por at√© 30 dias. O documento afirma 'Usando uma lista de verifica√ß√£o de sintomas, as rea√ß√µes adversas mais frequentemente relatadas foram dor no local da inje√ß√£o (22%) e fadiga (14%).' No entanto, a vigil√¢ncia ativa foi limitada ao acompanhamento de curto prazo. A vigil√¢ncia p√≥s-comercializa√ß√£o depende de relatos volunt√°rios ao VAERS."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dois estudos cl√≠nicos avaliaram especificamente a associa√ß√£o com esclerose m√∫ltipla (Se√ß√£o 5.7), n√£o encontrando associa√ß√£o com desenvolvimento de EM ou aumento do risco de reca√≠da. Os eventos adversos de ensaios cl√≠nicos inclu√≠ram dist√∫rbios do sistema nervoso (tontura, cefaleia, sonol√™ncia, formigamento) com incid√™ncia de 1-10% ou <1%. No entanto, protocolos de monitoramento neurol√≥gico sistem√°tico n√£o s√£o descritos. Relatos p√≥s-comercializa√ß√£o incluem eventos neurol√≥gicos graves: encefalite, encefalopatia, s√≠ndrome de Guillain-Barr√©, paralisia de Bell, mielite transversa, neurite √≥ptica, convuls√µes, parestesia."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "M√∫ltiplas popula√ß√µes vulner√°veis estudadas: beb√™s prematuros (<2000g ao nascer) com orienta√ß√£o de dosagem espec√≠fica; pessoas imunocomprometidas (Se√ß√£o 5.6 observa resposta imune diminu√≠da); pacientes em hemodi√°lise (n=56, com esquema de 4 doses); adultos com diabetes tipo 2 (n=416 com taxa de EAG de 3,8% versus 1,6% em controles, nenhum EAG considerado relacionado √† vacina); pacientes com hepatite C cr√¥nica (n=67); pessoas idosas acima de 60 anos com resposta de anticorpos diminu√≠da documentada. Dados de gravidez de 58 exposi√ß√µes inadvertidas e registro TWINRIX (245 mulheres)."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Estat√≠sticas resumidas fornecidas: frequ√™ncias de eventos adversos por categoria (<1%, 1-10%, 22% dor no local da inje√ß√£o), taxas de soroprote√ß√£o, TMGs com intervalos de confian√ßa de 95%. Taxas de EAG no estudo de diabetes (3,8% diab√©ticos, 1,6% controles). Oito refer√™ncias publicadas citadas. No entanto, dados individuais de pacientes n√£o dispon√≠veis, tabelas completas de eventos adversos n√£o inclu√≠das, e p√≥s-comercializa√ß√£o afirma 'nem sempre √© poss√≠vel estimar confiavelmente sua frequ√™ncia ou estabelecer uma rela√ß√£o causal.' Nenhum dado de mortalidade fornecido."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 fornece relato abrangente de eventos adversos p√≥s-comercializa√ß√£o organizado por classe de sistema org√¢nico. Relata informa√ß√µes de contato do VAERS (1-800-822-7967) e relato ao fabricante (1-888-825-5249). Os eventos incluem condi√ß√µes raras, mas graves: trombocitopenia, anafilaxia, s√≠ndrome tipo doen√ßa do soro, encefalite, s√≠ndrome de Guillain-Barr√©, s√≠ndrome de Stevens-Johnson, mielite transversa. Observa apropriadamente que relatos volunt√°rios n√£o podem estabelecer frequ√™ncia ou causalidade. Longo hist√≥rico desde a aprova√ß√£o em 1989."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A documenta√ß√£o de seguran√ßa de ENGERIX-B mostra tamanhos de amostra pedi√°trica adequados e boa cobertura de subgrupos vulner√°veis, incluindo beb√™s prematuros, pacientes em hemodi√°lise, diab√©ticos e idosos. A vigil√¢ncia p√≥s-comercializa√ß√£o est√° estabelecida com cataloga√ß√£o detalhada de eventos adversos. No entanto, existem limita√ß√µes significativas na avalia√ß√£o de seguran√ßa: a dura√ß√£o do acompanhamento prim√°rio de apenas 4 dias p√≥s-dose √© insuficiente para detectar rea√ß√µes tardias; nenhum grupo de compara√ß√£o placebo verdadeiro foi usado; a vigil√¢ncia ativa foi de curto prazo. Os estudos de associa√ß√£o com EM fornecem alguns dados de seguran√ßa neurol√≥gica, mas o monitoramento neurol√≥gico sistem√°tico n√£o foi descrito. A vacina est√° em uso desde 1989, fornecendo extensos dados de seguran√ßa do mundo real atrav√©s do VAERS, embora os relatos volunt√°rios tenham limita√ß√µes inerentes."
        }
      }
    },
    {
      "id": "hib_hiberix",
      "name": "Hiberix",
      "type": "Hib",
      "manufacturer": "GlaxoSmithKline",
      "description": "Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) for prevention of invasive disease caused by H. influenzae type b.",
      "sources": [
        "hib_hiberix_insert.pdf",
        "hib_hiberix_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Study 1 compared HIBERIX (n=2,963) with active comparators: Control PRP-T (Sanofi Pasteur SA) (n=520) and DTaP-IPV/Hib (Sanofi Pasteur Ltd.) (n=520). No inert placebo group was used.",
            "level_description": "The clinical trials used active vaccine comparators rather than saline placebo controls. All comparison groups received other Hib-containing vaccines, making it impossible to assess the true safety profile of HIBERIX against an unvaccinated baseline."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 1 is described as 'randomized, controlled clinical trial' but blinding is not explicitly mentioned. Study 2 is described as 'open-label, multicenter study.'",
            "level_description": "The main U.S. Study 1 appears to be randomized but blinding methodology is not documented. Study 2 and the 7 additional studies were explicitly open-label, meaning investigators and participants knew which vaccine was administered."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 1 is described as 'a randomized, controlled clinical trial conducted in the U.S.' with children randomized to receive HIBERIX (n=2,963), Control PRP-T (n=520), or DTaP-IPV/Hib (n=520).",
            "level_description": "Randomization is explicitly stated for the main U.S. trial (Study 1). However, the randomization methodology, allocation concealment, and stratification details are not provided."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 1 enrolled 2,963 children receiving HIBERIX for primary series and 2,336 for booster dose. Seven additional studies included 1,008 children receiving HIBERIX as a booster. Study 2 enrolled 371 children.",
            "level_description": "The total pediatric sample size across studies was substantial (over 4,000 children receiving HIBERIX). The main U.S. trial had nearly 3,000 subjects in the HIBERIX arm, which is adequate for detecting common adverse reactions."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Solicited adverse reactions were collected 'within 4 days of vaccination.' Serious adverse reactions in the 7 additional studies were reported 'in the 31-day period following booster immunization.'",
            "level_description": "Active follow-up for solicited reactions was extremely short at only 4 days post-vaccination. Serious adverse event monitoring extended to 31 days in some studies, but no long-term safety follow-up (months to years) is documented for chronic or delayed adverse effects."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Primary series given at 2, 4, and 6 months. Booster given at 15-18 months. In 7 additional studies, '172 (17.1%) subjects were aged 11 to 14 months, 642 (63.7%) subjects were aged 15 to 18 months, and 194 (19.2%) subjects were aged 19 to 25 months.'",
            "level_description": "Age distribution is documented for booster studies, but separate safety analyses by age subgroup are not presented. Results are aggregated across age groups rather than stratified for comparison."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document mentions contraindications (severe allergic reaction after previous Hib or tetanus toxoid vaccine) and warnings (Guillain-Barre syndrome within 6 weeks, premature infants, immunosuppressed children) but does not detail specific trial inclusion/exclusion criteria.",
            "level_description": "While contraindications and precautions are listed for clinical use, the actual clinical trial eligibility criteria (specific inclusion/exclusion criteria used to screen participants) are not documented in the prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited reactions were systematically collected with standardized grading: Grade 3 pain 'cried when limb was moved/spontaneously painful,' Grade 3 irritability 'crying that could not be comforted/prevented normal activity,' Grade 3 fever '>103.1F (>39.5C) rectally.'",
            "level_description": "The trials used standardized definitions and grading scales for solicited adverse events, with clear Grade 3 definitions provided for local and systemic reactions. Diary cards or standardized collection tools appear to have been used."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse reactions were reported: 'One of 2,963 subjects...experienced a serious adverse reaction...convulsion on Day 14 after Dose 1.' 'One of 2,336 subjects...experienced...new onset febrile seizure on Day 1 after Dose 4.' In 7 additional studies, '2 of 1,008 subjects reported a serious adverse reaction...in the 31-day period following booster immunization.'",
            "level_description": "Serious adverse events were captured during the trials with temporal associations noted. However, the methodology for active monitoring (frequency of contact, methods of ascertainment) is not described. The 31-day monitoring window is relatively short for detecting serious delayed reactions."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Guillain-Barre syndrome is mentioned as a warning if it occurred within 6 weeks of prior tetanus-containing vaccine. Postmarketing reports include 'Convulsions (with or without fever), hypotonic-hyporesponsive episode (i.e., sudden onset of hypotonia, hyporesponsiveness, and pallor or cyanosis).'",
            "level_description": "Neurological events are addressed in warnings and postmarketing sections, but proactive assessment of autoimmune or neurological outcomes in the clinical trials is not documented. The precaution about Guillain-Barre relates to prior history, not trial monitoring."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Warnings note: 'Safety and effectiveness of HIBERIX in immunosuppressed children have not been evaluated.' 'Apnea following intramuscular vaccination has been observed in some infants born prematurely.'",
            "level_description": "Vulnerable populations such as immunocompromised children and premature infants were explicitly not studied. The document acknowledges these gaps but does not provide safety data for these high-risk subgroups from the clinical trials."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Non-inferiority analyses were performed: 'HIBERIX was non-inferior to Control PRP-T for percent of subjects achieving anti-PRP >=0.15 mcg/mL (lower limit of 95% CI on difference of HIBERIX minus Control PRP-T >= predefined limit of -5%).'",
            "level_description": "Statistical methodology for immunogenicity non-inferiority comparisons is documented with confidence intervals and predefined non-inferiority margins. However, detailed statistical analysis plans for safety endpoints are not presented."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 1 is identified by clinical trial registry number NCT01000974. Adverse reaction rates are presented in detailed tables. However, the 7 additional studies are not identified by registry number.",
            "level_description": "Some transparency is provided through the NCT registry number for Study 1 and detailed adverse event tables. However, full data availability, access to raw data, or complete study protocols are not addressed. Several supporting studies lack registry identification."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 documents postmarketing experience including: 'Extensive swelling of the vaccinated limb, injection site induration,' 'Allergic reactions (including anaphylactic and anaphylactoid reactions), angioedema,' 'Convulsions (with or without fever), hypotonic-hyporesponsive episode,' and 'Apnea.'",
            "level_description": "A dedicated postmarketing surveillance section documents additional adverse reactions identified after approval. VAERS reporting is referenced. However, frequency estimates cannot be made from voluntary reports, as acknowledged in the document."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document identifies the manufacturer as GlaxoSmithKline Biologicals but does not disclose investigator conflicts of interest, funding sources for independent analyses, or relationships between trial investigators and the sponsor.",
            "level_description": "No information is provided about conflicts of interest for study investigators, independent oversight committees, or financial relationships. The manufacturer conducted the trials, but transparency about potential bias is not addressed."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report any deaths or all-cause mortality data from the clinical trials.",
            "level_description": "All-cause mortality is not addressed in the prescribing information. While specific serious adverse events are mentioned (convulsions, febrile seizures), there is no systematic reporting of deaths or mortality comparisons between treatment groups."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The Hiberix clinical program included a reasonably sized randomized controlled trial (Study 1, n=2,963 for HIBERIX) with standardized adverse event collection and documented statistical methodology for immunogenicity. However, significant limitations include: (1) use of active vaccine comparators rather than true placebo controls, (2) very short follow-up period of only 4 days for solicited reactions and 31 days for serious events, (3) open-label design in several supporting studies, (4) no data on vulnerable populations like immunocompromised or premature infants, (5) no reporting of all-cause mortality, and (6) absent conflict of interest disclosures. The postmarketing surveillance section provides additional safety signals but cannot establish causality or frequency. Overall, the evidence base meets minimum regulatory standards but has meaningful gaps for comprehensive safety assessment."
        }
      },
      "trial_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O Estudo 1 comparou HIBERIX (n=2.963) com comparadores ativos: PRP-T de Controle (Sanofi Pasteur SA) (n=520) e DTaP-IPV/Hib (Sanofi Pasteur Ltd.) (n=520). Nenhum grupo placebo inerte foi utilizado.",
            "level_description": "Os ensaios cl√≠nicos utilizaram comparadores de vacinas ativas em vez de controles com placebo salino. Todos os grupos de compara√ß√£o receberam outras vacinas contendo Hib, tornando imposs√≠vel avaliar o verdadeiro perfil de seguran√ßa do HIBERIX em rela√ß√£o a uma linha de base n√£o vacinada."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 1 √© descrito como 'ensaio cl√≠nico randomizado e controlado', mas o cegamento n√£o √© explicitamente mencionado. O Estudo 2 √© descrito como 'estudo multic√™ntrico aberto'.",
            "level_description": "O principal Estudo 1 nos EUA parece ser randomizado, mas a metodologia de cegamento n√£o est√° documentada. O Estudo 2 e os 7 estudos adicionais foram explicitamente abertos, significando que os investigadores e participantes sabiam qual vacina estava sendo administrada."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 1 √© descrito como 'um ensaio cl√≠nico randomizado e controlado conduzido nos EUA' com crian√ßas randomizadas para receber HIBERIX (n=2.963), PRP-T de Controle (n=520) ou DTaP-IPV/Hib (n=520).",
            "level_description": "A randomiza√ß√£o √© explicitamente declarada para o principal ensaio dos EUA (Estudo 1). No entanto, a metodologia de randomiza√ß√£o, oculta√ß√£o da aloca√ß√£o e detalhes de estratifica√ß√£o n√£o s√£o fornecidos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 1 incluiu 2.963 crian√ßas recebendo HIBERIX para a s√©rie prim√°ria e 2.336 para a dose de refor√ßo. Sete estudos adicionais inclu√≠ram 1.008 crian√ßas recebendo HIBERIX como refor√ßo. O Estudo 2 incluiu 371 crian√ßas.",
            "level_description": "O tamanho total da amostra pedi√°trica entre os estudos foi substancial (mais de 4.000 crian√ßas recebendo HIBERIX). O principal ensaio dos EUA teve quase 3.000 participantes no bra√ßo HIBERIX, o que √© adequado para detectar rea√ß√µes adversas comuns."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Rea√ß√µes adversas solicitadas foram coletadas 'dentro de 4 dias da vacina√ß√£o'. Rea√ß√µes adversas graves nos 7 estudos adicionais foram relatadas 'no per√≠odo de 31 dias ap√≥s a imuniza√ß√£o de refor√ßo'.",
            "level_description": "O acompanhamento ativo para rea√ß√µes solicitadas foi extremamente curto, de apenas 4 dias p√≥s-vacina√ß√£o. O monitoramento de eventos adversos graves se estendeu a 31 dias em alguns estudos, mas nenhum acompanhamento de seguran√ßa a longo prazo (meses a anos) est√° documentado para efeitos adversos cr√¥nicos ou tardios."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A s√©rie prim√°ria foi administrada aos 2, 4 e 6 meses. O refor√ßo foi administrado entre 15-18 meses. Em 7 estudos adicionais, '172 (17,1%) participantes tinham entre 11 e 14 meses, 642 (63,7%) participantes tinham entre 15 e 18 meses, e 194 (19,2%) participantes tinham entre 19 e 25 meses'.",
            "level_description": "A distribui√ß√£o et√°ria est√° documentada para os estudos de refor√ßo, mas an√°lises de seguran√ßa separadas por subgrupo et√°rio n√£o s√£o apresentadas. Os resultados s√£o agregados entre os grupos et√°rios em vez de estratificados para compara√ß√£o."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento menciona contraindica√ß√µes (rea√ß√£o al√©rgica grave ap√≥s vacina Hib ou toxoide tet√¢nico anterior) e advert√™ncias (s√≠ndrome de Guillain-Barr√© dentro de 6 semanas, beb√™s prematuros, crian√ßas imunossuprimidas), mas n√£o detalha os crit√©rios espec√≠ficos de inclus√£o/exclus√£o dos ensaios.",
            "level_description": "Embora contraindica√ß√µes e precau√ß√µes sejam listadas para uso cl√≠nico, os crit√©rios reais de elegibilidade dos ensaios cl√≠nicos (crit√©rios espec√≠ficos de inclus√£o/exclus√£o usados para triagem de participantes) n√£o est√£o documentados na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes solicitadas foram sistematicamente coletadas com gradua√ß√£o padronizada: dor Grau 3 'chorou quando o membro foi movido/espontaneamente doloroso', irritabilidade Grau 3 'choro que n√£o podia ser consolado/impedia atividade normal', febre Grau 3 '>103,1F (>39,5C) retal'.",
            "level_description": "Os ensaios utilizaram defini√ß√µes padronizadas e escalas de gradua√ß√£o para eventos adversos solicitados, com defini√ß√µes claras de Grau 3 fornecidas para rea√ß√µes locais e sist√™micas. Di√°rios ou ferramentas de coleta padronizadas parecem ter sido utilizados."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes adversas graves foram relatadas: 'Um de 2.963 participantes... experimentou uma rea√ß√£o adversa grave... convuls√£o no Dia 14 ap√≥s a Dose 1.' 'Um de 2.336 participantes... experimentou... nova convuls√£o febril no Dia 1 ap√≥s a Dose 4.' Nos 7 estudos adicionais, '2 de 1.008 participantes relataram uma rea√ß√£o adversa grave... no per√≠odo de 31 dias ap√≥s a imuniza√ß√£o de refor√ßo'.",
            "level_description": "Eventos adversos graves foram capturados durante os ensaios com associa√ß√µes temporais observadas. No entanto, a metodologia para monitoramento ativo (frequ√™ncia de contato, m√©todos de verifica√ß√£o) n√£o √© descrita. A janela de monitoramento de 31 dias √© relativamente curta para detectar rea√ß√µes graves tardias."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A s√≠ndrome de Guillain-Barr√© √© mencionada como advert√™ncia se ocorreu dentro de 6 semanas de vacina contendo t√©tano anterior. Relatos p√≥s-comercializa√ß√£o incluem 'Convuls√µes (com ou sem febre), epis√≥dio hipot√¥nico-hiporresponsivo (ou seja, in√≠cio s√∫bito de hipotonia, hiporresponsividade e palidez ou cianose)'.",
            "level_description": "Eventos neurol√≥gicos s√£o abordados nas se√ß√µes de advert√™ncias e p√≥s-comercializa√ß√£o, mas a avalia√ß√£o proativa de desfechos autoimunes ou neurol√≥gicos nos ensaios cl√≠nicos n√£o est√° documentada. A precau√ß√£o sobre Guillain-Barr√© refere-se ao hist√≥rico anterior, n√£o ao monitoramento do ensaio."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Advert√™ncias observam: 'A seguran√ßa e efic√°cia do HIBERIX em crian√ßas imunossuprimidas n√£o foram avaliadas.' 'Apneia ap√≥s vacina√ß√£o intramuscular foi observada em alguns beb√™s nascidos prematuramente'.",
            "level_description": "Popula√ß√µes vulner√°veis, como crian√ßas imunocomprometidas e beb√™s prematuros, explicitamente n√£o foram estudadas. O documento reconhece essas lacunas, mas n√£o fornece dados de seguran√ßa para esses subgrupos de alto risco dos ensaios cl√≠nicos."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "An√°lises de n√£o inferioridade foram realizadas: 'HIBERIX foi n√£o inferior ao PRP-T de Controle para a porcentagem de participantes atingindo anti-PRP >=0,15 mcg/mL (limite inferior do IC 95% na diferen√ßa de HIBERIX menos PRP-T de Controle >= limite predefinido de -5%)'.",
            "level_description": "A metodologia estat√≠stica para compara√ß√µes de n√£o inferioridade de imunogenicidade est√° documentada com intervalos de confian√ßa e margens de n√£o inferioridade predefinidas. No entanto, planos de an√°lise estat√≠stica detalhados para desfechos de seguran√ßa n√£o s√£o apresentados."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 1 √© identificado pelo n√∫mero de registro de ensaio cl√≠nico NCT01000974. As taxas de rea√ß√µes adversas s√£o apresentadas em tabelas detalhadas. No entanto, os 7 estudos adicionais n√£o s√£o identificados por n√∫mero de registro.",
            "level_description": "Alguma transpar√™ncia √© fornecida atrav√©s do n√∫mero de registro NCT para o Estudo 1 e tabelas detalhadas de eventos adversos. No entanto, disponibilidade completa de dados, acesso a dados brutos ou protocolos completos de estudo n√£o s√£o abordados. V√°rios estudos de apoio carecem de identifica√ß√£o de registro."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 documenta a experi√™ncia p√≥s-comercializa√ß√£o incluindo: 'Incha√ßo extenso do membro vacinado, indura√ß√£o no local da inje√ß√£o', 'Rea√ß√µes al√©rgicas (incluindo rea√ß√µes anafil√°ticas e anafilactoides), angioedema', 'Convuls√µes (com ou sem febre), epis√≥dio hipot√¥nico-hiporresponsivo' e 'Apneia'.",
            "level_description": "Uma se√ß√£o dedicada √† vigil√¢ncia p√≥s-comercializa√ß√£o documenta rea√ß√µes adversas adicionais identificadas ap√≥s a aprova√ß√£o. O relat√≥rio VAERS √© referenciado. No entanto, estimativas de frequ√™ncia n√£o podem ser feitas a partir de relatos volunt√°rios, conforme reconhecido no documento."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento identifica o fabricante como GlaxoSmithKline Biologicals, mas n√£o divulga conflitos de interesse dos investigadores, fontes de financiamento para an√°lises independentes ou relacionamentos entre os investigadores do ensaio e o patrocinador.",
            "level_description": "Nenhuma informa√ß√£o √© fornecida sobre conflitos de interesse para investigadores do estudo, comit√™s de supervis√£o independentes ou relacionamentos financeiros. O fabricante conduziu os ensaios, mas a transpar√™ncia sobre potencial vi√©s n√£o √© abordada."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata nenhuma morte ou dados de mortalidade por todas as causas dos ensaios cl√≠nicos.",
            "level_description": "A mortalidade por todas as causas n√£o √© abordada na bula. Embora eventos adversos graves espec√≠ficos sejam mencionados (convuls√µes, convuls√µes febris), n√£o h√° relato sistem√°tico de mortes ou compara√ß√µes de mortalidade entre os grupos de tratamento."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "O programa cl√≠nico do Hiberix incluiu um ensaio controlado randomizado de tamanho razo√°vel (Estudo 1, n=2.963 para HIBERIX) com coleta padronizada de eventos adversos e metodologia estat√≠stica documentada para imunogenicidade. No entanto, limita√ß√µes significativas incluem: (1) uso de comparadores de vacinas ativas em vez de controles com placebo verdadeiro, (2) per√≠odo de acompanhamento muito curto de apenas 4 dias para rea√ß√µes solicitadas e 31 dias para eventos graves, (3) desenho aberto em v√°rios estudos de apoio, (4) aus√™ncia de dados sobre popula√ß√µes vulner√°veis como beb√™s imunocomprometidos ou prematuros, (5) aus√™ncia de relato de mortalidade por todas as causas, e (6) aus√™ncia de divulga√ß√µes de conflitos de interesse. A se√ß√£o de vigil√¢ncia p√≥s-comercializa√ß√£o fornece sinais de seguran√ßa adicionais, mas n√£o pode estabelecer causalidade ou frequ√™ncia. No geral, a base de evid√™ncias atende aos padr√µes regulat√≥rios m√≠nimos, mas possui lacunas significativas para uma avalia√ß√£o abrangente de seguran√ßa."
        }
      },
      "safety_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Study 1 enrolled a substantial pediatric population: 2,963 children received HIBERIX for the primary series (at 2, 4, and 6 months), and 2,336 received the booster dose at 15-18 months. Control groups included 520 children each for Control PRP-T and DTaP-IPV/Hib. Seven additional studies contributed 1,008 children who received HIBERIX as a booster dose. The demographic breakdown shows 51.2% male, 61% white, 8% Asian, 9% black, and 22% other racial/ethnic groups. The total population across all trials is approximately 4,000+ children, which is adequate for detecting common adverse reactions."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Solicited adverse reactions were only collected within 4 days of vaccination (day of vaccination and the next 3 days). Serious adverse reactions were monitored for 31 days post-immunization in the 7 additional studies. There is no evidence of long-term safety follow-up extending months or years post-vaccination. This short follow-up window is insufficient to detect delayed adverse events or long-term safety signals."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Study 1 was a randomized, controlled clinical trial comparing HIBERIX against two active comparators: a U.S.-licensed monovalent Haemophilus b Conjugate Vaccine (Control PRP-T from Sanofi Pasteur SA) with n=520, and a U.S.-licensed combined DTaP-IPV/Hib vaccine (Sanofi Pasteur Ltd.) with n=520. While this uses active controls rather than placebo, it allows for direct comparison of safety profiles against established vaccines. However, it should be noted that seven additional studies lacked a comparator group receiving a U.S.-licensed Haemophilus b Conjugate Vaccine."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The trials employed active solicitation of adverse reactions. Solicited local reactions (pain, redness, swelling) and general adverse reactions (irritability, drowsiness, fever, loss of appetite, fussiness, restlessness) were systematically collected within 4 days of vaccination. The insert includes detailed tables (Tables 1, 2, and 3) with specific percentages for each adverse reaction by dose and grade severity. Grade 3 (severe) reactions were specifically tracked. This demonstrates structured active surveillance methodology, though limited to a 4-day window."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Neurological safety concerns are addressed but incompletely. Guillain-Barre Syndrome (GBS) is mentioned as a warning, noting that if GBS occurred within 6 weeks of a prior tetanus toxoid-containing vaccine, the decision to give HIBERIX should be based on risk-benefit analysis. Syncope with transient neurological signs (visual disturbance, paresthesia, tonic-clonic limb movements) is documented. Serious adverse reactions included 1 convulsion on Day 14 after Dose 1 (1/2,963) and 1 new onset febrile seizure on Day 1 after Dose 4 (1/2,336). Postmarketing reports include convulsions (with or without fever) and hypotonic-hyporesponsive episodes. However, there is no systematic neurological assessment protocol or long-term neurological follow-up described in the clinical trials."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Some vulnerable populations are addressed but with limitations. Premature infants: A warning notes that apnea following intramuscular vaccination has been observed in some infants born prematurely, advising individual risk-benefit assessment. Immunocompromised children: The insert states that safety and effectiveness in immunosuppressed children have not been evaluated, acknowledging this gap. The pediatric age range is specifically defined (6 weeks through 4 years). However, the document explicitly states safety and effectiveness have not been established in children younger than 6 weeks or aged 5-16 years. No specific data is provided for children with chronic illnesses or other high-risk conditions."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The insert provides substantial transparent safety data: detailed tables showing adverse reaction percentages by dose number and severity grade; breakdown of sample sizes for each study arm; demographic information (sex, race/ethnicity); specific NCT trial identifier (NCT01000974) for Study 1; clear definitions of grading scales (e.g., Grade 3 pain defined as 'cried when limb was moved/spontaneously painful'); and temperature thresholds for fever definitions. Geographic locations of additional studies (Europe, Canada, Latin America, Germany) are disclosed. However, raw data and confidence intervals for adverse reactions are not provided."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 documents postmarketing experience with specific adverse reactions identified after approval, including: extensive swelling of vaccinated limb, injection site induration, allergic reactions (including anaphylactic/anaphylactoid reactions), angioedema, convulsions (with or without fever), hypotonic-hyporesponsive episodes, somnolence, syncope, vasovagal responses, apnea, rash, and urticaria. The insert appropriately notes that voluntary reporting makes it impossible to reliably estimate frequency or establish causal relationships. VAERS reporting information is provided (1-800-822-7967). Manufacturer contact for reporting is included (GlaxoSmithKline at 1-888-825-5249)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "HIBERIX demonstrates adequate safety documentation in several areas: substantial pediatric sample size (~4,000+ children), randomized controlled comparison against licensed vaccines, active solicitation of adverse reactions with detailed severity grading, reasonable data transparency with published trial identifiers, and established postmarketing surveillance. However, significant limitations exist: follow-up duration is critically short (only 4 days for solicited reactions, 31 days for serious events), with no long-term safety monitoring. Neurological monitoring captured some serious events (convulsions, febrile seizures) but lacks systematic neurological assessment protocols. Vulnerable populations like immunocompromised children explicitly lack safety data. Overall, the safety profile is reasonably documented for short-term common reactions but insufficient for detecting delayed or rare adverse events."
        }
      },
      "safety_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo 1 incluiu uma popula√ß√£o pedi√°trica substancial: 2.963 crian√ßas receberam HIBERIX para a s√©rie prim√°ria (aos 2, 4 e 6 meses), e 2.336 receberam a dose de refor√ßo aos 15-18 meses. Os grupos controle inclu√≠ram 520 crian√ßas cada para o Controle PRP-T e DTaP-IPV/Hib. Sete estudos adicionais contribu√≠ram com 1.008 crian√ßas que receberam HIBERIX como dose de refor√ßo. A distribui√ß√£o demogr√°fica mostra 51,2% masculino, 61% brancos, 8% asi√°ticos, 9% negros e 22% outros grupos raciais/√©tnicos. A popula√ß√£o total em todos os ensaios √© de aproximadamente 4.000+ crian√ßas, o que √© adequado para detectar rea√ß√µes adversas comuns."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "As rea√ß√µes adversas solicitadas foram coletadas apenas dentro de 4 dias ap√≥s a vacina√ß√£o (dia da vacina√ß√£o e os 3 dias seguintes). Rea√ß√µes adversas graves foram monitoradas por 31 dias ap√≥s a imuniza√ß√£o nos 7 estudos adicionais. N√£o h√° evid√™ncia de acompanhamento de seguran√ßa a longo prazo estendendo-se por meses ou anos ap√≥s a vacina√ß√£o. Esta janela curta de acompanhamento √© insuficiente para detectar eventos adversos tardios ou sinais de seguran√ßa a longo prazo."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo 1 foi um ensaio cl√≠nico randomizado e controlado comparando HIBERIX contra dois comparadores ativos: uma Vacina Conjugada Haemophilus b monovalente licenciada nos EUA (Controle PRP-T da Sanofi Pasteur SA) com n=520, e uma vacina combinada DTaP-IPV/Hib licenciada nos EUA (Sanofi Pasteur Ltd.) com n=520. Embora use controles ativos em vez de placebo, permite compara√ß√£o direta dos perfis de seguran√ßa contra vacinas estabelecidas. No entanto, deve-se notar que sete estudos adicionais n√£o inclu√≠ram um grupo comparador recebendo uma Vacina Conjugada Haemophilus b licenciada nos EUA."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Os ensaios empregaram solicita√ß√£o ativa de rea√ß√µes adversas. Rea√ß√µes locais solicitadas (dor, vermelhid√£o, incha√ßo) e rea√ß√µes adversas gerais (irritabilidade, sonol√™ncia, febre, perda de apetite, agita√ß√£o, inquieta√ß√£o) foram sistematicamente coletadas dentro de 4 dias ap√≥s a vacina√ß√£o. A bula inclui tabelas detalhadas (Tabelas 1, 2 e 3) com porcentagens espec√≠ficas para cada rea√ß√£o adversa por dose e gravidade. Rea√ß√µes Grau 3 (graves) foram especificamente rastreadas. Isso demonstra metodologia de vigil√¢ncia ativa estruturada, embora limitada a uma janela de 4 dias."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Preocupa√ß√µes de seguran√ßa neurol√≥gica s√£o abordadas, mas de forma incompleta. A S√≠ndrome de Guillain-Barr√© (SGB) √© mencionada como advert√™ncia, observando que se a SGB ocorreu dentro de 6 semanas de uma vacina pr√©via contendo toxoide tet√¢nico, a decis√£o de administrar HIBERIX deve ser baseada na an√°lise de risco-benef√≠cio. S√≠ncope com sinais neurol√≥gicos transit√≥rios (dist√∫rbio visual, parestesia, movimentos t√¥nico-cl√¥nicos dos membros) est√° documentada. Rea√ß√µes adversas graves inclu√≠ram 1 convuls√£o no Dia 14 ap√≥s a Dose 1 (1/2.963) e 1 nova crise febril no Dia 1 ap√≥s a Dose 4 (1/2.336). Relatos p√≥s-comercializa√ß√£o incluem convuls√µes (com ou sem febre) e epis√≥dios hipot√¥nico-hiporresponsivos. No entanto, n√£o h√° protocolo sistem√°tico de avalia√ß√£o neurol√≥gica ou acompanhamento neurol√≥gico a longo prazo descrito nos ensaios cl√≠nicos."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Algumas popula√ß√µes vulner√°veis s√£o abordadas, mas com limita√ß√µes. Beb√™s prematuros: Uma advert√™ncia observa que apneia ap√≥s vacina√ß√£o intramuscular foi observada em alguns beb√™s nascidos prematuramente, aconselhando avalia√ß√£o individual de risco-benef√≠cio. Crian√ßas imunocomprometidas: A bula afirma que seguran√ßa e efic√°cia em crian√ßas imunossuprimidas n√£o foram avaliadas, reconhecendo essa lacuna. A faixa et√°ria pedi√°trica √© especificamente definida (6 semanas a 4 anos). No entanto, o documento declara explicitamente que seguran√ßa e efic√°cia n√£o foram estabelecidas em crian√ßas menores de 6 semanas ou com idade entre 5-16 anos. Nenhum dado espec√≠fico √© fornecido para crian√ßas com doen√ßas cr√¥nicas ou outras condi√ß√µes de alto risco."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A bula fornece dados de seguran√ßa transparentes substanciais: tabelas detalhadas mostrando porcentagens de rea√ß√µes adversas por n√∫mero de dose e grau de gravidade; discrimina√ß√£o dos tamanhos de amostra para cada bra√ßo do estudo; informa√ß√µes demogr√°ficas (sexo, ra√ßa/etnia); identificador espec√≠fico do ensaio NCT (NCT01000974) para o Estudo 1; defini√ß√µes claras de escalas de gradua√ß√£o (por exemplo, dor Grau 3 definida como 'chorou quando o membro foi movido/dor espont√¢nea'); e limites de temperatura para defini√ß√µes de febre. Localiza√ß√µes geogr√°ficas dos estudos adicionais (Europa, Canad√°, Am√©rica Latina, Alemanha) s√£o divulgadas. No entanto, dados brutos e intervalos de confian√ßa para rea√ß√µes adversas n√£o s√£o fornecidos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 documenta experi√™ncia p√≥s-comercializa√ß√£o com rea√ß√µes adversas espec√≠ficas identificadas ap√≥s a aprova√ß√£o, incluindo: incha√ßo extenso do membro vacinado, endurecimento no local da inje√ß√£o, rea√ß√µes al√©rgicas (incluindo rea√ß√µes anafil√°ticas/anafilactoides), angioedema, convuls√µes (com ou sem febre), epis√≥dios hipot√¥nico-hiporresponsivos, sonol√™ncia, s√≠ncope, respostas vasovagais, apneia, erup√ß√£o cut√¢nea e urtic√°ria. A bula observa apropriadamente que o relato volunt√°rio torna imposs√≠vel estimar confiavelmente a frequ√™ncia ou estabelecer rela√ß√µes causais. Informa√ß√µes de relato ao VAERS s√£o fornecidas (1-800-822-7967). Contato do fabricante para relatos est√° inclu√≠do (GlaxoSmithKline em 1-888-825-5249)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "HIBERIX demonstra documenta√ß√£o de seguran√ßa adequada em v√°rias √°reas: tamanho de amostra pedi√°trica substancial (~4.000+ crian√ßas), compara√ß√£o controlada randomizada contra vacinas licenciadas, solicita√ß√£o ativa de rea√ß√µes adversas com gradua√ß√£o detalhada de gravidade, transpar√™ncia razo√°vel de dados com identificadores de ensaios publicados e vigil√¢ncia p√≥s-comercializa√ß√£o estabelecida. No entanto, existem limita√ß√µes significativas: a dura√ß√£o do acompanhamento √© criticamente curta (apenas 4 dias para rea√ß√µes solicitadas, 31 dias para eventos graves), sem monitoramento de seguran√ßa a longo prazo. O monitoramento neurol√≥gico capturou alguns eventos graves (convuls√µes, crises febris), mas carece de protocolos sistem√°ticos de avalia√ß√£o neurol√≥gica. Popula√ß√µes vulner√°veis como crian√ßas imunocomprometidas explicitamente carecem de dados de seguran√ßa. No geral, o perfil de seguran√ßa est√° razoavelmente documentado para rea√ß√µes comuns de curto prazo, mas √© insuficiente para detectar eventos adversos tardios ou raros."
        }
      }
    },
    {
      "id": "hib_acthib",
      "name": "ActHIB",
      "type": "Hib",
      "manufacturer": "Sanofi Pasteur",
      "description": "Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) for prevention of invasive disease caused by H. influenzae type b.",
      "sources": [
        "hib_acthib_insert.pdf",
        "hib_acthib_approval.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hib_acthib",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Clinical trials compared ActHIB to other Hib conjugate vaccines (PRP-OMP, HbOC) but no true placebo control group was used. The document states trials were conducted with OPV and whole-cell DTP vaccines administered concomitantly.",
            "level_description": "No placebo-controlled trials described. Comparisons were made between different Hib conjugate vaccines without an inert placebo arm."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not mention whether the clinical trials were double-blinded or single-blinded.",
            "level_description": "No information provided about blinding methodology in any of the clinical trials."
          },
          "randomization": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not explicitly describe randomization procedures for the clinical trials.",
            "level_description": "No details provided regarding randomization methodology in the clinical studies."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "More than 7,000 infants and young children (<=2 years of age) received at least one dose during US clinical trials. Study P3T06 enrolled 1,454 children. Immunogenicity studies included 65-167 subjects per vaccine group in comparative trials.",
            "level_description": "Large total sample size exceeding 7,000 participants, with the main safety study (P3T06) enrolling 1,454 children for doses 1-3 and 418 for dose 4."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Adverse reactions were monitored within 48 hours following immunization (Table 1) and within 0-3 days after vaccination (Table 2). Serious adverse events were monitored within 30 days following vaccination.",
            "level_description": "Short-term follow-up of 48 hours for solicited reactions and 30 days for serious adverse events. No long-term follow-up data provided."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies separated data for children 2-6 months of age (primary series), 12-15 months, 15-20 months, and 17-24 months of age. Table 5 provides separate immunogenicity data by age group.",
            "level_description": "Clinical data presented for distinct pediatric age groups appropriate to the vaccination schedule."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Contraindications listed include severe allergic reaction after previous dose and Guillain-Barre syndrome within 6 weeks of prior tetanus toxoid-containing vaccine. Limited information on trial-specific inclusion/exclusion criteria.",
            "level_description": "Some criteria mentioned in contraindications section but comprehensive trial inclusion/exclusion criteria not detailed."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Tables 1 and 2 provide standardized categories for local reactions (tenderness, erythema, induration, swelling) and systemic reactions (fever, irritability, drowsiness, anorexia, vomiting, crying) with defined severity levels.",
            "level_description": "Standardized solicited adverse event categories with defined timepoints and severity grading (moderate, severe definitions provided)."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "In Study P3T06, within 30 days following any of Doses 1-3, 50 of 1,455 (3.4%) participants experienced a serious adverse event (SAE). One SAE of seizure with apnea was possibly related.",
            "level_description": "SAEs monitored for 30 days post-vaccination but limited description of active surveillance methodology."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Guillain-Barre syndrome is mentioned as a warning/precaution. Postmarketing reports include convulsions. One SAE of seizure with apnea was reported as possibly related to vaccination.",
            "level_description": "GBS noted as precaution and convulsions in postmarketing, but no systematic pre-licensure monitoring for autoimmune/neurological conditions described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Immunogenicity data provided for children with sickle cell anemia and Alaskan Native Americans (who have higher disease rates and lower vaccine responses). Notes that immunosuppressed persons may not achieve expected antibody responses.",
            "level_description": "Some vulnerable populations studied (sickle cell, Native Americans) but limited safety data specific to these groups."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Geometric Mean Concentrations (GMC) and percentage of subjects achieving >=1.0 mcg/mL anti-PRP antibody levels reported. No confidence intervals or detailed statistical methodology described.",
            "level_description": "Basic descriptive statistics provided but no detailed statistical analysis plan or significance testing reported."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "References cite 'Data on file, Sanofi Pasteur SA' and 'Data on file, Sanofi Pasteur Inc.' for key supporting data. Published literature references provided for some studies.",
            "level_description": "Key data referenced as proprietary 'data on file' rather than publicly accessible. Some published literature cited."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 describes postmarketing spontaneous reports including anaphylaxis, hypersensitivity reactions, convulsions, and limb swelling. VAERS reporting information provided.",
            "level_description": "Postmarketing surveillance system in place with adverse events reported to manufacturer and VAERS."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not provide information about funding sources for clinical trials or potential conflicts of interest among investigators.",
            "level_description": "No disclosure of conflicts of interest or funding sources for clinical trials."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report all-cause mortality data from clinical trials. Only mentions 'no serious or life threatening adverse reactions' in 1,064 subjects.",
            "level_description": "No mortality data reported from clinical trials."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ActHIB clinical trials included substantial pediatric sample sizes (>7,000 children) with standardized adverse event monitoring and age-stratified data. However, trials lacked placebo controls (comparing only to other Hib vaccines), had short follow-up periods (48 hours to 30 days), and provided limited transparency with key data held as proprietary. No information on blinding, randomization, or mortality outcomes was provided."
        }
      },
      "trial_pt": {
        "vaccine_id": "hib_acthib",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os ensaios cl√≠nicos compararam ActHIB a outras vacinas conjugadas Hib (PRP-OMP, HbOC), mas nenhum grupo controle placebo verdadeiro foi usado. O documento afirma que os ensaios foram conduzidos com vacinas OPV e DTP de c√©lulas inteiras administradas concomitantemente.",
            "level_description": "Nenhum ensaio controlado por placebo descrito. As compara√ß√µes foram feitas entre diferentes vacinas conjugadas Hib sem um bra√ßo placebo inerte."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o menciona se os ensaios cl√≠nicos foram duplo-cegos ou simples-cegos.",
            "level_description": "Nenhuma informa√ß√£o fornecida sobre metodologia de cegamento em qualquer um dos ensaios cl√≠nicos."
          },
          "randomization": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o descreve explicitamente procedimentos de randomiza√ß√£o para os ensaios cl√≠nicos.",
            "level_description": "Nenhum detalhe fornecido sobre metodologia de randomiza√ß√£o nos estudos cl√≠nicos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Mais de 7.000 beb√™s e crian√ßas pequenas (<=2 anos de idade) receberam pelo menos uma dose durante ensaios cl√≠nicos nos EUA. O Estudo P3T06 incluiu 1.454 crian√ßas. Estudos de imunogenicidade inclu√≠ram 65-167 indiv√≠duos por grupo de vacina em ensaios comparativos.",
            "level_description": "Grande tamanho total de amostra excedendo 7.000 participantes, com o principal estudo de seguran√ßa (P3T06) incluindo 1.454 crian√ßas para doses 1-3 e 418 para dose 4."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes adversas foram monitoradas dentro de 48 horas ap√≥s imuniza√ß√£o (Tabela 1) e dentro de 0-3 dias ap√≥s vacina√ß√£o (Tabela 2). Eventos adversos graves foram monitorados dentro de 30 dias ap√≥s vacina√ß√£o.",
            "level_description": "Acompanhamento de curto prazo de 48 horas para rea√ß√µes solicitadas e 30 dias para eventos adversos graves. Nenhum dado de acompanhamento a longo prazo fornecido."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos separaram dados para crian√ßas de 2-6 meses de idade (s√©rie prim√°ria), 12-15 meses, 15-20 meses e 17-24 meses de idade. A Tabela 5 fornece dados de imunogenicidade separados por faixa et√°ria.",
            "level_description": "Dados cl√≠nicos apresentados para faixas et√°rias pedi√°tricas distintas apropriadas ao esquema de vacina√ß√£o."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As contraindica√ß√µes listadas incluem rea√ß√£o al√©rgica grave ap√≥s dose anterior e s√≠ndrome de Guillain-Barr√© dentro de 6 semanas de vacina pr√©via contendo toxoide tet√¢nico. Informa√ß√£o limitada sobre crit√©rios espec√≠ficos de inclus√£o/exclus√£o dos ensaios.",
            "level_description": "Alguns crit√©rios mencionados na se√ß√£o de contraindica√ß√µes, mas crit√©rios abrangentes de inclus√£o/exclus√£o dos ensaios n√£o detalhados."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "As Tabelas 1 e 2 fornecem categorias padronizadas para rea√ß√µes locais (sensibilidade, eritema, indura√ß√£o, incha√ßo) e rea√ß√µes sist√™micas (febre, irritabilidade, sonol√™ncia, anorexia, v√¥mitos, choro) com n√≠veis de gravidade definidos.",
            "level_description": "Categorias padronizadas de eventos adversos solicitados com pontos de tempo definidos e gradua√ß√£o de gravidade (defini√ß√µes de moderado, grave fornecidas)."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "No Estudo P3T06, dentro de 30 dias ap√≥s qualquer uma das Doses 1-3, 50 de 1.455 (3,4%) participantes experimentaram um evento adverso grave (EAG). Um EAG de convuls√£o com apneia foi possivelmente relacionado.",
            "level_description": "EAGs monitorados por 30 dias p√≥s-vacina√ß√£o, mas descri√ß√£o limitada da metodologia de vigil√¢ncia ativa."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A s√≠ndrome de Guillain-Barr√© √© mencionada como advert√™ncia/precau√ß√£o. Relatos p√≥s-comercializa√ß√£o incluem convuls√µes. Um EAG de convuls√£o com apneia foi relatado como possivelmente relacionado √† vacina√ß√£o.",
            "level_description": "SGB observada como precau√ß√£o e convuls√µes em p√≥s-comercializa√ß√£o, mas nenhum monitoramento sistem√°tico pr√©-licenciamento para condi√ß√µes autoimunes/neurol√≥gicas descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados de imunogenicidade fornecidos para crian√ßas com anemia falciforme e nativos americanos do Alasca (que t√™m maiores taxas de doen√ßa e menores respostas vacinais). Observa que pessoas imunossuprimidas podem n√£o alcan√ßar respostas de anticorpos esperadas.",
            "level_description": "Algumas popula√ß√µes vulner√°veis estudadas (anemia falciforme, nativos americanos), mas dados de seguran√ßa limitados espec√≠ficos para esses grupos."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Concentra√ß√µes m√©dias geom√©tricas (CMG) e porcentagem de indiv√≠duos atingindo >=1,0 mcg/mL de anticorpos anti-PRP relatados. Nenhum intervalo de confian√ßa ou metodologia estat√≠stica detalhada descrita.",
            "level_description": "Estat√≠sticas descritivas b√°sicas fornecidas, mas nenhum plano de an√°lise estat√≠stica detalhado ou teste de signific√¢ncia relatado."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Refer√™ncias citam 'Dados em arquivo, Sanofi Pasteur SA' e 'Dados em arquivo, Sanofi Pasteur Inc.' para dados de suporte chave. Refer√™ncias de literatura publicada fornecidas para alguns estudos.",
            "level_description": "Dados-chave referenciados como 'dados em arquivo' propriet√°rios em vez de publicamente acess√≠veis. Alguma literatura publicada citada."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 descreve relatos espont√¢neos p√≥s-comercializa√ß√£o incluindo anafilaxia, rea√ß√µes de hipersensibilidade, convuls√µes e incha√ßo de membro. Informa√ß√µes de relato ao VAERS fornecidas.",
            "level_description": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o em funcionamento com eventos adversos relatados ao fabricante e VAERS."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o fornece informa√ß√µes sobre fontes de financiamento para ensaios cl√≠nicos ou potenciais conflitos de interesse entre investigadores.",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse ou fontes de financiamento para ensaios cl√≠nicos."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas dos ensaios cl√≠nicos. Apenas menciona 'nenhuma rea√ß√£o adversa grave ou com risco de vida' em 1.064 indiv√≠duos.",
            "level_description": "Nenhum dado de mortalidade relatado dos ensaios cl√≠nicos."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Os ensaios cl√≠nicos de ActHIB inclu√≠ram tamanhos de amostra pedi√°trica substanciais (>7.000 crian√ßas) com monitoramento padronizado de eventos adversos e dados estratificados por idade. No entanto, os ensaios n√£o tinham controles placebo (comparando apenas com outras vacinas Hib), tinham per√≠odos de acompanhamento curtos (48 horas a 30 dias) e forneciam transpar√™ncia limitada com dados-chave mantidos como propriet√°rios. Nenhuma informa√ß√£o sobre cegamento, randomiza√ß√£o ou desfechos de mortalidade foi fornecida."
        }
      },
      "safety_en": {
        "vaccine_id": "hib_acthib",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "More than 7,000 infants and young children (<=2 years of age) received at least one dose of ActHIB during US clinical trials. The main safety study (P3T06) enrolled 1,454 children for doses 1-3 and followed 418 children for dose 4. Additionally, 1,064 subjects aged 12-24 months received ActHIB alone with no serious or life-threatening adverse reactions reported."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Safety follow-up was limited to 48 hours for solicited local and systemic reactions (Table 1) and 0-3 days for systemic reactions in Study P3T06 (Table 2). Serious adverse events were monitored for only 30 days following vaccination. No long-term safety follow-up data (months to years) was provided in the document."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Clinical trials compared ActHIB to other Haemophilus influenzae type b conjugate vaccines (PRP-OMP/PedvaxHIB and HbOC/HibTITER) but did not include a true placebo or unvaccinated control group. Vaccines were also administered concomitantly with DTP, OPV, and other vaccines, making it difficult to isolate ActHIB-specific safety signals."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Solicited adverse reactions were actively monitored at defined time points (6, 24, and 48 hours post-vaccination). However, the surveillance period was very short. SAEs were monitored within 30 days, with 50/1,455 (3.4%) experiencing SAEs after doses 1-3 and 4/418 (1.0%) after dose 4. One seizure with apnea was assessed as possibly related."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Guillain-Barre syndrome is listed as a warning/precaution if it occurred within 6 weeks of prior tetanus toxoid-containing vaccine. Convulsions are listed in postmarketing reports. One SAE of seizure with apnea was reported as possibly vaccine-related. However, systematic neurological monitoring protocols are not described in the clinical trials."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Immunogenicity data was collected for children with sickle cell anemia (89% achieved protective antibody levels after 2 doses) and Alaskan Native Americans (75% achieved protective levels). The document notes immunosuppressed persons may have reduced immune responses. However, detailed safety data specific to these vulnerable populations is limited."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Key supporting data is referenced as 'Data on file, Sanofi Pasteur SA' and 'Data on file, Sanofi Pasteur Inc.' which is not publicly accessible. Some clinical trial results are published in peer-reviewed literature (references 9-12). Tables provide percentage rates but limited raw numbers and no confidence intervals for safety outcomes."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 describes postmarketing surveillance with spontaneous reports of immune system disorders (anaphylaxis, urticaria, angioedema), nervous system disorders (convulsions), and general disorders (extensive limb swelling, peripheral edema, rash). VAERS reporting is enabled and contact information for reporting adverse reactions is provided (1-800-822-2463)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ActHIB has adequate pediatric safety data from over 7,000 trial participants and established postmarketing surveillance. However, significant limitations include: very short follow-up periods (48 hours to 30 days), lack of placebo-controlled trials, concomitant administration with multiple other vaccines confounding safety assessment, limited neurological monitoring protocols, and key data held as proprietary rather than publicly accessible. The absence of long-term safety follow-up is a notable gap."
        }
      },
      "safety_pt": {
        "vaccine_id": "hib_acthib",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Mais de 7.000 beb√™s e crian√ßas pequenas (<=2 anos de idade) receberam pelo menos uma dose de ActHIB durante ensaios cl√≠nicos nos EUA. O principal estudo de seguran√ßa (P3T06) incluiu 1.454 crian√ßas para doses 1-3 e acompanhou 418 crian√ßas para dose 4. Adicionalmente, 1.064 indiv√≠duos de 12-24 meses receberam ActHIB sozinha sem rea√ß√µes adversas graves ou com risco de vida relatadas."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O acompanhamento de seguran√ßa foi limitado a 48 horas para rea√ß√µes locais e sist√™micas solicitadas (Tabela 1) e 0-3 dias para rea√ß√µes sist√™micas no Estudo P3T06 (Tabela 2). Eventos adversos graves foram monitorados por apenas 30 dias ap√≥s vacina√ß√£o. Nenhum dado de acompanhamento de seguran√ßa a longo prazo (meses a anos) foi fornecido no documento."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Os ensaios cl√≠nicos compararam ActHIB a outras vacinas conjugadas Haemophilus influenzae tipo b (PRP-OMP/PedvaxHIB e HbOC/HibTITER), mas n√£o inclu√≠ram um grupo controle placebo verdadeiro ou n√£o vacinado. As vacinas tamb√©m foram administradas concomitantemente com DTP, OPV e outras vacinas, dificultando o isolamento de sinais de seguran√ßa espec√≠ficos de ActHIB."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Rea√ß√µes adversas solicitadas foram ativamente monitoradas em pontos de tempo definidos (6, 24 e 48 horas p√≥s-vacina√ß√£o). No entanto, o per√≠odo de vigil√¢ncia foi muito curto. EAGs foram monitorados dentro de 30 dias, com 50/1.455 (3,4%) experimentando EAGs ap√≥s doses 1-3 e 4/418 (1,0%) ap√≥s dose 4. Uma convuls√£o com apneia foi avaliada como possivelmente relacionada."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A s√≠ndrome de Guillain-Barr√© √© listada como advert√™ncia/precau√ß√£o se ocorreu dentro de 6 semanas de vacina pr√©via contendo toxoide tet√¢nico. Convuls√µes s√£o listadas em relatos p√≥s-comercializa√ß√£o. Um EAG de convuls√£o com apneia foi relatado como possivelmente relacionado √† vacina. No entanto, protocolos sistem√°ticos de monitoramento neurol√≥gico n√£o s√£o descritos nos ensaios cl√≠nicos."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados de imunogenicidade foram coletados para crian√ßas com anemia falciforme (89% atingiram n√≠veis protetores de anticorpos ap√≥s 2 doses) e nativos americanos do Alasca (75% atingiram n√≠veis protetores). O documento observa que pessoas imunossuprimidas podem ter respostas imunes reduzidas. No entanto, dados de seguran√ßa detalhados espec√≠ficos para essas popula√ß√µes vulner√°veis s√£o limitados."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados de suporte chave s√£o referenciados como 'Dados em arquivo, Sanofi Pasteur SA' e 'Dados em arquivo, Sanofi Pasteur Inc.' que n√£o s√£o publicamente acess√≠veis. Alguns resultados de ensaios cl√≠nicos s√£o publicados em literatura revisada por pares (refer√™ncias 9-12). As tabelas fornecem taxas percentuais, mas n√∫meros brutos limitados e nenhum intervalo de confian√ßa para desfechos de seguran√ßa."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 descreve vigil√¢ncia p√≥s-comercializa√ß√£o com relatos espont√¢neos de dist√∫rbios do sistema imune (anafilaxia, urtic√°ria, angioedema), dist√∫rbios do sistema nervoso (convuls√µes) e dist√∫rbios gerais (incha√ßo extenso de membro, edema perif√©rico, erup√ß√£o cut√¢nea). Relato ao VAERS est√° habilitado e informa√ß√µes de contato para relato de rea√ß√µes adversas s√£o fornecidas (1-800-822-2463)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "ActHIB possui dados de seguran√ßa pedi√°trica adequados de mais de 7.000 participantes de ensaios e vigil√¢ncia p√≥s-comercializa√ß√£o estabelecida. No entanto, limita√ß√µes significativas incluem: per√≠odos de acompanhamento muito curtos (48 horas a 30 dias), falta de ensaios controlados por placebo, administra√ß√£o concomitante com m√∫ltiplas outras vacinas confundindo a avalia√ß√£o de seguran√ßa, protocolos de monitoramento neurol√≥gico limitados e dados-chave mantidos como propriet√°rios em vez de publicamente acess√≠veis. A aus√™ncia de acompanhamento de seguran√ßa a longo prazo √© uma lacuna not√°vel."
        }
      }
    },
    {
      "id": "hib_pedvaxhib",
      "name": "PedvaxHIB",
      "type": "Hib",
      "manufacturer": "Merck",
      "description": "Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) for prevention of invasive disease caused by H. influenzae type b.",
      "sources": [
        "hib_pedvaxhib_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hib_pedvaxhib",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The Protective Efficacy Study was a randomized, double-blind, placebo-controlled study in 3,486 Native American (Navajo) infants. Each infant received two doses of either placebo or lyophilized PedvaxHIB. 22 cases of invasive Hib disease occurred in the placebo group vs. only 1 case in the vaccine group, demonstrating 93% protective efficacy (95% CI: 57%-98%, p=0.001).",
            "level_description": "True placebo control with saline/inert comparator used in the pivotal efficacy study."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The Protective Efficacy Study is explicitly described as a 'randomized, double-blind, placebo-controlled study' conducted in 3,486 Native American (Navajo) infants.",
            "level_description": "The pivotal efficacy trial employed double-blind methodology where neither participants nor investigators knew treatment assignment."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The document explicitly states that PedvaxHIB was evaluated in a 'randomized, double-blind, placebo-controlled study.' Additionally, a study of poor responders mentions '34 children...were randomly assigned to 2 groups.'",
            "level_description": "Randomization was used in the pivotal efficacy trial and in comparative studies."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The Protective Efficacy Study enrolled 3,486 Native American (Navajo) infants who completed the primary two-dose regimen. Additional studies: 903 infants in the Liquid vs Lyophilized comparison study; 4,459 healthy Navajo infants 6-12 weeks in the safety evaluation; 8,086 doses administered to 5,027 healthy infants and children in early clinical studies.",
            "level_description": "Very large pediatric sample sizes across multiple studies, totaling thousands of infants and children."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Most subjects in the efficacy study were initially followed until 15-18 months of age. At study termination, placebo recipients were offered vaccine and all participants were then followed for an additional 2 years and 9 months. Efficacy was 96.6% (95% CI: 72.2-99.9%) in children under 18 months and 100% (95% CI: 23.5-100%) in children over 18 months. Adverse reactions were monitored during a 3-day period following vaccination.",
            "level_description": "Extended follow-up for efficacy endpoints (nearly 3 years post-study), but safety follow-up was limited to 48-72 hours for most adverse events."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies evaluated different age groups: infants 2-6 months, 2-3 months initial vaccination with follow-up at 12-15 months and 24 months, children 15-71 months, and children 27-61 months (poor responders). TABLE 2 shows antibody responses by age timepoints. Vaccination regimens are specified by age group (2-10 months, 11-14 months, 15-71 months).",
            "level_description": "Age stratification was performed across multiple studies with different age cohorts analyzed."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document indicates subjects were 'healthy infants' from the 'general U.S. population' or 'healthy Navajo infants.' Contraindications include hypersensitivity to vaccine components. The document notes that immunocompromised individuals may not achieve expected immune response. Not recommended for infants younger than 6 weeks or individuals 6 years and older.",
            "level_description": "Basic inclusion criteria (healthy infants) are mentioned but detailed exclusion criteria for trials are not provided in the package insert."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Adverse reactions were systematically collected and reported by frequency (>1%). TABLE 5 provides standardized reporting of fever and local reactions at specific timepoints (6, 24, 48 hours) post-vaccination. Specific measurements included: fever >38.3C rectal, erythema >2.5 cm diameter, swelling >2.5 cm diameter. Most frequently reported reactions listed in decreasing order of frequency.",
            "level_description": "Standardized adverse event collection with defined criteria and timepoints, though primarily focused on short-term reactions."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "In the Protective Efficacy Study with 4,459 Navajo infants, 'No differences were seen in the type and frequency of serious health problems expected in this Navajo population or in serious adverse experiences reported.' One serious reaction (tracheitis) was reported as possibly related to vaccine. Seizures occurred infrequently in both vaccine (9 cases) and placebo (8 cases) groups. Parents reported observations over a 48-hour period.",
            "level_description": "Some active monitoring through parental reporting but limited duration; serious adverse events compared between groups."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Seizures were specifically tracked: 9 occurred in vaccine recipients (8 also received DTP) vs. 8 in placebo recipients (7 also received DTP), and were not reported to be related to vaccine. Guillain-Barre syndrome is mentioned as a potential adverse reaction associated with other Haemophilus b vaccines, though 'cause and effect relationship...was not established.' Febrile seizures are listed under post-marketing adverse reactions.",
            "level_description": "Limited neurological monitoring with seizure data reported. Autoimmune conditions not systematically monitored in trials but mentioned in post-marketing."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies specifically included high-risk populations: Native Americans (Navajo, Apache) who have higher Hib disease incidence and lower antibody response; children with genetic deficiencies (Km(1) allotype negative Blacks, G2m(23) allotype negative Caucasians); poor responders to nonconjugated PRP vaccines; premature infants are addressed in dosing. Multiple racial/ethnic groups analyzed separately (Tables 3 & 4).",
            "level_description": "Extensive evaluation of high-risk and vulnerable subpopulations including Native Americans, genetic subgroups, and poor responders."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Protective efficacy calculated at 93% with 95% confidence interval of 57%-98% (p=0.001, two-tailed). Between-dose difference was statistically significant (p=0.008, two-tailed). Extended follow-up efficacy: 96.6% (95% CI: 72.2-99.9%) in children under 18 months. Antibody levels reported with geometric mean titers (GMT) and percentage achieving threshold levels (>0.15 mcg/mL and >1.0 mcg/mL).",
            "level_description": "Appropriate statistical methods with confidence intervals and p-values reported for key efficacy outcomes."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Multiple references are provided citing published studies in peer-reviewed journals. Antibody data presented in detailed tables (Tables 1-5). However, some data noted as 'Data on file at Merck Research Laboratories' (Reference 33), indicating not all data is publicly available.",
            "level_description": "Key results published in peer-reviewed journals with supporting tables, but some data remains unpublished manufacturer data."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Post-Marketing Adverse Reactions section lists: lymphadenopathy, rarely angioedema, febrile seizures, sterile injection site abscess. Document instructs healthcare providers to report serious adverse reactions through VAERS (1-800-822-7967). Reference 37 cites post-marketing surveillance of another Hib vaccine; Reference 48 cites Institute of Medicine report on adverse events.",
            "level_description": "Post-marketing surveillance system in place with VAERS reporting and documented post-marketing adverse reactions."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not disclose conflicts of interest for study investigators or funding sources beyond identifying Merck & Co., Inc. as the manufacturer. Reference 33 cites 'Data on file at Merck Research Laboratories.'",
            "level_description": "No disclosure of conflicts of interest or funding sources for clinical trials in the package insert."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report all-cause mortality data from clinical trials. While the efficacy study followed participants for extended periods, mortality outcomes are not specifically reported. The document mentions the mortality rate from Hib meningitis is about 5% as background information.",
            "level_description": "All-cause mortality data not reported in the clinical trial sections of the package insert."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "PedvaxHIB demonstrates strong clinical trial evidence with a well-designed randomized, double-blind, placebo-controlled efficacy study showing 93% protective efficacy. Large sample sizes (3,486 in pivotal trial, thousands more across studies) and evaluation across multiple vulnerable subpopulations (Native Americans, genetic risk groups) are strengths. The trial methodology is exemplary for efficacy endpoints. Limitations include short-term safety follow-up (primarily 48-72 hours), absence of all-cause mortality data, limited transparency with some data remaining on file at manufacturer, and no conflict of interest disclosures. Post-marketing surveillance is established through VAERS."
        }
      },
      "trial_pt": {
        "vaccine_id": "hib_pedvaxhib",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O Estudo de Efic√°cia Protetora foi um estudo randomizado, duplo-cego, controlado por placebo em 3.486 beb√™s nativos americanos (Navajo). Cada beb√™ recebeu duas doses de placebo ou PedvaxHIB liofilizado. 22 casos de doen√ßa invasiva por Hib ocorreram no grupo placebo versus apenas 1 caso no grupo vacina, demonstrando efic√°cia protetora de 93% (IC 95%: 57%-98%, p=0,001).",
            "level_description": "Controle placebo verdadeiro com comparador salino/inerte usado no estudo de efic√°cia pivotal."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O Estudo de Efic√°cia Protetora √© explicitamente descrito como um 'estudo randomizado, duplo-cego, controlado por placebo' conduzido em 3.486 beb√™s nativos americanos (Navajo).",
            "level_description": "O ensaio de efic√°cia pivotal empregou metodologia duplo-cego onde nem participantes nem investigadores conheciam a atribui√ß√£o de tratamento."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O documento afirma explicitamente que PedvaxHIB foi avaliada em um 'estudo randomizado, duplo-cego, controlado por placebo.' Adicionalmente, um estudo de respondedores fracos menciona '34 crian√ßas... foram atribu√≠das aleatoriamente a 2 grupos.'",
            "level_description": "A randomiza√ß√£o foi usada no ensaio de efic√°cia pivotal e em estudos comparativos."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O Estudo de Efic√°cia Protetora incluiu 3.486 beb√™s nativos americanos (Navajo) que completaram o regime prim√°rio de duas doses. Estudos adicionais: 903 beb√™s no estudo de compara√ß√£o L√≠quido versus Liofilizado; 4.459 beb√™s Navajo saud√°veis de 6-12 semanas na avalia√ß√£o de seguran√ßa; 8.086 doses administradas a 5.027 beb√™s e crian√ßas saud√°veis em estudos cl√≠nicos iniciais.",
            "level_description": "Tamanhos de amostra pedi√°trica muito grandes em m√∫ltiplos estudos, totalizando milhares de beb√™s e crian√ßas."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A maioria dos indiv√≠duos no estudo de efic√°cia foi inicialmente acompanhada at√© 15-18 meses de idade. No t√©rmino do estudo, os receptores de placebo receberam oferta da vacina e todos os participantes foram ent√£o acompanhados por um per√≠odo adicional de 2 anos e 9 meses. A efic√°cia foi de 96,6% (IC 95%: 72,2-99,9%) em crian√ßas menores de 18 meses e 100% (IC 95%: 23,5-100%) em crian√ßas maiores de 18 meses. Rea√ß√µes adversas foram monitoradas durante um per√≠odo de 3 dias ap√≥s vacina√ß√£o.",
            "level_description": "Acompanhamento estendido para desfechos de efic√°cia (quase 3 anos p√≥s-estudo), mas acompanhamento de seguran√ßa foi limitado a 48-72 horas para a maioria dos eventos adversos."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudos avaliaram diferentes faixas et√°rias: beb√™s de 2-6 meses, vacina√ß√£o inicial de 2-3 meses com acompanhamento aos 12-15 meses e 24 meses, crian√ßas de 15-71 meses e crian√ßas de 27-61 meses (respondedores fracos). A TABELA 2 mostra respostas de anticorpos por pontos de tempo de idade. Regimes de vacina√ß√£o s√£o especificados por faixa et√°ria (2-10 meses, 11-14 meses, 15-71 meses).",
            "level_description": "A estratifica√ß√£o por idade foi realizada em m√∫ltiplos estudos com diferentes coortes et√°rios analisados."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento indica que os indiv√≠duos eram 'beb√™s saud√°veis' da 'popula√ß√£o geral dos EUA' ou 'beb√™s Navajo saud√°veis.' Contraindica√ß√µes incluem hipersensibilidade aos componentes da vacina. O documento observa que indiv√≠duos imunocomprometidos podem n√£o alcan√ßar a resposta imune esperada. N√£o recomendado para beb√™s menores de 6 semanas ou indiv√≠duos de 6 anos ou mais.",
            "level_description": "Crit√©rios b√°sicos de inclus√£o (beb√™s saud√°veis) s√£o mencionados, mas crit√©rios detalhados de exclus√£o para ensaios n√£o s√£o fornecidos na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes adversas foram sistematicamente coletadas e relatadas por frequ√™ncia (>1%). A TABELA 5 fornece relato padronizado de febre e rea√ß√µes locais em pontos de tempo espec√≠ficos (6, 24, 48 horas) p√≥s-vacina√ß√£o. Medi√ß√µes espec√≠ficas inclu√≠ram: febre >38,3C retal, eritema >2,5 cm de di√¢metro, incha√ßo >2,5 cm de di√¢metro. Rea√ß√µes mais frequentemente relatadas listadas em ordem decrescente de frequ√™ncia.",
            "level_description": "Coleta padronizada de eventos adversos com crit√©rios e pontos de tempo definidos, embora principalmente focada em rea√ß√µes de curto prazo."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "No Estudo de Efic√°cia Protetora com 4.459 beb√™s Navajo, 'Nenhuma diferen√ßa foi observada no tipo e frequ√™ncia de problemas de sa√∫de graves esperados nesta popula√ß√£o Navajo ou em experi√™ncias adversas graves relatadas.' Uma rea√ß√£o grave (traque√≠te) foi relatada como possivelmente relacionada √† vacina. Convuls√µes ocorreram infrequentemente em ambos os grupos vacina (9 casos) e placebo (8 casos). Os pais relataram observa√ß√µes durante um per√≠odo de 48 horas.",
            "level_description": "Algum monitoramento ativo atrav√©s de relatos dos pais, mas dura√ß√£o limitada; eventos adversos graves comparados entre grupos."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Convuls√µes foram especificamente rastreadas: 9 ocorreram em receptores da vacina (8 tamb√©m receberam DTP) versus 8 em receptores de placebo (7 tamb√©m receberam DTP), e n√£o foram relatadas como relacionadas √† vacina. A s√≠ndrome de Guillain-Barr√© √© mencionada como uma potencial rea√ß√£o adversa associada a outras vacinas Haemophilus b, embora 'rela√ß√£o de causa e efeito... n√£o tenha sido estabelecida.' Convuls√µes febris s√£o listadas sob rea√ß√µes adversas p√≥s-comercializa√ß√£o.",
            "level_description": "Monitoramento neurol√≥gico limitado com dados de convuls√µes relatados. Condi√ß√µes autoimunes n√£o monitoradas sistematicamente em ensaios, mas mencionadas em p√≥s-comercializa√ß√£o."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudos inclu√≠ram especificamente popula√ß√µes de alto risco: nativos americanos (Navajo, Apache) que t√™m maior incid√™ncia de doen√ßa Hib e menor resposta de anticorpos; crian√ßas com defici√™ncias gen√©ticas (negros Km(1) al√≥tipo negativos, caucasianos G2m(23) al√≥tipo negativos); respondedores fracos a vacinas PRP n√£o conjugadas; beb√™s prematuros s√£o abordados na dosagem. M√∫ltiplos grupos raciais/√©tnicos analisados separadamente (Tabelas 3 & 4).",
            "level_description": "Avalia√ß√£o extensiva de subpopula√ß√µes de alto risco e vulner√°veis incluindo nativos americanos, subgrupos gen√©ticos e respondedores fracos."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Efic√°cia protetora calculada em 93% com intervalo de confian√ßa de 95% de 57%-98% (p=0,001, bicaudal). A diferen√ßa entre doses foi estatisticamente significativa (p=0,008, bicaudal). Efic√°cia no acompanhamento estendido: 96,6% (IC 95%: 72,2-99,9%) em crian√ßas menores de 18 meses. N√≠veis de anticorpos relatados com t√≠tulos m√©dios geom√©tricos (TMG) e porcentagem atingindo n√≠veis limiares (>0,15 mcg/mL e >1,0 mcg/mL).",
            "level_description": "M√©todos estat√≠sticos apropriados com intervalos de confian√ßa e valores-p relatados para principais desfechos de efic√°cia."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "M√∫ltiplas refer√™ncias s√£o fornecidas citando estudos publicados em revistas revisadas por pares. Dados de anticorpos apresentados em tabelas detalhadas (Tabelas 1-5). No entanto, alguns dados indicados como 'Dados em arquivo nos Merck Research Laboratories' (Refer√™ncia 33), indicando que nem todos os dados s√£o publicamente dispon√≠veis.",
            "level_description": "Resultados-chave publicados em revistas revisadas por pares com tabelas de suporte, mas alguns dados permanecem como dados n√£o publicados do fabricante."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A se√ß√£o de Rea√ß√µes Adversas P√≥s-Comercializa√ß√£o lista: linfadenopatia, raramente angioedema, convuls√µes febris, abscesso est√©ril no local da inje√ß√£o. O documento instrui profissionais de sa√∫de a relatar rea√ß√µes adversas graves atrav√©s do VAERS (1-800-822-7967). A refer√™ncia 37 cita vigil√¢ncia p√≥s-comercializa√ß√£o de outra vacina Hib; a refer√™ncia 48 cita relat√≥rio do Instituto de Medicina sobre eventos adversos.",
            "level_description": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o em funcionamento com relato ao VAERS e rea√ß√µes adversas p√≥s-comercializa√ß√£o documentadas."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o divulga conflitos de interesse para investigadores do estudo ou fontes de financiamento al√©m de identificar Merck & Co., Inc. como fabricante. A refer√™ncia 33 cita 'Dados em arquivo nos Merck Research Laboratories.'",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse ou fontes de financiamento para ensaios cl√≠nicos na bula."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas dos ensaios cl√≠nicos. Embora o estudo de efic√°cia tenha acompanhado participantes por per√≠odos estendidos, desfechos de mortalidade n√£o s√£o especificamente relatados. O documento menciona que a taxa de mortalidade por meningite Hib √© de cerca de 5% como informa√ß√£o de contexto.",
            "level_description": "Dados de mortalidade por todas as causas n√£o relatados nas se√ß√µes de ensaios cl√≠nicos da bula."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "PedvaxHIB demonstra forte evid√™ncia de ensaio cl√≠nico com um estudo de efic√°cia randomizado, duplo-cego, controlado por placebo bem desenhado mostrando 93% de efic√°cia protetora. Grandes tamanhos de amostra (3.486 no ensaio pivotal, milhares mais em estudos) e avalia√ß√£o em m√∫ltiplas subpopula√ß√µes vulner√°veis (nativos americanos, grupos de risco gen√©tico) s√£o pontos fortes. A metodologia do ensaio √© exemplar para desfechos de efic√°cia. Limita√ß√µes incluem acompanhamento de seguran√ßa de curto prazo (principalmente 48-72 horas), aus√™ncia de dados de mortalidade por todas as causas, transpar√™ncia limitada com alguns dados permanecendo em arquivo no fabricante, e nenhuma divulga√ß√£o de conflitos de interesse. A vigil√¢ncia p√≥s-comercializa√ß√£o est√° estabelecida atrav√©s do VAERS."
        }
      },
      "safety_en": {
        "vaccine_id": "hib_pedvaxhib",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Very large pediatric safety database: 4,459 healthy Navajo infants 6-12 weeks of age in the Protective Efficacy Study; 903 infants (678 receiving Liquid PedvaxHIB with 1,699 total doses) in the comparative formulation study; 8,086 doses of lyophilized PedvaxHIB administered to 5,027 healthy infants and children 2-71 months in early clinical studies. Combined, safety data from thousands of infants and young children across multiple trials."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Safety follow-up was primarily limited to short-term periods: 48-hour period for parent-reported observations (TABLE 5), and 3-day period for adverse reaction collection. The Protective Efficacy Study followed subjects until 15-18 months of age initially, then for an additional 2 years 9 months, but this extended follow-up focused on efficacy (disease occurrence) rather than comprehensive safety monitoring. Long-term safety follow-up beyond acute reactions is not documented."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "The pivotal Protective Efficacy Study included a true placebo control group among the 4,459 Navajo infants, allowing direct comparison of adverse events between vaccine and placebo recipients. 'No differences were seen in the type and frequency of serious health problems expected in this Navajo population or in serious adverse experiences reported among those who received lyophilized PedvaxHIB and those who received placebo.' Seizures occurred at similar rates in both groups (9 vaccine vs. 8 placebo)."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance consisted of parent-reported observations over a 48-hour period post-vaccination with standardized measurements (fever, injection site reactions at 6, 24, and 48 hours). Systematic collection of adverse reactions during 3-day post-vaccination period. However, no active long-term surveillance system described for detecting delayed adverse events. Monitoring relied heavily on passive reporting and parent observations rather than clinical examinations."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Seizures were specifically tracked in the Protective Efficacy Study: 9 in vaccine recipients (8 also received DTP) vs. 8 in placebo recipients (7 also received DTP), 'not reported to be related to lyophilized PedvaxHIB.' Guillain-Barre syndrome mentioned as potential adverse reaction associated with other Hib vaccines. Post-marketing reports include febrile seizures. However, no systematic neurological assessment protocol described, and neurological outcomes not a primary endpoint."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Safety was evaluated in high-risk populations including Native Americans (Navajo, Apache) who have documented higher disease incidence. Immunogenicity (and by extension safety monitoring) studied in genetically-defined subgroups: Km(1) allotype negative Blacks and G2m(23) allotype negative Caucasians who are hyporesponsive to nonconjugated vaccines. Premature infants addressed with recommendation to vaccinate at same chronological age as full-term infants. Safety noted as similar across racial/ethnic groups studied."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Key safety data presented in TABLE 5 with specific percentages and timepoints. Adverse reaction frequencies reported (>1% threshold). Multiple references to published peer-reviewed studies provided. However, some data cited as 'Data on file at Merck Research Laboratories' (Reference 33), indicating not all safety data is publicly available. Individual patient-level data not accessible. Detailed adverse event rates beyond the most common reactions not fully disclosed."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Established post-marketing surveillance through VAERS (Vaccine Adverse Event Reporting System), with specific phone number provided (1-800-822-7967). Healthcare providers instructed to report serious adverse reactions. Post-marketing adverse reactions documented: lymphadenopathy, rarely angioedema, febrile seizures, sterile injection site abscess. References include Institute of Medicine report on adverse events (Reference 48) and post-marketing surveillance of related vaccine (Reference 37)."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "PedvaxHIB demonstrates adequate safety evidence with an exceptionally large pediatric database (thousands of infants across multiple studies) and a true placebo-controlled comparison group in the pivotal trial showing no difference in serious adverse events between vaccine and placebo groups. Key limitations include short-term active safety follow-up (primarily 48-72 hours), lack of systematic neurological assessment protocols, and incomplete data transparency with some data remaining proprietary. Post-marketing surveillance through VAERS is established with documented post-marketing adverse reactions. The safety profile appears favorable with no serious vaccine-related adverse reactions reported in clinical trials, though long-term safety monitoring data is limited."
        }
      },
      "safety_pt": {
        "vaccine_id": "hib_pedvaxhib",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Base de dados de seguran√ßa pedi√°trica muito grande: 4.459 beb√™s Navajo saud√°veis de 6-12 semanas de idade no Estudo de Efic√°cia Protetora; 903 beb√™s (678 recebendo PedvaxHIB L√≠quido com 1.699 doses totais) no estudo comparativo de formula√ß√£o; 8.086 doses de PedvaxHIB liofilizado administradas a 5.027 beb√™s e crian√ßas saud√°veis de 2-71 meses em estudos cl√≠nicos iniciais. Combinados, dados de seguran√ßa de milhares de beb√™s e crian√ßas pequenas em m√∫ltiplos ensaios."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O acompanhamento de seguran√ßa foi primariamente limitado a per√≠odos de curto prazo: per√≠odo de 48 horas para observa√ß√µes relatadas pelos pais (TABELA 5), e per√≠odo de 3 dias para coleta de rea√ß√µes adversas. O Estudo de Efic√°cia Protetora acompanhou indiv√≠duos at√© 15-18 meses de idade inicialmente, depois por um per√≠odo adicional de 2 anos e 9 meses, mas este acompanhamento estendido focou em efic√°cia (ocorr√™ncia de doen√ßa) em vez de monitoramento abrangente de seguran√ßa. Acompanhamento de seguran√ßa a longo prazo al√©m das rea√ß√µes agudas n√£o est√° documentado."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "O Estudo de Efic√°cia Protetora pivotal incluiu um grupo controle placebo verdadeiro entre os 4.459 beb√™s Navajo, permitindo compara√ß√£o direta de eventos adversos entre receptores de vacina e placebo. 'Nenhuma diferen√ßa foi observada no tipo e frequ√™ncia de problemas de sa√∫de graves esperados nesta popula√ß√£o Navajo ou em experi√™ncias adversas graves relatadas entre aqueles que receberam PedvaxHIB liofilizado e aqueles que receberam placebo.' Convuls√µes ocorreram em taxas similares em ambos os grupos (9 vacina versus 8 placebo)."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A vigil√¢ncia ativa consistiu em observa√ß√µes relatadas pelos pais durante um per√≠odo de 48 horas p√≥s-vacina√ß√£o com medi√ß√µes padronizadas (febre, rea√ß√µes no local da inje√ß√£o √†s 6, 24 e 48 horas). Coleta sistem√°tica de rea√ß√µes adversas durante per√≠odo de 3 dias p√≥s-vacina√ß√£o. No entanto, nenhum sistema de vigil√¢ncia ativa a longo prazo descrito para detectar eventos adversos tardios. O monitoramento dependeu fortemente de relatos passivos e observa√ß√µes dos pais em vez de exames cl√≠nicos."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Convuls√µes foram especificamente rastreadas no Estudo de Efic√°cia Protetora: 9 em receptores de vacina (8 tamb√©m receberam DTP) versus 8 em receptores de placebo (7 tamb√©m receberam DTP), 'n√£o relatadas como relacionadas a PedvaxHIB liofilizado.' A s√≠ndrome de Guillain-Barr√© mencionada como potencial rea√ß√£o adversa associada a outras vacinas Hib. Relatos p√≥s-comercializa√ß√£o incluem convuls√µes febris. No entanto, nenhum protocolo sistem√°tico de avalia√ß√£o neurol√≥gica descrito, e desfechos neurol√≥gicos n√£o foram um desfecho prim√°rio."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A seguran√ßa foi avaliada em popula√ß√µes de alto risco incluindo nativos americanos (Navajo, Apache) que t√™m incid√™ncia de doen√ßa documentadamente mais alta. Imunogenicidade (e por extens√£o monitoramento de seguran√ßa) estudada em subgrupos definidos geneticamente: negros Km(1) al√≥tipo negativos e caucasianos G2m(23) al√≥tipo negativos que s√£o hiporresponsivos a vacinas n√£o conjugadas. Beb√™s prematuros abordados com recomenda√ß√£o para vacinar na mesma idade cronol√≥gica que beb√™s a termo. Seguran√ßa observada como similar entre grupos raciais/√©tnicos estudados."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados-chave de seguran√ßa apresentados na TABELA 5 com porcentagens e pontos de tempo espec√≠ficos. Frequ√™ncias de rea√ß√µes adversas relatadas (limiar >1%). M√∫ltiplas refer√™ncias a estudos publicados em revistas revisadas por pares fornecidas. No entanto, alguns dados citados como 'Dados em arquivo nos Merck Research Laboratories' (Refer√™ncia 33), indicando que nem todos os dados de seguran√ßa s√£o publicamente dispon√≠veis. Dados de n√≠vel individual de paciente n√£o acess√≠veis. Taxas detalhadas de eventos adversos al√©m das rea√ß√µes mais comuns n√£o totalmente divulgadas."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Vigil√¢ncia p√≥s-comercializa√ß√£o estabelecida atrav√©s do VAERS (Sistema de Notifica√ß√£o de Eventos Adversos de Vacinas), com n√∫mero de telefone espec√≠fico fornecido (1-800-822-7967). Profissionais de sa√∫de instru√≠dos a relatar rea√ß√µes adversas graves. Rea√ß√µes adversas p√≥s-comercializa√ß√£o documentadas: linfadenopatia, raramente angioedema, convuls√µes febris, abscesso est√©ril no local da inje√ß√£o. Refer√™ncias incluem relat√≥rio do Instituto de Medicina sobre eventos adversos (Refer√™ncia 48) e vigil√¢ncia p√≥s-comercializa√ß√£o de vacina relacionada (Refer√™ncia 37)."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "PedvaxHIB demonstra evid√™ncia de seguran√ßa adequada com uma base de dados pedi√°trica excepcionalmente grande (milhares de beb√™s em m√∫ltiplos estudos) e um grupo de compara√ß√£o controlado por placebo verdadeiro no ensaio pivotal mostrando nenhuma diferen√ßa em eventos adversos graves entre grupos vacina e placebo. Limita√ß√µes-chave incluem acompanhamento de seguran√ßa ativo de curto prazo (principalmente 48-72 horas), falta de protocolos sistem√°ticos de avalia√ß√£o neurol√≥gica e transpar√™ncia de dados incompleta com alguns dados permanecendo propriet√°rios. A vigil√¢ncia p√≥s-comercializa√ß√£o atrav√©s do VAERS est√° estabelecida com rea√ß√µes adversas p√≥s-comercializa√ß√£o documentadas. O perfil de seguran√ßa parece favor√°vel sem rea√ß√µes adversas graves relacionadas √† vacina relatadas em ensaios cl√≠nicos, embora dados de monitoramento de seguran√ßa a longo prazo sejam limitados."
        }
      }
    },
    {
      "id": "dtap_daptacel",
      "name": "Daptacel",
      "type": "DTaP",
      "manufacturer": "Sanofi Pasteur",
      "description": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed for active immunization against diphtheria, tetanus, and pertussis.",
      "sources": [
        "dtap_daptacel_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "dtap_daptacel",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The Sweden I Efficacy Trial (1992-1995) compared DAPTACEL with DT vaccine (as placebo), whole-cell pertussis DTP, and another acellular pertussis vaccine. N=2,587 received DAPTACEL, N=2,574 received DT. However, DT is not an inert placebo (saline) - it contains diphtheria and tetanus toxoids which can cause their own reactions, potentially masking vaccine-specific adverse events.",
            "level_description": "DT vaccine used as comparator rather than true inert placebo (saline). This is a significant limitation as DT-associated reactions could obscure DAPTACEL-specific safety signals."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The Sweden I Efficacy Trial is described as 'a randomized, double-blinded pertussis vaccine efficacy trial.' The US studies also reference double-blinding for certain aspects.",
            "level_description": "Double-blind methodology explicitly stated for the primary efficacy trial, meeting expected standards for bias reduction."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The Sweden I Efficacy Trial is described as 'randomized.' The US 4-dose study states children 'Based on random assignment, the fourth dose of DAPTACEL was administered either alone; concomitantly with Hib conjugate...' However, allocation concealment methods are not explicitly described.",
            "level_description": "Randomization documented for main trials, though allocation concealment details are not provided."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Approximately 18,000 doses administered across 9 clinical studies. Sweden I Efficacy Trial: N=2,587 infants received DAPTACEL at 2, 4, and 6 months. US study: 1,454 children received 4 doses. Fifth dose studies: 485 DAPTACEL-primed and 989 Pentacel-primed children. Total of 4,998 children received 3 doses, 1,725 received 4 doses, 485 received 5 doses.",
            "level_description": "Sample size of ~2,500 in main efficacy trial approaches but does not exceed 3,000 per age group threshold. Adequate for detecting events at 1:1,000 frequency but may miss rarer events."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'diary card was kept for 14 days after each dose and follow-up telephone calls were made 1 and 14 days after each injection. Telephone calls were made monthly to monitor the occurrence of severe events and/or hospitalizations for the 2 months after the last injection.' Mean follow-up for efficacy was 2 years. US study: 'Serious adverse events were monitored during the three studies, through 6 months following the last dose of DAPTACEL.' Solicited events recorded for Days 0-7.",
            "level_description": "Active solicited monitoring only 14 days post-dose; serious events monitored 2 months (Sweden) to 6 months (US) post-last dose. While efficacy follow-up was 2 years, safety monitoring window of 6 months is inadequate for detecting autoimmune or neurological conditions that may emerge later."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Studies included infants at 2, 4, 6 months; toddlers at 15-17/15-20 months; and children at 4-6 years. Data presented separately by dose number (which correlates with age) in Tables 1, 2, and 3. However, separate comprehensive safety analyses for distinct age bands (0-1, 1-5, 6-12) are not explicitly provided.",
            "level_description": "Data presented by dose number which corresponds to different ages, but no explicit separate analysis by standard pediatric age groups (0-1, 1-5, 6-12 years)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Contraindications listed: severe allergic reaction after previous dose, encephalopathy within 7 days of prior pertussis vaccine, progressive neurologic disorder. Warnings mention children with history of seizures, premature infants (apnea risk), and immunocompromised individuals. US study demographics: 51.7% female, 77.2% Caucasian, 6.3% Black, 6.5% Hispanic, 0.9% Asian, 9.1% other. Fifth dose subjects were 'non-random subsets' of previous trial participants.",
            "level_description": "Basic demographic data provided. Children with neurologic disorders and severe allergic reactions excluded, which limits generalizability. Selection of fifth dose cohorts as 'non-random subsets' is a methodological limitation."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited events with defined thresholds: fever >=38.0C (rectal), redness >=2cm, swelling >=2cm, tenderness severity graded (moderate: cries when touched; severe: cries when limb moved). Systemic events defined: HHE (hypotonic-hyporesponsive episode), persistent crying >=3 hours, seizures within 72 hours, fever >=40C. Table 3 provides detailed severity grading definitions for each adverse event type.",
            "level_description": "Standardized definitions with objective thresholds (temperature, measurements in cm/mm) and severity grading criteria provided. Does not explicitly reference Brighton Collaboration criteria but uses consistent definitions."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'follow-up telephone calls were made 1 and 14 days after each injection. Telephone calls were made monthly to monitor the occurrence of severe events and/or hospitalizations for the 2 months after the last injection.' US study: 'Periodic telephone calls were made to inquire about adverse events. Serious adverse events were monitored during the three studies, through 6 months following the last dose.' SAEs reported: bronchiolitis (1.9%), pneumonia, meningitis, sepsis, pertussis, 1 death (aspiration 222 days post-vaccination in subject with ependymoma).",
            "level_description": "Active monitoring via telephone calls documented, but only for limited duration (2 months Sweden, 6 months US post-last dose). Causality investigation methodology not described in detail."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Seizures tracked: 'No seizures were reported within 3 days of vaccination with DAPTACEL. Over the entire study period, 6 seizures were reported in the DAPTACEL group' (rate 2.3 per 1,000). One case of infantile spasms reported. US study: 5 subjects (0.3%) experienced seizure within 60 days. Warnings reference Guillain-Barre syndrome (GBS) risk with tetanus toxoid, based on Institute of Medicine review. Encephalopathy is a contraindication. No systematic long-term neurological or autoimmune monitoring described.",
            "level_description": "Seizures and HHE actively monitored short-term. GBS mentioned as a known tetanus toxoid risk. However, no scheduled neurological examinations or long-term autoimmune surveillance described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Warnings section addresses: premature infants ('Apnea following intramuscular vaccination has been observed in some infants born prematurely'), immunocompromised individuals ('expected immune response may not be obtained'), children with history of seizures (recommend antipyretic). However, these groups appear to have been excluded from or not separately analyzed in trials rather than intentionally included.",
            "level_description": "Vulnerable populations acknowledged in warnings/precautions but appear excluded from trials rather than included with separate analysis. No data on premature infants, immunocompromised, or children with chronic conditions presented."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Efficacy: 84.9% (95% CI 80.1 to 88.6) against WHO-defined pertussis. Statistical comparisons made: 'p<0.001: DAPTACEL versus whole-cell pertussis DTP' for multiple endpoints. Table notes indicate statistical significance testing. Non-inferiority criteria mentioned for immunogenicity. However, no power calculation for safety outcomes documented; trials appear powered for efficacy, not safety.",
            "level_description": "Confidence intervals and p-values provided for efficacy and some comparisons. However, no documented power calculation for safety outcomes - a fundamental limitation common to vaccine trials."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I Efficacy Trial conducted 'under the sponsorship of the National Institute of Allergy and Infectious Diseases.' References to peer-reviewed publications and Institute of Medicine review. Summary data in tables but individual participant data not mentioned. No mention of independent Data Safety Monitoring Board (DSMB) or availability of raw data.",
            "level_description": "Government-sponsored trial with published results. Summary tables provided. No mention of DSMB, raw data availability, or individual participant data access."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.2 lists postmarketing adverse events 'spontaneously reported during the postmarketing use of DAPTACEL in the US and other countries.' Includes: lymphadenopathy, cyanosis, nausea, injection site reactions, cellulitis, hypersensitivity/anaphylactic reactions, convulsions (febrile, grand mal, partial), HHE, hypotonia, somnolence, syncope, screaming. States: 'Because these events are reported voluntarily from a population of uncertain size, it may not be possible to reliably estimate their frequency.'",
            "level_description": "Passive postmarketing surveillance via voluntary reporting (VAERS mentioned). Acknowledges limitation that frequency cannot be reliably estimated. No active pharmacovigilance system with periodic public reports mentioned."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Manufactured by Sanofi Pasteur Limited (Toronto). Sweden I Efficacy Trial sponsored by National Institute of Allergy and Infectious Diseases (government). US studies appear to be manufacturer-conducted. Whole-cell DTP comparator in Sweden I was Sanofi Pasteur Inc. product. No explicit conflict of interest disclosures for researchers.",
            "level_description": "Main efficacy trial had independent government sponsorship (NIAID). However, other studies appear manufacturer-conducted and no researcher conflict disclosures provided."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'There were no instances of invasive bacterial infection or death.' US 4-dose study: 'There was one death due to aspiration 222 days post-vaccination in a subject with ependymoma' (judged unrelated). Statement that 'no deaths' in Sweden trial but deaths in all comparison groups not explicitly enumerated for comparison.",
            "level_description": "Deaths reported (0 in Sweden I, 1 unrelated in US study). However, all-cause mortality/morbidity not systematically reported across all groups for comparison; focus on 'vaccine-related' determinations."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "DAPTACEL's safety evidence is based primarily on the Sweden I Efficacy Trial (1992-1995), a randomized, double-blind study of 2,587 infants, with supporting US data from approximately 1,454 additional children. Key methodological strengths include randomization, double-blinding, standardized adverse event definitions, and active short-term monitoring. However, significant limitations exist: DT vaccine rather than true saline placebo was used as comparator (masking potential reactions), follow-up for safety was limited to 6 months maximum, no power calculations for safety outcomes were documented, vulnerable subgroups were excluded rather than studied, and long-term neurological/autoimmune surveillance was absent. The postmarketing section relies on passive voluntary reporting which cannot establish incidence rates. While the document demonstrates DAPTACEL has a more favorable reactogenicity profile than whole-cell pertussis vaccines, the trial design limitations mean rare or delayed adverse events may not have been adequately detected."
        }
      },
      "trial_pt": {
        "vaccine_id": "dtap_daptacel",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Ensaio de Efic√°cia Sweden I (1992-1995) comparou o DAPTACEL com a vacina DT (como placebo), DTP de c√©lula inteira contra coqueluche e outra vacina acelular contra coqueluche. N=2.587 receberam DAPTACEL, N=2.574 receberam DT. No entanto, DT n√£o √© um placebo inerte (solu√ß√£o salina) - cont√©m toxoides de difteria e t√©tano que podem causar suas pr√≥prias rea√ß√µes, potencialmente mascarando eventos adversos espec√≠ficos da vacina.",
            "level_description": "Vacina DT usada como comparador em vez de placebo inerte verdadeiro (solu√ß√£o salina). Esta √© uma limita√ß√£o significativa, pois as rea√ß√µes associadas √† DT poderiam obscurecer os sinais de seguran√ßa espec√≠ficos do DAPTACEL."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Ensaio de Efic√°cia Sweden I √© descrito como 'um ensaio randomizado, duplo-cego de efic√°cia da vacina contra coqueluche'. Os estudos dos EUA tamb√©m referenciam duplo-cego para certos aspectos.",
            "level_description": "Metodologia duplo-cega explicitamente declarada para o ensaio de efic√°cia prim√°rio, atendendo aos padr√µes esperados para redu√ß√£o de vi√©s."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Ensaio de Efic√°cia Sweden I √© descrito como 'randomizado'. O estudo de 4 doses dos EUA afirma que as crian√ßas 'Com base na atribui√ß√£o aleat√≥ria, a quarta dose de DAPTACEL foi administrada sozinha; concomitantemente com conjugado Hib...' No entanto, os m√©todos de oculta√ß√£o da aloca√ß√£o n√£o s√£o explicitamente descritos.",
            "level_description": "Randomiza√ß√£o documentada para os ensaios principais, embora os detalhes de oculta√ß√£o da aloca√ß√£o n√£o sejam fornecidos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Aproximadamente 18.000 doses administradas em 9 estudos cl√≠nicos. Ensaio de Efic√°cia Sweden I: N=2.587 beb√™s receberam DAPTACEL aos 2, 4 e 6 meses. Estudo dos EUA: 1.454 crian√ßas receberam 4 doses. Estudos de quinta dose: 485 crian√ßas primed com DAPTACEL e 989 primed com Pentacel. Total de 4.998 crian√ßas receberam 3 doses, 1.725 receberam 4 doses, 485 receberam 5 doses.",
            "level_description": "O tamanho da amostra de ~2.500 no ensaio de efic√°cia principal se aproxima, mas n√£o excede o limite de 3.000 por faixa et√°ria. Adequado para detectar eventos com frequ√™ncia de 1:1.000, mas pode n√£o detectar eventos mais raros."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'cart√£o de di√°rio foi mantido por 14 dias ap√≥s cada dose e liga√ß√µes telef√¥nicas de acompanhamento foram feitas 1 e 14 dias ap√≥s cada inje√ß√£o. Liga√ß√µes telef√¥nicas foram feitas mensalmente para monitorar a ocorr√™ncia de eventos graves e/ou hospitaliza√ß√µes pelos 2 meses ap√≥s a √∫ltima inje√ß√£o.' O acompanhamento m√©dio para efic√°cia foi de 2 anos. Estudo dos EUA: 'Eventos adversos graves foram monitorados durante os tr√™s estudos, por 6 meses ap√≥s a √∫ltima dose de DAPTACEL.' Eventos solicitados registrados para os Dias 0-7.",
            "level_description": "Monitoramento ativo solicitado apenas 14 dias p√≥s-dose; eventos graves monitorados por 2 meses (Sweden) a 6 meses (EUA) p√≥s-√∫ltima dose. Embora o acompanhamento de efic√°cia tenha sido de 2 anos, a janela de monitoramento de seguran√ßa de 6 meses √© inadequada para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem surgir posteriormente."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os estudos inclu√≠ram beb√™s aos 2, 4, 6 meses; crian√ßas pequenas aos 15-17/15-20 meses; e crian√ßas aos 4-6 anos. Dados apresentados separadamente por n√∫mero de dose (que se correlaciona com a idade) nas Tabelas 1, 2 e 3. No entanto, an√°lises de seguran√ßa separadas e abrangentes para faixas et√°rias distintas (0-1, 1-5, 6-12) n√£o s√£o explicitamente fornecidas.",
            "level_description": "Dados apresentados por n√∫mero de dose que corresponde a diferentes idades, mas sem an√°lise expl√≠cita separada por grupos et√°rios pedi√°tricos padr√£o (0-1, 1-5, 6-12 anos)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Contraindica√ß√µes listadas: rea√ß√£o al√©rgica grave ap√≥s dose anterior, encefalopatia dentro de 7 dias ap√≥s vacina anterior contra coqueluche, dist√∫rbio neurol√≥gico progressivo. Advert√™ncias mencionam crian√ßas com hist√≥rico de convuls√µes, beb√™s prematuros (risco de apneia) e indiv√≠duos imunocomprometidos. Demografia do estudo dos EUA: 51,7% feminino, 77,2% caucasiano, 6,3% negro, 6,5% hisp√¢nico, 0,9% asi√°tico, 9,1% outros. Os sujeitos da quinta dose foram 'subconjuntos n√£o aleat√≥rios' de participantes de ensaios anteriores.",
            "level_description": "Dados demogr√°ficos b√°sicos fornecidos. Crian√ßas com dist√∫rbios neurol√≥gicos e rea√ß√µes al√©rgicas graves foram exclu√≠das, o que limita a generaliza√ß√£o. A sele√ß√£o de coortes da quinta dose como 'subconjuntos n√£o aleat√≥rios' √© uma limita√ß√£o metodol√≥gica."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos solicitados com limites definidos: febre >=38,0C (retal), vermelhid√£o >=2cm, incha√ßo >=2cm, sensibilidade graduada por gravidade (moderada: chora quando tocado; grave: chora quando o membro √© movido). Eventos sist√™micos definidos: EHH (epis√≥dio hipot√¥nico-hiporresponsivo), choro persistente >=3 horas, convuls√µes dentro de 72 horas, febre >=40C. A Tabela 3 fornece defini√ß√µes detalhadas de gradua√ß√£o de gravidade para cada tipo de evento adverso.",
            "level_description": "Defini√ß√µes padronizadas com limites objetivos (temperatura, medidas em cm/mm) e crit√©rios de gradua√ß√£o de gravidade fornecidos. N√£o referencia explicitamente os crit√©rios da Brighton Collaboration, mas usa defini√ß√µes consistentes."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'liga√ß√µes telef√¥nicas de acompanhamento foram feitas 1 e 14 dias ap√≥s cada inje√ß√£o. Liga√ß√µes telef√¥nicas foram feitas mensalmente para monitorar a ocorr√™ncia de eventos graves e/ou hospitaliza√ß√µes pelos 2 meses ap√≥s a √∫ltima inje√ß√£o.' Estudo dos EUA: 'Liga√ß√µes telef√¥nicas peri√≥dicas foram feitas para perguntar sobre eventos adversos. Eventos adversos graves foram monitorados durante os tr√™s estudos, por 6 meses ap√≥s a √∫ltima dose.' EAGs relatados: bronquiolite (1,9%), pneumonia, meningite, sepse, coqueluche, 1 √≥bito (aspira√ß√£o 222 dias p√≥s-vacina√ß√£o em sujeito com ependimoma).",
            "level_description": "Monitoramento ativo via liga√ß√µes telef√¥nicas documentado, mas apenas por dura√ß√£o limitada (2 meses Sweden, 6 meses EUA p√≥s-√∫ltima dose). Metodologia de investiga√ß√£o de causalidade n√£o descrita em detalhe."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Convuls√µes rastreadas: 'Nenhuma convuls√£o foi relatada dentro de 3 dias da vacina√ß√£o com DAPTACEL. Durante todo o per√≠odo do estudo, 6 convuls√µes foram relatadas no grupo DAPTACEL' (taxa 2,3 por 1.000). Um caso de espasmos infantis relatado. Estudo dos EUA: 5 sujeitos (0,3%) tiveram convuls√µes dentro de 60 dias. Advert√™ncias referenciam risco de s√≠ndrome de Guillain-Barre (SGB) com toxoide tet√¢nico, baseado na revis√£o do Institute of Medicine. Encefalopatia √© uma contraindica√ß√£o. Nenhum monitoramento neurol√≥gico ou autoimune sistem√°tico de longo prazo descrito.",
            "level_description": "Convuls√µes e EHH monitorados ativamente a curto prazo. SGB mencionada como risco conhecido do toxoide tet√¢nico. No entanto, nenhum exame neurol√≥gico agendado ou vigil√¢ncia autoimune de longo prazo descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de Advert√™ncias aborda: beb√™s prematuros ('Apneia ap√≥s vacina√ß√£o intramuscular foi observada em alguns beb√™s nascidos prematuramente'), indiv√≠duos imunocomprometidos ('a resposta imune esperada pode n√£o ser obtida'), crian√ßas com hist√≥rico de convuls√µes (recomenda antipir√©tico). No entanto, esses grupos parecem ter sido exclu√≠dos ou n√£o analisados separadamente nos ensaios, em vez de intencionalmente inclu√≠dos.",
            "level_description": "Popula√ß√µes vulner√°veis reconhecidas em advert√™ncias/precau√ß√µes, mas parecem exclu√≠das dos ensaios em vez de inclu√≠das com an√°lise separada. Nenhum dado sobre beb√™s prematuros, imunocomprometidos ou crian√ßas com condi√ß√µes cr√¥nicas apresentado."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Efic√°cia: 84,9% (IC 95% 80,1 a 88,6) contra coqueluche definida pela OMS. Compara√ß√µes estat√≠sticas feitas: 'p<0,001: DAPTACEL versus DTP de c√©lula inteira contra coqueluche' para m√∫ltiplos desfechos. Notas das tabelas indicam testes de signific√¢ncia estat√≠stica. Crit√©rios de n√£o inferioridade mencionados para imunogenicidade. No entanto, nenhum c√°lculo de poder para desfechos de seguran√ßa documentado; os ensaios parecem ter sido dimensionados para efic√°cia, n√£o para seguran√ßa.",
            "level_description": "Intervalos de confian√ßa e valores-p fornecidos para efic√°cia e algumas compara√ß√µes. No entanto, nenhum c√°lculo de poder documentado para desfechos de seguran√ßa - uma limita√ß√£o fundamental comum aos ensaios de vacinas."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Ensaio de Efic√°cia Sweden I conduzido 'sob o patroc√≠nio do National Institute of Allergy and Infectious Diseases.' Refer√™ncias a publica√ß√µes revisadas por pares e revis√£o do Institute of Medicine. Dados resumidos em tabelas, mas dados individuais de participantes n√£o mencionados. Nenhuma men√ß√£o de Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB) ou disponibilidade de dados brutos.",
            "level_description": "Ensaio patrocinado pelo governo com resultados publicados. Tabelas resumidas fornecidas. Nenhuma men√ß√£o de DSMB, disponibilidade de dados brutos ou acesso a dados individuais de participantes."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.2 lista eventos adversos p√≥s-comercializa√ß√£o 'relatados espontaneamente durante o uso p√≥s-comercializa√ß√£o do DAPTACEL nos EUA e outros pa√≠ses.' Inclui: linfadenopatia, cianose, n√°usea, rea√ß√µes no local da inje√ß√£o, celulite, rea√ß√µes de hipersensibilidade/anafil√°ticas, convuls√µes (febr√≠s, grande mal, parciais), EHH, hipotonia, sonol√™ncia, s√≠ncope, gritos. Afirma: 'Como esses eventos s√£o relatados voluntariamente de uma popula√ß√£o de tamanho incerto, pode n√£o ser poss√≠vel estimar sua frequ√™ncia de forma confi√°vel.'",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o passiva via relatos volunt√°rios (VAERS mencionado). Reconhece a limita√ß√£o de que a frequ√™ncia n√£o pode ser estimada de forma confi√°vel. Nenhum sistema de farmacovigil√¢ncia ativa com relat√≥rios p√∫blicos peri√≥dicos mencionado."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Fabricado por Sanofi Pasteur Limited (Toronto). Ensaio de Efic√°cia Sweden I patrocinado pelo National Institute of Allergy and Infectious Diseases (governo). Estudos dos EUA parecem ter sido conduzidos pelo fabricante. O comparador DTP de c√©lula inteira no Sweden I era produto da Sanofi Pasteur Inc. Nenhuma divulga√ß√£o expl√≠cita de conflitos de interesse dos pesquisadores.",
            "level_description": "O ensaio de efic√°cia principal teve patroc√≠nio governamental independente (NIAID). No entanto, outros estudos parecem conduzidos pelo fabricante e nenhuma divulga√ß√£o de conflitos dos pesquisadores fornecida."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Sweden I: 'N√£o houve casos de infec√ß√£o bacteriana invasiva ou morte.' Estudo de 4 doses dos EUA: 'Houve uma morte por aspira√ß√£o 222 dias p√≥s-vacina√ß√£o em um sujeito com ependimoma' (julgada n√£o relacionada). Declara√ß√£o de que 'nenhuma morte' no ensaio Sweden, mas mortes em todos os grupos de compara√ß√£o n√£o explicitamente enumeradas para compara√ß√£o.",
            "level_description": "Mortes relatadas (0 no Sweden I, 1 n√£o relacionada no estudo dos EUA). No entanto, mortalidade/morbidade por todas as causas n√£o relatada sistematicamente em todos os grupos para compara√ß√£o; foco em determina√ß√µes 'relacionadas √† vacina'."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A evid√™ncia de seguran√ßa do DAPTACEL √© baseada principalmente no Ensaio de Efic√°cia Sweden I (1992-1995), um estudo randomizado, duplo-cego de 2.587 beb√™s, com dados de apoio dos EUA de aproximadamente 1.454 crian√ßas adicionais. Os pontos fortes metodol√≥gicos principais incluem randomiza√ß√£o, duplo-cego, defini√ß√µes padronizadas de eventos adversos e monitoramento ativo de curto prazo. No entanto, existem limita√ß√µes significativas: vacina DT em vez de placebo salino verdadeiro foi usada como comparador (mascarando rea√ß√µes potenciais), o acompanhamento de seguran√ßa foi limitado a no m√°ximo 6 meses, nenhum c√°lculo de poder para desfechos de seguran√ßa foi documentado, subgrupos vulner√°veis foram exclu√≠dos em vez de estudados, e vigil√¢ncia neurol√≥gica/autoimune de longo prazo estava ausente. A se√ß√£o de p√≥s-comercializa√ß√£o depende de relatos volunt√°rios passivos que n√£o podem estabelecer taxas de incid√™ncia. Embora o documento demonstre que o DAPTACEL tem um perfil de reatogenicidade mais favor√°vel do que as vacinas de c√©lula inteira contra coqueluche, as limita√ß√µes do design do ensaio significam que eventos adversos raros ou tardios podem n√£o ter sido adequadamente detectados."
        }
      },
      "safety_en": {
        "vaccine_id": "dtap_daptacel",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Approximately 18,000 doses administered across 9 clinical studies. The Sweden I Efficacy Trial enrolled 2,587 infants who received DAPTACEL at 2, 4, and 6 months of age. US studies added 1,454 children receiving 4 doses, plus 485 (DAPTACEL-primed) and 989 (Pentacel-primed) children for fifth dose evaluation. While approaching the 3,000 threshold considered adequate for detecting 1:1,000 events, the sample size remains insufficient to reliably detect rarer events (1:10,000 or rarer). Total exposure of ~4,998 children receiving at least 3 doses provides reasonable but not comprehensive safety data."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Active solicited monitoring was limited to 14 days post-vaccination (Sweden I) and Days 0-7 (US studies). Serious adverse events were monitored for only 2 months after the last dose in Sweden I and 6 months in US studies. While efficacy follow-up extended to 2 years, safety monitoring was truncated. The 6-month maximum safety follow-up period is grossly inadequate for detecting autoimmune conditions, neurological disorders, or developmental effects that may take months or years to manifest. The ideal minimum of 12 months to several years of safety monitoring was not met."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The Sweden I Efficacy Trial used DT vaccine (diphtheria-tetanus without pertussis) as the comparator/placebo group (N=2,574), not a true inert placebo such as saline solution. DT vaccine contains aluminum adjuvant and active toxoids that can cause their own adverse reactions. This design choice makes it impossible to distinguish DAPTACEL-specific adverse events from those caused by the diphtheria and tetanus components shared between groups. While randomization and double-blinding were employed, the lack of a true inert placebo is a fundamental limitation that could mask the true adverse event rate of the vaccine."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance elements included: diary cards kept for 14 days post-dose, telephone follow-up at days 1 and 14 post-injection, monthly telephone calls for 2 months after the last dose (Sweden I), and periodic telephone calls with SAE monitoring for 6 months (US studies). Parents recorded solicited local and systemic events for 7-14 days. However, the active monitoring period was short (maximum 6 months post-series), no regular medical examinations or review of medical records was described, and causality investigation methodology for serious events was not detailed. Signs/symptoms of HHE were specifically solicited only for days 0-1 following the first three doses."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Seizures were tracked: no seizures within 3 days of DAPTACEL vaccination in Sweden I; 6 seizures over entire study period (2.3/1,000 vaccinees); one case of infantile spasms; 5 subjects (0.3%) with seizures within 60 days in US study. HHE (hypotonic-hyporesponsive episodes) were monitored: 1 case following dose 2, overall rate 0.047% with related HCPDT vaccine. Encephalopathy within 7 days is a contraindication. GBS risk acknowledged based on Institute of Medicine findings for tetanus toxoid. However, no scheduled developmental assessments, neurological examinations, or long-term surveillance for conditions like skill regression, autism spectrum disorders, or other neurodevelopmental outcomes was described."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Vulnerable populations are mentioned only in the Warnings and Precautions section, not as studied subgroups. Premature infants: apnea risk noted, but no safety data from premature infant studies presented. Immunocompromised children: warning that 'expected immune response may not be obtained' but no safety data. Children with seizure history: antipyretic recommended, but this group appears excluded. Children with progressive neurologic disorders: explicitly contraindicated (excluded). The fifth dose study cohorts were 'non-random subsets' of previous participants, raising selection bias concerns. No intentional inclusion or separate safety analysis of high-risk pediatric populations is documented."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The Sweden I Efficacy Trial was conducted under NIAID sponsorship with results published. Summary tables provide percentages and rates for common adverse events across multiple studies. Selected adverse events are presented by dose number and severity grade. However, no mention of an independent Data Safety Monitoring Board (DSMB), no access to individual participant data or raw datasets is indicated, and complete adverse event data beyond selected/solicited events is not provided. The document references peer-reviewed publications and Institute of Medicine reviews but does not provide mechanisms for independent verification of the primary data."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Section 6.2 lists spontaneously reported postmarketing adverse events including: lymphadenopathy, cyanosis, GI disorders, injection site reactions (pain, rash, nodule, mass, extensive limb swelling), cellulitis/abscess, hypersensitivity/anaphylaxis, various rashes, convulsions (febrile, grand mal, partial seizures), HHE, hypotonia, somnolence, syncope, and screaming. The document explicitly acknowledges the limitation: 'Because these events are reported voluntarily from a population of uncertain size, it may not be possible to reliably estimate their frequency or establish a causal relationship.' Relies on passive VAERS reporting; no active pharmacovigilance system or periodic safety update reports are mentioned."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The DAPTACEL package insert provides moderate but incomplete safety evidence for children. Strengths include a reasonably sized (~2,500) randomized, double-blind efficacy trial with standardized adverse event definitions and short-term active monitoring. The vaccine shows a more favorable reactogenicity profile compared to whole-cell pertussis vaccines. However, critical limitations undermine confidence in comprehensive safety: (1) no true saline placebo control - DT vaccine was used, masking potential adverse events from shared components; (2) safety follow-up of only 6 months maximum is inadequate for detecting delayed autoimmune or neurological conditions; (3) vulnerable subgroups (premature infants, immunocompromised, children with chronic conditions) were excluded rather than studied; (4) no long-term developmental or neurological surveillance was conducted; (5) postmarketing surveillance relies solely on passive voluntary reporting which vastly underestimates true adverse event rates. While the document demonstrates short-term tolerability in healthy infants, it does not provide the robust long-term safety data needed to fully answer whether this vaccine is safe for a child now and in the future."
        }
      },
      "safety_pt": {
        "vaccine_id": "dtap_daptacel",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Aproximadamente 18.000 doses administradas em 9 estudos cl√≠nicos. O Ensaio de Efic√°cia Sweden I incluiu 2.587 beb√™s que receberam DAPTACEL aos 2, 4 e 6 meses de idade. Estudos dos EUA adicionaram 1.454 crian√ßas recebendo 4 doses, mais 485 (primed com DAPTACEL) e 989 (primed com Pentacel) crian√ßas para avalia√ß√£o da quinta dose. Embora se aproxime do limite de 3.000 considerado adequado para detectar eventos de 1:1.000, o tamanho da amostra permanece insuficiente para detectar eventos mais raros (1:10.000 ou mais raros). A exposi√ß√£o total de ~4.998 crian√ßas recebendo pelo menos 3 doses fornece dados de seguran√ßa razo√°veis, mas n√£o abrangentes."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O monitoramento ativo solicitado foi limitado a 14 dias p√≥s-vacina√ß√£o (Sweden I) e Dias 0-7 (estudos dos EUA). Eventos adversos graves foram monitorados por apenas 2 meses ap√≥s a √∫ltima dose no Sweden I e 6 meses nos estudos dos EUA. Embora o acompanhamento de efic√°cia tenha se estendido a 2 anos, o monitoramento de seguran√ßa foi truncado. O per√≠odo m√°ximo de acompanhamento de seguran√ßa de 6 meses √© grosseiramente inadequado para detectar condi√ß√µes autoimunes, dist√∫rbios neurol√≥gicos ou efeitos no desenvolvimento que podem levar meses ou anos para se manifestar. O m√≠nimo ideal de 12 meses a v√°rios anos de monitoramento de seguran√ßa n√£o foi atendido."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O Ensaio de Efic√°cia Sweden I usou a vacina DT (difteria-t√©tano sem coqueluche) como grupo comparador/placebo (N=2.574), n√£o um placebo inerte verdadeiro como solu√ß√£o salina. A vacina DT cont√©m adjuvante de alum√≠nio e toxoides ativos que podem causar suas pr√≥prias rea√ß√µes adversas. Este design torna imposs√≠vel distinguir eventos adversos espec√≠ficos do DAPTACEL daqueles causados pelos componentes de difteria e t√©tano compartilhados entre os grupos. Embora randomiza√ß√£o e duplo-cego tenham sido empregados, a falta de um placebo inerte verdadeiro √© uma limita√ß√£o fundamental que poderia mascarar a verdadeira taxa de eventos adversos da vacina."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Elementos de vigil√¢ncia ativa inclu√≠ram: cart√µes de di√°rio mantidos por 14 dias p√≥s-dose, acompanhamento telef√¥nico nos dias 1 e 14 p√≥s-inje√ß√£o, liga√ß√µes telef√¥nicas mensais por 2 meses ap√≥s a √∫ltima dose (Sweden I), e liga√ß√µes telef√¥nicas peri√≥dicas com monitoramento de EAGs por 6 meses (estudos dos EUA). Os pais registraram eventos locais e sist√™micos solicitados por 7-14 dias. No entanto, o per√≠odo de monitoramento ativo foi curto (m√°ximo 6 meses p√≥s-s√©rie), nenhum exame m√©dico regular ou revis√£o de prontu√°rios foi descrito, e a metodologia de investiga√ß√£o de causalidade para eventos graves n√£o foi detalhada. Sinais/sintomas de EHH foram especificamente solicitados apenas para os dias 0-1 ap√≥s as tr√™s primeiras doses."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Convuls√µes foram rastreadas: nenhuma convuls√£o dentro de 3 dias da vacina√ß√£o com DAPTACEL no Sweden I; 6 convuls√µes durante todo o per√≠odo do estudo (2,3/1.000 vacinados); um caso de espasmos infantis; 5 sujeitos (0,3%) com convuls√µes dentro de 60 dias no estudo dos EUA. EHH (epis√≥dios hipot√¥nicos-hiporresponsivos) foram monitorados: 1 caso ap√≥s a dose 2, taxa geral de 0,047% com vacina HCPDT relacionada. Encefalopatia dentro de 7 dias √© uma contraindica√ß√£o. Risco de SGB reconhecido com base nos achados do Institute of Medicine para toxoide tet√¢nico. No entanto, nenhuma avalia√ß√£o de desenvolvimento agendada, exames neurol√≥gicos ou vigil√¢ncia de longo prazo para condi√ß√µes como regress√£o de habilidades, transtornos do espectro autista ou outros desfechos do neurodesenvolvimento foi descrita."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Popula√ß√µes vulner√°veis s√£o mencionadas apenas na se√ß√£o de Advert√™ncias e Precau√ß√µes, n√£o como subgrupos estudados. Beb√™s prematuros: risco de apneia observado, mas nenhum dado de seguran√ßa de estudos com beb√™s prematuros apresentado. Crian√ßas imunocomprometidas: advert√™ncia de que 'a resposta imune esperada pode n√£o ser obtida', mas sem dados de seguran√ßa. Crian√ßas com hist√≥rico de convuls√µes: antipir√©tico recomendado, mas este grupo parece exclu√≠do. Crian√ßas com dist√∫rbios neurol√≥gicos progressivos: explicitamente contraindicadas (exclu√≠das). As coortes do estudo da quinta dose foram 'subconjuntos n√£o aleat√≥rios' de participantes anteriores, levantando preocupa√ß√µes de vi√©s de sele√ß√£o. Nenhuma inclus√£o intencional ou an√°lise de seguran√ßa separada de popula√ß√µes pedi√°tricas de alto risco √© documentada."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O Ensaio de Efic√°cia Sweden I foi conduzido sob patroc√≠nio do NIAID com resultados publicados. Tabelas resumidas fornecem porcentagens e taxas para eventos adversos comuns em m√∫ltiplos estudos. Eventos adversos selecionados s√£o apresentados por n√∫mero de dose e grau de gravidade. No entanto, n√£o h√° men√ß√£o de um Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB), nenhum acesso a dados individuais de participantes ou conjuntos de dados brutos √© indicado, e dados completos de eventos adversos al√©m dos eventos selecionados/solicitados n√£o s√£o fornecidos. O documento referencia publica√ß√µes revisadas por pares e revis√µes do Institute of Medicine, mas n√£o fornece mecanismos para verifica√ß√£o independente dos dados prim√°rios."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A Se√ß√£o 6.2 lista eventos adversos p√≥s-comercializa√ß√£o relatados espontaneamente incluindo: linfadenopatia, cianose, dist√∫rbios GI, rea√ß√µes no local da inje√ß√£o (dor, erup√ß√£o, n√≥dulo, massa, incha√ßo extenso do membro), celulite/abscesso, hipersensibilidade/anafilaxia, v√°rias erup√ß√µes, convuls√µes (febr√≠s, grande mal, convuls√µes parciais), EHH, hipotonia, sonol√™ncia, s√≠ncope e gritos. O documento reconhece explicitamente a limita√ß√£o: 'Como esses eventos s√£o relatados voluntariamente de uma popula√ß√£o de tamanho incerto, pode n√£o ser poss√≠vel estimar sua frequ√™ncia de forma confi√°vel ou estabelecer uma rela√ß√£o causal.' Depende de relatos passivos do VAERS; nenhum sistema de farmacovigil√¢ncia ativa ou relat√≥rios de atualiza√ß√£o de seguran√ßa peri√≥dicos s√£o mencionados."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula do DAPTACEL fornece evid√™ncias de seguran√ßa moderadas, mas incompletas, para crian√ßas. Os pontos fortes incluem um ensaio de efic√°cia randomizado, duplo-cego de tamanho razo√°vel (~2.500) com defini√ß√µes padronizadas de eventos adversos e monitoramento ativo de curto prazo. A vacina mostra um perfil de reatogenicidade mais favor√°vel em compara√ß√£o com vacinas de c√©lula inteira contra coqueluche. No entanto, limita√ß√µes cr√≠ticas prejudicam a confian√ßa na seguran√ßa abrangente: (1) nenhum controle placebo salino verdadeiro - vacina DT foi usada, mascarando potenciais eventos adversos de componentes compartilhados; (2) acompanhamento de seguran√ßa de apenas 6 meses no m√°ximo √© inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas tardias; (3) subgrupos vulner√°veis (beb√™s prematuros, imunocomprometidos, crian√ßas com condi√ß√µes cr√¥nicas) foram exclu√≠dos em vez de estudados; (4) nenhuma vigil√¢ncia de desenvolvimento ou neurol√≥gica de longo prazo foi conduzida; (5) vigil√¢ncia p√≥s-comercializa√ß√£o depende exclusivamente de relatos volunt√°rios passivos que subestimam vastamente as verdadeiras taxas de eventos adversos. Embora o documento demonstre tolerabilidade de curto prazo em beb√™s saud√°veis, n√£o fornece os dados robustos de seguran√ßa de longo prazo necess√°rios para responder completamente se esta vacina √© segura para uma crian√ßa agora e no futuro."
        }
      }
    },
    {
      "id": "dtap_infanrix",
      "name": "Infanrix",
      "type": "DTaP",
      "manufacturer": "GlaxoSmithKline",
      "description": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed for active immunization against diphtheria, tetanus, and pertussis.",
      "sources": [
        "dtap_infanrix_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "dtap_infanrix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The Italian efficacy trial was 'DT-controlled' (Diphtheria and Tetanus Toxoids), not placebo-controlled. The German household contact study compared vaccinated vs unvaccinated household contacts but was not a randomized placebo-controlled trial. No inert placebo (saline) group was used in any study.",
            "level_description": "Using another vaccine (DT) as comparator obscures the true adverse event rate. While better than no control, this design cannot distinguish adverse events caused by the pertussis component from those caused by the DT components or baseline rates."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The Italian efficacy trial is described as 'double-blind, randomized.' However, follow-up periods from 24-33 months and 3-6 years were conducted 'partially unblinded' and 'unblinded' respectively. The German household contact study had a physician 'blinded to the vaccination status' but was not a double-blind RCT.",
            "level_description": "Initial blinding was present for the Italian trial but was compromised in extended follow-up periods, limiting the reliability of long-term safety and efficacy data."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The Italian efficacy trial is described as 'double-blind, randomized' with 4,481 infants vaccinated with INFANRIX and 1,470 DT vaccinees. The document does not describe allocation concealment methods.",
            "level_description": "Randomization was documented for the Italian efficacy trial. However, no details on allocation concealment or randomization methodology are provided."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Approximately 95,000 doses administered in clinical studies. 29,243 infants received INFANRIX in primary series studies; 6,081 children received fourth dose; 1,764 received fifth dose. Italian efficacy trial: 4,696 INFANRIX vs 4,678 whole-cell DTP. German safety study: 22,505 infants (66,867 doses).",
            "level_description": "Sample sizes exceed the 3,000 threshold needed to detect 1:1,000 events. The large German safety study (22,505 infants) is particularly noteworthy for safety monitoring."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Solicited adverse reactions collected for only 4 consecutive days following each vaccine dose. The Italian trial mean follow-up was 17 months beginning 30 days after third dose for efficacy. German study monitored unsolicited adverse events within 28 days following vaccination; subset monitored within 8 days. Extended Italian follow-up to 6 years was unblinded.",
            "level_description": "Active safety monitoring was extremely short (4 days for solicited reactions, 28 days for unsolicited). This is grossly inadequate for detecting autoimmune or neurological conditions that may emerge weeks or months later. The 6-12 month minimum is not met for safety monitoring."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Studies were conducted at different dose stages (primary series at 2,4,6 months; booster at 15-20 months; fifth dose at 4-6 years). However, separate age-stratified analysis (0-1 years, 1-5 years, 6-12 years) is not presented.",
            "level_description": "While different studies covered different dose schedules, no formal age-stratified analysis of safety outcomes is presented to account for developmental differences in immune response."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "No detailed inclusion/exclusion criteria are provided in the package insert. Demographic information is given (e.g., 69% White, 16% Hispanic, 8% Black in one U.S. study). The document notes contraindications for use but not trial enrollment criteria.",
            "level_description": "Limited demographic data is provided but no discussion of inclusion/exclusion criteria or generalizability limitations. It is unclear what populations were excluded from trials."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Standardized diary cards were used. Objective thresholds defined: Pain graded (Grade 2: cried/protested on touch; Grade 3: cried when limb moved), Fever thresholds (100.4F, 101.3F, 102.2F, 103.1F, 104F), Redness/swelling measured in mm (>20mm, >50mm, >110mm). Large swelling reactions defined with specific criteria.",
            "level_description": "Clear operational definitions and grading scales were used for solicited adverse events. This allows for consistent measurement and comparison across studies."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Solicited reactions collected via standardized diary cards for 4 days. Unsolicited adverse events monitored within 28 days in German study. Selected serious reactions (fever >=104F, hypotonic-hyporesponsive episodes, persistent crying >=3 hours, seizures) were reported from the Italian trial (Table 4). Report cards supplemented by 'spontaneous reporting by parents.'",
            "level_description": "Active monitoring was limited to a very short window (4 days for solicited, 28 days for unsolicited). While serious events were tracked, the combination of short duration and partial reliance on spontaneous reporting limits detection of serious adverse events."
          },
          "autoimmune_neurological": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Seizures reported: 1 in INFANRIX group (0.07/1,000 doses) vs 3 in whole-cell DTP (0.22/1,000) in Italian trial. German study reported afebrile seizure (0.13/1,000), febrile seizure (0.0/1,000). Hypotonic-hyporesponsive episodes: 0 in INFANRIX vs 9 in whole-cell DTP. Post-marketing lists encephalopathy, hypotonia, syncope. No systematic long-term neurological or autoimmune monitoring described.",
            "level_description": "Only seizures and hypotonic-hyporesponsive episodes were tracked in trials with no long-term scheduled neurological assessments. Guillain-Barre syndrome is mentioned only as a warning, not as a monitored endpoint. Autoimmune conditions were not specifically monitored."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Warnings section mentions premature infants (apnea risk) and children at higher risk for seizures. However, no specific trial data is presented for premature infants, immunocompromised children, or children with allergies/chronic conditions. Section 8.4 states safety in infants <6 weeks and children 7-16 years not established.",
            "level_description": "While precautions for vulnerable populations are mentioned, these groups were not intentionally included in trials with separate analysis of their outcomes."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Efficacy data includes 95% confidence intervals (e.g., 84% efficacy, 95% CI: 76, 89). P-values reported for some comparisons (P <0.001 for fever, P = 0.002 for hypotonic-hyporesponsive episodes). Modified intent-to-treat cohort used. No power calculation for safety outcomes documented.",
            "level_description": "Statistical analysis for efficacy is documented with confidence intervals and p-values. However, there is no evidence that studies were powered for safety outcomes rather than just efficacy, which is a fundamental limitation."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Results from multiple studies summarized in package insert. References cite published literature (Plotkin SA, etc.). No mention of independent Data Safety Monitoring Board (DSMB), raw data availability, or individual participant data access.",
            "level_description": "Summary data is provided but there is no indication of independent safety oversight, raw data availability, or mechanisms for independent verification of results."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.2 lists post-marketing adverse reactions including encephalopathy, hypotonia, syncope, anaphylactic reaction, thrombocytopenia, SIDS, and others. States these are 'reported voluntarily from a population of uncertain size' so 'not always possible to reliably estimate their frequency or establish a causal relationship.' Reporting to VAERS mentioned.",
            "level_description": "Post-marketing surveillance relies on passive voluntary reporting (VAERS), which vastly underestimates true adverse event rates. No active pharmacovigilance system or periodic safety reports are described."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document identifies GlaxoSmithKline as manufacturer and distributor. No disclosure of funding sources for clinical trials, financial ties of investigators, or independence of data analysis is provided.",
            "level_description": "No information on conflicts of interest or funding sources for the clinical trials. The vaccine is manufactured by GSK, but there is no disclosure about whether trials were independently conducted or analyzed."
          },
          "all_cause_mortality": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "SIDS (Sudden Infant Death Syndrome) is listed as a post-marketing reported event. No all-cause mortality data from clinical trials is presented. No total deaths or hospitalizations reported across treatment groups.",
            "level_description": "The document does not report all-cause mortality or total hospitalizations from clinical trials. Only vaccine-related serious events are partially reported, which can miss overall harm if causality determination is subjective."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The INFANRIX package insert documents clinical trials with substantial sample sizes (29,243 infants in primary series, 22,505 in German safety study) and demonstrates efficacy against pertussis (84% efficacy in Italian trial). However, significant methodological limitations exist for safety assessment: (1) No true placebo control - trials used DT or whole-cell DTP as comparators; (2) Extremely short active safety monitoring (4 days for solicited reactions); (3) No systematic long-term monitoring for autoimmune or neurological conditions; (4) No all-cause mortality data reported; (5) Post-marketing surveillance relies on passive reporting systems; (6) No disclosure of conflicts of interest or independent safety oversight. While the vaccine has demonstrated efficacy and shows a better short-term safety profile than whole-cell pertussis vaccines, the evidence base for long-term safety in children is limited by study design choices that prioritize efficacy over comprehensive safety assessment."
        }
      },
      "trial_pt": {
        "vaccine_id": "dtap_infanrix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O ensaio de efic√°cia italiano foi 'controlado por DT' (Toxoides de Difteria e T√©tano), n√£o controlado por placebo. O estudo alem√£o de contato domiciliar comparou contatos domiciliares vacinados versus n√£o vacinados, mas n√£o foi um ensaio cl√≠nico randomizado controlado por placebo. Nenhum grupo placebo inerte (solu√ß√£o salina) foi usado em qualquer estudo.",
            "level_description": "Usar outra vacina (DT) como comparador obscurece a verdadeira taxa de eventos adversos. Embora melhor do que nenhum controle, este design n√£o pode distinguir eventos adversos causados pelo componente da coqueluche daqueles causados pelos componentes DT ou taxas basais."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O ensaio de efic√°cia italiano √© descrito como 'duplo-cego, randomizado'. No entanto, os per√≠odos de acompanhamento de 24-33 meses e 3-6 anos foram conduzidos 'parcialmente n√£o cegados' e 'n√£o cegados', respectivamente. O estudo alem√£o de contato domiciliar teve um m√©dico 'cego para o estado de vacina√ß√£o', mas n√£o foi um ECR duplo-cego.",
            "level_description": "O cegamento inicial estava presente para o ensaio italiano, mas foi comprometido em per√≠odos de acompanhamento estendido, limitando a confiabilidade dos dados de seguran√ßa e efic√°cia de longo prazo."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O ensaio de efic√°cia italiano √© descrito como 'duplo-cego, randomizado' com 4.481 beb√™s vacinados com INFANRIX e 1.470 vacinados com DT. O documento n√£o descreve m√©todos de oculta√ß√£o da aloca√ß√£o.",
            "level_description": "A randomiza√ß√£o foi documentada para o ensaio de efic√°cia italiano. No entanto, nenhum detalhe sobre oculta√ß√£o da aloca√ß√£o ou metodologia de randomiza√ß√£o √© fornecido."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Aproximadamente 95.000 doses administradas em estudos cl√≠nicos. 29.243 beb√™s receberam INFANRIX em estudos da s√©rie prim√°ria; 6.081 crian√ßas receberam a quarta dose; 1.764 receberam a quinta dose. Ensaio de efic√°cia italiano: 4.696 INFANRIX vs 4.678 DTP de c√©lula inteira. Estudo de seguran√ßa alem√£o: 22.505 beb√™s (66.867 doses).",
            "level_description": "Os tamanhos das amostras excedem o limite de 3.000 necess√°rio para detectar eventos de 1:1.000. O grande estudo de seguran√ßa alem√£o (22.505 beb√™s) √© particularmente not√°vel para monitoramento de seguran√ßa."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Rea√ß√µes adversas solicitadas coletadas por apenas 4 dias consecutivos ap√≥s cada dose de vacina. O ensaio italiano teve acompanhamento m√©dio de 17 meses come√ßando 30 dias ap√≥s a terceira dose para efic√°cia. O estudo alem√£o monitorou eventos adversos n√£o solicitados dentro de 28 dias ap√≥s a vacina√ß√£o; um subconjunto foi monitorado dentro de 8 dias. O acompanhamento italiano estendido at√© 6 anos foi n√£o cegado.",
            "level_description": "O monitoramento ativo de seguran√ßa foi extremamente curto (4 dias para rea√ß√µes solicitadas, 28 dias para n√£o solicitadas). Isso √© grosseiramente inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem surgir semanas ou meses depois. O m√≠nimo de 6-12 meses n√£o √© atendido para monitoramento de seguran√ßa."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os estudos foram conduzidos em diferentes est√°gios de doses (s√©rie prim√°ria aos 2, 4, 6 meses; refor√ßo aos 15-20 meses; quinta dose aos 4-6 anos). No entanto, an√°lise separada estratificada por idade (0-1 anos, 1-5 anos, 6-12 anos) n√£o √© apresentada.",
            "level_description": "Embora diferentes estudos tenham coberto diferentes esquemas de doses, nenhuma an√°lise formal estratificada por idade dos desfechos de seguran√ßa √© apresentada para considerar diferen√ßas de desenvolvimento na resposta imune."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Nenhum crit√©rio detalhado de inclus√£o/exclus√£o √© fornecido na bula. Informa√ß√µes demogr√°ficas s√£o fornecidas (ex., 69% brancos, 16% hisp√¢nicos, 8% negros em um estudo dos EUA). O documento observa contraindica√ß√µes para uso, mas n√£o crit√©rios de inscri√ß√£o no ensaio.",
            "level_description": "Dados demogr√°ficos limitados s√£o fornecidos, mas sem discuss√£o de crit√©rios de inclus√£o/exclus√£o ou limita√ß√µes de generaliza√ß√£o. N√£o est√° claro quais popula√ß√µes foram exclu√≠das dos ensaios."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Cart√µes de di√°rio padronizados foram usados. Limites objetivos definidos: Dor graduada (Grau 2: chorou/protestou ao toque; Grau 3: chorou quando o membro foi movido), Limites de febre (38,0¬∞C, 38,5¬∞C, 39,0¬∞C, 39,5¬∞C, 40,0¬∞C), Vermelhid√£o/incha√ßo medidos em mm (>20mm, >50mm, >110mm). Rea√ß√µes de incha√ßo grande definidas com crit√©rios espec√≠ficos.",
            "level_description": "Defini√ß√µes operacionais claras e escalas de gradua√ß√£o foram usadas para eventos adversos solicitados. Isso permite medi√ß√£o consistente e compara√ß√£o entre estudos."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes solicitadas coletadas via cart√µes de di√°rio padronizados por 4 dias. Eventos adversos n√£o solicitados monitorados dentro de 28 dias no estudo alem√£o. Rea√ß√µes graves selecionadas (febre >=40¬∞C, epis√≥dios hipot√¥nicos-hiporresponsivos, choro persistente >=3 horas, convuls√µes) foram relatadas do ensaio italiano (Tabela 4). Cart√µes de relato complementados por 'relatos espont√¢neos dos pais.'",
            "level_description": "O monitoramento ativo foi limitado a uma janela muito curta (4 dias para solicitados, 28 dias para n√£o solicitados). Embora eventos graves tenham sido rastreados, a combina√ß√£o de curta dura√ß√£o e depend√™ncia parcial de relatos espont√¢neos limita a detec√ß√£o de eventos adversos graves."
          },
          "autoimmune_neurological": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Convuls√µes relatadas: 1 no grupo INFANRIX (0,07/1.000 doses) vs 3 no DTP de c√©lula inteira (0,22/1.000) no ensaio italiano. Estudo alem√£o relatou convuls√£o afebril (0,13/1.000), convuls√£o febril (0,0/1.000). Epis√≥dios hipot√¥nicos-hiporresponsivos: 0 no INFANRIX vs 9 no DTP de c√©lula inteira. P√≥s-comercializa√ß√£o lista encefalopatia, hipotonia, s√≠ncope. Nenhum monitoramento neurol√≥gico ou autoimune sistem√°tico de longo prazo descrito.",
            "level_description": "Apenas convuls√µes e epis√≥dios hipot√¥nicos-hiporresponsivos foram rastreados nos ensaios sem avalia√ß√µes neurol√≥gicas agendadas de longo prazo. A s√≠ndrome de Guillain-Barre √© mencionada apenas como advert√™ncia, n√£o como desfecho monitorado. Condi√ß√µes autoimunes n√£o foram especificamente monitoradas."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de Advert√™ncias menciona beb√™s prematuros (risco de apneia) e crian√ßas com maior risco de convuls√µes. No entanto, nenhum dado espec√≠fico de ensaio √© apresentado para beb√™s prematuros, crian√ßas imunocomprometidas ou crian√ßas com alergias/condi√ß√µes cr√¥nicas. A Se√ß√£o 8.4 afirma que a seguran√ßa em beb√™s <6 semanas e crian√ßas de 7-16 anos n√£o foi estabelecida.",
            "level_description": "Embora precau√ß√µes para popula√ß√µes vulner√°veis sejam mencionadas, esses grupos n√£o foram intencionalmente inclu√≠dos nos ensaios com an√°lise separada de seus desfechos."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados de efic√°cia incluem intervalos de confian√ßa de 95% (ex., efic√°cia de 84%, IC 95%: 76, 89). Valores-p relatados para algumas compara√ß√µes (P <0,001 para febre, P = 0,002 para epis√≥dios hipot√¥nicos-hiporresponsivos). Coorte de inten√ß√£o de tratar modificada usada. Nenhum c√°lculo de poder para desfechos de seguran√ßa documentado.",
            "level_description": "An√°lise estat√≠stica para efic√°cia √© documentada com intervalos de confian√ßa e valores-p. No entanto, n√£o h√° evid√™ncia de que os estudos foram dimensionados para desfechos de seguran√ßa e n√£o apenas para efic√°cia, o que √© uma limita√ß√£o fundamental."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Resultados de m√∫ltiplos estudos resumidos na bula. Refer√™ncias citam literatura publicada (Plotkin SA, etc.). Nenhuma men√ß√£o de Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB), disponibilidade de dados brutos ou acesso a dados individuais de participantes.",
            "level_description": "Dados resumidos s√£o fornecidos, mas n√£o h√° indica√ß√£o de supervis√£o de seguran√ßa independente, disponibilidade de dados brutos ou mecanismos para verifica√ß√£o independente dos resultados."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.2 lista rea√ß√µes adversas p√≥s-comercializa√ß√£o incluindo encefalopatia, hipotonia, s√≠ncope, rea√ß√£o anafil√°tica, trombocitopenia, SMSI (s√≠ndrome da morte s√∫bita infantil) e outros. Afirma que estes s√£o 'relatados voluntariamente de uma popula√ß√£o de tamanho incerto', ent√£o 'nem sempre √© poss√≠vel estimar sua frequ√™ncia de forma confi√°vel ou estabelecer uma rela√ß√£o causal.' Relato ao VAERS mencionado.",
            "level_description": "A vigil√¢ncia p√≥s-comercializa√ß√£o depende de relatos volunt√°rios passivos (VAERS), que subestimam vastamente as verdadeiras taxas de eventos adversos. Nenhum sistema de farmacovigil√¢ncia ativa ou relat√≥rios de seguran√ßa peri√≥dicos s√£o descritos."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento identifica a GlaxoSmithKline como fabricante e distribuidora. Nenhuma divulga√ß√£o de fontes de financiamento para ensaios cl√≠nicos, v√≠nculos financeiros dos investigadores ou independ√™ncia da an√°lise de dados √© fornecida.",
            "level_description": "Nenhuma informa√ß√£o sobre conflitos de interesse ou fontes de financiamento para os ensaios cl√≠nicos. A vacina √© fabricada pela GSK, mas n√£o h√° divulga√ß√£o sobre se os ensaios foram conduzidos ou analisados de forma independente."
          },
          "all_cause_mortality": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "SMSI (S√≠ndrome da Morte S√∫bita Infantil) √© listada como evento relatado na p√≥s-comercializa√ß√£o. Nenhum dado de mortalidade por todas as causas dos ensaios cl√≠nicos √© apresentado. Nenhum total de mortes ou hospitaliza√ß√µes relatado entre os grupos de tratamento.",
            "level_description": "O documento n√£o relata mortalidade por todas as causas ou hospitaliza√ß√µes totais dos ensaios cl√≠nicos. Apenas eventos graves relacionados √† vacina s√£o parcialmente relatados, o que pode perder danos gerais se a determina√ß√£o de causalidade for subjetiva."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula do INFANRIX documenta ensaios cl√≠nicos com tamanhos de amostra substanciais (29.243 beb√™s na s√©rie prim√°ria, 22.505 no estudo de seguran√ßa alem√£o) e demonstra efic√°cia contra coqueluche (84% de efic√°cia no ensaio italiano). No entanto, existem limita√ß√µes metodol√≥gicas significativas para avalia√ß√£o de seguran√ßa: (1) Nenhum controle placebo verdadeiro - ensaios usaram DT ou DTP de c√©lula inteira como comparadores; (2) Monitoramento ativo de seguran√ßa extremamente curto (4 dias para rea√ß√µes solicitadas); (3) Nenhum monitoramento sistem√°tico de longo prazo para condi√ß√µes autoimunes ou neurol√≥gicas; (4) Nenhum dado de mortalidade por todas as causas relatado; (5) Vigil√¢ncia p√≥s-comercializa√ß√£o depende de sistemas de relato passivo; (6) Nenhuma divulga√ß√£o de conflitos de interesse ou supervis√£o de seguran√ßa independente. Embora a vacina tenha demonstrado efic√°cia e mostre um perfil de seguran√ßa de curto prazo melhor do que vacinas de c√©lula inteira contra coqueluche, a base de evid√™ncias para seguran√ßa de longo prazo em crian√ßas √© limitada por escolhas de design de estudo que priorizam efic√°cia sobre avalia√ß√£o abrangente de seguran√ßa."
        }
      },
      "safety_en": {
        "vaccine_id": "dtap_infanrix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Approximately 95,000 doses administered in clinical studies with 29,243 infants in primary series studies. German safety study enrolled 22,505 infants (66,867 doses). Italian efficacy trial included 4,696 children receiving INFANRIX. These numbers exceed the 3,000 threshold needed to detect adverse events occurring at 1:1,000 frequency, though rarer events (1:10,000 or less) would still be missed."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Solicited adverse reactions were collected for only 4 consecutive days following each vaccine dose (day of vaccination plus next 3 days). Unsolicited adverse events monitored for 28 days in the German study, with a subset monitored for 8 days. This is grossly inadequate for detecting autoimmune or neurological conditions that may take months or years to manifest. The 12+ month minimum standard for safety monitoring is not met."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "No true inert placebo (saline) group was used. The Italian efficacy trial compared INFANRIX to DT (Diphtheria-Tetanus) vaccine, and safety comparisons were made to whole-cell DTP vaccine. The German household contact study compared vaccinated vs unvaccinated contacts but was not a randomized controlled trial. Using another vaccine as comparator cannot distinguish which adverse events are caused by the pertussis component versus baseline rates or the DT components."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance via standardized diary cards was used, but only for 4 days post-vaccination for solicited reactions. Parents recorded symptoms using structured forms with defined grading scales. However, the extremely short monitoring window limits detection of serious adverse events. The German study used report cards for 28 days supplemented by 'spontaneous reporting by parents' - a mix of active and passive surveillance. No active investigation of hospitalizations or deaths with causality analysis is described."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Only seizures (1 case in INFANRIX group at 0.07/1,000 doses) and hypotonic-hyporesponsive episodes (0 cases) were tracked in clinical trials. No systematic long-term neurological or developmental assessments were performed. Guillain-Barre syndrome is mentioned only as a warning/precaution, not as a monitored trial endpoint. Post-marketing reports include encephalopathy, hypotonia, and syncope, but these are from passive surveillance. No scheduled developmental assessments or follow-up neurological exams are documented."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The Warnings section acknowledges risks for premature infants (apnea) and children at higher risk for seizures, with recommendations for clinical decision-making. However, no specific clinical trial data is presented for premature infants, immunocompromised children, or children with allergies/chronic conditions. These groups were not intentionally included in trials with separate safety analysis. Section 8.4 explicitly states that safety in infants younger than 6 weeks has not been established."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The package insert provides summary data from multiple studies including rates of adverse reactions in tabular format. References cite published literature. However, there is no mention of an independent Data Safety Monitoring Board (DSMB), no raw data or individual participant data availability, and no mechanism for independent verification. The clinical trials appear to be manufacturer-sponsored without disclosure of independent oversight."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Section 6.2 describes post-marketing experience listing adverse reactions including encephalopathy, thrombocytopenia, anaphylactic reaction, hypotonia, syncope, apnea, and SIDS. However, these are 'reported voluntarily from a population of uncertain size' making it 'not always possible to reliably estimate their frequency or establish a causal relationship to vaccination.' The system relies on passive reporting (VAERS) which is known to vastly underestimate true adverse event rates. No active pharmacovigilance system or periodic public safety reports are described."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The INFANRIX package insert provides limited confidence in long-term safety for children. While the sample sizes are adequate (29,243+ infants studied) and the vaccine shows a better short-term safety profile than whole-cell pertussis vaccines, critical gaps remain: (1) No true placebo comparison makes it impossible to determine the absolute rate of vaccine-caused adverse events; (2) Safety monitoring lasted only 4 days for most outcomes - far too short to detect autoimmune, neurological, or developmental problems that emerge over months or years; (3) No systematic long-term neurological or developmental assessments were performed; (4) Vulnerable populations (premature infants, immunocompromised) were not specifically studied; (5) Post-marketing surveillance relies on passive voluntary reporting which cannot establish true incidence rates. A parent reading this document cannot be confident that rare but serious long-term adverse effects have been adequately evaluated. The document demonstrates short-term tolerability compared to older whole-cell vaccines, but does not provide reassuring evidence about safety over months and years following vaccination."
        }
      },
      "safety_pt": {
        "vaccine_id": "dtap_infanrix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Aproximadamente 95.000 doses administradas em estudos cl√≠nicos com 29.243 beb√™s em estudos da s√©rie prim√°ria. O estudo de seguran√ßa alem√£o incluiu 22.505 beb√™s (66.867 doses). O ensaio de efic√°cia italiano incluiu 4.696 crian√ßas recebendo INFANRIX. Esses n√∫meros excedem o limite de 3.000 necess√°rio para detectar eventos adversos que ocorrem com frequ√™ncia de 1:1.000, embora eventos mais raros (1:10.000 ou menos) ainda n√£o seriam detectados."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Rea√ß√µes adversas solicitadas foram coletadas por apenas 4 dias consecutivos ap√≥s cada dose de vacina (dia da vacina√ß√£o mais os 3 dias seguintes). Eventos adversos n√£o solicitados foram monitorados por 28 dias no estudo alem√£o, com um subconjunto monitorado por 8 dias. Isso √© grosseiramente inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem levar meses ou anos para se manifestar. O padr√£o m√≠nimo de 12+ meses para monitoramento de seguran√ßa n√£o √© atendido."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Nenhum grupo placebo inerte verdadeiro (solu√ß√£o salina) foi usado. O ensaio de efic√°cia italiano comparou INFANRIX com vacina DT (Difteria-T√©tano), e compara√ß√µes de seguran√ßa foram feitas com vacina DTP de c√©lula inteira. O estudo alem√£o de contato domiciliar comparou contatos vacinados versus n√£o vacinados, mas n√£o foi um ensaio cl√≠nico randomizado controlado. Usar outra vacina como comparador n√£o pode distinguir quais eventos adversos s√£o causados pelo componente da coqueluche versus taxas basais ou componentes DT."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Vigil√¢ncia ativa via cart√µes de di√°rio padronizados foi usada, mas apenas por 4 dias p√≥s-vacina√ß√£o para rea√ß√µes solicitadas. Os pais registraram sintomas usando formul√°rios estruturados com escalas de gradua√ß√£o definidas. No entanto, a janela de monitoramento extremamente curta limita a detec√ß√£o de eventos adversos graves. O estudo alem√£o usou cart√µes de relato por 28 dias complementados por 'relatos espont√¢neos dos pais' - uma mistura de vigil√¢ncia ativa e passiva. Nenhuma investiga√ß√£o ativa de hospitaliza√ß√µes ou mortes com an√°lise de causalidade √© descrita."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Apenas convuls√µes (1 caso no grupo INFANRIX a 0,07/1.000 doses) e epis√≥dios hipot√¥nicos-hiporresponsivos (0 casos) foram rastreados em ensaios cl√≠nicos. Nenhuma avalia√ß√£o neurol√≥gica ou de desenvolvimento sistem√°tica de longo prazo foi realizada. A s√≠ndrome de Guillain-Barre √© mencionada apenas como advert√™ncia/precau√ß√£o, n√£o como desfecho de ensaio monitorado. Relatos p√≥s-comercializa√ß√£o incluem encefalopatia, hipotonia e s√≠ncope, mas estes s√£o de vigil√¢ncia passiva. Nenhuma avalia√ß√£o de desenvolvimento agendada ou exames neurol√≥gicos de acompanhamento s√£o documentados."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A se√ß√£o de Advert√™ncias reconhece riscos para beb√™s prematuros (apneia) e crian√ßas com maior risco de convuls√µes, com recomenda√ß√µes para tomada de decis√£o cl√≠nica. No entanto, nenhum dado espec√≠fico de ensaio cl√≠nico √© apresentado para beb√™s prematuros, crian√ßas imunocomprometidas ou crian√ßas com alergias/condi√ß√µes cr√¥nicas. Esses grupos n√£o foram intencionalmente inclu√≠dos nos ensaios com an√°lise de seguran√ßa separada. A Se√ß√£o 8.4 afirma explicitamente que a seguran√ßa em beb√™s menores de 6 semanas n√£o foi estabelecida."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A bula fornece dados resumidos de m√∫ltiplos estudos incluindo taxas de rea√ß√µes adversas em formato tabular. Refer√™ncias citam literatura publicada. No entanto, n√£o h√° men√ß√£o de um Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB), nenhuma disponibilidade de dados brutos ou de participantes individuais, e nenhum mecanismo para verifica√ß√£o independente. Os ensaios cl√≠nicos parecem ter sido patrocinados pelo fabricante sem divulga√ß√£o de supervis√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A Se√ß√£o 6.2 descreve a experi√™ncia p√≥s-comercializa√ß√£o listando rea√ß√µes adversas incluindo encefalopatia, trombocitopenia, rea√ß√£o anafil√°tica, hipotonia, s√≠ncope, apneia e SMSI. No entanto, estes s√£o 'relatados voluntariamente de uma popula√ß√£o de tamanho incerto', tornando 'nem sempre poss√≠vel estimar sua frequ√™ncia de forma confi√°vel ou estabelecer uma rela√ß√£o causal com a vacina√ß√£o.' O sistema depende de relatos passivos (VAERS), que √© conhecido por subestimar vastamente as verdadeiras taxas de eventos adversos. Nenhum sistema de farmacovigil√¢ncia ativa ou relat√≥rios de seguran√ßa p√∫blicos peri√≥dicos s√£o descritos."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula do INFANRIX fornece confian√ßa limitada na seguran√ßa de longo prazo para crian√ßas. Embora os tamanhos das amostras sejam adequados (29.243+ beb√™s estudados) e a vacina mostre um perfil de seguran√ßa de curto prazo melhor do que vacinas de c√©lula inteira contra coqueluche, lacunas cr√≠ticas permanecem: (1) Nenhuma compara√ß√£o com placebo verdadeiro torna imposs√≠vel determinar a taxa absoluta de eventos adversos causados pela vacina; (2) O monitoramento de seguran√ßa durou apenas 4 dias para a maioria dos desfechos - muito curto para detectar problemas autoimunes, neurol√≥gicos ou de desenvolvimento que surgem ao longo de meses ou anos; (3) Nenhuma avalia√ß√£o neurol√≥gica ou de desenvolvimento sistem√°tica de longo prazo foi realizada; (4) Popula√ß√µes vulner√°veis (beb√™s prematuros, imunocomprometidos) n√£o foram especificamente estudadas; (5) Vigil√¢ncia p√≥s-comercializa√ß√£o depende de relatos volunt√°rios passivos que n√£o podem estabelecer verdadeiras taxas de incid√™ncia. Um pai lendo este documento n√£o pode estar confiante de que efeitos adversos raros, mas graves, de longo prazo foram adequadamente avaliados. O documento demonstra tolerabilidade de curto prazo em compara√ß√£o com vacinas de c√©lula inteira mais antigas, mas n√£o fornece evid√™ncias tranquilizadoras sobre seguran√ßa ao longo de meses e anos ap√≥s a vacina√ß√£o."
        }
      }
    },
    {
      "id": "ipv_ipol",
      "name": "IPOL",
      "type": "IPV",
      "manufacturer": "Sanofi Pasteur",
      "description": "Poliovirus Vaccine Inactivated for active immunization against poliovirus types 1, 2, and 3.",
      "sources": [
        "ipv_ipol_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "ipv_ipol",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not describe any placebo-controlled trials. Clinical studies compared IPOL vaccine administered with DTP at separate sites or combined, with immunogenicity measured by seroconversion rates. Historical comparisons to DTP alone were made for adverse reactions, but no true placebo control group was used.",
            "level_description": "No placebo-controlled trials are described in the package insert. Studies used either open-label designs or compared to DTP vaccine alone, not to an inert placebo."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not mention blinding procedures for any of the clinical studies. Studies are described in terms of vaccine schedules and immunogenicity outcomes without reference to blinding methodology.",
            "level_description": "No mention of double-blind or single-blind study design. The clinical trials appear to have been open-label in nature."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document describes multiple study arms with different vaccination schedules (IPV only vs sequential IPV-OPV, subcutaneous vs intramuscular administration, separate sites vs combined with DTP), but does not explicitly describe randomization procedures.",
            "level_description": "While multiple treatment groups existed in the trials, the document does not explicitly confirm that subjects were randomly assigned to these groups."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "In the US, 219 infants received three doses of enhanced IPV. IPOL vaccine was administered to more than 700 infants between 2 to 18 months of age during three US clinical studies. Four additional US studies used IPOL vaccine in more than 1,300 infants. Outside the US, IPOL vaccine was administered to more than 3,000 infants with immunogenicity data from 1,485 infants.",
            "level_description": "Combined pediatric sample sizes across studies exceed 2,000 infants in US studies and over 3,000 internationally, providing adequate statistical power for immunogenicity assessment."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Adverse reactions were monitored at 6, 24, and 48 hours post-immunization. Persistence of antibodies was measured at 12 months, 18 months, and up to 6 years of age in some studies. A Swedish survey demonstrated persistence of neutralizing antibodies for at least 10 years.",
            "level_description": "Safety follow-up was limited to 48-72 hours post-vaccination. Long-term follow-up focused on immunogenicity (antibody persistence) rather than safety outcomes."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies included infants vaccinated at 2, 4, 6, and 12-18 months of age. Table 1 shows separate results for doses administered at different ages. The document also addresses adults separately with different dosing recommendations.",
            "level_description": "Data are presented separately for different age points (2, 4, 6, 12-18 months) with distinct immunogenicity results, and adult recommendations are addressed separately."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document does not describe specific inclusion/exclusion criteria for the clinical trials. It mentions contraindications (hypersensitivity to components, anaphylaxis after previous dose, acute febrile illness) but these are for clinical use, not trial enrollment.",
            "level_description": "Specific trial enrollment criteria are not detailed in the package insert. Only post-approval contraindications and precautions are provided."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Table 2 presents standardized local reactions (erythema >1\", swelling, tenderness) and systemic reactions (fever >102.2F, irritability, tiredness, anorexia, vomiting, persistent crying) measured at specific timepoints (6, 24, 48 hours) with percentage rates.",
            "level_description": "Adverse events were collected using standardized categories and definitions with consistent measurement timepoints across study visits."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document notes that deaths have occurred in temporal association after vaccination with IPV, though no causal relationship was established. GBS has been temporally related to administration of another inactivated poliovirus vaccine. Post-marketing surveillance identified additional serious events including anaphylactic reactions and convulsions.",
            "level_description": "Serious adverse events are mentioned but appear to come primarily from passive post-marketing surveillance rather than active monitoring in clinical trials."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Although no causal relationship between IPOL vaccine and Guillain-Barre Syndrome (GBS) has been established, GBS has been temporally related to administration of another inactivated poliovirus vaccine. Post-marketing experience includes convulsion, febrile convulsion, and paresthesia.",
            "level_description": "GBS is mentioned as a potential concern with IPV generally, and some neurological events are listed in post-marketing data, but systematic pre-approval monitoring for these conditions is not described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document discusses use in immunodeficient patients, HIV-infected individuals, premature infants (reference 21 mentions premature and term infants), and pregnant/nursing women. However, safety data specific to these subgroups from clinical trials is not presented. Safety in infants below 6 weeks of age has not been established.",
            "level_description": "Vulnerable populations are addressed in recommendations but specific safety data from clinical trials in these subgroups is limited or referenced from external studies."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document presents percentage rates for seroconversion and adverse events but does not describe statistical methods, confidence intervals, or significance testing. Sample sizes (N) are provided for immunogenicity tables.",
            "level_description": "Descriptive statistics (percentages, sample sizes) are provided but detailed statistical methodology and inferential statistics are not described."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Some unpublished data is referenced (references 11 and 12: 'Unpublished data available from Sanofi Pasteur SA' and 'Unpublished data available from Sanofi Pasteur Inc.'). Individual study results are summarized in tables but raw data is not accessible.",
            "level_description": "Key data sources are unpublished proprietary data from the manufacturer. Published references are provided for some studies but not all supporting data is publicly available."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The document includes a Post-marketing Experience section listing adverse events identified during postapproval use reported to VAERS. It describes the reporting system and encourages reporting of adverse events. Reference to VAERS and the National Vaccine Injury Compensation Program is included.",
            "level_description": "A structured post-marketing surveillance system is described with specific adverse events identified from voluntary reports, though limitations of passive surveillance are acknowledged."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not disclose conflicts of interest for clinical trial investigators or funding sources for the studies. Some unpublished data is noted as available from Sanofi Pasteur, the manufacturer.",
            "level_description": "No conflict of interest disclosures are provided in the package insert. The manufacturer conducted or sponsored the studies without disclosed independent oversight."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document states: 'Although no causal relationship has been established, deaths have occurred in temporal association after vaccination of infants with IPV.' Reference 37 (Stratton et al., Adverse Events Associated with Childhood Vaccines) is cited.",
            "level_description": "Deaths are acknowledged as having occurred temporally after vaccination, but systematic all-cause mortality data from clinical trials comparing vaccinated vs unvaccinated groups is not provided."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The IPOL package insert describes multiple clinical studies with adequate pediatric sample sizes (over 2,000 US infants, 3,000+ internationally) demonstrating high immunogenicity. However, the trials lack placebo controls, blinding, and explicit randomization descriptions. Safety follow-up was limited to 48-72 hours for most outcomes. Serious adverse events including deaths and GBS are mentioned but primarily from post-marketing surveillance. Key data sources include unpublished manufacturer data, and no conflict of interest disclosures are provided. The approval was based primarily on immunogenicity endpoints with comparison to DTP alone rather than comprehensive safety assessment with appropriate controls."
        }
      },
      "trial_pt": {
        "vaccine_id": "ipv_ipol",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o descreve nenhum ensaio controlado por placebo. Estudos cl√≠nicos compararam a vacina IPOL administrada com DTP em locais separados ou combinados, com imunogenicidade medida por taxas de soroconvers√£o. Compara√ß√µes hist√≥ricas com DTP sozinha foram feitas para rea√ß√µes adversas, mas nenhum grupo controle placebo verdadeiro foi usado.",
            "level_description": "Nenhum ensaio controlado por placebo √© descrito na bula. Os estudos usaram designs abertos ou compararam com vacina DTP sozinha, n√£o com um placebo inerte."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o menciona procedimentos de cegamento para nenhum dos estudos cl√≠nicos. Os estudos s√£o descritos em termos de esquemas de vacina√ß√£o e desfechos de imunogenicidade sem refer√™ncia √† metodologia de cegamento.",
            "level_description": "Nenhuma men√ß√£o de design de estudo duplo-cego ou simples-cego. Os ensaios cl√≠nicos parecem ter sido de natureza aberta."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento descreve m√∫ltiplos bra√ßos de estudo com diferentes esquemas de vacina√ß√£o (apenas IPV vs sequencial IPV-OPV, administra√ß√£o subcut√¢nea vs intramuscular, locais separados vs combinado com DTP), mas n√£o descreve explicitamente os procedimentos de randomiza√ß√£o.",
            "level_description": "Embora m√∫ltiplos grupos de tratamento existissem nos ensaios, o documento n√£o confirma explicitamente que os sujeitos foram aleatoriamente alocados a esses grupos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Nos EUA, 219 beb√™s receberam tr√™s doses de IPV aprimorada. A vacina IPOL foi administrada a mais de 700 beb√™s entre 2 a 18 meses de idade durante tr√™s estudos cl√≠nicos dos EUA. Quatro estudos adicionais dos EUA usaram a vacina IPOL em mais de 1.300 beb√™s. Fora dos EUA, a vacina IPOL foi administrada a mais de 3.000 beb√™s com dados de imunogenicidade de 1.485 beb√™s.",
            "level_description": "Os tamanhos de amostra pedi√°trica combinados entre os estudos excedem 2.000 beb√™s nos estudos dos EUA e mais de 3.000 internacionalmente, fornecendo poder estat√≠stico adequado para avalia√ß√£o de imunogenicidade."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes adversas foram monitoradas √†s 6, 24 e 48 horas p√≥s-imuniza√ß√£o. A persist√™ncia de anticorpos foi medida aos 12 meses, 18 meses e at√© 6 anos de idade em alguns estudos. Uma pesquisa sueca demonstrou persist√™ncia de anticorpos neutralizantes por pelo menos 10 anos.",
            "level_description": "O acompanhamento de seguran√ßa foi limitado a 48-72 horas p√≥s-vacina√ß√£o. O acompanhamento de longo prazo focou na imunogenicidade (persist√™ncia de anticorpos) em vez de desfechos de seguran√ßa."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos inclu√≠ram beb√™s vacinados aos 2, 4, 6 e 12-18 meses de idade. A Tabela 1 mostra resultados separados para doses administradas em diferentes idades. O documento tamb√©m aborda adultos separadamente com diferentes recomenda√ß√µes de dosagem.",
            "level_description": "Os dados s√£o apresentados separadamente para diferentes pontos de idade (2, 4, 6, 12-18 meses) com resultados de imunogenicidade distintos, e as recomenda√ß√µes para adultos s√£o abordadas separadamente."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento n√£o descreve crit√©rios espec√≠ficos de inclus√£o/exclus√£o para os ensaios cl√≠nicos. Menciona contraindica√ß√µes (hipersensibilidade a componentes, anafilaxia ap√≥s dose anterior, doen√ßa febril aguda), mas estas s√£o para uso cl√≠nico, n√£o para inscri√ß√£o no ensaio.",
            "level_description": "Crit√©rios espec√≠ficos de inscri√ß√£o nos ensaios n√£o s√£o detalhados na bula. Apenas contraindica√ß√µes e precau√ß√µes p√≥s-aprova√ß√£o s√£o fornecidas."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Tabela 2 apresenta rea√ß√µes locais padronizadas (eritema >2,5cm, incha√ßo, sensibilidade) e rea√ß√µes sist√™micas (febre >39¬∞C, irritabilidade, cansa√ßo, anorexia, v√¥mito, choro persistente) medidas em pontos de tempo espec√≠ficos (6, 24, 48 horas) com taxas percentuais.",
            "level_description": "Eventos adversos foram coletados usando categorias e defini√ß√µes padronizadas com pontos de tempo de medi√ß√£o consistentes entre as visitas do estudo."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento observa que mortes ocorreram em associa√ß√£o temporal ap√≥s vacina√ß√£o com IPV, embora nenhuma rela√ß√£o causal tenha sido estabelecida. SGB foi temporalmente relacionada √† administra√ß√£o de outra vacina inativada contra poliomielite. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos graves adicionais incluindo rea√ß√µes anafil√°ticas e convuls√µes.",
            "level_description": "Eventos adversos graves s√£o mencionados, mas parecem vir principalmente da vigil√¢ncia p√≥s-comercializa√ß√£o passiva em vez de monitoramento ativo em ensaios cl√≠nicos."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Embora nenhuma rela√ß√£o causal entre a vacina IPOL e a S√≠ndrome de Guillain-Barre (SGB) tenha sido estabelecida, a SGB foi temporalmente relacionada √† administra√ß√£o de outra vacina inativada contra poliomielite. A experi√™ncia p√≥s-comercializa√ß√£o inclui convuls√£o, convuls√£o febril e parestesia.",
            "level_description": "A SGB √© mencionada como uma potencial preocupa√ß√£o com IPV em geral, e alguns eventos neurol√≥gicos s√£o listados nos dados p√≥s-comercializa√ß√£o, mas o monitoramento sistem√°tico pr√©-aprova√ß√£o para essas condi√ß√µes n√£o √© descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento discute o uso em pacientes imunodeficientes, indiv√≠duos infectados pelo HIV, beb√™s prematuros (refer√™ncia 21 menciona beb√™s prematuros e a termo) e mulheres gr√°vidas/lactantes. No entanto, dados de seguran√ßa espec√≠ficos para esses subgrupos de ensaios cl√≠nicos n√£o s√£o apresentados. A seguran√ßa em beb√™s abaixo de 6 semanas de idade n√£o foi estabelecida.",
            "level_description": "Popula√ß√µes vulner√°veis s√£o abordadas nas recomenda√ß√µes, mas dados de seguran√ßa espec√≠ficos de ensaios cl√≠nicos nesses subgrupos s√£o limitados ou referenciados de estudos externos."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento apresenta taxas percentuais para soroconvers√£o e eventos adversos, mas n√£o descreve m√©todos estat√≠sticos, intervalos de confian√ßa ou testes de signific√¢ncia. Tamanhos de amostra (N) s√£o fornecidos para tabelas de imunogenicidade.",
            "level_description": "Estat√≠sticas descritivas (porcentagens, tamanhos de amostra) s√£o fornecidas, mas metodologia estat√≠stica detalhada e estat√≠sticas inferenciais n√£o s√£o descritas."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Alguns dados n√£o publicados s√£o referenciados (refer√™ncias 11 e 12: 'Dados n√£o publicados dispon√≠veis da Sanofi Pasteur SA' e 'Dados n√£o publicados dispon√≠veis da Sanofi Pasteur Inc.'). Resultados de estudos individuais s√£o resumidos em tabelas, mas os dados brutos n√£o s√£o acess√≠veis.",
            "level_description": "Fontes de dados principais s√£o dados propriet√°rios n√£o publicados do fabricante. Refer√™ncias publicadas s√£o fornecidas para alguns estudos, mas nem todos os dados de apoio s√£o publicamente dispon√≠veis."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O documento inclui uma se√ß√£o de Experi√™ncia P√≥s-comercializa√ß√£o listando eventos adversos identificados durante o uso p√≥s-aprova√ß√£o relatados ao VAERS. Descreve o sistema de relato e incentiva o relato de eventos adversos. Refer√™ncia ao VAERS e ao Programa Nacional de Compensa√ß√£o por Les√µes Vacinais est√° inclu√≠da.",
            "level_description": "Um sistema estruturado de vigil√¢ncia p√≥s-comercializa√ß√£o √© descrito com eventos adversos espec√≠ficos identificados de relatos volunt√°rios, embora limita√ß√µes da vigil√¢ncia passiva sejam reconhecidas."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o divulga conflitos de interesse para investigadores de ensaios cl√≠nicos ou fontes de financiamento para os estudos. Alguns dados n√£o publicados s√£o mencionados como dispon√≠veis da Sanofi Pasteur, o fabricante.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse √© fornecida na bula. O fabricante conduziu ou patrocinou os estudos sem supervis√£o independente divulgada."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento afirma: 'Embora nenhuma rela√ß√£o causal tenha sido estabelecida, mortes ocorreram em associa√ß√£o temporal ap√≥s vacina√ß√£o de beb√™s com IPV.' A refer√™ncia 37 (Stratton et al., Eventos Adversos Associados a Vacinas Infantis) √© citada.",
            "level_description": "Mortes s√£o reconhecidas como tendo ocorrido temporalmente ap√≥s a vacina√ß√£o, mas dados sistem√°ticos de mortalidade por todas as causas de ensaios cl√≠nicos comparando grupos vacinados versus n√£o vacinados n√£o s√£o fornecidos."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula da IPOL descreve m√∫ltiplos estudos cl√≠nicos com tamanhos de amostra pedi√°trica adequados (mais de 2.000 beb√™s nos EUA, 3.000+ internacionalmente) demonstrando alta imunogenicidade. No entanto, os ensaios carecem de controles placebo, cegamento e descri√ß√µes expl√≠citas de randomiza√ß√£o. O acompanhamento de seguran√ßa foi limitado a 48-72 horas para a maioria dos desfechos. Eventos adversos graves incluindo mortes e SGB s√£o mencionados, mas principalmente da vigil√¢ncia p√≥s-comercializa√ß√£o. Fontes de dados principais incluem dados propriet√°rios n√£o publicados do fabricante, e nenhuma divulga√ß√£o de conflito de interesse √© fornecida. A aprova√ß√£o foi baseada principalmente em desfechos de imunogenicidade com compara√ß√£o apenas com DTP, em vez de avalia√ß√£o abrangente de seguran√ßa com controles apropriados."
        }
      },
      "safety_en": {
        "vaccine_id": "ipv_ipol",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "US clinical studies enrolled more than 700 infants in three studies and over 1,300 infants in four additional studies, all aged 2-18 months. An earlier study included 219 infants. International studies included over 3,000 infants. Combined, this provides adequate sample size for detecting common adverse reactions, though may be insufficient for rare events."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Safety monitoring was limited to 6, 24, and 48 hours post-immunization for most outcomes. Persistent crying was monitored within 72 hours. No long-term safety follow-up (weeks, months, or years) is described in the clinical trial data. Long-term antibody persistence was tracked, but not long-term safety outcomes."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "No placebo control group was used. Adverse reactions were compared to historical data from DTP given alone without IPV or OPV. The document states systemic reactions 'could not be attributed to a specific vaccine' when IPOL was given concurrently with DTP, and were 'comparable in frequency and severity to that reported for DTP given alone.' This comparison methodology is inadequate for establishing vaccine-specific safety profiles."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance was conducted during clinical trials at defined timepoints (6, 24, 48 hours) for specified local and systemic reactions. However, post-approval surveillance relies on passive voluntary reporting to VAERS, which the document acknowledges may not reliably estimate frequency or establish causal relationships due to population uncertainty."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "GBS is mentioned as having been temporally related to another inactivated poliovirus vaccine, though no causal relationship with IPOL has been established. Post-marketing surveillance identified convulsion, febrile convulsion, paresthesia, somnolence, and syncope. However, systematic neurological monitoring during pre-approval trials is not described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document addresses immunocompromised patients (HIV, AIDS, immunosuppressive therapy), noting they may not develop protective responses. Safety in infants below 6 weeks is not established. Pregnancy studies have not been conducted. No specific safety data from trials in premature infants, though a referenced study (Adenyi-Jones) examined premature and term infants. Specific safety outcomes in these populations are not detailed."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Key safety data sources include unpublished proprietary data from Sanofi Pasteur SA and Sanofi Pasteur Inc. (references 11 and 12). Table 2 provides quantitative safety data with percentages and sample sizes, but raw data and detailed methodology are not accessible. Post-marketing adverse events are listed without frequency estimates due to passive reporting limitations."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A structured post-marketing surveillance section identifies adverse events from voluntary reports including: lymphadenopathy, injection site reactions, hypersensitivity/anaphylaxis, arthralgia, myalgia, convulsions, and skin reactions. The document references VAERS reporting requirements under the National Childhood Vaccine Injury Act and encourages healthcare providers and parents to report adverse events. Deaths have been reported in temporal association with IPV administration."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The IPOL safety profile is based on clinical trials with adequate pediatric sample sizes but significant methodological limitations. Safety follow-up was very short (48-72 hours), with no placebo control - only comparison to DTP vaccine alone. Serious events including deaths and neurological outcomes (convulsions, GBS temporal association) are acknowledged primarily through post-marketing surveillance rather than controlled trials. Key data sources remain unpublished proprietary information. While common local and systemic reactions are well-characterized, the safety evidence base for rare and serious adverse events relies heavily on passive post-marketing reporting with inherent limitations in establishing causality and frequency."
        }
      },
      "safety_pt": {
        "vaccine_id": "ipv_ipol",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Os estudos cl√≠nicos dos EUA inclu√≠ram mais de 700 beb√™s em tr√™s estudos e mais de 1.300 beb√™s em quatro estudos adicionais, todos com idades entre 2-18 meses. Um estudo anterior incluiu 219 beb√™s. Estudos internacionais inclu√≠ram mais de 3.000 beb√™s. Combinados, isso fornece tamanho de amostra adequado para detectar rea√ß√µes adversas comuns, embora possa ser insuficiente para eventos raros."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O monitoramento de seguran√ßa foi limitado a 6, 24 e 48 horas p√≥s-imuniza√ß√£o para a maioria dos desfechos. Choro persistente foi monitorado dentro de 72 horas. Nenhum acompanhamento de seguran√ßa de longo prazo (semanas, meses ou anos) √© descrito nos dados de ensaios cl√≠nicos. A persist√™ncia de anticorpos de longo prazo foi rastreada, mas n√£o os desfechos de seguran√ßa de longo prazo."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Nenhum grupo controle placebo foi usado. Rea√ß√µes adversas foram comparadas com dados hist√≥ricos de DTP administrada sozinha sem IPV ou OPV. O documento afirma que rea√ß√µes sist√™micas 'n√£o puderam ser atribu√≠das a uma vacina espec√≠fica' quando IPOL foi administrada concomitantemente com DTP, e foram 'compar√°veis em frequ√™ncia e gravidade √†s relatadas para DTP administrada sozinha.' Esta metodologia de compara√ß√£o √© inadequada para estabelecer perfis de seguran√ßa espec√≠ficos da vacina."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Vigil√¢ncia ativa foi conduzida durante ensaios cl√≠nicos em pontos de tempo definidos (6, 24, 48 horas) para rea√ß√µes locais e sist√™micas especificadas. No entanto, a vigil√¢ncia p√≥s-aprova√ß√£o depende de relatos volunt√°rios passivos ao VAERS, que o documento reconhece pode n√£o estimar frequ√™ncia de forma confi√°vel ou estabelecer rela√ß√µes causais devido √† incerteza da popula√ß√£o."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A SGB √© mencionada como tendo sido temporalmente relacionada a outra vacina inativada contra poliomielite, embora nenhuma rela√ß√£o causal com IPOL tenha sido estabelecida. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou convuls√£o, convuls√£o febril, parestesia, sonol√™ncia e s√≠ncope. No entanto, monitoramento neurol√≥gico sistem√°tico durante ensaios pr√©-aprova√ß√£o n√£o √© descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento aborda pacientes imunocomprometidos (HIV, AIDS, terapia imunossupressora), observando que podem n√£o desenvolver respostas protetoras. A seguran√ßa em beb√™s abaixo de 6 semanas n√£o est√° estabelecida. Estudos de gravidez n√£o foram conduzidos. Nenhum dado de seguran√ßa espec√≠fico de ensaios em beb√™s prematuros, embora um estudo referenciado (Adenyi-Jones) tenha examinado beb√™s prematuros e a termo. Desfechos de seguran√ßa espec√≠ficos nessas popula√ß√µes n√£o s√£o detalhados."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Fontes de dados de seguran√ßa principais incluem dados propriet√°rios n√£o publicados da Sanofi Pasteur SA e Sanofi Pasteur Inc. (refer√™ncias 11 e 12). A Tabela 2 fornece dados de seguran√ßa quantitativos com porcentagens e tamanhos de amostra, mas dados brutos e metodologia detalhada n√£o s√£o acess√≠veis. Eventos adversos p√≥s-comercializa√ß√£o s√£o listados sem estimativas de frequ√™ncia devido √†s limita√ß√µes dos relatos passivos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Uma se√ß√£o estruturada de vigil√¢ncia p√≥s-comercializa√ß√£o identifica eventos adversos de relatos volunt√°rios incluindo: linfadenopatia, rea√ß√µes no local da inje√ß√£o, hipersensibilidade/anafilaxia, artralgia, mialgia, convuls√µes e rea√ß√µes cut√¢neas. O documento referencia os requisitos de relato do VAERS sob o National Childhood Vaccine Injury Act e incentiva profissionais de sa√∫de e pais a relatarem eventos adversos. Mortes foram relatadas em associa√ß√£o temporal com a administra√ß√£o de IPV."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "O perfil de seguran√ßa da IPOL √© baseado em ensaios cl√≠nicos com tamanhos de amostra pedi√°trica adequados, mas com limita√ß√µes metodol√≥gicas significativas. O acompanhamento de seguran√ßa foi muito curto (48-72 horas), sem controle placebo - apenas compara√ß√£o com vacina DTP sozinha. Eventos graves incluindo mortes e desfechos neurol√≥gicos (convuls√µes, associa√ß√£o temporal com SGB) s√£o reconhecidos principalmente atrav√©s da vigil√¢ncia p√≥s-comercializa√ß√£o em vez de ensaios controlados. Fontes de dados principais permanecem como informa√ß√£o propriet√°ria n√£o publicada. Embora rea√ß√µes locais e sist√™micas comuns sejam bem caracterizadas, a base de evid√™ncias de seguran√ßa para eventos adversos raros e graves depende fortemente de relatos p√≥s-comercializa√ß√£o passivos com limita√ß√µes inerentes no estabelecimento de causalidade e frequ√™ncia."
        }
      }
    },
    {
      "id": "pcv_prevnar13",
      "name": "Prevnar 13",
      "type": "PCV",
      "manufacturer": "Pfizer",
      "description": "Pneumococcal 13-valent Conjugate Vaccine for prevention of invasive disease caused by Streptococcus pneumoniae.",
      "sources": [
        "pcv_prevnar13_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "pcv_prevnar13",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Pediatric trials used Prevnar (7-valent) as active control, not placebo. The adult efficacy study (Study 12) was a randomized, double-blind, placebo-controlled study with 84,496 subjects (42,240 Prevnar 13 vs 42,256 placebo). Some pediatric studies were open-label.",
            "level_description": "Placebo control present only in the adult efficacy trial; pediatric licensure was based on active-controlled and open-label studies comparing to previously licensed Prevnar vaccine."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The adult efficacy study (Study 12) was randomized double-blind placebo-controlled. Pediatric Study 2 was described as 'randomized, double-blind, active-controlled.' Some studies were 'modified double-blind' where site staff dispensing vaccine were unblinded. Several studies were open-label.",
            "level_description": "Double-blinding was used in key studies but some trials used modified double-blind or open-label designs, reducing overall rigor."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple studies described as randomized. Study 2: infants 'randomly assigned to receive either Prevnar 13 or Prevnar in a 1:1 ratio.' Study 12 (adult efficacy): '84,496 subjects received either a single dose of Prevnar 13 (42,240) or placebo (42,256) in a 1:1 randomization.'",
            "level_description": "Randomization was employed in the major clinical trials for both pediatric and adult populations."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety evaluated in 13 clinical trials with 4,729 infants and toddlers receiving at least one dose of Prevnar 13 and 2,760 receiving Prevnar control. US studies enrolled 1,907 subjects receiving Prevnar 13 and 701 receiving Prevnar. Additionally, 6,839 subjects globally received at least 1 dose of Prevnar 13.",
            "level_description": "Large pediatric sample sizes across multiple trials provide robust safety and immunogenicity data."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse reactions recorded for 7 consecutive days following each vaccination. Unsolicited adverse events monitored from first dose until one month after infant series and one month after toddler dose. 6-month follow-up telephone interview after fourth dose. Serious adverse events collected throughout study period. Adult Study 12 had median follow-up of 3.93 years.",
            "level_description": "Follow-up periods ranged from 7 days for solicited reactions to 6 months for serious adverse events in pediatric studies; adult efficacy trial had nearly 4-year follow-up."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Separate data presented for: infants 6 weeks-11 months, toddlers 12-15 months, children 7-11 months, 12-23 months, 24 months-5 years, 5-9 years, 10-17 years. Adults studied separately: 18-49 years, 50-59 years, 60-64 years, 65+ years, 70+ years.",
            "level_description": "Comprehensive age stratification with separate analyses and tables for multiple pediatric and adult age groups."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Subjects excluded from participation due to prior receipt of diphtheria toxoid-containing vaccines within 6 months. Adults with immunocompromising conditions or receiving immunosuppressive therapy excluded from efficacy study. Stable medical conditions allowed if no change in therapy or hospitalization for 12 weeks (6 weeks in one study).",
            "level_description": "Clear inclusion/exclusion criteria specified, though detailed criteria for all studies not fully enumerated in prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Solicited local reactions: redness, swelling, tenderness graded as Mild (0.5-2.0 cm), Moderate (2.5-7.0 cm), Severe (>7.0 cm). Fever graded: Mild (38-39C), Moderate (>39-40C), Severe (>40C). Electronic diaries used for recording. Standardized definitions applied across studies.",
            "level_description": "Standardized grading scales and systematic collection methods with electronic diaries used consistently across trials."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Serious adverse events collected throughout study period for all 13 pediatric clinical trials. SAEs reported in 8.2% of Prevnar 13 recipients vs 7.2% of Prevnar recipients. SAEs collected for 6 months after each vaccination in adult studies. Deaths reported: 3 (0.063%) in Prevnar 13 pediatric recipients (all SIDS).",
            "level_description": "Active monitoring for serious adverse events throughout study periods with systematic collection and reporting."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Hypotonic-hyporesponsive episodes reported: 1 (0.015%) in Prevnar 13 vs 3 (0.071%) in Prevnar globally. Post-marketing reports include: hypotonia, seizures (including febrile seizures), anaphylactic/anaphylactoid reactions. Apnea warning for premature infants.",
            "level_description": "Some neurological events (hypotonic-hyporesponsive episodes, seizures) tracked, but no systematic autoimmune disease monitoring protocol described."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 8.6 addresses high-risk populations: premature infants (N=100 studied), children with sickle cell disease, hematopoietic stem cell transplant recipients, HIV-infected individuals. Apnea warning specifically for premature infants. Adults with stable underlying conditions (cardiovascular, pulmonary, diabetes, liver disease) included.",
            "level_description": "Multiple vulnerable subgroups studied with dedicated sections, though sample sizes for some groups were limited."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Noninferiority criteria specified: lower limit of 95% CI for difference >-10% for responder rates; lower limit of 95% CI for GMC ratio >0.5. Vaccine efficacy calculated with 95.2% confidence intervals. Statistical significance noted as p<0.05 without multiplicity adjustment.",
            "level_description": "Pre-specified statistical criteria for noninferiority and efficacy endpoints with confidence intervals reported, though multiplicity adjustments not always applied."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "ClinicalTrials.gov identifiers provided for all 13 studies (NCT numbers listed in Section 15). Detailed tables with sample sizes, confidence intervals, and percentages provided. Individual study results referenced.",
            "level_description": "Trial registration numbers provided and detailed data tables included, though full study reports not directly accessible from prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.3 describes post-marketing experience with adverse events reported through passive surveillance. Events include: vaccination-site reactions, lymphadenopathy, cyanosis, anaphylactic reactions, hypotonia, angioneurotic edema, erythema multiforme, apnea, pallor. VAERS reporting encouraged.",
            "level_description": "Post-marketing surveillance system described with specific adverse events identified, though acknowledges limitations of voluntary reporting."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No disclosure of conflicts of interest, funding sources, or investigator relationships to manufacturer in the prescribing information document.",
            "level_description": "No conflict of interest disclosures included in the prescribing information."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Pediatric deaths: 3 (0.063%) in Prevnar 13 recipients, 1 (0.036%) in Prevnar recipients, all due to SIDS, rates consistent with background. Adult trials: 12 of 5,667 (0.21%) Prevnar 13 and 4 of 1,391 (0.29%) PPSV23 recipients died. Study 12: 3,006 deaths (7.1%) in Prevnar 13 vs 3,005 (7.1%) in placebo over ~4 years.",
            "level_description": "All-cause mortality reported for pediatric and adult studies with comparisons to control groups showing no evidence of causal relationship to vaccination."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Prevnar 13 was evaluated in extensive clinical trials with robust sample sizes, particularly for pediatric populations. The adult efficacy trial was a well-designed randomized, double-blind, placebo-controlled study demonstrating 45.6% efficacy against vaccine-type pneumococcal CAP. Pediatric approval was based primarily on immunological noninferiority to the previously licensed Prevnar vaccine rather than direct efficacy trials. Strengths include comprehensive age stratification, standardized adverse event monitoring, and systematic serious adverse event collection. Limitations include use of active comparator rather than placebo in pediatric studies, lack of conflict of interest disclosures, and limited systematic monitoring for autoimmune conditions. Post-marketing surveillance continues to identify rare adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "pcv_prevnar13",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os ensaios pedi√°tricos usaram Prevnar (7-valente) como controle ativo, n√£o placebo. O estudo de efic√°cia em adultos (Estudo 12) foi um estudo randomizado, duplo-cego, controlado por placebo com 84.496 sujeitos (42.240 Prevnar 13 vs 42.256 placebo). Alguns estudos pedi√°tricos foram abertos.",
            "level_description": "Controle placebo presente apenas no ensaio de efic√°cia em adultos; a licen√ßa pedi√°trica foi baseada em estudos com controle ativo e abertos comparando com a vacina Prevnar previamente licenciada."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo de efic√°cia em adultos (Estudo 12) foi randomizado, duplo-cego e controlado por placebo. O Estudo Pedi√°trico 2 foi descrito como 'randomizado, duplo-cego, com controle ativo.' Alguns estudos foram 'duplo-cego modificado' onde a equipe do local que dispensava a vacina n√£o era cega. V√°rios estudos foram abertos.",
            "level_description": "O duplo-cego foi usado em estudos principais, mas alguns ensaios usaram designs duplo-cego modificado ou abertos, reduzindo o rigor geral."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos estudos descritos como randomizados. Estudo 2: beb√™s 'aleatoriamente alocados para receber Prevnar 13 ou Prevnar em propor√ß√£o 1:1.' Estudo 12 (efic√°cia em adultos): '84.496 sujeitos receberam uma √∫nica dose de Prevnar 13 (42.240) ou placebo (42.256) em randomiza√ß√£o 1:1.'",
            "level_description": "Randomiza√ß√£o foi empregada nos principais ensaios cl√≠nicos para popula√ß√µes pedi√°tricas e adultas."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Seguran√ßa avaliada em 13 ensaios cl√≠nicos com 4.729 beb√™s e crian√ßas pequenas recebendo pelo menos uma dose de Prevnar 13 e 2.760 recebendo controle Prevnar. Estudos dos EUA inclu√≠ram 1.907 sujeitos recebendo Prevnar 13 e 701 recebendo Prevnar. Al√©m disso, 6.839 sujeitos globalmente receberam pelo menos 1 dose de Prevnar 13.",
            "level_description": "Grandes tamanhos de amostra pedi√°trica em m√∫ltiplos ensaios fornecem dados robustos de seguran√ßa e imunogenicidade."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes adversas solicitadas registradas por 7 dias consecutivos ap√≥s cada vacina√ß√£o. Eventos adversos n√£o solicitados monitorados desde a primeira dose at√© um m√™s ap√≥s a s√©rie infantil e um m√™s ap√≥s a dose de refor√ßo. Entrevista telef√¥nica de acompanhamento de 6 meses ap√≥s a quarta dose. Eventos adversos graves coletados durante todo o per√≠odo do estudo. O Estudo 12 em adultos teve acompanhamento mediano de 3,93 anos.",
            "level_description": "Os per√≠odos de acompanhamento variaram de 7 dias para rea√ß√µes solicitadas a 6 meses para eventos adversos graves em estudos pedi√°tricos; o ensaio de efic√°cia em adultos teve acompanhamento de quase 4 anos."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados separados apresentados para: beb√™s de 6 semanas-11 meses, crian√ßas pequenas de 12-15 meses, crian√ßas de 7-11 meses, 12-23 meses, 24 meses-5 anos, 5-9 anos, 10-17 anos. Adultos estudados separadamente: 18-49 anos, 50-59 anos, 60-64 anos, 65+ anos, 70+ anos.",
            "level_description": "Estratifica√ß√£o et√°ria abrangente com an√°lises e tabelas separadas para m√∫ltiplos grupos et√°rios pedi√°tricos e adultos."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Sujeitos exclu√≠dos da participa√ß√£o devido ao recebimento pr√©vio de vacinas contendo toxoide dift√©rico nos 6 meses anteriores. Adultos com condi√ß√µes imunocomprometedoras ou recebendo terapia imunossupressora exclu√≠dos do estudo de efic√°cia. Condi√ß√µes m√©dicas est√°veis permitidas se sem mudan√ßa na terapia ou hospitaliza√ß√£o por 12 semanas (6 semanas em um estudo).",
            "level_description": "Crit√©rios claros de inclus√£o/exclus√£o especificados, embora crit√©rios detalhados para todos os estudos n√£o sejam totalmente enumerados na bula."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rea√ß√µes locais solicitadas: vermelhid√£o, incha√ßo, sensibilidade graduados como Leve (0,5-2,0 cm), Moderado (2,5-7,0 cm), Grave (>7,0 cm). Febre graduada: Leve (38-39¬∞C), Moderada (>39-40¬∞C), Grave (>40¬∞C). Di√°rios eletr√¥nicos usados para registro. Defini√ß√µes padronizadas aplicadas entre estudos.",
            "level_description": "Escalas de gradua√ß√£o padronizadas e m√©todos de coleta sistem√°ticos com di√°rios eletr√¥nicos usados consistentemente entre ensaios."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos graves coletados durante todo o per√≠odo do estudo para todos os 13 ensaios cl√≠nicos pedi√°tricos. EAGs relatados em 8,2% dos receptores de Prevnar 13 vs 7,2% dos receptores de Prevnar. EAGs coletados por 6 meses ap√≥s cada vacina√ß√£o em estudos de adultos. Mortes relatadas: 3 (0,063%) em receptores pedi√°tricos de Prevnar 13 (todas SMSI).",
            "level_description": "Monitoramento ativo para eventos adversos graves durante todo o per√≠odo dos estudos com coleta e relato sistem√°ticos."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Epis√≥dios hipot√¥nicos-hiporresponsivos relatados: 1 (0,015%) em Prevnar 13 vs 3 (0,071%) em Prevnar globalmente. Relatos p√≥s-comercializa√ß√£o incluem: hipotonia, convuls√µes (incluindo convuls√µes febr√≠s), rea√ß√µes anafil√°ticas/anafilactoides. Advert√™ncia de apneia para beb√™s prematuros.",
            "level_description": "Alguns eventos neurol√≥gicos (epis√≥dios hipot√¥nicos-hiporresponsivos, convuls√µes) rastreados, mas nenhum protocolo sistem√°tico de monitoramento de doen√ßas autoimunes descrito."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 8.6 aborda popula√ß√µes de alto risco: beb√™s prematuros (N=100 estudados), crian√ßas com doen√ßa falciforme, receptores de transplante de c√©lulas-tronco hematopo√©ticas, indiv√≠duos infectados pelo HIV. Advert√™ncia de apneia especificamente para beb√™s prematuros. Adultos com condi√ß√µes subjacentes est√°veis (cardiovasculares, pulmonares, diabetes, doen√ßa hep√°tica) inclu√≠dos.",
            "level_description": "M√∫ltiplos subgrupos vulner√°veis estudados com se√ß√µes dedicadas, embora os tamanhos de amostra para alguns grupos fossem limitados."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios de n√£o inferioridade especificados: limite inferior do IC 95% para diferen√ßa >-10% para taxas de respondedores; limite inferior do IC 95% para raz√£o de CMG >0,5. Efic√°cia vacinal calculada com intervalos de confian√ßa de 95,2%. Signific√¢ncia estat√≠stica notada como p<0,05 sem ajuste de multiplicidade.",
            "level_description": "Crit√©rios estat√≠sticos pr√©-especificados para desfechos de n√£o inferioridade e efic√°cia com intervalos de confian√ßa relatados, embora ajustes de multiplicidade nem sempre aplicados."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Identificadores ClinicalTrials.gov fornecidos para todos os 13 estudos (n√∫meros NCT listados na Se√ß√£o 15). Tabelas detalhadas com tamanhos de amostra, intervalos de confian√ßa e porcentagens fornecidas. Resultados de estudos individuais referenciados.",
            "level_description": "N√∫meros de registro de ensaios fornecidos e tabelas de dados detalhadas inclu√≠das, embora relat√≥rios completos de estudos n√£o sejam diretamente acess√≠veis a partir da bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.3 descreve a experi√™ncia p√≥s-comercializa√ß√£o com eventos adversos relatados atrav√©s de vigil√¢ncia passiva. Os eventos incluem: rea√ß√µes no local da vacina√ß√£o, linfadenopatia, cianose, rea√ß√µes anafil√°ticas, hipotonia, angioedema, eritema multiforme, apneia, palidez. Relato ao VAERS encorajado.",
            "level_description": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o descrito com eventos adversos espec√≠ficos identificados, embora reconhe√ßa limita√ß√µes dos relatos volunt√°rios."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhuma divulga√ß√£o de conflitos de interesse, fontes de financiamento ou relacionamentos dos investigadores com o fabricante no documento de prescri√ß√£o.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse inclu√≠da na bula."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Mortes pedi√°tricas: 3 (0,063%) em receptores de Prevnar 13, 1 (0,036%) em receptores de Prevnar, todas devido a SMSI, taxas consistentes com o baseline. Ensaios em adultos: 12 de 5.667 (0,21%) Prevnar 13 e 4 de 1.391 (0,29%) receptores de PPSV23 morreram. Estudo 12: 3.006 mortes (7,1%) em Prevnar 13 vs 3.005 (7,1%) em placebo em ~4 anos.",
            "level_description": "Mortalidade por todas as causas relatada para estudos pedi√°tricos e adultos com compara√ß√µes aos grupos controle n√£o mostrando evid√™ncia de rela√ß√£o causal com a vacina√ß√£o."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "A Prevnar 13 foi avaliada em extensos ensaios cl√≠nicos com tamanhos de amostra robustos, particularmente para popula√ß√µes pedi√°tricas. O ensaio de efic√°cia em adultos foi um estudo bem desenhado, randomizado, duplo-cego e controlado por placebo demonstrando efic√°cia de 45,6% contra PAC pneumoc√≥cica por tipos vacinais. A aprova√ß√£o pedi√°trica foi baseada principalmente na n√£o inferioridade imunol√≥gica em rela√ß√£o √† vacina Prevnar previamente licenciada, em vez de ensaios de efic√°cia diretos. Os pontos fortes incluem estratifica√ß√£o et√°ria abrangente, monitoramento padronizado de eventos adversos e coleta sistem√°tica de eventos adversos graves. As limita√ß√µes incluem uso de comparador ativo em vez de placebo em estudos pedi√°tricos, falta de divulga√ß√µes de conflito de interesse e monitoramento sistem√°tico limitado para condi√ß√µes autoimunes. A vigil√¢ncia p√≥s-comercializa√ß√£o continua a identificar eventos adversos raros."
        }
      },
      "safety_en": {
        "vaccine_id": "pcv_prevnar13",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Extensive pediatric safety data from 13 clinical trials with 4,729 infants/toddlers receiving Prevnar 13 and 2,760 receiving Prevnar control. In the 3 US studies alone, 1,907 subjects received Prevnar 13. Globally, 6,839 subjects received at least 1 dose. Additional studies evaluated catch-up vaccination in 354 children (7 months-5 years) and 592 children (5-17 years). This represents one of the larger pediatric vaccine safety databases."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited adverse reactions collected for 7 consecutive days after each vaccination via electronic diaries. Unsolicited adverse events monitored from first dose through one month after infant series and one month after toddler dose. Scripted telephone interview conducted 6 months after fourth dose. Serious adverse events collected throughout entire study period. While short-term follow-up is comprehensive, long-term pediatric follow-up beyond 6 months post-vaccination is limited."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Pediatric studies used active comparator (Prevnar 7-valent vaccine) rather than true placebo, limiting ability to detect vaccine-class adverse events. Some studies were open-label. Adult efficacy trial (Study 12) appropriately used saline placebo. This active-comparator design for pediatric studies is justified ethically but limits safety signal detection for effects common to pneumococcal conjugate vaccines."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active surveillance employed using electronic diaries for daily recording of solicited local and systemic reactions for 7-14 days post-vaccination. Parents/guardians provided training on symptom assessment. Clinic visits and scripted telephone interviews used for follow-up data collection. Serious adverse events actively collected throughout study periods. The methodology represents standard active surveillance practices."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Hypotonic-hyporesponsive episodes tracked: 1 case (0.015%) in Prevnar 13 vs 3 cases (0.071%) in Prevnar globally, all occurring when given with whole cell pertussis vaccine. Seizures (including febrile seizures) noted as adverse reactions but systematic neurological examination protocol not described. Apnea specifically monitored in premature infants with warning in labeling. Post-marketing reports include hypotonia. No dedicated neurological assessment battery."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 8.6 provides dedicated data on high-risk populations: premature infants (<37 weeks, N=100) with noted reduced immune responses; children with sickle cell disease (N=95-131); hematopoietic stem cell transplant recipients; HIV-infected subjects (N=197-257). Warning included about apnea risk in premature infants. Adults with stable chronic conditions (cardiovascular, pulmonary, diabetes, liver disease, alcoholism, smoking) were included in trials. Effectiveness in these populations not established from limited data."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "All 13 clinical studies registered on ClinicalTrials.gov with NCT identifiers provided. Detailed safety tables with percentages, sample sizes, and 95% confidence intervals included. Adverse reaction rates compared between vaccine and control groups. Demographic breakdowns provided (race, ethnicity, sex). Deaths enumerated with causes. However, individual patient-level data and full study protocols not directly accessible from prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.3 describes post-marketing experience from passive surveillance since market introduction. Identified events include: vaccination-site dermatitis/pruritus/urticaria, lymphadenopathy, cyanosis, anaphylactic/anaphylactoid reactions including shock, hypotonia, angioneurotic edema, erythema multiforme, apnea, and pallor. VAERS reporting contact information provided. Document acknowledges limitations that voluntary reporting cannot reliably estimate frequency or establish causality. Initial US approval was 2010, providing substantial post-marketing experience."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Prevnar 13 has a robust pediatric safety database with over 4,700 infants/toddlers in clinical trials and extensive post-marketing surveillance since 2010 approval. Common solicited reactions include irritability (>70%), injection site tenderness (>50%), decreased appetite (>40%), sleep changes (>40%), and fever (>20%). Serious adverse events occurred in 8.2% of Prevnar 13 vs 7.2% of Prevnar recipients, primarily infections (bronchiolitis, gastroenteritis, pneumonia). Three deaths occurred in Prevnar 13 recipients, all attributed to SIDS at rates consistent with background. Key limitations include use of active comparator rather than placebo in pediatric studies, limited long-term follow-up, and lack of systematic neurological assessment protocols. Post-marketing surveillance has identified rare serious events including anaphylaxis, hypotonia, and apnea. Special warning exists for premature infants regarding apnea risk."
        }
      },
      "safety_pt": {
        "vaccine_id": "pcv_prevnar13",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Dados extensos de seguran√ßa pedi√°trica de 13 ensaios cl√≠nicos com 4.729 beb√™s/crian√ßas pequenas recebendo Prevnar 13 e 2.760 recebendo controle Prevnar. Apenas nos 3 estudos dos EUA, 1.907 sujeitos receberam Prevnar 13. Globalmente, 6.839 sujeitos receberam pelo menos 1 dose. Estudos adicionais avaliaram vacina√ß√£o de recupera√ß√£o em 354 crian√ßas (7 meses-5 anos) e 592 crian√ßas (5-17 anos). Isso representa um dos maiores bancos de dados de seguran√ßa de vacinas pedi√°tricas."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Rea√ß√µes adversas solicitadas coletadas por 7 dias consecutivos ap√≥s cada vacina√ß√£o via di√°rios eletr√¥nicos. Eventos adversos n√£o solicitados monitorados desde a primeira dose at√© um m√™s ap√≥s a s√©rie infantil e um m√™s ap√≥s a dose de refor√ßo. Entrevista telef√¥nica programada conduzida 6 meses ap√≥s a quarta dose. Eventos adversos graves coletados durante todo o per√≠odo do estudo. Embora o acompanhamento de curto prazo seja abrangente, o acompanhamento pedi√°trico de longo prazo al√©m de 6 meses p√≥s-vacina√ß√£o √© limitado."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os estudos pedi√°tricos usaram comparador ativo (vacina Prevnar 7-valente) em vez de placebo verdadeiro, limitando a capacidade de detectar eventos adversos da classe vacinal. Alguns estudos foram abertos. O ensaio de efic√°cia em adultos (Estudo 12) usou placebo salino apropriadamente. Este design de comparador ativo para estudos pedi√°tricos √© justificado eticamente, mas limita a detec√ß√£o de sinais de seguran√ßa para efeitos comuns √†s vacinas conjugadas pneumoc√≥cicas."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Vigil√¢ncia ativa empregada usando di√°rios eletr√¥nicos para registro di√°rio de rea√ß√µes locais e sist√™micas solicitadas por 7-14 dias p√≥s-vacina√ß√£o. Pais/respons√°veis receberam treinamento na avalia√ß√£o de sintomas. Visitas cl√≠nicas e entrevistas telef√¥nicas programadas usadas para coleta de dados de acompanhamento. Eventos adversos graves ativamente coletados durante os per√≠odos dos estudos. A metodologia representa pr√°ticas padr√£o de vigil√¢ncia ativa."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Epis√≥dios hipot√¥nicos-hiporresponsivos rastreados: 1 caso (0,015%) em Prevnar 13 vs 3 casos (0,071%) em Prevnar globalmente, todos ocorrendo quando administrada com vacina de c√©lula inteira contra coqueluche. Convuls√µes (incluindo convuls√µes febr√≠s) notadas como rea√ß√µes adversas, mas protocolo sistem√°tico de exame neurol√≥gico n√£o descrito. Apneia especificamente monitorada em beb√™s prematuros com advert√™ncia na bula. Relatos p√≥s-comercializa√ß√£o incluem hipotonia. Nenhuma bateria de avalia√ß√£o neurol√≥gica dedicada."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 8.6 fornece dados dedicados sobre popula√ß√µes de alto risco: beb√™s prematuros (<37 semanas, N=100) com respostas imunes reduzidas observadas; crian√ßas com doen√ßa falciforme (N=95-131); receptores de transplante de c√©lulas-tronco hematopo√©ticas; sujeitos infectados pelo HIV (N=197-257). Advert√™ncia inclu√≠da sobre risco de apneia em beb√™s prematuros. Adultos com condi√ß√µes cr√¥nicas est√°veis (cardiovasculares, pulmonares, diabetes, doen√ßa hep√°tica, alcoolismo, tabagismo) foram inclu√≠dos nos ensaios. Efic√°cia nessas popula√ß√µes n√£o estabelecida a partir de dados limitados."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Todos os 13 estudos cl√≠nicos registrados no ClinicalTrials.gov com identificadores NCT fornecidos. Tabelas de seguran√ßa detalhadas com porcentagens, tamanhos de amostra e intervalos de confian√ßa de 95% inclu√≠das. Taxas de rea√ß√µes adversas comparadas entre grupos de vacina e controle. Detalhamentos demogr√°ficos fornecidos (ra√ßa, etnia, sexo). Mortes enumeradas com causas. No entanto, dados individuais de participantes e protocolos completos de estudos n√£o s√£o diretamente acess√≠veis a partir da bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.3 descreve a experi√™ncia p√≥s-comercializa√ß√£o da vigil√¢ncia passiva desde a introdu√ß√£o no mercado. Eventos identificados incluem: dermatite/prurido/urtic√°ria no local da vacina√ß√£o, linfadenopatia, cianose, rea√ß√µes anafil√°ticas/anafilactoides incluindo choque, hipotonia, angioedema, eritema multiforme, apneia e palidez. Informa√ß√µes de contato para relato ao VAERS fornecidas. O documento reconhece limita√ß√µes de que relatos volunt√°rios n√£o podem estimar frequ√™ncia de forma confi√°vel ou estabelecer causalidade. A aprova√ß√£o inicial nos EUA foi em 2010, proporcionando experi√™ncia p√≥s-comercializa√ß√£o substancial."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "A Prevnar 13 possui um banco de dados de seguran√ßa pedi√°trica robusto com mais de 4.700 beb√™s/crian√ßas pequenas em ensaios cl√≠nicos e vigil√¢ncia p√≥s-comercializa√ß√£o extensa desde a aprova√ß√£o em 2010. Rea√ß√µes solicitadas comuns incluem irritabilidade (>70%), sensibilidade no local da inje√ß√£o (>50%), diminui√ß√£o do apetite (>40%), altera√ß√µes do sono (>40%) e febre (>20%). Eventos adversos graves ocorreram em 8,2% de Prevnar 13 vs 7,2% de receptores de Prevnar, principalmente infec√ß√µes (bronquiolite, gastroenterite, pneumonia). Tr√™s mortes ocorreram em receptores de Prevnar 13, todas atribu√≠das a SMSI em taxas consistentes com o baseline. As principais limita√ß√µes incluem uso de comparador ativo em vez de placebo em estudos pedi√°tricos, acompanhamento de longo prazo limitado e falta de protocolos sistem√°ticos de avalia√ß√£o neurol√≥gica. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos graves raros incluindo anafilaxia, hipotonia e apneia. Existe advert√™ncia especial para beb√™s prematuros sobre risco de apneia."
        }
      }
    },
    {
      "id": "pcv_prevnar20",
      "name": "Prevnar 20",
      "type": "PCV",
      "manufacturer": "Pfizer",
      "description": "Pneumococcal 20-valent Conjugate Vaccine for prevention of invasive disease caused by Streptococcus pneumoniae.",
      "sources": [
        "pcv_prevnar20_insert.pdf",
        "pcv_prevnar20_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "pcv_prevnar20",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study B7471007: In Cohort 1 (adults >=60 years), PCV20/Saline group received saline as second dose, while comparator PCV13/PPSV23 group received active vaccines. Vaccination 1 compared PCV20 vs PCV13 (active comparator, not placebo). In Cohorts 2 and 3 (adults 18-59), comparison was PCV20 vs PCV13 with no placebo arm at all. Saline was only used for dose 2 in Cohort 1 to maintain blinding, not as a true safety control.",
            "level_description": "No true inert placebo control for the primary vaccine dose. Active comparator (PCV13) was used, which obscures true adverse event rates attributable specifically to PCV20."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Vaccination 1 (PCV20 or PCV13) was administered in a double-blind fashion as vaccines were identical in appearance and pre-filled syringes were packaged in blinded cartons. Vaccination 2 (PPSV23 or saline) was prepared by unblinded third-party staff who did not participate in subject assessments. Serology testing was performed blinded. All other study staff and Wyeth were blinded until database lock.",
            "level_description": "Appropriate double-blinding for first vaccination with observer-blinding for second dose. Laboratory personnel remained blinded throughout."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study B7471007: Randomized, multicenter study. Randomization ratio was 1:1 in Cohort 1 (>=60 years) and 3:1 in Cohorts 2 and 3 (younger adults). Study B7471008: Site-based randomization in 2:2:2:1 ratio for lot consistency study. Subjects were included in vaccine group as randomized in analyses.",
            "level_description": "Documented random allocation with predefined ratios by cohort. Allocation concealment maintained through blinded packaging."
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "This BLA was for adults >=18 years only. The document explicitly states: 'The safety and effectiveness of Prevnar 20 in persons less than 18 years of age have not been established.' Pediatric studies (B7471011, B7471013, B7471014) are deferred postmarketing requirements under PREA for ages 6 weeks through 16 years.",
            "level_description": "No pediatric data included in this submission. Vaccine approved only for adults. Pediatric studies are pending as postmarketing requirements."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Safety follow-up was 6 months after Vaccination 1 for SAEs and newly diagnosed chronic medical conditions (NDCMC). Solicited local reactions monitored 10 days post-vaccination; systemic reactions monitored 7 days post-vaccination. Unsolicited AEs collected through 1 month after each vaccination. Duration of subject participation was approximately 6 months.",
            "level_description": "6-month follow-up is below the ideal 12+ month minimum for detecting delayed autoimmune or neurological effects. Short-term reactogenicity monitoring was adequate (7-10 days)."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Study B7471007 enrolled adults into 3 age-based cohorts: Cohort 1 (>=60 years, with subgroups 60-64, 65-69, 70-79, >=80), Cohort 2 (50-59 years), Cohort 3 (18-49 years). Study B7471006 examined previously vaccinated adults >=65 years. Immunogenicity and safety analyzed separately by age cohort. OPA GMTs decreased with increasing age.",
            "level_description": "Excellent stratification by adult age groups with separate immunogenicity and safety analyses. However, no pediatric age stratification as this was adult-only."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Documented inclusion criteria: adults >=18 years determined eligible by clinical assessment, including those with preexisting stable disease (not requiring significant therapy change in 6 weeks or hospitalization in 12 weeks). Key exclusions: previous pneumococcal vaccination, severe allergic reactions, serious chronic disorders, immunosuppressive therapy, known/suspected immunodeficiency, history of microbiologically proven invasive pneumococcal disease.",
            "level_description": "Clear, well-defined criteria. Exclusion of immunocompromised individuals limits generalizability to real-world populations at highest risk for pneumococcal disease."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "MedDRA coding dictionary (version 22.0 for B7471007, version 22.1 for B7471008) was used. Solicited local reactions graded by severity (mild/moderate/severe) with objective thresholds: pain (interference with activity), swelling/redness (>2.0-5.0cm mild, >5.0-10.0cm moderate, >10.0cm severe). Fever graded by temperature ranges. Grade 4 defined as ER visit/hospitalization. Electronic diaries (e-diary) used for standardized daily recording.",
            "level_description": "Exemplary use of standardized MedDRA coding, objective grading scales, and electronic diary capture with high daily transmission rates (>=85%)."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "SAEs and NDCMCs actively monitored through 6 months post-Vaccination 1. Immediate adverse reactions monitored within 30 minutes after each vaccination. Narratives provided for all subjects withdrawn due to AE/SAE. In Study B7471007 Cohort 1: 2.4% PCV20 vs 1.9% PCV13 reported SAEs within 6 months. No SAEs considered vaccine-related by investigators.",
            "level_description": "Active SAE surveillance with detailed narratives and causality assessment. Clear distinction between solicited and unsolicited events maintained."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No specific monitoring protocol for autoimmune or neurological conditions such as Guillain-Barre syndrome, seizures, or encephalitis was documented. NDCMCs were captured broadly but no predefined list of neurological/autoimmune conditions to watch for. Search for 'neurological', 'autoimmune', 'Guillain', 'seizure' in document returned no relevant results.",
            "level_description": "No evidence of specific long-term neurological or autoimmune monitoring protocols. This represents a significant gap in safety assessment methodology."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Immunocompromised individuals were explicitly excluded from all trials. Document states: 'The safety and effectiveness of Prevnar 20 have not been established in immunocompromised individuals.' Exclusion criteria included: immunosuppressive therapy, known/suspected immunodeficiency, HIV, leukemia, lymphoma, organ transplant. No premature infants or pediatric vulnerable groups studied.",
            "level_description": "Vulnerable populations at highest risk for pneumococcal disease (immunocompromised) were systematically excluded. This is a major limitation for real-world applicability."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study powered for immunogenicity (72% power for noninferiority in OPA GMTs across 20 serotypes). Sample size: ~3,880 adults planned in B7471007. Linear regression models adjusting for age, baseline OPA titer, sex, smoking status. 2-sided 95% CIs calculated. Noninferiority margin of 0.5 for GMT ratio. Safety analyses were descriptive without hypothesis testing.",
            "level_description": "Studies appropriately powered for immunogenicity outcomes. Safety analyses were descriptive, not powered to detect rare adverse events - a common limitation."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "This is an FDA Clinical Review document (STN 125731/0) with detailed Clinical Study Reports cited. Comprehensive tables with subject-level disposition, demographics, and outcomes provided. Analysis populations clearly defined (safety, evaluable immunogenicity, all-available). Clinical Study Report tables referenced throughout.",
            "level_description": "Regulatory review document with substantial detail. However, individual participant data (IPD) not publicly available. No mention of independent DSMB."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Wyeth agrees to routine pharmacovigilance (monitoring unanticipated risks in surveillance systems and postmarketing adverse reaction reports). Study B7471015 is a postmarketing requirement for adults >=65 years. Three pediatric studies (B7471011, B7471013, B7471014) are PREA postmarketing requirements. Pharmacovigilance plan deemed adequate by reviewer.",
            "level_description": "Standard passive pharmacovigilance proposed. Confirmatory effectiveness study required as condition of accelerated approval. No active surveillance system described beyond routine reporting."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Studies conducted by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. All investigators were non-sponsor employees (0 sponsor employees as investigators). 4 investigators had significant equity interest in sponsor. Dr. Susan Brown was counted 3 times across studies. No independent funding source; manufacturer-sponsored throughout.",
            "level_description": "All studies manufacturer-sponsored without independent funding. Some investigators held equity in Pfizer. Full industry control over study design, conduct, and analysis."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "One death reported in Study B7471007: a 60-year-old Cohort 1 PCV20/saline recipient with history of suicide attempts, died from self-inflicted gunshot wound 48 days after Vaccination 2 (saline). Death not considered vaccine-related. Study B7471008: No deaths reported. Total deaths and SAEs reported across all groups.",
            "level_description": "All-cause mortality reported for all groups. Single death was from documented pre-existing psychiatric condition, appropriately assessed as unrelated."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This FDA clinical review of Prevnar 20 (PCV20) demonstrates adequate trial methodology for immunogenicity in adults >=18 years with appropriate randomization, blinding, and standardized adverse event capture. However, several significant limitations exist: (1) No true placebo control - PCV13 active comparator used, obscuring true adverse event rates; (2) No pediatric data - vaccine approved only for adults with pediatric studies deferred; (3) Immunocompromised populations explicitly excluded, limiting applicability to highest-risk groups; (4) Only 6 months follow-up, insufficient for detecting delayed autoimmune/neurological effects; (5) No specific neurological monitoring protocols; (6) Entirely manufacturer-sponsored with potential conflicts of interest. The safety profile was comparable to licensed PCV13, but the study design fundamentally cannot establish absolute safety, only relative safety compared to another vaccine."
        }
      },
      "trial_pt": {
        "vaccine_id": "pcv_prevnar20",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo B7471007: Na Coorte 1 (adultos >=60 anos), o grupo PCV20/Salina recebeu salina como segunda dose, enquanto o grupo comparador PCV13/PPSV23 recebeu vacinas ativas. A Vacina√ß√£o 1 comparou PCV20 vs PCV13 (comparador ativo, n√£o placebo). Nas Coortes 2 e 3 (adultos 18-59), a compara√ß√£o foi PCV20 vs PCV13 sem nenhum bra√ßo placebo. Salina foi usada apenas para a dose 2 na Coorte 1 para manter o cegamento, n√£o como controle de seguran√ßa verdadeiro.",
            "level_description": "Nenhum controle placebo inerte verdadeiro para a dose prim√°ria da vacina. Comparador ativo (PCV13) foi usado, o que obscurece as verdadeiras taxas de eventos adversos atribu√≠veis especificamente √† PCV20."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Vacina√ß√£o 1 (PCV20 ou PCV13) foi administrada de forma duplo-cega, pois as vacinas eram id√™nticas em apar√™ncia e as seringas preenchidas foram embaladas em caixas cegas. A Vacina√ß√£o 2 (PPSV23 ou salina) foi preparada por equipe terceirizada n√£o cega que n√£o participou das avalia√ß√µes dos sujeitos. Os testes sorol√≥gicos foram realizados de forma cega. Toda a outra equipe do estudo e a Wyeth permaneceram cegos at√© o bloqueio do banco de dados.",
            "level_description": "Duplo-cego apropriado para a primeira vacina√ß√£o com cegamento do observador para a segunda dose. O pessoal de laborat√≥rio permaneceu cego durante todo o estudo."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo B7471007: Estudo randomizado, multic√™ntrico. A propor√ß√£o de randomiza√ß√£o foi 1:1 na Coorte 1 (>=60 anos) e 3:1 nas Coortes 2 e 3 (adultos mais jovens). Estudo B7471008: Randomiza√ß√£o baseada no local em propor√ß√£o 2:2:2:1 para estudo de consist√™ncia de lote. Os sujeitos foram inclu√≠dos no grupo de vacina conforme randomizados nas an√°lises.",
            "level_description": "Aloca√ß√£o aleat√≥ria documentada com propor√ß√µes predefinidas por coorte. Oculta√ß√£o da aloca√ß√£o mantida atrav√©s de embalagem cega."
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Esta BLA foi apenas para adultos >=18 anos. O documento afirma explicitamente: 'A seguran√ßa e efic√°cia da Prevnar 20 em pessoas com menos de 18 anos de idade n√£o foram estabelecidas.' Estudos pedi√°tricos (B7471011, B7471013, B7471014) s√£o requisitos de p√≥s-comercializa√ß√£o adiados sob PREA para idades de 6 semanas a 16 anos.",
            "level_description": "Nenhum dado pedi√°trico inclu√≠do nesta submiss√£o. Vacina aprovada apenas para adultos. Estudos pedi√°tricos est√£o pendentes como requisitos de p√≥s-comercializa√ß√£o."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O acompanhamento de seguran√ßa foi de 6 meses ap√≥s a Vacina√ß√£o 1 para EAGs e condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas (CMCRD). Rea√ß√µes locais solicitadas monitoradas por 10 dias p√≥s-vacina√ß√£o; rea√ß√µes sist√™micas monitoradas por 7 dias p√≥s-vacina√ß√£o. EAs n√£o solicitados coletados at√© 1 m√™s ap√≥s cada vacina√ß√£o. A dura√ß√£o da participa√ß√£o do sujeito foi de aproximadamente 6 meses.",
            "level_description": "O acompanhamento de 6 meses est√° abaixo do m√≠nimo ideal de 12+ meses para detectar efeitos autoimunes ou neurol√≥gicos tardios. O monitoramento de reatogenicidade de curto prazo foi adequado (7-10 dias)."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O Estudo B7471007 incluiu adultos em 3 coortes baseadas em idade: Coorte 1 (>=60 anos, com subgrupos 60-64, 65-69, 70-79, >=80), Coorte 2 (50-59 anos), Coorte 3 (18-49 anos). O Estudo B7471006 examinou adultos previamente vacinados >=65 anos. Imunogenicidade e seguran√ßa analisadas separadamente por coorte et√°ria. Os TMGs de OPA diminu√≠ram com o aumento da idade.",
            "level_description": "Excelente estratifica√ß√£o por grupos et√°rios adultos com an√°lises de imunogenicidade e seguran√ßa separadas. No entanto, nenhuma estratifica√ß√£o et√°ria pedi√°trica, pois este foi apenas para adultos."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios de inclus√£o documentados: adultos >=18 anos determinados eleg√≠veis por avalia√ß√£o cl√≠nica, incluindo aqueles com doen√ßa est√°vel preexistente (n√£o requerendo mudan√ßa significativa de terapia em 6 semanas ou hospitaliza√ß√£o em 12 semanas). Exclus√µes principais: vacina√ß√£o pneumoc√≥cica pr√©via, rea√ß√µes al√©rgicas graves, dist√∫rbios cr√¥nicos graves, terapia imunossupressora, imunodefici√™ncia conhecida/suspeita, hist√≥rico de doen√ßa pneumoc√≥cica invasiva comprovada microbiologicamente.",
            "level_description": "Crit√©rios claros e bem definidos. A exclus√£o de indiv√≠duos imunocomprometidos limita a generaliza√ß√£o para popula√ß√µes do mundo real com maior risco de doen√ßa pneumoc√≥cica."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dicion√°rio de codifica√ß√£o MedDRA (vers√£o 22.0 para B7471007, vers√£o 22.1 para B7471008) foi usado. Rea√ß√µes locais solicitadas graduadas por gravidade (leve/moderada/grave) com limites objetivos: dor (interfer√™ncia com atividade), incha√ßo/vermelhid√£o (>2,0-5,0cm leve, >5,0-10,0cm moderado, >10,0cm grave). Febre graduada por faixas de temperatura. Grau 4 definido como visita ao PS/hospitaliza√ß√£o. Di√°rios eletr√¥nicos (e-diary) usados para registro di√°rio padronizado.",
            "level_description": "Uso exemplar de codifica√ß√£o MedDRA padronizada, escalas de gradua√ß√£o objetivas e captura de di√°rio eletr√¥nico com altas taxas de transmiss√£o di√°ria (>=85%)."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "EAGs e CMCRDs ativamente monitorados por 6 meses p√≥s-Vacina√ß√£o 1. Rea√ß√µes adversas imediatas monitoradas dentro de 30 minutos ap√≥s cada vacina√ß√£o. Narrativas fornecidas para todos os sujeitos retirados devido a EA/EAG. No Estudo B7471007 Coorte 1: 2,4% PCV20 vs 1,9% PCV13 relataram EAGs dentro de 6 meses. Nenhum EAG considerado relacionado √† vacina pelos investigadores.",
            "level_description": "Vigil√¢ncia ativa de EAG com narrativas detalhadas e avalia√ß√£o de causalidade. Clara distin√ß√£o entre eventos solicitados e n√£o solicitados mantida."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum protocolo de monitoramento espec√≠fico para condi√ß√µes autoimunes ou neurol√≥gicas como s√≠ndrome de Guillain-Barre, convuls√µes ou encefalite foi documentado. CMCRDs foram capturadas de forma ampla, mas nenhuma lista predefinida de condi√ß√µes neurol√≥gicas/autoimunes para observar. Busca por 'neurol√≥gico', 'autoimune', 'Guillain', 'convuls√£o' no documento n√£o retornou resultados relevantes.",
            "level_description": "Nenhuma evid√™ncia de protocolos espec√≠ficos de monitoramento neurol√≥gico ou autoimune de longo prazo. Isso representa uma lacuna significativa na metodologia de avalia√ß√£o de seguran√ßa."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Indiv√≠duos imunocomprometidos foram explicitamente exclu√≠dos de todos os ensaios. O documento afirma: 'A seguran√ßa e efic√°cia da Prevnar 20 n√£o foram estabelecidas em indiv√≠duos imunocomprometidos.' Crit√©rios de exclus√£o inclu√≠ram: terapia imunossupressora, imunodefici√™ncia conhecida/suspeita, HIV, leucemia, linfoma, transplante de √≥rg√£o. Nenhum beb√™ prematuro ou grupo vulner√°vel pedi√°trico estudado.",
            "level_description": "Popula√ß√µes vulner√°veis com maior risco de doen√ßa pneumoc√≥cica (imunocomprometidos) foram sistematicamente exclu√≠das. Esta √© uma limita√ß√£o importante para aplicabilidade no mundo real."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo dimensionado para imunogenicidade (72% de poder para n√£o inferioridade em TMGs de OPA atrav√©s de 20 sorotipos). Tamanho da amostra: ~3.880 adultos planejados no B7471007. Modelos de regress√£o linear ajustando para idade, t√≠tulo de OPA basal, sexo, status de tabagismo. ICs de 95% bilaterais calculados. Margem de n√£o inferioridade de 0,5 para raz√£o de TMG. An√°lises de seguran√ßa foram descritivas sem teste de hip√≥teses.",
            "level_description": "Estudos apropriadamente dimensionados para desfechos de imunogenicidade. An√°lises de seguran√ßa foram descritivas, n√£o dimensionadas para detectar eventos adversos raros - uma limita√ß√£o comum."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Este √© um documento de Revis√£o Cl√≠nica da FDA (STN 125731/0) com Relat√≥rios de Estudos Cl√≠nicos detalhados citados. Tabelas abrangentes com disposi√ß√£o de sujeitos, demografia e desfechos fornecidas. Popula√ß√µes de an√°lise claramente definidas (seguran√ßa, imunogenicidade avali√°vel, todos dispon√≠veis). Tabelas de Relat√≥rios de Estudos Cl√≠nicos referenciadas ao longo do documento.",
            "level_description": "Documento de revis√£o regulat√≥ria com detalhes substanciais. No entanto, dados individuais de participantes (DIP) n√£o est√£o publicamente dispon√≠veis. Nenhuma men√ß√£o de DSMB independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Wyeth concorda com farmacovigil√¢ncia de rotina (monitoramento de riscos n√£o antecipados em sistemas de vigil√¢ncia e relatos de rea√ß√µes adversas p√≥s-comercializa√ß√£o). O Estudo B7471015 √© um requisito de p√≥s-comercializa√ß√£o para adultos >=65 anos. Tr√™s estudos pedi√°tricos (B7471011, B7471013, B7471014) s√£o requisitos de p√≥s-comercializa√ß√£o PREA. O plano de farmacovigil√¢ncia foi considerado adequado pelo revisor.",
            "level_description": "Farmacovigil√¢ncia passiva padr√£o proposta. Estudo de efic√°cia confirmat√≥ria requerido como condi√ß√£o de aprova√ß√£o acelerada. Nenhum sistema de vigil√¢ncia ativa descrito al√©m de relatos de rotina."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Estudos conduzidos pela Wyeth Pharmaceuticals LLC, subsidi√°ria da Pfizer Inc. Todos os investigadores eram funcion√°rios n√£o-patrocinadores (0 funcion√°rios do patrocinador como investigadores). 4 investigadores tinham participa√ß√£o acion√°ria significativa no patrocinador. Dra. Susan Brown foi contada 3 vezes entre os estudos. Nenhuma fonte de financiamento independente; patrocinado pelo fabricante ao longo de todo o estudo.",
            "level_description": "Todos os estudos patrocinados pelo fabricante sem financiamento independente. Alguns investigadores detinham participa√ß√£o acion√°ria na Pfizer. Controle total da ind√∫stria sobre design, condu√ß√£o e an√°lise do estudo."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Uma morte relatada no Estudo B7471007: um receptor de PCV20/salina da Coorte 1 de 60 anos com hist√≥rico de tentativas de suic√≠dio, morreu por ferimento autoinfligido por arma de fogo 48 dias ap√≥s a Vacina√ß√£o 2 (salina). Morte n√£o considerada relacionada √† vacina. Estudo B7471008: Nenhuma morte relatada. Total de mortes e EAGs relatados em todos os grupos.",
            "level_description": "Mortalidade por todas as causas relatada para todos os grupos. A √∫nica morte foi de condi√ß√£o psiqui√°trica preexistente documentada, apropriadamente avaliada como n√£o relacionada."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Esta revis√£o cl√≠nica da FDA da Prevnar 20 (PCV20) demonstra metodologia de ensaio adequada para imunogenicidade em adultos >=18 anos com randomiza√ß√£o apropriada, cegamento e captura padronizada de eventos adversos. No entanto, existem v√°rias limita√ß√µes significativas: (1) Nenhum controle placebo verdadeiro - comparador ativo PCV13 usado, obscurecendo verdadeiras taxas de eventos adversos; (2) Nenhum dado pedi√°trico - vacina aprovada apenas para adultos com estudos pedi√°tricos adiados; (3) Popula√ß√µes imunocomprometidas explicitamente exclu√≠das, limitando aplicabilidade aos grupos de maior risco; (4) Apenas 6 meses de acompanhamento, insuficiente para detectar efeitos autoimunes/neurol√≥gicos tardios; (5) Nenhum protocolo espec√≠fico de monitoramento neurol√≥gico; (6) Totalmente patrocinado pelo fabricante com potenciais conflitos de interesse. O perfil de seguran√ßa foi compar√°vel √† PCV13 licenciada, mas o design do estudo fundamentalmente n√£o pode estabelecer seguran√ßa absoluta, apenas seguran√ßa relativa em compara√ß√£o com outra vacina."
        }
      },
      "safety_en": {
        "vaccine_id": "pcv_prevnar20",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "This clinical review covers only adult populations (>=18 years). The document explicitly states: 'The safety and effectiveness of Prevnar 20 in persons less than 18 years of age have not been established.' No children were studied. Pediatric studies (B7471011, B7471013, B7471014) covering ages 6 weeks through 17 years are deferred postmarketing requirements under PREA, meaning children will only be studied after adult approval."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Safety follow-up was 6 months after first vaccination for SAEs and newly diagnosed chronic medical conditions. Solicited local reactions were monitored for only 10 days, and systemic reactions for 7 days post-vaccination. The 6-month total follow-up falls short of the ideal 12+ month minimum needed to detect delayed effects. For children (when eventually studied), this duration would be particularly inadequate given developmental concerns."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "No true placebo (saline) control for the primary vaccine dose. PCV13 (another vaccine) served as the active comparator. In Cohort 1, saline was used only as the second dose to maintain blinding, not as a safety control. This design can only demonstrate that PCV20 is 'as safe as PCV13' rather than establishing absolute safety. True adverse event rates cannot be determined without an inert placebo comparison. The study was randomized and double-blind for the first dose."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active surveillance included: immediate monitoring within 30 minutes post-vaccination; electronic diaries (e-diary) for daily recording of local (10 days) and systemic (7 days) reactions with high transmission rates (>=85% daily); active collection of SAEs and newly diagnosed chronic medical conditions through 6 months; detailed narratives for all subjects withdrawn due to adverse events. Causality assessment performed by investigators for all SAEs."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "No specific neurological or developmental monitoring protocol was documented. There was no predefined list of neurological conditions to watch for (e.g., Guillain-Barre syndrome, seizures, encephalitis). Newly diagnosed chronic medical conditions (NDCMCs) were captured broadly, but searches for 'neurological', 'autoimmune', 'Guillain', and 'seizure' in the document returned no relevant monitoring protocols. This is a significant gap, especially concerning for eventual pediatric use."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Vulnerable populations were systematically excluded rather than studied. Immunocompromised individuals (those on immunosuppressive therapy, with HIV, leukemia, lymphoma, or organ transplants) were excluded. The document states: 'The safety and effectiveness of Prevnar 20 have not been established in immunocompromised individuals.' This excludes the population at highest risk for pneumococcal disease. No premature infants, chronically ill children, or pediatric immunocompromised patients were studied."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "This FDA Clinical Review (STN 125731/0) provides comprehensive data including subject disposition, demographics, adverse events by severity, SAE narratives, and detailed statistical tables. Clinical Study Reports are extensively referenced. However, individual participant-level data (IPD) is not publicly available for independent verification, and no independent Data Safety Monitoring Board (DSMB) is mentioned. All studies were manufacturer-sponsored by Wyeth/Pfizer."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Routine pharmacovigilance is planned, consisting of monitoring for unanticipated risks through surveillance systems and postmarketing adverse reaction reports. Study B7471015 is a postmarketing requirement to verify clinical effectiveness in adults >=65 years. Three pediatric studies are PREA postmarketing requirements. The pharmacovigilance reviewer deemed the plan adequate. However, this relies primarily on passive reporting systems rather than active population-based surveillance."
          }
        },
        "overall": {
          "rating": "absent",
          "emoji": "‚ùì",
          "summary": "This document provides NO safety evidence for children (0-12 years). Prevnar 20 (PCV20) was approved solely for adults >=18 years based on this submission, with the explicit statement that safety and effectiveness in persons under 18 years have not been established. Pediatric studies are deferred postmarketing requirements, meaning children will only be studied after adult market approval. For the adult population studied, the safety profile was comparable to licensed PCV13, but critical limitations include: (1) No inert placebo control to establish absolute adverse event rates; (2) Only 6 months follow-up; (3) Complete exclusion of immunocompromised individuals; (4) No specific neurological/autoimmune monitoring; (5) Entirely manufacturer-sponsored research. A parent seeking reassurance about this vaccine's safety in children cannot find that evidence in this document - it simply does not exist yet."
        }
      },
      "safety_pt": {
        "vaccine_id": "pcv_prevnar20",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Esta revis√£o cl√≠nica cobre apenas popula√ß√µes adultas (>=18 anos). O documento afirma explicitamente: 'A seguran√ßa e efic√°cia da Prevnar 20 em pessoas com menos de 18 anos de idade n√£o foram estabelecidas.' Nenhuma crian√ßa foi estudada. Estudos pedi√°tricos (B7471011, B7471013, B7471014) cobrindo idades de 6 semanas a 17 anos s√£o requisitos de p√≥s-comercializa√ß√£o adiados sob PREA, significando que crian√ßas s√≥ ser√£o estudadas ap√≥s a aprova√ß√£o para adultos."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O acompanhamento de seguran√ßa foi de 6 meses ap√≥s a primeira vacina√ß√£o para EAGs e condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas. Rea√ß√µes locais solicitadas foram monitoradas por apenas 10 dias, e rea√ß√µes sist√™micas por 7 dias p√≥s-vacina√ß√£o. O acompanhamento total de 6 meses fica aqu√©m do m√≠nimo ideal de 12+ meses necess√°rio para detectar efeitos tardios. Para crian√ßas (quando eventualmente estudadas), esta dura√ß√£o seria particularmente inadequada dadas as preocupa√ß√µes de desenvolvimento."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Nenhum controle placebo verdadeiro (salina) para a dose prim√°ria da vacina. PCV13 (outra vacina) serviu como comparador ativo. Na Coorte 1, salina foi usada apenas como segunda dose para manter o cegamento, n√£o como controle de seguran√ßa. Este design s√≥ pode demonstrar que PCV20 √© 't√£o segura quanto PCV13' em vez de estabelecer seguran√ßa absoluta. As verdadeiras taxas de eventos adversos n√£o podem ser determinadas sem uma compara√ß√£o com placebo inerte. O estudo foi randomizado e duplo-cego para a primeira dose."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A vigil√¢ncia ativa incluiu: monitoramento imediato dentro de 30 minutos p√≥s-vacina√ß√£o; di√°rios eletr√¥nicos (e-diary) para registro di√°rio de rea√ß√µes locais (10 dias) e sist√™micas (7 dias) com altas taxas de transmiss√£o (>=85% di√°rio); coleta ativa de EAGs e condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas por 6 meses; narrativas detalhadas para todos os sujeitos retirados devido a eventos adversos. Avalia√ß√£o de causalidade realizada pelos investigadores para todos os EAGs."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Nenhum protocolo espec√≠fico de monitoramento neurol√≥gico ou de desenvolvimento foi documentado. N√£o havia lista predefinida de condi√ß√µes neurol√≥gicas para observar (ex., s√≠ndrome de Guillain-Barre, convuls√µes, encefalite). Condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas (CMCRDs) foram capturadas de forma ampla, mas buscas por 'neurol√≥gico', 'autoimune', 'Guillain' e 'convuls√£o' no documento n√£o retornaram protocolos de monitoramento relevantes. Esta √© uma lacuna significativa, especialmente preocupante para eventual uso pedi√°trico."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Popula√ß√µes vulner√°veis foram sistematicamente exclu√≠das em vez de estudadas. Indiv√≠duos imunocomprometidos (aqueles em terapia imunossupressora, com HIV, leucemia, linfoma ou transplantes de √≥rg√£os) foram exclu√≠dos. O documento afirma: 'A seguran√ßa e efic√°cia da Prevnar 20 n√£o foram estabelecidas em indiv√≠duos imunocomprometidos.' Isso exclui a popula√ß√£o com maior risco de doen√ßa pneumoc√≥cica. Nenhum beb√™ prematuro, crian√ßa cronicamente doente ou paciente pedi√°trico imunocomprometido foi estudado."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Esta Revis√£o Cl√≠nica da FDA (STN 125731/0) fornece dados abrangentes incluindo disposi√ß√£o de sujeitos, demografia, eventos adversos por gravidade, narrativas de EAG e tabelas estat√≠sticas detalhadas. Relat√≥rios de Estudos Cl√≠nicos s√£o extensivamente referenciados. No entanto, dados individuais de participantes (DIP) n√£o est√£o publicamente dispon√≠veis para verifica√ß√£o independente, e nenhum Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB) √© mencionado. Todos os estudos foram patrocinados pelo fabricante Wyeth/Pfizer."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Farmacovigil√¢ncia de rotina est√° planejada, consistindo em monitoramento de riscos n√£o antecipados atrav√©s de sistemas de vigil√¢ncia e relatos de rea√ß√µes adversas p√≥s-comercializa√ß√£o. O Estudo B7471015 √© um requisito de p√≥s-comercializa√ß√£o para verificar a efic√°cia cl√≠nica em adultos >=65 anos. Tr√™s estudos pedi√°tricos s√£o requisitos de p√≥s-comercializa√ß√£o PREA. O revisor de farmacovigil√¢ncia considerou o plano adequado. No entanto, isso depende principalmente de sistemas de relato passivo em vez de vigil√¢ncia ativa de base populacional."
          }
        },
        "overall": {
          "rating": "absent",
          "emoji": "‚ùì",
          "summary": "Este documento N√ÉO fornece evid√™ncias de seguran√ßa para crian√ßas (0-12 anos). A Prevnar 20 (PCV20) foi aprovada exclusivamente para adultos >=18 anos com base nesta submiss√£o, com a afirma√ß√£o expl√≠cita de que a seguran√ßa e efic√°cia em pessoas com menos de 18 anos n√£o foram estabelecidas. Estudos pedi√°tricos s√£o requisitos de p√≥s-comercializa√ß√£o adiados, significando que crian√ßas s√≥ ser√£o estudadas ap√≥s a aprova√ß√£o para comercializa√ß√£o em adultos. Para a popula√ß√£o adulta estudada, o perfil de seguran√ßa foi compar√°vel √† PCV13 licenciada, mas limita√ß√µes cr√≠ticas incluem: (1) Nenhum controle placebo inerte para estabelecer taxas absolutas de eventos adversos; (2) Apenas 6 meses de acompanhamento; (3) Exclus√£o completa de indiv√≠duos imunocomprometidos; (4) Nenhum monitoramento neurol√≥gico/autoimune espec√≠fico; (5) Pesquisa totalmente patrocinada pelo fabricante. Um pai buscando seguran√ßa sobre a seguran√ßa desta vacina em crian√ßas n√£o pode encontrar essa evid√™ncia neste documento - ela simplesmente ainda n√£o existe."
        }
      }
    },
    {
      "id": "pcv_vaxneuvance",
      "name": "Vaxneuvance",
      "type": "PCV",
      "manufacturer": "Merck",
      "description": "Pneumococcal 15-valent Conjugate Vaccine for prevention of invasive disease caused by Streptococcus pneumoniae.",
      "sources": [
        "pcv_vaxneuvance_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "pcv_vaxneuvance",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All clinical studies used active comparator (Prevnar 13) rather than placebo. Studies 8-12 in children and Studies 1-7 in adults compared VAXNEUVANCE to Prevnar 13. No true placebo-controlled trials were conducted.",
            "level_description": "No placebo control groups were used; all trials compared against an existing pneumococcal conjugate vaccine (Prevnar 13), limiting the ability to assess true vaccine efficacy and safety versus no intervention."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The document consistently describes studies as 'double-blind, active comparator-controlled' clinical studies. Study 8 was 'a multicenter, double-blind, active comparator-controlled study.' Studies 1-5 and 7 in adults and Studies 8-12 in children were all double-blind.",
            "level_description": "Robust double-blinding was implemented across all major clinical trials in both pediatric and adult populations, minimizing bias in outcome assessment."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "All studies were randomized. Study 8 randomized participants to VAXNEUVANCE (N=860) or Prevnar 13 (N=860). Study 9 randomized in 1:1:1:1:1 ratio. Study 2 was randomized 9:1. Study 4 was randomized 3:1. Study 12 randomized participants to VAXNEUVANCE (N=303) or Prevnar 13 (N=303).",
            "level_description": "Clear randomization schemes were implemented across all clinical studies with specified allocation ratios, ensuring proper distribution of participants between vaccination groups."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "3,349 participants received at least one dose of VAXNEUVANCE in the 4-dose series studies (Studies 8-11). 1,814 received Prevnar 13. Study 8 alone had N=858 VAXNEUVANCE and N=855 Prevnar 13. In the US, 2,827 participants received at least one dose. Study 12 had N=303 VAXNEUVANCE in catch-up vaccination.",
            "level_description": "Large pediatric sample sizes exceeding 3,000 participants for VAXNEUVANCE across multiple studies provide robust statistical power for safety and immunogenicity assessments."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Safety follow-up for serious adverse events was 1 month in Study 11 and 6 months in Studies 8-10 for children. In adults, follow-up was 1 month (Study 5), 2 months (Study 7), 6 months (Studies 1, 2, 4, 6), and 12 months (Study 3). Solicited adverse reactions monitored for 14 days post-vaccination.",
            "level_description": "Follow-up periods varied from 1 to 12 months depending on study, with most having 6-month serious adverse event follow-up. Short-term solicited reactions tracked for 14 days."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Distinct age cohorts were studied: infants 6 weeks-15 months (4-dose series), 7-11 months, 12-23 months, 2-17 years (catch-up), adults 18-49 years, adults 50+ years, and adults 65+ years. Special populations included preterm infants, children with sickle cell disease, and HIV-infected individuals.",
            "level_description": "Comprehensive age stratification across multiple pediatric and adult cohorts with separate analyses for different developmental stages and risk groups."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The prescribing information provides limited detail on inclusion/exclusion criteria. Studies included 'healthy infants' and 'children.' Adult studies included those 'with stable underlying medical conditions' and 'behavioral risk factors.' Contraindication mentioned for severe allergic reaction to vaccine components.",
            "level_description": "General eligibility descriptions provided but detailed inclusion/exclusion criteria are not fully specified in the prescribing information document."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety monitored using Vaccination Report Card (VRC) for up to 14 days post-vaccination. Solicited injection-site reactions (pain, induration, erythema, swelling) and systemic reactions (irritability, somnolence, fever, decreased appetite) were standardized. Severity grades defined (mild, moderate, severe).",
            "level_description": "Standardized adverse event collection with predefined categories, severity scales, and consistent monitoring across studies using validated instruments."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Serious adverse events were actively monitored for up to 6 months in most pediatric studies and 6-12 months in adult studies. In children, SAEs up to 6 months were 9.6% (VAXNEUVANCE) vs 8.9% (Prevnar 13). In adults, SAEs within 30 days were 0.4% (VAXNEUVANCE) vs 0.7% (Prevnar 13); within 6 months, 2.5% vs 2.4%.",
            "level_description": "Active serious adverse event monitoring was conducted with specified follow-up periods and comparative analysis between groups, though reliance on active comparator limits absolute safety assessment."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One febrile seizure reported in a 9-week-old female one day after receiving VAXNEUVANCE Dose 1 and recommended infant vaccines. Apnea in premature infants is mentioned as a warning. No specific monitoring or reporting of autoimmune conditions described.",
            "level_description": "Limited neurological event reporting (febrile seizure mentioned). No systematic autoimmune condition monitoring described in the document."
          },
          "vulnerable_subgroups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Multiple vulnerable populations studied: preterm infants (<37 weeks gestation, N=142 VAXNEUVANCE vs N=144 Prevnar 13), children with sickle cell disease (N=70 vs N=34), HIV-infected children (N=203 vs N=204), HIV-infected adults (N=152 vs N=150), hematopoietic stem cell transplant recipients (N=139 vs N=138), adults with underlying conditions.",
            "level_description": "Comprehensive evaluation in immunocompromised and vulnerable populations including preterm infants, sickle cell disease, HIV infection, and transplant recipients with dedicated study arms."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Noninferiority criteria specified: IgG response rates >-10 percentage points, GMC ratios >0.5. Statistical methods included Miettinen & Nurminen method for CIs, t-distribution for GMC ratios, constrained longitudinal data analysis (cLDA) models. 95% confidence intervals provided throughout.",
            "level_description": "Rigorous statistical methodology with pre-specified noninferiority margins, appropriate models, and comprehensive confidence interval reporting for immunogenicity endpoints."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "ClinicalTrials.gov identifiers provided for all studies (NCT03893448, NCT03620162, NCT03692871, NCT02987972, etc.). Detailed tables of adverse reactions and immunogenicity data presented. GMTs, GMCs, response rates, and confidence intervals reported.",
            "level_description": "Clinical trial registration numbers provided, detailed numerical data in tables. Full study protocols and individual participant data not included in prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Instructions to report suspected adverse reactions to Merck at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov. Patient counseling section instructs reporting serious adverse reactions through healthcare providers to VAERS.",
            "level_description": "Standard post-marketing surveillance mechanisms through VAERS are referenced. No active post-marketing study commitments or results described in the document."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No disclosure of conflicts of interest, study funding sources, or investigator relationships mentioned in the prescribing information.",
            "level_description": "The prescribing information does not contain conflict of interest disclosures. Studies conducted by manufacturer (Merck) but no specific COI statements provided."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No all-cause mortality data reported in the prescribing information. Serious adverse events reported as percentages but deaths not specifically enumerated or discussed.",
            "level_description": "All-cause mortality is not reported in the prescribing information document for either treatment group in any study."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "VAXNEUVANCE clinical trials demonstrate robust methodology with double-blind, randomized design across large pediatric (>3,300) and adult (>5,600) populations. Studies used active comparator (Prevnar 13) rather than placebo control, limiting true efficacy/safety assessment vs no intervention. Excellent age stratification and vulnerable subgroup evaluation including preterm infants, sickle cell disease, HIV infection, and transplant recipients. Standardized adverse event monitoring with 6-month serious adverse event follow-up in most studies. Statistical analyses well-specified with noninferiority criteria. Key gaps include absence of placebo control, limited autoimmune/neurological monitoring detail, no all-cause mortality reporting, and no conflict of interest disclosure."
        }
      },
      "trial_pt": {
        "vaccine_id": "pcv_vaxneuvance",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos cl√≠nicos utilizaram comparador ativo (Prevnar 13) em vez de placebo. Os Estudos 8-12 em crian√ßas e os Estudos 1-7 em adultos compararam VAXNEUVANCE ao Prevnar 13. Nenhum ensaio controlado por placebo verdadeiro foi conduzido.",
            "level_description": "Nenhum grupo de controle com placebo foi utilizado; todos os ensaios foram comparados com uma vacina conjugada pneumoc√≥cica existente (Prevnar 13), limitando a capacidade de avaliar a verdadeira efic√°cia e seguran√ßa da vacina versus nenhuma interven√ß√£o."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O documento descreve consistentemente os estudos como 'estudos cl√≠nicos duplo-cegos, controlados por comparador ativo'. O Estudo 8 foi 'um estudo multic√™ntrico, duplo-cego, controlado por comparador ativo'. Os Estudos 1-5 e 7 em adultos e os Estudos 8-12 em crian√ßas foram todos duplo-cegos.",
            "level_description": "Duplo-cegamento robusto foi implementado em todos os principais ensaios cl√≠nicos em popula√ß√µes pedi√°tricas e adultas, minimizando o vi√©s na avalia√ß√£o dos resultados."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Todos os estudos foram randomizados. O Estudo 8 randomizou participantes para VAXNEUVANCE (N=860) ou Prevnar 13 (N=860). O Estudo 9 randomizou na propor√ß√£o 1:1:1:1:1. O Estudo 2 foi randomizado 9:1. O Estudo 4 foi randomizado 3:1. O Estudo 12 randomizou participantes para VAXNEUVANCE (N=303) ou Prevnar 13 (N=303).",
            "level_description": "Esquemas claros de randomiza√ß√£o foram implementados em todos os estudos cl√≠nicos com propor√ß√µes de aloca√ß√£o especificadas, garantindo distribui√ß√£o adequada dos participantes entre os grupos de vacina√ß√£o."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "3.349 participantes receberam pelo menos uma dose de VAXNEUVANCE na s√©rie de 4 doses (Estudos 8-11). 1.814 receberam Prevnar 13. Somente o Estudo 8 teve N=858 VAXNEUVANCE e N=855 Prevnar 13. Nos EUA, 2.827 participantes receberam pelo menos uma dose. O Estudo 12 teve N=303 VAXNEUVANCE em vacina√ß√£o de resgate.",
            "level_description": "Grandes amostras pedi√°tricas excedendo 3.000 participantes para VAXNEUVANCE em m√∫ltiplos estudos fornecem poder estat√≠stico robusto para avalia√ß√µes de seguran√ßa e imunogenicidade."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O acompanhamento de seguran√ßa para eventos adversos graves foi de 1 m√™s no Estudo 11 e 6 meses nos Estudos 8-10 para crian√ßas. Em adultos, o acompanhamento foi de 1 m√™s (Estudo 5), 2 meses (Estudo 7), 6 meses (Estudos 1, 2, 4, 6) e 12 meses (Estudo 3). Rea√ß√µes adversas solicitadas monitoradas por 14 dias ap√≥s a vacina√ß√£o.",
            "level_description": "Os per√≠odos de acompanhamento variaram de 1 a 12 meses dependendo do estudo, com a maioria tendo 6 meses de acompanhamento de eventos adversos graves. Rea√ß√µes solicitadas de curto prazo rastreadas por 14 dias."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Coortes et√°rios distintos foram estudados: beb√™s de 6 semanas a 15 meses (s√©rie de 4 doses), 7-11 meses, 12-23 meses, 2-17 anos (resgate), adultos de 18-49 anos, adultos 50+ anos e adultos 65+ anos. Popula√ß√µes especiais inclu√≠ram beb√™s prematuros, crian√ßas com doen√ßa falciforme e indiv√≠duos infectados pelo HIV.",
            "level_description": "Estratifica√ß√£o et√°ria abrangente em m√∫ltiplas coortes pedi√°tricas e adultas com an√°lises separadas para diferentes est√°gios de desenvolvimento e grupos de risco."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A bula fornece detalhes limitados sobre os crit√©rios de inclus√£o/exclus√£o. Os estudos inclu√≠ram 'beb√™s saud√°veis' e 'crian√ßas'. Estudos em adultos inclu√≠ram aqueles 'com condi√ß√µes m√©dicas subjacentes est√°veis' e 'fatores de risco comportamentais'. Contraindica√ß√£o mencionada para rea√ß√£o al√©rgica grave a componentes da vacina.",
            "level_description": "Descri√ß√µes gerais de elegibilidade fornecidas, mas crit√©rios detalhados de inclus√£o/exclus√£o n√£o est√£o totalmente especificados no documento de prescri√ß√£o."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Seguran√ßa monitorada usando Cart√£o de Registro de Vacina√ß√£o (VRC) por at√© 14 dias ap√≥s a vacina√ß√£o. Rea√ß√µes solicitadas no local da inje√ß√£o (dor, endurecimento, eritema, incha√ßo) e rea√ß√µes sist√™micas (irritabilidade, sonol√™ncia, febre, diminui√ß√£o do apetite) foram padronizadas. Graus de gravidade definidos (leve, moderado, grave).",
            "level_description": "Coleta padronizada de eventos adversos com categorias predefinidas, escalas de gravidade e monitoramento consistente entre estudos usando instrumentos validados."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos graves foram monitorados ativamente por at√© 6 meses na maioria dos estudos pedi√°tricos e 6-12 meses em estudos com adultos. Em crian√ßas, EAGs at√© 6 meses foram 9,6% (VAXNEUVANCE) vs 8,9% (Prevnar 13). Em adultos, EAGs dentro de 30 dias foram 0,4% (VAXNEUVANCE) vs 0,7% (Prevnar 13); dentro de 6 meses, 2,5% vs 2,4%.",
            "level_description": "Monitoramento ativo de eventos adversos graves foi conduzido com per√≠odos de acompanhamento especificados e an√°lise comparativa entre grupos, embora a depend√™ncia de comparador ativo limite a avalia√ß√£o absoluta de seguran√ßa."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Uma convuls√£o febril foi relatada em uma beb√™ feminina de 9 semanas um dia ap√≥s receber a Dose 1 de VAXNEUVANCE e vacinas infantis recomendadas. Apneia em beb√™s prematuros √© mencionada como advert√™ncia. Nenhum monitoramento ou relato espec√≠fico de condi√ß√µes autoimunes foi descrito.",
            "level_description": "Relato limitado de eventos neurol√≥gicos (convuls√£o febril mencionada). Nenhum monitoramento sistem√°tico de condi√ß√µes autoimunes descrito no documento."
          },
          "vulnerable_subgroups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "M√∫ltiplas popula√ß√µes vulner√°veis estudadas: beb√™s prematuros (<37 semanas de gesta√ß√£o, N=142 VAXNEUVANCE vs N=144 Prevnar 13), crian√ßas com doen√ßa falciforme (N=70 vs N=34), crian√ßas infectadas pelo HIV (N=203 vs N=204), adultos infectados pelo HIV (N=152 vs N=150), receptores de transplante de c√©lulas-tronco hematopoi√©ticas (N=139 vs N=138), adultos com condi√ß√µes subjacentes.",
            "level_description": "Avalia√ß√£o abrangente em popula√ß√µes imunocomprometidas e vulner√°veis, incluindo beb√™s prematuros, doen√ßa falciforme, infec√ß√£o por HIV e receptores de transplante com bra√ßos de estudo dedicados."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Crit√©rios de n√£o-inferioridade especificados: taxas de resposta de IgG >-10 pontos percentuais, raz√µes de GMC >0,5. M√©todos estat√≠sticos inclu√≠ram m√©todo de Miettinen & Nurminen para ICs, distribui√ß√£o t para raz√µes de GMC, modelos de an√°lise de dados longitudinais restritos (cLDA). Intervalos de confian√ßa de 95% fornecidos ao longo do documento.",
            "level_description": "Metodologia estat√≠stica rigorosa com margens de n√£o-inferioridade pr√©-especificadas, modelos apropriados e relat√≥rio abrangente de intervalos de confian√ßa para desfechos de imunogenicidade."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Identificadores do ClinicalTrials.gov fornecidos para todos os estudos (NCT03893448, NCT03620162, NCT03692871, NCT02987972, etc.). Tabelas detalhadas de rea√ß√µes adversas e dados de imunogenicidade apresentadas. GMTs, GMCs, taxas de resposta e intervalos de confian√ßa relatados.",
            "level_description": "N√∫meros de registro de ensaios cl√≠nicos fornecidos, dados num√©ricos detalhados em tabelas. Protocolos completos de estudos e dados individuais de participantes n√£o inclu√≠dos na bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Instru√ß√µes para relatar rea√ß√µes adversas suspeitas √† Merck em 1-877-888-4231 ou ao VAERS em 1-800-822-7967 ou www.vaers.hhs.gov. A se√ß√£o de aconselhamento ao paciente instrui a relatar rea√ß√µes adversas graves atrav√©s de profissionais de sa√∫de ao VAERS.",
            "level_description": "Mecanismos padr√£o de vigil√¢ncia p√≥s-comercializa√ß√£o atrav√©s do VAERS s√£o referenciados. Nenhum compromisso ou resultado de estudo p√≥s-comercializa√ß√£o ativo descrito no documento."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhuma divulga√ß√£o de conflitos de interesse, fontes de financiamento de estudos ou relacionamentos de investigadores mencionada na bula.",
            "level_description": "A bula n√£o cont√©m divulga√ß√µes de conflito de interesse. Estudos conduzidos pelo fabricante (Merck), mas nenhuma declara√ß√£o espec√≠fica de COI fornecida."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum dado de mortalidade por todas as causas relatado na bula. Eventos adversos graves relatados como porcentagens, mas mortes n√£o s√£o especificamente enumeradas ou discutidas.",
            "level_description": "Mortalidade por todas as causas n√£o √© relatada no documento de prescri√ß√£o para nenhum grupo de tratamento em qualquer estudo."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Os ensaios cl√≠nicos de VAXNEUVANCE demonstram metodologia robusta com desenho duplo-cego randomizado em grandes popula√ß√µes pedi√°tricas (>3.300) e adultas (>5.600). Os estudos usaram comparador ativo (Prevnar 13) em vez de controle placebo, limitando a verdadeira avalia√ß√£o de efic√°cia/seguran√ßa vs nenhuma interven√ß√£o. Excelente estratifica√ß√£o et√°ria e avalia√ß√£o de subgrupos vulner√°veis incluindo beb√™s prematuros, doen√ßa falciforme, infec√ß√£o por HIV e receptores de transplante. Monitoramento padronizado de eventos adversos com acompanhamento de 6 meses para eventos adversos graves na maioria dos estudos. An√°lises estat√≠sticas bem especificadas com crit√©rios de n√£o-inferioridade. Lacunas principais incluem aus√™ncia de controle placebo, detalhes limitados de monitoramento autoimune/neurol√≥gico, nenhum relato de mortalidade por todas as causas e nenhuma divulga√ß√£o de conflito de interesse."
        }
      },
      "safety_en": {
        "vaccine_id": "pcv_vaxneuvance",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "3,349 children received at least one dose of VAXNEUVANCE in the 4-dose series across Studies 8-11. 1,814 received Prevnar 13 as comparator. In the US alone, 2,827 participants received at least one dose and 2,409 completed the 4-dose series. Study 12 (catch-up vaccination) included 303 participants receiving VAXNEUVANCE ages 7 months to 17 years. Special populations included 142 preterm infants, 70 children with sickle cell disease, and 203 HIV-infected children. This represents a substantial pediatric safety database across multiple age groups and risk categories."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited adverse reactions monitored for 14 days post-vaccination using Vaccination Report Cards. Fever specifically monitored for 7 days. Unsolicited adverse events collected through 14 days. Serious adverse events followed for 1 month in Study 11, 6 months in Studies 8-10 and 12 for children. While the 6-month SAE follow-up is reasonable, longer-term safety monitoring (1-2+ years) would strengthen the safety profile assessment, particularly for potential delayed adverse events."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "All studies used Prevnar 13 (another pneumococcal conjugate vaccine) as active comparator rather than true placebo. While this allows head-to-head comparison with existing standard of care, it limits ability to assess absolute safety profile. SAEs in children: 9.6% VAXNEUVANCE vs 8.9% Prevnar 13 at 6 months. In adults within 30 days: 0.4% vs 0.7%; within 6 months: 2.5% vs 2.4%. The lack of placebo arm means background rates of adverse events cannot be determined, and any safety signals common to both vaccines would not be detected."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active surveillance implemented using standardized Vaccination Report Cards reviewed by investigators 15 days post-vaccination. Solicited local reactions (pain, induration, erythema, swelling) and systemic reactions (irritability, somnolence, fever, decreased appetite, urticaria in children; fatigue, headache, myalgia, arthralgia in adults) systematically collected. Severity grading defined (mild, moderate, severe with specific criteria). Temperature monitored via rectal or axillary measurement in children. However, active follow-up limited to 14 days for most outcomes."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Limited neurological adverse event reporting. One febrile seizure documented in a 9-week-old female one day after receiving VAXNEUVANCE Dose 1 with concomitant infant vaccines. Apnea in premature infants mentioned as a warning in Section 5.3, with recommendation that vaccination timing be based on individual infant's medical status. No systematic monitoring for other neurological conditions (e.g., Guillain-Barre syndrome, encephalitis, other seizure disorders) described. No specific autoimmune condition surveillance mentioned."
          },
          "vulnerable_subgroups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Extensive vulnerable population assessment: (1) Preterm infants <37 weeks gestation (N=142 VAXNEUVANCE, N=144 Prevnar 13) - safety profile similar to term infants and Prevnar 13; (2) Children with sickle cell disease ages 5-17 (N=70 vs N=34) - similar safety to Prevnar 13; (3) HIV-infected children 6-17 years with CD4+ >=200 cells/uL (N=203 vs N=204) - similar safety profile; (4) HIV-infected adults 18+ with CD4+ >=50 cells/uL (N=152 vs N=150); (5) Allogeneic HSCT recipients 3-6 months post-transplant (N=139 vs N=138). Adults with stable underlying conditions (diabetes, renal, cardiac, liver, lung disease) and behavioral risk factors also included."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "ClinicalTrials.gov identifiers provided for all studies enabling verification (NCT03893448, NCT03620162, NCT03692871, NCT02987972, NCT03885934, NCT03950622, NCT03950856, NCT03480763, NCT03547167, NCT02573181, NCT03615482, NCT03480802, NCT03731182, NCT03921424, NCT03565900). Detailed safety tables with percentages for solicited adverse reactions by severity grade, dose number, and age group. SAE percentages reported. However, individual serious adverse event descriptions, detailed breakdown by SAE type, and deaths are not enumerated. Raw data not available in prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Standard post-marketing surveillance mechanisms established through VAERS (Vaccine Adverse Event Reporting System) at 1-800-822-7967 or www.vaers.hhs.gov, and manufacturer reporting to Merck at 1-877-888-4231. Patient counseling section specifically instructs healthcare providers and patients/guardians to report serious adverse reactions. However, no active post-marketing surveillance studies or commitments described. No post-marketing safety data included (vaccine approved in 2021). Effectiveness in special populations (preterm infants, sickle cell disease, HIV, HSCT recipients) explicitly noted as not established."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "VAXNEUVANCE demonstrates an adequate safety profile based on substantial clinical trial data. Strengths include large pediatric sample size (>3,300 children), excellent vulnerable subgroup evaluation (preterm infants, sickle cell disease, HIV infection, HSCT recipients), and standardized active surveillance using validated instruments with severity grading. The safety profile was generally similar to Prevnar 13 across all age groups and special populations. Key limitations include: (1) lack of true placebo control prevents absolute safety assessment; (2) relatively short follow-up (6 months for most SAEs, 14 days for solicited events); (3) limited neurological event monitoring beyond febrile seizure; (4) no all-cause mortality data reported. Most common reactions were injection-site pain, irritability, somnolence, and fever in children - generally mild and resolving within 3 days. SAE rates were low and comparable between groups with no notable patterns suggesting causal relationship."
        }
      },
      "safety_pt": {
        "vaccine_id": "pcv_vaxneuvance",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "3.349 crian√ßas receberam pelo menos uma dose de VAXNEUVANCE na s√©rie de 4 doses nos Estudos 8-11. 1.814 receberam Prevnar 13 como comparador. Somente nos EUA, 2.827 participantes receberam pelo menos uma dose e 2.409 completaram a s√©rie de 4 doses. O Estudo 12 (vacina√ß√£o de resgate) incluiu 303 participantes recebendo VAXNEUVANCE de 7 meses a 17 anos. Popula√ß√µes especiais inclu√≠ram 142 beb√™s prematuros, 70 crian√ßas com doen√ßa falciforme e 203 crian√ßas infectadas pelo HIV. Isso representa um banco de dados substancial de seguran√ßa pedi√°trica em m√∫ltiplos grupos et√°rios e categorias de risco."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Rea√ß√µes adversas solicitadas monitoradas por 14 dias ap√≥s a vacina√ß√£o usando Cart√µes de Registro de Vacina√ß√£o. Febre especificamente monitorada por 7 dias. Eventos adversos n√£o solicitados coletados at√© 14 dias. Eventos adversos graves acompanhados por 1 m√™s no Estudo 11, 6 meses nos Estudos 8-10 e 12 para crian√ßas. Embora o acompanhamento de 6 meses para EAGs seja razo√°vel, monitoramento de seguran√ßa de longo prazo (1-2+ anos) fortaleceria a avalia√ß√£o do perfil de seguran√ßa, particularmente para potenciais eventos adversos tardios."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Todos os estudos usaram Prevnar 13 (outra vacina conjugada pneumoc√≥cica) como comparador ativo em vez de placebo verdadeiro. Embora isso permita compara√ß√£o direta com o padr√£o de cuidado existente, limita a capacidade de avaliar o perfil de seguran√ßa absoluto. EAGs em crian√ßas: 9,6% VAXNEUVANCE vs 8,9% Prevnar 13 aos 6 meses. Em adultos dentro de 30 dias: 0,4% vs 0,7%; dentro de 6 meses: 2,5% vs 2,4%. A falta de bra√ßo placebo significa que as taxas de base de eventos adversos n√£o podem ser determinadas, e quaisquer sinais de seguran√ßa comuns a ambas as vacinas n√£o seriam detectados."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Vigil√¢ncia ativa implementada usando Cart√µes de Registro de Vacina√ß√£o padronizados revisados pelos investigadores 15 dias ap√≥s a vacina√ß√£o. Rea√ß√µes locais solicitadas (dor, endurecimento, eritema, incha√ßo) e rea√ß√µes sist√™micas (irritabilidade, sonol√™ncia, febre, diminui√ß√£o do apetite, urtic√°ria em crian√ßas; fadiga, dor de cabe√ßa, mialgia, artralgia em adultos) coletadas sistematicamente. Gradua√ß√£o de gravidade definida (leve, moderada, grave com crit√©rios espec√≠ficos). Temperatura monitorada via medi√ß√£o retal ou axilar em crian√ßas. No entanto, acompanhamento ativo limitado a 14 dias para a maioria dos desfechos."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Relato limitado de eventos adversos neurol√≥gicos. Uma convuls√£o febril documentada em uma beb√™ feminina de 9 semanas um dia ap√≥s receber a Dose 1 de VAXNEUVANCE com vacinas infantis concomitantes. Apneia em beb√™s prematuros mencionada como advert√™ncia na Se√ß√£o 5.3, com recomenda√ß√£o de que o momento da vacina√ß√£o seja baseado no estado m√©dico individual do beb√™. Nenhum monitoramento sistem√°tico para outras condi√ß√µes neurol√≥gicas (por exemplo, s√≠ndrome de Guillain-Barr√©, encefalite, outros dist√∫rbios convulsivos) descrito. Nenhuma vigil√¢ncia espec√≠fica de condi√ß√µes autoimunes mencionada."
          },
          "vulnerable_subgroups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Avalia√ß√£o extensa de popula√ß√µes vulner√°veis: (1) Beb√™s prematuros <37 semanas de gesta√ß√£o (N=142 VAXNEUVANCE, N=144 Prevnar 13) - perfil de seguran√ßa semelhante a beb√™s a termo e Prevnar 13; (2) Crian√ßas com doen√ßa falciforme de 5-17 anos (N=70 vs N=34) - seguran√ßa semelhante ao Prevnar 13; (3) Crian√ßas infectadas pelo HIV de 6-17 anos com CD4+ >=200 c√©lulas/uL (N=203 vs N=204) - perfil de seguran√ßa semelhante; (4) Adultos infectados pelo HIV 18+ com CD4+ >=50 c√©lulas/uL (N=152 vs N=150); (5) Receptores de TCTH alog√™nico 3-6 meses p√≥s-transplante (N=139 vs N=138). Adultos com condi√ß√µes subjacentes est√°veis (diabetes, doen√ßas renais, card√≠acas, hep√°ticas, pulmonares) e fatores de risco comportamentais tamb√©m inclu√≠dos."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Identificadores do ClinicalTrials.gov fornecidos para todos os estudos permitindo verifica√ß√£o (NCT03893448, NCT03620162, NCT03692871, NCT02987972, NCT03885934, NCT03950622, NCT03950856, NCT03480763, NCT03547167, NCT02573181, NCT03615482, NCT03480802, NCT03731182, NCT03921424, NCT03565900). Tabelas detalhadas de seguran√ßa com porcentagens para rea√ß√µes adversas solicitadas por grau de gravidade, n√∫mero da dose e grupo et√°rio. Porcentagens de EAGs relatadas. No entanto, descri√ß√µes de eventos adversos graves individuais, detalhamento por tipo de EAG e mortes n√£o s√£o enumerados. Dados brutos n√£o dispon√≠veis na bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Mecanismos padr√£o de vigil√¢ncia p√≥s-comercializa√ß√£o estabelecidos atrav√©s do VAERS (Sistema de Notifica√ß√£o de Eventos Adversos de Vacinas) em 1-800-822-7967 ou www.vaers.hhs.gov, e relato ao fabricante para Merck em 1-877-888-4231. A se√ß√£o de aconselhamento ao paciente instrui especificamente os profissionais de sa√∫de e pacientes/respons√°veis a relatar rea√ß√µes adversas graves. No entanto, nenhum estudo de vigil√¢ncia p√≥s-comercializa√ß√£o ativo ou compromissos descritos. Nenhum dado de seguran√ßa p√≥s-comercializa√ß√£o inclu√≠do (vacina aprovada em 2021). Efetividade em popula√ß√µes especiais (beb√™s prematuros, doen√ßa falciforme, HIV, receptores de TCTH) explicitamente n√£o estabelecida."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "VAXNEUVANCE demonstra um perfil de seguran√ßa adequado baseado em dados substanciais de ensaios cl√≠nicos. Os pontos fortes incluem grande tamanho de amostra pedi√°trica (>3.300 crian√ßas), excelente avalia√ß√£o de subgrupos vulner√°veis (beb√™s prematuros, doen√ßa falciforme, infec√ß√£o por HIV, receptores de TCTH) e vigil√¢ncia ativa padronizada usando instrumentos validados com gradua√ß√£o de gravidade. O perfil de seguran√ßa foi geralmente semelhante ao Prevnar 13 em todos os grupos et√°rios e popula√ß√µes especiais. Limita√ß√µes principais incluem: (1) falta de controle placebo verdadeiro impede avalia√ß√£o de seguran√ßa absoluta; (2) acompanhamento relativamente curto (6 meses para a maioria dos EAGs, 14 dias para eventos solicitados); (3) monitoramento limitado de eventos neurol√≥gicos al√©m de convuls√£o febril; (4) nenhum dado de mortalidade por todas as causas relatado. As rea√ß√µes mais comuns foram dor no local da inje√ß√£o, irritabilidade, sonol√™ncia e febre em crian√ßas - geralmente leves e resolvendo dentro de 3 dias. As taxas de EAGs foram baixas e compar√°veis entre os grupos sem padr√µes not√°veis sugerindo rela√ß√£o causal."
        }
      }
    },
    {
      "id": "rv_rotarix",
      "name": "Rotarix",
      "type": "RV",
      "manufacturer": "GlaxoSmithKline",
      "description": "Rotavirus Vaccine, Live, Oral for prevention of rotavirus gastroenteritis.",
      "sources": [
        "rv_rotarix_insert.pdf",
        "rv_rotarix_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "rv_rotarix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 was a double-blind, randomized, placebo-controlled study. The placebo formulation matched the vaccine (same diluent lots DD05A003A and DD05A003C) ensuring true inert comparison. Study Rota-036 also used identical placebo-controlled design.",
            "level_description": "True inert placebo used with identical appearance to vaccine, enabling unbiased assessment of adverse events."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Both Rota-023 and Rota-036 were explicitly described as double-blind studies. The document states 'The validity of the results was strengthened by the double-blinded, placebo-controlled, multi-center study design.' Access to individual treatment decode was strictly controlled until the end of the efficacy follow-up periods.",
            "level_description": "Rigorous double-blinding maintained throughout with strict control of treatment codes, preventing observer and reporting bias."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 randomized subjects 1:1 to Rotarix or placebo, and Rota-036 used 2:1 randomization. The document confirms 'randomization was balanced between groups' with allocation concealment maintained. Demographic characteristics were balanced between groups (median age, gender ratios, ethnicity).",
            "level_description": "Proper randomization with documented allocation concealment and verified balance of baseline characteristics between groups."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023: Total safety cohort N=63,225 (Rotarix 31,673, Placebo 31,552). Rota-036: TVC N=3,994 (Rotarix 2,646, Placebo 1,348). Core Integrated Safety Summary pooled 36,755 subjects receiving Rotarix at licensure potency.",
            "level_description": "Exceptionally large sample size exceeding 63,000 subjects, far surpassing the 3,000 minimum needed to detect 1:1,000 events."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rota-023: Follow-up through Visit 6 (approximately 2 years). First year efficacy period plus second efficacy period to Visit 6. Median interval from Dose 1 to Visit 3 was 100 days. Rota-036: Follow-up to Visit 7 (22-24 months intended duration). Deaths tracked up to September 10, 2004 lock date.",
            "level_description": "Two-year follow-up meets the minimum standard, though longer surveillance would better capture late-onset autoimmune conditions."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Enrollment limited to infants 6-24 weeks of age at Dose 1 (Rota-023) and 6-14 weeks (Rota-036). Median age at Dose 1 was 7 weeks, at Dose 2 was 15 weeks. Additional analyses by age at Dose 1 (57-84 days stratum) were performed for mortality.",
            "level_description": "Age range very narrow (infants only). No separate analysis for toddlers or older children since vaccine is only indicated for infants."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Inclusion: Healthy infants 6-24 weeks old, birth weight >2000g, free of obvious health problems. Exclusion: History of congenital GI malformation, IS, immunodeficiency/HIV, chronic GI disease, use of immunosuppressants >14 days, immunoglobulins/blood products.",
            "level_description": "Clearly documented criteria with appropriate exclusions for safety, though excludes children with underlying conditions limiting generalizability."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Adverse events coded using MedDRA classification with Preferred Terms (PTs) and System Organ Classes (SOCs). Vesikari 20-point scale used for severity grading of GE. Clark 24-point scale used as exploratory measure. Brighton Collaboration case definitions used for IS diagnosis.",
            "level_description": "Standardized international coding systems (MedDRA, Brighton Collaboration) used with validated severity scales."
          },
          "active_monitoring_serious": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Active case ascertainment via weekly telephone contact from Day 7 post-Dose 1 throughout study. Parents instructed to contact investigator immediately for SAEs/IS. SAEs ascertained at planned visits and contacts. Independent Data Monitoring Committee reviewed SAEs/IS cases. Clinical Endpoint Committee adjudicated IS cases.",
            "level_description": "Robust active surveillance with weekly contact, independent IDMC oversight, and Clinical Endpoint Committee adjudication."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Convulsions tracked: 16 Rotarix vs 6 placebo (PT Convulsions), not significant when convulsion-related PTs pooled (20 vs 12, p=0.219). Kawasaki's disease: 1 case in Rotarix recipient (onset 19 months post-Dose 2). No specific autoimmune panel or developmental monitoring protocol described.",
            "level_description": "Convulsions and Kawasaki's disease tracked through SAE surveillance, but no systematic neurological exam schedule or autoimmune screening protocol."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Preterm infants excluded (birth weight >2000g required). Immunocompromised children excluded. Document mentions 'Although data was limited, Rotarix appeared to be safe when administered to preterm infants.' Separate analysis planned in post-marketing studies.",
            "level_description": "Vulnerable subgroups excluded from main trials; limited data on preterm infants mentioned but not presented in detail."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 powered for 90% power to rule out 10-fold IS increase with 60,000 subjects. VE calculated with 95% CIs and p-values. Risk differences with 90% and 95% CIs calculated for IS. Cox proportional-hazard model used. CBER statistical reviewer verified calculations.",
            "level_description": "Study explicitly powered for primary safety endpoint (IS), with rigorous statistical methodology and independent verification."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Independent Data Monitoring Committee (IDMC) and Clinical Endpoint Committee (CEC) reviewed data. FDA/CBER reviewer independently verified calculations. Some discrepancies noted but minor. Study reports submitted to FDA with detailed tables.",
            "level_description": "Independent oversight committees reviewed data; FDA conducted independent verification. Raw data available to regulators."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Post-licensure observational safety study planned to evaluate IS risk in US population. Between July 2004 and July 2007, 12,309,365 doses distributed in 100 countries. Periodic Safety Update Reports submitted. Pharmacovigilance plan focused on IS, pneumonia mortality, RV strain distribution.",
            "level_description": "Comprehensive post-marketing surveillance plan with prospective US study, but document pre-dates full post-marketing data availability."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Studies conducted by GSK Biologicals (manufacturer). Rotarix lots manufactured by GSK. Analysis performed by applicant with some independent CBER verification. No explicit funding disclosure or conflict of interest statements in the reviewed document.",
            "level_description": "Studies sponsored and conducted by manufacturer; independent regulatory review provided, but no explicit COI disclosures documented."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Total 99 deaths reported (Rotarix 56, Placebo 43; p=0.198). Detailed breakdown: before Visit 3 (51 vs 32, p=0.051), within 31 days (22 vs 11, p=0.057). Pneumonia deaths analyzed: 16 vs 6 when pooled (p=0.0345). All deaths investigated; none assessed as vaccine-related.",
            "level_description": "Complete reporting of all-cause mortality with detailed temporal and cause analysis, including pneumonia signal investigation."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The Rotarix clinical development program represents a high-quality vaccine safety evaluation with exemplary features including true placebo control, double-blinding, massive sample size (>63,000 subjects), standardized adverse event coding, active surveillance with independent oversight, and comprehensive all-cause mortality reporting. The study was specifically powered to detect a 10-fold increase in intussusception risk. Key limitations include the narrow age range (infants only), exclusion of vulnerable subgroups (preterm, immunocompromised), lack of systematic neurological/developmental monitoring beyond SAE surveillance, manufacturer sponsorship without explicit COI disclosure, and follow-up duration of approximately 2 years which may miss very late-onset autoimmune conditions. A non-significant numerical imbalance in deaths (56 vs 43) and statistically significant pneumonia mortality signal (16 vs 6 pooled) warrant ongoing post-marketing surveillance. Overall, this represents a rigorous safety evaluation that meets or exceeds typical standards for vaccine licensure studies."
        }
      },
      "trial_pt": {
        "vaccine_id": "rv_rotarix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 foi um estudo duplo-cego, randomizado, controlado por placebo. A formula√ß√£o do placebo correspondia √† vacina (mesmos lotes de diluente DD05A003A e DD05A003C), garantindo compara√ß√£o verdadeiramente inerte. O estudo Rota-036 tamb√©m usou desenho id√™ntico controlado por placebo.",
            "level_description": "Placebo verdadeiramente inerte usado com apar√™ncia id√™ntica √† vacina, permitindo avalia√ß√£o imparcial de eventos adversos."
          },
          "double_blind": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Tanto Rota-023 quanto Rota-036 foram explicitamente descritos como estudos duplo-cegos. O documento afirma 'A validade dos resultados foi fortalecida pelo desenho do estudo duplo-cego, controlado por placebo e multic√™ntrico.' O acesso √† decodifica√ß√£o individual do tratamento foi rigorosamente controlado at√© o final dos per√≠odos de acompanhamento de efic√°cia.",
            "level_description": "Duplo-cegamento rigoroso mantido ao longo do estudo com controle estrito dos c√≥digos de tratamento, prevenindo vi√©s de observador e de relato."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 randomizou sujeitos 1:1 para Rotarix ou placebo, e Rota-036 usou randomiza√ß√£o 2:1. O documento confirma que 'a randomiza√ß√£o foi equilibrada entre os grupos' com oculta√ß√£o de aloca√ß√£o mantida. As caracter√≠sticas demogr√°ficas foram equilibradas entre os grupos (idade mediana, propor√ß√µes de g√™nero, etnia).",
            "level_description": "Randomiza√ß√£o adequada com oculta√ß√£o de aloca√ß√£o documentada e equil√≠brio verificado das caracter√≠sticas basais entre os grupos."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023: Coorte de seguran√ßa total N=63.225 (Rotarix 31.673, Placebo 31.552). Rota-036: TVC N=3.994 (Rotarix 2.646, Placebo 1.348). O Resumo Integrado de Seguran√ßa Principal agrupou 36.755 sujeitos recebendo Rotarix na pot√™ncia de licenciamento.",
            "level_description": "Tamanho de amostra excepcionalmente grande excedendo 63.000 sujeitos, muito superior ao m√≠nimo de 3.000 necess√°rio para detectar eventos de 1:1.000."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rota-023: Acompanhamento at√© a Visita 6 (aproximadamente 2 anos). Primeiro per√≠odo de efic√°cia mais segundo per√≠odo de efic√°cia at√© a Visita 6. Intervalo mediano da Dose 1 √† Visita 3 foi de 100 dias. Rota-036: Acompanhamento at√© a Visita 7 (dura√ß√£o pretendida de 22-24 meses). √ìbitos rastreados at√© a data de fechamento de 10 de setembro de 2004.",
            "level_description": "Acompanhamento de dois anos atende ao padr√£o m√≠nimo, embora vigil√¢ncia mais longa capturaria melhor condi√ß√µes autoimunes de in√≠cio tardio."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A inscri√ß√£o foi limitada a beb√™s de 6-24 semanas de idade na Dose 1 (Rota-023) e 6-14 semanas (Rota-036). A idade mediana na Dose 1 foi de 7 semanas, na Dose 2 foi de 15 semanas. An√°lises adicionais por idade na Dose 1 (estrato de 57-84 dias) foram realizadas para mortalidade.",
            "level_description": "Faixa et√°ria muito estreita (apenas beb√™s). Nenhuma an√°lise separada para crian√ßas pequenas ou mais velhas, pois a vacina √© indicada apenas para beb√™s."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Inclus√£o: Beb√™s saud√°veis de 6-24 semanas de idade, peso ao nascer >2000g, livres de problemas de sa√∫de √≥bvios. Exclus√£o: Hist√≥rico de malforma√ß√£o GI cong√™nita, IS, imunodefici√™ncia/HIV, doen√ßa GI cr√¥nica, uso de imunossupressores >14 dias, imunoglobulinas/produtos sangu√≠neos.",
            "level_description": "Crit√©rios claramente documentados com exclus√µes apropriadas para seguran√ßa, embora exclua crian√ßas com condi√ß√µes subjacentes limitando a generaliza√ß√£o."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Eventos adversos codificados usando classifica√ß√£o MedDRA com Termos Preferenciais (TPs) e Classes de Sistemas de √ìrg√£os (CSOs). Escala Vesikari de 20 pontos usada para gradua√ß√£o de gravidade de GE. Escala Clark de 24 pontos usada como medida explorat√≥ria. Defini√ß√µes de caso da Brighton Collaboration usadas para diagn√≥stico de IS.",
            "level_description": "Sistemas de codifica√ß√£o internacionais padronizados (MedDRA, Brighton Collaboration) usados com escalas de gravidade validadas."
          },
          "active_monitoring_serious": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Busca ativa de casos via contato telef√¥nico semanal a partir do Dia 7 p√≥s-Dose 1 ao longo do estudo. Pais instru√≠dos a contatar o investigador imediatamente para EAGs/IS. EAGs verificados em visitas e contatos planejados. Comit√™ Independente de Monitoramento de Dados revisou casos de EAGs/IS. Comit√™ de Desfechos Cl√≠nicos adjudicou casos de IS.",
            "level_description": "Vigil√¢ncia ativa robusta com contato semanal, supervis√£o independente do CIMD e adjudica√ß√£o pelo Comit√™ de Desfechos Cl√≠nicos."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Convuls√µes rastreadas: 16 Rotarix vs 6 placebo (TP Convuls√µes), n√£o significativo quando TPs relacionados a convuls√µes agrupados (20 vs 12, p=0,219). Doen√ßa de Kawasaki: 1 caso em receptor de Rotarix (in√≠cio 19 meses p√≥s-Dose 2). Nenhum painel autoimune espec√≠fico ou protocolo de monitoramento de desenvolvimento descrito.",
            "level_description": "Convuls√µes e doen√ßa de Kawasaki rastreadas atrav√©s de vigil√¢ncia de EAGs, mas nenhum cronograma sistem√°tico de exame neurol√≥gico ou protocolo de triagem autoimune."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Beb√™s prematuros exclu√≠dos (peso ao nascer >2000g requerido). Crian√ßas imunocomprometidas exclu√≠das. O documento menciona 'Embora os dados fossem limitados, Rotarix pareceu ser segura quando administrada a beb√™s prematuros.' An√°lise separada planejada em estudos p√≥s-comercializa√ß√£o.",
            "level_description": "Subgrupos vulner√°veis exclu√≠dos dos principais ensaios; dados limitados sobre beb√™s prematuros mencionados, mas n√£o apresentados em detalhes."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rota-023 dimensionado para 90% de poder para descartar aumento de 10 vezes no IS com 60.000 sujeitos. EV calculada com ICs de 95% e valores-p. Diferen√ßas de risco com ICs de 90% e 95% calculadas para IS. Modelo de riscos proporcionais de Cox usado. Revisor estat√≠stico do CBER verificou os c√°lculos.",
            "level_description": "Estudo explicitamente dimensionado para desfecho prim√°rio de seguran√ßa (IS), com metodologia estat√≠stica rigorosa e verifica√ß√£o independente."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Comit√™ Independente de Monitoramento de Dados (CIMD) e Comit√™ de Desfechos Cl√≠nicos (CDC) revisaram os dados. Revisor do FDA/CBER verificou c√°lculos independentemente. Algumas discrep√¢ncias notadas, mas menores. Relat√≥rios de estudos submetidos √† FDA com tabelas detalhadas.",
            "level_description": "Comit√™s de supervis√£o independentes revisaram os dados; FDA conduziu verifica√ß√£o independente. Dados brutos dispon√≠veis para reguladores."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo observacional de seguran√ßa p√≥s-licenciamento planejado para avaliar risco de IS na popula√ß√£o dos EUA. Entre julho de 2004 e julho de 2007, 12.309.365 doses distribu√≠das em 100 pa√≠ses. Relat√≥rios Peri√≥dicos de Atualiza√ß√£o de Seguran√ßa submetidos. Plano de farmacovigil√¢ncia focado em IS, mortalidade por pneumonia, distribui√ß√£o de cepas de RV.",
            "level_description": "Plano abrangente de vigil√¢ncia p√≥s-comercializa√ß√£o com estudo prospectivo nos EUA, mas documento anterior √† disponibilidade completa de dados p√≥s-comercializa√ß√£o."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudos conduzidos pela GSK Biologicals (fabricante). Lotes de Rotarix fabricados pela GSK. An√°lise realizada pelo requerente com alguma verifica√ß√£o independente do CBER. Nenhuma divulga√ß√£o expl√≠cita de financiamento ou declara√ß√µes de conflito de interesse no documento revisado.",
            "level_description": "Estudos patrocinados e conduzidos pelo fabricante; revis√£o regulat√≥ria independente fornecida, mas nenhuma divulga√ß√£o expl√≠cita de COI documentada."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Total de 99 √≥bitos relatados (Rotarix 56, Placebo 43; p=0,198). Detalhamento: antes da Visita 3 (51 vs 32, p=0,051), dentro de 31 dias (22 vs 11, p=0,057). √ìbitos por pneumonia analisados: 16 vs 6 quando agrupados (p=0,0345). Todos os √≥bitos investigados; nenhum avaliado como relacionado √† vacina.",
            "level_description": "Relato completo de mortalidade por todas as causas com an√°lise temporal e de causa detalhada, incluindo investiga√ß√£o de sinal de pneumonia."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de desenvolvimento cl√≠nico de Rotarix representa uma avalia√ß√£o de seguran√ßa de vacina de alta qualidade com caracter√≠sticas exemplares incluindo verdadeiro controle placebo, duplo-cegamento, tamanho de amostra massivo (>63.000 sujeitos), codifica√ß√£o padronizada de eventos adversos, vigil√¢ncia ativa com supervis√£o independente e relato abrangente de mortalidade por todas as causas. O estudo foi especificamente dimensionado para detectar um aumento de 10 vezes no risco de intussuscep√ß√£o. Limita√ß√µes principais incluem a faixa et√°ria estreita (apenas beb√™s), exclus√£o de subgrupos vulner√°veis (prematuros, imunocomprometidos), falta de monitoramento neurol√≥gico/de desenvolvimento sistem√°tico al√©m da vigil√¢ncia de EAGs, patroc√≠nio do fabricante sem divulga√ß√£o expl√≠cita de COI, e dura√ß√£o de acompanhamento de aproximadamente 2 anos que pode perder condi√ß√µes autoimunes de in√≠cio muito tardio. Um desequil√≠brio num√©rico n√£o significativo em √≥bitos (56 vs 43) e sinal de mortalidade por pneumonia estatisticamente significativo (16 vs 6 agrupados) justificam vigil√¢ncia p√≥s-comercializa√ß√£o cont√≠nua. No geral, isso representa uma avalia√ß√£o de seguran√ßa rigorosa que atende ou excede os padr√µes t√≠picos para estudos de licenciamento de vacinas."
        }
      },
      "safety_en": {
        "vaccine_id": "rv_rotarix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Exceptional sample size of 63,225 infants in the main safety study (Rota-023), with 31,673 receiving Rotarix and 31,552 receiving placebo. Additional 3,994 subjects in Rota-036. Integrated Safety Summary pooled 36,755 subjects at licensure potency. This massive sample far exceeds the 3,000 per group needed to detect 1:1,000 events, enabling detection of rare adverse events like intussusception."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Follow-up extended approximately 2 years through Visit 6 in Rota-023 and to Visit 7 (22-24 months) in Rota-036. This meets the minimum 12-month standard and provides reasonable assessment of medium-term safety. However, longer surveillance (3-5 years) would better capture late-onset autoimmune or developmental effects. The 2-year timeframe is adequate for assessing intussusception risk, which typically occurs within weeks of vaccination."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "True inert placebo used with identical appearance (same diluent lots). Double-blind randomization at 1:1 ratio (Rota-023) and 2:1 ratio (Rota-036) with allocation concealment. Baseline demographics balanced between groups. This gold-standard design enables valid causal inference about vaccine-related adverse events."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Comprehensive active surveillance implemented: weekly telephone contact with families from Day 7 post-Dose 1, bi-weekly during non-epidemic periods, returning to weekly during rotavirus season. Parents instructed to immediately contact investigators for SAEs. SAEs ascertained at all planned visits. Independent Data Monitoring Committee (IDMC) conducted unblinded reviews of each SAE, IS case, and fatality. Clinical Endpoint Committee adjudicated IS cases. 98% of subjects completed at least 31 days follow-up after each dose."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Convulsive disorders tracked through SAE surveillance: 16 Rotarix vs 6 placebo for PT Convulsions initially (when 5 convulsion-related PTs pooled: 20 vs 12, p=0.219, not significant). Individual case reviews conducted. Kawasaki's disease: 1 Rotarix case at 19 months post-vaccination. However, no systematic neurological examination schedule or developmental milestone assessments were implemented. Monitoring relied on SAE reporting rather than proactive neurological evaluations."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Vulnerable populations were explicitly excluded: preterm infants (birth weight <2000g), immunocompromised children, those with HIV, congenital GI malformations, history of IS, or on immunosuppressants. Document mentions limited data suggests safety in preterm infants but details not provided. Post-marketing studies planned for preterm and immunocompromised populations. This limits generalizability to the very populations who may be at highest risk."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Independent oversight provided: Data Monitoring Committee and Clinical Endpoint Committee reviewed unblinded data. FDA/CBER conducted independent statistical verification with minor discrepancies noted. Complete SAE tables with MedDRA coding submitted to regulators. CBER reviewer notes confirm calculations were verified. However, no mention of public release of individual participant data or complete raw datasets for independent academic analysis."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Robust post-marketing plan documented: prospective US observational safety study planned to evaluate intussusception risk with adequate power. Between July 2004 and July 2007, 12,309,365 doses distributed across 100 countries. Periodic Safety Update Reports submitted covering July 2006 to July 2007. Pharmacovigilance plan addresses IS, pneumonia mortality, RV strain distribution, and vaccine effectiveness. Note that this document predates full post-marketing data availability, representing planned rather than completed surveillance."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "This Rotarix safety evaluation provides reasonably strong evidence of vaccine safety in healthy infants, with several exemplary features: an exceptionally large sample of over 63,000 infants, true placebo-controlled double-blind design, active surveillance with independent oversight, and comprehensive mortality tracking. The study was specifically powered to detect intussusception risk, and no statistically significant increase was found (6 Rotarix vs 7 placebo within 31 days). Key limitations that prevent full confidence include: exclusion of vulnerable subgroups (preterm, immunocompromised) who may react differently; lack of systematic neurological/developmental assessments beyond SAE reporting; a 2-year follow-up that may miss very late-onset effects; and a numerical (non-significant) imbalance in deaths (56 vs 43) and pneumonia mortality (16 vs 6 pooled, p=0.035) that warrant ongoing monitoring. The document demonstrates good safety in the studied population of healthy infants, but parents of children with underlying conditions should discuss with their healthcare provider given limited data in vulnerable groups."
        }
      },
      "safety_pt": {
        "vaccine_id": "rv_rotarix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Tamanho de amostra excepcional de 63.225 beb√™s no principal estudo de seguran√ßa (Rota-023), com 31.673 recebendo Rotarix e 31.552 recebendo placebo. 3.994 sujeitos adicionais no Rota-036. O Resumo Integrado de Seguran√ßa agrupou 36.755 sujeitos na pot√™ncia de licenciamento. Esta amostra massiva excede em muito os 3.000 por grupo necess√°rios para detectar eventos de 1:1.000, permitindo a detec√ß√£o de eventos adversos raros como intussuscep√ß√£o."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O acompanhamento estendeu-se por aproximadamente 2 anos at√© a Visita 6 no Rota-023 e at√© a Visita 7 (22-24 meses) no Rota-036. Isso atende ao padr√£o m√≠nimo de 12 meses e fornece avalia√ß√£o razo√°vel da seguran√ßa a m√©dio prazo. No entanto, vigil√¢ncia mais longa (3-5 anos) capturaria melhor efeitos autoimunes ou de desenvolvimento de in√≠cio tardio. O per√≠odo de 2 anos √© adequado para avaliar o risco de intussuscep√ß√£o, que tipicamente ocorre dentro de semanas da vacina√ß√£o."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Placebo verdadeiramente inerte usado com apar√™ncia id√™ntica (mesmos lotes de diluente). Randomiza√ß√£o duplo-cega na propor√ß√£o 1:1 (Rota-023) e 2:1 (Rota-036) com oculta√ß√£o de aloca√ß√£o. Dados demogr√°ficos basais equilibrados entre os grupos. Este desenho padr√£o-ouro permite infer√™ncia causal v√°lida sobre eventos adversos relacionados √† vacina."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Vigil√¢ncia ativa abrangente implementada: contato telef√¥nico semanal com fam√≠lias a partir do Dia 7 p√≥s-Dose 1, quinzenal durante per√≠odos n√£o-epid√™micos, retornando a semanal durante a temporada de rotav√≠rus. Pais instru√≠dos a contatar investigadores imediatamente para EAGs. EAGs verificados em todas as visitas planejadas. Comit√™ Independente de Monitoramento de Dados (CIMD) conduziu revis√µes n√£o-cegas de cada EAG, caso de IS e √≥bito. Comit√™ de Desfechos Cl√≠nicos adjudicou casos de IS. 98% dos sujeitos completaram pelo menos 31 dias de acompanhamento ap√≥s cada dose."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dist√∫rbios convulsivos rastreados atrav√©s de vigil√¢ncia de EAGs: 16 Rotarix vs 6 placebo para TP Convuls√µes inicialmente (quando 5 TPs relacionados a convuls√µes agrupados: 20 vs 12, p=0,219, n√£o significativo). Revis√µes de casos individuais conduzidas. Doen√ßa de Kawasaki: 1 caso Rotarix aos 19 meses p√≥s-vacina√ß√£o. No entanto, nenhum cronograma sistem√°tico de exame neurol√≥gico ou avalia√ß√µes de marcos de desenvolvimento foi implementado. O monitoramento dependeu de relato de EAGs em vez de avalia√ß√µes neurol√≥gicas proativas."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Popula√ß√µes vulner√°veis foram explicitamente exclu√≠das: beb√™s prematuros (peso ao nascer <2000g), crian√ßas imunocomprometidas, aquelas com HIV, malforma√ß√µes GI cong√™nitas, hist√≥rico de IS, ou em imunossupressores. O documento menciona que dados limitados sugerem seguran√ßa em beb√™s prematuros, mas detalhes n√£o s√£o fornecidos. Estudos p√≥s-comercializa√ß√£o planejados para popula√ß√µes prematuras e imunocomprometidas. Isso limita a generaliza√ß√£o para as popula√ß√µes que podem estar em maior risco."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Supervis√£o independente fornecida: Comit√™ de Monitoramento de Dados e Comit√™ de Desfechos Cl√≠nicos revisaram dados n√£o-cegos. FDA/CBER conduziu verifica√ß√£o estat√≠stica independente com discrep√¢ncias menores notadas. Tabelas completas de EAGs com codifica√ß√£o MedDRA submetidas aos reguladores. Notas do revisor do CBER confirmam que c√°lculos foram verificados. No entanto, n√£o h√° men√ß√£o de libera√ß√£o p√∫blica de dados individuais de participantes ou conjuntos de dados brutos completos para an√°lise acad√™mica independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Plano robusto de p√≥s-comercializa√ß√£o documentado: estudo observacional de seguran√ßa prospectivo nos EUA planejado para avaliar risco de intussuscep√ß√£o com poder adequado. Entre julho de 2004 e julho de 2007, 12.309.365 doses distribu√≠das em 100 pa√≠ses. Relat√≥rios Peri√≥dicos de Atualiza√ß√£o de Seguran√ßa submetidos cobrindo julho de 2006 a julho de 2007. Plano de farmacovigil√¢ncia aborda IS, mortalidade por pneumonia, distribui√ß√£o de cepas de RV e efetividade da vacina. Note que este documento antecede a disponibilidade completa de dados p√≥s-comercializa√ß√£o, representando vigil√¢ncia planejada em vez de conclu√≠da."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Esta avalia√ß√£o de seguran√ßa de Rotarix fornece evid√™ncia razoavelmente forte de seguran√ßa da vacina em beb√™s saud√°veis, com v√°rias caracter√≠sticas exemplares: uma amostra excepcionalmente grande de mais de 63.000 beb√™s, desenho verdadeiramente controlado por placebo e duplo-cego, vigil√¢ncia ativa com supervis√£o independente e rastreamento abrangente de mortalidade. O estudo foi especificamente dimensionado para detectar risco de intussuscep√ß√£o, e nenhum aumento estatisticamente significativo foi encontrado (6 Rotarix vs 7 placebo dentro de 31 dias). Limita√ß√µes principais que impedem confian√ßa total incluem: exclus√£o de subgrupos vulner√°veis (prematuros, imunocomprometidos) que podem reagir diferentemente; falta de avalia√ß√µes neurol√≥gicas/de desenvolvimento sistem√°ticas al√©m do relato de EAGs; um acompanhamento de 2 anos que pode perder efeitos de in√≠cio muito tardio; e um desequil√≠brio num√©rico (n√£o significativo) em √≥bitos (56 vs 43) e mortalidade por pneumonia (16 vs 6 agrupados, p=0,035) que justifica monitoramento cont√≠nuo. O documento demonstra boa seguran√ßa na popula√ß√£o estudada de beb√™s saud√°veis, mas pais de crian√ßas com condi√ß√µes subjacentes devem discutir com seu profissional de sa√∫de dado os dados limitados em grupos vulner√°veis."
        }
      }
    },
    {
      "id": "rv_rotateq",
      "name": "RotaTeq",
      "type": "RV",
      "manufacturer": "Merck",
      "description": "Rotavirus Vaccine, Live, Oral, Pentavalent for prevention of rotavirus gastroenteritis.",
      "sources": [
        "rv_rotateq_insert.pdf",
        "rv_rotateq_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "rv_rotateq",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "71,725 infants were evaluated in 3 placebo-controlled clinical trials including 36,165 infants in the group that received RotaTeq and 35,560 infants in the group that received placebo. The document clearly describes placebo-controlled design across multiple phase 3 studies (Study 006, 007, 009, 029).",
            "level_description": "True placebo control used in all major trials with clear comparison data presented"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 029 is described as 'a Phase 3 randomized, blinded, placebo-controlled study conducted in Japan.' Study 006 (REST) used randomized design. The document indicates blinded design but does not explicitly detail double-blind procedures for all studies.",
            "level_description": "Blinding described for major studies but procedural details not fully elaborated"
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Overall, 73,086 infants were randomized in 4 placebo-controlled, phase 3 studies conducted in 12 countries on 4 continents. Study 029 explicitly described as 'randomized, blinded, placebo-controlled study.'",
            "level_description": "Large-scale randomization across multiple international studies with clear documentation"
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "71,725 infants evaluated in clinical trials (36,165 RotaTeq, 35,560 placebo). For intussusception monitoring, Study 006 included 34,837 vaccine recipients and 34,788 placebo recipients. Efficacy data from 7,744 infants from US, Finland, and Japan.",
            "level_description": "Exceptionally large pediatric sample size exceeding 70,000 infants across studies"
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Parents/guardians were contacted on days 7, 14, and 42 after each dose. For intussusception, subjects were monitored at 7, 14, and 42 days after each dose, and every 6 weeks thereafter for 1 year after the first dose. Efficacy evaluated through first and second rotavirus seasons postvaccination.",
            "level_description": "Follow-up of 42 days for adverse events, 1 year for intussusception, and 2 rotavirus seasons for efficacy"
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Data presented for pre-term infants (25 to 36 weeks gestational age, median 34 weeks) with 2,070 pre-term infants studied. Vaccine approved for infants 6-32 weeks of age. Subset of 308 pre-term infants monitored for all adverse experiences.",
            "level_description": "Pre-term infants analyzed separately but no detailed breakdown by other age subgroups within the 6-32 week range"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Contraindications clearly stated: hypersensitivity, SCID, history of intussusception. Exclusions for immunocompromised infants, those with GI disorders, blood transfusion within 42 days. Inclusion: healthy infants 6-32 weeks of age.",
            "level_description": "Clear inclusion/exclusion criteria documented with specific contraindications listed"
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Detailed Safety Cohort of 11,711 infants used Vaccination Report Card to record temperature, diarrhea, vomiting daily for first week. Adverse events categorized as solicited (Table 4) and unsolicited. Serious adverse events systematically reported with specific categories (bronchiolitis, gastroenteritis, pneumonia, fever, UTI).",
            "level_description": "Standardized reporting with vaccination report cards, systematic categorization, and detailed tables"
          },
          "active_monitoring_serious": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "In Study 006, 34,837 vaccine recipients and 34,788 placebo recipients were monitored by active surveillance to identify potential cases of intussusception at 7, 14, and 42 days after each dose. Parents/guardians were contacted on days 7, 14, and 42 after each dose regarding intussusception and any other serious adverse events.",
            "level_description": "Active surveillance for intussusception with scheduled contacts and systematic case identification"
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Seizures reported: 33 RotaTeq vs 24 placebo within 42 days of any dose. Kawasaki disease reported in 5 of 36,150 vaccine recipients and 1 of 35,536 placebo recipients. No specific autoimmune conditions systematically tracked beyond Kawasaki disease.",
            "level_description": "Seizures and Kawasaki disease monitored; other autoimmune/neurological conditions not systematically addressed"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Pre-term infants (2,070) studied according to age in weeks since birth. Infants with controlled gastroesophageal reflux disease included. However, document explicitly states: 'No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.'",
            "level_description": "Pre-term infants included; immunocompromised infants explicitly excluded from trials"
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Relative risk calculations with 95% confidence intervals provided throughout (e.g., RR 1.6 [0.4, 6.4] for intussusception). Efficacy estimates with confidence intervals (e.g., 74.0% [66.8, 79.9]). Per protocol and intent-to-treat analyses conducted. Statistical significance noted for adverse events (2-sided p-value <0.05).",
            "level_description": "Comprehensive statistical analysis with confidence intervals, relative risk, multiple analysis approaches"
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Detailed tables provided for adverse events, intussusception cases by day range, efficacy by rotavirus type. Racial and gender distribution reported (69% White, 14% Hispanic, 8% Black, etc.; 51% male, 49% female). Post-marketing surveillance data from PRISM program with >1.2 million vaccinations.",
            "level_description": "Substantial data provided in tables with demographic breakdowns, though not all raw data accessible"
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Post-marketing surveillance via VAERS. PRISM program evaluated >1.2 million RotaTeq vaccinations from 2004-2011. Prospective post-marketing observational cohort study among 85,150 infants from 2006-2009. Found approximately 1-1.5 excess cases of intussusception per 100,000 vaccinated infants within 21 days.",
            "level_description": "Extensive post-marketing surveillance through multiple systems with quantified risk estimates"
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document manufactured and distributed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. No disclosure of conflicts of interest or funding sources for clinical trials provided in the package insert.",
            "level_description": "No conflict of interest disclosures included in document"
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Across clinical studies, 52 deaths were reported. There were 25 deaths in the RotaTeq recipients compared to 27 deaths in the placebo recipients. The most commonly reported cause of death was sudden infant death syndrome, observed in 8 recipients of RotaTeq and 9 placebo recipients. Pre-term infant deaths: 2 vaccine (1 SIDS, 1 motor vehicle accident), 2 placebo (1 SIDS, 1 unknown).",
            "level_description": "All-cause mortality reported with breakdown by cause of death and comparison between groups"
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "RotaTeq demonstrates exemplary trial design with large-scale placebo-controlled studies involving over 70,000 infants, robust randomization across 12 countries, and excellent active surveillance for intussusception. The trials feature comprehensive statistical analysis with confidence intervals, detailed mortality reporting (52 total deaths with comparable rates between groups), and extensive post-marketing surveillance through PRISM and VAERS. Notable strengths include standardized adverse event collection via vaccination report cards and multi-season efficacy follow-up. Limitations include absence of conflict of interest disclosure, limited data on immunocompromised populations (explicitly excluded), and partial monitoring of autoimmune/neurological conditions beyond seizures and Kawasaki disease. Pre-term infant safety data are available but represent a subset analysis."
        }
      },
      "trial_pt": {
        "vaccine_id": "rv_rotateq",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "71.725 beb√™s foram avaliados em 3 ensaios cl√≠nicos controlados por placebo, incluindo 36.165 beb√™s no grupo que recebeu RotaTeq e 35.560 beb√™s no grupo que recebeu placebo. O documento descreve claramente o desenho controlado por placebo em m√∫ltiplos estudos fase 3 (Estudo 006, 007, 009, 029).",
            "level_description": "Controle placebo verdadeiro usado em todos os principais ensaios com dados de compara√ß√£o claros apresentados"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 029 √© descrito como 'um estudo fase 3 randomizado, cego, controlado por placebo conduzido no Jap√£o.' O Estudo 006 (REST) usou desenho randomizado. O documento indica desenho cego, mas n√£o detalha explicitamente os procedimentos de duplo-cegamento para todos os estudos.",
            "level_description": "Cegamento descrito para os principais estudos, mas detalhes procedimentais n√£o totalmente elaborados"
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "No total, 73.086 beb√™s foram randomizados em 4 estudos fase 3 controlados por placebo, conduzidos em 12 pa√≠ses em 4 continentes. O Estudo 029 foi explicitamente descrito como 'estudo randomizado, cego, controlado por placebo.'",
            "level_description": "Randomiza√ß√£o em larga escala em m√∫ltiplos estudos internacionais com documenta√ß√£o clara"
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "71.725 beb√™s avaliados em ensaios cl√≠nicos (36.165 RotaTeq, 35.560 placebo). Para monitoramento de intussuscep√ß√£o, o Estudo 006 incluiu 34.837 receptores da vacina e 34.788 receptores de placebo. Dados de efic√°cia de 7.744 beb√™s dos EUA, Finl√¢ndia e Jap√£o.",
            "level_description": "Tamanho de amostra pedi√°trica excepcionalmente grande excedendo 70.000 beb√™s em todos os estudos"
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Pais/respons√°veis foram contatados nos dias 7, 14 e 42 ap√≥s cada dose. Para intussuscep√ß√£o, os sujeitos foram monitorados nos dias 7, 14 e 42 ap√≥s cada dose, e a cada 6 semanas depois por 1 ano ap√≥s a primeira dose. Efic√°cia avaliada durante a primeira e segunda temporada de rotav√≠rus p√≥s-vacina√ß√£o.",
            "level_description": "Acompanhamento de 42 dias para eventos adversos, 1 ano para intussuscep√ß√£o e 2 temporadas de rotav√≠rus para efic√°cia"
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados apresentados para beb√™s prematuros (25 a 36 semanas de idade gestacional, mediana de 34 semanas) com 2.070 beb√™s prematuros estudados. Vacina aprovada para beb√™s de 6-32 semanas de idade. Subconjunto de 308 beb√™s prematuros monitorados para todas as experi√™ncias adversas.",
            "level_description": "Beb√™s prematuros analisados separadamente, mas sem detalhamento por outros subgrupos et√°rios dentro da faixa de 6-32 semanas"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Contraindica√ß√µes claramente declaradas: hipersensibilidade, IDCG, hist√≥rico de intussuscep√ß√£o. Exclus√µes para beb√™s imunocomprometidos, aqueles com dist√∫rbios GI, transfus√£o de sangue dentro de 42 dias. Inclus√£o: beb√™s saud√°veis de 6-32 semanas de idade.",
            "level_description": "Crit√©rios claros de inclus√£o/exclus√£o documentados com contraindica√ß√µes espec√≠ficas listadas"
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Coorte de Seguran√ßa Detalhada de 11.711 beb√™s usou Cart√£o de Registro de Vacina√ß√£o para registrar temperatura, diarreia, v√¥mito diariamente na primeira semana. Eventos adversos categorizados como solicitados (Tabela 4) e n√£o solicitados. Eventos adversos graves sistematicamente relatados com categorias espec√≠ficas (bronquiolite, gastroenterite, pneumonia, febre, ITU).",
            "level_description": "Relato padronizado com cart√µes de registro de vacina√ß√£o, categoriza√ß√£o sistem√°tica e tabelas detalhadas"
          },
          "active_monitoring_serious": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "No Estudo 006, 34.837 receptores da vacina e 34.788 receptores de placebo foram monitorados por vigil√¢ncia ativa para identificar casos potenciais de intussuscep√ß√£o nos dias 7, 14 e 42 ap√≥s cada dose. Pais/respons√°veis foram contatados nos dias 7, 14 e 42 ap√≥s cada dose sobre intussuscep√ß√£o e quaisquer outros eventos adversos graves.",
            "level_description": "Vigil√¢ncia ativa para intussuscep√ß√£o com contatos programados e identifica√ß√£o sistem√°tica de casos"
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Convuls√µes relatadas: 33 RotaTeq vs 24 placebo dentro de 42 dias de qualquer dose. Doen√ßa de Kawasaki relatada em 5 de 36.150 receptores da vacina e 1 de 35.536 receptores de placebo. Nenhuma condi√ß√£o autoimune espec√≠fica rastreada sistematicamente al√©m da doen√ßa de Kawasaki.",
            "level_description": "Convuls√µes e doen√ßa de Kawasaki monitoradas; outras condi√ß√µes autoimunes/neurol√≥gicas n√£o abordadas sistematicamente"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Beb√™s prematuros (2.070) estudados de acordo com a idade em semanas desde o nascimento. Beb√™s com doen√ßa do refluxo gastroesof√°gico controlada inclu√≠dos. No entanto, o documento afirma explicitamente: 'Nenhum dado de seguran√ßa ou efic√°cia est√° dispon√≠vel de ensaios cl√≠nicos sobre a administra√ß√£o de RotaTeq a beb√™s potencialmente imunocomprometidos.'",
            "level_description": "Beb√™s prematuros inclu√≠dos; beb√™s imunocomprometidos explicitamente exclu√≠dos dos ensaios"
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "C√°lculos de risco relativo com intervalos de confian√ßa de 95% fornecidos ao longo (por exemplo, RR 1,6 [0,4, 6,4] para intussuscep√ß√£o). Estimativas de efic√°cia com intervalos de confian√ßa (por exemplo, 74,0% [66,8, 79,9]). An√°lises per protocol e por inten√ß√£o de tratar conduzidas. Signific√¢ncia estat√≠stica notada para eventos adversos (valor-p bilateral <0,05).",
            "level_description": "An√°lise estat√≠stica abrangente com intervalos de confian√ßa, risco relativo, m√∫ltiplas abordagens de an√°lise"
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Tabelas detalhadas fornecidas para eventos adversos, casos de intussuscep√ß√£o por intervalo de dias, efic√°cia por tipo de rotav√≠rus. Distribui√ß√£o racial e de g√™nero relatada (69% brancos, 14% hisp√¢nicos, 8% negros, etc.; 51% masculinos, 49% femininos). Dados de vigil√¢ncia p√≥s-comercializa√ß√£o do programa PRISM com >1,2 milh√£o de vacina√ß√µes.",
            "level_description": "Dados substanciais fornecidos em tabelas com detalhamentos demogr√°ficos, embora nem todos os dados brutos sejam acess√≠veis"
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Vigil√¢ncia p√≥s-comercializa√ß√£o via VAERS. O programa PRISM avaliou >1,2 milh√£o de vacina√ß√µes com RotaTeq de 2004-2011. Estudo de coorte observacional prospectivo p√≥s-comercializa√ß√£o entre 85.150 beb√™s de 2006-2009. Encontrou aproximadamente 1-1,5 casos excessivos de intussuscep√ß√£o por 100.000 beb√™s vacinados dentro de 21 dias.",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o extensa atrav√©s de m√∫ltiplos sistemas com estimativas de risco quantificadas"
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Documento fabricado e distribu√≠do pela Merck Sharp & Dohme Corp., uma subsidi√°ria da Merck & Co., Inc. Nenhuma divulga√ß√£o de conflitos de interesse ou fontes de financiamento para ensaios cl√≠nicos fornecida na bula.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse inclu√≠da no documento"
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Em todos os estudos cl√≠nicos, 52 √≥bitos foram relatados. Houve 25 √≥bitos nos receptores de RotaTeq comparados a 27 √≥bitos nos receptores de placebo. A causa de √≥bito mais comumente relatada foi s√≠ndrome da morte s√∫bita infantil, observada em 8 receptores de RotaTeq e 9 receptores de placebo. √ìbitos de beb√™s prematuros: 2 vacina (1 SMSI, 1 acidente de ve√≠culo motor), 2 placebo (1 SMSI, 1 desconhecido).",
            "level_description": "Mortalidade por todas as causas relatada com detalhamento por causa de √≥bito e compara√ß√£o entre grupos"
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "RotaTeq demonstra desenho de ensaio exemplar com estudos controlados por placebo em larga escala envolvendo mais de 70.000 beb√™s, randomiza√ß√£o robusta em 12 pa√≠ses e excelente vigil√¢ncia ativa para intussuscep√ß√£o. Os ensaios apresentam an√°lise estat√≠stica abrangente com intervalos de confian√ßa, relato detalhado de mortalidade (52 √≥bitos totais com taxas compar√°veis entre grupos) e vigil√¢ncia p√≥s-comercializa√ß√£o extensa atrav√©s do PRISM e VAERS. Pontos fortes not√°veis incluem coleta padronizada de eventos adversos via cart√µes de registro de vacina√ß√£o e acompanhamento de efic√°cia multi-temporada. Limita√ß√µes incluem aus√™ncia de divulga√ß√£o de conflito de interesse, dados limitados sobre popula√ß√µes imunocomprometidas (explicitamente exclu√≠das) e monitoramento parcial de condi√ß√µes autoimunes/neurol√≥gicas al√©m de convuls√µes e doen√ßa de Kawasaki. Dados de seguran√ßa de beb√™s prematuros est√£o dispon√≠veis, mas representam uma an√°lise de subconjunto."
        }
      },
      "safety_en": {
        "vaccine_id": "rv_rotateq",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Safety data from 71,725 infants in placebo-controlled trials (36,165 RotaTeq, 35,560 placebo). Detailed Safety Cohort included 11,711 infants (6,138 RotaTeq). For intussusception monitoring, Study 006 included 69,625 infants total. This exceptionally large sample size provides robust statistical power for detecting adverse events including rare outcomes."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Systematic follow-up at days 7, 14, and 42 after each dose for serious adverse events. Active intussusception surveillance continued every 6 weeks for 1 year after first dose in Study 006. Solicited adverse events recorded daily for first week post-vaccination. While 42-day follow-up is reasonable for acute events, longer-term safety follow-up beyond 1 year was limited."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "True placebo control used in all major trials with near-equal group sizes (34,837 vaccine vs 34,788 placebo in Study 006 intussusception analysis). Adverse event rates directly compared between groups with statistical analysis. Post-marketing study used concurrent DTaP controls (n=62,617) and historical controls (n=100,000). This rigorous comparative design enables meaningful safety signal detection."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Active surveillance implemented for intussusception with scheduled contacts at days 7, 14, 42 and every 6 weeks for 1 year. Vaccination Report Cards used for daily parent recording of temperature, vomiting, diarrhea during first week. Post-marketing active surveillance through PRISM program evaluated >1.2 million vaccinations. This represents one of the most comprehensive active surveillance programs for a pediatric vaccine."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Seizures systematically tracked: 33 cases in RotaTeq vs 24 in placebo within 42 days (10 febrile seizures total, 5 each group). Serious seizure events occurred in <0.1% of both groups. However, no dedicated neurological assessment protocol described, and other neurological outcomes beyond seizures were not specifically monitored. Post-marketing reports include Kawasaki disease which can have neurological manifestations."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Pre-term infants (25-36 weeks gestational age, n=2,070) studied with subset of 308 monitored for all adverse events. Infants with controlled GERD included. However, immunocompromised infants explicitly excluded with 'no safety or efficacy data available.' Contraindicated in SCID due to post-marketing reports of severe gastroenteritis and prolonged vaccine virus shedding. This represents a significant gap in safety data for vulnerable populations."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Detailed tables provided for adverse events by dose, day range, and severity. Intussusception cases enumerated by day window and dose number (Tables 1, 2). Serious adverse event rates reported (2.4% vaccine vs 2.6% placebo). Mortality data transparent with causes of death specified. Racial/ethnic and gender distribution reported. Some limitations in access to individual-level data."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Comprehensive post-marketing surveillance through VAERS and PRISM program. PRISM evaluated >1.2 million vaccinations (507,000 first doses) from 2004-2011 identifying temporal association with intussusception (1-1.5 excess cases per 100,000 within 21 days of first dose). Additional cohort study of 85,150 infants (2006-2009). Post-marketing adverse events documented including intussusception (including death), anaphylaxis, gastroenteritis in SCID infants, urticaria, angioedema, and Kawasaki disease."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "RotaTeq demonstrates a strong safety profile supported by exceptionally large clinical trials (>70,000 infants) with rigorous placebo-controlled design and exemplary active surveillance systems. Key strengths include the PRISM post-marketing program that quantified intussusception risk (1-1.5 excess cases per 100,000 vaccinated infants within 21 days of first dose) against a background rate of 34 per 100,000 annually. Serious adverse events were comparable between groups (2.4% vs 2.6%). All-cause mortality was balanced (25 vaccine vs 27 placebo deaths). Limitations include the exclusion of immunocompromised infants from trials, partial neurological monitoring beyond seizures, and the identification of SCID as a contraindication only through post-marketing surveillance. Pre-term infant data provide reassurance but represent a subset analysis."
        }
      },
      "safety_pt": {
        "vaccine_id": "rv_rotateq",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Dados de seguran√ßa de 71.725 beb√™s em ensaios controlados por placebo (36.165 RotaTeq, 35.560 placebo). A Coorte de Seguran√ßa Detalhada incluiu 11.711 beb√™s (6.138 RotaTeq). Para monitoramento de intussuscep√ß√£o, o Estudo 006 incluiu 69.625 beb√™s no total. Este tamanho de amostra excepcionalmente grande fornece poder estat√≠stico robusto para detectar eventos adversos, incluindo desfechos raros."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Acompanhamento sistem√°tico nos dias 7, 14 e 42 ap√≥s cada dose para eventos adversos graves. Vigil√¢ncia ativa de intussuscep√ß√£o continuou a cada 6 semanas por 1 ano ap√≥s a primeira dose no Estudo 006. Eventos adversos solicitados registrados diariamente na primeira semana p√≥s-vacina√ß√£o. Embora o acompanhamento de 42 dias seja razo√°vel para eventos agudos, o acompanhamento de seguran√ßa de longo prazo al√©m de 1 ano foi limitado."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Controle placebo verdadeiro usado em todos os principais ensaios com tamanhos de grupo quase iguais (34.837 vacina vs 34.788 placebo na an√°lise de intussuscep√ß√£o do Estudo 006). Taxas de eventos adversos comparadas diretamente entre grupos com an√°lise estat√≠stica. Estudo p√≥s-comercializa√ß√£o usou controles contempor√¢neos de DTaP (n=62.617) e controles hist√≥ricos (n=100.000). Este desenho comparativo rigoroso permite detec√ß√£o significativa de sinais de seguran√ßa."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Vigil√¢ncia ativa implementada para intussuscep√ß√£o com contatos programados nos dias 7, 14, 42 e a cada 6 semanas por 1 ano. Cart√µes de Registro de Vacina√ß√£o usados para registro di√°rio pelos pais de temperatura, v√¥mito, diarreia durante a primeira semana. Vigil√¢ncia ativa p√≥s-comercializa√ß√£o atrav√©s do programa PRISM avaliou >1,2 milh√£o de vacina√ß√µes. Isso representa um dos programas de vigil√¢ncia ativa mais abrangentes para uma vacina pedi√°trica."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Convuls√µes rastreadas sistematicamente: 33 casos em RotaTeq vs 24 em placebo dentro de 42 dias (10 convuls√µes febris no total, 5 cada grupo). Eventos graves de convuls√£o ocorreram em <0,1% de ambos os grupos. No entanto, nenhum protocolo dedicado de avalia√ß√£o neurol√≥gica descrito, e outros desfechos neurol√≥gicos al√©m de convuls√µes n√£o foram especificamente monitorados. Relat√≥rios p√≥s-comercializa√ß√£o incluem doen√ßa de Kawasaki que pode ter manifesta√ß√µes neurol√≥gicas."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Beb√™s prematuros (25-36 semanas de idade gestacional, n=2.070) estudados com subconjunto de 308 monitorados para todos os eventos adversos. Beb√™s com DRGE controlada inclu√≠dos. No entanto, beb√™s imunocomprometidos explicitamente exclu√≠dos com 'nenhum dado de seguran√ßa ou efic√°cia dispon√≠vel.' Contraindicado em IDCG devido a relat√≥rios p√≥s-comercializa√ß√£o de gastroenterite grave e elimina√ß√£o prolongada do v√≠rus vacinal. Isso representa uma lacuna significativa nos dados de seguran√ßa para popula√ß√µes vulner√°veis."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Tabelas detalhadas fornecidas para eventos adversos por dose, intervalo de dias e gravidade. Casos de intussuscep√ß√£o enumerados por janela de dias e n√∫mero da dose (Tabelas 1, 2). Taxas de eventos adversos graves relatadas (2,4% vacina vs 2,6% placebo). Dados de mortalidade transparentes com causas de √≥bito especificadas. Distribui√ß√£o racial/√©tnica e de g√™nero relatada. Algumas limita√ß√µes no acesso a dados de n√≠vel individual."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Vigil√¢ncia p√≥s-comercializa√ß√£o abrangente atrav√©s do VAERS e programa PRISM. PRISM avaliou >1,2 milh√£o de vacina√ß√µes (507.000 primeiras doses) de 2004-2011 identificando associa√ß√£o temporal com intussuscep√ß√£o (1-1,5 casos excessivos por 100.000 dentro de 21 dias da primeira dose). Estudo de coorte adicional de 85.150 beb√™s (2006-2009). Eventos adversos p√≥s-comercializa√ß√£o documentados incluindo intussuscep√ß√£o (incluindo √≥bito), anafilaxia, gastroenterite em beb√™s com IDCG, urtic√°ria, angioedema e doen√ßa de Kawasaki."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "RotaTeq demonstra um forte perfil de seguran√ßa apoiado por ensaios cl√≠nicos excepcionalmente grandes (>70.000 beb√™s) com desenho rigoroso controlado por placebo e sistemas exemplares de vigil√¢ncia ativa. Pontos fortes principais incluem o programa p√≥s-comercializa√ß√£o PRISM que quantificou o risco de intussuscep√ß√£o (1-1,5 casos excessivos por 100.000 beb√™s vacinados dentro de 21 dias da primeira dose) contra uma taxa de base de 34 por 100.000 anualmente. Eventos adversos graves foram compar√°veis entre os grupos (2,4% vs 2,6%). Mortalidade por todas as causas foi equilibrada (25 √≥bitos vacina vs 27 placebo). Limita√ß√µes incluem a exclus√£o de beb√™s imunocomprometidos dos ensaios, monitoramento neurol√≥gico parcial al√©m de convuls√µes, e a identifica√ß√£o de IDCG como contraindica√ß√£o apenas atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o. Dados de beb√™s prematuros fornecem tranquiliza√ß√£o, mas representam uma an√°lise de subconjunto."
        }
      }
    },
    {
      "id": "mmr_mmrii",
      "name": "M-M-R II",
      "type": "MMR",
      "manufacturer": "Merck",
      "description": "Measles, Mumps, and Rubella Virus Vaccine Live for prevention of measles, mumps, and rubella.",
      "sources": [
        "mmr_mmrii_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The main licensure studies (442, 443, 467, 511, 513) compared M-M-R (RA 27/3) against other active vaccines: measles-rubella vaccine, rubella-only vaccine, or M-M-R with HPV-77 rubella strain. Study 459 protocol mentions a placebo group of 50 children in the study design, but this was only 9% of the total 550 planned subjects, with remaining children receiving various active vaccine formulations.",
            "level_description": "The clinical studies supporting M-M-R II licensure primarily compared different vaccine formulations (RA 27/3 vs HPV-77 rubella strains, combined vs single-component vaccines) rather than using true inert placebo controls. While Study 459 mentions a small placebo group (50/550), the overall safety assessment was based on active comparators, making it impossible to determine the true baseline rate of adverse events attributable to the vaccine versus coincidental events."
          },
          "double_blind": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The document does not describe blinding procedures for any of the main studies (442, 443, 467, 511, 513). Study 459 mentions that 'coded vials' were supplied by Merck Sharp & Dohme, suggesting some potential for blinding, but explicit blinding methodology is not described.",
            "level_description": "No explicit double-blinding is documented for the clinical trials. The studies appear to be predominantly open-label, with investigators and participants potentially aware of which vaccine formulation was administered. The mention of 'coded vials' in one study is insufficient evidence of proper double-blinding procedures."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 459 states children will be 'randomly assigned' to receive one of the vaccine groups. However, most other studies (442, 443, 467, 511, 513) describe children being 'assigned' or receiving vaccines without explicit mention of randomization methodology.",
            "level_description": "Randomization is mentioned for Study 459, but the allocation method, concealment procedures, and stratification are not documented. Other major studies lack explicit documentation of randomization. The methodology falls short of demonstrating proper random allocation with concealment."
          },
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Total vaccinations documented: 834 children received combined live M-M-R (RA 27/3) vaccine across lot numbers 621, 60664, 60665, and 60666. Individual studies: Study 442 (199 children with MMR), Study 443 (102 children with MMR), Study 467 (269 children), Study 511 (226 children), Study 513 (163 children).",
            "level_description": "The total sample size of approximately 834 children is grossly inadequate for detecting rare adverse events. Standard safety assessment requires at least 3,000 children per age group to detect events occurring at 1:1,000 frequency with statistical confidence. This sample size could only reliably detect adverse events occurring more frequently than approximately 1 in 100 children."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All studies followed children for 42 days (6 weeks) post-vaccination. Blood samples were obtained 'six weeks after vaccination' for serological testing. Clinical surveillance recorded complaints for '42 days following vaccination.'",
            "level_description": "The 42-day (6-week) follow-up period is severely inadequate for detecting delayed adverse reactions, particularly autoimmune conditions, neurological complications, or other chronic sequelae that may emerge weeks to months after vaccination. Modern safety standards require minimum 6-12 months of follow-up, with ideal multi-year surveillance for pediatric vaccines."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Children ranged from 10 months to 8 years of age across studies. Mean ages were documented: Study 442 (3.7 years), Study 443 (1.7 years), Study 467 (1.9 years). Some tables break down serological results by individual age years (10 months, 11 months, 1 year, 2 years, etc.).",
            "level_description": "While age data is collected and some tables show results by individual ages, the studies do not provide formal stratified safety analyses by distinct developmental age groups (infants 0-12 months, toddlers 1-2 years, preschoolers 3-5 years). Aggregated safety data may mask age-specific reaction patterns."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Documented exclusion criteria: sensitivity to egg, chicken, chicken feathers, or neomycin; leukemia or other immunologic disorders; persons receiving immunosuppressive drugs; febrile respiratory illness or other active febrile infection. Children were required to have negative history for vaccination with and illness caused by viruses represented in the vaccine.",
            "level_description": "The studies document clear exclusion criteria related to allergies, immunocompromised status, and concurrent illness. Entry criteria required negative disease and vaccination history. While these criteria are documented, the exclusion of children with chronic conditions limits generalizability to real-world populations."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Clinical complaints were categorized into: fever (by temperature ranges: <99F, 99-100.9F, 101-102.9F, 103-104.9F, >105F), irritability, malaise, headache, upper respiratory illness, otitis, ophthalmopathy, gastrointestinal illness, anorexia, rash, lymphadenopathy, myalgia, arthralgia. Temperature was recorded as oral or rectal.",
            "level_description": "The studies used consistent categories for adverse event reporting with temperature grading. However, no standardized criteria such as Brighton Collaboration definitions or MedDRA coding were used (predating these standards). Subjective categories like 'irritability' and 'malaise' lacked objective thresholds. Modern standardized adverse event definitions were not available in 1978."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Protocols state: 'Any serious or alarming reaction, including death due to any cause during the investigation, whether related or not related to the test material, must be reported immediately to Merck & Co., Inc.' Parents were asked to 'contact the physician should any significant or bothersome reaction occur.' In some studies, observations were made by 'medical or paramedical personnel.'",
            "level_description": "There was a passive reporting mechanism for serious events with instructions to report deaths and serious reactions. However, this relied on parental observation and voluntary reporting rather than systematic active surveillance with scheduled clinical assessments. The methodology for serious adverse event ascertainment falls short of active monitoring standards."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No mention of autoimmune conditions, encephalitis, Guillain-Barre syndrome, seizures, convulsions, or other neurological assessments in the clinical trial documentation. High fevers (up to 105F) were documented in some children, but neurological evaluation was not described.",
            "level_description": "The clinical trials did not include any specific monitoring, assessment, or reporting of autoimmune or neurological adverse events. Given that MMR vaccine has subsequently been associated with rare cases of febrile seizures, immune thrombocytopenic purpura, and encephalitis, the absence of any such monitoring in the original trials represents a significant gap."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Children with leukemia, immunologic disorders, or receiving immunosuppressive drugs were explicitly excluded from the trials. No separate analysis or inclusion of premature infants, children with allergies, chronic diseases, or other vulnerable populations is documented.",
            "level_description": "Vulnerable subgroups were systematically excluded from the clinical trials rather than studied. There is no safety data from the pre-licensure trials for immunocompromised children, premature infants, or children with chronic health conditions who would subsequently receive this vaccine in real-world use."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A memo describes 'Analysis of variance was conducted on post titers' comparing rubella vaccine groups. Seroconversion rates and geometric mean titers are reported with percentages. One memo states 'No significant difference exists among the three groups.'",
            "level_description": "Basic statistical analysis (ANOVA, seroconversion rates, geometric mean titers) was performed for immunogenicity outcomes. However, no power calculations for safety detection are documented, and the small sample sizes preclude meaningful statistical analysis of adverse events. The studies were powered for efficacy, not safety."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document was released through a FOIA request dated August 2019, over 40 years after the 1978 licensure. The cover letter notes that 'portions of pages' were withheld under Exemption 4 (trade secrets) and Exemption 6 (personal privacy). Detailed background records were stated to be 'on file in Virus and Cell Biology Research, Merck Institute.'",
            "level_description": "This document was obtained only through FOIA request decades after approval, with portions redacted. Individual patient data are not publicly available. No independent Data Safety Monitoring Board is mentioned. The delayed and partial release of clinical trial data limits independent verification of safety findings."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document covers pre-licensure clinical trials only. No post-marketing surveillance plan, passive reporting system (such as VAERS, which did not exist until 1990), or ongoing safety monitoring is described.",
            "level_description": "The 1978 licensure document contains no post-marketing surveillance provisions. VAERS was not established until 1990. The complete absence of post-marketing safety monitoring in the original approval documents means the safety assessment relied entirely on the limited pre-licensure trials."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All clinical studies were conducted under the overall responsibility of Dr. Maurice R. Hilleman, Vice President, Virus and Cell Biology Research, Merck Institute for Therapeutic Research. Vaccines were prepared by Merck Sharp and Dohme Biologics Manufacturing. Serologic testing was performed in Merck laboratories. Clinical investigators reported directly to Merck.",
            "level_description": "The trials were entirely designed, managed, and analyzed by the vaccine manufacturer. The lead investigator was a Vice President at Merck. No independent oversight, external monitoring, or disclosure of financial relationships is documented. This represents a fundamental conflict of interest with no mitigation measures described."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Protocols mention that 'death due to any cause during the investigation, whether related or not related to the test material, must be reported immediately.' However, no mortality data, death reports, or systematic mortality analysis appears in the results documentation.",
            "level_description": "While the protocol required death reporting, no mortality data is presented in the clinical trial results. There is no systematic comparison of all-cause mortality between vaccine groups or documentation of whether any deaths occurred during the 42-day follow-up period."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "The 1978 M-M-R II licensure studies demonstrate significant methodological limitations by any safety assessment standard. The trials enrolled only approximately 834 children receiving the combined vaccine, far below the minimum 3,000 per age group needed to detect rare adverse events. Follow-up was limited to 42 days, precluding detection of delayed autoimmune or neurological reactions. No true placebo control was used - instead comparing different vaccine formulations. Studies lacked double-blinding, with most appearing to be open-label. The trials excluded vulnerable populations (immunocompromised, premature infants) who would later receive the vaccine. No assessment of autoimmune or neurological outcomes was performed despite these being subsequently identified as rare adverse events. The entire research program was conducted by the manufacturer with no independent oversight, representing an unmitigated conflict of interest. While the studies may have been standard for their era, they fall dramatically short of modern pediatric vaccine safety evaluation requirements and leave substantial uncertainty about the true adverse event profile of M-M-R II."
        }
      },
      "trial_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os principais estudos de licenciamento (442, 443, 467, 511, 513) compararam a M-M-R (RA 27/3) com outras vacinas ativas: vacina sarampo-rub√©ola, vacina somente de rub√©ola, ou M-M-R com cepa de rub√©ola HPV-77. O protocolo do Estudo 459 menciona um grupo placebo de 50 crian√ßas no desenho do estudo, mas isso representava apenas 9% do total de 550 participantes planejados, com as crian√ßas restantes recebendo v√°rias formula√ß√µes de vacinas ativas.",
            "level_description": "Os estudos cl√≠nicos que fundamentaram o licenciamento da M-M-R II compararam principalmente diferentes formula√ß√µes de vacinas (cepas de rub√©ola RA 27/3 vs HPV-77, vacinas combinadas vs componentes √∫nicos) em vez de usar controles placebo verdadeiramente inertes. Embora o Estudo 459 mencione um pequeno grupo placebo (50/550), a avalia√ß√£o geral de seguran√ßa baseou-se em comparadores ativos, tornando imposs√≠vel determinar a verdadeira taxa basal de eventos adversos atribu√≠veis √† vacina versus eventos coincidentes."
          },
          "double_blind": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O documento n√£o descreve procedimentos de cegamento para nenhum dos estudos principais (442, 443, 467, 511, 513). O Estudo 459 menciona que 'frascos codificados' foram fornecidos pela Merck Sharp & Dohme, sugerindo algum potencial para cegamento, mas a metodologia expl√≠cita de cegamento n√£o √© descrita.",
            "level_description": "N√£o h√° documenta√ß√£o expl√≠cita de duplo-cego para os ensaios cl√≠nicos. Os estudos parecem ser predominantemente abertos, com investigadores e participantes potencialmente cientes de qual formula√ß√£o de vacina foi administrada. A men√ß√£o de 'frascos codificados' em um estudo √© evid√™ncia insuficiente de procedimentos adequados de duplo-cego."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 459 afirma que as crian√ßas ser√£o 'atribu√≠das aleatoriamente' para receber um dos grupos de vacina. No entanto, a maioria dos outros estudos (442, 443, 467, 511, 513) descreve crian√ßas sendo 'atribu√≠das' ou recebendo vacinas sem men√ß√£o expl√≠cita da metodologia de randomiza√ß√£o.",
            "level_description": "A randomiza√ß√£o √© mencionada para o Estudo 459, mas o m√©todo de aloca√ß√£o, procedimentos de oculta√ß√£o e estratifica√ß√£o n√£o est√£o documentados. Outros estudos importantes carecem de documenta√ß√£o expl√≠cita de randomiza√ß√£o. A metodologia n√£o demonstra adequadamente aloca√ß√£o aleat√≥ria apropriada com oculta√ß√£o."
          },
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Total de vacina√ß√µes documentadas: 834 crian√ßas receberam a vacina combinada M-M-R viva (RA 27/3) atrav√©s dos lotes 621, 60664, 60665 e 60666. Estudos individuais: Estudo 442 (199 crian√ßas com MMR), Estudo 443 (102 crian√ßas com MMR), Estudo 467 (269 crian√ßas), Estudo 511 (226 crian√ßas), Estudo 513 (163 crian√ßas).",
            "level_description": "O tamanho total da amostra de aproximadamente 834 crian√ßas √© grosseiramente inadequado para detectar eventos adversos raros. A avalia√ß√£o padr√£o de seguran√ßa requer pelo menos 3.000 crian√ßas por faixa et√°ria para detectar eventos que ocorrem na frequ√™ncia de 1:1.000 com confian√ßa estat√≠stica. Este tamanho de amostra s√≥ poderia detectar de forma confi√°vel eventos adversos que ocorrem com mais frequ√™ncia do que aproximadamente 1 em 100 crian√ßas."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos acompanharam as crian√ßas por 42 dias (6 semanas) ap√≥s a vacina√ß√£o. Amostras de sangue foram obtidas 'seis semanas ap√≥s a vacina√ß√£o' para testes sorol√≥gicos. A vigil√¢ncia cl√≠nica registrou queixas por '42 dias ap√≥s a vacina√ß√£o.'",
            "level_description": "O per√≠odo de acompanhamento de 42 dias (6 semanas) √© severamente inadequado para detectar rea√ß√µes adversas tardias, particularmente condi√ß√µes autoimunes, complica√ß√µes neurol√≥gicas ou outras sequelas cr√¥nicas que podem surgir semanas a meses ap√≥s a vacina√ß√£o. Os padr√µes modernos de seguran√ßa exigem um m√≠nimo de 6-12 meses de acompanhamento, com vigil√¢ncia ideal de m√∫ltiplos anos para vacinas pedi√°tricas."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As crian√ßas variaram de 10 meses a 8 anos de idade entre os estudos. Idades m√©dias foram documentadas: Estudo 442 (3,7 anos), Estudo 443 (1,7 anos), Estudo 467 (1,9 anos). Algumas tabelas apresentam resultados sorol√≥gicos por idades individuais (10 meses, 11 meses, 1 ano, 2 anos, etc.).",
            "level_description": "Embora os dados de idade sejam coletados e algumas tabelas mostrem resultados por idades individuais, os estudos n√£o fornecem an√°lises de seguran√ßa formalmente estratificadas por grupos et√°rios de desenvolvimento distintos (beb√™s 0-12 meses, crian√ßas pequenas 1-2 anos, pr√©-escolares 3-5 anos). Dados de seguran√ßa agregados podem mascarar padr√µes de rea√ß√£o espec√≠ficos por idade."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios de exclus√£o documentados: sensibilidade a ovo, frango, penas de frango ou neomicina; leucemia ou outros dist√∫rbios imunol√≥gicos; pessoas recebendo medicamentos imunossupressores; doen√ßa respirat√≥ria febril ou outra infec√ß√£o febril ativa. As crian√ßas deveriam ter hist√≥rico negativo para vacina√ß√£o e doen√ßa causada pelos v√≠rus representados na vacina.",
            "level_description": "Os estudos documentam crit√©rios de exclus√£o claros relacionados a alergias, estado imunocomprometido e doen√ßas concomitantes. Os crit√©rios de entrada exigiam hist√≥rico negativo de doen√ßa e vacina√ß√£o. Embora esses crit√©rios estejam documentados, a exclus√£o de crian√ßas com condi√ß√µes cr√¥nicas limita a generaliza√ß√£o para popula√ß√µes do mundo real."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As queixas cl√≠nicas foram categorizadas em: febre (por faixas de temperatura: <99F, 99-100,9F, 101-102,9F, 103-104,9F, >105F), irritabilidade, mal-estar, dor de cabe√ßa, doen√ßa respirat√≥ria superior, otite, oftalmopatia, doen√ßa gastrointestinal, anorexia, erup√ß√£o cut√¢nea, linfadenopatia, mialgia, artralgia. A temperatura foi registrada como oral ou retal.",
            "level_description": "Os estudos usaram categorias consistentes para relato de eventos adversos com gradua√ß√£o de temperatura. No entanto, nenhum crit√©rio padronizado como defini√ß√µes da Brighton Collaboration ou codifica√ß√£o MedDRA foi usado (antecedendo esses padr√µes). Categorias subjetivas como 'irritabilidade' e 'mal-estar' n√£o tinham limiares objetivos. Defini√ß√µes modernas padronizadas de eventos adversos n√£o estavam dispon√≠veis em 1978."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os protocolos afirmam: 'Qualquer rea√ß√£o s√©ria ou alarmante, incluindo morte por qualquer causa durante a investiga√ß√£o, relacionada ou n√£o ao material de teste, deve ser relatada imediatamente √† Merck & Co., Inc.' Os pais foram solicitados a 'contatar o m√©dico caso ocorra qualquer rea√ß√£o significativa ou inc√¥moda.' Em alguns estudos, as observa√ß√µes foram feitas por 'pessoal m√©dico ou param√©dico.'",
            "level_description": "Havia um mecanismo de notifica√ß√£o passiva para eventos graves com instru√ß√µes para relatar mortes e rea√ß√µes s√©rias. No entanto, isso dependia da observa√ß√£o parental e notifica√ß√£o volunt√°ria, em vez de vigil√¢ncia ativa sistem√°tica com avalia√ß√µes cl√≠nicas programadas. A metodologia para identifica√ß√£o de eventos adversos graves fica aqu√©m dos padr√µes de monitoramento ativo."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "N√£o h√° men√ß√£o de condi√ß√µes autoimunes, encefalite, s√≠ndrome de Guillain-Barr√©, convuls√µes ou outras avalia√ß√µes neurol√≥gicas na documenta√ß√£o dos ensaios cl√≠nicos. Febres altas (at√© 105F) foram documentadas em algumas crian√ßas, mas avalia√ß√£o neurol√≥gica n√£o foi descrita.",
            "level_description": "Os ensaios cl√≠nicos n√£o inclu√≠ram nenhum monitoramento, avalia√ß√£o ou relato espec√≠fico de eventos adversos autoimunes ou neurol√≥gicos. Dado que a vacina MMR foi subsequentemente associada a casos raros de convuls√µes febris, p√∫rpura trombocitop√™nica imune e encefalite, a aus√™ncia de qualquer monitoramento nos ensaios originais representa uma lacuna significativa."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Crian√ßas com leucemia, dist√∫rbios imunol√≥gicos ou recebendo medicamentos imunossupressores foram explicitamente exclu√≠das dos ensaios. Nenhuma an√°lise separada ou inclus√£o de beb√™s prematuros, crian√ßas com alergias, doen√ßas cr√¥nicas ou outras popula√ß√µes vulner√°veis est√° documentada.",
            "level_description": "Subgrupos vulner√°veis foram sistematicamente exclu√≠dos dos ensaios cl√≠nicos em vez de estudados. N√£o h√° dados de seguran√ßa dos ensaios pr√©-licenciamento para crian√ßas imunocomprometidas, beb√™s prematuros ou crian√ßas com condi√ß√µes cr√¥nicas de sa√∫de que posteriormente receberiam esta vacina no uso do mundo real."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um memorando descreve 'An√°lise de vari√¢ncia foi conduzida nos t√≠tulos p√≥s' comparando grupos de vacina de rub√©ola. Taxas de soroconvers√£o e t√≠tulos m√©dios geom√©tricos s√£o relatados com porcentagens. Um memorando afirma 'N√£o existe diferen√ßa significativa entre os tr√™s grupos.'",
            "level_description": "An√°lise estat√≠stica b√°sica (ANOVA, taxas de soroconvers√£o, t√≠tulos m√©dios geom√©tricos) foi realizada para desfechos de imunogenicidade. No entanto, nenhum c√°lculo de poder para detec√ß√£o de seguran√ßa est√° documentado, e os pequenos tamanhos de amostra impedem an√°lise estat√≠stica significativa de eventos adversos. Os estudos foram dimensionados para efic√°cia, n√£o para seguran√ßa."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento foi liberado atrav√©s de uma solicita√ß√£o FOIA datada de agosto de 2019, mais de 40 anos ap√≥s o licenciamento de 1978. A carta de apresenta√ß√£o observa que 'partes de p√°ginas' foram retidas sob a Isen√ß√£o 4 (segredos comerciais) e Isen√ß√£o 6 (privacidade pessoal). Registros detalhados de antecedentes foram declarados como estando 'arquivados na Pesquisa de V√≠rus e Biologia Celular, Instituto Merck.'",
            "level_description": "Este documento foi obtido apenas atrav√©s de solicita√ß√£o FOIA d√©cadas ap√≥s a aprova√ß√£o, com partes redigidas. Dados individuais de pacientes n√£o est√£o dispon√≠veis publicamente. Nenhum Comit√™ Independente de Monitoramento de Seguran√ßa de Dados √© mencionado. A libera√ß√£o tardia e parcial dos dados dos ensaios cl√≠nicos limita a verifica√ß√£o independente dos achados de seguran√ßa."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento cobre apenas ensaios cl√≠nicos pr√©-licenciamento. Nenhum plano de vigil√¢ncia p√≥s-comercializa√ß√£o, sistema de notifica√ß√£o passiva (como o VAERS, que n√£o existia at√© 1990), ou monitoramento cont√≠nuo de seguran√ßa √© descrito.",
            "level_description": "O documento de licenciamento de 1978 n√£o cont√©m disposi√ß√µes de vigil√¢ncia p√≥s-comercializa√ß√£o. O VAERS n√£o foi estabelecido at√© 1990. A aus√™ncia completa de monitoramento de seguran√ßa p√≥s-comercializa√ß√£o nos documentos de aprova√ß√£o originais significa que a avalia√ß√£o de seguran√ßa dependeu inteiramente dos ensaios pr√©-licenciamento limitados."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos cl√≠nicos foram conduzidos sob a responsabilidade geral do Dr. Maurice R. Hilleman, Vice-Presidente de Pesquisa em V√≠rus e Biologia Celular, Instituto Merck de Pesquisa Terap√™utica. As vacinas foram preparadas pela Merck Sharp and Dohme Biologics Manufacturing. Testes sorol√≥gicos foram realizados em laborat√≥rios da Merck. Os investigadores cl√≠nicos reportavam diretamente √† Merck.",
            "level_description": "Os ensaios foram inteiramente projetados, gerenciados e analisados pelo fabricante da vacina. O investigador principal era Vice-Presidente da Merck. Nenhuma supervis√£o independente, monitoramento externo ou divulga√ß√£o de relacionamentos financeiros est√° documentada. Isso representa um conflito de interesse fundamental sem medidas de mitiga√ß√£o descritas."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Os protocolos mencionam que 'morte por qualquer causa durante a investiga√ß√£o, relacionada ou n√£o ao material de teste, deve ser relatada imediatamente.' No entanto, nenhum dado de mortalidade, relato de morte ou an√°lise sistem√°tica de mortalidade aparece na documenta√ß√£o dos resultados.",
            "level_description": "Embora o protocolo exigisse notifica√ß√£o de mortes, nenhum dado de mortalidade √© apresentado nos resultados dos ensaios cl√≠nicos. N√£o h√° compara√ß√£o sistem√°tica de mortalidade por todas as causas entre os grupos de vacina ou documenta√ß√£o sobre se ocorreram mortes durante o per√≠odo de acompanhamento de 42 dias."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "Os estudos de licenciamento da M-M-R II de 1978 demonstram limita√ß√µes metodol√≥gicas significativas por qualquer padr√£o de avalia√ß√£o de seguran√ßa. Os ensaios inclu√≠ram apenas aproximadamente 834 crian√ßas recebendo a vacina combinada, muito abaixo do m√≠nimo de 3.000 por faixa et√°ria necess√°rio para detectar eventos adversos raros. O acompanhamento foi limitado a 42 dias, impossibilitando a detec√ß√£o de rea√ß√µes autoimunes ou neurol√≥gicas tardias. Nenhum controle placebo verdadeiro foi usado - em vez disso, compararam-se diferentes formula√ß√µes de vacinas. Os estudos n√£o tinham duplo-cego, com a maioria parecendo ser aberta. Os ensaios exclu√≠ram popula√ß√µes vulner√°veis (imunocomprometidos, beb√™s prematuros) que posteriormente receberiam a vacina. Nenhuma avalia√ß√£o de desfechos autoimunes ou neurol√≥gicos foi realizada, apesar de estes terem sido posteriormente identificados como eventos adversos raros. Todo o programa de pesquisa foi conduzido pelo fabricante sem supervis√£o independente, representando um conflito de interesse n√£o mitigado. Embora os estudos possam ter sido padr√£o para sua √©poca, eles ficam dramaticamente aqu√©m dos requisitos modernos de avalia√ß√£o de seguran√ßa de vacinas pedi√°tricas e deixam incerteza substancial sobre o verdadeiro perfil de eventos adversos da M-M-R II."
        }
      },
      "safety_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The document reports a total of 834 children vaccinated across multiple studies (442, 443, 459, 467, 473, 484, 511, 513). While this represents a substantial effort for the era, it is far below the modern standard of >3,000 children per age group needed to detect rare adverse events (1 in 1,000 or 1 in 10,000). The sample size of 834 can only reliably detect events occurring at a frequency of approximately 1 in 100-300. Children ranged from 10 months to 15 years of age (mean ages typically 1.4-4.3 years), with no breakdown by age group sufficient for subgroup safety analysis."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Follow-up was limited to 6 weeks (42 days) post-vaccination across all studies. The protocol explicitly states: 'Each child will be followed clinically for 42 days following vaccination.' Parents were asked to 'take daily temperatures and record all symptoms which occur during the following six weeks.' This timeframe is grossly inadequate to detect autoimmune conditions, neurological sequelae, or developmental effects that may manifest months or years after vaccination. The ideal minimum is 12 months, with 2-3+ years preferred for long-term safety assessment."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Study 459 included a planned placebo group of 50 children, comparing reactions in children receiving M-M-R vaccines vs. individual component vaccines vs. placebo. However, most studies (442, 443, 467, 473, 511, 513) compared different vaccine formulations (HPV-77 vs RA 27/3 rubella strains) rather than using a true saline placebo control. The comparison was primarily between active vaccines, not vaccine vs. no vaccine. The placebo group in Study 459 was limited to 50 children, which is statistically underpowered for safety signal detection."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Surveillance methodology varied by study. In studies by Drs. Weibel, Lerman, Gershon, and McCollum, 'observations were recorded daily by the mother' using parent-completed reaction cards and thermometers. Parents were asked to contact physicians for 'significant or bothersome reactions.' In Dr. Villarejos' studies (Nicaragua/Costa Rica), observations were made by 'medical or paramedical personnel' with physicians notified of 'significant illness.' The protocol required reporting of 'any serious or alarming reaction, including death due to any cause' to Merck. However, there is no evidence of systematic medical examinations, proactive outreach, medical record review, or hospitalization/death investigation with formal causality analysis."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "The document contains no evidence of systematic neurological or developmental monitoring. The word 'neurology' appears only as a department name at University of Nebraska. No scheduled developmental assessments, neurological examinations, or surveillance for conditions such as seizures, encephalitis, Guillain-Barre syndrome, or developmental regression are documented. Clinical complaints tracked were limited to fever, rash, irritability, malaise, upper respiratory illness, otitis, gastrointestinal symptoms, and arthralgia. There is no mention of neurological examination protocols or developmental milestone tracking."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "The document explicitly EXCLUDES vulnerable populations rather than including them. The protocols state that children 'with leukemia or other immunologic disorders and persons receiving immunosuppressive drugs should not be vaccinated.' There is no documentation of intentional inclusion of premature infants, immunocompromised children, or children with chronic conditions. No separate safety analysis for any special population subgroup is presented. The study population consisted entirely of healthy children from the 'open population' without documented special conditions."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document provides summary tables of antibody responses (seroconversion rates, geometric mean titers) and clinical complaints aggregated by vaccine group and time period. Individual case-level serological data is presented in some tables. Temperature and symptom data are presented as percentages. However, complete individual patient records, raw adverse event data, and case narratives are not included in this FOIA release. The document notes that 'detailed background records are on file in Virus and Cell Biology Research, Merck Institute' and 'are available for review at any time,' but these were not part of the submission. Some portions were withheld under FOIA Exemption 4 (trade secrets) and Exemption 6 (privacy)."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "This is a pre-licensure clinical trial document from 1978. There is no mention of post-marketing surveillance plans, pharmacovigilance systems, VAERS (which was not established until 1990), or ongoing safety monitoring after licensure. The document contains no discussion of how safety would be monitored once the vaccine was in widespread use, no mention of periodic safety reviews, and no reference to mechanisms for detecting rare adverse events that might only appear with millions of doses administered."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This 1978 FDA FOIA document provides limited safety evidence for M-M-R II vaccine licensure. While the clinical trials demonstrated immunogenicity with seroconversion rates of 95-99% across components, the safety evaluation has significant limitations: only 834 children were studied (insufficient to detect rare events), follow-up was limited to 42 days (inadequate for detecting delayed autoimmune or neurological effects), most studies lacked true placebo controls (comparing vaccine formulations instead), there was no systematic neurological monitoring, vulnerable populations were explicitly excluded, and no post-marketing surveillance was planned. The passive surveillance methodology relied heavily on parent-completed daily cards documenting temperature and symptoms, with no protocol for medical record review or structured causality assessment. The document shows the vaccine produced expected reactions (fever, rash, irritability) at rates considered acceptable for the era, but cannot provide confidence regarding rare serious adverse events or long-term safety in children."
        }
      },
      "safety_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O documento relata um total de 834 crian√ßas vacinadas em m√∫ltiplos estudos (442, 443, 459, 467, 473, 484, 511, 513). Embora isso represente um esfor√ßo substancial para a √©poca, est√° muito abaixo do padr√£o moderno de >3.000 crian√ßas por faixa et√°ria necess√°rio para detectar eventos adversos raros (1 em 1.000 ou 1 em 10.000). O tamanho amostral de 834 pode detectar de forma confi√°vel apenas eventos que ocorrem com frequ√™ncia aproximada de 1 em 100-300. As crian√ßas tinham entre 10 meses e 15 anos de idade (idades m√©dias tipicamente de 1,4-4,3 anos), sem divis√£o por faixa et√°ria suficiente para an√°lise de seguran√ßa por subgrupo."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento foi limitado a 6 semanas (42 dias) p√≥s-vacina√ß√£o em todos os estudos. O protocolo declara explicitamente: 'Cada crian√ßa ser√° acompanhada clinicamente por 42 dias ap√≥s a vacina√ß√£o.' Os pais foram orientados a 'medir a temperatura diariamente e registrar todos os sintomas que ocorrerem durante as seis semanas seguintes.' Este per√≠odo √© grosseiramente inadequado para detectar condi√ß√µes autoimunes, sequelas neurol√≥gicas ou efeitos no desenvolvimento que podem se manifestar meses ou anos ap√≥s a vacina√ß√£o. O m√≠nimo ideal √© de 12 meses, sendo prefer√≠vel 2-3+ anos para avalia√ß√£o de seguran√ßa a longo prazo."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O Estudo 459 incluiu um grupo placebo planejado de 50 crian√ßas, comparando rea√ß√µes em crian√ßas recebendo vacinas M-M-R vs. vacinas de componentes individuais vs. placebo. No entanto, a maioria dos estudos (442, 443, 467, 473, 511, 513) comparou diferentes formula√ß√µes de vacina (cepas de rub√©ola HPV-77 vs RA 27/3) em vez de usar um controle placebo de solu√ß√£o salina verdadeiro. A compara√ß√£o foi principalmente entre vacinas ativas, n√£o vacina vs. nenhuma vacina. O grupo placebo no Estudo 459 foi limitado a 50 crian√ßas, o que √© estatisticamente insuficiente para detec√ß√£o de sinais de seguran√ßa."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A metodologia de vigil√¢ncia variou por estudo. Nos estudos dos Drs. Weibel, Lerman, Gershon e McCollum, 'as observa√ß√µes eram registradas diariamente pela m√£e' usando cart√µes de rea√ß√£o preenchidos pelos pais e term√¥metros. Os pais foram orientados a contatar os m√©dicos para 'rea√ß√µes significativas ou inc√¥modas.' Nos estudos do Dr. Villarejos (Nicar√°gua/Costa Rica), as observa√ß√µes eram feitas por 'pessoal m√©dico ou param√©dico' com m√©dicos notificados de 'doen√ßas significativas.' O protocolo exigia relato de 'qualquer rea√ß√£o s√©ria ou alarmante, incluindo morte por qualquer causa' √† Merck. No entanto, n√£o h√° evid√™ncia de exames m√©dicos sistem√°ticos, contato proativo, revis√£o de prontu√°rios m√©dicos ou investiga√ß√£o de hospitaliza√ß√£o/morte com an√°lise formal de causalidade."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "O documento n√£o cont√©m evid√™ncia de monitoramento neurol√≥gico ou do desenvolvimento sistem√°tico. A palavra 'neurologia' aparece apenas como nome de departamento na Universidade de Nebraska. N√£o h√° avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos ou vigil√¢ncia para condi√ß√µes como convuls√µes, encefalite, s√≠ndrome de Guillain-Barr√© ou regress√£o do desenvolvimento documentados. As queixas cl√≠nicas rastreadas foram limitadas a febre, erup√ß√£o cut√¢nea, irritabilidade, mal-estar, doen√ßa respirat√≥ria alta, otite, sintomas gastrointestinais e artralgia. N√£o h√° men√ß√£o de protocolos de exame neurol√≥gico ou acompanhamento de marcos do desenvolvimento."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "O documento EXCLUI explicitamente popula√ß√µes vulner√°veis em vez de inclu√≠-las. Os protocolos afirmam que crian√ßas 'com leucemia ou outros dist√∫rbios imunol√≥gicos e pessoas recebendo drogas imunossupressoras n√£o devem ser vacinadas.' N√£o h√° documenta√ß√£o de inclus√£o intencional de beb√™s prematuros, crian√ßas imunocomprometidas ou crian√ßas com condi√ß√µes cr√¥nicas. Nenhuma an√°lise de seguran√ßa separada para qualquer subgrupo de popula√ß√£o especial √© apresentada. A popula√ß√£o do estudo consistiu inteiramente de crian√ßas saud√°veis da 'popula√ß√£o aberta' sem condi√ß√µes especiais documentadas."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento fornece tabelas resumidas de respostas de anticorpos (taxas de soroconvers√£o, t√≠tulos m√©dios geom√©tricos) e queixas cl√≠nicas agregadas por grupo de vacina e per√≠odo de tempo. Dados sorol√≥gicos individuais de n√≠vel de caso s√£o apresentados em algumas tabelas. Dados de temperatura e sintomas s√£o apresentados como porcentagens. No entanto, registros individuais completos de pacientes, dados brutos de eventos adversos e narrativas de casos n√£o est√£o inclu√≠dos nesta libera√ß√£o FOIA. O documento observa que 'registros detalhados de base est√£o arquivados na Pesquisa de V√≠rus e Biologia Celular, Instituto Merck' e 'est√£o dispon√≠veis para revis√£o a qualquer momento,' mas estes n√£o faziam parte da submiss√£o. Algumas partes foram retidas sob a Isen√ß√£o 4 da FOIA (segredos comerciais) e Isen√ß√£o 6 (privacidade)."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Este √© um documento de ensaio cl√≠nico pr√©-licenciamento de 1978. N√£o h√° men√ß√£o de planos de vigil√¢ncia p√≥s-comercializa√ß√£o, sistemas de farmacovigil√¢ncia, VAERS (que s√≥ foi estabelecido em 1990) ou monitoramento de seguran√ßa cont√≠nuo ap√≥s o licenciamento. O documento n√£o cont√©m discuss√£o sobre como a seguran√ßa seria monitorada uma vez que a vacina estivesse em uso generalizado, nenhuma men√ß√£o de revis√µes peri√≥dicas de seguran√ßa e nenhuma refer√™ncia a mecanismos para detectar eventos adversos raros que podem aparecer apenas com milh√µes de doses administradas."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Este documento FOIA da FDA de 1978 fornece evid√™ncia de seguran√ßa limitada para o licenciamento da vacina M-M-R II. Embora os ensaios cl√≠nicos tenham demonstrado imunogenicidade com taxas de soroconvers√£o de 95-99% em todos os componentes, a avalia√ß√£o de seguran√ßa tem limita√ß√µes significativas: apenas 834 crian√ßas foram estudadas (insuficiente para detectar eventos raros), o acompanhamento foi limitado a 42 dias (inadequado para detectar efeitos autoimunes ou neurol√≥gicos tardios), a maioria dos estudos n√£o tinha controles placebo verdadeiros (comparando formula√ß√µes de vacinas em vez disso), n√£o houve monitoramento neurol√≥gico sistem√°tico, popula√ß√µes vulner√°veis foram explicitamente exclu√≠das e nenhuma vigil√¢ncia p√≥s-comercializa√ß√£o foi planejada. A metodologia de vigil√¢ncia passiva dependia fortemente de cart√µes di√°rios preenchidos pelos pais documentando temperatura e sintomas, sem protocolo para revis√£o de prontu√°rios m√©dicos ou avalia√ß√£o estruturada de causalidade. O documento mostra que a vacina produziu rea√ß√µes esperadas (febre, erup√ß√£o cut√¢nea, irritabilidade) em taxas consideradas aceit√°veis para a √©poca, mas n√£o pode fornecer confian√ßa em rela√ß√£o a eventos adversos s√©rios raros ou seguran√ßa a longo prazo em crian√ßas."
        }
      }
    },
    {
      "id": "var_varivax",
      "name": "Varivax",
      "type": "VAR",
      "manufacturer": "Merck",
      "description": "Varicella Virus Vaccine Live for prevention of varicella (chickenpox).",
      "sources": [
        "var_varivax_insert.pdf",
        "var_varivax_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "var_varivax",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One double-blind, placebo-controlled study among 914 healthy children and adolescents (n=491 vaccine, n=465 placebo) using a prior formulation (17,000 PFU). The current refrigerator-stable VARIVAX formulation was NOT tested in a placebo-controlled trial. Most clinical trials used historical controls or compared vaccinated cohorts to expected incidence rates rather than true placebo groups.",
            "level_description": "While a placebo-controlled trial exists, it used an older formulation and a relatively small sample. The current marketed formulation has not been evaluated in a placebo-controlled setting, relying instead on comparisons to historical incidence rates."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Document states 'a double-blind, placebo-controlled study among 914 healthy children and adolescents' was conducted. However, this was for an older formulation. Many other trials mentioned were open-label (e.g., NCT00432523 was 'randomized open-label').",
            "level_description": "Double-blinding was used in one key study with an older formulation, but many subsequent trials including those with the current formulation were open-label, introducing potential bias in adverse event assessment."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple studies described randomization: '2216 children 12 months to 12 years of age with a negative history of varicella were randomized to receive either 1 dose of VARIVAX (n=1114) or 2 doses.' NCT00432523 was described as 'randomized open-label clinical trial.'",
            "level_description": "Randomization was documented in multiple clinical trials, including the key efficacy and immunogenicity studies. Allocation concealment methods are not explicitly described."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Over 11,000 healthy children, adolescents, and adults received VARIVAX in clinical trials. For children 1-12 years: 8,824-8,913 subjects in fever/adverse event tables; 9,454 healthy children vaccinated and followed for herpes zoster; 4,240 children in early trials; 1,114 children in later 10-year trials; 2,216 children in 1-dose vs 2-dose study; 752 children in NCT00432523.",
            "level_description": "The pediatric sample size exceeds 3,000 children substantially, with large cohorts followed for various endpoints. This is adequate for detecting common adverse events but may still miss rare events (1:10,000)."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Primary safety monitoring was 42 days post-vaccination. However, long-term efficacy studies followed children for up to 10 years. Herpes zoster follow-up: 42,556 person-years in children, 5,410 person-years in adolescents/adults. Antibody persistence tracked for 1-10 years in various studies.",
            "level_description": "While active safety monitoring was limited to 42 days (inadequate for detecting delayed autoimmune reactions), long-term efficacy follow-up extends to 10 years. The 42-day safety window is typical for vaccine trials but misses late-onset adverse events."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Data presented separately for: Children 1-12 years (One-Dose Regimen, Two-Dose Regimen); Adolescents 13+ years and Adults (separate table with dose 1 and dose 2 data); Children 12-23 months in specific studies. NCT00432523 studied children 12-18 months specifically.",
            "level_description": "Age groups are analyzed separately with distinct tables for children vs. adolescents/adults. However, further stratification within children (e.g., 1-2 years, 3-5 years, 6-12 years) is not consistently provided."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Contraindications specify exclusions: immunosuppression, moderate/severe febrile illness, active TB, pregnancy, severe allergic reactions. Study enrolled 'healthy children,' 'serologically confirmed to be susceptible to varicella.' Warnings mention family history of immunodeficiency as deferral criterion.",
            "level_description": "Inclusion criteria focus on healthy, varicella-susceptible individuals. Exclusion criteria are clearly documented in contraindications. However, real-world applicability to children with underlying conditions is limited by these restrictions."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Adverse events defined with objective thresholds: fever defined as >=102.0F (38.9C) oral for children, >=100.0F (37.8C) for adolescents/adults. Injection site reactions categorized (mild <=2.5cm, moderate >2.5-5.0cm, severe >5.0cm). Pain intensity defined. Diary cards used for systematic collection. Rashes characterized as measles-like, rubella-like, varicella-like.",
            "level_description": "Standardized definitions with objective temperature thresholds and lesion measurements are used. Diary cards provided systematic data collection. However, Brighton Collaboration criteria are not explicitly mentioned."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Active follow-up conducted for 42 days after vaccination using diary cards. 'Subjects were actively followed for varicella, any varicella-like illness, or herpes zoster.' Serious adverse events reported: '0.3% and 1% in the intramuscular and subcutaneous groups.' Six subjects reported serious adverse events in one study. Febrile seizures occurred at <0.1% rate.",
            "level_description": "Active monitoring was performed but limited to 42 days. Serious adverse events were tracked and reported, but the short follow-up window and lack of detailed causality investigation protocols described limits confidence in detecting delayed serious events."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Post-marketing section lists neurological events: encephalitis, cerebrovascular accident, transverse myelitis, Guillain-Barre syndrome, Bell's palsy, ataxia, non-febrile seizures, aseptic meningitis, meningitis, paresthesia. Clinical trials report febrile seizures at <0.1%. No specific pre-planned monitoring protocol for autoimmune/neurological conditions described in clinical trials.",
            "level_description": "Serious neurological events are documented in post-marketing experience but were not systematically monitored in clinical trials. The 42-day follow-up is inadequate for detecting conditions like Guillain-Barre (typically 2-8 weeks post-exposure) or autoimmune disorders."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Contraindications explicitly exclude immunocompromised individuals. Section 5.2 notes ACIP has recommendations for HIV-infected individuals but does not provide trial data. Section 8.4: 'No clinical data are available on safety or efficacy of VARIVAX in children less than 12 months of age.' Premature infants, children with chronic conditions not specifically studied.",
            "level_description": "Vulnerable subgroups (immunocompromised, premature infants, children <12 months, children with chronic conditions) were largely excluded from trials rather than intentionally studied. This significantly limits understanding of safety in these populations."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Confidence intervals provided for efficacy: '94% (95% CI, 93%, 96%)' and '90% (95% CI, 82%, 96%)'. P-values reported: 'significantly (p<0.05) greater rate' for injection-site reactions; '98% for 2 doses (p<0.001)'. Studies described as powered for efficacy, not safety. No explicit safety power calculations documented.",
            "level_description": "Standard statistical methods used with CIs and p-values reported. However, studies were powered for efficacy endpoints, not safety outcomes. No safety power calculations are documented, meaning rare adverse events may be missed due to inadequate statistical power."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "References provided to 18 peer-reviewed publications. NCT00432523 registered as clinical trial. No mention of independent Data Safety Monitoring Board (DSMB). Raw data/individual participant data availability not mentioned. Package insert summarizes data without providing complete datasets.",
            "level_description": "Peer-reviewed publications and clinical trial registrations provide some transparency. However, no DSMB is mentioned, raw data availability is not discussed, and complete adverse event datasets are not accessible for independent verification."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 describes post-marketing experience with detailed adverse event categories. VAERS reporting encouraged. Pregnancy registry maintained 1995-2013 (1,522 women enrolled, 905 with known outcomes). Reference to 'A 10-Year Review' safety profile publication (Galea 2008). Herpes zoster calculated incidence: 18.8 cases per 100,000 person-years in children.",
            "level_description": "Post-marketing surveillance is documented with VAERS integration, a pregnancy registry, and periodic safety reviews. However, VAERS is a passive reporting system known to underestimate true adverse event rates."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Manufacturer: Merck Sharp & Dohme LLC. Clinical trials conducted at 'Research Laboratories of Merck Sharp & Dohme LLC, Rahway, NJ.' No disclosure of funding sources for individual trials, researcher financial relationships, or independent oversight. All referenced studies appear to be manufacturer-sponsored.",
            "level_description": "The vaccine is manufactured by Merck and clinical trials were conducted by Merck researchers. No independent funding sources or conflict of interest disclosures are provided. Industry sponsorship without independent oversight raises concerns about potential bias."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not report all-cause mortality data. No deaths reported in clinical trials section. Post-marketing mentions monitoring for deaths in context of active surveillance but provides no aggregate mortality data comparing vaccine vs. placebo groups.",
            "level_description": "All-cause mortality data are not reported. While no deaths are explicitly mentioned in clinical trials, the absence of systematic mortality reporting (deaths in vaccine vs. control groups) prevents assessment of overall mortality impact."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "VARIVAX clinical trials demonstrate adequate methodology in several areas including large pediatric sample sizes (>11,000 subjects), randomization in key studies, standardized adverse event definitions with objective thresholds, and 10-year efficacy follow-up. However, significant limitations exist: the current formulation was not tested in placebo-controlled trials, active safety monitoring was limited to 42 days (inadequate for detecting delayed autoimmune/neurological conditions), vulnerable subgroups were excluded rather than studied, studies were powered for efficacy rather than safety, no independent oversight or conflict of interest disclosures are provided, and all-cause mortality data are not reported. The trial methodology is adequate for demonstrating immunogenicity and short-term tolerability but provides limited evidence for rare, delayed, or serious adverse events, particularly in vulnerable populations."
        }
      },
      "trial_pt": {
        "vaccine_id": "var_varivax",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um estudo duplo-cego controlado por placebo entre 914 crian√ßas e adolescentes saud√°veis (n=491 vacina, n=465 placebo) usando uma formula√ß√£o anterior (17.000 PFU). A formula√ß√£o VARIVAX est√°vel em refrigera√ß√£o atual N√ÉO foi testada em um ensaio controlado por placebo. A maioria dos ensaios cl√≠nicos usou controles hist√≥ricos ou comparou coortes vacinadas com taxas de incid√™ncia esperadas em vez de grupos placebo verdadeiros.",
            "level_description": "Embora exista um ensaio controlado por placebo, ele usou uma formula√ß√£o mais antiga e uma amostra relativamente pequena. A formula√ß√£o comercializada atual n√£o foi avaliada em um ambiente controlado por placebo, dependendo em vez disso de compara√ß√µes com taxas de incid√™ncia hist√≥ricas."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento afirma 'um estudo duplo-cego controlado por placebo entre 914 crian√ßas e adolescentes saud√°veis' foi conduzido. No entanto, isso foi para uma formula√ß√£o mais antiga. Muitos outros ensaios mencionados eram abertos (por exemplo, NCT00432523 era 'randomizado aberto').",
            "level_description": "Duplo-cegamento foi usado em um estudo chave com uma formula√ß√£o mais antiga, mas muitos ensaios subsequentes incluindo aqueles com a formula√ß√£o atual eram abertos, introduzindo potencial vi√©s na avalia√ß√£o de eventos adversos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos estudos descreveram randomiza√ß√£o: '2216 crian√ßas de 12 meses a 12 anos de idade com hist√≥rico negativo de varicela foram randomizadas para receber 1 dose de VARIVAX (n=1114) ou 2 doses.' NCT00432523 foi descrito como 'ensaio cl√≠nico randomizado aberto.'",
            "level_description": "Randomiza√ß√£o foi documentada em m√∫ltiplos ensaios cl√≠nicos, incluindo os principais estudos de efic√°cia e imunogenicidade. M√©todos de oculta√ß√£o de aloca√ß√£o n√£o s√£o explicitamente descritos."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Mais de 11.000 crian√ßas, adolescentes e adultos saud√°veis receberam VARIVAX em ensaios cl√≠nicos. Para crian√ßas de 1-12 anos: 8.824-8.913 sujeitos nas tabelas de febre/eventos adversos; 9.454 crian√ßas saud√°veis vacinadas e acompanhadas para herpes zoster; 4.240 crian√ßas em ensaios iniciais; 1.114 crian√ßas em ensaios posteriores de 10 anos; 2.216 crian√ßas no estudo de 1 dose vs 2 doses; 752 crian√ßas no NCT00432523.",
            "level_description": "O tamanho da amostra pedi√°trica excede substancialmente 3.000 crian√ßas, com grandes coortes acompanhadas para v√°rios desfechos. Isso √© adequado para detectar eventos adversos comuns, mas ainda pode perder eventos raros (1:10.000)."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Monitoramento de seguran√ßa prim√°rio foi de 42 dias ap√≥s a vacina√ß√£o. No entanto, estudos de efic√°cia de longo prazo acompanharam crian√ßas por at√© 10 anos. Acompanhamento de herpes zoster: 42.556 pessoas-ano em crian√ßas, 5.410 pessoas-ano em adolescentes/adultos. Persist√™ncia de anticorpos rastreada por 1-10 anos em v√°rios estudos.",
            "level_description": "Embora o monitoramento de seguran√ßa ativo fosse limitado a 42 dias (inadequado para detectar rea√ß√µes autoimunes tardias), o acompanhamento de efic√°cia de longo prazo estende-se por 10 anos. A janela de seguran√ßa de 42 dias √© t√≠pica para ensaios de vacinas, mas perde eventos adversos de in√≠cio tardio."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Dados apresentados separadamente para: Crian√ßas de 1-12 anos (Regime de Uma Dose, Regime de Duas Doses); Adolescentes 13+ anos e Adultos (tabela separada com dados de dose 1 e dose 2); Crian√ßas de 12-23 meses em estudos espec√≠ficos. NCT00432523 estudou crian√ßas de 12-18 meses especificamente.",
            "level_description": "Grupos et√°rios s√£o analisados separadamente com tabelas distintas para crian√ßas vs. adolescentes/adultos. No entanto, estratifica√ß√£o adicional dentro de crian√ßas (por exemplo, 1-2 anos, 3-5 anos, 6-12 anos) n√£o √© consistentemente fornecida."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Contraindica√ß√µes especificam exclus√µes: imunossupress√£o, doen√ßa febril moderada/grave, TB ativa, gravidez, rea√ß√µes al√©rgicas graves. Estudo incluiu 'crian√ßas saud√°veis', 'confirmadas sorologicamente como suscet√≠veis √† varicela.' Advert√™ncias mencionam hist√≥rico familiar de imunodefici√™ncia como crit√©rio de adiamento.",
            "level_description": "Crit√©rios de inclus√£o focam em indiv√≠duos saud√°veis e suscet√≠veis √† varicela. Crit√©rios de exclus√£o est√£o claramente documentados nas contraindica√ß√µes. No entanto, aplicabilidade no mundo real a crian√ßas com condi√ß√µes subjacentes √© limitada por essas restri√ß√µes."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos definidos com limiares objetivos: febre definida como >=102,0F (38,9C) oral para crian√ßas, >=100,0F (37,8C) para adolescentes/adultos. Rea√ß√µes no local da inje√ß√£o categorizadas (leve <=2,5cm, moderada >2,5-5,0cm, grave >5,0cm). Intensidade da dor definida. Cart√µes di√°rios usados para coleta sistem√°tica. Erup√ß√µes cut√¢neas caracterizadas como semelhantes a sarampo, semelhantes a rub√©ola, semelhantes a varicela.",
            "level_description": "Defini√ß√µes padronizadas com limiares objetivos de temperatura e medi√ß√µes de les√µes s√£o usadas. Cart√µes di√°rios forneceram coleta sistem√°tica de dados. No entanto, crit√©rios da Brighton Collaboration n√£o s√£o explicitamente mencionados."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Acompanhamento ativo conduzido por 42 dias ap√≥s a vacina√ß√£o usando cart√µes di√°rios. 'Sujeitos foram acompanhados ativamente para varicela, qualquer doen√ßa semelhante √† varicela ou herpes zoster.' Eventos adversos graves relatados: '0,3% e 1% nos grupos intramuscular e subcut√¢neo.' Seis sujeitos relataram eventos adversos graves em um estudo. Convuls√µes febris ocorreram em taxa <0,1%.",
            "level_description": "Monitoramento ativo foi realizado, mas limitado a 42 dias. Eventos adversos graves foram rastreados e relatados, mas a curta janela de acompanhamento e falta de protocolos detalhados de investiga√ß√£o de causalidade descritos limita a confian√ßa na detec√ß√£o de eventos graves tardios."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o p√≥s-comercializa√ß√£o lista eventos neurol√≥gicos: encefalite, acidente cerebrovascular, mielite transversa, s√≠ndrome de Guillain-Barr√©, paralisia de Bell, ataxia, convuls√µes n√£o-febris, meningite ass√©ptica, meningite, parestesia. Ensaios cl√≠nicos relatam convuls√µes febris em <0,1%. Nenhum protocolo de monitoramento pr√©-planejado espec√≠fico para condi√ß√µes autoimunes/neurol√≥gicas descrito em ensaios cl√≠nicos.",
            "level_description": "Eventos neurol√≥gicos graves s√£o documentados na experi√™ncia p√≥s-comercializa√ß√£o, mas n√£o foram sistematicamente monitorados em ensaios cl√≠nicos. O acompanhamento de 42 dias √© inadequado para detectar condi√ß√µes como Guillain-Barr√© (tipicamente 2-8 semanas p√≥s-exposi√ß√£o) ou dist√∫rbios autoimunes."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Contraindica√ß√µes explicitamente excluem indiv√≠duos imunocomprometidos. Se√ß√£o 5.2 observa que ACIP tem recomenda√ß√µes para indiv√≠duos infectados pelo HIV, mas n√£o fornece dados de ensaio. Se√ß√£o 8.4: 'Nenhum dado cl√≠nico est√° dispon√≠vel sobre seguran√ßa ou efic√°cia de VARIVAX em crian√ßas menores de 12 meses de idade.' Beb√™s prematuros, crian√ßas com condi√ß√µes cr√¥nicas n√£o especificamente estudadas.",
            "level_description": "Subgrupos vulner√°veis (imunocomprometidos, beb√™s prematuros, crian√ßas <12 meses, crian√ßas com condi√ß√µes cr√¥nicas) foram largamente exclu√≠dos dos ensaios em vez de intencionalmente estudados. Isso limita significativamente a compreens√£o da seguran√ßa nessas popula√ß√µes."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Intervalos de confian√ßa fornecidos para efic√°cia: '94% (IC 95%, 93%, 96%)' e '90% (IC 95%, 82%, 96%)'. Valores-p relatados: 'taxa significativamente (p<0,05) maior' para rea√ß√µes no local da inje√ß√£o; '98% para 2 doses (p<0,001)'. Estudos descritos como dimensionados para efic√°cia, n√£o seguran√ßa. Nenhum c√°lculo de poder para seguran√ßa explicitamente documentado.",
            "level_description": "M√©todos estat√≠sticos padr√£o usados com ICs e valores-p relatados. No entanto, estudos foram dimensionados para desfechos de efic√°cia, n√£o de seguran√ßa. Nenhum c√°lculo de poder para seguran√ßa est√° documentado, significando que eventos adversos raros podem ser perdidos devido a poder estat√≠stico inadequado."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Refer√™ncias fornecidas para 18 publica√ß√µes revisadas por pares. NCT00432523 registrado como ensaio cl√≠nico. Nenhuma men√ß√£o de Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (CIMD). Disponibilidade de dados brutos/dados individuais de participantes n√£o mencionada. Bula resume dados sem fornecer conjuntos de dados completos.",
            "level_description": "Publica√ß√µes revisadas por pares e registros de ensaios cl√≠nicos fornecem alguma transpar√™ncia. No entanto, nenhum CIMD √© mencionado, disponibilidade de dados brutos n√£o √© discutida, e conjuntos de dados completos de eventos adversos n√£o s√£o acess√≠veis para verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Se√ß√£o 6.2 descreve experi√™ncia p√≥s-comercializa√ß√£o com categorias detalhadas de eventos adversos. Relato ao VAERS encorajado. Registro de gravidez mantido 1995-2013 (1.522 mulheres inscritas, 905 com desfechos conhecidos). Refer√™ncia √† publica√ß√£o 'Uma Revis√£o de 10 Anos' do perfil de seguran√ßa (Galea 2008). Incid√™ncia calculada de herpes zoster: 18,8 casos por 100.000 pessoas-ano em crian√ßas.",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o est√° documentada com integra√ß√£o ao VAERS, um registro de gravidez e revis√µes peri√≥dicas de seguran√ßa. No entanto, VAERS √© um sistema de relato passivo conhecido por subestimar as taxas verdadeiras de eventos adversos."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Fabricante: Merck Sharp & Dohme LLC. Ensaios cl√≠nicos conduzidos nos 'Laborat√≥rios de Pesquisa da Merck Sharp & Dohme LLC, Rahway, NJ.' Nenhuma divulga√ß√£o de fontes de financiamento para ensaios individuais, relacionamentos financeiros de pesquisadores ou supervis√£o independente. Todos os estudos referenciados parecem ser patrocinados pelo fabricante.",
            "level_description": "A vacina √© fabricada pela Merck e os ensaios cl√≠nicos foram conduzidos por pesquisadores da Merck. Nenhuma fonte de financiamento independente ou divulga√ß√µes de conflito de interesse s√£o fornecidas. Patroc√≠nio da ind√∫stria sem supervis√£o independente levanta preocupa√ß√µes sobre potencial vi√©s."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas. Nenhuma morte relatada na se√ß√£o de ensaios cl√≠nicos. P√≥s-comercializa√ß√£o menciona monitoramento de √≥bitos no contexto de vigil√¢ncia ativa, mas n√£o fornece dados agregados de mortalidade comparando grupos de vacina vs. placebo.",
            "level_description": "Dados de mortalidade por todas as causas n√£o s√£o relatados. Embora nenhuma morte seja explicitamente mencionada em ensaios cl√≠nicos, a aus√™ncia de relato sistem√°tico de mortalidade (√≥bitos em grupos de vacina vs. controle) impede a avalia√ß√£o do impacto geral de mortalidade."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Os ensaios cl√≠nicos de VARIVAX demonstram metodologia adequada em v√°rias √°reas incluindo grandes tamanhos de amostra pedi√°trica (>11.000 sujeitos), randomiza√ß√£o em estudos-chave, defini√ß√µes padronizadas de eventos adversos com limiares objetivos e acompanhamento de efic√°cia de 10 anos. No entanto, existem limita√ß√µes significativas: a formula√ß√£o atual n√£o foi testada em ensaios controlados por placebo, monitoramento de seguran√ßa ativo foi limitado a 42 dias (inadequado para detectar condi√ß√µes autoimunes/neurol√≥gicas tardias), subgrupos vulner√°veis foram exclu√≠dos em vez de estudados, estudos foram dimensionados para efic√°cia em vez de seguran√ßa, nenhuma supervis√£o independente ou divulga√ß√µes de conflito de interesse s√£o fornecidas, e dados de mortalidade por todas as causas n√£o s√£o relatados. A metodologia do ensaio √© adequada para demonstrar imunogenicidade e tolerabilidade de curto prazo, mas fornece evid√™ncia limitada para eventos adversos raros, tardios ou graves, particularmente em popula√ß√µes vulner√°veis."
        }
      },
      "safety_en": {
        "vaccine_id": "var_varivax",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Over 11,000 children, adolescents, and adults received VARIVAX in clinical trials. Specifically for children 1-12 years: approximately 8,824-8,913 subjects monitored for fever and adverse reactions; 9,454 healthy children followed for herpes zoster (42,556 person-years); 4,240 children in early clinical trials; 2,216 children in the 1-dose vs 2-dose randomized study. This sample size exceeds the 3,000+ threshold needed to detect adverse events occurring at 1:1,000 frequency, though events rarer than 1:10,000 may still be missed."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active safety monitoring was limited to 42 days post-vaccination in clinical trials, which is inadequate for detecting delayed autoimmune or neurological adverse events. While long-term efficacy follow-up extended to 10 years and herpes zoster incidence was tracked over 42,556 person-years in children, this was primarily for breakthrough disease and antibody persistence, not systematic safety surveillance. The 42-day window is standard industry practice but insufficient to detect conditions with delayed onset like Guillain-Barre syndrome (typically 2-8 weeks), autoimmune disorders, or developmental impacts."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A placebo-controlled, double-blind study was conducted with 914 children and adolescents (491 vaccine, 465 placebo), but this used an older formulation (17,000 PFU per dose). The current refrigerator-stable VARIVAX was NOT tested against a true placebo. Most studies compared to historical controls or expected incidence rates. The 2-dose vs 1-dose study (n=2,216) compared vaccine regimens, not vaccine vs. placebo. Without contemporary placebo comparison for the marketed formulation, attributing adverse events specifically to the vaccine versus coincidental illness is challenging."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance was conducted using diary cards for 42 days post-vaccination, with investigators reviewing cards at day 42 visits. Parents/guardians recorded local reactions for 4 days and systemic reactions for 42 days. Serious adverse events were collected, occurring at 0.3-1% rates in specific studies. However, the short duration limits detection of delayed events. Post-marketing relies on VAERS passive reporting, which significantly underestimates true adverse event rates. A pregnancy registry (1995-2013) actively followed 1,522 women with 905 known outcomes."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "No specific pre-planned neurological or developmental monitoring protocol is described in clinical trials. Febrile seizures were reported at <0.1% rate. Post-marketing section identifies serious neurological events including encephalitis, transverse myelitis, Guillain-Barre syndrome, Bell's palsy, ataxia, non-febrile seizures, aseptic meningitis, and meningitis - these were discovered through passive post-marketing surveillance, not proactive clinical trial monitoring. No scheduled neurological exams, developmental assessments, or predefined list of neurological conditions to actively monitor is documented."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Vulnerable populations were largely excluded rather than studied. Contraindications explicitly exclude immunocompromised individuals; 'disseminated varicella disease' has occurred in immunosuppressed individuals inadvertently vaccinated. No clinical data available for children <12 months of age. Premature infants are mentioned only in context of transmission risk, not safety data. Children with chronic conditions, developmental disorders, or concurrent illnesses were not specifically included or analyzed. The package insert acknowledges insufficient data for several populations (e.g., geriatric subjects)."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document references 18 peer-reviewed publications and at least one registered clinical trial (NCT00432523). Adverse event data are presented in summary tables with percentages and confidence intervals. However, no independent Data Safety Monitoring Board (DSMB) is mentioned. Raw data and individual participant data are not publicly available. Complete adverse event listings beyond percentages are not provided. All studies appear manufacturer-sponsored without independent analysis or verification opportunities."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Post-marketing surveillance is documented through multiple channels: VAERS (Vaccine Adverse Event Reporting System) reporting is encouraged with provided contact information; a pregnancy exposure registry was maintained from 1995-2013 with 1,522 women enrolled; a 10-year safety review was published (Galea 2008); herpes zoster incidence calculated at 18.8 per 100,000 person-years in children. Post-marketing identified serious adverse events including anaphylaxis, neurological conditions, aplastic anemia, and thrombocytopenia. However, VAERS is a passive system with significant underreporting, and the document acknowledges 'it is not always possible to reliably estimate their frequency or establish a causal relationship.'"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The VARIVAX package insert provides partial reassurance about short-term safety in healthy children, supported by a large sample size (>11,000 subjects) and documented common adverse events (fever 14.7%, injection-site reactions 19.3%, varicella-like rash 3-4%). However, several critical limitations undermine confidence in comprehensive safety: (1) active safety monitoring was only 42 days, inadequate for detecting delayed autoimmune or neurological conditions; (2) the current marketed formulation was not tested against a true placebo; (3) vulnerable populations (immunocompromised, premature infants, children <12 months, those with chronic conditions) were excluded from trials rather than studied; (4) no systematic neurological/developmental monitoring protocol was employed; and (5) serious neurological events (encephalitis, Guillain-Barre, transverse myelitis) were discovered only through post-marketing passive surveillance, not proactive trial design. For a parent asking 'Is this vaccine safe for my child now and in the future?' - this document demonstrates acceptable short-term tolerability in healthy children but does not adequately address long-term safety, rare serious events, or safety in children with underlying conditions."
        }
      },
      "safety_pt": {
        "vaccine_id": "var_varivax",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Mais de 11.000 crian√ßas, adolescentes e adultos receberam VARIVAX em ensaios cl√≠nicos. Especificamente para crian√ßas de 1-12 anos: aproximadamente 8.824-8.913 sujeitos monitorados para febre e rea√ß√µes adversas; 9.454 crian√ßas saud√°veis acompanhadas para herpes zoster (42.556 pessoas-ano); 4.240 crian√ßas em ensaios cl√≠nicos iniciais; 2.216 crian√ßas no estudo randomizado de 1 dose vs 2 doses. Este tamanho de amostra excede o limiar de 3.000+ necess√°rio para detectar eventos adversos ocorrendo na frequ√™ncia de 1:1.000, embora eventos mais raros que 1:10.000 ainda possam ser perdidos."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Monitoramento de seguran√ßa ativo foi limitado a 42 dias p√≥s-vacina√ß√£o em ensaios cl√≠nicos, o que √© inadequado para detectar eventos adversos autoimunes ou neurol√≥gicos tardios. Embora o acompanhamento de efic√°cia de longo prazo tenha se estendido por 10 anos e a incid√™ncia de herpes zoster tenha sido rastreada por 42.556 pessoas-ano em crian√ßas, isso foi principalmente para doen√ßa de ruptura e persist√™ncia de anticorpos, n√£o vigil√¢ncia sistem√°tica de seguran√ßa. A janela de 42 dias √© pr√°tica padr√£o da ind√∫stria, mas insuficiente para detectar condi√ß√µes com in√≠cio tardio como s√≠ndrome de Guillain-Barr√© (tipicamente 2-8 semanas), dist√∫rbios autoimunes ou impactos no desenvolvimento."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Um estudo controlado por placebo, duplo-cego foi conduzido com 914 crian√ßas e adolescentes (491 vacina, 465 placebo), mas isso usou uma formula√ß√£o mais antiga (17.000 PFU por dose). A VARIVAX est√°vel em refrigera√ß√£o atual N√ÉO foi testada contra um placebo verdadeiro. A maioria dos estudos comparou com controles hist√≥ricos ou taxas de incid√™ncia esperadas. O estudo de 2 doses vs 1 dose (n=2.216) comparou regimes de vacina, n√£o vacina vs. placebo. Sem compara√ß√£o contempor√¢nea com placebo para a formula√ß√£o comercializada, atribuir eventos adversos especificamente √† vacina versus doen√ßa coincidente √© desafiador."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Vigil√¢ncia ativa foi conduzida usando cart√µes di√°rios por 42 dias p√≥s-vacina√ß√£o, com investigadores revisando cart√µes nas visitas do dia 42. Pais/respons√°veis registraram rea√ß√µes locais por 4 dias e rea√ß√µes sist√™micas por 42 dias. Eventos adversos graves foram coletados, ocorrendo em taxas de 0,3-1% em estudos espec√≠ficos. No entanto, a curta dura√ß√£o limita a detec√ß√£o de eventos tardios. P√≥s-comercializa√ß√£o depende do relato passivo do VAERS, que subestima significativamente as taxas verdadeiras de eventos adversos. Um registro de gravidez (1995-2013) acompanhou ativamente 1.522 mulheres com 905 desfechos conhecidos."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Nenhum protocolo de monitoramento neurol√≥gico ou de desenvolvimento pr√©-planejado espec√≠fico √© descrito em ensaios cl√≠nicos. Convuls√µes febris foram relatadas em taxa <0,1%. A se√ß√£o p√≥s-comercializa√ß√£o identifica eventos neurol√≥gicos graves incluindo encefalite, mielite transversa, s√≠ndrome de Guillain-Barr√©, paralisia de Bell, ataxia, convuls√µes n√£o-febris, meningite ass√©ptica e meningite - estas foram descobertas atrav√©s de vigil√¢ncia passiva p√≥s-comercializa√ß√£o, n√£o monitoramento proativo de ensaio cl√≠nico. Nenhum exame neurol√≥gico programado, avalia√ß√£o de desenvolvimento ou lista predefinida de condi√ß√µes neurol√≥gicas para monitorar ativamente est√° documentada."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Popula√ß√µes vulner√°veis foram largamente exclu√≠das em vez de estudadas. Contraindica√ß√µes explicitamente excluem indiv√≠duos imunocomprometidos; 'doen√ßa disseminada por varicela' ocorreu em indiv√≠duos imunossuprimidos inadvertidamente vacinados. Nenhum dado cl√≠nico dispon√≠vel para crian√ßas <12 meses de idade. Beb√™s prematuros s√£o mencionados apenas no contexto de risco de transmiss√£o, n√£o dados de seguran√ßa. Crian√ßas com condi√ß√µes cr√¥nicas, dist√∫rbios do desenvolvimento ou doen√ßas concomitantes n√£o foram especificamente inclu√≠das ou analisadas. A bula reconhece dados insuficientes para v√°rias popula√ß√µes (por exemplo, sujeitos geri√°tricos)."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento referencia 18 publica√ß√µes revisadas por pares e pelo menos um ensaio cl√≠nico registrado (NCT00432523). Dados de eventos adversos s√£o apresentados em tabelas resumidas com porcentagens e intervalos de confian√ßa. No entanto, nenhum Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (CIMD) √© mencionado. Dados brutos e dados individuais de participantes n√£o est√£o publicamente dispon√≠veis. Listagens completas de eventos adversos al√©m de porcentagens n√£o s√£o fornecidas. Todos os estudos parecem patrocinados pelo fabricante sem oportunidades de an√°lise ou verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Vigil√¢ncia p√≥s-comercializa√ß√£o est√° documentada atrav√©s de m√∫ltiplos canais: relato ao VAERS (Sistema de Notifica√ß√£o de Eventos Adversos de Vacinas) √© encorajado com informa√ß√µes de contato fornecidas; um registro de exposi√ß√£o na gravidez foi mantido de 1995-2013 com 1.522 mulheres inscritas; uma revis√£o de seguran√ßa de 10 anos foi publicada (Galea 2008); incid√™ncia de herpes zoster calculada em 18,8 por 100.000 pessoas-ano em crian√ßas. P√≥s-comercializa√ß√£o identificou eventos adversos graves incluindo anafilaxia, condi√ß√µes neurol√≥gicas, anemia apl√°stica e trombocitopenia. No entanto, VAERS √© um sistema passivo com subnotifica√ß√£o significativa, e o documento reconhece 'nem sempre √© poss√≠vel estimar confiavelmente sua frequ√™ncia ou estabelecer uma rela√ß√£o causal.'"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula de VARIVAX fornece garantia parcial sobre seguran√ßa de curto prazo em crian√ßas saud√°veis, apoiada por um grande tamanho de amostra (>11.000 sujeitos) e eventos adversos comuns documentados (febre 14,7%, rea√ß√µes no local da inje√ß√£o 19,3%, erup√ß√£o cut√¢nea semelhante √† varicela 3-4%). No entanto, v√°rias limita√ß√µes cr√≠ticas comprometem a confian√ßa em seguran√ßa abrangente: (1) monitoramento de seguran√ßa ativo foi apenas 42 dias, inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas tardias; (2) a formula√ß√£o comercializada atual n√£o foi testada contra um placebo verdadeiro; (3) popula√ß√µes vulner√°veis (imunocomprometidos, beb√™s prematuros, crian√ßas <12 meses, aquelas com condi√ß√µes cr√¥nicas) foram exclu√≠das dos ensaios em vez de estudadas; (4) nenhum protocolo de monitoramento neurol√≥gico/de desenvolvimento sistem√°tico foi empregado; e (5) eventos neurol√≥gicos graves (encefalite, Guillain-Barr√©, mielite transversa) foram descobertos apenas atrav√©s de vigil√¢ncia passiva p√≥s-comercializa√ß√£o, n√£o desenho proativo de ensaio. Para um pai perguntando 'Esta vacina √© segura para meu filho agora e no futuro?' - este documento demonstra tolerabilidade aceit√°vel de curto prazo em crian√ßas saud√°veis, mas n√£o aborda adequadamente seguran√ßa de longo prazo, eventos graves raros ou seguran√ßa em crian√ßas com condi√ß√µes subjacentes."
        }
      }
    },
    {
      "id": "hepa_havrix",
      "name": "Havrix",
      "type": "HepA",
      "manufacturer": "GlaxoSmithKline",
      "description": "Hepatitis A Vaccine, Inactivated for prevention of disease caused by hepatitis A virus.",
      "sources": [
        "hepa_havrix_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hepa_havrix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The pivotal efficacy study used an active comparator (ENGERIX-B Hepatitis B Vaccine) rather than a true placebo. 40,119 children were randomized to receive either HAVRIX 360 EL.U. or ENGERIX-B 10 mcg. No inert placebo group was included in the effectiveness study.",
            "level_description": "Active comparator used instead of true placebo control; provides some comparison data but not against inert placebo."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The pediatric effectiveness study in Thailand is described as a 'double-blind, randomized controlled study in school children.' However, many immunogenicity studies were open-label, such as Study HAV 210 which was 'prospective, open-label, multicenter.'",
            "level_description": "Primary efficacy study was double-blind, though many supporting immunogenicity studies were open-label."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The pivotal efficacy study randomized 40,119 children. Multiple supporting studies also used randomization: Study HAV 231 'randomized' 1,241 children into 3 groups; Study HAV 232 randomized 468 subjects; Study HAV 220 randomized 433 children.",
            "level_description": "Randomization was employed in the primary efficacy study and multiple supporting clinical trials."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety evaluated in approximately 37,000 individuals across 61 clinical trials. The pivotal pediatric efficacy study included 40,119 children aged 1-16 years. Additionally, 3,152 children aged 11-25 months received at least 1 dose in coadministration studies. Over 22,000 subjects aged 1-18 years were evaluated for safety and effectiveness.",
            "level_description": "Exceptionally large pediatric sample sizes across multiple age groups and studies."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The efficacy study observed children for 8 months after day 138 surveillance entry. Study HAV 231 conducted telephone follow-up 6 months after last vaccination. Immunogenicity studies followed subjects 1 month after booster doses. The document explicitly states: 'The duration of immunity following a complete schedule of immunization with HAVRIX has not been established.'",
            "level_description": "Short-term follow-up (6-8 months) in most studies; long-term immunity duration not established."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Clinical data stratified by age: 11-13 months, 15-18 months, 23-25 months, 2-18 years, 2-19 years, and adults 18-50 years. Study HAV 210 specifically compared immune responses across three pediatric age groups. Separate dosing for children/adolescents (720 EL.U./0.5 mL) and adults (1440 EL.U./1 mL).",
            "level_description": "Comprehensive age-stratified data with specific immunogenicity comparisons across pediatric age groups."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document mentions subjects were 'seronegative for hepatitis A antibodies at baseline' for some studies. Contraindications include severe allergic reaction to previous hepatitis A vaccine or components including neomycin. Demographics reported (gender, race/ethnicity) but detailed inclusion/exclusion criteria not specified.",
            "level_description": "Some baseline criteria mentioned but comprehensive inclusion/exclusion criteria not detailed in prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Adverse events categorized by MedDRA system organ classes (Metabolism/Nutrition Disorders, Gastrointestinal Disorders, etc.). Solicited reactions recorded on diary cards for 4 days (Days 0-3). Unsolicited events recorded for 31 days. Events graded (e.g., Grade 3 drowsiness 'prevented normal daily activities'). Incidence rates categorized as 1-10% or <1%.",
            "level_description": "Standardized adverse event classification using MedDRA with severity grading and specified monitoring periods."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Serious adverse events reported within 31-day period: 0.9% (29/3,152) of subjects aged 11-25 months. Telephone follow-up at 6 months inquired about 'serious adverse events, new onset chronic illnesses, and medically significant events.' Four seizures reported within 31 days post-vaccination.",
            "level_description": "Active monitoring for serious adverse events with 31-day collection period and 6-month telephone follow-up."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Postmarketing section lists neurological events: convulsion, dizziness, encephalopathy, Guillain-Barre syndrome, hypoesthesia, multiple sclerosis, myelitis, neuropathy, paresthesia, somnolence, syncope. Four seizures reported in clinical trials (days 2, 9, 27, and 12 post-vaccination). However, systematic monitoring for autoimmune conditions in clinical trials not described.",
            "level_description": "Neurological events captured in postmarketing surveillance; seizures reported in trials, but systematic autoimmune monitoring not detailed."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Immunocompromised persons addressed: 'may have a diminished immune response.' Chronic liver disease studied in 220 adults (hepatitis B, hepatitis C, alcoholic cirrhosis, autoimmune hepatitis, etc.) showing lower GMTs. Hepatic impairment section notes lower antibody response. Pregnancy data from 175 women (inadvertent exposure). Geriatric section notes insufficient data for age 65+.",
            "level_description": "Several vulnerable populations studied including chronic liver disease, immunocompromised noted, pregnancy data available, though geriatric data limited."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Efficacy rate calculated: 94% (95% CI: 74, 98) for clinical hepatitis A prevention. GMT non-inferiority comparisons performed between age groups with stated criteria (lower limit of 2-sided 95% CI >= 0.5). Seroconversion rates reported with 95% confidence intervals. Secondary efficacy analysis: 84% (95% CI: 60, 94).",
            "level_description": "Appropriate statistical methods including confidence intervals, efficacy calculations, and non-inferiority analyses."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Summary data presented with seroconversion rates, GMTs, and adverse event percentages. Table 1 provides detailed adverse reaction data. Study identifiers provided (HAV 210, HAV 220, HAV 231, HAV 232). However, individual patient data, full study protocols, and complete raw data not included in prescribing information.",
            "level_description": "Summary-level data and study identifiers provided; detailed raw data and protocols not included in this document."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 details postmarketing experience including rare events: thrombocytopenia, anaphylactic reactions, Guillain-Barre syndrome, multiple sclerosis, myelitis, hepatitis, vasculitis, erythema multiforme. VAERS reporting encouraged (1-800-822-7967). Manufacturer reporting at 1-888-825-5249.",
            "level_description": "Postmarketing surveillance system in place with reporting mechanisms and documented rare adverse events."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No conflict of interest disclosures or funding source transparency statements are included in this prescribing information document. Manufactured by GlaxoSmithKline Biologicals.",
            "level_description": "No conflict of interest information or funding disclosures provided in the prescribing information."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No all-cause mortality data is reported in the document. Serious adverse events mentioned but deaths not specifically discussed or enumerated.",
            "level_description": "All-cause mortality data not reported or discussed in the prescribing information."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "HAVRIX demonstrates adequate trial methodology with a large-scale double-blind randomized efficacy study in over 40,000 children showing 94% efficacy. Strengths include exemplary pediatric sample sizes (37,000+ across 61 trials), comprehensive age-stratified data, and standardized adverse event monitoring. Limitations include use of active comparator rather than placebo, short follow-up duration with unestablished long-term immunity, absence of all-cause mortality data, and no conflict of interest disclosures. Postmarketing surveillance has identified rare neurological events requiring ongoing monitoring."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepa_havrix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo pivotal de efic√°cia utilizou um comparador ativo (Vacina contra Hepatite B ENGERIX-B) em vez de um placebo verdadeiro. 40.119 crian√ßas foram randomizadas para receber HAVRIX 360 EL.U. ou ENGERIX-B 10 mcg. Nenhum grupo com placebo inerte foi inclu√≠do no estudo de efetividade.",
            "level_description": "Comparador ativo utilizado em vez de controle com placebo verdadeiro; fornece alguns dados comparativos, mas n√£o contra placebo inerte."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O estudo de efetividade pedi√°trico na Tail√¢ndia √© descrito como um 'estudo controlado, randomizado e duplo-cego em crian√ßas em idade escolar.' No entanto, muitos estudos de imunogenicidade foram abertos, como o Estudo HAV 210, que foi 'prospectivo, aberto e multic√™ntrico.'",
            "level_description": "O estudo prim√°rio de efic√°cia foi duplo-cego, embora muitos estudos de imunogenicidade de apoio tenham sido abertos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O estudo pivotal de efic√°cia randomizou 40.119 crian√ßas. M√∫ltiplos estudos de apoio tamb√©m utilizaram randomiza√ß√£o: Estudo HAV 231 'randomizou' 1.241 crian√ßas em 3 grupos; Estudo HAV 232 randomizou 468 participantes; Estudo HAV 220 randomizou 433 crian√ßas.",
            "level_description": "A randomiza√ß√£o foi empregada no estudo prim√°rio de efic√°cia e em m√∫ltiplos ensaios cl√≠nicos de apoio."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "A seguran√ßa foi avaliada em aproximadamente 37.000 indiv√≠duos em 61 ensaios cl√≠nicos. O estudo pivotal de efic√°cia pedi√°trica incluiu 40.119 crian√ßas de 1 a 16 anos. Al√©m disso, 3.152 crian√ßas de 11 a 25 meses receberam pelo menos 1 dose em estudos de coadministra√ß√£o. Mais de 22.000 participantes de 1 a 18 anos foram avaliados quanto √† seguran√ßa e efic√°cia.",
            "level_description": "Tamanhos de amostra pedi√°trica excepcionalmente grandes em m√∫ltiplos grupos et√°rios e estudos."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo de efic√°cia observou as crian√ßas por 8 meses ap√≥s a entrada na vigil√¢ncia no dia 138. O Estudo HAV 231 conduziu acompanhamento telef√¥nico 6 meses ap√≥s a √∫ltima vacina√ß√£o. Estudos de imunogenicidade acompanharam os participantes por 1 m√™s ap√≥s as doses de refor√ßo. O documento afirma explicitamente: 'A dura√ß√£o da imunidade ap√≥s um esquema completo de imuniza√ß√£o com HAVRIX n√£o foi estabelecida.'",
            "level_description": "Acompanhamento de curto prazo (6-8 meses) na maioria dos estudos; dura√ß√£o da imunidade a longo prazo n√£o estabelecida."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados cl√≠nicos estratificados por idade: 11-13 meses, 15-18 meses, 23-25 meses, 2-18 anos, 2-19 anos e adultos de 18-50 anos. O Estudo HAV 210 comparou especificamente as respostas imunes em tr√™s grupos et√°rios pedi√°tricos. Dosagem separada para crian√ßas/adolescentes (720 EL.U./0,5 mL) e adultos (1440 EL.U./1 mL).",
            "level_description": "Dados abrangentes estratificados por idade com compara√ß√µes espec√≠ficas de imunogenicidade entre grupos et√°rios pedi√°tricos."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento menciona que os participantes eram 'soronegativos para anticorpos contra hepatite A no in√≠cio' em alguns estudos. As contraindica√ß√µes incluem rea√ß√£o al√©rgica grave a vacina anterior contra hepatite A ou componentes, incluindo neomicina. Dados demogr√°ficos relatados (g√™nero, ra√ßa/etnia), mas crit√©rios detalhados de inclus√£o/exclus√£o n√£o especificados.",
            "level_description": "Alguns crit√©rios basais mencionados, mas crit√©rios abrangentes de inclus√£o/exclus√£o n√£o detalhados na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os eventos adversos foram categorizados por classes de sistemas de √≥rg√£os MedDRA (Dist√∫rbios do Metabolismo/Nutri√ß√£o, Dist√∫rbios Gastrointestinais, etc.). Rea√ß√µes solicitadas foram registradas em cart√µes-di√°rio por 4 dias (Dias 0-3). Eventos n√£o solicitados foram registrados por 31 dias. Eventos foram graduados (ex.: sonol√™ncia Grau 3 'impediu atividades di√°rias normais'). Taxas de incid√™ncia categorizadas como 1-10% ou <1%.",
            "level_description": "Classifica√ß√£o padronizada de eventos adversos usando MedDRA com gradua√ß√£o de gravidade e per√≠odos de monitoramento especificados."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos graves relatados dentro do per√≠odo de 31 dias: 0,9% (29/3.152) dos participantes de 11-25 meses. Acompanhamento telef√¥nico aos 6 meses investigou 'eventos adversos graves, doen√ßas cr√¥nicas de in√≠cio recente e eventos clinicamente significativos.' Quatro convuls√µes relatadas dentro de 31 dias p√≥s-vacina√ß√£o.",
            "level_description": "Monitoramento ativo de eventos adversos graves com per√≠odo de coleta de 31 dias e acompanhamento telef√¥nico de 6 meses."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de p√≥s-comercializa√ß√£o lista eventos neurol√≥gicos: convuls√£o, tontura, encefalopatia, s√≠ndrome de Guillain-Barr√©, hipoestesia, esclerose m√∫ltipla, mielite, neuropatia, parestesia, sonol√™ncia, s√≠ncope. Quatro convuls√µes relatadas em ensaios cl√≠nicos (dias 2, 9, 27 e 12 p√≥s-vacina√ß√£o). No entanto, monitoramento sistem√°tico de condi√ß√µes autoimunes em ensaios cl√≠nicos n√£o foi descrito.",
            "level_description": "Eventos neurol√≥gicos capturados em vigil√¢ncia p√≥s-comercializa√ß√£o; convuls√µes relatadas em ensaios, mas monitoramento sistem√°tico de condi√ß√µes autoimunes n√£o detalhado."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Pessoas imunocomprometidas abordadas: 'podem ter resposta imune diminu√≠da.' Doen√ßa hep√°tica cr√¥nica estudada em 220 adultos (hepatite B, hepatite C, cirrose alco√≥lica, hepatite autoimune, etc.) mostrando GMTs mais baixos. Se√ß√£o sobre comprometimento hep√°tico observa resposta de anticorpos mais baixa. Dados de gravidez de 175 mulheres (exposi√ß√£o inadvertida). Se√ß√£o geri√°trica observa dados insuficientes para idade 65+.",
            "level_description": "V√°rias popula√ß√µes vulner√°veis estudadas, incluindo doen√ßa hep√°tica cr√¥nica, imunocomprometidos observados, dados de gravidez dispon√≠veis, embora dados geri√°tricos sejam limitados."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Taxa de efic√°cia calculada: 94% (IC 95%: 74, 98) para preven√ß√£o de hepatite A cl√≠nica. Compara√ß√µes de n√£o inferioridade de GMT realizadas entre grupos et√°rios com crit√©rios estabelecidos (limite inferior do IC bilateral de 95% >= 0,5). Taxas de soroconvers√£o relatadas com intervalos de confian√ßa de 95%. An√°lise de efic√°cia secund√°ria: 84% (IC 95%: 60, 94).",
            "level_description": "M√©todos estat√≠sticos apropriados, incluindo intervalos de confian√ßa, c√°lculos de efic√°cia e an√°lises de n√£o inferioridade."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados resumidos apresentados com taxas de soroconvers√£o, GMTs e porcentagens de eventos adversos. A Tabela 1 fornece dados detalhados de rea√ß√µes adversas. Identificadores de estudos fornecidos (HAV 210, HAV 220, HAV 231, HAV 232). No entanto, dados individuais de pacientes, protocolos completos de estudos e dados brutos completos n√£o est√£o inclu√≠dos na bula.",
            "level_description": "Dados em n√≠vel de resumo e identificadores de estudos fornecidos; dados brutos detalhados e protocolos n√£o inclu√≠dos neste documento."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 detalha a experi√™ncia p√≥s-comercializa√ß√£o incluindo eventos raros: trombocitopenia, rea√ß√µes anafil√°ticas, s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla, mielite, hepatite, vasculite, eritema multiforme. Notifica√ß√£o ao VAERS encorajada (1-800-822-7967). Notifica√ß√£o ao fabricante em 1-888-825-5249.",
            "level_description": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o implementado com mecanismos de notifica√ß√£o e eventos adversos raros documentados."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhuma declara√ß√£o de conflito de interesses ou transpar√™ncia sobre fontes de financiamento est√° inclu√≠da nesta bula. Fabricado pela GlaxoSmithKline Biologicals.",
            "level_description": "Nenhuma informa√ß√£o sobre conflito de interesses ou declara√ß√µes de financiamento fornecida na bula."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum dado de mortalidade por todas as causas √© relatado no documento. Eventos adversos graves mencionados, mas mortes n√£o s√£o especificamente discutidas ou enumeradas.",
            "level_description": "Dados de mortalidade por todas as causas n√£o relatados ou discutidos na bula."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "HAVRIX demonstra metodologia de ensaio adequada com um estudo de efic√°cia duplo-cego randomizado em larga escala em mais de 40.000 crian√ßas, mostrando efic√°cia de 94%. Os pontos fortes incluem tamanhos de amostra pedi√°trica exemplares (37.000+ em 61 ensaios), dados abrangentes estratificados por idade e monitoramento padronizado de eventos adversos. As limita√ß√µes incluem o uso de comparador ativo em vez de placebo, curta dura√ß√£o de acompanhamento com imunidade de longo prazo n√£o estabelecida, aus√™ncia de dados de mortalidade por todas as causas e nenhuma declara√ß√£o de conflito de interesses. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos neurol√≥gicos raros que requerem monitoramento cont√≠nuo."
        }
      },
      "safety_en": {
        "vaccine_id": "hepa_havrix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Safety evaluated in approximately 37,000 individuals across 61 clinical trials with various dose formulations. Over 22,000 subjects aged 1-18 years evaluated. Specifically, 3,152 children aged 11-25 months received at least 1 dose in coadministration studies (HAV 210 N=1,084; HAV 232 N=394; HAV 220 N=433; HAV 231 N=1,241). This represents an exceptionally large pediatric safety database across multiple age groups."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Primary safety monitoring limited to 4 days (Days 0-3) for solicited reactions and 31 days for unsolicited events. Telephone follow-up at 6 months after last vaccination in Study HAV 231 inquired about serious adverse events and new onset chronic illnesses. However, systematic long-term safety follow-up (beyond 6 months) not described. The document states duration of immunity not established, and long-term safety surveillance relies primarily on postmarketing data."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The pivotal efficacy study used ENGERIX-B (Hepatitis B vaccine) as an active comparator rather than inert placebo. Some coadministration studies included groups receiving HAVRIX alone versus with other vaccines (e.g., Study HAV 231 had HAVRIX alone, HAVRIX+MMR+Varicella, and MMR+Varicella groups). However, true placebo-controlled safety data is not presented in the prescribing information."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited adverse reactions actively collected via parent/guardian diary cards for 4 days (Days 0-3) post-vaccination. Unsolicited events recorded for 31 days. Serious adverse events actively monitored with 0.9% (29/3,152) reporting SAEs within 31 days in children 11-25 months. Telephone follow-up at 6 months specifically inquired about serious adverse events, new onset chronic illnesses, and medically significant events. Grade 3 severity criteria defined for key symptoms."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials reported 4 seizures within 31 days post-vaccination (at days 2, 9, 27 after dose 1 and day 12 after dose 2). Syncope can be accompanied by transient neurological signs (visual disturbance, paresthesia, tonic-clonic limb movements). Postmarketing identified: convulsion, encephalopathy, Guillain-Barre syndrome, multiple sclerosis, myelitis, neuropathy, paresthesia. However, systematic prospective neurological monitoring protocols not described in the prescribing information."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Several vulnerable populations evaluated: Immunocompromised individuals noted to have diminished immune response. Chronic liver disease studied in 220 adults across multiple etiologies (hepatitis B/C, alcoholic cirrhosis, autoimmune hepatitis, primary biliary cirrhosis) with safety data showing local injection site reactions similar to healthy subjects and no serious vaccine-attributed reactions. Pregnancy data from 175 inadvertent exposures showed rates consistent with background. Geriatric section acknowledges insufficient data for age 65+."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Summary safety data presented with specific percentages for solicited reactions (Table 1 provides detailed breakdown). Study identifiers disclosed (HAV 210, 220, 231, 232). Serious adverse event rates reported (0.9-1.0% within 31 days). However, individual patient data, complete study protocols, and comprehensive raw safety data not included. Postmarketing adverse events reported without frequency estimates due to voluntary reporting limitations."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active postmarketing surveillance system with identified rare adverse reactions including: thrombocytopenia, anaphylactic/anaphylactoid reactions, serum sickness-like syndrome, Guillain-Barre syndrome, multiple sclerosis, myelitis, encephalopathy, hepatitis, vasculitis, angioedema, erythema multiforme, congenital anomaly. Dual reporting mechanisms: VAERS (1-800-822-7967 or www.vaers.hhs.gov) and manufacturer (GlaxoSmithKline 1-888-825-5249). Document acknowledges frequency cannot be reliably estimated from voluntary reports."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "HAVRIX demonstrates adequate safety evidence with an exemplary pediatric sample size of over 37,000 subjects across 61 trials. Active solicited adverse event surveillance was conducted with diary cards and 6-month telephone follow-up for serious events. Common reactions include injection-site soreness (21-56%), irritability (27-44% in young children), and drowsiness (21-35%). Limitations include short primary follow-up (4-31 days), use of active comparator rather than placebo, and reliance on postmarketing surveillance for rare neurological events. Postmarketing has identified serious rare events including Guillain-Barre syndrome and other neurological conditions requiring ongoing vigilance."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepa_havrix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "A seguran√ßa foi avaliada em aproximadamente 37.000 indiv√≠duos em 61 ensaios cl√≠nicos com v√°rias formula√ß√µes de dose. Mais de 22.000 participantes de 1-18 anos foram avaliados. Especificamente, 3.152 crian√ßas de 11-25 meses receberam pelo menos 1 dose em estudos de coadministra√ß√£o (HAV 210 N=1.084; HAV 232 N=394; HAV 220 N=433; HAV 231 N=1.241). Isso representa um banco de dados de seguran√ßa pedi√°trica excepcionalmente grande em m√∫ltiplos grupos et√°rios."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O monitoramento prim√°rio de seguran√ßa foi limitado a 4 dias (Dias 0-3) para rea√ß√µes solicitadas e 31 dias para eventos n√£o solicitados. Acompanhamento telef√¥nico aos 6 meses ap√≥s a √∫ltima vacina√ß√£o no Estudo HAV 231 investigou eventos adversos graves e doen√ßas cr√¥nicas de in√≠cio recente. No entanto, acompanhamento sistem√°tico de seguran√ßa a longo prazo (al√©m de 6 meses) n√£o foi descrito. O documento afirma que a dura√ß√£o da imunidade n√£o foi estabelecida, e a vigil√¢ncia de seguran√ßa a longo prazo depende principalmente de dados p√≥s-comercializa√ß√£o."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O estudo pivotal de efic√°cia usou ENGERIX-B (vacina contra Hepatite B) como comparador ativo em vez de placebo inerte. Alguns estudos de coadministra√ß√£o inclu√≠ram grupos recebendo HAVRIX sozinha versus com outras vacinas (ex.: Estudo HAV 231 teve grupos HAVRIX sozinha, HAVRIX+MMR+Varicela e MMR+Varicela). No entanto, dados de seguran√ßa controlados por placebo verdadeiro n√£o s√£o apresentados na bula."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Rea√ß√µes adversas solicitadas foram ativamente coletadas via cart√µes-di√°rio dos pais/respons√°veis por 4 dias (Dias 0-3) p√≥s-vacina√ß√£o. Eventos n√£o solicitados foram registrados por 31 dias. Eventos adversos graves foram ativamente monitorados com 0,9% (29/3.152) relatando EAGs em 31 dias em crian√ßas de 11-25 meses. Acompanhamento telef√¥nico aos 6 meses investigou especificamente eventos adversos graves, doen√ßas cr√¥nicas de in√≠cio recente e eventos clinicamente significativos. Crit√©rios de gravidade Grau 3 definidos para sintomas principais."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Ensaios cl√≠nicos relataram 4 convuls√µes dentro de 31 dias p√≥s-vacina√ß√£o (nos dias 2, 9, 27 ap√≥s a dose 1 e dia 12 ap√≥s a dose 2). S√≠ncope pode ser acompanhada por sinais neurol√≥gicos transit√≥rios (dist√∫rbio visual, parestesia, movimentos t√¥nico-cl√¥nicos dos membros). P√≥s-comercializa√ß√£o identificou: convuls√£o, encefalopatia, s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla, mielite, neuropatia, parestesia. No entanto, protocolos de monitoramento neurol√≥gico prospectivo sistem√°tico n√£o s√£o descritos na bula."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "V√°rias popula√ß√µes vulner√°veis avaliadas: Indiv√≠duos imunocomprometidos observados como tendo resposta imune diminu√≠da. Doen√ßa hep√°tica cr√¥nica estudada em 220 adultos com m√∫ltiplas etiologias (hepatite B/C, cirrose alco√≥lica, hepatite autoimune, cirrose biliar prim√°ria) com dados de seguran√ßa mostrando rea√ß√µes no local da inje√ß√£o similares a indiv√≠duos saud√°veis e nenhuma rea√ß√£o grave atribu√≠da √† vacina. Dados de gravidez de 175 exposi√ß√µes inadvertidas mostraram taxas consistentes com o hist√≥rico. Se√ß√£o geri√°trica reconhece dados insuficientes para idade 65+."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados resumidos de seguran√ßa apresentados com porcentagens espec√≠ficas para rea√ß√µes solicitadas (Tabela 1 fornece detalhamento). Identificadores de estudos divulgados (HAV 210, 220, 231, 232). Taxas de eventos adversos graves relatadas (0,9-1,0% em 31 dias). No entanto, dados individuais de pacientes, protocolos completos de estudos e dados brutos abrangentes de seguran√ßa n√£o est√£o inclu√≠dos. Eventos adversos p√≥s-comercializa√ß√£o relatados sem estimativas de frequ√™ncia devido √†s limita√ß√µes de notifica√ß√£o volunt√°ria."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Sistema ativo de vigil√¢ncia p√≥s-comercializa√ß√£o com rea√ß√µes adversas raras identificadas incluindo: trombocitopenia, rea√ß√µes anafil√°ticas/anafilactoides, s√≠ndrome semelhante √† doen√ßa do soro, s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla, mielite, encefalopatia, hepatite, vasculite, angioedema, eritema multiforme, anomalia cong√™nita. Mecanismos duplos de notifica√ß√£o: VAERS (1-800-822-7967 ou www.vaers.hhs.gov) e fabricante (GlaxoSmithKline 1-888-825-5249). O documento reconhece que a frequ√™ncia n√£o pode ser estimada de forma confi√°vel a partir de relatos volunt√°rios."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "HAVRIX demonstra evid√™ncia de seguran√ßa adequada com um tamanho de amostra pedi√°trica exemplar de mais de 37.000 participantes em 61 ensaios. Vigil√¢ncia ativa de eventos adversos solicitados foi conduzida com cart√µes-di√°rio e acompanhamento telef√¥nico de 6 meses para eventos graves. Rea√ß√µes comuns incluem dor no local da inje√ß√£o (21-56%), irritabilidade (27-44% em crian√ßas pequenas) e sonol√™ncia (21-35%). As limita√ß√µes incluem curto acompanhamento prim√°rio (4-31 dias), uso de comparador ativo em vez de placebo e depend√™ncia de vigil√¢ncia p√≥s-comercializa√ß√£o para eventos neurol√≥gicos raros. A p√≥s-comercializa√ß√£o identificou eventos raros graves, incluindo s√≠ndrome de Guillain-Barr√© e outras condi√ß√µes neurol√≥gicas que requerem vigil√¢ncia cont√≠nua."
        }
      }
    },
    {
      "id": "hepa_vaqta",
      "name": "Vaqta",
      "type": "HepA",
      "manufacturer": "Merck",
      "description": "Hepatitis A Vaccine, Inactivated for prevention of disease caused by hepatitis A virus.",
      "sources": [
        "hepa_vaqta_insert.pdf",
        "hepa_vaqta_study.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hepa_vaqta",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The Monroe Efficacy Study was a double-blind, placebo-controlled efficacy trial with 1037 healthy children and adolescents ages 2-16. Subjects received either VAQTA (25U) (N=519) or placebo (alum diluent) (N=518). Placebo was amorphous aluminum hydroxyphosphate sulfate.",
            "level_description": "The pivotal efficacy study used a true placebo-controlled design with alum diluent as placebo. However, this was an aluminum adjuvant rather than a saline placebo, which limits the ability to detect adjuvant-related adverse events."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The Monroe Efficacy Study is described as 'a randomized, double-blind, placebo-controlled study.' However, many other clinical trials described were 'open-label' studies.",
            "level_description": "The pivotal efficacy study was properly double-blinded. However, multiple other safety and immunogenicity trials were conducted as open-label studies, which may introduce observation bias in safety assessments."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple studies describe randomization. The Monroe Efficacy Study: 'Each child received an intramuscular dose of VAQTA (25U) (N=519) or placebo (alum diluent) (N=518).' Other studies: 'children 12 to 23 months of age were randomized to receive a first dose of VAQTA with ProQuad and Prevnar concomitantly (N=330) or a first dose of ProQuad and pneumococcal 7-valent conjugate vaccine concomitantly.'",
            "level_description": "Randomization was employed in the efficacy trial and several immunogenicity studies. However, specific randomization methods are not detailed in the document."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Safety was evaluated in 4374 children 12-23 months of age across five clinical trials, and 2615 children/adolescents 2-18 years of age in 11 clinical trials. The Monroe Efficacy Study included 1037 children ages 2-16.",
            "level_description": "Sample sizes for pediatric populations are adequate for detecting common adverse events. The combined pediatric sample exceeds 6,900 subjects, providing reasonable statistical power for safety signal detection."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Subjects were followed for 'days 1 to 5 postvaccination for fever and local adverse reactions and days 1 to 14 for systemic adverse events.' Serious adverse events were collected over 14, 28, or 42 days depending on protocol. Long-term immunogenicity follow-up extended to 10 years in some subjects.",
            "level_description": "Follow-up for adverse events was relatively short (5-42 days depending on event type). While immunogenicity was tracked for up to 10 years, systematic safety follow-up was limited to weeks rather than months or years, which may miss delayed adverse events."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Separate safety and immunogenicity data are provided for: Children 12-23 months of age, Children/Adolescents 2-18 years of age, and Adults 19 years and older. Different dosages are specified: 25U/0.5mL for pediatric and 50U/1mL for adult populations.",
            "level_description": "The document provides comprehensive separate analysis for three distinct age groups with age-appropriate dosing, detailed adverse event rates, and immunogenicity data specific to each population."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Studies enrolled 'healthy children,' 'healthy adults,' and 'susceptible healthy children and adolescents.' Contraindications specify exclusion of those with history of allergic reactions to hepatitis A vaccine or neomycin.",
            "level_description": "Basic inclusion criteria (healthy subjects, seronegative status) are mentioned, but detailed inclusion/exclusion criteria for clinical trials are not provided in the prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Adverse events were categorized by body system using standardized terminology (e.g., 'General Disorders and Administration Site Conditions,' 'Nervous system disorders,' 'Gastrointestinal disorders'). Local and systemic reactions were systematically recorded on diary cards.",
            "level_description": "The document uses standardized Medical Dictionary for Regulatory Activities (MedDRA) terminology for adverse event classification. Solicited and unsolicited events were captured systematically."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse events in children 12-23 months: '0.7% (32/4374) of subjects reported a serious adverse event following any dose of VAQTA, and 0.1% (5/4374) of subjects reported a serious adverse event judged to be vaccine related.' Vaccine-related SAEs included febrile seizure (0.05%), dehydration (0.02%), gastroenteritis (0.02%), and cellulitis (0.02%).",
            "level_description": "Serious adverse events were collected in clinical trials with rates reported. However, the monitoring period was limited (14-42 days), and determination of vaccine-relatedness was made by investigators rather than independent adjudication."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Post-marketing reports include: 'Guillain-Barre syndrome; cerebellar ataxia; encephalitis' under nervous system disorders. Clinical trials do not specifically report monitoring for these conditions.",
            "level_description": "Neurological adverse events (GBS, cerebellar ataxia, encephalitis) are mentioned only in post-marketing experience, indicating they were not systematically monitored in pre-approval trials. No specific autoimmune monitoring protocol is described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Immunocompromised individuals section states they 'may have a diminished immune response to VAQTA and may not be protected against HAV infection.' Pregnancy data from post-approval voluntary reports only. Geriatric use: 68 subjects 65+ years vaccinated in clinical trials. No clinical data in infants below 12 months.",
            "level_description": "Limited data on vulnerable populations. Immunocompromised subjects were studied for immunogenicity only. Pregnancy data is from post-marketing reports, not controlled trials. Very limited geriatric trial data."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "95% confidence intervals are provided for seroconversion rates and GMTs throughout. Table 5 notes 'No statistically significant differences between the two groups.' P-values provided for efficacy (p<0.001 for efficacy endpoint).",
            "level_description": "Statistical methods include confidence intervals and significance testing. However, detailed statistical methodology (power calculations, handling of missing data, multiplicity adjustments) is not provided in the prescribing information."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Demographic data provided (race, gender distribution). Adverse event rates and immunogenicity data presented in tables. Individual patient data not available. Trial registration information not included.",
            "level_description": "Summary data is provided in tables with demographic information. However, raw data, complete analysis datasets, and clinical study reports are not publicly available through the prescribing information."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A post-marketing 60-day safety surveillance study was conducted at a large HMO with 42,110 individuals. Post-marketing adverse events reported include thrombocytopenia, Guillain-Barre syndrome, cerebellar ataxia, and encephalitis. VAERS reporting information is provided.",
            "level_description": "A formal post-marketing observational study was conducted with over 42,000 subjects. Ongoing passive surveillance through VAERS exists. Rare serious adverse events have been identified through post-marketing surveillance."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No disclosure of conflicts of interest for study investigators or funding sources is provided in the prescribing information. The manufacturer (Merck) conducted the studies.",
            "level_description": "The document does not address conflicts of interest. All studies appear to be manufacturer-sponsored, but no specific COI disclosures are made regarding investigators or consultants."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Post-marketing study mentions that 'deaths' were searched in the automated medical records database. 'None of the serious adverse events identified were assessed as being related to vaccine by the investigator.' No specific mortality data from clinical trials is reported.",
            "level_description": "Death was monitored in post-marketing surveillance, but specific mortality rates from clinical trials are not reported in the prescribing information. All-cause mortality comparison between vaccine and placebo groups is not provided."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "VAQTA's clinical trial program included a well-designed pivotal efficacy study (Monroe) with randomization, double-blinding, and placebo control, demonstrating 100% efficacy. Safety was evaluated in over 10,000 subjects across multiple trials with adequate pediatric sample sizes and separate age group analyses. Key limitations include: short follow-up periods (5-42 days) for adverse events, use of aluminum adjuvant as placebo rather than saline, limited systematic monitoring for autoimmune/neurological conditions, and insufficient data on vulnerable populations. Post-marketing surveillance identified rare serious neurological events not detected in trials."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepa_vaqta",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo de Efic√°cia Monroe foi um ensaio de efic√°cia duplo-cego, controlado por placebo com 1.037 crian√ßas e adolescentes saud√°veis de 2-16 anos. Os participantes receberam VAQTA (25U) (N=519) ou placebo (diluente de alum) (N=518). O placebo era sulfato de hidroxifosfato de alum√≠nio amorfo.",
            "level_description": "O estudo pivotal de efic√°cia usou um desenho verdadeiro controlado por placebo com diluente de alum como placebo. No entanto, este era um adjuvante de alum√≠nio em vez de placebo salino, o que limita a capacidade de detectar eventos adversos relacionados ao adjuvante."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo de Efic√°cia Monroe √© descrito como 'um estudo randomizado, duplo-cego, controlado por placebo.' No entanto, muitos outros ensaios cl√≠nicos descritos foram estudos 'abertos'.",
            "level_description": "O estudo pivotal de efic√°cia foi adequadamente duplo-cego. No entanto, m√∫ltiplos outros ensaios de seguran√ßa e imunogenicidade foram conduzidos como estudos abertos, o que pode introduzir vi√©s de observa√ß√£o nas avalia√ß√µes de seguran√ßa."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos estudos descrevem randomiza√ß√£o. O Estudo de Efic√°cia Monroe: 'Cada crian√ßa recebeu uma dose intramuscular de VAQTA (25U) (N=519) ou placebo (diluente de alum) (N=518).' Outros estudos: 'crian√ßas de 12 a 23 meses de idade foram randomizadas para receber uma primeira dose de VAQTA com ProQuad e Prevnar concomitantemente (N=330) ou uma primeira dose de ProQuad e vacina conjugada pneumoc√≥cica 7-valente concomitantemente.'",
            "level_description": "A randomiza√ß√£o foi empregada no ensaio de efic√°cia e em v√°rios estudos de imunogenicidade. No entanto, m√©todos espec√≠ficos de randomiza√ß√£o n√£o s√£o detalhados no documento."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A seguran√ßa foi avaliada em 4.374 crian√ßas de 12-23 meses de idade em cinco ensaios cl√≠nicos, e 2.615 crian√ßas/adolescentes de 2-18 anos de idade em 11 ensaios cl√≠nicos. O Estudo de Efic√°cia Monroe incluiu 1.037 crian√ßas de 2-16 anos.",
            "level_description": "Os tamanhos de amostra para popula√ß√µes pedi√°tricas s√£o adequados para detectar eventos adversos comuns. A amostra pedi√°trica combinada excede 6.900 participantes, fornecendo poder estat√≠stico razo√°vel para detec√ß√£o de sinais de seguran√ßa."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os participantes foram acompanhados por 'dias 1 a 5 p√≥s-vacina√ß√£o para febre e rea√ß√µes adversas locais e dias 1 a 14 para eventos adversos sist√™micos.' Eventos adversos graves foram coletados por 14, 28 ou 42 dias dependendo do protocolo. O acompanhamento de imunogenicidade a longo prazo se estendeu por 10 anos em alguns participantes.",
            "level_description": "O acompanhamento para eventos adversos foi relativamente curto (5-42 dias dependendo do tipo de evento). Embora a imunogenicidade tenha sido rastreada por at√© 10 anos, o acompanhamento sistem√°tico de seguran√ßa foi limitado a semanas em vez de meses ou anos, o que pode deixar passar eventos adversos tardios."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados separados de seguran√ßa e imunogenicidade s√£o fornecidos para: Crian√ßas de 12-23 meses de idade, Crian√ßas/Adolescentes de 2-18 anos de idade e Adultos de 19 anos ou mais. Dosagens diferentes s√£o especificadas: 25U/0,5mL para pedi√°tricos e 50U/1mL para popula√ß√µes adultas.",
            "level_description": "O documento fornece an√°lise separada abrangente para tr√™s grupos et√°rios distintos com dosagem apropriada para idade, taxas detalhadas de eventos adversos e dados de imunogenicidade espec√≠ficos para cada popula√ß√£o."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os estudos recrutaram 'crian√ßas saud√°veis,' 'adultos saud√°veis' e 'crian√ßas e adolescentes saud√°veis suscept√≠veis.' As contraindica√ß√µes especificam exclus√£o daqueles com hist√≥rico de rea√ß√µes al√©rgicas √† vacina contra hepatite A ou neomicina.",
            "level_description": "Crit√©rios b√°sicos de inclus√£o (participantes saud√°veis, status soronegativo) s√£o mencionados, mas crit√©rios detalhados de inclus√£o/exclus√£o para ensaios cl√≠nicos n√£o s√£o fornecidos na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os eventos adversos foram categorizados por sistema corporal usando terminologia padronizada (ex.: 'Dist√∫rbios Gerais e Condi√ß√µes do Local de Administra√ß√£o', 'Dist√∫rbios do sistema nervoso', 'Dist√∫rbios gastrointestinais'). Rea√ß√µes locais e sist√™micas foram sistematicamente registradas em cart√µes-di√°rio.",
            "level_description": "O documento usa terminologia padronizada do Dicion√°rio M√©dico para Atividades Regulat√≥rias (MedDRA) para classifica√ß√£o de eventos adversos. Eventos solicitados e n√£o solicitados foram capturados sistematicamente."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos graves em crian√ßas de 12-23 meses: '0,7% (32/4.374) dos participantes relataram um evento adverso grave ap√≥s qualquer dose de VAQTA, e 0,1% (5/4.374) dos participantes relataram um evento adverso grave julgado como relacionado √† vacina.' EAGs relacionados √† vacina inclu√≠ram convuls√£o febril (0,05%), desidrata√ß√£o (0,02%), gastroenterite (0,02%) e celulite (0,02%).",
            "level_description": "Eventos adversos graves foram coletados em ensaios cl√≠nicos com taxas relatadas. No entanto, o per√≠odo de monitoramento foi limitado (14-42 dias), e a determina√ß√£o de rela√ß√£o com a vacina foi feita por investigadores em vez de adjudica√ß√£o independente."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Relatos p√≥s-comercializa√ß√£o incluem: 'S√≠ndrome de Guillain-Barr√©; ataxia cerebelar; encefalite' sob dist√∫rbios do sistema nervoso. Ensaios cl√≠nicos n√£o relatam especificamente monitoramento para essas condi√ß√µes.",
            "level_description": "Eventos adversos neurol√≥gicos (SGB, ataxia cerebelar, encefalite) s√£o mencionados apenas na experi√™ncia p√≥s-comercializa√ß√£o, indicando que n√£o foram sistematicamente monitorados em ensaios pr√©-aprova√ß√£o. Nenhum protocolo espec√≠fico de monitoramento autoimune √© descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de indiv√≠duos imunocomprometidos afirma que eles 'podem ter uma resposta imune diminu√≠da √† VAQTA e podem n√£o estar protegidos contra infec√ß√£o por HAV.' Dados de gravidez apenas de relatos volunt√°rios p√≥s-aprova√ß√£o. Uso geri√°trico: 68 participantes de 65+ anos vacinados em ensaios cl√≠nicos. Sem dados cl√≠nicos em beb√™s abaixo de 12 meses.",
            "level_description": "Dados limitados sobre popula√ß√µes vulner√°veis. Participantes imunocomprometidos foram estudados apenas para imunogenicidade. Dados de gravidez s√£o de relatos p√≥s-comercializa√ß√£o, n√£o de ensaios controlados. Dados muito limitados de ensaios geri√°tricos."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Intervalos de confian√ßa de 95% s√£o fornecidos para taxas de soroconvers√£o e GMTs ao longo do documento. A Tabela 5 observa 'Sem diferen√ßas estatisticamente significativas entre os dois grupos.' Valores-p fornecidos para efic√°cia (p<0,001 para desfecho de efic√°cia).",
            "level_description": "Os m√©todos estat√≠sticos incluem intervalos de confian√ßa e testes de signific√¢ncia. No entanto, metodologia estat√≠stica detalhada (c√°lculos de poder, tratamento de dados faltantes, ajustes de multiplicidade) n√£o √© fornecida na bula."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados demogr√°ficos fornecidos (ra√ßa, distribui√ß√£o por g√™nero). Taxas de eventos adversos e dados de imunogenicidade apresentados em tabelas. Dados individuais de pacientes n√£o dispon√≠veis. Informa√ß√µes de registro de ensaios n√£o inclu√≠das.",
            "level_description": "Dados resumidos s√£o fornecidos em tabelas com informa√ß√µes demogr√°ficas. No entanto, dados brutos, conjuntos de dados de an√°lise completos e relat√≥rios de estudos cl√≠nicos n√£o est√£o dispon√≠veis publicamente atrav√©s da bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Um estudo de vigil√¢ncia de seguran√ßa p√≥s-comercializa√ß√£o de 60 dias foi conduzido em uma grande HMO com 42.110 indiv√≠duos. Eventos adversos p√≥s-comercializa√ß√£o relatados incluem trombocitopenia, s√≠ndrome de Guillain-Barr√©, ataxia cerebelar e encefalite. Informa√ß√µes de notifica√ß√£o ao VAERS s√£o fornecidas.",
            "level_description": "Um estudo observacional formal p√≥s-comercializa√ß√£o foi conduzido com mais de 42.000 participantes. Vigil√¢ncia passiva cont√≠nua atrav√©s do VAERS existe. Eventos adversos graves raros foram identificados atrav√©s da vigil√¢ncia p√≥s-comercializa√ß√£o."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhuma divulga√ß√£o de conflitos de interesse para investigadores de estudos ou fontes de financiamento √© fornecida na bula. O fabricante (Merck) conduziu os estudos.",
            "level_description": "O documento n√£o aborda conflitos de interesse. Todos os estudos parecem ser patrocinados pelo fabricante, mas nenhuma divulga√ß√£o espec√≠fica de COI √© feita em rela√ß√£o a investigadores ou consultores."
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo p√≥s-comercializa√ß√£o menciona que 'mortes' foram pesquisadas no banco de dados de registros m√©dicos automatizados. 'Nenhum dos eventos adversos graves identificados foi avaliado como relacionado √† vacina pelo investigador.' Nenhum dado de mortalidade espec√≠fico de ensaios cl√≠nicos √© relatado.",
            "level_description": "A morte foi monitorada na vigil√¢ncia p√≥s-comercializa√ß√£o, mas taxas de mortalidade espec√≠ficas de ensaios cl√≠nicos n√£o s√£o relatadas na bula. Compara√ß√£o de mortalidade por todas as causas entre grupos vacina e placebo n√£o √© fornecida."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de ensaios cl√≠nicos da VAQTA incluiu um estudo pivotal de efic√°cia bem desenhado (Monroe) com randomiza√ß√£o, duplo-cego e controle por placebo, demonstrando 100% de efic√°cia. A seguran√ßa foi avaliada em mais de 10.000 participantes em m√∫ltiplos ensaios com tamanhos de amostra pedi√°trica adequados e an√°lises separadas por grupo et√°rio. As principais limita√ß√µes incluem: curtos per√≠odos de acompanhamento (5-42 dias) para eventos adversos, uso de adjuvante de alum√≠nio como placebo em vez de solu√ß√£o salina, monitoramento sistem√°tico limitado para condi√ß√µes autoimunes/neurol√≥gicas e dados insuficientes sobre popula√ß√µes vulner√°veis. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos neurol√≥gicos graves raros n√£o detectados em ensaios."
        }
      },
      "safety_en": {
        "vaccine_id": "hepa_vaqta",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Safety was evaluated in 4,374 children aged 12-23 months across five clinical trials, and 2,615 children/adolescents aged 2-18 years in eleven clinical trials. Combined pediatric safety database exceeds 6,900 subjects, which is adequate for detecting adverse events occurring at a rate of approximately 1 in 1,000 or more frequently. The sample provides reasonable statistical power for common adverse event detection but may miss rare events."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active safety monitoring was limited to 5 days for local reactions and fever, and 14 days for systemic adverse events. Serious adverse events were collected over 14, 28, or 42 days depending on the protocol. This short follow-up period is insufficient for detecting delayed adverse events such as autoimmune conditions, which may manifest weeks to months after vaccination. Long-term safety data relies primarily on post-marketing surveillance."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The Monroe Efficacy Study used a randomized placebo-controlled design with aluminum hydroxyphosphate sulfate (alum diluent) as placebo. This allows comparison of vaccine-specific adverse events but does not control for adjuvant-related effects since both groups received aluminum. Other studies used concomitant vaccine comparisons or historical controls, which provide less rigorous safety comparisons."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Local and systemic adverse events were actively solicited via diary cards for 5-14 days post-vaccination. However, the post-marketing observational study used passive surveillance through electronic medical records rather than active follow-up. Active surveillance duration was too brief to capture delayed adverse events, and unsolicited events relied on subject self-reporting."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Clinical trials did not include specific protocols for monitoring neurological adverse events. Post-marketing surveillance identified Guillain-Barre syndrome, cerebellar ataxia, and encephalitis, but these were not systematically tracked in pre-licensure studies. The febrile seizure rate of 0.05% in children 12-23 months was reported, but comprehensive neurological assessment was not part of the trial design."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Data on immunocompromised individuals is limited to immunogenicity concerns without dedicated safety studies. Pregnancy safety data comes from post-approval spontaneous reports only (30 pregnancies with known outcomes). Only 68 geriatric subjects (65+) were included in clinical trials. Safety in infants under 12 months has not been established. No specific data on subjects with chronic diseases or allergic conditions beyond general contraindications."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The prescribing information provides summary adverse event rates with 95% confidence intervals, demographic breakdowns by race and gender, and tabulated data for major adverse reactions. However, individual patient-level data, complete safety databases, detailed statistical analysis plans, and clinical study reports are not publicly accessible. Trial registration details and raw data availability are not addressed."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A structured post-marketing 60-day safety surveillance study was conducted at a large HMO (Kaiser) including 42,110 individuals (13,735 children/adolescents, 28,375 adults). Passive surveillance through VAERS is ongoing. Post-marketing experience has identified rare serious events (thrombocytopenia, GBS, cerebellar ataxia, encephalitis) not detected in trials. The manufacturer maintains adverse event reporting at 1-877-888-4231."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "VAQTA's safety profile is supported by clinical trial data from over 10,000 subjects across multiple age groups, including a placebo-controlled pivotal study. The most common adverse reactions are injection-site reactions (pain, tenderness, erythema) and systemic events (fever, headache). Serious adverse events were rare (0.7% in children 12-23 months) with vaccine-related SAEs at 0.1%. Key safety limitations include short follow-up periods (5-42 days), lack of systematic neurological monitoring, limited data on vulnerable populations, and use of aluminum adjuvant as placebo. Post-marketing surveillance has identified rare neurological events (GBS, encephalitis) warranting ongoing vigilance."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepa_vaqta",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A seguran√ßa foi avaliada em 4.374 crian√ßas de 12-23 meses em cinco ensaios cl√≠nicos, e 2.615 crian√ßas/adolescentes de 2-18 anos em onze ensaios cl√≠nicos. O banco de dados combinado de seguran√ßa pedi√°trica excede 6.900 participantes, o que √© adequado para detectar eventos adversos ocorrendo a uma taxa de aproximadamente 1 em 1.000 ou mais frequentemente. A amostra fornece poder estat√≠stico razo√°vel para detec√ß√£o de eventos adversos comuns, mas pode n√£o detectar eventos raros."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O monitoramento ativo de seguran√ßa foi limitado a 5 dias para rea√ß√µes locais e febre, e 14 dias para eventos adversos sist√™micos. Eventos adversos graves foram coletados por 14, 28 ou 42 dias dependendo do protocolo. Este curto per√≠odo de acompanhamento √© insuficiente para detectar eventos adversos tardios como condi√ß√µes autoimunes, que podem se manifestar semanas a meses ap√≥s a vacina√ß√£o. Os dados de seguran√ßa a longo prazo dependem principalmente da vigil√¢ncia p√≥s-comercializa√ß√£o."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo de Efic√°cia Monroe usou um desenho randomizado controlado por placebo com sulfato de hidroxifosfato de alum√≠nio (diluente de alum) como placebo. Isso permite compara√ß√£o de eventos adversos espec√≠ficos da vacina, mas n√£o controla efeitos relacionados ao adjuvante, j√° que ambos os grupos receberam alum√≠nio. Outros estudos usaram compara√ß√µes de vacinas concomitantes ou controles hist√≥ricos, que fornecem compara√ß√µes de seguran√ßa menos rigorosas."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Eventos adversos locais e sist√™micos foram ativamente solicitados via cart√µes-di√°rio por 5-14 dias p√≥s-vacina√ß√£o. No entanto, o estudo observacional p√≥s-comercializa√ß√£o usou vigil√¢ncia passiva atrav√©s de registros m√©dicos eletr√¥nicos em vez de acompanhamento ativo. A dura√ß√£o da vigil√¢ncia ativa foi muito breve para capturar eventos adversos tardios, e eventos n√£o solicitados dependiam de auto-relato dos participantes."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Ensaios cl√≠nicos n√£o inclu√≠ram protocolos espec√≠ficos para monitoramento de eventos adversos neurol√≥gicos. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou s√≠ndrome de Guillain-Barr√©, ataxia cerebelar e encefalite, mas estes n√£o foram sistematicamente rastreados em estudos pr√©-licenciamento. A taxa de convuls√£o febril de 0,05% em crian√ßas de 12-23 meses foi relatada, mas avalia√ß√£o neurol√≥gica abrangente n√£o fez parte do desenho do ensaio."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os dados sobre indiv√≠duos imunocomprometidos s√£o limitados a preocupa√ß√µes de imunogenicidade sem estudos de seguran√ßa dedicados. Os dados de seguran√ßa na gravidez v√™m apenas de relatos espont√¢neos p√≥s-aprova√ß√£o (30 gesta√ß√µes com desfechos conhecidos). Apenas 68 participantes geri√°tricos (65+) foram inclu√≠dos em ensaios cl√≠nicos. A seguran√ßa em beb√™s com menos de 12 meses n√£o foi estabelecida. Nenhum dado espec√≠fico sobre participantes com doen√ßas cr√¥nicas ou condi√ß√µes al√©rgicas al√©m das contraindica√ß√µes gerais."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A bula fornece taxas resumidas de eventos adversos com intervalos de confian√ßa de 95%, detalhamentos demogr√°ficos por ra√ßa e g√™nero, e dados tabulados para principais rea√ß√µes adversas. No entanto, dados em n√≠vel de paciente individual, bancos de dados de seguran√ßa completos, planos de an√°lise estat√≠stica detalhados e relat√≥rios de estudos cl√≠nicos n√£o s√£o acess√≠veis publicamente. Detalhes de registro de ensaios e disponibilidade de dados brutos n√£o s√£o abordados."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Um estudo estruturado de vigil√¢ncia de seguran√ßa p√≥s-comercializa√ß√£o de 60 dias foi conduzido em uma grande HMO (Kaiser) incluindo 42.110 indiv√≠duos (13.735 crian√ßas/adolescentes, 28.375 adultos). Vigil√¢ncia passiva atrav√©s do VAERS est√° em andamento. A experi√™ncia p√≥s-comercializa√ß√£o identificou eventos graves raros (trombocitopenia, SGB, ataxia cerebelar, encefalite) n√£o detectados em ensaios. O fabricante mant√©m notifica√ß√£o de eventos adversos em 1-877-888-4231."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O perfil de seguran√ßa da VAQTA √© apoiado por dados de ensaios cl√≠nicos de mais de 10.000 participantes em m√∫ltiplos grupos et√°rios, incluindo um estudo pivotal controlado por placebo. As rea√ß√µes adversas mais comuns s√£o rea√ß√µes no local da inje√ß√£o (dor, sensibilidade, eritema) e eventos sist√™micos (febre, cefaleia). Eventos adversos graves foram raros (0,7% em crian√ßas de 12-23 meses) com EAGs relacionados √† vacina em 0,1%. As principais limita√ß√µes de seguran√ßa incluem curtos per√≠odos de acompanhamento (5-42 dias), falta de monitoramento neurol√≥gico sistem√°tico, dados limitados sobre popula√ß√µes vulner√°veis e uso de adjuvante de alum√≠nio como placebo. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos neurol√≥gicos raros (SGB, encefalite) que justificam vigil√¢ncia cont√≠nua."
        }
      }
    },
    {
      "id": "tdap_boostrix",
      "name": "Boostrix",
      "type": "Tdap",
      "manufacturer": "GlaxoSmithKline",
      "description": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine for booster immunization.",
      "sources": [
        "tdap_boostrix_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "tdap_boostrix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The main clinical trials used active comparators (Td vaccine or another Tdap vaccine) rather than true placebo controls. Only the pregnancy study (NCT02377349) used a placebo (saline) control group with 341 BOOSTRIX and 346 placebo recipients.",
            "level_description": "Limited placebo use; most trials used active comparator vaccines (Td or Tdap) for immunogenicity and safety comparisons."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The U.S. Adolescent Study and U.S. Adult Study were 'observer-blinded' studies. The U.S. Elderly Study was also 'randomized, observer-blinded.' Revaccination studies were 'open-label.' The pregnancy study was 'randomized, controlled.'",
            "level_description": "Most pivotal trials were observer-blinded rather than fully double-blinded; some studies were open-label."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple studies describe randomization: 'multicenter, randomized, observer-blinded, controlled study' for the U.S. Adolescent Study (NCT00109330), U.S. Adult Study (NCT00346073), U.S. Elderly Study (NCT00835237), and the pregnancy study (NCT02377349).",
            "level_description": "Randomization was consistently employed across pivotal clinical trials."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The U.S. Adolescent Study enrolled 3,080 BOOSTRIX recipients and 1,034 Td recipients (aged 10-18 years). The German Adolescent Study enrolled 319 subjects aged 10-12 years. Total adolescent subjects vaccinated with BOOSTRIX in clinical studies: 4,949.",
            "level_description": "Large adolescent sample sizes (over 4,900 subjects aged 10-18 years) provide adequate statistical power for this age group."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse events monitored for 4-15 days post-vaccination depending on study. Unsolicited adverse events monitored for 30-31 days. Serious adverse events monitored for 6 months post-vaccination in initial-dose studies, 31 days in revaccination and concomitant studies, up to 12 months in SHINGRIX coadministration study.",
            "level_description": "Follow-up periods varied but serious adverse events were tracked for 6 months in pivotal initial-dose studies."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Studies were conducted separately in adolescents (10-18 years), adults (19-64 years), elderly (65+ years), and pregnant women (18-45 years). Additional revaccination studies in adults aged 20-29 years and 28-73 years. Safety and efficacy data reported separately for each age cohort.",
            "level_description": "Comprehensive age-stratified studies with distinct populations and separate reporting of outcomes."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Document states subjects 'had not received a tetanus-diphtheria booster within 5 years' and approximately 98% had received recommended DTaP series in childhood. Contraindications listed include severe allergic reaction history and encephalopathy within 7 days of prior pertussis vaccine.",
            "level_description": "Some inclusion/exclusion criteria mentioned but full details not provided in the prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Subjects were monitored using 'standardized diary cards' for solicited adverse events. Local reactions (pain, redness, swelling, arm circumference) and general events (headache, fatigue, GI symptoms, fever) were systematically collected with grading scales (Grade 1, 2, 3).",
            "level_description": "Standardized diary cards with defined grading scales for systematic adverse event collection across all trials."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Serious adverse events were monitored for 6 months post-vaccination in initial-dose studies. Document reports SAE rates: 1.4% BOOSTRIX vs 1.7% Tdap in adult study; 0.7% BOOSTRIX vs 0.9% Td in 31-day period in elderly study; 4.2% vs 2.2% during 6-month period in elderly.",
            "level_description": "Active surveillance for serious adverse events with 6-month monitoring period in pivotal studies."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Document specifically addresses Guillain-Barre syndrome warning, brachial neuritis, and notes IOM found causal relationship with tetanus toxoid. SAE monitoring specifically evaluated events 'of potential autoimmune origin or new onset and chronic in nature.' One case of insulin-dependent diabetes reported 20 days post-vaccination.",
            "level_description": "Explicit monitoring for autoimmune and neurological events including GBS, with specific warnings in prescribing information."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Pregnant women studied in NCT02377349 (341 BOOSTRIX, 346 placebo). Elderly aged 65+ studied (887 BOOSTRIX, 445 Td) including 299 subjects aged 75+. Immunocompromised persons addressed in warnings section. Document notes vaccine not indicated for children under 10 years.",
            "level_description": "Dedicated studies in pregnant women and elderly populations; immunocompromised persons addressed in warnings."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Non-inferiority analyses conducted with pre-defined criteria. Example: 'upper limit of 2-sided 95% CI for the difference [BOOSTRIX minus Td] <=4%' for Grade 3 pain. GMC ratio comparisons with 'lower limit of 95% CI for GMC ratio >=0.67.' Seroprotection rate comparisons performed.",
            "level_description": "Pre-specified non-inferiority criteria with appropriate statistical methods for immunogenicity endpoints."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Clinical trial registration numbers provided (NCT00109330, NCT00263679, NCT00346073, NCT00835237, etc.). Detailed tables with percentages, confidence intervals, and sample sizes. ATP (according-to-protocol) cohort analyses clearly defined.",
            "level_description": "Trial registration numbers provided; detailed statistical results with confidence intervals in multiple tables."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 describes postmarketing experience with adverse events identified during postapproval use worldwide. VAERS reporting encouraged (1-800-822-7967). Pregnancy registry maintained (1-888-452-9622). Document notes these are voluntary reports from 'population of uncertain size.'",
            "level_description": "Active postmarketing surveillance with VAERS reporting and pregnancy registry; limitations of voluntary reporting acknowledged."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not disclose funding sources for clinical trials or potential conflicts of interest of investigators. Studies were conducted by GlaxoSmithKline Biologicals who manufactures the vaccine.",
            "level_description": "No disclosure of conflicts of interest or detailed funding information in the prescribing information."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report all-cause mortality data from clinical trials. Serious adverse events are reported as percentages but deaths are not specifically enumerated or compared between groups.",
            "level_description": "No explicit all-cause mortality data reported in the prescribing information."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "BOOSTRIX clinical development program includes multiple randomized trials across age groups with over 9,000 total subjects. Strengths include standardized adverse event collection, age-stratified studies, 6-month SAE monitoring, and documented immunogenicity with non-inferiority analyses. Limitations include predominant use of active comparators rather than placebo controls, observer-blinding rather than full double-blinding, absence of all-cause mortality data, and no conflict of interest disclosure. The evidence base supports the approved indications with adequate safety characterization for a booster vaccine."
        }
      },
      "trial_pt": {
        "vaccine_id": "tdap_boostrix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os principais ensaios cl√≠nicos usaram comparadores ativos (vacina Td ou outra vacina Tdap) em vez de controles placebo verdadeiros. Apenas o estudo em gestantes (NCT02377349) usou um grupo controle com placebo (solu√ß√£o salina) com 341 receptoras de BOOSTRIX e 346 de placebo.",
            "level_description": "Uso limitado de placebo; a maioria dos ensaios usou vacinas comparadoras ativas (Td ou Tdap) para compara√ß√µes de imunogenicidade e seguran√ßa."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo em Adolescentes dos EUA e o Estudo em Adultos dos EUA foram estudos 'com cegamento do observador'. O Estudo em Idosos dos EUA tamb√©m foi 'randomizado, com cegamento do observador.' Estudos de revacina√ß√£o foram 'abertos.' O estudo em gestantes foi 'randomizado, controlado.'",
            "level_description": "A maioria dos ensaios pivotais foi com cegamento do observador em vez de totalmente duplo-cego; alguns estudos foram abertos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos estudos descrevem randomiza√ß√£o: 'estudo multic√™ntrico, randomizado, com cegamento do observador, controlado' para o Estudo em Adolescentes dos EUA (NCT00109330), Estudo em Adultos dos EUA (NCT00346073), Estudo em Idosos dos EUA (NCT00835237) e o estudo em gestantes (NCT02377349).",
            "level_description": "A randomiza√ß√£o foi consistentemente empregada em todos os ensaios cl√≠nicos pivotais."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo em Adolescentes dos EUA recrutou 3.080 receptores de BOOSTRIX e 1.034 receptores de Td (10-18 anos). O Estudo em Adolescentes da Alemanha recrutou 319 participantes de 10-12 anos. Total de participantes adolescentes vacinados com BOOSTRIX em estudos cl√≠nicos: 4.949.",
            "level_description": "Grandes tamanhos de amostra adolescente (mais de 4.900 participantes de 10-18 anos) fornecem poder estat√≠stico adequado para este grupo et√°rio."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos solicitados monitorados por 4-15 dias p√≥s-vacina√ß√£o dependendo do estudo. Eventos adversos n√£o solicitados monitorados por 30-31 dias. Eventos adversos graves monitorados por 6 meses p√≥s-vacina√ß√£o em estudos de dose inicial, 31 dias em estudos de revacina√ß√£o e concomitantes, at√© 12 meses no estudo de coadministra√ß√£o com SHINGRIX.",
            "level_description": "Os per√≠odos de acompanhamento variaram, mas eventos adversos graves foram rastreados por 6 meses nos estudos pivotais de dose inicial."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Estudos foram conduzidos separadamente em adolescentes (10-18 anos), adultos (19-64 anos), idosos (65+ anos) e gestantes (18-45 anos). Estudos adicionais de revacina√ß√£o em adultos de 20-29 anos e 28-73 anos. Dados de seguran√ßa e efic√°cia relatados separadamente para cada coorte et√°ria.",
            "level_description": "Estudos abrangentes estratificados por idade com popula√ß√µes distintas e relat√≥rio separado de desfechos."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento afirma que os participantes 'n√£o haviam recebido refor√ßo de t√©tano-difteria nos 5 anos anteriores' e aproximadamente 98% haviam recebido a s√©rie recomendada de DTaP na inf√¢ncia. As contraindica√ß√µes listadas incluem hist√≥rico de rea√ß√£o al√©rgica grave e encefalopatia dentro de 7 dias ap√≥s vacina anterior contra coqueluche.",
            "level_description": "Alguns crit√©rios de inclus√£o/exclus√£o mencionados, mas detalhes completos n√£o fornecidos na bula."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Os participantes foram monitorados usando 'cart√µes-di√°rio padronizados' para eventos adversos solicitados. Rea√ß√µes locais (dor, vermelhid√£o, incha√ßo, circunfer√™ncia do bra√ßo) e eventos gerais (cefaleia, fadiga, sintomas gastrointestinais, febre) foram sistematicamente coletados com escalas de gradua√ß√£o (Grau 1, 2, 3).",
            "level_description": "Cart√µes-di√°rio padronizados com escalas de gradua√ß√£o definidas para coleta sistem√°tica de eventos adversos em todos os ensaios."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos graves foram monitorados por 6 meses p√≥s-vacina√ß√£o em estudos de dose inicial. O documento relata taxas de EAG: 1,4% BOOSTRIX vs 1,7% Tdap no estudo em adultos; 0,7% BOOSTRIX vs 0,9% Td no per√≠odo de 31 dias no estudo em idosos; 4,2% vs 2,2% durante per√≠odo de 6 meses em idosos.",
            "level_description": "Vigil√¢ncia ativa de eventos adversos graves com per√≠odo de monitoramento de 6 meses em estudos pivotais."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O documento aborda especificamente a advert√™ncia sobre s√≠ndrome de Guillain-Barr√©, neurite braquial e observa que o IOM encontrou rela√ß√£o causal com toxoide tet√¢nico. O monitoramento de EAG avaliou especificamente eventos 'de origem autoimune potencial ou de in√≠cio recente e natureza cr√¥nica.' Um caso de diabetes insulino-dependente relatado 20 dias p√≥s-vacina√ß√£o.",
            "level_description": "Monitoramento expl√≠cito de eventos autoimunes e neurol√≥gicos incluindo SGB, com advert√™ncias espec√≠ficas na bula."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Gestantes estudadas no NCT02377349 (341 BOOSTRIX, 346 placebo). Idosos de 65+ anos estudados (887 BOOSTRIX, 445 Td) incluindo 299 participantes de 75+ anos. Pessoas imunocomprometidas abordadas na se√ß√£o de advert√™ncias. O documento observa que a vacina n√£o √© indicada para crian√ßas menores de 10 anos.",
            "level_description": "Estudos dedicados em gestantes e popula√ß√µes idosas; pessoas imunocomprometidas abordadas nas advert√™ncias."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "An√°lises de n√£o inferioridade conduzidas com crit√©rios pr√©-definidos. Exemplo: 'limite superior do IC bilateral de 95% para a diferen√ßa [BOOSTRIX menos Td] <=4%' para dor Grau 3. Compara√ß√µes de raz√£o GMC com 'limite inferior do IC 95% >=0,67.' Compara√ß√µes de taxas de soroprote√ß√£o realizadas.",
            "level_description": "Crit√©rios de n√£o inferioridade pr√©-especificados com m√©todos estat√≠sticos apropriados para desfechos de imunogenicidade."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "N√∫meros de registro de ensaios cl√≠nicos fornecidos (NCT00109330, NCT00263679, NCT00346073, NCT00835237, etc.). Tabelas detalhadas com porcentagens, intervalos de confian√ßa e tamanhos de amostra. An√°lises de coorte ATP (de acordo com o protocolo) claramente definidas.",
            "level_description": "N√∫meros de registro de ensaios fornecidos; resultados estat√≠sticos detalhados com intervalos de confian√ßa em m√∫ltiplas tabelas."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 descreve experi√™ncia p√≥s-comercializa√ß√£o com eventos adversos identificados durante uso p√≥s-aprova√ß√£o mundial. Notifica√ß√£o ao VAERS encorajada (1-800-822-7967). Registro de gravidez mantido (1-888-452-9622). O documento observa que s√£o relatos volunt√°rios de 'popula√ß√£o de tamanho incerto.'",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o ativa com notifica√ß√£o ao VAERS e registro de gravidez; limita√ß√µes da notifica√ß√£o volunt√°ria reconhecidas."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o divulga fontes de financiamento para ensaios cl√≠nicos ou potenciais conflitos de interesse de investigadores. Os estudos foram conduzidos pela GlaxoSmithKline Biologicals, que fabrica a vacina.",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse ou informa√ß√µes detalhadas de financiamento na bula."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas de ensaios cl√≠nicos. Eventos adversos graves s√£o relatados como porcentagens, mas mortes n√£o s√£o especificamente enumeradas ou comparadas entre grupos.",
            "level_description": "Nenhum dado expl√≠cito de mortalidade por todas as causas relatado na bula."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de desenvolvimento cl√≠nico da BOOSTRIX inclui m√∫ltiplos ensaios randomizados em grupos et√°rios com mais de 9.000 participantes no total. Os pontos fortes incluem coleta padronizada de eventos adversos, estudos estratificados por idade, monitoramento de EAG por 6 meses e imunogenicidade documentada com an√°lises de n√£o inferioridade. As limita√ß√µes incluem uso predominante de comparadores ativos em vez de controles placebo, cegamento do observador em vez de duplo-cego completo, aus√™ncia de dados de mortalidade por todas as causas e nenhuma divulga√ß√£o de conflito de interesses. A base de evid√™ncias apoia as indica√ß√µes aprovadas com caracteriza√ß√£o de seguran√ßa adequada para uma vacina de refor√ßo."
        }
      },
      "safety_en": {
        "vaccine_id": "tdap_boostrix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The vaccine is indicated for ages 10 and older, not younger children. For adolescents (10-18 years), 4,949 subjects were vaccinated with BOOSTRIX across clinical trials. The U.S. Adolescent Study enrolled 3,080 BOOSTRIX and 1,034 Td recipients. The German Adolescent Study included 319 subjects aged 10-12. Sample sizes are adequate for detecting common adverse events in the adolescent population."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited adverse events were monitored for 4-15 days post-vaccination depending on the study. Unsolicited adverse events were tracked for 30-31 days. Serious adverse events were monitored for 6 months in initial-dose studies. The pregnancy study monitored SAEs from vaccination through 2 months after delivery. The SHINGRIX coadministration study monitored for up to 12 months. These durations are adequate for detecting acute and some delayed safety signals."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Most trials used active comparator vaccines rather than placebo controls. The U.S. Adolescent Study compared to Td vaccine, the Adult Study compared to another Tdap (ADACEL), and the Elderly Study compared to Td vaccine. Only the pregnancy study (NCT02377349) used a true placebo (saline) control with 341 BOOSTRIX vs 346 placebo recipients. Active comparators limit the ability to detect vaccine-attributable adverse events."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Subjects were actively monitored using standardized diary cards for solicited local reactions (pain, redness, swelling, arm circumference increase) and general adverse events (headache, fatigue, gastrointestinal symptoms, fever). Grade severity scales were employed (Grade 2 = painful when limb moved; Grade 3 = spontaneously painful and/or prevented normal activity). This systematic approach ensures comprehensive capture of common adverse events."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The document explicitly addresses neurological safety concerns. Warnings include Guillain-Barre syndrome risk within 6 weeks of tetanus toxoid vaccines, with IOM evidence supporting causal relationship. Brachial neuritis is also mentioned. Progressive or unstable neurologic disorders are contraindications. Postmarketing reports include convulsions, encephalitis, facial palsy, loss of consciousness, paresthesia, and syncope. Specific monitoring for autoimmune/neurological SAEs was conducted during 6-month follow-up."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Pregnant women were studied in a randomized placebo-controlled trial (NCT02377349) with 687 participants during third trimester. Elderly aged 65+ were studied (887 BOOSTRIX, 445 Td) including 299 subjects aged 75 and older. Immunocompromised individuals are addressed with caution that expected immune response may not be obtained. Pregnancy registry maintained for ongoing surveillance. Lactation data noted as not available."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Clinical trial registration numbers (NCT identifiers) are provided for all major studies. Detailed safety tables present percentages and 95% confidence intervals for adverse events by grade severity. ATP (according-to-protocol) cohorts are defined. Sample sizes are clearly stated. VAERS reporting is encouraged (1-800-822-7967). Postmarketing adverse events are listed by system organ class. Pregnancy exposure registry data from 2005-2022 (1,523 reports) is summarized."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 provides comprehensive postmarketing experience from worldwide use since 2005 approval. Adverse events identified include: lymphadenitis, allergic/anaphylactic reactions, myocarditis, extensive limb swelling, musculoskeletal disorders (arthralgia, back pain, myalgia), nervous system disorders (convulsions, encephalitis, facial palsy, syncope), and skin disorders (angioedema, urticaria, Henoch-Schonlein purpura). VAERS reporting encouraged. Pregnancy registry actively maintained. Limitations of voluntary reporting acknowledged."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "BOOSTRIX safety profile is supported by clinical trial data from over 9,000 subjects across adolescents, adults, elderly, and pregnant women. Strengths include standardized adverse event collection with grading scales, 6-month serious adverse event monitoring, dedicated studies in vulnerable populations (pregnant women, elderly 65+), active postmarketing surveillance with VAERS and pregnancy registry, and explicit neurological safety warnings (GBS, brachial neuritis). Key limitations are the predominant use of active comparators rather than placebo controls (limiting causal attribution of adverse events), and voluntary nature of postmarketing reports. Common adverse reactions are well-characterized (injection site pain 22-78%, headache 12-43%, fatigue 13-37%). Serious neurological and autoimmune events are rare but monitored."
        }
      },
      "safety_pt": {
        "vaccine_id": "tdap_boostrix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A vacina √© indicada para idades de 10 anos ou mais, n√£o para crian√ßas mais novas. Para adolescentes (10-18 anos), 4.949 participantes foram vacinados com BOOSTRIX em ensaios cl√≠nicos. O Estudo em Adolescentes dos EUA recrutou 3.080 BOOSTRIX e 1.034 receptores de Td. O Estudo em Adolescentes da Alemanha incluiu 319 participantes de 10-12 anos. Os tamanhos de amostra s√£o adequados para detectar eventos adversos comuns na popula√ß√£o adolescente."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Eventos adversos solicitados foram monitorados por 4-15 dias p√≥s-vacina√ß√£o dependendo do estudo. Eventos adversos n√£o solicitados foram rastreados por 30-31 dias. Eventos adversos graves foram monitorados por 6 meses em estudos de dose inicial. O estudo em gestantes monitorou EAGs desde a vacina√ß√£o at√© 2 meses ap√≥s o parto. O estudo de coadministra√ß√£o com SHINGRIX monitorou por at√© 12 meses. Essas dura√ß√µes s√£o adequadas para detectar sinais de seguran√ßa agudos e alguns tardios."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A maioria dos ensaios usou vacinas comparadoras ativas em vez de controles placebo. O Estudo em Adolescentes dos EUA comparou com vacina Td, o Estudo em Adultos comparou com outra Tdap (ADACEL), e o Estudo em Idosos comparou com vacina Td. Apenas o estudo em gestantes (NCT02377349) usou um controle placebo verdadeiro (solu√ß√£o salina) com 341 BOOSTRIX vs 346 receptoras de placebo. Comparadores ativos limitam a capacidade de detectar eventos adversos atribu√≠veis √† vacina."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Os participantes foram ativamente monitorados usando cart√µes-di√°rio padronizados para rea√ß√µes locais solicitadas (dor, vermelhid√£o, incha√ßo, aumento da circunfer√™ncia do bra√ßo) e eventos adversos gerais (cefaleia, fadiga, sintomas gastrointestinais, febre). Escalas de gravidade foram empregadas (Grau 2 = doloroso quando o membro se movia; Grau 3 = espontaneamente doloroso e/ou impediu atividade normal). Esta abordagem sistem√°tica garante captura abrangente de eventos adversos comuns."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O documento aborda explicitamente preocupa√ß√µes de seguran√ßa neurol√≥gica. As advert√™ncias incluem risco de s√≠ndrome de Guillain-Barr√© dentro de 6 semanas ap√≥s vacinas de toxoide tet√¢nico, com evid√™ncia do IOM apoiando rela√ß√£o causal. Neurite braquial tamb√©m √© mencionada. Dist√∫rbios neurol√≥gicos progressivos ou inst√°veis s√£o contraindica√ß√µes. Relatos p√≥s-comercializa√ß√£o incluem convuls√µes, encefalite, paralisia facial, perda de consci√™ncia, parestesia e s√≠ncope. Monitoramento espec√≠fico para EAGs autoimunes/neurol√≥gicos foi conduzido durante acompanhamento de 6 meses."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Gestantes foram estudadas em um ensaio randomizado controlado por placebo (NCT02377349) com 687 participantes durante o terceiro trimestre. Idosos de 65+ anos foram estudados (887 BOOSTRIX, 445 Td) incluindo 299 participantes de 75 anos ou mais. Indiv√≠duos imunocomprometidos s√£o abordados com cautela de que a resposta imune esperada pode n√£o ser obtida. Registro de gravidez mantido para vigil√¢ncia cont√≠nua. Dados de lacta√ß√£o observados como n√£o dispon√≠veis."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "N√∫meros de registro de ensaios cl√≠nicos (identificadores NCT) s√£o fornecidos para todos os principais estudos. Tabelas detalhadas de seguran√ßa apresentam porcentagens e intervalos de confian√ßa de 95% para eventos adversos por gravidade. Coortes ATP (de acordo com o protocolo) s√£o definidas. Tamanhos de amostra s√£o claramente declarados. Notifica√ß√£o ao VAERS √© encorajada (1-800-822-7967). Eventos adversos p√≥s-comercializa√ß√£o s√£o listados por classe de sistema de √≥rg√£os. Dados do registro de exposi√ß√£o na gravidez de 2005-2022 (1.523 relatos) s√£o resumidos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 fornece experi√™ncia p√≥s-comercializa√ß√£o abrangente do uso mundial desde a aprova√ß√£o em 2005. Eventos adversos identificados incluem: linfadenite, rea√ß√µes al√©rgicas/anafil√°ticas, miocardite, incha√ßo extenso de membro, dist√∫rbios musculoesquel√©ticos (artralgia, dor nas costas, mialgia), dist√∫rbios do sistema nervoso (convuls√µes, encefalite, paralisia facial, s√≠ncope) e dist√∫rbios da pele (angioedema, urtic√°ria, p√∫rpura de Henoch-Schonlein). Notifica√ß√£o ao VAERS encorajada. Registro de gravidez mantido ativamente. Limita√ß√µes da notifica√ß√£o volunt√°ria reconhecidas."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O perfil de seguran√ßa da BOOSTRIX √© apoiado por dados de ensaios cl√≠nicos de mais de 9.000 participantes incluindo adolescentes, adultos, idosos e gestantes. Os pontos fortes incluem coleta padronizada de eventos adversos com escalas de gradua√ß√£o, monitoramento de eventos adversos graves por 6 meses, estudos dedicados em popula√ß√µes vulner√°veis (gestantes, idosos 65+), vigil√¢ncia p√≥s-comercializa√ß√£o ativa com VAERS e registro de gravidez, e advert√™ncias expl√≠citas de seguran√ßa neurol√≥gica (SGB, neurite braquial). As principais limita√ß√µes s√£o o uso predominante de comparadores ativos em vez de controles placebo (limitando atribui√ß√£o causal de eventos adversos) e a natureza volunt√°ria dos relatos p√≥s-comercializa√ß√£o. Rea√ß√µes adversas comuns s√£o bem caracterizadas (dor no local da inje√ß√£o 22-78%, cefaleia 12-43%, fadiga 13-37%). Eventos neurol√≥gicos e autoimunes graves s√£o raros, mas monitorados."
        }
      }
    },
    {
      "id": "tdap_adacel",
      "name": "Adacel",
      "type": "Tdap",
      "manufacturer": "Sanofi Pasteur",
      "description": "Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine for booster immunization.",
      "sources": [
        "tdap_adacel_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "tdap_adacel",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Clinical trials used active comparators (Td vaccine - DECAVAC or TENIVAC) rather than inert placebo. Study Td506 compared Adacel to Td vaccine in adolescents and adults. Study NCT01439165 compared second dose of Adacel to Td vaccine. No saline placebo control group was used.",
            "level_description": "Using another vaccine as comparator obscures true adverse event rates. Without an inert placebo, it is impossible to determine which reactions are caused by the vaccine versus coincidental events."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study Td506 was described as 'observer-blind' (not double-blind). Study NCT01439165 was also 'observer-blind, active-controlled.' Study Td505 was 'randomized, double-blind.' Study NCT00347958 was 'open-label.' Mixed blinding across studies.",
            "level_description": "Observer-blind is weaker than double-blind as it doesn't ensure participants are unaware of their treatment group. Only some studies used double-blinding."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study Td506 was a 'randomized, observer-blind, active-controlled trial.' Study NCT01439165 was 'randomized, observer-blind, active-controlled, multi-center study.' Study Td505 was 'randomized, double-blind, multi-center trial.' Enrollment was stratified by age to ensure adequate representation across the age range.",
            "level_description": "Randomization was documented in multiple studies. Stratification by age was mentioned. However, specific allocation concealment methods were not described."
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Adacel is NOT approved for individuals less than 10 years of age. The document states: 'Safety and effectiveness of Adacel in persons less than 10 years of age in the U.S. have not been established.' The youngest subjects studied were 10-11 years old (N=1,302 in study NCT01311557). No children ages 0-9 were studied.",
            "level_description": "No pediatric safety data exists for children under 10 years. The vaccine is explicitly not indicated for this population. This criterion cannot be evaluated for the pediatric 0-12 age group as traditionally defined."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study Td506: Solicited reactions monitored for 14 days via diary card. Days 14-28: adverse events requiring medical contact collected via telephone/clinic. Days 28 to 6 months: monitoring for physician visits, ER visits, serious illness, hospitalizations. At least 96% completed 6-month follow-up. Study NCT01439165: Solicited reactions for 7 days, unsolicited for 28 days, SAEs for 6 months.",
            "level_description": "Maximum follow-up was 6 months, which is inadequate for detecting autoimmune or neurological conditions that may emerge months or years later. The methodology recommends minimum 6-12 months, ideally several years."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Data presented separately for adolescents 11-17 years (N=4,695 across studies) and adults 18-64 years (N=2,448). Study NCT01311557 specifically compared 10 to <11 years vs 11 to <12 years age groups. Tables show separate results for these age categories.",
            "level_description": "Age groups were analyzed separately for adolescents and adults. However, no separation for younger pediatric age groups (0-1, 1-5, 6-9 years) since these populations were not studied."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Participants had not received tetanus or diphtheria-containing vaccines within the previous 5 years. Contraindications listed include severe allergic reaction to previous doses and encephalopathy within 7 days of prior pertussis vaccine. Demographic data: 86% Caucasian, 8% Black, 3% Hispanic, 1% Asian, 2% other.",
            "level_description": "Basic inclusion criteria mentioned but detailed exclusion criteria not fully documented. Population skewed toward Caucasian participants (86-95%). No explicit discussion of generalizability limitations."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse reactions defined with objective thresholds: fever >=38.0C, >=38.8C to <=39.4C, >=39.5C. Injection site swelling measured in cm (1.0-3.4 cm moderate, >=3.5 cm severe, >=5 cm severe). Pain categorized as moderate (interfered with activities) and severe (incapacitating). Diary cards used for standardized collection.",
            "level_description": "Standardized definitions with objective thresholds were used. Categories of severity were defined. However, no mention of Brighton Collaboration criteria or MedDRA coding."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited local and systemic reactions monitored daily for 14 days using diary cards. Days 14-28: telephone interview or clinic visit for adverse events requiring medical contact. Days 28 to 6 months: monitoring for physician visits, ER visits, serious illness, hospitalizations. SAEs reported in 1.5% of Adacel vs 1.4% of Td recipients. Two neuropathic SAEs noted within 28 days.",
            "level_description": "Active solicitation during initial period with follow-up monitoring for serious events. Clear tracking of hospitalizations and serious illness. However, relies partly on telephone contact and participant self-reporting for longer-term follow-up."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Warnings mention Guillain-Barre syndrome risk if occurred within 6 weeks of prior tetanus toxoid vaccine. Institute of Medicine found evidence for causal relation between tetanus toxoid and brachial neuritis. Two SAEs were neuropathic events within 28 days (severe migraine with facial paralysis, nerve compression). Post-marketing reports include: GBS, brachial neuritis, facial palsy, convulsion, syncope, myelitis, myocarditis.",
            "level_description": "Neurological conditions acknowledged but no systematic long-term monitoring protocol described. Conditions identified primarily through post-marketing surveillance rather than prospective trial design."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Section 5.5 notes immunocompromised persons may not achieve expected immune response. No specific data on premature infants, immunocompromised, or children with chronic conditions. Pregnancy data available but limited (retrospective study N=225 exposed, registry data N=1,236). No intentional inclusion of vulnerable pediatric subgroups.",
            "level_description": "Vulnerable subgroups were not intentionally included or analyzed separately. Immunocompromised persons mentioned only as a warning. Since vaccine is for ages 10+, no data on premature infants or immunocompromised children."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "95% confidence intervals provided throughout tables. Non-inferiority criteria specified (e.g., upper limit of 95% CI <10% for seroprotection rates). Pre-specified acceptable booster response rates defined. GMC ratios calculated with CIs. Statistical comparison between Adacel and comparator vaccines with specified criteria (lower limit of 95% CI on ratio >0.67).",
            "level_description": "Statistical methods documented with confidence intervals and non-inferiority criteria. However, studies were powered for immunogenicity (efficacy), not safety outcomes. No power calculations for detecting rare safety events."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "ClinicalTrials.gov identifiers provided (NCT01439165, NCT00347958, NCT01311557, NCT00258882, NCT05040802). Reference to published studies including Sweden I Efficacy trial. Data presented in package insert format with summary tables. No mention of independent DSMB or availability of individual participant data.",
            "level_description": "Trial registrations referenced but no mention of independent Data Safety Monitoring Board. Raw data or individual participant data not mentioned as available for independent verification."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.2 describes postmarketing experience with spontaneously reported adverse events from US and other countries. Events included based on severity, frequency, or evidence for causal relationship. Lists immune, nervous system, cardiac, skin disorders. VAERS reporting mentioned. States frequency cannot be reliably estimated from voluntary reports.",
            "level_description": "Relies on passive voluntary reporting (VAERS) which vastly underestimates true rates. Acknowledges inability to reliably estimate frequency. No active pharmacovigilance system with periodic public reports described."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Manufactured by Sanofi Pasteur Limited (Canada), distributed by Sanofi Pasteur Inc. (USA). Studies referenced include those conducted by Sanofi Pasteur. No disclosure of funding sources, financial ties of investigators, or independence of analysis.",
            "level_description": "No conflict of interest disclosures in the package insert. Manufacturer conducted the clinical trials. No mention of independent funding or researchers without conflicts."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No deaths reported in the clinical trial sections. SAE rates mentioned (1.5% Adacel vs 1.4% Td in study Td506; 0.8% Adacel vs 0.3% Td in NCT01439165) but all-cause mortality data not explicitly provided. No breakdown of total deaths in vaccine vs control groups.",
            "level_description": "All-cause mortality and morbidity not systematically reported. Focus on 'vaccine-related' outcomes rather than total deaths and hospitalizations across all groups."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The Adacel package insert documents clinical trials that meet some but not all criteria for robust safety evaluation. Key limitations include: (1) No true placebo control - all comparisons were to another active vaccine (Td), making it impossible to determine true vaccine-attributable adverse event rates; (2) Maximum 6-month follow-up, inadequate for detecting delayed autoimmune/neurological conditions; (3) No pediatric data for children under 10 years as the vaccine is not indicated for this population; (4) Reliance on passive post-marketing surveillance (VAERS) for rare events; (5) No conflict of interest disclosures despite manufacturer-conducted trials; (6) No all-cause mortality reporting. Strengths include randomization, standardized adverse event definitions, separate age group analyses, and active solicitation of reactions during the initial post-vaccination period. The evidence base is primarily designed to demonstrate immunogenicity non-inferiority rather than comprehensively characterize safety."
        }
      },
      "trial_pt": {
        "vaccine_id": "tdap_adacel",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os ensaios cl√≠nicos usaram comparadores ativos (vacina Td - DECAVAC ou TENIVAC) em vez de placebo inerte. O Estudo Td506 comparou Adacel √† vacina Td em adolescentes e adultos. O Estudo NCT01439165 comparou segunda dose de Adacel √† vacina Td. Nenhum grupo controle com placebo salino foi usado.",
            "level_description": "Usar outra vacina como comparador obscurece as verdadeiras taxas de eventos adversos. Sem placebo inerte, √© imposs√≠vel determinar quais rea√ß√µes s√£o causadas pela vacina versus eventos coincidentes."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo Td506 foi descrito como 'com cegamento do observador' (n√£o duplo-cego). O Estudo NCT01439165 tamb√©m foi 'com cegamento do observador, controlado ativo.' O Estudo Td505 foi 'randomizado, duplo-cego.' O Estudo NCT00347958 foi 'aberto.' Cegamento misto entre estudos.",
            "level_description": "Cegamento do observador √© mais fraco que duplo-cego, pois n√£o garante que os participantes desconhe√ßam seu grupo de tratamento. Apenas alguns estudos usaram duplo-cego."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo Td506 foi um 'ensaio randomizado, com cegamento do observador, controlado ativo.' O Estudo NCT01439165 foi um 'estudo multic√™ntrico, randomizado, com cegamento do observador, controlado ativo.' O Estudo Td505 foi um 'ensaio multic√™ntrico, randomizado, duplo-cego.' A inclus√£o foi estratificada por idade para garantir representa√ß√£o adequada em toda a faixa et√°ria.",
            "level_description": "A randomiza√ß√£o foi documentada em m√∫ltiplos estudos. A estratifica√ß√£o por idade foi mencionada. No entanto, m√©todos espec√≠ficos de oculta√ß√£o de aloca√ß√£o n√£o foram descritos."
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Adacel N√ÉO √© aprovada para indiv√≠duos menores de 10 anos de idade. O documento afirma: 'A seguran√ßa e efic√°cia de Adacel em pessoas menores de 10 anos de idade nos EUA n√£o foram estabelecidas.' Os participantes mais jovens estudados tinham 10-11 anos (N=1.302 no estudo NCT01311557). Nenhuma crian√ßa de 0-9 anos foi estudada.",
            "level_description": "N√£o existem dados de seguran√ßa pedi√°trica para crian√ßas menores de 10 anos. A vacina explicitamente n√£o √© indicada para esta popula√ß√£o. Este crit√©rio n√£o pode ser avaliado para o grupo et√°rio pedi√°trico de 0-12 anos tradicionalmente definido."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo Td506: Rea√ß√µes solicitadas monitoradas por 14 dias via cart√£o-di√°rio. Dias 14-28: eventos adversos que requeriam contato m√©dico coletados via telefone/cl√≠nica. Dias 28 a 6 meses: monitoramento de consultas m√©dicas, visitas ao pronto-socorro, doen√ßas graves, hospitaliza√ß√µes. Pelo menos 96% completaram o acompanhamento de 6 meses. Estudo NCT01439165: Rea√ß√µes solicitadas por 7 dias, n√£o solicitadas por 28 dias, EAGs por 6 meses.",
            "level_description": "O acompanhamento m√°ximo foi de 6 meses, o que √© inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem surgir meses ou anos depois. A metodologia recomenda m√≠nimo de 6-12 meses, idealmente v√°rios anos."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Dados apresentados separadamente para adolescentes de 11-17 anos (N=4.695 nos estudos) e adultos de 18-64 anos (N=2.448). O Estudo NCT01311557 comparou especificamente grupos et√°rios de 10 a <11 anos vs 11 a <12 anos. Tabelas mostram resultados separados para essas categorias et√°rias.",
            "level_description": "Os grupos et√°rios foram analisados separadamente para adolescentes e adultos. No entanto, n√£o h√° separa√ß√£o para grupos et√°rios pedi√°tricos mais jovens (0-1, 1-5, 6-9 anos) j√° que essas popula√ß√µes n√£o foram estudadas."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os participantes n√£o haviam recebido vacinas contendo t√©tano ou difteria nos 5 anos anteriores. As contraindica√ß√µes listadas incluem rea√ß√£o al√©rgica grave a doses anteriores e encefalopatia dentro de 7 dias ap√≥s vacina anterior contra coqueluche. Dados demogr√°ficos: 86% caucasianos, 8% negros, 3% hisp√¢nicos, 1% asi√°ticos, 2% outros.",
            "level_description": "Crit√©rios b√°sicos de inclus√£o mencionados, mas crit√©rios detalhados de exclus√£o n√£o totalmente documentados. Popula√ß√£o enviesada para participantes caucasianos (86-95%). Nenhuma discuss√£o expl√≠cita das limita√ß√µes de generaliza√ß√£o."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes adversas solicitadas definidas com limites objetivos: febre >=38,0C, >=38,8C a <=39,4C, >=39,5C. Incha√ßo no local da inje√ß√£o medido em cm (1,0-3,4 cm moderado, >=3,5 cm grave, >=5 cm grave). Dor categorizada como moderada (interferiu nas atividades) e grave (incapacitante). Cart√µes-di√°rio usados para coleta padronizada.",
            "level_description": "Defini√ß√µes padronizadas com limites objetivos foram usadas. Categorias de gravidade foram definidas. No entanto, n√£o h√° men√ß√£o de crit√©rios da Brighton Collaboration ou codifica√ß√£o MedDRA."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes locais e sist√™micas solicitadas monitoradas diariamente por 14 dias usando cart√µes-di√°rio. Dias 14-28: entrevista telef√¥nica ou visita cl√≠nica para eventos adversos que requeriam contato m√©dico. Dias 28 a 6 meses: monitoramento de consultas m√©dicas, visitas ao pronto-socorro, doen√ßas graves, hospitaliza√ß√µes. EAGs relatados em 1,5% de Adacel vs 1,4% de receptores de Td. Dois EAGs neurop√°ticos observados em 28 dias.",
            "level_description": "Solicita√ß√£o ativa durante o per√≠odo inicial com monitoramento de acompanhamento para eventos graves. Rastreamento claro de hospitaliza√ß√µes e doen√ßas graves. No entanto, depende parcialmente de contato telef√¥nico e auto-relato dos participantes para acompanhamento de longo prazo."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As advert√™ncias mencionam risco de s√≠ndrome de Guillain-Barr√© se ocorreu dentro de 6 semanas ap√≥s vacina anterior de toxoide tet√¢nico. O Institute of Medicine encontrou evid√™ncia de rela√ß√£o causal entre toxoide tet√¢nico e neurite braquial. Dois EAGs foram eventos neurop√°ticos em 28 dias (enxaqueca grave com paralisia facial, compress√£o nervosa). Relatos p√≥s-comercializa√ß√£o incluem: SGB, neurite braquial, paralisia facial, convuls√£o, s√≠ncope, mielite, miocardite.",
            "level_description": "Condi√ß√µes neurol√≥gicas reconhecidas, mas nenhum protocolo de monitoramento sistem√°tico de longo prazo descrito. Condi√ß√µes identificadas principalmente atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o em vez de desenho prospectivo de ensaio."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "A Se√ß√£o 5.5 observa que pessoas imunocomprometidas podem n√£o alcan√ßar a resposta imune esperada. Nenhum dado espec√≠fico sobre prematuros, imunocomprometidos ou crian√ßas com condi√ß√µes cr√¥nicas. Dados de gravidez dispon√≠veis, mas limitados (estudo retrospectivo N=225 expostos, dados de registro N=1.236). Nenhuma inclus√£o intencional de subgrupos pedi√°tricos vulner√°veis.",
            "level_description": "Subgrupos vulner√°veis n√£o foram intencionalmente inclu√≠dos ou analisados separadamente. Pessoas imunocomprometidas mencionadas apenas como advert√™ncia. Como a vacina √© para idades de 10+, n√£o h√° dados sobre prematuros ou crian√ßas imunocomprometidas."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Intervalos de confian√ßa de 95% fornecidos em todas as tabelas. Crit√©rios de n√£o inferioridade especificados (ex.: limite superior do IC 95% <10% para taxas de soroprote√ß√£o). Taxas de resposta de refor√ßo aceit√°veis pr√©-especificadas definidas. Raz√µes GMC calculadas com ICs. Compara√ß√£o estat√≠stica entre Adacel e vacinas comparadoras com crit√©rios especificados (limite inferior do IC 95% na raz√£o >0,67).",
            "level_description": "M√©todos estat√≠sticos documentados com intervalos de confian√ßa e crit√©rios de n√£o inferioridade. No entanto, os estudos foram dimensionados para imunogenicidade (efic√°cia), n√£o para desfechos de seguran√ßa. Nenhum c√°lculo de poder para detectar eventos raros de seguran√ßa."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Identificadores ClinicalTrials.gov fornecidos (NCT01439165, NCT00347958, NCT01311557, NCT00258882, NCT05040802). Refer√™ncia a estudos publicados incluindo ensaio de efic√°cia Su√©cia I. Dados apresentados em formato de bula com tabelas resumidas. Nenhuma men√ß√£o de DSMB independente ou disponibilidade de dados individuais de participantes.",
            "level_description": "Registros de ensaios referenciados, mas nenhuma men√ß√£o de Comit√™ Independente de Monitoramento de Seguran√ßa de Dados. Dados brutos ou dados individuais de participantes n√£o mencionados como dispon√≠veis para verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.2 descreve experi√™ncia p√≥s-comercializa√ß√£o com eventos adversos relatados espontaneamente dos EUA e outros pa√≠ses. Eventos inclu√≠dos com base na gravidade, frequ√™ncia ou evid√™ncia de rela√ß√£o causal. Lista dist√∫rbios imunol√≥gicos, do sistema nervoso, card√≠acos e da pele. Notifica√ß√£o ao VAERS mencionada. Afirma que a frequ√™ncia n√£o pode ser estimada de forma confi√°vel a partir de relatos volunt√°rios.",
            "level_description": "Depende de notifica√ß√£o volunt√°ria passiva (VAERS) que subestima vastamente as verdadeiras taxas. Reconhece a incapacidade de estimar a frequ√™ncia de forma confi√°vel. Nenhum sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos descrito."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Fabricado por Sanofi Pasteur Limited (Canad√°), distribu√≠do por Sanofi Pasteur Inc. (EUA). Estudos referenciados incluem aqueles conduzidos pela Sanofi Pasteur. Nenhuma divulga√ß√£o de fontes de financiamento, v√≠nculos financeiros de investigadores ou independ√™ncia de an√°lise.",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse na bula. O fabricante conduziu os ensaios cl√≠nicos. Nenhuma men√ß√£o de financiamento independente ou pesquisadores sem conflitos."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhuma morte relatada nas se√ß√µes de ensaios cl√≠nicos. Taxas de EAG mencionadas (1,5% Adacel vs 1,4% Td no estudo Td506; 0,8% Adacel vs 0,3% Td no NCT01439165), mas dados de mortalidade por todas as causas n√£o fornecidos explicitamente. Nenhum detalhamento de mortes totais nos grupos vacina vs controle.",
            "level_description": "Mortalidade por todas as causas e morbidade n√£o relatadas sistematicamente. Foco em desfechos 'relacionados √† vacina' em vez de mortes totais e hospitaliza√ß√µes em todos os grupos."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula de Adacel documenta ensaios cl√≠nicos que atendem alguns, mas n√£o todos os crit√©rios para avalia√ß√£o robusta de seguran√ßa. As principais limita√ß√µes incluem: (1) Nenhum controle placebo verdadeiro - todas as compara√ß√µes foram com outra vacina ativa (Td), impossibilitando determinar as verdadeiras taxas de eventos adversos atribu√≠veis √† vacina; (2) Acompanhamento m√°ximo de 6 meses, inadequado para detectar condi√ß√µes autoimunes/neurol√≥gicas tardias; (3) Nenhum dado pedi√°trico para crian√ßas menores de 10 anos, pois a vacina n√£o √© indicada para esta popula√ß√£o; (4) Depend√™ncia de vigil√¢ncia p√≥s-comercializa√ß√£o passiva (VAERS) para eventos raros; (5) Nenhuma divulga√ß√£o de conflito de interesses apesar de ensaios conduzidos pelo fabricante; (6) Nenhum relato de mortalidade por todas as causas. Os pontos fortes incluem randomiza√ß√£o, defini√ß√µes padronizadas de eventos adversos, an√°lises separadas por grupo et√°rio e solicita√ß√£o ativa de rea√ß√µes durante o per√≠odo inicial p√≥s-vacina√ß√£o. A base de evid√™ncias √© principalmente projetada para demonstrar n√£o inferioridade de imunogenicidade em vez de caracterizar a seguran√ßa de forma abrangente."
        }
      },
      "safety_en": {
        "vaccine_id": "tdap_adacel",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Adacel is NOT approved for children under 10 years of age. The document explicitly states: 'Safety and effectiveness of Adacel in persons less than 10 years of age in the U.S. have not been established.' The youngest subjects studied were 10-11 years old (1,302 participants in study NCT01311557). For the traditional pediatric population (0-9 years), no safety data exists. For adolescents 10-17 years, approximately 4,695 were studied across trials - meeting the >3,000 threshold for that specific age group, but this does not address younger children."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Maximum follow-up was 6 months in the primary trials. Study Td506: solicited reactions for 14 days, then monitoring for serious events up to 6 months via telephone contact. Study NCT01439165: solicited reactions for 7 days, unsolicited for 28 days, SAEs for 6 months. This falls significantly short of the ideal 12 months minimum or 2-3+ years needed to detect delayed autoimmune and neurological conditions. The 6-month timeframe is grossly inadequate for comprehensive long-term safety assessment."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "No true placebo (saline) control was used. All trials compared Adacel to another active vaccine - Td (Tetanus and Diphtheria Toxoids Adsorbed). Study Td506: Adacel vs DECAVAC (Td). Study NCT01439165: Adacel vs TENIVAC (Td). This design makes it impossible to determine which adverse events are caused by the vaccine versus coincidental occurrences. Both vaccines contain similar components, so comparing them obscures the true safety profile. The trials were randomized and observer-blind but the active comparator fundamentally limits safety conclusions."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active solicitation was conducted during the initial post-vaccination period: daily diary card monitoring for 14 days (study Td506) or 7 days (NCT01439165) for local and systemic reactions. Days 14-28 involved telephone interviews or clinic visits for events requiring medical contact. However, days 28 to 6 months relied on monitoring for physician/ER visits rather than proactive follow-up. SAE rates: 1.5% Adacel vs 1.4% Td in Td506. Two neuropathic SAEs within 28 days (severe migraine with facial paralysis, nerve compression). Causality investigation was not described in detail."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document acknowledges neurological risks but lacks systematic prospective monitoring. Warnings note: Guillain-Barre syndrome risk if occurred within 6 weeks of prior tetanus toxoid vaccine; Institute of Medicine found causal relation between tetanus toxoid and brachial neuritis. Post-marketing reports include GBS, brachial neuritis, facial palsy, convulsion, syncope, myelitis. However, no scheduled neurological exams or developmental assessments were described in trial protocols. Neurological events appear to have been identified reactively rather than through proactive surveillance."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Vulnerable subgroups were not intentionally included or analyzed separately. The document notes immunocompromised persons may not achieve expected immune response (section 5.5) but provides no specific safety data for this group. No data on premature infants, children with chronic conditions, or immunocompromised individuals. Since the vaccine is for ages 10+, premature infants are not relevant, but immunocompromised adolescents were not studied. Pregnancy registry data exists (N=225 exposed in retrospective study, N=1,236 in ongoing registry) with outcomes consistent with background rates."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trial registration numbers provided (NCT01439165, NCT00347958, NCT01311557, NCT00258882, NCT05040802). Summary tables with percentages and confidence intervals included. References to peer-reviewed publications (Sweden I Efficacy trial, published pregnancy studies). However, no mention of independent Data Safety Monitoring Board (DSMB). Raw data and individual participant data (IPD) not mentioned as available. Manufacturer (Sanofi Pasteur) conducted the trials with no disclosed independent oversight."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Section 6.2 describes spontaneously reported adverse events from post-marketing experience in US and other countries. Adverse events listed by system: immune (anaphylaxis, hypersensitivity), nervous (GBS, brachial neuritis, facial palsy, convulsion, myelitis), cardiac (myocarditis), skin (pruritus, urticaria), musculoskeletal (myositis), and injection site reactions. VAERS reporting encouraged. However, the document acknowledges: 'Because these events are reported voluntarily from a population of uncertain size, it may not be possible to reliably estimate their frequency.' This passive system vastly underestimates true rates. No active pharmacovigilance with periodic public reports described."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This document does NOT provide confidence that Adacel is safe for children ages 0-9 years because the vaccine was never studied in or approved for this population. For adolescents 10+ years, the safety evidence has significant limitations: (1) No true placebo control - all comparisons used another vaccine (Td), making it impossible to determine true adverse event rates; (2) Maximum 6-month follow-up is inadequate to detect delayed autoimmune or neurological conditions that may emerge months or years later; (3) No systematic neurological monitoring - serious conditions like GBS and myelitis identified primarily through passive post-marketing surveillance; (4) Vulnerable subgroups (immunocompromised adolescents) were not studied; (5) Post-marketing surveillance relies on voluntary VAERS reporting which vastly underestimates true event rates. The document demonstrates that ~7,143 individuals ages 10-64 received Adacel in clinical trials with active monitoring for 14 days and passive follow-up to 6 months, showing a safety profile similar to the Td comparator vaccine. However, parents seeking evidence of long-term safety for their child would find this evidence base incomplete, particularly given the absence of inert placebo comparisons, short follow-up duration, and reliance on passive surveillance to detect rare serious events."
        }
      },
      "safety_pt": {
        "vaccine_id": "tdap_adacel",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Adacel N√ÉO √© aprovada para crian√ßas menores de 10 anos de idade. O documento afirma explicitamente: 'A seguran√ßa e efic√°cia de Adacel em pessoas menores de 10 anos de idade nos EUA n√£o foram estabelecidas.' Os participantes mais jovens estudados tinham 10-11 anos (1.302 participantes no estudo NCT01311557). Para a popula√ß√£o pedi√°trica tradicional (0-9 anos), n√£o existem dados de seguran√ßa. Para adolescentes de 10-17 anos, aproximadamente 4.695 foram estudados nos ensaios - atendendo ao limiar de >3.000 para esse grupo et√°rio espec√≠fico, mas isso n√£o aborda crian√ßas mais novas."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento m√°ximo foi de 6 meses nos ensaios prim√°rios. Estudo Td506: rea√ß√µes solicitadas por 14 dias, depois monitoramento de eventos graves por at√© 6 meses via contato telef√¥nico. Estudo NCT01439165: rea√ß√µes solicitadas por 7 dias, n√£o solicitadas por 28 dias, EAGs por 6 meses. Isso fica significativamente aqu√©m do m√≠nimo ideal de 12 meses ou 2-3+ anos necess√°rios para detectar condi√ß√µes autoimunes e neurol√≥gicas tardias. O prazo de 6 meses √© grosseiramente inadequado para avalia√ß√£o abrangente de seguran√ßa a longo prazo."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Nenhum placebo verdadeiro (solu√ß√£o salina) foi usado. Todos os ensaios compararam Adacel a outra vacina ativa - Td (Toxoides de T√©tano e Difteria Adsorvidos). Estudo Td506: Adacel vs DECAVAC (Td). Estudo NCT01439165: Adacel vs TENIVAC (Td). Este desenho torna imposs√≠vel determinar quais eventos adversos s√£o causados pela vacina versus ocorr√™ncias coincidentes. Ambas as vacinas cont√™m componentes similares, ent√£o compar√°-las obscurece o verdadeiro perfil de seguran√ßa. Os ensaios foram randomizados e com cegamento do observador, mas o comparador ativo limita fundamentalmente as conclus√µes de seguran√ßa."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Solicita√ß√£o ativa foi conduzida durante o per√≠odo inicial p√≥s-vacina√ß√£o: monitoramento di√°rio com cart√£o-di√°rio por 14 dias (estudo Td506) ou 7 dias (NCT01439165) para rea√ß√µes locais e sist√™micas. Dias 14-28 envolveram entrevistas telef√¥nicas ou visitas cl√≠nicas para eventos que requeriam contato m√©dico. No entanto, dias 28 a 6 meses dependeram de monitoramento de consultas m√©dicas/visitas ao pronto-socorro em vez de acompanhamento proativo. Taxas de EAG: 1,5% Adacel vs 1,4% Td no Td506. Dois EAGs neurop√°ticos em 28 dias (enxaqueca grave com paralisia facial, compress√£o nervosa). Investiga√ß√£o de causalidade n√£o foi descrita em detalhes."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento reconhece riscos neurol√≥gicos, mas carece de monitoramento prospectivo sistem√°tico. As advert√™ncias observam: risco de s√≠ndrome de Guillain-Barr√© se ocorreu dentro de 6 semanas ap√≥s vacina anterior de toxoide tet√¢nico; Institute of Medicine encontrou rela√ß√£o causal entre toxoide tet√¢nico e neurite braquial. Relatos p√≥s-comercializa√ß√£o incluem SGB, neurite braquial, paralisia facial, convuls√£o, s√≠ncope, mielite. No entanto, exames neurol√≥gicos programados ou avalia√ß√µes de desenvolvimento n√£o foram descritos nos protocolos de ensaio. Eventos neurol√≥gicos parecem ter sido identificados reativamente em vez de atrav√©s de vigil√¢ncia proativa."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Subgrupos vulner√°veis n√£o foram intencionalmente inclu√≠dos ou analisados separadamente. O documento observa que pessoas imunocomprometidas podem n√£o alcan√ßar a resposta imune esperada (se√ß√£o 5.5), mas n√£o fornece dados de seguran√ßa espec√≠ficos para este grupo. Nenhum dado sobre prematuros, crian√ßas com condi√ß√µes cr√¥nicas ou indiv√≠duos imunocomprometidos. Como a vacina √© para idades de 10+, prematuros n√£o s√£o relevantes, mas adolescentes imunocomprometidos n√£o foram estudados. Dados de registro de gravidez existem (N=225 expostos em estudo retrospectivo, N=1.236 em registro em andamento) com desfechos consistentes com taxas de base."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "N√∫meros de registro de ensaios cl√≠nicos fornecidos (NCT01439165, NCT00347958, NCT01311557, NCT00258882, NCT05040802). Tabelas resumidas com porcentagens e intervalos de confian√ßa inclu√≠das. Refer√™ncias a publica√ß√µes revisadas por pares (ensaio de efic√°cia Su√©cia I, estudos de gravidez publicados). No entanto, nenhuma men√ß√£o de Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB). Dados brutos e dados individuais de participantes (IPD) n√£o mencionados como dispon√≠veis. Fabricante (Sanofi Pasteur) conduziu os ensaios sem supervis√£o independente divulgada."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A Se√ß√£o 6.2 descreve eventos adversos relatados espontaneamente da experi√™ncia p√≥s-comercializa√ß√£o nos EUA e outros pa√≠ses. Eventos adversos listados por sistema: imunol√≥gico (anafilaxia, hipersensibilidade), nervoso (SGB, neurite braquial, paralisia facial, convuls√£o, mielite), card√≠aco (miocardite), pele (prurido, urtic√°ria), musculoesquel√©tico (miosite) e rea√ß√µes no local da inje√ß√£o. Notifica√ß√£o ao VAERS encorajada. No entanto, o documento reconhece: 'Como esses eventos s√£o relatados voluntariamente de uma popula√ß√£o de tamanho incerto, pode n√£o ser poss√≠vel estimar sua frequ√™ncia de forma confi√°vel.' Este sistema passivo subestima vastamente as verdadeiras taxas. Nenhuma farmacovigil√¢ncia ativa com relat√≥rios p√∫blicos peri√≥dicos descrita."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Este documento N√ÉO fornece confian√ßa de que Adacel √© segura para crian√ßas de 0-9 anos porque a vacina nunca foi estudada ou aprovada para esta popula√ß√£o. Para adolescentes de 10+ anos, a evid√™ncia de seguran√ßa tem limita√ß√µes significativas: (1) Nenhum controle placebo verdadeiro - todas as compara√ß√µes usaram outra vacina (Td), impossibilitando determinar as verdadeiras taxas de eventos adversos; (2) Acompanhamento m√°ximo de 6 meses √© inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas tardias que podem surgir meses ou anos depois; (3) Nenhum monitoramento neurol√≥gico sistem√°tico - condi√ß√µes graves como SGB e mielite identificadas principalmente atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o passiva; (4) Subgrupos vulner√°veis (adolescentes imunocomprometidos) n√£o foram estudados; (5) A vigil√¢ncia p√≥s-comercializa√ß√£o depende de notifica√ß√£o volunt√°ria ao VAERS, que subestima vastamente as verdadeiras taxas de eventos. O documento demonstra que ~7.143 indiv√≠duos de 10-64 anos receberam Adacel em ensaios cl√≠nicos com monitoramento ativo por 14 dias e acompanhamento passivo por 6 meses, mostrando um perfil de seguran√ßa semelhante √† vacina comparadora Td. No entanto, pais buscando evid√™ncia de seguran√ßa a longo prazo para seus filhos achariam esta base de evid√™ncias incompleta, particularmente dada a aus√™ncia de compara√ß√µes com placebo inerte, curta dura√ß√£o de acompanhamento e depend√™ncia de vigil√¢ncia passiva para detectar eventos graves raros."
        }
      }
    },
    {
      "id": "hpv_gardasil9",
      "name": "Gardasil 9",
      "type": "HPV",
      "manufacturer": "Merck",
      "description": "Human Papillomavirus 9-valent Vaccine, Recombinant for prevention of HPV-related diseases.",
      "sources": [
        "hpv_gardasil9_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hpv_gardasil9",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study V503-001 was randomized, double-blind, controlled with Gardasil (qHPV) as active comparator, not a true placebo. The document states 'qHPV-controlled' design. No saline or inert placebo was used. Historical placebo comparisons from prior Gardasil trials were used for supportive analyses only.",
            "level_description": "Active comparator (qHPV) rather than true placebo control. This design was chosen because withholding an effective vaccine would be ethically problematic, but it limits ability to assess absolute safety profile of 9vHPV."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study described as 'randomized, double-blinded (with in-house blinding)' where in-house blinding was defined as 'blinding of the sponsor's research personnel except the statistician creating the schedule.' Pathology Panel members independently reviewed slides blinded to vaccination group and HPV status.",
            "level_description": "Double-blind design maintained throughout efficacy assessment with appropriate blinding of investigators, participants, and pathology panel reviewers."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Part A (Phase 2b) randomized 1:1:1:1 to low-dose, mid-dose, high-dose 9vHPV or qHPV. Part B (Phase 3) randomized 1:1 to mid-dose 9vHPV or qHPV. 14,215 females randomized in efficacy study: 7,106 to 9vHPV and 7,109 to qHPV. Demographics well-balanced between groups.",
            "level_description": "Rigorous randomization with appropriate stratification and well-balanced demographic characteristics between treatment groups across multiple studies."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Study V503-002 enrolled 2,999 subjects including 1,890 girls and 644 boys ages 9-15 years. Study V503-001 enrolled 14,215 females ages 16-26 years. Total safety database included over 15,000 subjects exposed to 9vHPV across all studies.",
            "level_description": "Large sample sizes for both pediatric (9-15 years) and adolescent/young adult populations, exceeding typical requirements for vaccine licensure."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Median follow-up in V503-001 was approximately 40 months post-Day 1. Subjects followed through at least Month 42. Safety follow-up for SAEs collected from Day 1 through 180 days post-dose 3. V503-002 followed subjects for 12 months.",
            "level_description": "Follow-up of approximately 40 months adequate for detecting efficacy endpoints; SAE monitoring limited to 6 months post-vaccination may miss delayed adverse events."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Separate analyses conducted for: females 16-26 years (V503-001), girls 9-15 years, boys 9-15 years, and women 16-26 years (V503-002). Age subgroup analyses performed for <=20 vs >=21 years. Immunobridging between age groups explicitly conducted.",
            "level_description": "Clear separation and analysis of different age groups with appropriate immunobridging studies to support efficacy claims across age ranges."
          },
          "inclusion_exclusion_criteria": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Detailed inclusion criteria: age-specific requirements, sexual history limits (0-4 partners), normal Pap test history, good physical health. Extensive exclusion criteria: abnormal Pap/biopsy history, immunocompromised status, autoimmune conditions, prior HPV vaccination, pregnancy, coagulation disorders, allergies to vaccine components.",
            "level_description": "Comprehensive and well-defined inclusion/exclusion criteria appropriate for vaccine efficacy study in target population."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Vaccination Report Cards (VRC) used to collect standardized data: oral temperature for 5 days, injection-site reactions (pain, swelling, erythema) for 5 days, all adverse events for 15 days post-vaccination. SAEs collected Day 1 through 180 days post-dose 3. Events classified by MedDRA preferred terms and system organ class.",
            "level_description": "Highly standardized adverse event collection using validated instruments with clear definitions for solicited and unsolicited events."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "SAEs collected regardless of causality from Day 1 through 6 months following last vaccination. Deaths, vaccine-related SAEs, and study procedure-related SAEs collected throughout study. VRC used for active 15-day post-vaccination monitoring. 30-minute observation after each vaccination.",
            "level_description": "Active monitoring for serious adverse events with defined collection periods, though 6-month post-vaccination window may miss late-onset serious events."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "New medical conditions potentially indicative of autoimmune disorders tracked: 57 subjects (0.8%) in 9vHPV group, 47 (0.7%) in qHPV group. Multiple sclerosis cases: 5 in 9vHPV group, 2 in qHPV group. Thyroiditis, rheumatoid arthritis, type 1 diabetes, and other autoimmune conditions documented by preferred term.",
            "level_description": "Systematic tracking of autoimmune and neurological conditions with detailed case narratives, though small numbers limit definitive conclusions."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Pregnancy outcomes monitored with detailed analysis of spontaneous abortions. Subjects with autoimmune conditions excluded at enrollment. No data on immunocompromised patients. PREA waiver granted for children 0-8 years. Study V503-006 evaluated subjects previously vaccinated with qHPV.",
            "level_description": "Pregnancy outcomes and prior vaccination studied, but immunocompromised patients explicitly excluded and no data collected for this vulnerable population."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Pre-specified success criteria: efficacy LB 95% CI >25% for primary endpoint; GMT ratio LB 95% CI >0.67 for non-inferiority. Sensitivity analyses for losses-to-follow-up with imputation of cases. Per-protocol and modified intent-to-treat analyses conducted. Statistical reviewer verified primary analyses supported by submitted data.",
            "level_description": "Rigorous statistical methodology with pre-specified endpoints, appropriate multiplicity adjustments, and comprehensive sensitivity analyses."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "FDA clinical review document provides extensive data tables, case narratives for deaths and SAEs, and detailed efficacy/safety analyses. Individual subject data referenced by allocation numbers. Some data redacted for proprietary information (marked as b)(4)). Financial disclosures provided for investigators.",
            "level_description": "Substantial data transparency through FDA review document, though some proprietary information redacted and raw datasets not publicly available."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "FDA recommends Mini-Sentinel study for autoimmunity-associated diagnoses including MS. CDC/FDA collaboration for Vaccine Safety Datalink study on spontaneous abortions. Merck to sponsor pregnancy registry. VAERS monitoring referenced from prior qHPV experience (56 million doses, 21,194 reports).",
            "level_description": "Comprehensive post-marketing surveillance plan including multiple FDA-sponsored studies, manufacturer registry, and ongoing VAERS monitoring."
          },
          "conflict_of_interest": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Five investigators received Significant Payments from Merck for symposia, consulting, medical education, research, speaker fees, and advisory board participation. Financial disclosure information provided per FDA guidance. Primary endpoint case analysis showed only one case from sites with disclosed financial interests.",
            "level_description": "Financial conflicts disclosed per regulatory requirements; some investigators received significant payments but bias mitigation measures in place through blinding."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "11 deaths reported (5 in 9vHPV, 5 in qHPV during efficacy study, 1 in 9vHPV after cutoff date). Causes: automobile accidents (2), suicide (1), leukemia (2), airplane crash (1), cerebral hemorrhage (1), gunshot trauma (1), stomach cancer (1), sudden death (1), septic shock (1). None deemed vaccine-related.",
            "level_description": "Complete reporting of all deaths with detailed narratives, causality assessment, and balanced distribution between treatment groups."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The Gardasil 9 clinical trial program demonstrates a well-designed pivotal efficacy study (V503-001) with robust randomization, appropriate blinding, and large sample sizes. Primary efficacy of 96.7% against HPV 31/33/45/52/58-related high-grade lesions was demonstrated. Key limitations include: use of active comparator (qHPV) rather than true placebo which limits absolute safety assessment, exclusion of immunocompromised populations, and numerical imbalances in multiple sclerosis cases (5 vs 2) and spontaneous abortions requiring post-marketing surveillance. The safety profile was generally similar to licensed qHPV with higher injection-site reactions. Comprehensive post-marketing commitments address residual safety questions."
        }
      },
      "trial_pt": {
        "vaccine_id": "hpv_gardasil9",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo V503-001 foi randomizado, duplo-cego, controlado com Gardasil (qHPV) como comparador ativo, n√£o um placebo verdadeiro. O documento afirma desenho 'controlado por qHPV'. Nenhum placebo salino ou inerte foi usado. Compara√ß√µes hist√≥ricas de placebo de ensaios anteriores do Gardasil foram usadas apenas para an√°lises de suporte.",
            "level_description": "Comparador ativo (qHPV) em vez de controle placebo verdadeiro. Este desenho foi escolhido porque reter uma vacina eficaz seria eticamente problem√°tico, mas limita a capacidade de avaliar o perfil de seguran√ßa absoluto da 9vHPV."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O estudo foi descrito como 'randomizado, duplo-cego (com cegamento interno)' onde o cegamento interno foi definido como 'cegamento do pessoal de pesquisa do patrocinador, exceto o estat√≠stico que cria o cronograma.' Os membros do Painel de Patologia revisaram as l√¢minas de forma independente, cegos ao grupo de vacina√ß√£o e status de HPV.",
            "level_description": "Desenho duplo-cego mantido ao longo da avalia√ß√£o de efic√°cia com cegamento apropriado de investigadores, participantes e revisores do painel de patologia."
          },
          "randomization": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Parte A (Fase 2b) randomizou 1:1:1:1 para dose baixa, dose m√©dia, dose alta de 9vHPV ou qHPV. Parte B (Fase 3) randomizou 1:1 para dose m√©dia de 9vHPV ou qHPV. 14.215 mulheres randomizadas no estudo de efic√°cia: 7.106 para 9vHPV e 7.109 para qHPV. Demografia bem balanceada entre os grupos.",
            "level_description": "Randomiza√ß√£o rigorosa com estratifica√ß√£o apropriada e caracter√≠sticas demogr√°ficas bem balanceadas entre os grupos de tratamento em m√∫ltiplos estudos."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "O Estudo V503-002 recrutou 2.999 participantes incluindo 1.890 meninas e 644 meninos de 9-15 anos. O Estudo V503-001 recrutou 14.215 mulheres de 16-26 anos. O banco de dados total de seguran√ßa incluiu mais de 15.000 participantes expostos a 9vHPV em todos os estudos.",
            "level_description": "Grandes tamanhos de amostra para popula√ß√µes pedi√°tricas (9-15 anos) e adolescentes/adultos jovens, excedendo os requisitos t√≠picos para licenciamento de vacinas."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O acompanhamento mediano no V503-001 foi de aproximadamente 40 meses ap√≥s o Dia 1. Participantes acompanhados pelo menos at√© o M√™s 42. Acompanhamento de seguran√ßa para EAGs coletado do Dia 1 at√© 180 dias ap√≥s a dose 3. V503-002 acompanhou participantes por 12 meses.",
            "level_description": "Acompanhamento de aproximadamente 40 meses adequado para detectar desfechos de efic√°cia; monitoramento de EAGs limitado a 6 meses p√≥s-vacina√ß√£o pode n√£o detectar eventos adversos tardios."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "An√°lises separadas conduzidas para: mulheres de 16-26 anos (V503-001), meninas de 9-15 anos, meninos de 9-15 anos e mulheres de 16-26 anos (V503-002). An√°lises de subgrupos et√°rios realizadas para <=20 vs >=21 anos. Imunobridging entre grupos et√°rios conduzido explicitamente.",
            "level_description": "Separa√ß√£o clara e an√°lise de diferentes grupos et√°rios com estudos de imunobridging apropriados para apoiar alega√ß√µes de efic√°cia em todas as faixas et√°rias."
          },
          "inclusion_exclusion_criteria": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Crit√©rios de inclus√£o detalhados: requisitos espec√≠ficos por idade, limites de hist√≥rico sexual (0-4 parceiros), hist√≥rico normal de Papanicolau, boa sa√∫de f√≠sica. Crit√©rios de exclus√£o extensos: hist√≥rico anormal de Papanicolau/bi√≥psia, status imunocomprometido, condi√ß√µes autoimunes, vacina√ß√£o pr√©via contra HPV, gravidez, dist√∫rbios de coagula√ß√£o, alergias a componentes da vacina.",
            "level_description": "Crit√©rios de inclus√£o/exclus√£o abrangentes e bem definidos, apropriados para estudo de efic√°cia de vacina na popula√ß√£o-alvo."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Cart√µes de Relat√≥rio de Vacina√ß√£o (VRC) usados para coletar dados padronizados: temperatura oral por 5 dias, rea√ß√µes no local da inje√ß√£o (dor, incha√ßo, eritema) por 5 dias, todos os eventos adversos por 15 dias p√≥s-vacina√ß√£o. EAGs coletados do Dia 1 at√© 180 dias ap√≥s a dose 3. Eventos classificados por termos preferenciais MedDRA e classe de sistema de √≥rg√£os.",
            "level_description": "Coleta de eventos adversos altamente padronizada usando instrumentos validados com defini√ß√µes claras para eventos solicitados e n√£o solicitados."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "EAGs coletados independentemente de causalidade do Dia 1 at√© 6 meses ap√≥s a √∫ltima vacina√ß√£o. Mortes, EAGs relacionados √† vacina e EAGs relacionados a procedimentos do estudo coletados ao longo do estudo. VRC usado para monitoramento ativo de 15 dias p√≥s-vacina√ß√£o. Observa√ß√£o de 30 minutos ap√≥s cada vacina√ß√£o.",
            "level_description": "Monitoramento ativo de eventos adversos graves com per√≠odos de coleta definidos, embora a janela de 6 meses p√≥s-vacina√ß√£o possa n√£o detectar eventos graves de in√≠cio tardio."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Novas condi√ß√µes m√©dicas potencialmente indicativas de dist√∫rbios autoimunes rastreadas: 57 participantes (0,8%) no grupo 9vHPV, 47 (0,7%) no grupo qHPV. Casos de esclerose m√∫ltipla: 5 no grupo 9vHPV, 2 no grupo qHPV. Tireoidite, artrite reumatoide, diabetes tipo 1 e outras condi√ß√µes autoimunes documentadas por termo preferencial.",
            "level_description": "Rastreamento sistem√°tico de condi√ß√µes autoimunes e neurol√≥gicas com narrativas detalhadas de casos, embora n√∫meros pequenos limitem conclus√µes definitivas."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Desfechos de gravidez monitorados com an√°lise detalhada de abortos espont√¢neos. Participantes com condi√ß√µes autoimunes exclu√≠dos na inclus√£o. Nenhum dado sobre pacientes imunocomprometidos. Isen√ß√£o PREA concedida para crian√ßas de 0-8 anos. O Estudo V503-006 avaliou participantes previamente vacinados com qHPV.",
            "level_description": "Desfechos de gravidez e vacina√ß√£o pr√©via estudados, mas pacientes imunocomprometidos explicitamente exclu√≠dos e nenhum dado coletado para esta popula√ß√£o vulner√°vel."
          },
          "statistical_analysis": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Crit√©rios de sucesso pr√©-especificados: LI do IC 95% da efic√°cia >25% para desfecho prim√°rio; raz√£o GMT LI do IC 95% >0,67 para n√£o inferioridade. An√°lises de sensibilidade para perdas de acompanhamento com imputa√ß√£o de casos. An√°lises por protocolo e inten√ß√£o de tratar modificada conduzidas. Revisor estat√≠stico verificou que an√°lises prim√°rias s√£o apoiadas pelos dados submetidos.",
            "level_description": "Metodologia estat√≠stica rigorosa com desfechos pr√©-especificados, ajustes de multiplicidade apropriados e an√°lises de sensibilidade abrangentes."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O documento de revis√£o cl√≠nica da FDA fornece tabelas de dados extensas, narrativas de casos para mortes e EAGs, e an√°lises detalhadas de efic√°cia/seguran√ßa. Dados de participantes individuais referenciados por n√∫meros de aloca√ß√£o. Alguns dados redigidos por informa√ß√£o propriet√°ria (marcados como b)(4)). Declara√ß√µes financeiras fornecidas para investigadores.",
            "level_description": "Transpar√™ncia substancial de dados atrav√©s do documento de revis√£o da FDA, embora algumas informa√ß√µes propriet√°rias estejam redigidas e conjuntos de dados brutos n√£o estejam dispon√≠veis publicamente."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "A FDA recomenda estudo Mini-Sentinel para diagn√≥sticos associados a autoimunidade incluindo EM. Colabora√ß√£o CDC/FDA para estudo Vaccine Safety Datalink sobre abortos espont√¢neos. Merck patrocinar√° registro de gravidez. Monitoramento VAERS referenciado da experi√™ncia pr√©via com qHPV (56 milh√µes de doses, 21.194 relatos).",
            "level_description": "Plano abrangente de vigil√¢ncia p√≥s-comercializa√ß√£o incluindo m√∫ltiplos estudos patrocinados pela FDA, registro do fabricante e monitoramento VAERS cont√≠nuo."
          },
          "conflict_of_interest": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Cinco investigadores receberam Pagamentos Significativos da Merck por simp√≥sios, consultoria, educa√ß√£o m√©dica, pesquisa, honor√°rios de palestrante e participa√ß√£o em conselhos consultivos. Informa√ß√µes de declara√ß√£o financeira fornecidas conforme orienta√ß√£o da FDA. A an√°lise de casos do desfecho prim√°rio mostrou apenas um caso de sites com interesses financeiros declarados.",
            "level_description": "Conflitos financeiros declarados conforme requisitos regulat√≥rios; alguns investigadores receberam pagamentos significativos, mas medidas de mitiga√ß√£o de vi√©s implementadas atrav√©s de cegamento."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "11 mortes relatadas (5 em 9vHPV, 5 em qHPV durante estudo de efic√°cia, 1 em 9vHPV ap√≥s data de corte). Causas: acidentes automobil√≠sticos (2), suic√≠dio (1), leucemia (2), acidente de avi√£o (1), hemorragia cerebral (1), trauma por arma de fogo (1), c√¢ncer de est√¥mago (1), morte s√∫bita (1), choque s√©ptico (1). Nenhuma considerada relacionada √† vacina.",
            "level_description": "Relato completo de todas as mortes com narrativas detalhadas, avalia√ß√£o de causalidade e distribui√ß√£o equilibrada entre grupos de tratamento."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de ensaios cl√≠nicos da Gardasil 9 demonstra um estudo pivotal de efic√°cia (V503-001) bem desenhado com randomiza√ß√£o robusta, cegamento apropriado e grandes tamanhos de amostra. Efic√°cia prim√°ria de 96,7% contra les√µes de alto grau relacionadas ao HPV 31/33/45/52/58 foi demonstrada. As principais limita√ß√µes incluem: uso de comparador ativo (qHPV) em vez de placebo verdadeiro, o que limita a avalia√ß√£o de seguran√ßa absoluta, exclus√£o de popula√ß√µes imunocomprometidas e desequil√≠brios num√©ricos em casos de esclerose m√∫ltipla (5 vs 2) e abortos espont√¢neos que requerem vigil√¢ncia p√≥s-comercializa√ß√£o. O perfil de seguran√ßa foi geralmente similar ao qHPV licenciado, com rea√ß√µes mais intensas no local da inje√ß√£o. Compromissos abrangentes de p√≥s-comercializa√ß√£o abordam quest√µes residuais de seguran√ßa."
        }
      },
      "safety_en": {
        "vaccine_id": "hpv_gardasil9",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Extensive pediatric safety database: Study V503-002 enrolled 1,890 girls and 644 boys ages 9-15 years. Study V503-005 enrolled 1,241 children ages 11-15 years. Study V503-007 enrolled 1,054 children ages 11-15 years. Total pediatric exposure across studies exceeds 3,500 subjects, providing robust safety data for the target pediatric population."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Safety follow-up periods: solicited adverse reactions collected for 15 days post-vaccination via Vaccination Report Cards. SAEs collected from Day 1 through 180 days (6 months) following last vaccination. Deaths and vaccine-related SAEs collected throughout entire study period. V503-001 median follow-up approximately 40 months for new medical conditions. Six-month SAE window adequate for acute reactions but may miss delayed autoimmune or neurological events."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active comparator design: Gardasil (qHPV) used as control rather than inert placebo. Both vaccines contain aluminum adjuvant (AAHS - 500 mcg in 9vHPV vs 225 mcg in qHPV). This design limits assessment of absolute safety profile and adjuvant-related effects. Historical placebo comparisons from prior qHPV studies used only for supportive analyses. The qHPV comparator is appropriate ethically but masks potential effects common to both vaccines."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Comprehensive active surveillance system: Vaccination Report Cards for standardized collection of injection-site reactions (pain, swelling, erythema) and oral temperature for 5 days post-vaccination; all adverse events for 15 days post-vaccination. 30-minute post-vaccination observation period. SAEs actively collected regardless of causality. New medical conditions tracked throughout study. Data Safety Monitoring Board reviewed safety data."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Neurological adverse events documented: 7 cases of multiple sclerosis (5 in 9vHPV, 2 in qHPV). Detailed case narratives provided including symptom onset timing relative to vaccination. Hypoesthesia/paresthesia cases evaluated (AN 10888, AN 74925). Headache and dizziness tracked as systemic adverse reactions. MS incidence rate in 9vHPV group (20.7/100,000 person-years) on upper end of general population range. The numerical imbalance in MS cases noted as requiring post-marketing surveillance."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Limited vulnerable population data: Pregnancy outcomes actively monitored with concerning signal - spontaneous abortion rate 19.1% in 9vHPV recipients who became pregnant within 30 days of vaccination vs 9.6% outside that window and vs 8.0% in qHPV group. Immunocompromised patients excluded from all studies. No data on subjects with autoimmune conditions (exclusion criterion). Prior qHPV recipients studied in V503-006 showed similar safety profile. PREA waiver granted for ages 0-8 years."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "FDA review document provides detailed safety tables by system organ class, severity, and time since vaccination. Individual SAE narratives with allocation numbers provided. All deaths documented with causality assessment. Autoimmune conditions tabulated by preferred term. Some data redacted (marked b)(4)) for proprietary information. GCP compliance issues at two sites led to data exclusion with sensitivity analyses demonstrating minimal impact. Financial disclosures provided."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Robust post-marketing safety commitments: FDA-sponsored Mini-Sentinel study for autoimmunity-associated diagnoses including MS. FDA/CDC collaboration for Vaccine Safety Datalink study on spontaneous abortions. Merck to sponsor pregnancy registry to evaluate pregnancy outcomes. VAERS monitoring ongoing based on qHPV experience (56 million doses distributed, 21,194 adverse event reports, 92% non-serious). Post-marketing safety studies specifically designed to address signals identified in clinical trials."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The Gardasil 9 safety profile is based on a large clinical database (>15,000 subjects exposed to 9vHPV) with systematic adverse event collection. Key safety findings: injection-site reactions more common with 9vHPV (90.2%) vs qHPV (84.0%); systemic reactions similar between groups. Safety signals requiring monitoring: numerical imbalance in MS cases (5 vs 2, rates 20.7 vs 8.3 per 100,000 person-years); elevated spontaneous abortion rate (19.1%) when conception occurs within 30 days of vaccination. Limitations include: active comparator design preventing true placebo comparison, exclusion of immunocompromised populations, and 6-month SAE collection window. Post-marketing surveillance adequately designed to address residual safety questions."
        }
      },
      "safety_pt": {
        "vaccine_id": "hpv_gardasil9",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Extenso banco de dados de seguran√ßa pedi√°trica: O Estudo V503-002 recrutou 1.890 meninas e 644 meninos de 9-15 anos. O Estudo V503-005 recrutou 1.241 crian√ßas de 11-15 anos. O Estudo V503-007 recrutou 1.054 crian√ßas de 11-15 anos. A exposi√ß√£o pedi√°trica total nos estudos excede 3.500 participantes, fornecendo dados de seguran√ßa robustos para a popula√ß√£o pedi√°trica-alvo."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Per√≠odos de acompanhamento de seguran√ßa: rea√ß√µes adversas solicitadas coletadas por 15 dias p√≥s-vacina√ß√£o via Cart√µes de Relat√≥rio de Vacina√ß√£o. EAGs coletados do Dia 1 at√© 180 dias (6 meses) ap√≥s a √∫ltima vacina√ß√£o. Mortes e EAGs relacionados √† vacina coletados durante todo o per√≠odo do estudo. V503-001 acompanhamento mediano de aproximadamente 40 meses para novas condi√ß√µes m√©dicas. Janela de EAG de seis meses adequada para rea√ß√µes agudas, mas pode n√£o detectar eventos autoimunes ou neurol√≥gicos tardios."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Desenho com comparador ativo: Gardasil (qHPV) usado como controle em vez de placebo inerte. Ambas as vacinas cont√™m adjuvante de alum√≠nio (AAHS - 500 mcg em 9vHPV vs 225 mcg em qHPV). Este desenho limita a avalia√ß√£o do perfil de seguran√ßa absoluto e efeitos relacionados ao adjuvante. Compara√ß√µes hist√≥ricas de placebo de estudos anteriores de qHPV usadas apenas para an√°lises de suporte. O comparador qHPV √© eticamente apropriado, mas mascara efeitos potenciais comuns a ambas as vacinas."
          },
          "active_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Sistema de vigil√¢ncia ativa abrangente: Cart√µes de Relat√≥rio de Vacina√ß√£o para coleta padronizada de rea√ß√µes no local da inje√ß√£o (dor, incha√ßo, eritema) e temperatura oral por 5 dias p√≥s-vacina√ß√£o; todos os eventos adversos por 15 dias p√≥s-vacina√ß√£o. Per√≠odo de observa√ß√£o de 30 minutos p√≥s-vacina√ß√£o. EAGs ativamente coletados independentemente de causalidade. Novas condi√ß√µes m√©dicas rastreadas ao longo do estudo. Comit√™ de Monitoramento de Seguran√ßa de Dados revisou dados de seguran√ßa."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Eventos adversos neurol√≥gicos documentados: 7 casos de esclerose m√∫ltipla (5 em 9vHPV, 2 em qHPV). Narrativas detalhadas de casos fornecidas incluindo tempo de in√≠cio dos sintomas em rela√ß√£o √† vacina√ß√£o. Casos de hipoestesia/parestesia avaliados (AN 10888, AN 74925). Cefaleia e tontura rastreadas como rea√ß√µes adversas sist√™micas. Taxa de incid√™ncia de EM no grupo 9vHPV (20,7/100.000 pessoas-ano) no limite superior da faixa da popula√ß√£o geral. O desequil√≠brio num√©rico em casos de EM observado como requerendo vigil√¢ncia p√≥s-comercializa√ß√£o."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados limitados de popula√ß√µes vulner√°veis: Desfechos de gravidez ativamente monitorados com sinal preocupante - taxa de aborto espont√¢neo de 19,1% em receptoras de 9vHPV que engravidaram dentro de 30 dias da vacina√ß√£o vs 9,6% fora dessa janela e vs 8,0% no grupo qHPV. Pacientes imunocomprometidos exclu√≠dos de todos os estudos. Nenhum dado sobre participantes com condi√ß√µes autoimunes (crit√©rio de exclus√£o). Receptores anteriores de qHPV estudados no V503-006 mostraram perfil de seguran√ßa similar. Isen√ß√£o PREA concedida para idades de 0-8 anos."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O documento de revis√£o da FDA fornece tabelas detalhadas de seguran√ßa por classe de sistema de √≥rg√£os, gravidade e tempo desde a vacina√ß√£o. Narrativas individuais de EAGs com n√∫meros de aloca√ß√£o fornecidas. Todas as mortes documentadas com avalia√ß√£o de causalidade. Condi√ß√µes autoimunes tabuladas por termo preferencial. Alguns dados redigidos (marcados b)(4)) por informa√ß√£o propriet√°ria. Problemas de conformidade GCP em dois sites levaram √† exclus√£o de dados com an√°lises de sensibilidade demonstrando impacto m√≠nimo. Declara√ß√µes financeiras fornecidas."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Compromissos robustos de seguran√ßa p√≥s-comercializa√ß√£o: Estudo Mini-Sentinel patrocinado pela FDA para diagn√≥sticos associados a autoimunidade incluindo EM. Colabora√ß√£o FDA/CDC para estudo Vaccine Safety Datalink sobre abortos espont√¢neos. Merck patrocinar√° registro de gravidez para avaliar desfechos gestacionais. Monitoramento VAERS em andamento baseado na experi√™ncia com qHPV (56 milh√µes de doses distribu√≠das, 21.194 relatos de eventos adversos, 92% n√£o graves). Estudos de seguran√ßa p√≥s-comercializa√ß√£o especificamente desenhados para abordar sinais identificados em ensaios cl√≠nicos."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O perfil de seguran√ßa da Gardasil 9 √© baseado em um grande banco de dados cl√≠nico (>15.000 participantes expostos a 9vHPV) com coleta sistem√°tica de eventos adversos. Principais achados de seguran√ßa: rea√ß√µes no local da inje√ß√£o mais comuns com 9vHPV (90,2%) vs qHPV (84,0%); rea√ß√µes sist√™micas similares entre grupos. Sinais de seguran√ßa que requerem monitoramento: desequil√≠brio num√©rico em casos de EM (5 vs 2, taxas de 20,7 vs 8,3 por 100.000 pessoas-ano); taxa elevada de aborto espont√¢neo (19,1%) quando a concep√ß√£o ocorre dentro de 30 dias da vacina√ß√£o. As limita√ß√µes incluem: desenho com comparador ativo impedindo compara√ß√£o verdadeira com placebo, exclus√£o de popula√ß√µes imunocomprometidas e janela de coleta de EAG de 6 meses. A vigil√¢ncia p√≥s-comercializa√ß√£o est√° adequadamente desenhada para abordar quest√µes residuais de seguran√ßa."
        }
      }
    },
    {
      "id": "men4_menactra",
      "name": "Menactra",
      "type": "MenACWY",
      "manufacturer": "Sanofi Pasteur",
      "description": "Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.",
      "sources": [
        "men4_menactra_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "men4_menactra",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The primary safety studies were randomized, active-controlled trials comparing Menactra to Menomune (another meningococcal polysaccharide vaccine). For infants 9-12 months, control groups received other childhood vaccines without Menactra. No true placebo (saline) control was used in any pivotal trial.",
            "level_description": "No placebo-controlled trials were conducted. All comparisons were against active comparators (Menomune vaccine) or other childhood vaccines. This limits the ability to assess true vaccine-attributable adverse events."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The adolescent Td concomitant study and adult Typhim Vi study were double-blind. However, for the primary safety studies comparing Menactra to Menomune, the document states: 'As the route of administration differed for the two vaccines (Menactra given intramuscularly, Menomune given subcutaneously), study personnel collecting the safety data differed from personnel administering the vaccine.'",
            "level_description": "Observer-blinded design was used in main trials due to different administration routes, but not full double-blinding. Some concomitant administration studies were double-blind."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The three primary safety studies were randomized, active-controlled trials. Multiple studies described as 'randomized, parallel group' or 'double-blind, randomized, controlled trial.'",
            "level_description": "Randomization was employed in the primary clinical trials comparing Menactra to Menomune and in concomitant vaccine administration studies."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Children 9-12 months: 3,721 participants received Menactra, with control group of 997 children. Children 2-10 years: Menactra N=1,713 vs Menomune N=1,519. Adolescents 11-18 years: Menactra N=2,270 vs Menomune N=972. Total 10,057 Menactra recipients ages 2-55 years.",
            "level_description": "Sample sizes were substantial across pediatric age groups, with thousands of participants in each category, adequate for detecting common adverse events."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Participants were monitored for 20 or 30 minutes for immediate reactions, depending on the study. Solicited reactions recorded for 7 consecutive days. Participants were monitored for 28 days (30 days for infants) for unsolicited adverse events and for 6 months post-vaccination for ER visits, unexpected physician visits, and serious adverse events.",
            "level_description": "Active solicited monitoring was only 7 days. Six-month follow-up was conducted but via telephone interview for SAEs and ER visits only. This duration may miss delayed adverse events."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety and immunogenicity data presented separately for: 9-12 months, 2-10 years (with subset 2-3 years and 4-10 years), 11-18 years, 18-55 years. Tables 1-4 present solicited adverse reactions by specific age groups.",
            "level_description": "Comprehensive stratification by age groups with detailed safety tables for each population, allowing age-specific risk assessment."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Document does not explicitly list inclusion/exclusion criteria for clinical trials. Contraindications listed: 'Severe allergic reaction after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component.'",
            "level_description": "Detailed inclusion/exclusion criteria for the trials are not provided in the package insert. Only contraindications for use are specified."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse events were systematically collected via diary cards with defined severity grades. Grade definitions provided (e.g., Pain Grade 2: interferes with normal activities, Grade 3: disabling). Both local (tenderness, erythema, swelling, pain, redness, induration) and systemic (irritability, fever, headache, fatigue, etc.) reactions were standardized.",
            "level_description": "Standardized severity grading scales were used for solicited adverse events with clear definitions for each grade level."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse events were reported during a 6-month time period following vaccinations. SAEs occurred at rates of 0.6-2.5% depending on age group. Information regarding adverse events in the 6-month period was obtained via scripted telephone interview.",
            "level_description": "SAEs were monitored for 6 months but via telephone interview rather than active clinical follow-up. SAE rates reported but without detailed breakdown of event types in the main text."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "GBS warning included with post-marketing retrospective cohort study evaluating 9,578,688 individuals ages 11-18, with 1,431,906 receiving Menactra. Of 72 confirmed GBS cases, none received Menactra within 42 days prior to symptom onset. Attributable risk estimated 0-5 additional cases per 1,000,000 vaccinees within 6 weeks. Post-marketing reports include: GBS, acute disseminated encephalomyelitis, transverse myelitis, facial palsy, convulsion.",
            "level_description": "Post-marketing surveillance specifically evaluated GBS risk with large retrospective cohort study. Neurological events monitored and reported in post-marketing experience section."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section on Altered Immunocompetence states some individuals may have reduced immune responses. Complement deficiency discussed. Pregnancy registry mentioned but no controlled studies in pregnant women. Lactation data not available. Not approved for infants under 9 months or adults over 55 years.",
            "level_description": "Limited data on immunocompromised populations. Pregnancy registry exists but no well-controlled studies. Specific vulnerable populations (complement deficiency) mentioned but not formally studied."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Non-inferiority analyses conducted using 10% non-inferiority margin and one-sided Type I error rate of 0.025 or 0.05. 95% confidence intervals provided for proportions (Clopper-Pearson Exact method) and GMTs (normal approximation). Statistical significance denoted at p<0.05 using Chi Square test.",
            "level_description": "Appropriate statistical methods used including non-inferiority analyses, confidence intervals, and significance testing with specified error rates."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Detailed tables presenting percentages of adverse reactions by severity grade. Immunogenicity data with GMTs and confidence intervals. Study participant numbers clearly stated. References provided for published studies including CDC MMWR and Harvard Medical School GBS study.",
            "level_description": "Comprehensive safety and immunogenicity data presented in tables with confidence intervals. Key studies referenced. However, full raw data not accessible in package insert."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 Post-Marketing Experience lists adverse events by system organ class including: lymphadenopathy, hypersensitivity reactions, GBS, paraesthesia, syncope, convulsion, facial palsy, ADEM, transverse myelitis, myalgia, large injection site reactions. Post-marketing safety study on GBS conducted. VAERS reporting encouraged.",
            "level_description": "Post-marketing surveillance system in place with voluntary adverse event reporting. Large retrospective GBS study conducted. Multiple serious events identified post-marketing."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not provide information about conflicts of interest for clinical trial investigators or funding sources beyond Sanofi Pasteur Inc. as manufacturer.",
            "level_description": "No disclosure of conflicts of interest or funding relationships for clinical trial investigators provided in the package insert."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not report all-cause mortality data from clinical trials. Only mentions SAE rates ranging from 0.6% to 3.6% without mortality breakdown.",
            "level_description": "All-cause mortality was not reported in the clinical trials section. Deaths, if any occurred, were not detailed in the safety data."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Menactra clinical trials demonstrate adequate methodology with randomized, active-controlled design and substantial sample sizes across age groups. Key limitations include lack of true placebo controls (all comparisons against another meningococcal vaccine), relatively short active safety monitoring (7 days solicited, 6 months for SAEs via telephone), and absence of mortality data. Strengths include comprehensive age stratification, standardized adverse event collection, post-marketing GBS surveillance study, and transparent statistical analysis. The trials support immunogenicity but the active-comparator design limits absolute safety assessment."
        }
      },
      "trial_pt": {
        "vaccine_id": "men4_menactra",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os estudos prim√°rios de seguran√ßa foram ensaios randomizados e controlados por comparador ativo, comparando Menactra com Menomune (outra vacina polissacar√≠dica meningoc√≥cica). Para beb√™s de 9-12 meses, os grupos controle receberam outras vacinas infantis sem Menactra. Nenhum placebo verdadeiro (solu√ß√£o salina) foi utilizado em nenhum ensaio pivotal.",
            "level_description": "Nenhum ensaio controlado por placebo foi realizado. Todas as compara√ß√µes foram feitas contra comparadores ativos (vacina Menomune) ou outras vacinas infantis. Isso limita a capacidade de avaliar eventos adversos verdadeiramente atribu√≠veis √† vacina."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo concomitante de Td em adolescentes e o estudo de Typhim Vi em adultos foram duplo-cegos. No entanto, para os estudos prim√°rios de seguran√ßa comparando Menactra com Menomune, o documento afirma: 'Como a via de administra√ß√£o diferia entre as duas vacinas (Menactra administrada por via intramuscular, Menomune por via subcut√¢nea), a equipe que coletou os dados de seguran√ßa foi diferente da equipe que administrou a vacina.'",
            "level_description": "O desenho com observador cego foi utilizado nos ensaios principais devido √†s diferentes vias de administra√ß√£o, mas n√£o houve cegamento duplo completo. Alguns estudos de administra√ß√£o concomitante foram duplo-cegos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os tr√™s estudos prim√°rios de seguran√ßa foram ensaios randomizados e controlados por comparador ativo. M√∫ltiplos estudos foram descritos como 'randomizados, grupos paralelos' ou 'ensaio cl√≠nico duplo-cego, randomizado e controlado.'",
            "level_description": "A randomiza√ß√£o foi empregada nos ensaios cl√≠nicos prim√°rios comparando Menactra com Menomune e nos estudos de administra√ß√£o concomitante de vacinas."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crian√ßas de 9-12 meses: 3.721 participantes receberam Menactra, com grupo controle de 997 crian√ßas. Crian√ßas de 2-10 anos: Menactra N=1.713 vs Menomune N=1.519. Adolescentes de 11-18 anos: Menactra N=2.270 vs Menomune N=972. Total de 10.057 receptores de Menactra com idades entre 2-55 anos.",
            "level_description": "Os tamanhos amostrais foram substanciais em todas as faixas et√°rias pedi√°tricas, com milhares de participantes em cada categoria, adequados para detectar eventos adversos comuns."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os participantes foram monitorados por 20 ou 30 minutos para rea√ß√µes imediatas, dependendo do estudo. Rea√ß√µes solicitadas foram registradas por 7 dias consecutivos. Os participantes foram monitorados por 28 dias (30 dias para beb√™s) para eventos adversos n√£o solicitados e por 6 meses ap√≥s a vacina√ß√£o para visitas ao pronto-socorro, consultas m√©dicas inesperadas e eventos adversos graves.",
            "level_description": "O monitoramento ativo solicitado foi de apenas 7 dias. O acompanhamento de 6 meses foi realizado, mas via entrevista telef√¥nica apenas para EAGs e visitas ao pronto-socorro. Essa dura√ß√£o pode n√£o detectar eventos adversos tardios."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados de seguran√ßa e imunogenicidade apresentados separadamente para: 9-12 meses, 2-10 anos (com subgrupos de 2-3 anos e 4-10 anos), 11-18 anos, 18-55 anos. As Tabelas 1-4 apresentam rea√ß√µes adversas solicitadas por faixas et√°rias espec√≠ficas.",
            "level_description": "Estratifica√ß√£o abrangente por faixas et√°rias com tabelas de seguran√ßa detalhadas para cada popula√ß√£o, permitindo avalia√ß√£o de risco espec√≠fica por idade."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento n√£o lista explicitamente os crit√©rios de inclus√£o/exclus√£o para os ensaios cl√≠nicos. As contraindica√ß√µes listadas s√£o: 'Rea√ß√£o al√©rgica grave ap√≥s dose anterior de vacina contendo polissacar√≠deo capsular meningoc√≥cico, toxoide dift√©rico ou CRM197, ou a qualquer componente.'",
            "level_description": "Crit√©rios detalhados de inclus√£o/exclus√£o para os ensaios n√£o s√£o fornecidos na bula. Apenas contraindica√ß√µes para uso s√£o especificadas."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos adversos solicitados foram sistematicamente coletados via cart√µes-di√°rio com graus de gravidade definidos. Defini√ß√µes de graus fornecidas (ex.: Dor Grau 2: interfere nas atividades normais, Grau 3: incapacitante). Tanto rea√ß√µes locais (sensibilidade, eritema, incha√ßo, dor, vermelhid√£o, endurecimento) quanto sist√™micas (irritabilidade, febre, dor de cabe√ßa, fadiga, etc.) foram padronizadas.",
            "level_description": "Escalas padronizadas de gradua√ß√£o de gravidade foram utilizadas para eventos adversos solicitados com defini√ß√µes claras para cada n√≠vel de gradua√ß√£o."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos graves foram relatados durante um per√≠odo de 6 meses ap√≥s as vacina√ß√µes. EAGs ocorreram em taxas de 0,6-2,5% dependendo da faixa et√°ria. Informa√ß√µes sobre eventos adversos no per√≠odo de 6 meses foram obtidas via entrevista telef√¥nica roteirizada.",
            "level_description": "EAGs foram monitorados por 6 meses, mas via entrevista telef√¥nica em vez de acompanhamento cl√≠nico ativo. Taxas de EAG relatadas, mas sem detalhamento dos tipos de eventos no texto principal."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Alerta sobre SGB inclu√≠do com estudo de coorte retrospectivo p√≥s-comercializa√ß√£o avaliando 9.578.688 indiv√≠duos de 11-18 anos, com 1.431.906 recebendo Menactra. Dos 72 casos confirmados de SGB, nenhum recebeu Menactra nos 42 dias anteriores ao in√≠cio dos sintomas. Risco atribu√≠vel estimado de 0-5 casos adicionais por 1.000.000 de vacinados em 6 semanas. Relatos p√≥s-comercializa√ß√£o incluem: SGB, encefalomielite disseminada aguda, mielite transversa, paralisia facial, convuls√£o.",
            "level_description": "A vigil√¢ncia p√≥s-comercializa√ß√£o avaliou especificamente o risco de SGB com grande estudo de coorte retrospectivo. Eventos neurol√≥gicos monitorados e relatados na se√ß√£o de experi√™ncia p√≥s-comercializa√ß√£o."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o sobre Imunocompet√™ncia Alterada afirma que alguns indiv√≠duos podem ter respostas imunes reduzidas. Defici√™ncia de complemento discutida. Registro de gravidez mencionado, mas sem estudos controlados em mulheres gr√°vidas. Dados de lacta√ß√£o n√£o dispon√≠veis. N√£o aprovada para beb√™s menores de 9 meses ou adultos acima de 55 anos.",
            "level_description": "Dados limitados sobre popula√ß√µes imunocomprometidas. Registro de gravidez existe, mas sem estudos bem controlados. Popula√ß√µes vulner√°veis espec√≠ficas (defici√™ncia de complemento) mencionadas, mas n√£o estudadas formalmente."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "An√°lises de n√£o inferioridade realizadas utilizando margem de n√£o inferioridade de 10% e taxa de erro Tipo I unilateral de 0,025 ou 0,05. Intervalos de confian√ßa de 95% fornecidos para propor√ß√µes (m√©todo Exato de Clopper-Pearson) e TMGs (aproxima√ß√£o normal). Signific√¢ncia estat√≠stica denotada em p<0,05 usando teste Qui-Quadrado.",
            "level_description": "M√©todos estat√≠sticos apropriados utilizados, incluindo an√°lises de n√£o inferioridade, intervalos de confian√ßa e testes de signific√¢ncia com taxas de erro especificadas."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Tabelas detalhadas apresentando porcentagens de rea√ß√µes adversas por grau de gravidade. Dados de imunogenicidade com TMGs e intervalos de confian√ßa. N√∫mero de participantes do estudo claramente declarado. Refer√™ncias fornecidas para estudos publicados, incluindo CDC MMWR e estudo de SGB da Harvard Medical School.",
            "level_description": "Dados abrangentes de seguran√ßa e imunogenicidade apresentados em tabelas com intervalos de confian√ßa. Estudos principais referenciados. No entanto, dados brutos completos n√£o s√£o acess√≠veis na bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 Experi√™ncia P√≥s-Comercializa√ß√£o lista eventos adversos por classe de sistema de √≥rg√£os, incluindo: linfadenopatia, rea√ß√µes de hipersensibilidade, SGB, parestesia, s√≠ncope, convuls√£o, paralisia facial, EMDA, mielite transversa, mialgia, grandes rea√ß√µes no local da inje√ß√£o. Estudo de seguran√ßa p√≥s-comercializa√ß√£o sobre SGB realizado. Relato ao VAERS incentivado.",
            "level_description": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o em funcionamento com relato volunt√°rio de eventos adversos. Grande estudo retrospectivo de SGB realizado. M√∫ltiplos eventos graves identificados p√≥s-comercializa√ß√£o."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o fornece informa√ß√µes sobre conflitos de interesse para investigadores de ensaios cl√≠nicos ou fontes de financiamento al√©m da Sanofi Pasteur Inc. como fabricante.",
            "level_description": "Nenhuma divulga√ß√£o de conflitos de interesse ou rela√ß√µes de financiamento para investigadores de ensaios cl√≠nicos fornecida na bula."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata dados de mortalidade por todas as causas dos ensaios cl√≠nicos. Menciona apenas taxas de EAG variando de 0,6% a 3,6% sem detalhamento de mortalidade.",
            "level_description": "Mortalidade por todas as causas n√£o foi relatada na se√ß√£o de ensaios cl√≠nicos. √ìbitos, se ocorreram, n√£o foram detalhados nos dados de seguran√ßa."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Os ensaios cl√≠nicos de Menactra demonstram metodologia adequada com desenho randomizado e controlado por comparador ativo, e tamanhos amostrais substanciais em todas as faixas et√°rias. Limita√ß√µes principais incluem aus√™ncia de controles com placebo verdadeiro (todas as compara√ß√µes contra outra vacina meningoc√≥cica), monitoramento de seguran√ßa ativo relativamente curto (7 dias solicitados, 6 meses para EAGs via telefone) e aus√™ncia de dados de mortalidade. Pontos fortes incluem estratifica√ß√£o abrangente por idade, coleta padronizada de eventos adversos, estudo de vigil√¢ncia p√≥s-comercializa√ß√£o de SGB e an√°lise estat√≠stica transparente. Os ensaios apoiam a imunogenicidade, mas o desenho com comparador ativo limita a avalia√ß√£o absoluta de seguran√ßa."
        }
      },
      "safety_en": {
        "vaccine_id": "men4_menactra",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Substantial pediatric enrollment across age groups: 3,721 children ages 9-12 months received Menactra with 997 controls; 1,713 children ages 2-10 years received Menactra vs 1,519 Menomune controls; 2,270 adolescents ages 11-18 years vs 972 controls. These sample sizes provide adequate power to detect common adverse events (occurring at >1% frequency) but may be insufficient for rare serious events."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active solicited monitoring lasted only 7 days post-vaccination for local and systemic reactions. Unsolicited adverse events monitored for 28-30 days. Serious adverse events and emergency room visits tracked for 6 months via scripted telephone interview. This follow-up period is limited for detecting delayed-onset autoimmune or neurological conditions. The 6-month SAE window relies on passive reporting through phone contact rather than active clinical assessment."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "All primary studies used active comparators rather than true placebo controls. Main comparator was Menomune (meningococcal polysaccharide vaccine) which has its own reactogenicity profile. For infants, controls received routine childhood vaccines without Menactra. This design allows relative safety comparison between vaccines but cannot establish absolute vaccine-attributable risk compared to no intervention. SAE rates ranged from 0.6-1.3% for Menactra vs 0.7-1.3% for Menomune in older children and adults."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Participants monitored 20-30 minutes post-vaccination for immediate reactions. Diary cards used for 7-day solicited adverse events. However, 6-month SAE monitoring was conducted via telephone interview, not active clinical surveillance. Unsolicited adverse event information obtained by telephone interview or interim clinic visit. Post-marketing safety relies on voluntary VAERS reporting plus one retrospective cohort study for GBS."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "GBS risk specifically evaluated in large post-marketing retrospective cohort study of 9.6 million individuals ages 11-18. Of 72 confirmed GBS cases, none occurred within 42 days of Menactra vaccination. Attributable risk estimated 0-5 cases per million vaccinees. Warning included for persons with prior GBS. Post-marketing reports include GBS, acute disseminated encephalomyelitis (ADEM), transverse myelitis, facial palsy, convulsion, and paraesthesia. Seizures monitored as solicited adverse event (0% in clinical trials)."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Limited safety data for vulnerable populations. Immunocompromised individuals may have reduced immune response but no dedicated safety studies. Complement-deficient patients remain at disease risk even after vaccination. Pregnancy registry exists (222 reports over 11 years with 2 major birth defects and 6 miscarriages among 87 known outcomes) but no controlled studies. No lactation safety data. Not established for infants <9 months or adults >55 years. Chilean site enrolled some participants (22% in one study) but subgroup analysis not detailed."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Comprehensive adverse event tables presenting reaction rates by age group and severity grade with 95% confidence intervals. SAE rates reported by age group and vaccine type. Post-marketing adverse events categorized by system organ class. Key references cited including CDC MMWR report on GBS and Harvard Medical School GBS study. However, complete individual-level trial data not publicly accessible from package insert alone."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active post-marketing surveillance system established. Large retrospective cohort study (9.6 million individuals) specifically evaluated GBS risk. Voluntary adverse event reporting through Sanofi Pasteur (1-800-822-2463) and VAERS encouraged. Post-marketing identified additional serious events not seen in trials: anaphylaxis, GBS, ADEM, transverse myelitis, facial palsy, convulsion, large injection site reactions, extensive limb swelling. Pregnancy registry maintained since 2005."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Menactra demonstrates an adequate safety profile based on clinical trials with over 10,000 vaccine recipients and extensive post-marketing surveillance. Common adverse events are well-characterized (injection site reactions in 30-60%, systemic symptoms like headache and fatigue in 25-40%). Key limitations include: (1) no true placebo-controlled trials limiting absolute risk assessment; (2) short active monitoring period of 7 days; (3) limited data on immunocompromised and pregnant populations. Strengths include: large post-marketing GBS study showing no confirmed cases within 42 days of vaccination; comprehensive age-stratified safety data; ongoing pregnancy registry; and robust post-marketing surveillance identifying rare serious events. The GBS warning reflects appropriate precaution despite limited confirmed association."
        }
      },
      "safety_pt": {
        "vaccine_id": "men4_menactra",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Inclus√£o pedi√°trica substancial em todas as faixas et√°rias: 3.721 crian√ßas de 9-12 meses receberam Menactra com 997 controles; 1.713 crian√ßas de 2-10 anos receberam Menactra vs 1.519 controles Menomune; 2.270 adolescentes de 11-18 anos vs 972 controles. Esses tamanhos amostrais fornecem poder adequado para detectar eventos adversos comuns (ocorrendo em >1% de frequ√™ncia), mas podem ser insuficientes para eventos graves raros."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O monitoramento ativo solicitado durou apenas 7 dias ap√≥s a vacina√ß√£o para rea√ß√µes locais e sist√™micas. Eventos adversos n√£o solicitados foram monitorados por 28-30 dias. Eventos adversos graves e visitas ao pronto-socorro foram acompanhados por 6 meses via entrevista telef√¥nica roteirizada. Esse per√≠odo de acompanhamento √© limitado para detectar condi√ß√µes autoimunes ou neurol√≥gicas de in√≠cio tardio. A janela de 6 meses para EAGs depende de relato passivo atrav√©s de contato telef√¥nico em vez de avalia√ß√£o cl√≠nica ativa."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Todos os estudos prim√°rios usaram comparadores ativos em vez de controles com placebo verdadeiro. O principal comparador foi Menomune (vacina polissacar√≠dica meningoc√≥cica) que possui seu pr√≥prio perfil de reatogenicidade. Para beb√™s, os controles receberam vacinas infantis de rotina sem Menactra. Esse desenho permite compara√ß√£o de seguran√ßa relativa entre vacinas, mas n√£o pode estabelecer risco absoluto atribu√≠vel √† vacina em compara√ß√£o com nenhuma interven√ß√£o. As taxas de EAG variaram de 0,6-1,3% para Menactra vs 0,7-1,3% para Menomune em crian√ßas maiores e adultos."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os participantes foram monitorados por 20-30 minutos ap√≥s a vacina√ß√£o para rea√ß√µes imediatas. Cart√µes-di√°rio foram usados para eventos adversos solicitados por 7 dias. No entanto, o monitoramento de EAG por 6 meses foi realizado via entrevista telef√¥nica, n√£o vigil√¢ncia cl√≠nica ativa. Informa√ß√µes sobre eventos adversos n√£o solicitados foram obtidas por entrevista telef√¥nica ou visita cl√≠nica intermedi√°ria. A seguran√ßa p√≥s-comercializa√ß√£o depende de relato volunt√°rio ao VAERS mais um estudo de coorte retrospectivo para SGB."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O risco de SGB foi especificamente avaliado em grande estudo de coorte retrospectivo p√≥s-comercializa√ß√£o com 9,6 milh√µes de indiv√≠duos de 11-18 anos. Dos 72 casos confirmados de SGB, nenhum ocorreu dentro de 42 dias da vacina√ß√£o com Menactra. Risco atribu√≠vel estimado de 0-5 casos por milh√£o de vacinados. Alerta inclu√≠do para pessoas com SGB pr√©vio. Relatos p√≥s-comercializa√ß√£o incluem SGB, encefalomielite disseminada aguda (EMDA), mielite transversa, paralisia facial, convuls√£o e parestesia. Convuls√µes monitoradas como evento adverso solicitado (0% nos ensaios cl√≠nicos)."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Dados de seguran√ßa limitados para popula√ß√µes vulner√°veis. Indiv√≠duos imunocomprometidos podem ter resposta imune reduzida, mas n√£o h√° estudos de seguran√ßa dedicados. Pacientes com defici√™ncia de complemento permanecem em risco de doen√ßa mesmo ap√≥s vacina√ß√£o. Registro de gravidez existe (222 relatos em 11 anos com 2 defeitos cong√™nitos maiores e 6 abortos espont√¢neos entre 87 desfechos conhecidos), mas sem estudos controlados. Sem dados de seguran√ßa na lacta√ß√£o. N√£o estabelecido para beb√™s <9 meses ou adultos >55 anos. Um local chileno incluiu alguns participantes (22% em um estudo), mas an√°lise de subgrupo n√£o detalhada."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Tabelas abrangentes de eventos adversos apresentando taxas de rea√ß√£o por faixa et√°ria e grau de gravidade com intervalos de confian√ßa de 95%. Taxas de EAG relatadas por faixa et√°ria e tipo de vacina. Eventos adversos p√≥s-comercializa√ß√£o categorizados por classe de sistema de √≥rg√£os. Refer√™ncias principais citadas incluindo relat√≥rio do CDC MMWR sobre SGB e estudo de SGB da Harvard Medical School. No entanto, dados completos em n√≠vel individual de ensaios n√£o s√£o acess√≠veis publicamente apenas pela bula."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o ativo estabelecido. Grande estudo de coorte retrospectivo (9,6 milh√µes de indiv√≠duos) avaliou especificamente o risco de SGB. Relato volunt√°rio de eventos adversos atrav√©s da Sanofi Pasteur (1-800-822-2463) e VAERS incentivado. P√≥s-comercializa√ß√£o identificou eventos graves adicionais n√£o vistos nos ensaios: anafilaxia, SGB, EMDA, mielite transversa, paralisia facial, convuls√£o, grandes rea√ß√µes no local da inje√ß√£o, incha√ßo extenso do membro. Registro de gravidez mantido desde 2005."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Menactra demonstra um perfil de seguran√ßa adequado baseado em ensaios cl√≠nicos com mais de 10.000 receptores da vacina e vigil√¢ncia p√≥s-comercializa√ß√£o extensiva. Eventos adversos comuns s√£o bem caracterizados (rea√ß√µes no local da inje√ß√£o em 30-60%, sintomas sist√™micos como dor de cabe√ßa e fadiga em 25-40%). Limita√ß√µes principais incluem: (1) aus√™ncia de ensaios controlados por placebo verdadeiro limitando a avalia√ß√£o de risco absoluto; (2) curto per√≠odo de monitoramento ativo de 7 dias; (3) dados limitados sobre popula√ß√µes imunocomprometidas e gr√°vidas. Pontos fortes incluem: grande estudo de SGB p√≥s-comercializa√ß√£o n√£o mostrando casos confirmados dentro de 42 dias da vacina√ß√£o; dados de seguran√ßa abrangentes estratificados por idade; registro de gravidez cont√≠nuo; e vigil√¢ncia p√≥s-comercializa√ß√£o robusta identificando eventos graves raros. O alerta de SGB reflete precau√ß√£o apropriada apesar de associa√ß√£o confirmada limitada."
        }
      }
    },
    {
      "id": "men4_menveo",
      "name": "Menveo",
      "type": "MenACWY",
      "manufacturer": "GlaxoSmithKline",
      "description": "Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine.",
      "sources": [
        "men4_menveo_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "men4_menveo",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Clinical trials used active comparators (MENACTRA, MENOMUNE) rather than placebo controls. In infant studies, control groups received routine vaccines only without MENVEO. No true placebo-controlled trials were conducted.",
            "level_description": "Active comparator design used rather than placebo control, which is standard for licensed vaccine comparisons but limits ability to assess absolute safety profile."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The booster study (NCT02986854) was described as open-label. The one-vial presentation study (NCT03433482) was observer-blind. Most primary vaccination studies do not explicitly state blinding methodology in the prescribing information.",
            "level_description": "Mixed blinding approaches across studies with some open-label and observer-blind designs documented."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple randomized clinical studies were conducted including NCT00474526, NCT00806195, NCT01000311 for infants, NCT00616421 for children 2-10 years, and NCT00450437 for adolescents/adults. Studies were described as randomized multicenter trials.",
            "level_description": "Randomization was employed across clinical trials for various age groups, though specific randomization methods are not detailed."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Overall 36,146 individuals 2 months through 55 years received at least one dose. Infant studies (2-23 months): 8,735 infants received MENVEO in 3 studies plus 2,864 controls. Children 2-10 years: 3,181 received MENVEO in 4 trials. Toddler studies: 1,985 received 2 doses.",
            "level_description": "Very large pediatric sample sizes across multiple age groups with thousands of subjects in each category."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited reactions monitored for 7 days post-vaccination. Medically significant adverse events and SAEs monitored for 6 months after vaccination in children, adolescents, and adults aged 2-55 years. Body temperature collected for 28 days in MMRV co-administration study.",
            "level_description": "Six-month follow-up for serious adverse events is adequate for vaccine safety assessment, though longer-term follow-up data is limited."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety and immunogenicity data presented separately for: infants 2-23 months (4-dose series), children 7-23 months (2-dose series), children 2-5 years, children 6-10 years, adolescents 11-18 years, and adults 19-55 years. Different dosing schedules by age group.",
            "level_description": "Excellent stratification by age groups with dedicated analyses for each pediatric age range."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Document mentions 'healthy infants' and 'healthy adolescents' for specific studies. Contraindications include severe allergic reaction to previous dose or components. Specific detailed inclusion/exclusion criteria not provided in prescribing information.",
            "level_description": "Basic eligibility criteria implied but detailed inclusion/exclusion criteria not provided in this document."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Standardized solicited adverse reactions with defined severity grades: local reactions (tenderness, erythema, induration with size thresholds >50mm, >100mm), systemic reactions (irritability, sleepiness, crying, eating habits, fever with temperature ranges). Diary cards used for 7-day collection.",
            "level_description": "Comprehensive standardized adverse event collection with clear severity definitions and consistent methodology across studies."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "SAEs monitored for 6 months post-vaccination. Medically-attended adverse events tracked. Detailed SAE rates provided: 2.7% vs 2.2% during infant series, specific SAEs listed including wheezing, pneumonia, gastroenteritis, convulsions. Deaths reported and assessed for relationship to vaccination.",
            "level_description": "Active monitoring of serious adverse events with 6-month follow-up and detailed categorization of SAE types."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "GBS warning included noting temporal relationship with another meningococcal vaccine. Acute disseminated encephalomyelitis case reported (29 days post Dose 4). Postmarketing: Bell's palsy showed increased risk (adjusted relative incidence 2.9). Convulsions monitored in trials. Kawasaki Disease tracked (3/12,049 MENVEO recipients).",
            "level_description": "Neurological conditions monitored with specific warnings for GBS and documented cases of ADEM and Bell's palsy."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Premature infants: apnea warning with individualized vaccination decision. Immunocompromised: reduced immune response noted. Complement deficiency: increased disease risk despite vaccination. Pregnancy registry data (82 subjects). No data for adults >55 years.",
            "level_description": "Key vulnerable populations addressed including premature infants and immunocompromised individuals with specific warnings."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Non-inferiority analyses performed comparing MENVEO to MENACTRA with 95% CI and -10% non-inferiority margin. Seroresponse rates, GMTs with 95% CIs provided. Per-protocol populations defined. Pre-specified criteria for immunogenicity (lower limit 95% CI >80% for serogroup A, >85% for C, W, Y).",
            "level_description": "Appropriate statistical methods with non-inferiority design, confidence intervals, and pre-specified success criteria."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "ClinicalTrials.gov identifiers provided for all major studies (NCT numbers). Detailed tables with sample sizes, percentages, confidence intervals. Demographic breakdowns by race/ethnicity and sex. Per-protocol population numbers specified.",
            "level_description": "Good transparency with trial registration, detailed data tables, and demographic information provided."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Postmarketing observational study in US HMO with 48,899 persons aged 11-21 years using electronic health records. Self-controlled case series method used. Multiple postmarketing adverse reactions identified across organ systems. VAERS reporting encouraged.",
            "level_description": "Comprehensive postmarketing surveillance with large observational study, electronic health record analysis, and voluntary reporting system."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not contain information about conflicts of interest, funding sources for clinical trials, or investigator financial disclosures.",
            "level_description": "No conflict of interest disclosures provided in the prescribing information."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Deaths reported: 2 deaths in MENVEO groups aged 2-23 months within 28 days (sudden death, sepsis) vs 0 in control. None assessed as vaccine-related. No deaths in one-vial presentation studies. Mortality tracked as part of SAE monitoring.",
            "level_description": "All-cause mortality tracked and reported with causality assessment, though numbers are limited."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "MENVEO clinical trials demonstrate adequate to exemplary methodology in most areas. Strengths include very large pediatric sample sizes (36,146 total subjects), excellent age group stratification, standardized adverse event collection with severity grading, and comprehensive postmarketing surveillance including a 48,899-person observational study. The 6-month safety follow-up and neurological condition monitoring (GBS, ADEM, Bell's palsy, Kawasaki Disease) are appropriate. Key limitations include the use of active comparators rather than true placebo controls, mixed blinding approaches, and absence of conflict of interest disclosures. Statistical methods employed non-inferiority designs with appropriate pre-specified criteria."
        }
      },
      "trial_pt": {
        "vaccine_id": "men4_menveo",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os ensaios cl√≠nicos usaram comparadores ativos (MENACTRA, MENOMUNE) em vez de controles com placebo. Nos estudos em beb√™s, os grupos controle receberam apenas vacinas de rotina sem MENVEO. Nenhum ensaio controlado por placebo verdadeiro foi realizado.",
            "level_description": "Desenho com comparador ativo utilizado em vez de controle com placebo, o que √© padr√£o para compara√ß√µes de vacinas licenciadas, mas limita a capacidade de avaliar o perfil de seguran√ßa absoluto."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo de refor√ßo (NCT02986854) foi descrito como aberto. O estudo de apresenta√ß√£o em frasco √∫nico (NCT03433482) foi com observador cego. A maioria dos estudos de vacina√ß√£o prim√°ria n√£o declara explicitamente a metodologia de cegamento na bula.",
            "level_description": "Abordagens de cegamento mistas entre os estudos, com alguns desenhos abertos e com observador cego documentados."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos estudos cl√≠nicos randomizados foram realizados, incluindo NCT00474526, NCT00806195, NCT01000311 para beb√™s, NCT00616421 para crian√ßas de 2-10 anos, e NCT00450437 para adolescentes/adultos. Os estudos foram descritos como ensaios multic√™ntricos randomizados.",
            "level_description": "A randomiza√ß√£o foi empregada em ensaios cl√≠nicos para v√°rias faixas et√°rias, embora m√©todos espec√≠ficos de randomiza√ß√£o n√£o sejam detalhados."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "No geral, 36.146 indiv√≠duos de 2 meses a 55 anos receberam pelo menos uma dose. Estudos em beb√™s (2-23 meses): 8.735 beb√™s receberam MENVEO em 3 estudos mais 2.864 controles. Crian√ßas de 2-10 anos: 3.181 receberam MENVEO em 4 ensaios. Estudos em crian√ßas pequenas: 1.985 receberam 2 doses.",
            "level_description": "Tamanhos amostrais pedi√°tricos muito grandes em m√∫ltiplas faixas et√°rias com milhares de participantes em cada categoria."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes solicitadas foram monitoradas por 7 dias ap√≥s a vacina√ß√£o. Eventos adversos clinicamente significativos e EAGs foram monitorados por 6 meses ap√≥s a vacina√ß√£o em crian√ßas, adolescentes e adultos de 2-55 anos. Temperatura corporal coletada por 28 dias no estudo de coadministra√ß√£o com MMRV.",
            "level_description": "O acompanhamento de 6 meses para eventos adversos graves √© adequado para avalia√ß√£o de seguran√ßa de vacinas, embora dados de acompanhamento de longo prazo sejam limitados."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados de seguran√ßa e imunogenicidade apresentados separadamente para: beb√™s de 2-23 meses (s√©rie de 4 doses), crian√ßas de 7-23 meses (s√©rie de 2 doses), crian√ßas de 2-5 anos, crian√ßas de 6-10 anos, adolescentes de 11-18 anos e adultos de 19-55 anos. Diferentes esquemas de dosagem por faixa et√°ria.",
            "level_description": "Excelente estratifica√ß√£o por faixas et√°rias com an√°lises dedicadas para cada faixa et√°ria pedi√°trica."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento menciona 'beb√™s saud√°veis' e 'adolescentes saud√°veis' para estudos espec√≠ficos. Contraindica√ß√µes incluem rea√ß√£o al√©rgica grave a dose anterior ou componentes. Crit√©rios detalhados espec√≠ficos de inclus√£o/exclus√£o n√£o s√£o fornecidos na bula.",
            "level_description": "Crit√©rios b√°sicos de elegibilidade impl√≠citos, mas crit√©rios detalhados de inclus√£o/exclus√£o n√£o fornecidos neste documento."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Rea√ß√µes adversas solicitadas padronizadas com graus de gravidade definidos: rea√ß√µes locais (sensibilidade, eritema, endurecimento com limites de tamanho >50mm, >100mm), rea√ß√µes sist√™micas (irritabilidade, sonol√™ncia, choro, h√°bitos alimentares, febre com faixas de temperatura). Cart√µes-di√°rio usados para coleta de 7 dias.",
            "level_description": "Coleta abrangente de eventos adversos padronizados com defini√ß√µes claras de gravidade e metodologia consistente entre os estudos."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "EAGs monitorados por 6 meses ap√≥s a vacina√ß√£o. Eventos adversos com atendimento m√©dico rastreados. Taxas detalhadas de EAG fornecidas: 2,7% vs 2,2% durante a s√©rie em beb√™s, EAGs espec√≠ficos listados incluindo sibil√¢ncia, pneumonia, gastroenterite, convuls√µes. √ìbitos relatados e avaliados quanto √† rela√ß√£o com a vacina√ß√£o.",
            "level_description": "Monitoramento ativo de eventos adversos graves com acompanhamento de 6 meses e categoriza√ß√£o detalhada dos tipos de EAG."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Alerta de SGB inclu√≠do observando rela√ß√£o temporal com outra vacina meningoc√≥cica. Caso de encefalomielite disseminada aguda relatado (29 dias ap√≥s Dose 4). P√≥s-comercializa√ß√£o: paralisia de Bell mostrou risco aumentado (incid√™ncia relativa ajustada 2,9). Convuls√µes monitoradas nos ensaios. Doen√ßa de Kawasaki rastreada (3/12.049 receptores de MENVEO).",
            "level_description": "Condi√ß√µes neurol√≥gicas monitoradas com alertas espec√≠ficos para SGB e casos documentados de EMDA e paralisia de Bell."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Beb√™s prematuros: alerta de apneia com decis√£o de vacina√ß√£o individualizada. Imunocomprometidos: resposta imune reduzida observada. Defici√™ncia de complemento: risco aumentado de doen√ßa apesar da vacina√ß√£o. Dados do registro de gravidez (82 participantes). Sem dados para adultos >55 anos.",
            "level_description": "Popula√ß√µes vulner√°veis principais abordadas, incluindo beb√™s prematuros e indiv√≠duos imunocomprometidos com alertas espec√≠ficos."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "An√°lises de n√£o inferioridade realizadas comparando MENVEO a MENACTRA com IC 95% e margem de n√£o inferioridade de -10%. Taxas de sororesposta, TMGs com IC 95% fornecidos. Popula√ß√µes por protocolo definidas. Crit√©rios pr√©-especificados para imunogenicidade (limite inferior IC 95% >80% para sorogrupo A, >85% para C, W, Y).",
            "level_description": "M√©todos estat√≠sticos apropriados com desenho de n√£o inferioridade, intervalos de confian√ßa e crit√©rios de sucesso pr√©-especificados."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Identificadores do ClinicalTrials.gov fornecidos para todos os principais estudos (n√∫meros NCT). Tabelas detalhadas com tamanhos amostrais, porcentagens, intervalos de confian√ßa. Detalhamentos demogr√°ficos por ra√ßa/etnia e sexo. N√∫meros da popula√ß√£o por protocolo especificados.",
            "level_description": "Boa transpar√™ncia com registro de ensaios, tabelas de dados detalhadas e informa√ß√µes demogr√°ficas fornecidas."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Estudo observacional p√≥s-comercializa√ß√£o em HMO dos EUA com 48.899 pessoas de 11-21 anos usando prontu√°rios eletr√¥nicos de sa√∫de. M√©todo de s√©rie de casos auto-controlados utilizado. M√∫ltiplas rea√ß√µes adversas p√≥s-comercializa√ß√£o identificadas em sistemas de √≥rg√£os. Relato ao VAERS incentivado.",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o abrangente com grande estudo observacional, an√°lise de prontu√°rios eletr√¥nicos de sa√∫de e sistema de relato volunt√°rio."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o cont√©m informa√ß√µes sobre conflitos de interesse, fontes de financiamento para ensaios cl√≠nicos ou divulga√ß√µes financeiras de investigadores.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse fornecida na bula."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "√ìbitos relatados: 2 √≥bitos nos grupos MENVEO de 2-23 meses em 28 dias (morte s√∫bita, sepse) vs 0 no controle. Nenhum avaliado como relacionado √† vacina. Nenhum √≥bito nos estudos de apresenta√ß√£o em frasco √∫nico. Mortalidade rastreada como parte do monitoramento de EAG.",
            "level_description": "Mortalidade por todas as causas rastreada e relatada com avalia√ß√£o de causalidade, embora os n√∫meros sejam limitados."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "Os ensaios cl√≠nicos de MENVEO demonstram metodologia adequada a exemplar na maioria das √°reas. Pontos fortes incluem tamanhos amostrais pedi√°tricos muito grandes (36.146 participantes no total), excelente estratifica√ß√£o por faixa et√°ria, coleta padronizada de eventos adversos com gradua√ß√£o de gravidade e vigil√¢ncia p√≥s-comercializa√ß√£o abrangente incluindo estudo observacional com 48.899 pessoas. O acompanhamento de seguran√ßa de 6 meses e o monitoramento de condi√ß√µes neurol√≥gicas (SGB, EMDA, paralisia de Bell, Doen√ßa de Kawasaki) s√£o apropriados. Limita√ß√µes principais incluem o uso de comparadores ativos em vez de controles com placebo verdadeiro, abordagens de cegamento mistas e aus√™ncia de divulga√ß√µes de conflito de interesse. M√©todos estat√≠sticos empregaram desenhos de n√£o inferioridade com crit√©rios pr√©-especificados apropriados."
        }
      },
      "safety_en": {
        "vaccine_id": "men4_menveo",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Exceptional pediatric safety database with 36,146 individuals 2 months through 55 years receiving at least one dose. Infants 2-23 months: 8,735 received MENVEO across 3 randomized multicenter studies (NCT00474526, NCT00806195, NCT01000311) plus 2,864 controls. Children 7-23 months: 1,985 received 2-dose series. Children 2-10 years: 3,181 received MENVEO in 4 trials. This represents one of the larger pediatric vaccine safety databases for a meningococcal conjugate vaccine."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited local and systemic adverse reactions monitored daily for 7 days following vaccination via diary cards. Medically significant adverse events and serious adverse events (SAEs) monitored for 6 months after vaccination in subjects aged 2-55 years. In infant/toddler studies, medically-attended or medically-significant adverse events collected between infant and toddler doses and during 6-month period after toddler dose. Temperature monitored for 28 days in MMRV co-administration study. While 6 months is adequate for acute and subacute safety signals, longer-term follow-up data beyond 6 months is limited."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active comparator design used throughout: MENACTRA (n=1,757 in adolescent/adult studies, n=1,255 in pediatric studies) and MENOMUNE (n=861 in pediatric, n=209 in adolescent/adult studies) served as comparators. In infant studies, control groups received routine vaccines only (DTaP, IPV, Hib, HBV, rotavirus, PCV7) without MENVEO (n=2,864). No true saline placebo groups were included. This design allows comparison to licensed products but limits ability to determine absolute attributable risk of adverse events."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active solicitation of adverse reactions using diary cards for 7 days post-vaccination with standardized severity grading. Local reactions graded by size (>50mm moderate, >100mm severe). Systemic reactions graded by functional impact. Unsolicited adverse events including medically-attended events collected. SAE rates by study period: infant series 2.7% MENVEO vs 2.2% controls, between doses 2.5% vs 2.5%, 1-month post-toddler 0.3% vs 0.3%, 6-month follow-up 1.6% vs 2.2%."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Multiple neurological conditions monitored: Guillain-Barre syndrome (GBS) warning included based on temporal association with another meningococcal conjugate vaccine. One case of acute disseminated encephalomyelitis (ADEM) reported 29 days post Dose 4 with concomitant MMR and varicella vaccines. Convulsions tracked as SAEs (febrile convulsion, tonic convulsion reported). Kawasaki Disease monitored: 3/12,049 (0.02%) MENVEO vs 0/2,877 controls. Postmarketing observational study (48,899 persons) found Bell's palsy with adjusted relative incidence 2.9 (95% CI: 1.1-7.5) in 1-84 days post-vaccination; all 8 cases resolved."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Premature infants: specific warning about apnea following intramuscular vaccination with recommendation for individualized benefit-risk assessment. Immunocompromised individuals: noted to have reduced immune responses including those on immunosuppressant therapy. Complement deficiency: warning that vaccinated persons remain at increased risk despite antibody development. Pregnancy: registry data from 2014-2017 with 82 pregnancies - miscarriage rate 12.2% (10/82) and major birth defects 3.6% (2/55 live births), consistent with background rates. No data provided for adults over 55 years."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "ClinicalTrials.gov identifiers provided for all major studies enabling independent verification. Detailed data tables with sample sizes (n values), percentages, and 95% confidence intervals. Demographic information provided by race/ethnicity and sex for study populations. Per-protocol and as-treated safety populations defined. SAE rates and types specified by study period and vaccine group. Adverse reaction definitions and severity grading criteria explicitly stated."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Comprehensive postmarketing surveillance system including: 1) Large observational safety study in US HMO using electronic health records of 48,899 persons aged 11-21 years with self-controlled case series methodology identifying Bell's palsy signal. 2) Voluntary adverse event reporting with detailed categorization by organ system (blood/lymphatic, ear/labyrinth, eye, general, immune, infections, injury, investigations, musculoskeletal, nervous system, respiratory, skin disorders). 3) VAERS reporting encouraged (1-800-822-7967). 4) Manufacturer reporting available (GlaxoSmithKline 1-888-825-5249). Multiple postmarketing signals identified and characterized."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "MENVEO demonstrates a robust safety profile supported by an exemplary pediatric database (36,146 subjects across multiple age groups), adequate 6-month safety follow-up, and exemplary postmarketing surveillance including a 48,899-person observational study. Active surveillance methodologies employed standardized adverse event collection with severity grading. Key neurological conditions were monitored with warnings for GBS and documented cases of ADEM, Bell's palsy (with quantified risk), and Kawasaki Disease. Vulnerable populations including premature infants, immunocompromised individuals, and pregnant women are addressed with specific guidance. The main limitation is the use of active comparators rather than true placebo controls, which is typical for licensed vaccine comparisons but limits absolute risk determination. Common adverse reactions are well-characterized: injection site reactions (24-44%), irritability (18-57%), sleepiness (14-50%), and headache (11-30%) vary by age group."
        }
      },
      "safety_pt": {
        "vaccine_id": "men4_menveo",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Base de dados de seguran√ßa pedi√°trica excepcional com 36.146 indiv√≠duos de 2 meses a 55 anos recebendo pelo menos uma dose. Beb√™s de 2-23 meses: 8.735 receberam MENVEO em 3 estudos multic√™ntricos randomizados (NCT00474526, NCT00806195, NCT01000311) mais 2.864 controles. Crian√ßas de 7-23 meses: 1.985 receberam s√©rie de 2 doses. Crian√ßas de 2-10 anos: 3.181 receberam MENVEO em 4 ensaios. Isso representa uma das maiores bases de dados de seguran√ßa pedi√°trica para uma vacina conjugada meningoc√≥cica."
          },
          "follow_up_duration": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Rea√ß√µes adversas locais e sist√™micas solicitadas foram monitoradas diariamente por 7 dias ap√≥s a vacina√ß√£o via cart√µes-di√°rio. Eventos adversos clinicamente significativos e eventos adversos graves (EAGs) foram monitorados por 6 meses ap√≥s a vacina√ß√£o em participantes de 2-55 anos. Em estudos de beb√™s/crian√ßas pequenas, eventos adversos com atendimento m√©dico ou clinicamente significativos foram coletados entre as doses de beb√™ e crian√ßa pequena e durante o per√≠odo de 6 meses ap√≥s a dose de crian√ßa pequena. Temperatura monitorada por 28 dias no estudo de coadministra√ß√£o com MMRV. Embora 6 meses seja adequado para sinais de seguran√ßa agudos e subagudos, dados de acompanhamento de longo prazo al√©m de 6 meses s√£o limitados."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Desenho com comparador ativo usado em todos os estudos: MENACTRA (n=1.757 em estudos de adolescentes/adultos, n=1.255 em estudos pedi√°tricos) e MENOMUNE (n=861 em pedi√°tricos, n=209 em estudos de adolescentes/adultos) serviram como comparadores. Em estudos de beb√™s, grupos controle receberam apenas vacinas de rotina (DTaP, IPV, Hib, HBV, rotav√≠rus, PCV7) sem MENVEO (n=2.864). Nenhum grupo de placebo salino verdadeiro foi inclu√≠do. Esse desenho permite compara√ß√£o com produtos licenciados, mas limita a capacidade de determinar o risco atribu√≠vel absoluto de eventos adversos."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicita√ß√£o ativa de rea√ß√µes adversas usando cart√µes-di√°rio por 7 dias ap√≥s a vacina√ß√£o com gradua√ß√£o de gravidade padronizada. Rea√ß√µes locais graduadas por tamanho (>50mm moderada, >100mm grave). Rea√ß√µes sist√™micas graduadas por impacto funcional. Eventos adversos n√£o solicitados incluindo eventos com atendimento m√©dico coletados. Taxas de EAG por per√≠odo de estudo: s√©rie de beb√™s 2,7% MENVEO vs 2,2% controles, entre doses 2,5% vs 2,5%, 1 m√™s p√≥s-crian√ßa pequena 0,3% vs 0,3%, acompanhamento de 6 meses 1,6% vs 2,2%."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "M√∫ltiplas condi√ß√µes neurol√≥gicas monitoradas: alerta de S√≠ndrome de Guillain-Barr√© (SGB) inclu√≠do com base em associa√ß√£o temporal com outra vacina conjugada meningoc√≥cica. Um caso de encefalomielite disseminada aguda (EMDA) relatado 29 dias ap√≥s Dose 4 com vacinas concomitantes MMR e varicela. Convuls√µes rastreadas como EAGs (convuls√£o febril, convuls√£o t√¥nica relatadas). Doen√ßa de Kawasaki monitorada: 3/12.049 (0,02%) MENVEO vs 0/2.877 controles. Estudo observacional p√≥s-comercializa√ß√£o (48.899 pessoas) encontrou paralisia de Bell com incid√™ncia relativa ajustada de 2,9 (IC 95%: 1,1-7,5) em 1-84 dias ap√≥s vacina√ß√£o; todos os 8 casos resolveram."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Beb√™s prematuros: alerta espec√≠fico sobre apneia ap√≥s vacina√ß√£o intramuscular com recomenda√ß√£o de avalia√ß√£o individualizada de benef√≠cio-risco. Indiv√≠duos imunocomprometidos: observado que t√™m respostas imunes reduzidas, incluindo aqueles em terapia imunossupressora. Defici√™ncia de complemento: alerta de que pessoas vacinadas permanecem em risco aumentado apesar do desenvolvimento de anticorpos. Gravidez: dados do registro de 2014-2017 com 82 gesta√ß√µes - taxa de aborto espont√¢neo 12,2% (10/82) e defeitos cong√™nitos maiores 3,6% (2/55 nascidos vivos), consistentes com taxas de base. Sem dados fornecidos para adultos acima de 55 anos."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Identificadores do ClinicalTrials.gov fornecidos para todos os principais estudos, permitindo verifica√ß√£o independente. Tabelas de dados detalhadas com tamanhos amostrais (valores n), porcentagens e intervalos de confian√ßa de 95%. Informa√ß√µes demogr√°ficas fornecidas por ra√ßa/etnia e sexo para popula√ß√µes do estudo. Popula√ß√µes por protocolo e de seguran√ßa conforme tratadas definidas. Taxas e tipos de EAG especificados por per√≠odo de estudo e grupo de vacina. Defini√ß√µes de rea√ß√µes adversas e crit√©rios de gradua√ß√£o de gravidade explicitamente declarados."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Sistema de vigil√¢ncia p√≥s-comercializa√ß√£o abrangente incluindo: 1) Grande estudo de seguran√ßa observacional em HMO dos EUA usando prontu√°rios eletr√¥nicos de sa√∫de de 48.899 pessoas de 11-21 anos com metodologia de s√©rie de casos auto-controlados identificando sinal de paralisia de Bell. 2) Relato volunt√°rio de eventos adversos com categoriza√ß√£o detalhada por sistema de √≥rg√£os (sangue/linf√°tico, ouvido/labirinto, olho, geral, imune, infec√ß√µes, les√µes, investiga√ß√µes, musculoesquel√©tico, sistema nervoso, respirat√≥rio, dist√∫rbios da pele). 3) Relato ao VAERS incentivado (1-800-822-7967). 4) Relato ao fabricante dispon√≠vel (GlaxoSmithKline 1-888-825-5249). M√∫ltiplos sinais p√≥s-comercializa√ß√£o identificados e caracterizados."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "MENVEO demonstra um perfil de seguran√ßa robusto apoiado por uma base de dados pedi√°trica exemplar (36.146 participantes em m√∫ltiplas faixas et√°rias), acompanhamento de seguran√ßa adequado de 6 meses e vigil√¢ncia p√≥s-comercializa√ß√£o exemplar incluindo estudo observacional com 48.899 pessoas. Metodologias de vigil√¢ncia ativa empregaram coleta padronizada de eventos adversos com gradua√ß√£o de gravidade. Condi√ß√µes neurol√≥gicas principais foram monitoradas com alertas para SGB e casos documentados de EMDA, paralisia de Bell (com risco quantificado) e Doen√ßa de Kawasaki. Popula√ß√µes vulner√°veis incluindo beb√™s prematuros, indiv√≠duos imunocomprometidos e mulheres gr√°vidas s√£o abordadas com orienta√ß√£o espec√≠fica. A principal limita√ß√£o √© o uso de comparadores ativos em vez de controles com placebo verdadeiro, o que √© t√≠pico para compara√ß√µes de vacinas licenciadas, mas limita a determina√ß√£o de risco absoluto. Rea√ß√µes adversas comuns s√£o bem caracterizadas: rea√ß√µes no local da inje√ß√£o (24-44%), irritabilidade (18-57%), sonol√™ncia (14-50%) e dor de cabe√ßa (11-30%) variam por faixa et√°ria."
        }
      }
    },
    {
      "id": "men4_menquadfi",
      "name": "MenQuadfi",
      "type": "MenACWY",
      "manufacturer": "Sanofi Pasteur",
      "description": "Meningococcal (Groups A, C, Y and W) Conjugate Vaccine for prevention of invasive meningococcal disease.",
      "sources": [
        "men4_menquadfi_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "men4_menquadfi",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "All ten clinical studies were active-controlled, comparing MenQuadfi to other meningococcal vaccines (Menveo, Menactra, or Menomune). No placebo (saline) control group was used in any study. The document explicitly states trials were 'randomized, active-controlled, multi-center clinical studies.'",
            "level_description": "No inert placebo group was used. Active comparators (other vaccines) obscure true adverse event rates since both groups receive potentially reactogenic products."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document describes trials as 'randomized, active-controlled' but does not mention blinding status (double-blind, single-blind, or open-label). No mention of allocation concealment or blinding procedures for participants, investigators, or outcome assessors.",
            "level_description": "Blinding methodology is not documented. Without this information, observer bias in adverse event assessment cannot be ruled out."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document states studies were 'randomized' and mentions assignment ratios (e.g., Study 1 had 2:1 MenQuadfi:Menveo ratio). However, no details on randomization method, sequence generation, or allocation concealment are provided.",
            "level_description": "Randomization is mentioned but not adequately described. Without details on method and concealment, the quality of randomization cannot be verified."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Total of 4,273 participants <2 years received at least one dose (3,807 in 4-dose series, 466 in 2-dose series). For 4-dose series in Study 1: N=1,727 MenQuadfi; Study 2: N=2,080 MenQuadfi. Children 2-9 years: N=498 MenQuadfi (Study 4). Adolescents 10-17: N=3,196 across Studies 5 and 6.",
            "level_description": "Pediatric sample sizes exceed 3,000 for infants in the 4-dose series, meeting the threshold for detecting 1:1,000 adverse events. Sample sizes for 2-9 year olds (N=498) are smaller and may miss rarer events."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Solicited adverse reactions recorded for 7 days post-vaccination. Unsolicited adverse events collected within 30 days. SAEs and medically-attended events collected for 6 months after vaccination (except Study 10 which collected for only 1 month).",
            "level_description": "6-month SAE follow-up is better than typical 30-42 day periods but still inadequate for detecting long-term autoimmune or neurological conditions that may emerge months to years later. No multi-year follow-up documented."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Safety data presented separately for: Infants 6 weeks-23 months (4-dose and 2-dose series), Children 2-9 years (Study 4), Adolescents 10-17 years (Studies 5, 6), Adults 18-55 years (Study 6), Adults 56+ years (Study 7), Older adults 59+ years (Study 10). Tables present data by dose and age strata.",
            "level_description": "Excellent stratification by age groups with detailed separate analyses for each population, exceeding typical standards."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Limited details on inclusion/exclusion criteria. Document mentions 'healthy' participants for vaccine-naive studies. Contraindication stated: severe allergic reaction to vaccine components or previous tetanus toxoid-containing vaccine. Exclusions of children with health conditions not explicitly discussed.",
            "level_description": "Criteria are not fully detailed in the package insert. No explicit discussion of generalizability limitations or how restrictive enrollment criteria might limit real-world applicability."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse reactions defined with standardized grading: Fever (Any: ‚â•100.4F/38.0C; Grade 3: ‚â•103.1F/39.5C for infants, ‚â•102.1F/39.0C for older). Erythema/Swelling (Any: >0mm; Grade 3: ‚â•50mm). Tenderness/Pain graded by functional impact. Systemic reactions graded by severity (Grade 3 prevents daily activity).",
            "level_description": "Standardized grading scales with objective thresholds are used consistently across studies, enabling comparison. However, Brighton Collaboration criteria not explicitly mentioned."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Participants monitored 30 minutes post-vaccination for immediate reactions. Diary cards used daily for 7 days. SAEs collected for at least 6 months (except Study 10: 1 month). Medically-attended events (ER visits, unexpected healthcare visits) tracked. SAE rates reported: 5.3% MenQuadfi vs 3.6% Menveo in infant 4-dose series studies.",
            "level_description": "Active solicited surveillance with diary cards and scheduled visits. SAE monitoring extends to 6 months for most studies. Medically-attended events tracked as a category."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Warnings section mentions GBS has been reported following another meningococcal conjugate vaccine. Two febrile seizures reported as SAEs possibly related to vaccination at 12-month dose with concomitant vaccines. Postmarketing reports: febrile seizure, convulsion, syncope. No systematic long-term neurological/autoimmune monitoring protocol described.",
            "level_description": "GBS warning included and individual seizure events reported, but no predefined systematic monitoring protocol for autoimmune/neurological conditions. No scheduled developmental assessments or neurological exams described."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Preterm infants included: Study 1 had 133 (7.7%) preterm infants (31 to <37 weeks gestation), Study 2 had 89 (4.3%) preterm. Document states 'no notable differences in rates and severity of adverse reactions between preterm and full-term infants.' Immunocompromised persons mentioned in warnings (may have reduced immune response).",
            "level_description": "Preterm infants intentionally included with separate analysis noted showing no differences from full-term infants. However, immunocompromised children were not actively studied (only mentioned in warnings)."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Non-inferiority analysis described for immunogenicity (lower limit of 95% CI > -10%). 95% CIs provided for seroresponse rates and GMTs. Per-protocol and safety analysis sets defined. No mention of statistical powering for safety endpoints or power calculations for detecting rare adverse events.",
            "level_description": "Statistical methods adequately described for immunogenicity but studies were powered for efficacy/immunogenicity, not safety. No safety-specific power calculations documented."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "ClinicalTrials.gov identifiers provided for all studies (NCT03537508, NCT03673462, NCT03691610, NCT03077438, NCT02199691, NCT02842853, NCT02842866, NCT02752906, NCT04084769, NCT04142242). Detailed tables with percentages and 95% CIs included. No mention of DSMB or availability of raw/individual participant data.",
            "level_description": "Trial registrations and aggregate data provided, but no mention of independent Data Safety Monitoring Board (DSMB) oversight or raw data availability for independent verification."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Postmarketing Experience section exists but notes 'Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.' Reports include: anaphylaxis, hypersensitivity, febrile seizure, convulsion, syncope. VAERS reporting encouraged.",
            "level_description": "Relies on passive reporting (VAERS) which vastly underestimates true rates. No active pharmacovigilance system with periodic public reports mentioned."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Manufactured by Sanofi Pasteur Inc. No disclosure of funding sources for clinical trials, financial ties of investigators, or conflicts of interest. All studies appear to be industry-sponsored given manufacturer production of package insert.",
            "level_description": "No conflict of interest disclosure. Studies were conducted by the manufacturer, creating inherent potential for bias. No mention of independent funding or analysis."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No all-cause mortality data reported. Deaths are not mentioned except as part of SAE definition ('hospitalization, sequelae, deaths with causal investigation'). No table or count of total deaths in either vaccine or comparator groups.",
            "level_description": "All-cause mortality is not reported. Without this data, it is impossible to assess whether overall deaths differed between groups regardless of perceived causality."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "MenQuadfi's clinical trial program demonstrates adequate sample sizes for infants and excellent age-stratified analysis, but has significant methodological limitations for safety assessment. The absence of placebo controls (all active-controlled), undocumented blinding status, and lack of true long-term follow-up (maximum 6 months for SAEs) limit the ability to establish a true baseline adverse event rate and detect rare long-term outcomes. Positive aspects include standardized adverse event grading, active solicited monitoring with diary cards, and intentional inclusion of preterm infants with separate analysis. However, the studies were powered for immunogenicity rather than safety, no DSMB is mentioned, all-cause mortality is not reported, and post-marketing surveillance relies on passive reporting systems. The absence of conflict of interest disclosure and independent funding raises questions about potential industry bias in a program entirely conducted by the manufacturer."
        }
      },
      "trial_pt": {
        "vaccine_id": "men4_menquadfi",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Todos os dez estudos cl√≠nicos foram controlados por comparador ativo, comparando MenQuadfi a outras vacinas meningoc√≥cicas (Menveo, Menactra ou Menomune). Nenhum grupo controle com placebo (solu√ß√£o salina) foi usado em nenhum estudo. O documento afirma explicitamente que os ensaios foram 'estudos cl√≠nicos multic√™ntricos randomizados e controlados por comparador ativo.'",
            "level_description": "Nenhum grupo de placebo inerte foi usado. Comparadores ativos (outras vacinas) obscurecem as verdadeiras taxas de eventos adversos, j√° que ambos os grupos recebem produtos potencialmente reatog√™nicos."
          },
          "double_blind": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento descreve os ensaios como 'randomizados, controlados por comparador ativo', mas n√£o menciona o status de cegamento (duplo-cego, simples-cego ou aberto). Nenhuma men√ß√£o de oculta√ß√£o de aloca√ß√£o ou procedimentos de cegamento para participantes, investigadores ou avaliadores de desfechos.",
            "level_description": "A metodologia de cegamento n√£o est√° documentada. Sem essa informa√ß√£o, o vi√©s do observador na avalia√ß√£o de eventos adversos n√£o pode ser descartado."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento afirma que os estudos foram 'randomizados' e menciona propor√ß√µes de aloca√ß√£o (ex.: Estudo 1 teve propor√ß√£o 2:1 MenQuadfi:Menveo). No entanto, nenhum detalhe sobre m√©todo de randomiza√ß√£o, gera√ß√£o de sequ√™ncia ou oculta√ß√£o de aloca√ß√£o √© fornecido.",
            "level_description": "A randomiza√ß√£o √© mencionada, mas n√£o adequadamente descrita. Sem detalhes sobre m√©todo e oculta√ß√£o, a qualidade da randomiza√ß√£o n√£o pode ser verificada."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Total de 4.273 participantes <2 anos receberam pelo menos uma dose (3.807 na s√©rie de 4 doses, 466 na s√©rie de 2 doses). Para s√©rie de 4 doses no Estudo 1: N=1.727 MenQuadfi; Estudo 2: N=2.080 MenQuadfi. Crian√ßas de 2-9 anos: N=498 MenQuadfi (Estudo 4). Adolescentes de 10-17: N=3.196 nos Estudos 5 e 6.",
            "level_description": "Tamanhos amostrais pedi√°tricos excedem 3.000 para beb√™s na s√©rie de 4 doses, atendendo o limiar para detectar eventos adversos de 1:1.000. Tamanhos amostrais para 2-9 anos (N=498) s√£o menores e podem n√£o detectar eventos mais raros."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes adversas solicitadas registradas por 7 dias ap√≥s a vacina√ß√£o. Eventos adversos n√£o solicitados coletados em 30 dias. EAGs e eventos com atendimento m√©dico coletados por 6 meses ap√≥s a vacina√ß√£o (exceto Estudo 10 que coletou por apenas 1 m√™s).",
            "level_description": "O acompanhamento de 6 meses para EAGs √© melhor que os per√≠odos t√≠picos de 30-42 dias, mas ainda inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas de longo prazo que podem surgir meses a anos depois. Nenhum acompanhamento de v√°rios anos documentado."
          },
          "separate_age_groups": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Dados de seguran√ßa apresentados separadamente para: Beb√™s de 6 semanas-23 meses (s√©ries de 4 doses e 2 doses), Crian√ßas de 2-9 anos (Estudo 4), Adolescentes de 10-17 anos (Estudos 5, 6), Adultos de 18-55 anos (Estudo 6), Adultos 56+ anos (Estudo 7), Adultos mais velhos 59+ anos (Estudo 10). Tabelas apresentam dados por dose e estratos et√°rios.",
            "level_description": "Excelente estratifica√ß√£o por faixas et√°rias com an√°lises separadas detalhadas para cada popula√ß√£o, excedendo os padr√µes t√≠picos."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Detalhes limitados sobre crit√©rios de inclus√£o/exclus√£o. Documento menciona participantes 'saud√°veis' para estudos com participantes naive √† vacina. Contraindica√ß√£o declarada: rea√ß√£o al√©rgica grave a componentes da vacina ou vacina anterior contendo toxoide tet√¢nico. Exclus√µes de crian√ßas com condi√ß√µes de sa√∫de n√£o discutidas explicitamente.",
            "level_description": "Os crit√©rios n√£o s√£o totalmente detalhados na bula. Nenhuma discuss√£o expl√≠cita de limita√ß√µes de generaliza√ß√£o ou como crit√©rios de inclus√£o restritivos podem limitar a aplicabilidade no mundo real."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes adversas solicitadas definidas com gradua√ß√£o padronizada: Febre (Qualquer: ‚â•100,4F/38,0C; Grau 3: ‚â•103,1F/39,5C para beb√™s, ‚â•102,1F/39,0C para mais velhos). Eritema/Incha√ßo (Qualquer: >0mm; Grau 3: ‚â•50mm). Sensibilidade/Dor graduadas por impacto funcional. Rea√ß√µes sist√™micas graduadas por gravidade (Grau 3 impede atividade di√°ria).",
            "level_description": "Escalas de gradua√ß√£o padronizadas com limiares objetivos s√£o usadas consistentemente entre os estudos, permitindo compara√ß√£o. No entanto, crit√©rios da Brighton Collaboration n√£o s√£o explicitamente mencionados."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Participantes monitorados por 30 minutos ap√≥s a vacina√ß√£o para rea√ß√µes imediatas. Cart√µes-di√°rio usados diariamente por 7 dias. EAGs coletados por pelo menos 6 meses (exceto Estudo 10: 1 m√™s). Eventos com atendimento m√©dico (visitas ao pronto-socorro, consultas m√©dicas inesperadas) rastreados. Taxas de EAG relatadas: 5,3% MenQuadfi vs 3,6% Menveo nos estudos de s√©rie de 4 doses em beb√™s.",
            "level_description": "Vigil√¢ncia ativa solicitada com cart√µes-di√°rio e visitas programadas. Monitoramento de EAG estende-se a 6 meses para a maioria dos estudos. Eventos com atendimento m√©dico rastreados como categoria."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de Advert√™ncias menciona que SGB foi relatada ap√≥s outra vacina conjugada meningoc√≥cica. Duas convuls√µes febris relatadas como EAGs possivelmente relacionadas √† vacina√ß√£o na dose de 12 meses com vacinas concomitantes. Relatos p√≥s-comercializa√ß√£o: convuls√£o febril, convuls√£o, s√≠ncope. Nenhum protocolo sistem√°tico de monitoramento neurol√≥gico/autoimune de longo prazo descrito.",
            "level_description": "Alerta de SGB inclu√≠do e eventos individuais de convuls√£o relatados, mas sem protocolo de monitoramento sistem√°tico predefinido para condi√ß√µes autoimunes/neurol√≥gicas. Sem avalia√ß√µes de desenvolvimento programadas ou exames neurol√≥gicos descritos."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Beb√™s prematuros inclu√≠dos: Estudo 1 teve 133 (7,7%) beb√™s prematuros (31 a <37 semanas de gesta√ß√£o), Estudo 2 teve 89 (4,3%) prematuros. Documento afirma 'nenhuma diferen√ßa not√°vel nas taxas e gravidade de rea√ß√µes adversas entre beb√™s prematuros e a termo.' Pessoas imunocomprometidas mencionadas nas advert√™ncias (podem ter resposta imune reduzida).",
            "level_description": "Beb√™s prematuros intencionalmente inclu√≠dos com an√°lise separada observando n√£o haver diferen√ßas em rela√ß√£o a beb√™s a termo. No entanto, crian√ßas imunocomprometidas n√£o foram ativamente estudadas (apenas mencionadas nas advert√™ncias)."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "An√°lise de n√£o inferioridade descrita para imunogenicidade (limite inferior do IC 95% > -10%). IC 95% fornecidos para taxas de sororesposta e TMGs. Conjuntos de an√°lise por protocolo e de seguran√ßa definidos. Nenhuma men√ß√£o de poder estat√≠stico para desfechos de seguran√ßa ou c√°lculos de poder para detectar eventos adversos raros.",
            "level_description": "M√©todos estat√≠sticos adequadamente descritos para imunogenicidade, mas estudos foram dimensionados para efic√°cia/imunogenicidade, n√£o seguran√ßa. Nenhum c√°lculo de poder espec√≠fico para seguran√ßa documentado."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Identificadores do ClinicalTrials.gov fornecidos para todos os estudos (NCT03537508, NCT03673462, NCT03691610, NCT03077438, NCT02199691, NCT02842853, NCT02842866, NCT02752906, NCT04084769, NCT04142242). Tabelas detalhadas com porcentagens e IC 95% inclu√≠das. Nenhuma men√ß√£o de DSMB ou disponibilidade de dados brutos/dados individuais de participantes.",
            "level_description": "Registros de ensaios e dados agregados fornecidos, mas nenhuma men√ß√£o de supervis√£o independente do Comit√™ de Monitoramento de Seguran√ßa de Dados (DSMB) ou disponibilidade de dados brutos para verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de Experi√™ncia P√≥s-Comercializa√ß√£o existe, mas observa 'Como essas rea√ß√µes s√£o relatadas voluntariamente de uma popula√ß√£o de tamanho incerto, nem sempre √© poss√≠vel estimar de forma confi√°vel sua frequ√™ncia.' Relatos incluem: anafilaxia, hipersensibilidade, convuls√£o febril, convuls√£o, s√≠ncope. Relato ao VAERS incentivado.",
            "level_description": "Depende de relato passivo (VAERS) que subestima vastamente as taxas reais. Nenhum sistema de farmacovigil√¢ncia ativa com relat√≥rios p√∫blicos peri√≥dicos mencionado."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Fabricado pela Sanofi Pasteur Inc. Nenhuma divulga√ß√£o de fontes de financiamento para ensaios cl√≠nicos, v√≠nculos financeiros de investigadores ou conflitos de interesse. Todos os estudos parecem ser patrocinados pela ind√∫stria, dado que o fabricante produziu a bula.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse. Estudos foram conduzidos pelo fabricante, criando potencial inerente de vi√©s. Nenhuma men√ß√£o de financiamento ou an√°lise independente."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum dado de mortalidade por todas as causas relatado. √ìbitos n√£o s√£o mencionados exceto como parte da defini√ß√£o de EAG ('hospitaliza√ß√£o, sequelas, √≥bitos com investiga√ß√£o causal'). Nenhuma tabela ou contagem de √≥bitos totais em grupos de vacina ou comparador.",
            "level_description": "Mortalidade por todas as causas n√£o √© relatada. Sem esses dados, √© imposs√≠vel avaliar se os √≥bitos totais diferiram entre os grupos, independentemente da causalidade percebida."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "O programa de ensaios cl√≠nicos de MenQuadfi demonstra tamanhos amostrais adequados para beb√™s e excelente an√°lise estratificada por idade, mas tem limita√ß√µes metodol√≥gicas significativas para avalia√ß√£o de seguran√ßa. A aus√™ncia de controles com placebo (todos controlados por comparador ativo), status de cegamento n√£o documentado e falta de acompanhamento verdadeiramente de longo prazo (m√°ximo de 6 meses para EAGs) limitam a capacidade de estabelecer uma verdadeira taxa basal de eventos adversos e detectar desfechos raros de longo prazo. Aspectos positivos incluem gradua√ß√£o padronizada de eventos adversos, monitoramento ativo solicitado com cart√µes-di√°rio e inclus√£o intencional de beb√™s prematuros com an√°lise separada. No entanto, os estudos foram dimensionados para imunogenicidade em vez de seguran√ßa, nenhum DSMB √© mencionado, mortalidade por todas as causas n√£o √© relatada, e a vigil√¢ncia p√≥s-comercializa√ß√£o depende de sistemas de relato passivo. A aus√™ncia de divulga√ß√£o de conflito de interesse e financiamento independente levanta quest√µes sobre potencial vi√©s da ind√∫stria em um programa inteiramente conduzido pelo fabricante."
        }
      },
      "safety_en": {
        "vaccine_id": "men4_menquadfi",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A total of 4,273 children under 2 years received at least one dose of MenQuadfi across three infant studies: 3,807 in the 4-dose series and 466 in the 2-dose series. The largest study (Study 2) enrolled 2,080 infants, and Study 1 enrolled 1,727 infants. For children 2-9 years, 498 participants received MenQuadfi. These numbers exceed the minimum threshold of 1,000 and approach the ideal of 3,000+ for the infant population, providing reasonable power to detect adverse events occurring at 1:1,000 frequency. However, the 2-9 year age group sample (N=498) is below ideal."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Solicited adverse reactions were monitored for only 7 days post-vaccination using diary cards. Unsolicited adverse events were collected for 30 days. Serious adverse events (SAEs) were collected for 6 months after the final vaccination in most studies (Study 10 collected SAEs for only 1 month). While 6 months is better than typical vaccine trials (30-42 days), it remains grossly inadequate for detecting autoimmune and neurological conditions that may emerge months to years after vaccination. No long-term follow-up (1-3+ years) was conducted, leaving significant uncertainty about delayed safety signals."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "All ten clinical studies used active controls (other vaccines) rather than true placebo (saline). Comparators included: Menveo (Studies 1-5), Menactra (Studies 3, 6, 8), and Menomune (Studies 7, 10). Using other vaccines as controls obscures the true baseline rate of adverse events, as both groups receive reactogenic products. This design makes it impossible to determine what proportion of adverse events would occur without vaccination. The document states no placebo-controlled trials were conducted."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active surveillance was implemented through multiple mechanisms: 30-minute post-vaccination monitoring for immediate reactions, daily diary cards completed by parents/guardians for 7 days documenting solicited reactions, follow-up visits at 1-2 months where diary cards were reviewed with investigators, and collection of medically-attended adverse events (ER visits, unexpected healthcare visits) for 6 months. SAE rates were reported (5.3% MenQuadfi vs 3.6% Menveo in 4-dose infant series). Two febrile seizures were identified as possibly vaccine-related. The structured solicited monitoring is adequate for short-term assessment."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The Warnings section includes a specific mention of Guillain-Barre Syndrome (GBS) reported with another meningococcal conjugate vaccine. Two febrile seizures were reported as SAEs possibly related to MenQuadfi (both occurred with concomitant MMR, varicella, and PCV13 at 12 months). Postmarketing reports include febrile seizure, convulsion, and syncope. However, there was no systematic protocol for neurological assessment, no scheduled developmental evaluations, and no predefined list of neurological/autoimmune conditions to monitor. The package insert does not describe any active surveillance for conditions like GBS, encephalitis, or developmental regression."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Preterm infants were intentionally included: Study 1 included 133 preterm infants (7.7% of MenQuadfi recipients, 31 to <37 weeks gestation), and Study 2 included 89 preterm infants (4.3%). The document specifically notes 'no notable differences in the rates and severity of adverse reactions between preterm and full-term infants.' However, immunocompromised children were not actively studied; the Warnings section only states they 'may have reduced immune responses.' No data is presented for children with allergies, chronic conditions, or on concurrent medications beyond routine childhood vaccines."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "All ten clinical studies are registered on ClinicalTrials.gov with identifiers provided (NCT03537508, NCT03673462, NCT03691610, NCT03077438, NCT02199691, NCT02842853, NCT02842866, NCT02752906, NCT04084769, NCT04142242). Detailed tables include percentages, 95% confidence intervals, and grade severity breakdowns. However, there is no mention of an independent Data Safety Monitoring Board (DSMB), no indication that raw data or individual participant data (IPD) are available for independent analysis, and no peer-reviewed publications are referenced in the package insert."
          },
          "post_marketing_surveillance": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The Postmarketing Experience section acknowledges significant limitations: 'Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship.' Identified postmarketing signals include anaphylaxis, hypersensitivity, febrile seizure, convulsion, and syncope. The document directs healthcare providers to report to VAERS, which is a passive reporting system known to capture only a fraction of actual adverse events. There is no mention of active pharmacovigilance programs, periodic safety update reports, or systematic post-marketing studies to detect rare events in millions of doses."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The MenQuadfi package insert provides partial reassurance of safety in children, with significant gaps that prevent confident conclusions about long-term safety. Strengths include adequate pediatric sample sizes for infants (4,273 total under age 2), good active solicited monitoring with diary cards, intentional inclusion of preterm infants with reassuring results showing no differences from full-term infants, and excellent age-stratified reporting. However, critical limitations undermine confidence: (1) No true placebo control - all studies used other vaccines as comparators, making it impossible to determine the true vaccine-attributable adverse event rate; (2) Inadequate follow-up duration - maximum 6 months for SAEs is insufficient to detect autoimmune or neurological conditions that may emerge years later; (3) Passive post-marketing surveillance relying on VAERS will vastly underestimate rare adverse events. The two febrile seizures identified as possibly related and the GBS warning suggest neurological signals warrant attention, but no systematic monitoring protocol exists. Parents can have reasonable confidence about common, short-term reactions but the document does not adequately address rare, long-term safety concerns."
        }
      },
      "safety_pt": {
        "vaccine_id": "men4_menquadfi",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Um total de 4.273 crian√ßas menores de 2 anos receberam pelo menos uma dose de MenQuadfi em tr√™s estudos em beb√™s: 3.807 na s√©rie de 4 doses e 466 na s√©rie de 2 doses. O maior estudo (Estudo 2) incluiu 2.080 beb√™s, e o Estudo 1 incluiu 1.727 beb√™s. Para crian√ßas de 2-9 anos, 498 participantes receberam MenQuadfi. Esses n√∫meros excedem o limiar m√≠nimo de 1.000 e aproximam-se do ideal de 3.000+ para a popula√ß√£o de beb√™s, fornecendo poder razo√°vel para detectar eventos adversos ocorrendo em frequ√™ncia de 1:1.000. No entanto, a amostra da faixa et√°ria de 2-9 anos (N=498) est√° abaixo do ideal."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Rea√ß√µes adversas solicitadas foram monitoradas por apenas 7 dias ap√≥s a vacina√ß√£o usando cart√µes-di√°rio. Eventos adversos n√£o solicitados foram coletados por 30 dias. Eventos adversos graves (EAGs) foram coletados por 6 meses ap√≥s a √∫ltima vacina√ß√£o na maioria dos estudos (Estudo 10 coletou EAGs por apenas 1 m√™s). Embora 6 meses seja melhor que ensaios de vacinas t√≠picos (30-42 dias), permanece grosseiramente inadequado para detectar condi√ß√µes autoimunes e neurol√≥gicas que podem surgir meses a anos ap√≥s a vacina√ß√£o. Nenhum acompanhamento de longo prazo (1-3+ anos) foi realizado, deixando incerteza significativa sobre sinais de seguran√ßa tardios."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Todos os dez estudos cl√≠nicos usaram controles ativos (outras vacinas) em vez de placebo verdadeiro (solu√ß√£o salina). Comparadores inclu√≠ram: Menveo (Estudos 1-5), Menactra (Estudos 3, 6, 8) e Menomune (Estudos 7, 10). Usar outras vacinas como controles obscurece a verdadeira taxa basal de eventos adversos, j√° que ambos os grupos recebem produtos reatog√™nicos. Esse desenho torna imposs√≠vel determinar qual propor√ß√£o de eventos adversos ocorreria sem vacina√ß√£o. O documento afirma que nenhum ensaio controlado por placebo foi realizado."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Vigil√¢ncia ativa foi implementada atrav√©s de m√∫ltiplos mecanismos: monitoramento de 30 minutos ap√≥s a vacina√ß√£o para rea√ß√µes imediatas, cart√µes-di√°rio di√°rios preenchidos por pais/respons√°veis por 7 dias documentando rea√ß√µes solicitadas, visitas de acompanhamento em 1-2 meses onde cart√µes-di√°rio foram revisados com investigadores, e coleta de eventos adversos com atendimento m√©dico (visitas ao pronto-socorro, consultas m√©dicas inesperadas) por 6 meses. Taxas de EAG foram relatadas (5,3% MenQuadfi vs 3,6% Menveo na s√©rie de 4 doses em beb√™s). Duas convuls√µes febris foram identificadas como possivelmente relacionadas √† vacina. O monitoramento solicitado estruturado √© adequado para avalia√ß√£o de curto prazo."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A se√ß√£o de Advert√™ncias inclui men√ß√£o espec√≠fica de S√≠ndrome de Guillain-Barr√© (SGB) relatada com outra vacina conjugada meningoc√≥cica. Duas convuls√µes febris foram relatadas como EAGs possivelmente relacionadas a MenQuadfi (ambas ocorreram com MMR, varicela e PCV13 concomitantes aos 12 meses). Relatos p√≥s-comercializa√ß√£o incluem convuls√£o febril, convuls√£o e s√≠ncope. No entanto, n√£o houve protocolo sistem√°tico para avalia√ß√£o neurol√≥gica, nenhuma avalia√ß√£o de desenvolvimento programada e nenhuma lista predefinida de condi√ß√µes neurol√≥gicas/autoimunes para monitorar. A bula n√£o descreve nenhuma vigil√¢ncia ativa para condi√ß√µes como SGB, encefalite ou regress√£o do desenvolvimento."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Beb√™s prematuros foram intencionalmente inclu√≠dos: Estudo 1 incluiu 133 beb√™s prematuros (7,7% dos receptores de MenQuadfi, 31 a <37 semanas de gesta√ß√£o), e Estudo 2 incluiu 89 beb√™s prematuros (4,3%). O documento observa especificamente 'nenhuma diferen√ßa not√°vel nas taxas e gravidade de rea√ß√µes adversas entre beb√™s prematuros e a termo.' No entanto, crian√ßas imunocomprometidas n√£o foram ativamente estudadas; a se√ß√£o de Advert√™ncias apenas afirma que elas 'podem ter respostas imunes reduzidas.' Nenhum dado √© apresentado para crian√ßas com alergias, condi√ß√µes cr√¥nicas ou em medica√ß√µes concomitantes al√©m das vacinas infantis de rotina."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Todos os dez estudos cl√≠nicos est√£o registrados no ClinicalTrials.gov com identificadores fornecidos (NCT03537508, NCT03673462, NCT03691610, NCT03077438, NCT02199691, NCT02842853, NCT02842866, NCT02752906, NCT04084769, NCT04142242). Tabelas detalhadas incluem porcentagens, intervalos de confian√ßa de 95% e detalhamentos por grau de gravidade. No entanto, n√£o h√° men√ß√£o de um Comit√™ de Monitoramento de Seguran√ßa de Dados (DSMB) independente, nenhuma indica√ß√£o de que dados brutos ou dados individuais de participantes (DIP) estejam dispon√≠veis para an√°lise independente, e nenhuma publica√ß√£o revisada por pares √© referenciada na bula."
          },
          "post_marketing_surveillance": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "A se√ß√£o de Experi√™ncia P√≥s-Comercializa√ß√£o reconhece limita√ß√µes significativas: 'Como essas rea√ß√µes s√£o relatadas voluntariamente de uma popula√ß√£o de tamanho incerto, nem sempre √© poss√≠vel estimar de forma confi√°vel sua frequ√™ncia ou estabelecer uma rela√ß√£o causal.' Sinais p√≥s-comercializa√ß√£o identificados incluem anafilaxia, hipersensibilidade, convuls√£o febril, convuls√£o e s√≠ncope. O documento orienta profissionais de sa√∫de a relatar ao VAERS, que √© um sistema de relato passivo conhecido por capturar apenas uma fra√ß√£o dos eventos adversos reais. N√£o h√° men√ß√£o de programas de farmacovigil√¢ncia ativa, relat√≥rios peri√≥dicos de atualiza√ß√£o de seguran√ßa ou estudos sistem√°ticos p√≥s-comercializa√ß√£o para detectar eventos raros em milh√µes de doses."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A bula de MenQuadfi fornece garantia parcial de seguran√ßa em crian√ßas, com lacunas significativas que impedem conclus√µes confiantes sobre seguran√ßa de longo prazo. Pontos fortes incluem tamanhos amostrais pedi√°tricos adequados para beb√™s (4.273 no total menores de 2 anos), bom monitoramento ativo solicitado com cart√µes-di√°rio, inclus√£o intencional de beb√™s prematuros com resultados tranquilizadores n√£o mostrando diferen√ßas em rela√ß√£o a beb√™s a termo, e excelente relato estratificado por idade. No entanto, limita√ß√µes cr√≠ticas minam a confian√ßa: (1) Nenhum controle com placebo verdadeiro - todos os estudos usaram outras vacinas como comparadores, tornando imposs√≠vel determinar a verdadeira taxa de eventos adversos atribu√≠veis √† vacina; (2) Dura√ß√£o de acompanhamento inadequada - m√°ximo de 6 meses para EAGs √© insuficiente para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem surgir anos depois; (3) Vigil√¢ncia p√≥s-comercializa√ß√£o passiva dependendo do VAERS subestimar√° vastamente eventos adversos raros. As duas convuls√µes febris identificadas como possivelmente relacionadas e o alerta de SGB sugerem que sinais neurol√≥gicos merecem aten√ß√£o, mas nenhum protocolo de monitoramento sistem√°tico existe. Pais podem ter confian√ßa razo√°vel sobre rea√ß√µes comuns de curto prazo, mas o documento n√£o aborda adequadamente preocupa√ß√µes de seguran√ßa raras e de longo prazo."
        }
      }
    },
    {
      "id": "menb_bexsero",
      "name": "Bexsero",
      "type": "MenB",
      "manufacturer": "GlaxoSmithKline",
      "description": "Meningococcal Group B Vaccine for prevention of invasive disease caused by Neisseria meningitidis serogroup B.",
      "sources": [
        "menb_bexsero_summary.pdf",
        "menb_bexsero_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "menb_bexsero",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study V72_41 (Canada/Australia) used MenACWY-CRM (Menveo) as comparator, not true placebo. Study V72_29 (UK) used MenACWY-CRM as comparator. Study V72P10 (Chile) used aluminum hydroxide-saline placebo for some groups through Month 3 only, then no control from Month 6-12. Study V102_03 used saline placebo (sodium chloride with water) for the Menveo comparator group only. The main adolescent trials lacked true inert placebo controls - they used active vaccine comparators.",
            "level_description": "Present, but with significant flaws - most main trials used another vaccine (Menveo) as comparator rather than inert placebo, which obscures true adverse event rates. Only partial placebo control in Chilean study through Month 3."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study V72_41: observer-blind design where study personnel administering vaccines were not blinded but assessors were. Study V72_29: observer-blind design. Study V72P10: observer-blind design with placebo containing aluminum hydroxide-saline to maintain blinding. Study V102_03: observer-blinded, controlled, randomized study. Studies used diary cards reviewed by blinded personnel.",
            "level_description": "Observer-blind methodology was consistently used across main trials, with documented procedures to prevent bias in outcome assessment. However, not full double-blind as vaccine administrators were unblinded."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study V72_41: subjects randomized 2:1 (rMenB+OMV: Menveo). Study V72_29: subjects randomized 2:2:1 across groups. Study V72P10: subjects randomized 1:1:1:1:1:1:1:1 across 8 groups. Study V102_03: subjects randomized 1:1:1:1 across 4 treatment groups. All studies used documented random allocation procedures.",
            "level_description": "Documented random allocation with specified ratios across all main clinical trials. Randomization procedures were protocol-defined."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Main trials in adolescents/young adults (10-25 years): V72_41: 1631 enrolled (1,097 received rMenB+OMV). V72_29: 3304 enrolled. V72P10: 1631 enrolled (1622 received at least one dose rMenB+OMV). V102_03: 484 enrolled (122 in rMenB+OMV group). Total in main trials: 3,058 subjects received at least one dose. Pre-licensure vaccination campaigns: 15,351 participants at US universities.",
            "level_description": "Combined sample size of 3,058 in controlled clinical trials plus 15,351 in expanded access campaigns provides adequate power to detect adverse events at 1:1,000 level. However, the 10-25 year age group is not strictly pediatric (0-12 years)."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study V72_41: subjects followed for 6 months post-last vaccination. Study V72_29: 12 months follow-up, with subjects evaluated at 6 months and 11 months post-2nd dose. Study V72P10: 12-month study period with SAE monitoring throughout. Study V102_03: 8 months total duration (6 months post-last dose). Solicited adverse events monitored for 7 days post-vaccination; unsolicited AEs for 30 days. SAEs and MAAEs collected throughout study periods.",
            "level_description": "Follow-up ranged from 6-12 months across studies. While some studies had 12-month follow-up, this is minimal for detecting long-term autoimmune or neurological effects. 7-day solicited AE monitoring is standard but short."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies separated by age: V72_41 enrolled 11-17 year olds. V72_29 enrolled two cohorts: 11-17 years and 18-24 years with separate analysis presented. V72P10 enrolled 11-17 year olds. V102_03 enrolled 10-25 years with demographic subanalyses. Additional infant studies (V72P13, V72P16) in 2-month-old infants evaluated separately. Mean age reported: V72_41 13.8 years; V72_29 adolescents 14.1 years, young adults 20.6 years; V102_03 15.0 years.",
            "level_description": "Age-specific enrollment and analysis was conducted, with adolescents (11-17) and young adults (18-24) studied separately in the UK trial. Different studies focused on different age cohorts."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Detailed inclusion/exclusion criteria documented: healthy subjects, no prior meningococcal vaccination, no history of meningococcal disease, no chronic/progressive disease, no immunocompromise, no severe allergic reactions to vaccines. Excluded: pregnancy, fever >38C within 7 days, antibiotics within 7 days, blood products within 90 days, other vaccines within 14-28 days. Female subjects required acceptable birth control methods.",
            "level_description": "Clear and detailed criteria were documented. However, criteria were restrictive (healthy subjects only), limiting generalizability to children with underlying health conditions."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "MedDRA coding system used for adverse event classification throughout. Brighton Collaboration guidelines referenced for fever definition (T>38.0C). Severity grading scales defined: local reactions (pain: mild/moderate/severe; erythema/induration by mm ranges); systemic reactions (none, mild, moderate, severe based on limitation of daily activity). Specific temperature thresholds: 38.0C, 38.5C, 39.0C, 39.5C, 40.0C documented.",
            "level_description": "Standardized MedDRA coding, Brighton Collaboration fever criteria, and objective severity grading scales were consistently applied across studies. Clear documentation of measurement methods."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited AEs actively collected via diary cards for 7 days post-vaccination. SAEs actively monitored throughout study periods (6-12 months). Protocol included: telephone calls on Days 3-5 and Day 63-65 to query for SAEs; scheduled visits for safety assessment; 30-minute post-vaccination observation. Medical Attended Adverse Events (MAAEs) tracked. Deaths investigated with causality assessment. 35 SAEs reported in V72P10 with detailed narratives and investigator assessments.",
            "level_description": "Active solicitation of adverse events via diary cards, phone calls, and scheduled visits. SAEs monitored with causality assessment. Clear distinction between solicited and unsolicited events documented."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Two cases of juvenile arthritis reported in V72P10 (170 and 198 days post-vaccination) - one assessed as possibly related. One case of acute thyroiditis in V72_29. One case of convulsion/epilepsy (pre-existing condition). Syncope with seizure manifestations (vasovagal, related to venipuncture). One case bacterial meningitis (Streptococcus pneumoniae, not related). Reviewer concluded data does not suggest association between vaccination and autoimmune conditions. No systematic screening protocol for these conditions documented.",
            "level_description": "Some autoimmune/neurological events were captured and analyzed, but there was no predefined systematic monitoring protocol for these specific conditions. Monitoring was reactive rather than proactive."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Immunocompromised patients excluded from trials - package insert notes 'reduced immune responses' may occur. Pregnant women excluded; pregnancy registry established. Study V72P4 enrolled 53 'at-risk' adults (laboratory workers). Pre-existing conditions noted as exclusion criteria. Document states safety and effectiveness not established in adults >65 years or children <10 years. Pediatric Study Plan includes deferred studies for 6 weeks to <10 years.",
            "level_description": "Vulnerable groups (immunocompromised, pregnant, premature) were excluded from trials rather than studied. Limited data on real-world applicability to children with chronic conditions."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies powered for immunogenicity endpoints with pre-specified criteria (4-fold increase in hSBA titers). Safety analyses were descriptive without hypothesis testing. Lot-to-lot consistency evaluated with 2-sided 95% CI criteria (interval 0.50-2.00). Missing data: no imputations performed. Per protocol and intention-to-treat populations defined. Immunogenicity analyzed using PP population. Baseline imbalances noted and discussed.",
            "level_description": "Studies were adequately powered for immunogenicity but safety analysis was descriptive only - a common limitation. Statistical methods were appropriate for the study designs."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "FDA BLA review document (STN: 125546/0) with detailed clinical study reports cited. Data Safety Monitoring Board (DMC) established for V102_03 to evaluate first 10% of subjects. BIMO site inspections conducted revealing some documentation issues (16 withdrawals due to injection site reactions not captured in CRFs). Detailed tables of adverse events by group provided. Individual SAE narratives included. CSR amendments and protocol changes documented.",
            "level_description": "FDA review process with DSMB oversight, site inspections, and detailed adverse event reporting. Some data collection issues identified and documented. Raw IPD not publicly available."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Pre-licensure vaccination campaigns at Princeton University and UCSB provided post-marketing-like data on 15,351 participants under CDC Expanded Access IND. SAE surveillance for 30 days post-2nd dose via intake screening, electronic surveys, 24-hour safety hotlines, health services visits, hospital reports. 50 SAEs reported and analyzed including anaphylaxis (1 case - assessed as expected rate), appendicitis (9 cases), rhabdomyolysis (2 cases), 1 death (drowning, unrelated). Pregnancy registry established.",
            "level_description": "Extensive pre-licensure surveillance through university vaccination campaigns provided real-world safety data. Pregnancy registry for ongoing monitoring. Standard passive reporting systems (VAERS) implied but not detailed."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Applicant identified as Novartis Vaccines and Diagnostics. Studies conducted under IND with CBER regulatory input. Clinical trials were manufacturer-sponsored. FDA clinical reviewer (Anuja Rastogi) conducted independent assessment. No explicit statement of financial disclosures for investigators. Study sites included commercial research centers (e.g., Dr. Stanley Block, Dr. Wendy Daly) and academic institutions.",
            "level_description": "Industry-funded trials without explicit disclosure of investigator financial ties. FDA provided independent regulatory review. No independent academic replication of results documented."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "3 deaths reported in V72P10: (1) 17yo female - craniocerebral trauma from car accident 4 months post-vaccination, not related; (2) 17yo female - paracetamol overdose/suicide ~31 days post-vaccination, not related; (3) infant born to vaccinated subject - sudden death at 1.5 months, not related. 1 death in UCSB campaign: 19yo male drowning (shallow water blackout), unrelated. All deaths investigated with causality assessment. No vaccine-related deaths reported.",
            "level_description": "All-cause mortality was tracked and reported across all groups. Each death was investigated with causality determination. Total of 4 deaths across all studies, none attributed to vaccine."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The Bexsero clinical development program included 4 main clinical trials with 3,058 subjects aged 10-25 years plus expanded access data on 15,351 university students. The trials employed adequate randomization and observer-blind methodology with standardized adverse event definitions (MedDRA, Brighton criteria). Key limitations include: use of active vaccine comparators (Menveo) rather than true placebo in most studies, limiting ability to determine true adverse event rates; follow-up duration of 6-12 months is minimal for detecting long-term autoimmune/neurological effects; vulnerable populations were excluded rather than studied; and trials were powered for immunogenicity rather than safety. The safety profile showed common reactions (injection site pain 90%, severe pain 20-29%, myalgia, headache) consistent with other adolescent vaccines. SAEs including 2 cases of juvenile arthritis were reviewed but no definitive safety signal identified. Overall, the program meets regulatory standards for accelerated approval but has inherent limitations in detecting rare, delayed adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "menb_bexsero",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo V72_41 (Canad√°/Austr√°lia) usou MenACWY-CRM (Menveo) como comparador, n√£o placebo verdadeiro. O Estudo V72_29 (Reino Unido) usou MenACWY-CRM como comparador. O Estudo V72P10 (Chile) usou placebo de hidr√≥xido de alum√≠nio-solu√ß√£o salina para alguns grupos apenas at√© o M√™s 3, depois nenhum controle do M√™s 6-12. O Estudo V102_03 usou placebo salino (cloreto de s√≥dio com √°gua) apenas para o grupo comparador Menveo. Os principais ensaios em adolescentes n√£o tiveram controles com placebo inerte verdadeiro - usaram comparadores de vacina ativa.",
            "level_description": "Presente, mas com falhas significativas - a maioria dos ensaios principais usou outra vacina (Menveo) como comparador em vez de placebo inerte, o que obscurece as verdadeiras taxas de eventos adversos. Apenas controle parcial com placebo no estudo chileno at√© o M√™s 3."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo V72_41: desenho com observador cego onde a equipe do estudo que administrou as vacinas n√£o foi cegada, mas os avaliadores foram. Estudo V72_29: desenho com observador cego. Estudo V72P10: desenho com observador cego com placebo contendo hidr√≥xido de alum√≠nio-solu√ß√£o salina para manter o cegamento. Estudo V102_03: estudo randomizado, controlado, com observador cego. Estudos usaram cart√µes-di√°rio revisados por equipe cega.",
            "level_description": "A metodologia com observador cego foi usada consistentemente nos ensaios principais, com procedimentos documentados para prevenir vi√©s na avalia√ß√£o de desfechos. No entanto, n√£o houve duplo-cego completo, pois os administradores das vacinas n√£o foram cegos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo V72_41: participantes randomizados 2:1 (rMenB+OMV: Menveo). Estudo V72_29: participantes randomizados 2:2:1 entre os grupos. Estudo V72P10: participantes randomizados 1:1:1:1:1:1:1:1 entre 8 grupos. Estudo V102_03: participantes randomizados 1:1:1:1 entre 4 grupos de tratamento. Todos os estudos usaram procedimentos documentados de aloca√ß√£o aleat√≥ria.",
            "level_description": "Aloca√ß√£o aleat√≥ria documentada com propor√ß√µes especificadas em todos os principais ensaios cl√≠nicos. Procedimentos de randomiza√ß√£o foram definidos em protocolo."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Ensaios principais em adolescentes/adultos jovens (10-25 anos): V72_41: 1631 inclu√≠dos (1.097 receberam rMenB+OMV). V72_29: 3304 inclu√≠dos. V72P10: 1631 inclu√≠dos (1622 receberam pelo menos uma dose de rMenB+OMV). V102_03: 484 inclu√≠dos (122 no grupo rMenB+OMV). Total nos ensaios principais: 3.058 participantes receberam pelo menos uma dose. Campanhas de vacina√ß√£o pr√©-licenciamento: 15.351 participantes em universidades dos EUA.",
            "level_description": "Tamanho amostral combinado de 3.058 em ensaios cl√≠nicos controlados mais 15.351 em campanhas de acesso expandido fornece poder adequado para detectar eventos adversos no n√≠vel de 1:1.000. No entanto, a faixa et√°ria de 10-25 anos n√£o √© estritamente pedi√°trica (0-12 anos)."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo V72_41: participantes acompanhados por 6 meses ap√≥s a √∫ltima vacina√ß√£o. Estudo V72_29: 12 meses de acompanhamento, com participantes avaliados aos 6 meses e 11 meses ap√≥s a 2¬™ dose. Estudo V72P10: per√≠odo de estudo de 12 meses com monitoramento de EAG durante todo o per√≠odo. Estudo V102_03: 8 meses de dura√ß√£o total (6 meses ap√≥s a √∫ltima dose). Eventos adversos solicitados monitorados por 7 dias ap√≥s a vacina√ß√£o; EAs n√£o solicitados por 30 dias. EAGs e EAAMs coletados durante os per√≠odos de estudo.",
            "level_description": "O acompanhamento variou de 6-12 meses entre os estudos. Embora alguns estudos tenham tido acompanhamento de 12 meses, isso √© m√≠nimo para detectar efeitos autoimunes ou neurol√≥gicos de longo prazo. Monitoramento de EA solicitado de 7 dias √© padr√£o, mas curto."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudos separados por idade: V72_41 incluiu 11-17 anos. V72_29 incluiu duas coortes: 11-17 anos e 18-24 anos com an√°lise separada apresentada. V72P10 incluiu 11-17 anos. V102_03 incluiu 10-25 anos com suban√°lises demogr√°ficas. Estudos adicionais em beb√™s (V72P13, V72P16) em beb√™s de 2 meses avaliados separadamente. Idade m√©dia relatada: V72_41 13,8 anos; V72_29 adolescentes 14,1 anos, adultos jovens 20,6 anos; V102_03 15,0 anos.",
            "level_description": "Inclus√£o e an√°lise espec√≠ficas por idade foram realizadas, com adolescentes (11-17) e adultos jovens (18-24) estudados separadamente no ensaio do Reino Unido. Diferentes estudos focaram em diferentes coortes et√°rios."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios detalhados de inclus√£o/exclus√£o documentados: participantes saud√°veis, sem vacina√ß√£o meningoc√≥cica pr√©via, sem hist√≥rico de doen√ßa meningoc√≥cica, sem doen√ßa cr√¥nica/progressiva, sem imunocomprometimento, sem rea√ß√µes al√©rgicas graves a vacinas. Exclu√≠dos: gravidez, febre >38C nos 7 dias anteriores, antibi√≥ticos nos 7 dias anteriores, hemoderivados nos 90 dias anteriores, outras vacinas em 14-28 dias. Participantes do sexo feminino exigiam m√©todos contraceptivos aceit√°veis.",
            "level_description": "Crit√©rios claros e detalhados foram documentados. No entanto, crit√©rios foram restritivos (apenas participantes saud√°veis), limitando a generaliza√ß√£o para crian√ßas com condi√ß√µes de sa√∫de subjacentes."
          },
          "standardized_adverse_events": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Sistema de codifica√ß√£o MedDRA usado para classifica√ß√£o de eventos adversos em todo o estudo. Diretrizes da Brighton Collaboration referenciadas para defini√ß√£o de febre (T>38,0C). Escalas de gradua√ß√£o de gravidade definidas: rea√ß√µes locais (dor: leve/moderada/grave; eritema/endurecimento por faixas de mm); rea√ß√µes sist√™micas (nenhuma, leve, moderada, grave com base na limita√ß√£o de atividade di√°ria). Limiares espec√≠ficos de temperatura: 38,0C, 38,5C, 39,0C, 39,5C, 40,0C documentados.",
            "level_description": "Codifica√ß√£o MedDRA padronizada, crit√©rios de febre da Brighton Collaboration e escalas objetivas de gradua√ß√£o de gravidade foram aplicados consistentemente entre os estudos. Documenta√ß√£o clara dos m√©todos de medi√ß√£o."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "EAs solicitados coletados ativamente via cart√µes-di√°rio por 7 dias ap√≥s a vacina√ß√£o. EAGs monitorados ativamente durante os per√≠odos de estudo (6-12 meses). Protocolo incluiu: chamadas telef√¥nicas nos Dias 3-5 e Dias 63-65 para consultar sobre EAGs; visitas programadas para avalia√ß√£o de seguran√ßa; observa√ß√£o de 30 minutos ap√≥s vacina√ß√£o. Eventos Adversos com Atendimento M√©dico (EAAMs) rastreados. √ìbitos investigados com avalia√ß√£o de causalidade. 35 EAGs relatados em V72P10 com narrativas detalhadas e avalia√ß√µes dos investigadores.",
            "level_description": "Solicita√ß√£o ativa de eventos adversos via cart√µes-di√°rio, chamadas telef√¥nicas e visitas programadas. EAGs monitorados com avalia√ß√£o de causalidade. Distin√ß√£o clara entre eventos solicitados e n√£o solicitados documentada."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dois casos de artrite juvenil relatados em V72P10 (170 e 198 dias ap√≥s a vacina√ß√£o) - um avaliado como possivelmente relacionado. Um caso de tireoidite aguda em V72_29. Um caso de convuls√£o/epilepsia (condi√ß√£o pr√©-existente). S√≠ncope com manifesta√ß√µes convulsivas (vasovagal, relacionada √† venopun√ß√£o). Um caso de meningite bacteriana (Streptococcus pneumoniae, n√£o relacionado). O revisor concluiu que os dados n√£o sugerem associa√ß√£o entre vacina√ß√£o e condi√ß√µes autoimunes. Nenhum protocolo de triagem sistem√°tico para essas condi√ß√µes documentado.",
            "level_description": "Alguns eventos autoimunes/neurol√≥gicos foram capturados e analisados, mas n√£o houve protocolo de monitoramento sistem√°tico predefinido para essas condi√ß√µes espec√≠ficas. Monitoramento foi reativo em vez de proativo."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Pacientes imunocomprometidos exclu√≠dos dos ensaios - a bula observa que 'respostas imunes reduzidas' podem ocorrer. Mulheres gr√°vidas exclu√≠das; registro de gravidez estabelecido. Estudo V72P4 incluiu 53 adultos 'em risco' (trabalhadores de laborat√≥rio). Condi√ß√µes pr√©-existentes observadas como crit√©rios de exclus√£o. Documento afirma que seguran√ßa e efic√°cia n√£o estabelecidas em adultos >65 anos ou crian√ßas <10 anos. Plano de Estudo Pedi√°trico inclui estudos adiados para 6 semanas a <10 anos.",
            "level_description": "Grupos vulner√°veis (imunocomprometidos, gr√°vidas, prematuros) foram exclu√≠dos dos ensaios em vez de estudados. Dados limitados sobre aplicabilidade no mundo real para crian√ßas com condi√ß√µes cr√¥nicas."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudos dimensionados para desfechos de imunogenicidade com crit√©rios pr√©-especificados (aumento de 4 vezes nos t√≠tulos de hSBA). An√°lises de seguran√ßa foram descritivas sem teste de hip√≥teses. Consist√™ncia lote-a-lote avaliada com crit√©rios de IC 95% bilateral (intervalo 0,50-2,00). Dados faltantes: nenhuma imputa√ß√£o realizada. Popula√ß√µes por protocolo e inten√ß√£o de tratar definidas. Imunogenicidade analisada usando popula√ß√£o PP. Desequil√≠brios basais observados e discutidos.",
            "level_description": "Estudos foram adequadamente dimensionados para imunogenicidade, mas an√°lise de seguran√ßa foi apenas descritiva - uma limita√ß√£o comum. M√©todos estat√≠sticos foram apropriados para os desenhos de estudo."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Documento de revis√£o de BLA da FDA (STN: 125546/0) com relat√≥rios de estudos cl√≠nicos detalhados citados. Comit√™ de Monitoramento de Seguran√ßa de Dados (DMC) estabelecido para V102_03 para avaliar os primeiros 10% dos participantes. Inspe√ß√µes BIMO em locais revelaram alguns problemas de documenta√ß√£o (16 retiradas devido a rea√ß√µes no local da inje√ß√£o n√£o capturadas nos CRFs). Tabelas detalhadas de eventos adversos por grupo fornecidas. Narrativas de EAG individuais inclu√≠das. Emendas de CSR e mudan√ßas de protocolo documentadas.",
            "level_description": "Processo de revis√£o da FDA com supervis√£o de DSMB, inspe√ß√µes em locais e relato detalhado de eventos adversos. Alguns problemas de coleta de dados identificados e documentados. DIP brutos n√£o dispon√≠veis publicamente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Campanhas de vacina√ß√£o pr√©-licenciamento na Universidade de Princeton e UCSB forneceram dados semelhantes a p√≥s-comercializa√ß√£o em 15.351 participantes sob IND de Acesso Expandido do CDC. Vigil√¢ncia de EAG por 30 dias ap√≥s a 2¬™ dose via triagem de admiss√£o, pesquisas eletr√¥nicas, linhas diretas de seguran√ßa 24 horas, visitas a servi√ßos de sa√∫de, relat√≥rios hospitalares. 50 EAGs relatados e analisados incluindo anafilaxia (1 caso - avaliado como taxa esperada), apendicite (9 casos), rabdomi√≥lise (2 casos), 1 √≥bito (afogamento, n√£o relacionado). Registro de gravidez estabelecido.",
            "level_description": "Vigil√¢ncia extensiva pr√©-licenciamento atrav√©s de campanhas de vacina√ß√£o universit√°ria forneceu dados de seguran√ßa do mundo real. Registro de gravidez para monitoramento cont√≠nuo. Sistemas de relato passivo padr√£o (VAERS) impl√≠citos, mas n√£o detalhados."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Requerente identificado como Novartis Vaccines and Diagnostics. Estudos conduzidos sob IND com contribui√ß√£o regulat√≥ria do CBER. Ensaios cl√≠nicos foram patrocinados pelo fabricante. Revisor cl√≠nico da FDA (Anuja Rastogi) realizou avalia√ß√£o independente. Nenhuma declara√ß√£o expl√≠cita de divulga√ß√µes financeiras para investigadores. Locais de estudo inclu√≠ram centros de pesquisa comerciais (ex.: Dr. Stanley Block, Dra. Wendy Daly) e institui√ß√µes acad√™micas.",
            "level_description": "Ensaios financiados pela ind√∫stria sem divulga√ß√£o expl√≠cita de v√≠nculos financeiros de investigadores. FDA forneceu revis√£o regulat√≥ria independente. Nenhuma replica√ß√£o acad√™mica independente dos resultados documentada."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "3 √≥bitos relatados em V72P10: (1) mulher de 17 anos - trauma cranioencef√°lico por acidente de carro 4 meses ap√≥s vacina√ß√£o, n√£o relacionado; (2) mulher de 17 anos - overdose de paracetamol/suic√≠dio ~31 dias ap√≥s vacina√ß√£o, n√£o relacionado; (3) beb√™ nascido de participante vacinada - morte s√∫bita aos 1,5 meses, n√£o relacionado. 1 √≥bito na campanha UCSB: homem de 19 anos, afogamento (blackout em √°guas rasas), n√£o relacionado. Todos os √≥bitos investigados com avalia√ß√£o de causalidade. Nenhum √≥bito relacionado √† vacina relatado.",
            "level_description": "Mortalidade por todas as causas foi rastreada e relatada em todos os grupos. Cada √≥bito foi investigado com determina√ß√£o de causalidade. Total de 4 √≥bitos em todos os estudos, nenhum atribu√≠do √† vacina."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de desenvolvimento cl√≠nico de Bexsero incluiu 4 ensaios cl√≠nicos principais com 3.058 participantes de 10-25 anos, al√©m de dados de acesso expandido em 15.351 estudantes universit√°rios. Os ensaios empregaram randomiza√ß√£o adequada e metodologia com observador cego com defini√ß√µes padronizadas de eventos adversos (MedDRA, crit√©rios Brighton). Limita√ß√µes principais incluem: uso de comparadores de vacina ativa (Menveo) em vez de placebo verdadeiro na maioria dos estudos, limitando a capacidade de determinar taxas verdadeiras de eventos adversos; dura√ß√£o de acompanhamento de 6-12 meses √© m√≠nima para detectar efeitos autoimunes/neurol√≥gicos de longo prazo; popula√ß√µes vulner√°veis foram exclu√≠das em vez de estudadas; e ensaios foram dimensionados para imunogenicidade em vez de seguran√ßa. O perfil de seguran√ßa mostrou rea√ß√µes comuns (dor no local da inje√ß√£o 90%, dor grave 20-29%, mialgia, dor de cabe√ßa) consistentes com outras vacinas para adolescentes. EAGs incluindo 2 casos de artrite juvenil foram revisados, mas nenhum sinal de seguran√ßa definitivo identificado. No geral, o programa atende aos padr√µes regulat√≥rios para aprova√ß√£o acelerada, mas tem limita√ß√µes inerentes na detec√ß√£o de eventos adversos raros e tardios."
        }
      },
      "safety_en": {
        "vaccine_id": "menb_bexsero",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The BLA sought approval for ages 10-25 years, not young children (0-12). In the target age group: 3,058 subjects received at least one dose across 4 main clinical trials (V72_41: 1,097; V72_29: 2,646 per protocol; V72P10: 1,622; V102_03: 122). Additional 15,351 received vaccine in pre-licensure university campaigns. For infant data (supportive only): V72P13 studied ~2,500 infants at 2,4,6 months; V72P16 studied ~1,500 infants. The combined sample is adequate for detecting 1:1,000 events in adolescents, but the approval did not include children <10 years. Pediatric studies (6 weeks to <10 years) were deferred under PREA."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Follow-up periods varied by study: V72_41: 6 months post-last vaccination; V72_29: 12 months with assessments at 6 and 11 months post-second dose; V72P10: 12 months total; V102_03: 8 months (6 months post-last dose). Solicited adverse events were collected for only 7 days post-vaccination. Unsolicited AEs monitored for 30 days. SAEs monitored throughout study periods. The 6-12 month follow-up is insufficient to detect autoimmune or neurological conditions that may emerge months or years later. No multi-year follow-up data provided for the adolescent population."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Most main trials used another vaccine (MenACWY-CRM/Menveo) as comparator rather than true inert placebo, making it difficult to determine true adverse event rates attributable to Bexsero. V72_41: Menveo comparator (2:1 ratio). V72_29: Menveo comparator (2:2:1 ratio). V72P10: Only study with placebo control (aluminum hydroxide-saline) but only through Month 3, then no control from Month 6-12. V102_03: Saline placebo used only for Menveo group, not direct comparison. The use of active comparators obscures the true reactogenicity profile of the vaccine."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active surveillance methods were employed: 7-day diary cards completed by subjects/parents for solicited local and systemic reactions; telephone contacts on Days 3-5 and Days 63-65 to query for SAEs; scheduled study visits with physical examination; 30-minute post-vaccination observation period; Memory Aide for 8-month follow-up. SAEs actively monitored with detailed case narratives and causality assessment by investigators. MAAEs (Medically Attended Adverse Events) tracked. 35 SAEs in V72P10 and 50 SAEs in university campaigns were individually reviewed. BIMO site inspections revealed some documentation gaps (16 withdrawals due to injection site reactions not captured in CRFs)."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "No systematic scheduled neurological or developmental assessments were documented. Neurological events captured included: syncope with seizure manifestations (vasovagal, related to venipuncture, not vaccine); convulsion/epilepsy in one subject (pre-existing condition exacerbated); one case of bacterial meningitis (S. pneumoniae, unrelated to vaccine). One new-onset generalized tonic-clonic seizure in UCSB campaign (22 days post-dose, assessed as not related). Two cases of juvenile arthritis (170 and 198 days post-vaccination) were identified and reviewed - one assessed as possibly related. No predefined protocol for actively screening seizures, developmental delays, or autoimmune conditions."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Vulnerable groups were excluded from trials rather than studied: Immunocompromised individuals explicitly excluded; document notes they 'may have reduced immune responses.' Pregnant and nursing women excluded; pregnancy registry established for post-marketing only. Premature infants not specifically studied in adolescent trials. Children with chronic diseases excluded. No separate analysis of subjects with allergies, asthma, or concurrent medications. Package insert states safety not established in adults >65 or children <10 years. Pediatric studies for ages 6 weeks to <10 years were deferred. This limits confidence in safety for children who may need the vaccine most."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "FDA BLA review document (STN: 125546/0) provides detailed Clinical Study Reports. Data Safety Monitoring Committee (DMC) established for V102_03 to evaluate safety data on first 10% of subjects. FDA BIMO conducted clinical site inspections at two sites in Chile (sites #14 and #41), identifying documentation issues. Detailed adverse event tables by treatment group, dose, and severity provided. Individual SAE narratives with causality assessments included. Protocol amendments and statistical analysis plan changes documented. Raw individual participant data not publicly available. No independent replication by academic researchers documented."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Pre-licensure expanded access vaccination campaigns at Princeton University (5,520 1st doses, 5,165 2nd doses) and UCSB (9,831 1st doses, 7,707 2nd doses) under CDC-sponsored IND provided real-world surveillance data on 15,351 participants. SAE collection methods: intake screening prior to 2nd dose, electronic survey 30 days post-2nd dose, 24-hour vaccine safety hotline, university health services visits, local hospital/ER reports. Results: 23 SAEs at Princeton, 27 at UCSB. Key findings: 9 appendicitis cases (consistent with background rates), 1 anaphylaxis (expected rate per CDC), 2 rhabdomyolysis (with confounders), 1 accidental death (drowning, unrelated). Pregnancy registry established for ongoing monitoring."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This FDA clinical review document provides limited reassurance regarding pediatric safety because: (1) the vaccine was approved for ages 10-25 years, not young children - pediatric studies for ages 6 weeks to <10 years were deferred; (2) most trials used another vaccine (Menveo) as comparator rather than true placebo, obscuring the true adverse event rate; (3) follow-up of 6-12 months is insufficient to detect long-term autoimmune or neurological effects; (4) vulnerable children (immunocompromised, chronic conditions, premature) were excluded rather than studied; and (5) no systematic protocol for neurological/developmental monitoring existed. The data shows high reactogenicity (90% injection site pain, 20-29% severe pain) and rare SAEs including 2 cases of juvenile arthritis were reviewed without establishing clear causality. The expanded access data on 15,351 university students provides additional real-world evidence but in an older population. For a parent asking 'Is this safe for my child?' - this document provides moderate confidence for healthy adolescents 10+ years but does not address safety in younger children or those with underlying conditions."
        }
      },
      "safety_pt": {
        "vaccine_id": "menb_bexsero",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O BLA buscou aprova√ß√£o para idades de 10-25 anos, n√£o crian√ßas pequenas (0-12). Na faixa et√°ria alvo: 3.058 participantes receberam pelo menos uma dose em 4 ensaios cl√≠nicos principais (V72_41: 1.097; V72_29: 2.646 por protocolo; V72P10: 1.622; V102_03: 122). Adicionalmente, 15.351 receberam a vacina em campanhas universit√°rias pr√©-licenciamento. Para dados de beb√™s (apenas de suporte): V72P13 estudou ~2.500 beb√™s aos 2,4,6 meses; V72P16 estudou ~1.500 beb√™s. A amostra combinada √© adequada para detectar eventos de 1:1.000 em adolescentes, mas a aprova√ß√£o n√£o incluiu crian√ßas <10 anos. Estudos pedi√°tricos (6 semanas a <10 anos) foram adiados sob PREA."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os per√≠odos de acompanhamento variaram por estudo: V72_41: 6 meses ap√≥s a √∫ltima vacina√ß√£o; V72_29: 12 meses com avalia√ß√µes aos 6 e 11 meses ap√≥s a segunda dose; V72P10: 12 meses no total; V102_03: 8 meses (6 meses ap√≥s a √∫ltima dose). Eventos adversos solicitados foram coletados por apenas 7 dias ap√≥s a vacina√ß√£o. EAs n√£o solicitados monitorados por 30 dias. EAGs monitorados durante os per√≠odos de estudo. O acompanhamento de 6-12 meses √© insuficiente para detectar condi√ß√µes autoimunes ou neurol√≥gicas que podem surgir meses ou anos depois. Nenhum dado de acompanhamento de v√°rios anos fornecido para a popula√ß√£o adolescente."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A maioria dos ensaios principais usou outra vacina (MenACWY-CRM/Menveo) como comparador em vez de placebo inerte verdadeiro, dificultando a determina√ß√£o das verdadeiras taxas de eventos adversos atribu√≠veis a Bexsero. V72_41: comparador Menveo (propor√ß√£o 2:1). V72_29: comparador Menveo (propor√ß√£o 2:2:1). V72P10: √önico estudo com controle placebo (hidr√≥xido de alum√≠nio-solu√ß√£o salina), mas apenas at√© o M√™s 3, depois nenhum controle do M√™s 6-12. V102_03: Placebo salino usado apenas para o grupo Menveo, n√£o compara√ß√£o direta. O uso de comparadores ativos obscurece o verdadeiro perfil de reatogenicidade da vacina."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "M√©todos de vigil√¢ncia ativa foram empregados: cart√µes-di√°rio de 7 dias preenchidos por participantes/pais para rea√ß√µes locais e sist√™micas solicitadas; contatos telef√¥nicos nos Dias 3-5 e Dias 63-65 para consultar sobre EAGs; visitas de estudo programadas com exame f√≠sico; per√≠odo de observa√ß√£o de 30 minutos ap√≥s vacina√ß√£o; Aux√≠lio de Mem√≥ria para acompanhamento de 8 meses. EAGs monitorados ativamente com narrativas de casos detalhadas e avalia√ß√£o de causalidade pelos investigadores. EAAMs (Eventos Adversos com Atendimento M√©dico) rastreados. 35 EAGs em V72P10 e 50 EAGs nas campanhas universit√°rias foram revisados individualmente. Inspe√ß√µes BIMO revelaram algumas lacunas de documenta√ß√£o (16 retiradas por rea√ß√µes no local da inje√ß√£o n√£o capturadas nos CRFs)."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Nenhuma avalia√ß√£o neurol√≥gica ou de desenvolvimento programada sistem√°tica foi documentada. Eventos neurol√≥gicos capturados inclu√≠ram: s√≠ncope com manifesta√ß√µes convulsivas (vasovagal, relacionada √† venopun√ß√£o, n√£o √† vacina); convuls√£o/epilepsia em um participante (condi√ß√£o pr√©-existente exacerbada); um caso de meningite bacteriana (S. pneumoniae, n√£o relacionado √† vacina). Uma nova convuls√£o t√¥nico-cl√¥nica generalizada na campanha UCSB (22 dias ap√≥s a dose, avaliada como n√£o relacionada). Dois casos de artrite juvenil (170 e 198 dias ap√≥s vacina√ß√£o) foram identificados e revisados - um avaliado como possivelmente relacionado. Nenhum protocolo predefinido para triagem ativa de convuls√µes, atrasos de desenvolvimento ou condi√ß√µes autoimunes."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Grupos vulner√°veis foram exclu√≠dos dos ensaios em vez de estudados: Indiv√≠duos imunocomprometidos explicitamente exclu√≠dos; documento observa que eles 'podem ter respostas imunes reduzidas.' Mulheres gr√°vidas e lactantes exclu√≠das; registro de gravidez estabelecido apenas para p√≥s-comercializa√ß√£o. Beb√™s prematuros n√£o especificamente estudados nos ensaios de adolescentes. Crian√ßas com doen√ßas cr√¥nicas exclu√≠das. Nenhuma an√°lise separada de participantes com alergias, asma ou medica√ß√µes concomitantes. A bula afirma que seguran√ßa n√£o estabelecida em adultos >65 ou crian√ßas <10 anos. Estudos pedi√°tricos para idades de 6 semanas a <10 anos foram adiados. Isso limita a confian√ßa na seguran√ßa para crian√ßas que podem mais precisar da vacina."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Documento de revis√£o de BLA da FDA (STN: 125546/0) fornece Relat√≥rios de Estudos Cl√≠nicos detalhados. Comit√™ de Monitoramento de Seguran√ßa de Dados (DMC) estabelecido para V102_03 para avaliar dados de seguran√ßa dos primeiros 10% dos participantes. FDA BIMO realizou inspe√ß√µes cl√≠nicas em dois locais no Chile (locais #14 e #41), identificando problemas de documenta√ß√£o. Tabelas detalhadas de eventos adversos por grupo de tratamento, dose e gravidade fornecidas. Narrativas de EAG individuais com avalia√ß√µes de causalidade inclu√≠das. Emendas de protocolo e mudan√ßas no plano de an√°lise estat√≠stica documentadas. Dados brutos individuais de participantes n√£o dispon√≠veis publicamente. Nenhuma replica√ß√£o independente por pesquisadores acad√™micos documentada."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Campanhas de vacina√ß√£o de acesso expandido pr√©-licenciamento na Universidade de Princeton (5.520 1¬™s doses, 5.165 2¬™s doses) e UCSB (9.831 1¬™s doses, 7.707 2¬™s doses) sob IND patrocinado pelo CDC forneceram dados de vigil√¢ncia do mundo real em 15.351 participantes. M√©todos de coleta de EAG: triagem de admiss√£o antes da 2¬™ dose, pesquisa eletr√¥nica 30 dias ap√≥s a 2¬™ dose, linha direta de seguran√ßa de vacinas 24 horas, visitas aos servi√ßos de sa√∫de universit√°rios, relat√≥rios de hospitais/pronto-socorro locais. Resultados: 23 EAGs em Princeton, 27 na UCSB. Achados principais: 9 casos de apendicite (consistentes com taxas de base), 1 anafilaxia (taxa esperada por CDC), 2 rabdomi√≥lise (com fatores de confus√£o), 1 √≥bito acidental (afogamento, n√£o relacionado). Registro de gravidez estabelecido para monitoramento cont√≠nuo."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Este documento de revis√£o cl√≠nica da FDA fornece garantia limitada sobre seguran√ßa pedi√°trica porque: (1) a vacina foi aprovada para idades de 10-25 anos, n√£o crian√ßas pequenas - estudos pedi√°tricos para idades de 6 semanas a <10 anos foram adiados; (2) a maioria dos ensaios usou outra vacina (Menveo) como comparador em vez de placebo verdadeiro, obscurecendo a verdadeira taxa de eventos adversos; (3) acompanhamento de 6-12 meses √© insuficiente para detectar efeitos autoimunes ou neurol√≥gicos de longo prazo; (4) crian√ßas vulner√°veis (imunocomprometidas, condi√ß√µes cr√¥nicas, prematuras) foram exclu√≠das em vez de estudadas; e (5) nenhum protocolo sistem√°tico para monitoramento neurol√≥gico/de desenvolvimento existia. Os dados mostram alta reatogenicidade (90% dor no local da inje√ß√£o, 20-29% dor grave) e EAGs raros incluindo 2 casos de artrite juvenil foram revisados sem estabelecer causalidade clara. Os dados de acesso expandido em 15.351 estudantes universit√°rios fornecem evid√™ncia adicional do mundo real, mas em popula√ß√£o mais velha. Para um pai perguntando 'Isso √© seguro para meu filho?' - este documento fornece confian√ßa moderada para adolescentes saud√°veis de 10+ anos, mas n√£o aborda seguran√ßa em crian√ßas mais jovens ou aquelas com condi√ß√µes subjacentes."
        }
      }
    },
    {
      "id": "menb_trumenba",
      "name": "Trumenba",
      "type": "MenB",
      "manufacturer": "Pfizer",
      "description": "Meningococcal Group B Vaccine for prevention of invasive disease caused by Neisseria meningitidis serogroup B.",
      "sources": [
        "menb_trumenba_summary.pdf",
        "menb_trumenba_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "menb_trumenba",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Controlled studies used saline as placebo in some groups (e.g., B1971011 Group 3 received saline+HPV4, Group 2 received rLP2086+saline). However, most comparisons involved active comparators (HPV4, Tdap, dTaP-IPV) rather than true inert placebo. The control groups varied by study: saline alone, saline + non-meningococcal vaccine, or non-meningococcal vaccine alone (e.g., Tdap).",
            "level_description": "Present but flawed - While saline was used in some arms, most safety comparisons involved active vaccine comparators which can obscure true adverse event rates attributable to the MenB vaccine."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study B1971011 was 'observer-blinded' - subjects, investigators and applicant were blinded, but vaccine dispensing/administering personnel were not blinded because vaccine and saline appearance differed. Studies B1971012 and B1971010 were 'single-blinded' (subjects blinded only). Study B1971004 was open-label.",
            "level_description": "Present but flawed - Observer-blinding was implemented in the main US study, but not full double-blinding. Personnel collecting safety information were separate from dispensing staff, but complete blinding was not achieved."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies used randomized allocation via interactive response systems. Study B1971011: randomized 2499 participants (Group 1 n=999, Group 2 n=998, Group 3 n=502) with stratification. Study B1971012: randomized in 3:3:3:2:1 ratio with stratification by age group. An independent statistical center (ISC) provided blinded subject listings to laboratory personnel.",
            "level_description": "Meets expected standards - Documented random allocation with computerized systems and allocation concealment through independent statistical centers."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Total of 4335 subjects received final formulation (120ug). Of 4282 subjects ages 11-25 years, 99.3% were ages 11-18 years (adolescent). Core safety database from 4 controlled studies: 2566 subjects received at least 1 dose of Trumenba, 1012 in control groups. Study B1971011 alone had 1982 adolescent Trumenba recipients.",
            "level_description": "Meets expected standards - Sample size exceeds 3,000 adolescents overall, adequate to detect events at 1:1,000 frequency, though most subjects were 11-18 years, not younger children."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Safety follow-up was 6 months after the last vaccination in most studies. The vaccination phase was Day 1 through one month after the 3rd vaccination, with follow-up extending to 6 months post-final dose. Total monitoring period approximately 12 months from first dose to study completion.",
            "level_description": "Present but flawed - Six months post-vaccination is inadequate for detecting delayed autoimmune or neurological conditions that may emerge over years. The 12-month total duration is below the ideal minimum of several years."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Analyses stratified by age 11 to <14 years (58.1%) and 15 to <18 years (40.0%). Study B1971012 enrolled ages 11-19 with stratification by 11-14 and 14-19 years. Only 2.0% were >18 years. No children <10 years were included; studies in ages 1-10 were deferred.",
            "level_description": "Present but flawed - Limited to two adolescent subgroups. No data for infants, toddlers, or younger children (ages 0-10). Studies in children 1-10 years were deferred as post-marketing requirements."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Exclusion criteria included: known immune system defects, immunosuppressive therapy, neuroinflammatory or autoimmune conditions (transverse myelitis, uveitis, optic neuritis, multiple sclerosis), significant neurological disorders, history of seizures (excluding febrile), previous anaphylactic reactions to vaccines. Healthy subjects only were enrolled.",
            "level_description": "Present but flawed - Highly restrictive criteria excluding immunocompromised children, those with autoimmune conditions, and neurological disorders limits generalizability to real-world populations who may receive the vaccine."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Used MedDRA coding for adverse events. Objective grading scales defined: Injection site redness/swelling (measured in cm), pain severity by interference with activity, fever thresholds (38.0-38.4C, 38.5-38.9C, 39.0-40.0C, >40.0C). Solicited reactions recorded daily for 7 days via electronic diary.",
            "level_description": "Meets expected standards - Standardized MedDRA coding and objective grading criteria were used consistently across studies with electronic diary capture."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Active solicitation of SAEs from Day 1 through 6 months after last vaccination. External Data Monitoring Committee (EDMC/DMC) responsible for ongoing safety monitoring. SAEs, hospitalizations, newly diagnosed chronic medical conditions (NDCMCs), and neuroinflammatory/autoimmune conditions were specifically queried by study personnel at each visit.",
            "level_description": "Meets expected standards - Active surveillance with DMC oversight, specific prompts for autoimmune/neuroinflammatory conditions, and systematic SAE collection throughout the study period."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Specific monitoring for neuroinflammatory and autoimmune conditions with extensive MedDRA term list for case identification. 14 cases identified: 13 autoimmune (psoriasis exacerbation, celiac disease, autoimmune thyroiditis, ITP, post-infectious arthritis, Sydenham's chorea, IgA nephropathy, Crohn's disease, rheumatoid arthritis, Basedow-Graves disease, hypothyroidism x2) and 1 neuroinflammatory (Bell's palsy). Baseline serum samples were analyzed retrospectively to determine pre-existing conditions.",
            "level_description": "Meets expected standards - Dedicated surveillance protocol for autoimmune/neuroinflammatory conditions with investigator prompts, extensive case work-ups, retrospective baseline testing, and individual case narratives."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Vulnerable populations explicitly excluded: immunocompromised, those with autoimmune conditions, neurological disorders, premature infants (not tested). Studies in infants showed 90% fever rate with 60ug dose, leading to discontinuation. Studies in children 1-10 years deferred. Population was primarily Caucasian (90.8%), limiting racial/ethnic diversity.",
            "level_description": "Inadequate - Immunocompromised children, those with chronic conditions, and infants were excluded. Infant study showed concerning safety signals (90% fever rate). No data on vulnerable subgroups who may need the vaccine most."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Sample size calculations documented with 83.6% overall study power for primary objectives. Non-inferiority criteria specified (GMT ratio >0.67). Statistical analyses performed by independent statistical center (ISC). Sensitivity analyses conducted for missing data. 95% confidence intervals reported. Modified intent-to-treat and per-protocol populations defined.",
            "level_description": "Meets expected standards - Proper power calculations, pre-specified hypotheses, independent statistical analysis, and sensitivity analyses were performed. Studies primarily powered for immunogenicity rather than safety."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Independent Data Safety Monitoring Board (EDMC/DMC) reviewed safety data. FDA BioResearch Monitoring inspections at 3 clinical sites. CBER statistical reviewers performed independent analyses. Financial disclosures provided (10 investigators with disclosable interests of 1036 total). FDA clinical review document publicly available.",
            "level_description": "Meets expected standards - Independent oversight through DMC, FDA review and inspection, financial disclosure. Raw individual participant data not publicly available but FDA had full data access."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Post-marketing requirements include confirmatory studies B1971009 and B1971016 for broader strain coverage, PREA studies B1971017 and B1971035 for ages 1-10 years. Post-marketing commitments include safety study B1971014 (~10,000 additional subjects), concomitant vaccine study B1971015, and pregnancy outcomes study B1971052. Routine pharmacovigilance planned.",
            "level_description": "Meets expected standards - Comprehensive post-marketing plan including confirmatory efficacy studies, pediatric studies, additional safety data collection, and pregnancy registry. Accelerated approval pathway ensures ongoing monitoring."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Financial disclosures: 10 of 1036 investigators had disclosable financial interests. 9 received 'significant payments of other sorts', 1 held 'significant equity interest in sponsor'. Sponsor was Wyeth Pharmaceuticals (Pfizer subsidiary). Steps to minimize bias were described. No independent funding source.",
            "level_description": "Present but flawed - All studies were industry-funded by Pfizer/Wyeth. While financial disclosures were provided, the lack of independent funding increases risk of favorable outcome bias."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "One death reported: motor vehicle accident 38 days after 1st vaccination, deemed unrelated to vaccine. Deaths tracked throughout studies. Total SAE rates reported for all groups: 1.7% Trumenba vs 1.6% control (controlled studies). All-cause SAE rates by SOC documented.",
            "level_description": "Meets expected standards - All-cause mortality tracked and reported. The single death was clearly unrelated to vaccination. Total SAEs reported by group without restricting to 'vaccine-related' only."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The Trumenba clinical development program demonstrates adequate methodology for immunogenicity assessment under accelerated approval, with proper randomization, standardized adverse event definitions, active safety surveillance for autoimmune/neuroinflammatory conditions, and transparent regulatory oversight. However, significant limitations exist for comprehensive pediatric safety evaluation: the use of active comparators rather than true placebos in most arms, observer-blinding rather than double-blinding, follow-up duration of only 6 months post-vaccination (inadequate for long-term autoimmune detection), exclusion of vulnerable populations (immunocompromised, children with chronic conditions), lack of data in children under 10 years (deferred), concerning safety signals in infants (90% fever rate leading to study discontinuation), and industry funding without independent verification. The 14 autoimmune/neuroinflammatory cases in vaccine recipients versus 0 in controls warrants continued surveillance, though rates were deemed within background population rates. Overall, the studies meet regulatory standards for accelerated approval but fall short of ideal safety study standards for a pediatric vaccine intended for broad population use."
        }
      },
      "trial_pt": {
        "vaccine_id": "menb_trumenba",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudos controlados usaram solu√ß√£o salina como placebo em alguns grupos (ex.: B1971011 Grupo 3 recebeu salina+HPV4, Grupo 2 recebeu rLP2086+salina). No entanto, a maioria das compara√ß√µes envolveu comparadores ativos (HPV4, Tdap, dTaP-IPV) em vez de placebo inerte verdadeiro. Os grupos controle variaram por estudo: salina sozinha, salina + vacina n√£o-meningoc√≥cica, ou vacina n√£o-meningoc√≥cica sozinha (ex.: Tdap).",
            "level_description": "Presente mas com falhas - Embora salina tenha sido usada em alguns bra√ßos, a maioria das compara√ß√µes de seguran√ßa envolveu comparadores de vacina ativa que podem obscurecer as verdadeiras taxas de eventos adversos atribu√≠veis √† vacina MenB."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo B1971011 foi 'com observador cego' - participantes, investigadores e requerente foram cegos, mas a equipe de dispensa√ß√£o/administra√ß√£o da vacina n√£o foi cegada porque a apar√™ncia da vacina e da salina diferia. Estudos B1971012 e B1971010 foram 'simples-cegos' (apenas participantes cegos). Estudo B1971004 foi aberto.",
            "level_description": "Presente mas com falhas - Cegamento do observador foi implementado no estudo principal dos EUA, mas n√£o duplo-cego completo. A equipe que coletou informa√ß√µes de seguran√ßa foi separada da equipe de dispensa√ß√£o, mas cegamento completo n√£o foi alcan√ßado."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudos usaram aloca√ß√£o randomizada via sistemas de resposta interativa. Estudo B1971011: randomizou 2499 participantes (Grupo 1 n=999, Grupo 2 n=998, Grupo 3 n=502) com estratifica√ß√£o. Estudo B1971012: randomizado em propor√ß√£o 3:3:3:2:1 com estratifica√ß√£o por faixa et√°ria. Um centro estat√≠stico independente (ISC) forneceu listagens de participantes cegos para a equipe de laborat√≥rio.",
            "level_description": "Atende aos padr√µes esperados - Aloca√ß√£o aleat√≥ria documentada com sistemas computadorizados e oculta√ß√£o de aloca√ß√£o atrav√©s de centros estat√≠sticos independentes."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Total de 4335 participantes receberam a formula√ß√£o final (120ug). Dos 4282 participantes de 11-25 anos, 99,3% tinham 11-18 anos (adolescentes). Base de dados de seguran√ßa central de 4 estudos controlados: 2566 participantes receberam pelo menos 1 dose de Trumenba, 1012 em grupos controle. Apenas o Estudo B1971011 teve 1982 receptores adolescentes de Trumenba.",
            "level_description": "Atende aos padr√µes esperados - Tamanho amostral excede 3.000 adolescentes no geral, adequado para detectar eventos na frequ√™ncia de 1:1.000, embora a maioria dos participantes tinha 11-18 anos, n√£o crian√ßas mais jovens."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Acompanhamento de seguran√ßa foi de 6 meses ap√≥s a √∫ltima vacina√ß√£o na maioria dos estudos. A fase de vacina√ß√£o foi do Dia 1 at√© um m√™s ap√≥s a 3¬™ vacina√ß√£o, com acompanhamento estendendo-se a 6 meses ap√≥s a dose final. Per√≠odo total de monitoramento aproximadamente 12 meses da primeira dose at√© a conclus√£o do estudo.",
            "level_description": "Presente mas com falhas - Seis meses ap√≥s a vacina√ß√£o √© inadequado para detectar condi√ß√µes autoimunes ou neurol√≥gicas tardias que podem surgir ao longo de anos. A dura√ß√£o total de 12 meses est√° abaixo do m√≠nimo ideal de v√°rios anos."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "An√°lises estratificadas por idade 11 a <14 anos (58,1%) e 15 a <18 anos (40,0%). Estudo B1971012 incluiu idades 11-19 com estratifica√ß√£o por 11-14 e 14-19 anos. Apenas 2,0% tinham >18 anos. Nenhuma crian√ßa <10 anos foi inclu√≠da; estudos em idades 1-10 foram adiados.",
            "level_description": "Presente mas com falhas - Limitado a dois subgrupos adolescentes. Nenhum dado para beb√™s, crian√ßas pequenas ou crian√ßas mais jovens (idades 0-10). Estudos em crian√ßas de 1-10 anos foram adiados como requisitos p√≥s-comercializa√ß√£o."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Crit√©rios de exclus√£o inclu√≠ram: defeitos conhecidos do sistema imune, terapia imunossupressora, condi√ß√µes neuroinflamat√≥rias ou autoimunes (mielite transversa, uve√≠te, neurite √≥ptica, esclerose m√∫ltipla), dist√∫rbios neurol√≥gicos significativos, hist√≥rico de convuls√µes (exceto febris), rea√ß√µes anafil√°ticas pr√©vias a vacinas. Apenas participantes saud√°veis foram inclu√≠dos.",
            "level_description": "Presente mas com falhas - Crit√©rios altamente restritivos excluindo crian√ßas imunocomprometidas, aquelas com condi√ß√µes autoimunes e dist√∫rbios neurol√≥gicos limitam a generaliza√ß√£o para popula√ß√µes do mundo real que podem receber a vacina."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Usou codifica√ß√£o MedDRA para eventos adversos. Escalas de gradua√ß√£o objetivas definidas: Vermelhid√£o/incha√ßo no local da inje√ß√£o (medido em cm), gravidade da dor por interfer√™ncia na atividade, limiares de febre (38,0-38,4C, 38,5-38,9C, 39,0-40,0C, >40,0C). Rea√ß√µes solicitadas registradas diariamente por 7 dias via di√°rio eletr√¥nico.",
            "level_description": "Atende aos padr√µes esperados - Codifica√ß√£o MedDRA padronizada e crit√©rios de gradua√ß√£o objetivos foram usados consistentemente entre os estudos com captura por di√°rio eletr√¥nico."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicita√ß√£o ativa de EAGs do Dia 1 at√© 6 meses ap√≥s a √∫ltima vacina√ß√£o. Comit√™ Externo de Monitoramento de Dados (EDMC/DMC) respons√°vel pelo monitoramento cont√≠nuo de seguran√ßa. EAGs, hospitaliza√ß√µes, condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas (NDCMCs) e condi√ß√µes neuroinflamat√≥rias/autoimunes foram especificamente consultadas pela equipe do estudo em cada visita.",
            "level_description": "Atende aos padr√µes esperados - Vigil√¢ncia ativa com supervis√£o de DMC, solicita√ß√µes espec√≠ficas para condi√ß√µes autoimunes/neuroinflamat√≥rias e coleta sistem√°tica de EAG durante todo o per√≠odo de estudo."
          },
          "autoimmune_neurological": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Monitoramento espec√≠fico para condi√ß√µes neuroinflamat√≥rias e autoimunes com lista extensa de termos MedDRA para identifica√ß√£o de casos. 14 casos identificados: 13 autoimunes (exacerba√ß√£o de psor√≠ase, doen√ßa cel√≠aca, tireoidite autoimune, PTI, artrite p√≥s-infecciosa, coreia de Sydenham, nefropatia por IgA, doen√ßa de Crohn, artrite reumatoide, doen√ßa de Basedow-Graves, hipotireoidismo x2) e 1 neuroinflamat√≥rio (paralisia de Bell). Amostras de soro basais foram analisadas retrospectivamente para determinar condi√ß√µes pr√©-existentes.",
            "level_description": "Atende aos padr√µes esperados - Protocolo de vigil√¢ncia dedicado para condi√ß√µes autoimunes/neuroinflamat√≥rias com solicita√ß√µes aos investigadores, investiga√ß√µes extensas de casos, testes basais retrospectivos e narrativas de casos individuais."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Popula√ß√µes vulner√°veis explicitamente exclu√≠das: imunocomprometidos, aqueles com condi√ß√µes autoimunes, dist√∫rbios neurol√≥gicos, beb√™s prematuros (n√£o testados). Estudos em beb√™s mostraram taxa de febre de 90% com dose de 60ug, levando √† descontinua√ß√£o. Estudos em crian√ßas de 1-10 anos adiados. Popula√ß√£o foi predominantemente caucasiana (90,8%), limitando diversidade racial/√©tnica.",
            "level_description": "Inadequado - Crian√ßas imunocomprometidas, aquelas com condi√ß√µes cr√¥nicas e beb√™s foram exclu√≠dos. Estudo em beb√™s mostrou sinais de seguran√ßa preocupantes (taxa de febre de 90%). Nenhum dado sobre subgrupos vulner√°veis que podem mais precisar da vacina."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "C√°lculos de tamanho amostral documentados com 83,6% de poder geral do estudo para objetivos prim√°rios. Crit√©rios de n√£o inferioridade especificados (raz√£o de TMG >0,67). An√°lises estat√≠sticas realizadas por centro estat√≠stico independente (ISC). An√°lises de sensibilidade realizadas para dados faltantes. Intervalos de confian√ßa de 95% relatados. Popula√ß√µes de inten√ß√£o de tratar modificada e por protocolo definidas.",
            "level_description": "Atende aos padr√µes esperados - C√°lculos de poder adequados, hip√≥teses pr√©-especificadas, an√°lise estat√≠stica independente e an√°lises de sensibilidade foram realizadas. Estudos foram primariamente dimensionados para imunogenicidade em vez de seguran√ßa."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (EDMC/DMC) revisou dados de seguran√ßa. Inspe√ß√µes FDA BioResearch Monitoring em 3 locais cl√≠nicos. Revisores estat√≠sticos do CBER realizaram an√°lises independentes. Divulga√ß√µes financeiras fornecidas (10 investigadores com interesses divulg√°veis de 1036 no total). Documento de revis√£o cl√≠nica da FDA dispon√≠vel publicamente.",
            "level_description": "Atende aos padr√µes esperados - Supervis√£o independente atrav√©s de DMC, revis√£o e inspe√ß√£o da FDA, divulga√ß√£o financeira. Dados brutos individuais de participantes n√£o dispon√≠veis publicamente, mas FDA teve acesso completo aos dados."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Requisitos p√≥s-comercializa√ß√£o incluem estudos confirmat√≥rios B1971009 e B1971016 para cobertura mais ampla de cepas, estudos PREA B1971017 e B1971035 para idades 1-10 anos. Compromissos p√≥s-comercializa√ß√£o incluem estudo de seguran√ßa B1971014 (~10.000 participantes adicionais), estudo de vacinas concomitantes B1971015 e estudo de desfechos de gravidez B1971052. Farmacovigil√¢ncia de rotina planejada.",
            "level_description": "Atende aos padr√µes esperados - Plano p√≥s-comercializa√ß√£o abrangente incluindo estudos confirmat√≥rios de efic√°cia, estudos pedi√°tricos, coleta adicional de dados de seguran√ßa e registro de gravidez. Caminho de aprova√ß√£o acelerada garante monitoramento cont√≠nuo."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Divulga√ß√µes financeiras: 10 de 1036 investigadores tinham interesses financeiros divulg√°veis. 9 receberam 'pagamentos significativos de outros tipos', 1 detinha 'interesse patrimonial significativo no patrocinador'. Patrocinador foi Wyeth Pharmaceuticals (subsidi√°ria da Pfizer). Medidas para minimizar vi√©s foram descritas. Nenhuma fonte de financiamento independente.",
            "level_description": "Presente mas com falhas - Todos os estudos foram financiados pela ind√∫stria pela Pfizer/Wyeth. Embora divulga√ß√µes financeiras tenham sido fornecidas, a falta de financiamento independente aumenta o risco de vi√©s de desfecho favor√°vel."
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Um √≥bito relatado: acidente automobil√≠stico 38 dias ap√≥s a 1¬™ vacina√ß√£o, considerado n√£o relacionado √† vacina. √ìbitos rastreados durante todos os estudos. Taxas totais de EAG relatadas para todos os grupos: 1,7% Trumenba vs 1,6% controle (estudos controlados). Taxas de EAG por todas as causas por SOC documentadas.",
            "level_description": "Atende aos padr√µes esperados - Mortalidade por todas as causas rastreada e relatada. O √∫nico √≥bito foi claramente n√£o relacionado √† vacina√ß√£o. EAGs totais relatados por grupo sem restringir apenas a 'relacionados √† vacina'."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "O programa de desenvolvimento cl√≠nico de Trumenba demonstra metodologia adequada para avalia√ß√£o de imunogenicidade sob aprova√ß√£o acelerada, com randomiza√ß√£o adequada, defini√ß√µes padronizadas de eventos adversos, vigil√¢ncia ativa de seguran√ßa para condi√ß√µes autoimunes/neuroinflamat√≥rias e supervis√£o regulat√≥ria transparente. No entanto, existem limita√ß√µes significativas para avalia√ß√£o abrangente de seguran√ßa pedi√°trica: uso de comparadores ativos em vez de placebos verdadeiros na maioria dos bra√ßos, cegamento de observador em vez de duplo-cego, dura√ß√£o de acompanhamento de apenas 6 meses ap√≥s a vacina√ß√£o (inadequado para detec√ß√£o de autoimunidade de longo prazo), exclus√£o de popula√ß√µes vulner√°veis (imunocomprometidos, crian√ßas com condi√ß√µes cr√¥nicas), falta de dados em crian√ßas menores de 10 anos (adiado), sinais de seguran√ßa preocupantes em beb√™s (taxa de febre de 90% levando √† descontinua√ß√£o do estudo), e financiamento pela ind√∫stria sem verifica√ß√£o independente. Os 14 casos autoimunes/neuroinflamat√≥rios em receptores da vacina versus 0 nos controles justificam vigil√¢ncia cont√≠nua, embora as taxas tenham sido consideradas dentro das taxas populacionais de base. No geral, os estudos atendem aos padr√µes regulat√≥rios para aprova√ß√£o acelerada, mas ficam aqu√©m dos padr√µes ideais de estudo de seguran√ßa para uma vacina pedi√°trica destinada ao uso populacional amplo."
        }
      },
      "safety_en": {
        "vaccine_id": "menb_trumenba",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Total of 4,335 subjects received the final 120ug formulation. Core safety database from 4 controlled studies included 2,566 adolescents receiving Trumenba and 1,012 controls. Of the 4,282 subjects ages 11-25 years, 99.3% were adolescents (11-18 years). Sample size of >3,000 is adequate to detect adverse events occurring at 1:1,000 frequency, meeting the threshold for reasonable safety detection. However, sample is limited to adolescents with no children <10 years included in the license application."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Safety monitoring extended 6 months after the final (third) vaccination, with total study duration approximately 12 months from first dose. This duration is inadequate for detecting delayed autoimmune or neurological conditions that may emerge months to years after vaccination. The ideal minimum of 12-24 months post-final dose, with several years for long-term effects, was not met. The 14 autoimmune/neuroinflammatory cases identified within 6 months may represent only a fraction of potential delayed reactions."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Four controlled studies used varying comparison groups: saline alone in some arms, but most comparisons involved active vaccines (HPV4, Tdap, dTaP-IPV). Study B1971011 had a saline+HPV4 control but the main comparison group received rLP2086+saline vs rLP2086+HPV4. Observer-blinding was used (not true double-blind), with vaccine dispensing staff unblinded due to different appearances. Studies were randomized with computerized allocation. The lack of consistent true placebo (inert saline only) control limits the ability to attribute adverse events specifically to Trumenba."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active solicitation of adverse events through electronic diaries for 7 days post-vaccination (local and systemic reactions). External Data Monitoring Committee (EDMC/DMC) provided ongoing safety oversight. SAEs actively collected from Day 1 through 6 months post-final dose. Investigators specifically prompted to inquire about autoimmune and neuroinflammatory conditions at each study visit. Medically attended AEs, newly diagnosed chronic medical conditions, and hospitalizations were systematically recorded. FDA BioResearch Monitoring conducted inspections at 3 clinical sites."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Specific surveillance protocol for neuroinflammatory and autoimmune conditions using extensive MedDRA term list. 14 cases identified in vaccine recipients (13 autoimmune, 1 neuroinflammatory) vs 0 in controls: Bell's palsy (Lyme-related), Sydenham's chorea, IgA nephropathy, ITP, Crohn's disease, rheumatoid arthritis, thyroid disorders (4 cases), celiac disease (2 cases), psoriasis exacerbation, and post-infectious arthritis. Baseline serum samples were retrospectively analyzed to determine pre-existing conditions. However, developmental assessments and scheduled neurological exams were not performed, and the 6-month follow-up is insufficient for long-term neurological monitoring."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Vulnerable populations were explicitly excluded from studies: immunocompromised children, those with autoimmune conditions, neurological disorders, and history of seizures (except febrile). Premature infants not studied. A separate infant study (B1971008) was discontinued after 90% of infants receiving half-dose (60ug) developed fever >38C after the first dose. Studies in children ages 1-10 years were deferred as post-marketing requirements. Population was 90.8% Caucasian with limited racial/ethnic diversity. No separate analysis of children with chronic conditions or concurrent medications who represent real-world vaccine recipients."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Independent DMC reviewed safety data throughout the program. CBER performed independent statistical analyses including autoimmune condition rate calculations with confidence intervals. FDA clinical review document (this document) publicly available with detailed safety narratives for all 14 autoimmune/neuroinflammatory cases. Financial disclosures provided showing 10 of 1,036 investigators had financial interests. Studies industry-funded by Pfizer/Wyeth without independent funding source. Individual participant data not publicly available but full data access provided to FDA."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Comprehensive post-marketing plan as conditions of accelerated approval: confirmatory efficacy studies (B1971009 for ages 10-19, B1971016 for ages 18-26), PREA pediatric studies (B1971017 for ages 2-10, B1971035 for ages 12-24 months, Phase 3 study planned). Post-marketing commitments include additional safety study B1971014 in ~10,000 subjects ages 10-26 years, concomitant vaccine study B1971015 (Tdap, MenACWY), and pregnancy outcomes observational study B1971052. Routine pharmacovigilance through adverse event reporting systems (VAERS). Continued DMC review of ongoing Phase 3 studies."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The Trumenba safety evidence provides partial reassurance for adolescents (ages 10-25) but significant gaps remain for broader pediatric confidence. STRENGTHS: Adequate sample size (>3,000 adolescents), active surveillance with DMC oversight, specific monitoring for autoimmune/neuroinflammatory conditions yielding 14 cases with detailed narratives, and comprehensive post-marketing surveillance plan. LIMITATIONS: (1) Follow-up of only 6 months post-vaccination is insufficient to detect delayed autoimmune/neurological conditions; (2) 14 autoimmune/neuroinflammatory cases in Trumenba recipients vs 0 in controls raises concern despite being within background rates; (3) Vulnerable populations (immunocompromised, those with chronic conditions) were excluded; (4) No data in children <10 years (studies deferred); (5) Infant study discontinued due to 90% fever rate with half-dose; (6) Most comparisons used active vaccine controls rather than true placebo; (7) Industry funding without independent verification. This document provides confidence that short-term safety in healthy adolescents is acceptable, but does NOT provide adequate evidence for long-term safety or safety in younger children, infants, or immunocompromised populations. Parents of healthy adolescents can have reasonable short-term confidence; long-term and broader population safety remains to be established through post-marketing surveillance."
        }
      },
      "safety_pt": {
        "vaccine_id": "menb_trumenba",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Total de 4.335 participantes receberam a formula√ß√£o final de 120ug. Base de dados de seguran√ßa central de 4 estudos controlados incluiu 2.566 adolescentes recebendo Trumenba e 1.012 controles. Dos 4.282 participantes de 11-25 anos, 99,3% eram adolescentes (11-18 anos). Tamanho amostral de >3.000 √© adequado para detectar eventos adversos ocorrendo em frequ√™ncia de 1:1.000, atendendo o limiar para detec√ß√£o razo√°vel de seguran√ßa. No entanto, a amostra √© limitada a adolescentes sem crian√ßas <10 anos inclu√≠das no pedido de licen√ßa."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Monitoramento de seguran√ßa estendeu-se por 6 meses ap√≥s a vacina√ß√£o final (terceira), com dura√ß√£o total do estudo de aproximadamente 12 meses desde a primeira dose. Essa dura√ß√£o √© inadequada para detectar condi√ß√µes autoimunes ou neurol√≥gicas tardias que podem surgir meses a anos ap√≥s a vacina√ß√£o. O m√≠nimo ideal de 12-24 meses ap√≥s a dose final, com v√°rios anos para efeitos de longo prazo, n√£o foi atendido. Os 14 casos autoimunes/neuroinflamat√≥rios identificados em 6 meses podem representar apenas uma fra√ß√£o das potenciais rea√ß√µes tardias."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Quatro estudos controlados usaram grupos de compara√ß√£o variados: salina sozinha em alguns bra√ßos, mas a maioria das compara√ß√µes envolveu vacinas ativas (HPV4, Tdap, dTaP-IPV). Estudo B1971011 teve um controle salina+HPV4, mas o principal grupo de compara√ß√£o recebeu rLP2086+salina vs rLP2086+HPV4. Cegamento de observador foi usado (n√£o verdadeiro duplo-cego), com equipe de dispensa√ß√£o de vacinas n√£o cegada devido a apar√™ncias diferentes. Estudos foram randomizados com aloca√ß√£o computadorizada. A falta de controle placebo verdadeiro consistente (apenas salina inerte) limita a capacidade de atribuir eventos adversos especificamente a Trumenba."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicita√ß√£o ativa de eventos adversos atrav√©s de di√°rios eletr√¥nicos por 7 dias ap√≥s a vacina√ß√£o (rea√ß√µes locais e sist√™micas). Comit√™ Externo de Monitoramento de Dados (EDMC/DMC) forneceu supervis√£o cont√≠nua de seguran√ßa. EAGs coletados ativamente do Dia 1 at√© 6 meses ap√≥s a dose final. Investigadores especificamente instru√≠dos a perguntar sobre condi√ß√µes autoimunes e neuroinflamat√≥rias em cada visita do estudo. EAs com atendimento m√©dico, condi√ß√µes m√©dicas cr√¥nicas rec√©m-diagnosticadas e hospitaliza√ß√µes foram sistematicamente registrados. FDA BioResearch Monitoring realizou inspe√ß√µes em 3 locais cl√≠nicos."
          },
          "neurological_monitoring": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Protocolo de vigil√¢ncia espec√≠fico para condi√ß√µes neuroinflamat√≥rias e autoimunes usando lista extensa de termos MedDRA. 14 casos identificados em receptores da vacina (13 autoimunes, 1 neuroinflamat√≥rio) vs 0 nos controles: paralisia de Bell (relacionada a Lyme), coreia de Sydenham, nefropatia por IgA, PTI, doen√ßa de Crohn, artrite reumatoide, dist√∫rbios da tireoide (4 casos), doen√ßa cel√≠aca (2 casos), exacerba√ß√£o de psor√≠ase e artrite p√≥s-infecciosa. Amostras de soro basais foram analisadas retrospectivamente para determinar condi√ß√µes pr√©-existentes. No entanto, avalia√ß√µes de desenvolvimento e exames neurol√≥gicos programados n√£o foram realizados, e o acompanhamento de 6 meses √© insuficiente para monitoramento neurol√≥gico de longo prazo."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Popula√ß√µes vulner√°veis foram explicitamente exclu√≠das dos estudos: crian√ßas imunocomprometidas, aquelas com condi√ß√µes autoimunes, dist√∫rbios neurol√≥gicos e hist√≥rico de convuls√µes (exceto febris). Beb√™s prematuros n√£o estudados. Um estudo separado em beb√™s (B1971008) foi descontinuado ap√≥s 90% dos beb√™s recebendo meia dose (60ug) desenvolverem febre >38C ap√≥s a primeira dose. Estudos em crian√ßas de 1-10 anos foram adiados como requisitos p√≥s-comercializa√ß√£o. Popula√ß√£o foi 90,8% caucasiana com diversidade racial/√©tnica limitada. Nenhuma an√°lise separada de crian√ßas com condi√ß√µes cr√¥nicas ou medica√ß√µes concomitantes que representam receptores de vacinas do mundo real."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "DMC independente revisou dados de seguran√ßa durante todo o programa. CBER realizou an√°lises estat√≠sticas independentes incluindo c√°lculos de taxa de condi√ß√µes autoimunes com intervalos de confian√ßa. Documento de revis√£o cl√≠nica da FDA (este documento) dispon√≠vel publicamente com narrativas de seguran√ßa detalhadas para todos os 14 casos autoimunes/neuroinflamat√≥rios. Divulga√ß√µes financeiras fornecidas mostrando que 10 de 1.036 investigadores tinham interesses financeiros. Estudos financiados pela ind√∫stria pela Pfizer/Wyeth sem fonte de financiamento independente. Dados individuais de participantes n√£o dispon√≠veis publicamente, mas acesso completo aos dados fornecido √† FDA."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Plano p√≥s-comercializa√ß√£o abrangente como condi√ß√µes de aprova√ß√£o acelerada: estudos confirmat√≥rios de efic√°cia (B1971009 para idades 10-19, B1971016 para idades 18-26), estudos pedi√°tricos PREA (B1971017 para idades 2-10, B1971035 para idades 12-24 meses, estudo Fase 3 planejado). Compromissos p√≥s-comercializa√ß√£o incluem estudo de seguran√ßa adicional B1971014 em ~10.000 participantes de 10-26 anos, estudo de vacinas concomitantes B1971015 (Tdap, MenACWY), e estudo observacional de desfechos de gravidez B1971052. Farmacovigil√¢ncia de rotina atrav√©s de sistemas de relato de eventos adversos (VAERS). Revis√£o cont√≠nua do DMC de estudos Fase 3 em andamento."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A evid√™ncia de seguran√ßa de Trumenba fornece garantia parcial para adolescentes (idades 10-25), mas lacunas significativas permanecem para confian√ßa pedi√°trica mais ampla. PONTOS FORTES: Tamanho amostral adequado (>3.000 adolescentes), vigil√¢ncia ativa com supervis√£o de DMC, monitoramento espec√≠fico para condi√ß√µes autoimunes/neuroinflamat√≥rias resultando em 14 casos com narrativas detalhadas, e plano abrangente de vigil√¢ncia p√≥s-comercializa√ß√£o. LIMITA√á√ïES: (1) Acompanhamento de apenas 6 meses ap√≥s a vacina√ß√£o √© insuficiente para detectar condi√ß√µes autoimunes/neurol√≥gicas tardias; (2) 14 casos autoimunes/neuroinflamat√≥rios em receptores de Trumenba vs 0 nos controles levanta preocupa√ß√£o apesar de estar dentro das taxas de base; (3) Popula√ß√µes vulner√°veis (imunocomprometidos, aqueles com condi√ß√µes cr√¥nicas) foram exclu√≠das; (4) Nenhum dado em crian√ßas <10 anos (estudos adiados); (5) Estudo em beb√™s descontinuado devido a taxa de febre de 90% com meia dose; (6) Maioria das compara√ß√µes usou controles de vacina ativa em vez de placebo verdadeiro; (7) Financiamento pela ind√∫stria sem verifica√ß√£o independente. Este documento fornece confian√ßa de que a seguran√ßa de curto prazo em adolescentes saud√°veis √© aceit√°vel, mas N√ÉO fornece evid√™ncia adequada para seguran√ßa de longo prazo ou seguran√ßa em crian√ßas mais jovens, beb√™s ou popula√ß√µes imunocomprometidas. Pais de adolescentes saud√°veis podem ter confian√ßa razo√°vel de curto prazo; seguran√ßa de longo prazo e para popula√ß√£o mais ampla permanece a ser estabelecida atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o."
        }
      }
    },
    {
      "id": "ppsv23_pneumovax23",
      "name": "Pneumovax 23",
      "type": "PPSV23",
      "manufacturer": "Merck",
      "description": "Pneumococcal Vaccine Polyvalent for prevention of pneumococcal disease caused by the 23 serotypes.",
      "sources": [
        "ppsv23_pneumovax23_fda.pdf"
      ],
      "trial_en": {
        "vaccine_id": "ppsv23_pneumovax23",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The main adult trial (50+ years) used saline containing 0.25% phenol as placebo in a randomized, double-blind, placebo-controlled crossover design. Historical South African efficacy studies used either meningococcal polysaccharide serogroup A vaccine or saline placebo as control groups. The phenol-containing saline is not a pure inert placebo but is closer to inert than an active vaccine comparator.",
            "level_description": "Meets expectations with a saline-based placebo (though containing 0.25% phenol preservative), allowing reasonable comparison of adverse event rates"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The main clinical trial in adults 50 years and older was described as 'randomized, double-blind, placebo-controlled crossover clinical trial.' The sequential administration study with Prevnar 13 was also 'randomized, double-blind, placebo-controlled, multicenter study.'",
            "level_description": "Meets what would be expected; double-blinding was implemented in the primary safety trials"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The main study states subjects were 'randomized to receive intramuscular injections of PNEUMOVAX 23 followed by placebo, or placebo followed by PNEUMOVAX 23.' The Prevnar 13 sequential study randomized 400 subjects 1:1 into two groups. However, no specific description of allocation concealment methods.",
            "level_description": "Randomization was documented, though details on allocation concealment were not provided"
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document explicitly states 'PNEUMOVAX 23 is not approved for use in children less than 2 years of age' and 'Antibody responses to most pneumococcal capsular types are generally low or inconsistent in children less than 2 years of age.' The clinical trials described enrolled only adults 50 years and older. No pediatric safety studies in children 0-12 years are documented.",
            "level_description": "Not documented. The package insert contains no pediatric clinical trial data for children ages 0-12 years. All clinical safety data is from adults 50+ years old."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The main safety trial followed subjects 'for 14 days following each vaccination.' The sequential Prevnar 13 study evaluated injection site reactions 'during Days 1 through 5 postvaccination' and systemic reactions 'during Days 1 through 14 postvaccination,' with SAEs collected through Week 30. Historical efficacy studies observed attack rates '2 weeks through about 1 year after vaccination.'",
            "level_description": "Mentioned but inadequate - 14 days is grossly insufficient to detect autoimmune, neurological, or other delayed adverse events. Week 30 SAE collection is better but still falls far short of the 6-12+ months ideal."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The adult trial separated subjects into cohorts by age (50-64 years and 65+ years). The document provides separate analysis showing injection-site adverse reaction rate was higher following revaccination (79.3%) vs initial vaccination (52.9%) in subjects 65+ years, and similar rates (79.6% vs 72.8%) in 50-64 year cohort. No pediatric age group stratification exists (0-1, 1-5, 6-12).",
            "level_description": "Present but with significant limitations - age stratification exists only for adults (50-64 and 65+). No stratification for pediatric populations (children 2-12 years who are approved for use at increased risk)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Limited description: subjects in the geriatric trial 'had underlying chronic illness but were in stable condition; at least 1 medical condition at enrollment was reported by 86.3% of subjects who were 50 to 64 years old, and by 96.7% of subjects who were 65 to 91 years old.' Contraindications include hypersensitivity to vaccine components. Exclusion/inclusion for pediatric populations not documented.",
            "level_description": "Present but with flaws - basic demographics are provided (age, sex, race), but detailed inclusion/exclusion criteria and generalizability limitations are not explicitly discussed"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The document distinguishes between 'Solicited Events' and 'Unsolicited Events' in Table 1. Local reactions were systematically categorized (pain/soreness/tenderness, swelling/induration, erythema) with specific measurements for swelling (0 to <2.5 cm, 2.5 to <5.1 cm, etc.). Pain severity was characterized as mild, moderate, or severe with definitions. Fever was defined as temperature 100.4F or higher.",
            "level_description": "Meets expectations with objective thresholds defined (fever >100.4F, swelling measurements in cm, pain severity scale) and clear distinction between solicited and unsolicited events"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse events were reported: '10 subjects had serious adverse experiences within 14 days of vaccination: 6 who received PNEUMOVAX 23 and 4 who received placebo.' SAEs included angina pectoris, heart failure, chest pain, ulcerative colitis, depression, and headache/tremor/stiffness/sweating. One death from pancreatitis/myocardial infarction was reported. However, systematic active surveillance methodology is not described.",
            "level_description": "Present but with significant flaws - SAEs were collected but methodology for active surveillance and causality investigation not clearly documented. The 14-day window limits detection of delayed serious events."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Post-marketing experience section lists: Paresthesia, Radiculoneuropathy, Guillain-Barre syndrome, Febrile convulsion under 'Nervous System.' However, there is no documentation of scheduled assessments or predefined monitoring protocols for these conditions in the clinical trials themselves.",
            "level_description": "Present but flawed - autoimmune/neurological events are acknowledged in post-marketing but no systematic pre-specified monitoring protocol documented in clinical trials"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 8.6 states immunocompromised individuals 'may have a diminished immune response.' Subjects with 'underlying chronic illness but were in stable condition' were included in the geriatric study (86.3-96.7% had at least one medical condition). However, no separate safety analysis for vulnerable subgroups is provided, and premature infants or children with special conditions were not studied.",
            "level_description": "Present but with flaws - immunocompromised mentioned but not separately analyzed. No pediatric vulnerable subgroup data. Pregnant women and lactating mothers noted but with limited data."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "For efficacy studies, protective effectiveness is reported with 95% confidence intervals (e.g., '57% (95%CI: 45% to 66%) overall protective effectiveness,' '77% (95%CI: 51% to 89%)'). Immunogenicity analysis used 'constrained Longitudinal Data Analysis model' with GMT ratios and 95% CIs. No power calculation for safety endpoints is documented.",
            "level_description": "Present but with limitations - confidence intervals provided for efficacy, but study was clearly not powered for safety outcomes; no safety-specific power calculations documented"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Adverse event rates are presented in tables with specific percentages. Data from multiple studies cited (South African gold miner studies, French nursing home study, CDC retrospective cohort). However, no mention of independent DSMB, no raw data availability, and no reference to peer-reviewed publication of the primary safety data.",
            "level_description": "Present but flawed - summary data provided in package insert, but no mention of DSMB oversight, raw data access, or independent verification mechanisms"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 provides extensive post-marketing experience list including: cellulitis, fever >102F, decreased limb mobility, injection-site necrosis, thrombocytopenia, hemolytic anemia, Guillain-Barre syndrome, febrile convulsion, serum sickness, erythema multiforme. VAERS reporting is referenced (1-800-822-7967 or www.vaers.hhs.gov). However, this relies on passive reporting.",
            "level_description": "Meets expectations with acknowledgment of post-marketing surveillance (VAERS referenced, manufacturer reporting line provided) and documented post-marketing findings, though primarily passive system"
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not disclose funding sources for clinical trials, researcher conflicts of interest, or financial relationships. Merck Sharp & Dohme Corp. is identified as manufacturer. No statement regarding independent funding or financial ties of researchers.",
            "level_description": "Not documented - no disclosure of conflicts of interest, funding sources, or financial relationships for the clinical trials"
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Deaths are mentioned: 'pancreatitis/myocardial infarction resulting in death' after PNEUMOVAX 23 and 'motor vehicle accident resulting in death' after placebo. However, total mortality numbers in each group are not systematically reported, and causality determination appears subjective.",
            "level_description": "Present but flawed - individual deaths mentioned but all-cause mortality not systematically reported by treatment group; only deaths judged noteworthy are listed"
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "This package insert provides inadequate evidence for pediatric safety assessment because PNEUMOVAX 23 was studied exclusively in adults aged 50 years and older. The vaccine is approved for high-risk children 2 years and older, yet no pediatric clinical trial data is presented in this document. The adult trials demonstrate reasonable methodology (double-blind, randomized, placebo-controlled) but are limited by short follow-up duration (14 days primary, 30 weeks maximum), lack of power for safety outcomes, and reliance on passive post-marketing surveillance. While post-marketing data identifies serious neurological events (Guillain-Barre syndrome, febrile convulsions), no systematic long-term safety monitoring was conducted. For parents of children 0-12 years, this document fundamentally fails to demonstrate safety because no children were studied in the clinical trials described."
        }
      },
      "trial_pt": {
        "vaccine_id": "ppsv23_pneumovax23",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O principal estudo em adultos (50+ anos) utilizou solu√ß√£o salina contendo 0,25% de fenol como placebo em um desenho cruzado randomizado, duplo-cego e controlado por placebo. Estudos hist√≥ricos de efic√°cia sul-africanos usaram vacina polissacar√≠dica meningoc√≥cica sorogrupo A ou placebo salino como grupos de controle. A solu√ß√£o salina contendo fenol n√£o √© um placebo inerte puro, mas est√° mais pr√≥xima de ser inerte do que um comparador de vacina ativa.",
            "level_description": "Atende √†s expectativas com placebo √† base de solu√ß√£o salina (embora contenha 0,25% de fenol como conservante), permitindo compara√ß√£o razo√°vel das taxas de eventos adversos"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O principal ensaio cl√≠nico em adultos com 50 anos ou mais foi descrito como 'ensaio cl√≠nico randomizado, duplo-cego, controlado por placebo, com desenho cruzado'. O estudo de administra√ß√£o sequencial com Prevnar 13 tamb√©m foi 'estudo multic√™ntrico randomizado, duplo-cego e controlado por placebo'.",
            "level_description": "Atende ao esperado; o duplo-cegamento foi implementado nos principais estudos de seguran√ßa"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O estudo principal afirma que os participantes foram 'randomizados para receber inje√ß√µes intramusculares de PNEUMOVAX 23 seguidas de placebo, ou placebo seguido de PNEUMOVAX 23'. O estudo sequencial com Prevnar 13 randomizou 400 participantes 1:1 em dois grupos. No entanto, n√£o h√° descri√ß√£o espec√≠fica dos m√©todos de oculta√ß√£o da aloca√ß√£o.",
            "level_description": "A randomiza√ß√£o foi documentada, embora detalhes sobre a oculta√ß√£o da aloca√ß√£o n√£o tenham sido fornecidos"
          },
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento afirma explicitamente que 'PNEUMOVAX 23 n√£o est√° aprovada para uso em crian√ßas menores de 2 anos' e que 'As respostas de anticorpos √† maioria dos tipos capsulares pneumoc√≥cicos s√£o geralmente baixas ou inconsistentes em crian√ßas menores de 2 anos'. Os ensaios cl√≠nicos descritos inclu√≠ram apenas adultos com 50 anos ou mais. Nenhum estudo de seguran√ßa pedi√°trica em crian√ßas de 0-12 anos est√° documentado.",
            "level_description": "N√£o documentado. A bula n√£o cont√©m dados de ensaios cl√≠nicos pedi√°tricos para crian√ßas de 0 a 12 anos. Todos os dados de seguran√ßa cl√≠nica s√£o de adultos com 50 anos ou mais."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O principal estudo de seguran√ßa acompanhou os participantes 'por 14 dias ap√≥s cada vacina√ß√£o'. O estudo sequencial com Prevnar 13 avaliou rea√ß√µes no local da inje√ß√£o 'durante os dias 1 a 5 p√≥s-vacina√ß√£o' e rea√ß√µes sist√™micas 'durante os dias 1 a 14 p√≥s-vacina√ß√£o', com eventos adversos graves coletados at√© a semana 30. Estudos hist√≥ricos de efic√°cia observaram taxas de ataque '2 semanas at√© cerca de 1 ano ap√≥s a vacina√ß√£o'.",
            "level_description": "Mencionado, mas inadequado - 14 dias √© grosseiramente insuficiente para detectar eventos adversos autoimunes, neurol√≥gicos ou outros eventos tardios. A coleta de eventos adversos graves at√© a semana 30 √© melhor, mas ainda fica muito aqu√©m dos 6-12+ meses ideais."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo em adultos separou os participantes em coortes por idade (50-64 anos e 65+ anos). O documento fornece an√°lise separada mostrando que a taxa de rea√ß√µes adversas no local da inje√ß√£o foi maior ap√≥s revacina√ß√£o (79,3%) vs vacina√ß√£o inicial (52,9%) em participantes com 65+ anos, e taxas semelhantes (79,6% vs 72,8%) na coorte de 50-64 anos. N√£o existe estratifica√ß√£o por faixa et√°ria pedi√°trica (0-1, 1-5, 6-12).",
            "level_description": "Presente, mas com limita√ß√µes significativas - a estratifica√ß√£o por idade existe apenas para adultos (50-64 e 65+). N√£o h√° estratifica√ß√£o para popula√ß√µes pedi√°tricas (crian√ßas de 2-12 anos que est√£o aprovadas para uso em caso de risco aumentado)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Descri√ß√£o limitada: os participantes do estudo geri√°trico 'tinham doen√ßa cr√¥nica subjacente, mas estavam em condi√ß√£o est√°vel; pelo menos uma condi√ß√£o m√©dica no momento da inscri√ß√£o foi relatada por 86,3% dos participantes de 50 a 64 anos e por 96,7% dos participantes de 65 a 91 anos'. As contraindica√ß√µes incluem hipersensibilidade aos componentes da vacina. Crit√©rios de exclus√£o/inclus√£o para popula√ß√µes pedi√°tricas n√£o foram documentados.",
            "level_description": "Presente, mas com falhas - dados demogr√°ficos b√°sicos s√£o fornecidos (idade, sexo, ra√ßa), mas crit√©rios detalhados de inclus√£o/exclus√£o e limita√ß√µes de generaliza√ß√£o n√£o s√£o explicitamente discutidos"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O documento distingue entre 'Eventos Solicitados' e 'Eventos N√£o Solicitados' na Tabela 1. As rea√ß√µes locais foram sistematicamente categorizadas (dor/sensibilidade/hipersensibilidade, incha√ßo/endurecimento, eritema) com medidas espec√≠ficas para incha√ßo (0 a <2,5 cm, 2,5 a <5,1 cm, etc.). A gravidade da dor foi caracterizada como leve, moderada ou grave com defini√ß√µes. Febre foi definida como temperatura de 38¬∞C ou superior.",
            "level_description": "Atende √†s expectativas com limites objetivos definidos (febre >38¬∞C, medidas de incha√ßo em cm, escala de gravidade da dor) e distin√ß√£o clara entre eventos solicitados e n√£o solicitados"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos graves foram relatados: '10 participantes tiveram experi√™ncias adversas graves dentro de 14 dias da vacina√ß√£o: 6 que receberam PNEUMOVAX 23 e 4 que receberam placebo'. Os eventos adversos graves inclu√≠ram angina pectoris, insufici√™ncia card√≠aca, dor tor√°cica, colite ulcerativa, depress√£o e cefaleia/tremor/rigidez/sudorese. Uma morte por pancreatite/infarto do mioc√°rdio foi relatada. No entanto, a metodologia de vigil√¢ncia ativa sistem√°tica n√£o est√° descrita.",
            "level_description": "Presente, mas com falhas significativas - eventos adversos graves foram coletados, mas a metodologia para vigil√¢ncia ativa e investiga√ß√£o de causalidade n√£o est√° claramente documentada. A janela de 14 dias limita a detec√ß√£o de eventos graves tardios."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o de experi√™ncia p√≥s-comercializa√ß√£o lista: Parestesia, Radiculoneuropatia, S√≠ndrome de Guillain-Barre, Convuls√£o febril em 'Sistema Nervoso'. No entanto, n√£o h√° documenta√ß√£o de avalia√ß√µes programadas ou protocolos de monitoramento predefinidos para essas condi√ß√µes nos pr√≥prios ensaios cl√≠nicos.",
            "level_description": "Presente, mas com falhas - eventos autoimunes/neurol√≥gicos s√£o reconhecidos na p√≥s-comercializa√ß√£o, mas nenhum protocolo de monitoramento sistem√°tico pr√©-especificado foi documentado nos ensaios cl√≠nicos"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A se√ß√£o 8.6 afirma que indiv√≠duos imunocomprometidos 'podem ter uma resposta imune diminu√≠da'. Participantes com 'doen√ßa cr√¥nica subjacente, mas em condi√ß√£o est√°vel' foram inclu√≠dos no estudo geri√°trico (86,3-96,7% tinham pelo menos uma condi√ß√£o m√©dica). No entanto, nenhuma an√°lise de seguran√ßa separada para subgrupos vulner√°veis √© fornecida, e prematuros ou crian√ßas com condi√ß√µes especiais n√£o foram estudados.",
            "level_description": "Presente, mas com falhas - imunocomprometidos mencionados, mas n√£o analisados separadamente. Sem dados de subgrupos pedi√°tricos vulner√°veis. Gestantes e lactantes mencionadas, mas com dados limitados."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Para estudos de efic√°cia, a efetividade protetora √© relatada com intervalos de confian√ßa de 95% (por exemplo, '57% (IC 95%: 45% a 66%) de efetividade protetora geral', '77% (IC 95%: 51% a 89%)'). A an√°lise de imunogenicidade utilizou 'modelo de An√°lise de Dados Longitudinais restrito' com raz√µes de GMT e ICs de 95%. Nenhum c√°lculo de poder para desfechos de seguran√ßa est√° documentado.",
            "level_description": "Presente, mas com limita√ß√µes - intervalos de confian√ßa fornecidos para efic√°cia, mas o estudo claramente n√£o tinha poder estat√≠stico para desfechos de seguran√ßa; nenhum c√°lculo de poder espec√≠fico para seguran√ßa foi documentado"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As taxas de eventos adversos s√£o apresentadas em tabelas com porcentagens espec√≠ficas. Dados de m√∫ltiplos estudos s√£o citados (estudos de mineradores de ouro sul-africanos, estudo franc√™s em casas de repouso, coorte retrospectiva do CDC). No entanto, n√£o h√° men√ß√£o de DSMB independente, disponibilidade de dados brutos ou refer√™ncia a publica√ß√£o revisada por pares dos dados prim√°rios de seguran√ßa.",
            "level_description": "Presente, mas com falhas - dados resumidos fornecidos na bula, mas sem men√ß√£o de supervis√£o por DSMB, acesso a dados brutos ou mecanismos de verifica√ß√£o independente"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A se√ß√£o 6.2 fornece extensa lista de experi√™ncia p√≥s-comercializa√ß√£o incluindo: celulite, febre >39¬∞C, diminui√ß√£o da mobilidade do membro, necrose no local da inje√ß√£o, trombocitopenia, anemia hemol√≠tica, S√≠ndrome de Guillain-Barre, convuls√£o febril, doen√ßa do soro, eritema multiforme. O VAERS √© referenciado (1-800-822-7967 ou www.vaers.hhs.gov). No entanto, isso depende de notifica√ß√£o passiva.",
            "level_description": "Atende √†s expectativas com reconhecimento de vigil√¢ncia p√≥s-comercializa√ß√£o (VAERS referenciado, linha de notifica√ß√£o do fabricante fornecida) e achados p√≥s-comercializa√ß√£o documentados, embora seja principalmente um sistema passivo"
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o divulga fontes de financiamento para ensaios cl√≠nicos, conflitos de interesse dos pesquisadores ou rela√ß√µes financeiras. A Merck Sharp & Dohme Corp. √© identificada como fabricante. N√£o h√° declara√ß√£o sobre financiamento independente ou v√≠nculos financeiros dos pesquisadores.",
            "level_description": "N√£o documentado - nenhuma divulga√ß√£o de conflitos de interesse, fontes de financiamento ou rela√ß√µes financeiras para os ensaios cl√≠nicos"
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Mortes s√£o mencionadas: 'pancreatite/infarto do mioc√°rdio resultando em morte' ap√≥s PNEUMOVAX 23 e 'acidente de ve√≠culo motorizado resultando em morte' ap√≥s placebo. No entanto, os n√∫meros totais de mortalidade em cada grupo n√£o s√£o sistematicamente relatados, e a determina√ß√£o de causalidade parece subjetiva.",
            "level_description": "Presente, mas com falhas - mortes individuais mencionadas, mas a mortalidade por todas as causas n√£o √© sistematicamente relatada por grupo de tratamento; apenas mortes consideradas not√°veis s√£o listadas"
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "Esta bula fornece evid√™ncias inadequadas para avalia√ß√£o de seguran√ßa pedi√°trica porque a PNEUMOVAX 23 foi estudada exclusivamente em adultos com 50 anos ou mais. A vacina est√° aprovada para crian√ßas de alto risco com 2 anos ou mais, por√©m nenhum dado de ensaio cl√≠nico pedi√°trico √© apresentado neste documento. Os estudos em adultos demonstram metodologia razo√°vel (duplo-cego, randomizado, controlado por placebo), mas s√£o limitados pela curta dura√ß√£o do acompanhamento (14 dias prim√°rio, 30 semanas m√°ximo), falta de poder estat√≠stico para desfechos de seguran√ßa e depend√™ncia de vigil√¢ncia passiva p√≥s-comercializa√ß√£o. Embora os dados p√≥s-comercializa√ß√£o identifiquem eventos neurol√≥gicos graves (S√≠ndrome de Guillain-Barre, convuls√µes febris), nenhum monitoramento de seguran√ßa sistem√°tico de longo prazo foi conduzido. Para pais de crian√ßas de 0-12 anos, este documento falha fundamentalmente em demonstrar seguran√ßa porque nenhuma crian√ßa foi estudada nos ensaios cl√≠nicos descritos."
        }
      },
      "safety_en": {
        "vaccine_id": "ppsv23_pneumovax23",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "No pediatric clinical trial data is documented. All clinical trials described in the package insert enrolled adults 50 years of age and older (N=444 initial vaccination, N=564 revaccination in the main trial; N=400 in the Prevnar 13 sequential study). The document explicitly states the vaccine is 'not approved for use in children less than 2 years of age' due to poor immune response, but provides zero clinical safety data for children ages 2-12 years who are approved for vaccination when at increased risk for pneumococcal disease."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The primary follow-up was only 14 days post-vaccination, with serious adverse events collected through Week 30 in one study. This is grossly inadequate to detect autoimmune conditions, neurological complications, or other delayed adverse events that may take months or years to manifest. The ideal minimum is 12 months with scheduled assessments; 14 days captures only immediate reactions. Historical efficacy studies followed participants for about 1 year but safety follow-up details from those studies are not provided."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The main adult clinical trial used a true placebo (saline containing 0.25% phenol) with double-blind randomization in a crossover design. All 1008 subjects received placebo injections for comparison. This design allows reasonable differentiation between vaccine-related and coincidental adverse events. However, no comparison group data exists for children, and the phenol in the placebo is not completely inert."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The trials distinguished between 'solicited' and 'unsolicited' events, indicating some active surveillance for predefined reactions. Serious adverse events were collected within 14 days (6 SAEs after PNEUMOVAX 23 vs 4 after placebo) and through Week 30 in the Prevnar 13 study (24 SAEs in 20 subjects, none considered vaccine-related). However, the methodology for active surveillance is not clearly described, and the short follow-up window limits detection of delayed serious events. No systematic investigation of causality for serious events is documented."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The package insert does not document any scheduled neurological assessments, developmental evaluations, or systematic monitoring for seizures, Guillain-Barre syndrome, or other neurological conditions during clinical trials. Post-marketing surveillance has identified paresthesia, radiculoneuropathy, Guillain-Barre syndrome, and febrile convulsion, but these were detected through passive reporting after licensure, not through active clinical trial monitoring. No neurodevelopmental follow-up for any population is described."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document acknowledges that immunocompromised individuals 'may have a diminished immune response' and that elderly individuals 'may not tolerate medical interventions as well as younger individuals.' In the adult trial, 86.3-96.7% of subjects had at least one underlying chronic medical condition. However, no separate safety analysis for these vulnerable groups is provided. Critically, no data exists for premature infants, immunocompromised children, children with chronic conditions, or other pediatric vulnerable subgroups. Pregnancy and lactation sections state data are insufficient."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The package insert provides adverse event rates in tabular format with specific percentages and categorization. Serious adverse events are listed individually. However, there is no mention of an independent Data Safety Monitoring Board (DSMB), no reference to peer-reviewed publication of primary safety data, no access to raw data or individual participant data for independent verification, and no indication that the complete study protocols are publicly available."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 documents an extensive list of post-marketing adverse events across multiple body systems: cellulitis, fever >102F, injection-site necrosis, thrombocytopenia, hemolytic anemia, Guillain-Barre syndrome, febrile convulsion, anaphylactoid reactions, serum sickness, and erythema multiforme. VAERS reporting is referenced with contact information. The manufacturer reporting line is provided (1-877-888-4231). However, this is primarily a passive surveillance system with acknowledged limitations ('from a population of uncertain size, it is not always possible to reliably estimate their frequency')."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "This document does not provide confidence that PNEUMOVAX 23 is safe for children. The fundamental problem is that no children were studied - all clinical trial safety data comes exclusively from adults aged 50 years and older. While the vaccine is approved for high-risk children 2 years and older based on immunogenicity considerations, the package insert contains zero pediatric safety data from clinical trials. Furthermore, even the adult studies are limited by very short follow-up (14 days primary), absence of systematic neurological monitoring, and no separate analysis of vulnerable subgroups. Post-marketing surveillance has identified serious neurological events including Guillain-Barre syndrome and febrile convulsions, but these were detected passively rather than through rigorous clinical monitoring. A parent asking whether this vaccine is safe for their child cannot find evidence in this document to answer that question, as children 0-12 years were simply not studied."
        }
      },
      "safety_pt": {
        "vaccine_id": "ppsv23_pneumovax23",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Nenhum dado de ensaio cl√≠nico pedi√°trico est√° documentado. Todos os ensaios cl√≠nicos descritos na bula inclu√≠ram adultos com 50 anos ou mais (N=444 vacina√ß√£o inicial, N=564 revacina√ß√£o no estudo principal; N=400 no estudo sequencial com Prevnar 13). O documento afirma explicitamente que a vacina 'n√£o est√° aprovada para uso em crian√ßas menores de 2 anos' devido √† resposta imune inadequada, mas fornece zero dados de seguran√ßa cl√≠nica para crian√ßas de 2-12 anos que est√£o aprovadas para vacina√ß√£o quando em risco aumentado de doen√ßa pneumoc√≥cica."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento prim√°rio foi de apenas 14 dias p√≥s-vacina√ß√£o, com eventos adversos graves coletados at√© a semana 30 em um estudo. Isso √© grosseiramente inadequado para detectar condi√ß√µes autoimunes, complica√ß√µes neurol√≥gicas ou outros eventos adversos tardios que podem levar meses ou anos para se manifestar. O m√≠nimo ideal √© de 12 meses com avalia√ß√µes programadas; 14 dias capturam apenas rea√ß√µes imediatas. Estudos hist√≥ricos de efic√°cia acompanharam participantes por cerca de 1 ano, mas detalhes do acompanhamento de seguran√ßa desses estudos n√£o s√£o fornecidos."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O principal ensaio cl√≠nico em adultos utilizou um placebo verdadeiro (solu√ß√£o salina contendo 0,25% de fenol) com randomiza√ß√£o duplo-cega em um desenho cruzado. Todos os 1008 participantes receberam inje√ß√µes de placebo para compara√ß√£o. Este desenho permite diferencia√ß√£o razo√°vel entre eventos adversos relacionados √† vacina e coincidentes. No entanto, n√£o existem dados de grupo de compara√ß√£o para crian√ßas, e o fenol no placebo n√£o √© completamente inerte."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os estudos distinguiram entre eventos 'solicitados' e 'n√£o solicitados', indicando alguma vigil√¢ncia ativa para rea√ß√µes predefinidas. Eventos adversos graves foram coletados dentro de 14 dias (6 eventos adversos graves ap√≥s PNEUMOVAX 23 vs 4 ap√≥s placebo) e at√© a semana 30 no estudo com Prevnar 13 (24 eventos adversos graves em 20 participantes, nenhum considerado relacionado √† vacina). No entanto, a metodologia para vigil√¢ncia ativa n√£o est√° claramente descrita, e a curta janela de acompanhamento limita a detec√ß√£o de eventos graves tardios. Nenhuma investiga√ß√£o sistem√°tica de causalidade para eventos graves est√° documentada."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "A bula n√£o documenta quaisquer avalia√ß√µes neurol√≥gicas programadas, avalia√ß√µes de desenvolvimento ou monitoramento sistem√°tico para convuls√µes, S√≠ndrome de Guillain-Barre ou outras condi√ß√µes neurol√≥gicas durante os ensaios cl√≠nicos. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou parestesia, radiculoneuropatia, S√≠ndrome de Guillain-Barre e convuls√£o febril, mas estes foram detectados atrav√©s de notifica√ß√£o passiva ap√≥s licenciamento, n√£o atrav√©s de monitoramento ativo em ensaios cl√≠nicos. Nenhum acompanhamento do neurodesenvolvimento para qualquer popula√ß√£o est√° descrito."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento reconhece que indiv√≠duos imunocomprometidos 'podem ter uma resposta imune diminu√≠da' e que indiv√≠duos idosos 'podem n√£o tolerar interven√ß√µes m√©dicas t√£o bem quanto indiv√≠duos mais jovens'. No estudo em adultos, 86,3-96,7% dos participantes tinham pelo menos uma condi√ß√£o m√©dica cr√¥nica subjacente. No entanto, nenhuma an√°lise de seguran√ßa separada para esses grupos vulner√°veis √© fornecida. Criticamente, n√£o existem dados para prematuros, crian√ßas imunocomprometidas, crian√ßas com condi√ß√µes cr√¥nicas ou outros subgrupos pedi√°tricos vulner√°veis. As se√ß√µes de gravidez e lacta√ß√£o afirmam que os dados s√£o insuficientes."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A bula fornece taxas de eventos adversos em formato tabular com porcentagens espec√≠ficas e categoriza√ß√£o. Eventos adversos graves s√£o listados individualmente. No entanto, n√£o h√° men√ß√£o de um Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB), nenhuma refer√™ncia a publica√ß√£o revisada por pares dos dados prim√°rios de seguran√ßa, nenhum acesso a dados brutos ou dados de participantes individuais para verifica√ß√£o independente, e nenhuma indica√ß√£o de que os protocolos completos do estudo est√£o dispon√≠veis publicamente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A se√ß√£o 6.2 documenta uma extensa lista de eventos adversos p√≥s-comercializa√ß√£o em m√∫ltiplos sistemas corporais: celulite, febre >39¬∞C, necrose no local da inje√ß√£o, trombocitopenia, anemia hemol√≠tica, S√≠ndrome de Guillain-Barre, convuls√£o febril, rea√ß√µes anafilactoides, doen√ßa do soro e eritema multiforme. O VAERS √© referenciado com informa√ß√µes de contato. A linha de notifica√ß√£o do fabricante √© fornecida (1-877-888-4231). No entanto, este √© principalmente um sistema de vigil√¢ncia passiva com limita√ß√µes reconhecidas ('de uma popula√ß√£o de tamanho incerto, nem sempre √© poss√≠vel estimar sua frequ√™ncia de forma confi√°vel')."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "Este documento n√£o fornece confian√ßa de que a PNEUMOVAX 23 √© segura para crian√ßas. O problema fundamental √© que nenhuma crian√ßa foi estudada - todos os dados de seguran√ßa de ensaios cl√≠nicos v√™m exclusivamente de adultos com 50 anos ou mais. Embora a vacina esteja aprovada para crian√ßas de alto risco com 2 anos ou mais com base em considera√ß√µes de imunogenicidade, a bula cont√©m zero dados de seguran√ßa pedi√°trica de ensaios cl√≠nicos. Al√©m disso, mesmo os estudos em adultos s√£o limitados pelo acompanhamento muito curto (14 dias prim√°rio), aus√™ncia de monitoramento neurol√≥gico sistem√°tico e nenhuma an√°lise separada de subgrupos vulner√°veis. A vigil√¢ncia p√≥s-comercializa√ß√£o identificou eventos neurol√≥gicos graves, incluindo S√≠ndrome de Guillain-Barre e convuls√µes febris, mas estes foram detectados passivamente em vez de atrav√©s de monitoramento cl√≠nico rigoroso. Um pai perguntando se esta vacina √© segura para seu filho n√£o consegue encontrar evid√™ncias neste documento para responder a essa pergunta, pois crian√ßas de 0-12 anos simplesmente n√£o foram estudadas."
        }
      }
    },
    {
      "id": "covid19_comirnaty",
      "name": "Comirnaty",
      "type": "COVID-19",
      "manufacturer": "Pfizer-BioNTech",
      "description": "COVID-19 mRNA Vaccine for prevention of COVID-19 disease.",
      "sources": [
        "covid19_comirnaty_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "covid19_comirnaty",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 2 (main Phase 2/3 trial) and Study 3 (pediatric 5-11 years) used saline placebo as comparator. Study 2: 22,026 COMIRNATY vs 22,021 placebo for ages 16+; 1,131 vs 1,129 for ages 12-15. Study 3: 3,109 COMIRNATY vs 1,538 placebo for ages 5-11. Studies described as 'saline placebo-controlled'.",
            "level_description": "Uses inert saline placebo as comparator, allowing proper identification of vaccine-related events. Meets standard for randomized controlled trials."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 2 described as 'Phase 1/2/3 multicenter, randomized, saline placebo-controlled, double-blinded (Phase 2/3)'. Study 3 described as 'observer-blind' for Phase 2/3. Participants monitored via electronic diary (e-diary) for solicited reactions.",
            "level_description": "Main efficacy trial (Study 2) was double-blinded. Pediatric study (Study 3) was observer-blind. Meets expectations for reducing bias in outcome assessment."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 2: 'Randomization was stratified by age: 12 through 15 years of age, 16 through 55 years of age, or 56 years of age and older, with a minimum of 40% of participants in the >=56-year stratum.' Participants 'randomized equally' to vaccine or placebo groups.",
            "level_description": "Documented stratified randomization with 1:1 allocation. Meets standard for ensuring comparable groups."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Ages 5-11: Study 3 enrolled 3,109 COMIRNATY recipients in Phase 2/3 placebo-controlled period. Ages 12-15: Study 2 enrolled 1,131 COMIRNATY recipients. The 5-11 age group meets the >3,000 threshold; the 12-15 group is at the minimum acceptable level (~1,000).",
            "level_description": "The 5-11 year old group (3,109) meets the ideal threshold for detecting 1:1,000 events. The 12-15 group is smaller but still adequate for primary safety assessment."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 2 (16+ years): 'At the time of analysis... there were 25,651 (58.2%) participants 16 years of age and older followed for >=4 months after the second dose.' Study 3 (5-11 years): 'median of 1.9 months (range 0.1 to 7.5 months) after the second dose.' For 12-15 year olds: '69.0% adolescents followed for >=4 months after the second dose.'",
            "level_description": "Solicited adverse reactions monitored for only 7 days. Blinded placebo-controlled follow-up was 4-6 months for most participants. This is grossly inadequate for detecting autoimmune/neurological reactions that may emerge months or years later. The document acknowledges: 'Information is not yet available about potential long-term sequelae.'"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Document presents separate analyses for: 5-11 years, 12-15 years, 16-55 years, and 56+ years. Tables 3-12 provide separate safety data by age group. Efficacy also analyzed separately by age strata.",
            "level_description": "Appropriate age stratification with separate safety and efficacy analyses for pediatric, adolescent, adult, and elderly populations."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 2: 'excluded participants who were immunocompromised and those who had previous clinical or microbiological diagnosis of COVID-19.' Included: 'participants with preexisting stable disease... participants with known stable infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).' HIV-positive participants (n=200) were 'summarized separately in the safety analyses.'",
            "level_description": "While some vulnerable populations (stable HIV) were included, immunocompromised individuals were excluded from main trial. Limited discussion of generalizability to real-world populations with unstable conditions."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited local reactions (pain, redness, swelling) and systemic reactions (fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, joint pain) collected via electronic diary (e-diary) from Day 1 to Day 7. Severity grading defined: Mild/Moderate/Severe/Grade 4 with specific thresholds (e.g., fever >=38.0C, redness >2cm). Tables provide detailed frequency by severity grade.",
            "level_description": "Uses standardized solicited adverse event categories with defined severity thresholds. Systematic collection via e-diary. Meets standard for consistent adverse event reporting."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Solicited reactions actively monitored via e-diary for 7 days post-vaccination. Unsolicited adverse events monitored 'from Dose 1 through 1 month [all unsolicited adverse events] or through 6 months [serious adverse events] after the last vaccination.' SAE rates: Study 2 adults 0.8% vaccine vs 0.9% placebo; adolescents 0.9% vs 0.2%.",
            "level_description": "Active solicitation limited to 7-day window for common reactions. Beyond this, relied on participant/investigator reporting (semi-passive). Short active monitoring window may miss delayed serious events."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Bell's palsy reported: 4 COMIRNATY vs 2 placebo (stated: 'Currently available information is insufficient to determine a causal relationship'). Myocarditis/pericarditis identified post-marketing: '~8 cases per million doses in individuals 6 months through 64 years of age and ~27 cases per million doses in males 12 through 24 years of age.' For children 5-11: febrile seizures reported post-marketing. No specific long-term neurological/autoimmune monitoring protocol described.",
            "level_description": "Some neurological events tracked (Bell's palsy, syncope), but no systematic protocol for autoimmune/neurological monitoring with scheduled assessments. Myocarditis signal detected primarily post-marketing, not in trials."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Stable HIV participants (n=200) included and analyzed separately. Comorbidities tracked: 46% of adults and ~26% of children had conditions increasing severe COVID-19 risk. However, immunocompromised individuals explicitly excluded. Document states: 'Immunocompromised persons... may have a diminished immune response.' No premature infants, no concurrent medication subgroup analyses presented.",
            "level_description": "Limited vulnerable subgroup inclusion. Immunocompromised excluded from main trials. No separate analysis for premature children, those with allergies, or concurrent medications."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Efficacy analysis: 95.0% (95% credible interval: 90.3, 97.6) meeting 'pre-specified success criterion.' Confidence intervals provided for efficacy and immunogenicity comparisons. Noninferiority criteria specified for immunobridging (GMR >0.67). However, no explicit statement that study was powered for safety outcomes.",
            "level_description": "Statistical analysis adequate for efficacy endpoints. Standard confidence intervals and p-values for immunogenicity. However, trials were powered for efficacy, not safety - a fundamental limitation for detecting rare adverse events."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Multiple studies registered on ClinicalTrials.gov (NCT04368728, NCT04816643, NCT04955626, NCT05472038, NCT05543616). Results published in peer-reviewed journals. Document does not mention independent Data Safety Monitoring Board (DSMB) or availability of individual participant data (IPD) for independent analysis.",
            "level_description": "Clinical trial registration and peer-reviewed publication present. However, no mention of DSMB oversight or raw data availability for independent verification."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 Postmarketing Experience lists identified adverse reactions: myocarditis, pericarditis, severe allergic reactions, febrile seizures (in children 5-11). Document cites postmarketing data sources including 'commercial health insurance claims data.' References VAERS for adverse event reporting. Mentions ongoing myocarditis follow-up study (MACiV multicenter study).",
            "level_description": "Active postmarketing surveillance with identification of new safety signals (myocarditis/pericarditis). Uses multiple data sources. However, VAERS is passive reporting system with known underreporting limitations."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document is a package insert manufactured by Pfizer Inc. and BioNTech Manufacturing GmbH. No disclosure of funding sources for clinical trials or potential conflicts of interest of investigators. No statement about independent analysis.",
            "level_description": "No conflict of interest disclosure in document. Studies conducted by manufacturer. No mention of independent funding or analysis."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Document does not provide all-cause mortality data comparing vaccine and placebo groups. Death is mentioned only as a component of severe COVID-19 definition and as a potential outcome requiring investigation in adverse event monitoring. No total death counts presented for either group.",
            "level_description": "All-cause mortality not reported. Document focuses on vaccine-related outcomes without providing total deaths in vaccine vs placebo groups, preventing assessment of overall mortality impact."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The COMIRNATY clinical trials demonstrate reasonable design for efficacy assessment, with randomized, placebo-controlled, blinded studies across multiple age groups. The pediatric sample size for ages 5-11 (n=3,109) meets the threshold for detecting 1:1,000 adverse events. However, significant limitations exist for pediatric safety assessment: (1) follow-up duration was inadequate at 1.9 months median for children 5-11 and 4-6 months for older participants, far short of the 6-12 month minimum needed to detect autoimmune/neurological complications; (2) the critical myocarditis signal was detected primarily through post-marketing surveillance rather than clinical trials; (3) no all-cause mortality data is provided; (4) immunocompromised children were excluded; (5) no conflict of interest disclosure despite manufacturer-conducted trials. The document explicitly acknowledges 'Information is not yet available about potential long-term sequelae of myocarditis or pericarditis.' While the vaccine demonstrated strong efficacy (88.2% in children 5-11), the safety evidence has notable gaps that limit confidence in long-term pediatric safety."
        }
      },
      "trial_pt": {
        "vaccine_id": "covid19_comirnaty",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 2 (principal ensaio Fase 2/3) e o Estudo 3 (pedi√°trico 5-11 anos) utilizaram placebo salino como comparador. Estudo 2: 22.026 COMIRNATY vs 22.021 placebo para idades 16+; 1.131 vs 1.129 para idades 12-15. Estudo 3: 3.109 COMIRNATY vs 1.538 placebo para idades 5-11. Os estudos foram descritos como 'controlados por placebo salino'.",
            "level_description": "Utiliza placebo salino inerte como comparador, permitindo identifica√ß√£o adequada de eventos relacionados √† vacina. Atende ao padr√£o para ensaios cl√≠nicos randomizados."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 2 foi descrito como 'multic√™ntrico, randomizado, controlado por placebo salino, duplo-cego (Fase 2/3) Fase 1/2/3'. O Estudo 3 foi descrito como 'cego para o observador' para Fase 2/3. Os participantes foram monitorados via di√°rio eletr√¥nico (e-diary) para rea√ß√µes solicitadas.",
            "level_description": "O principal ensaio de efic√°cia (Estudo 2) foi duplo-cego. O estudo pedi√°trico (Estudo 3) foi cego para o observador. Atende √†s expectativas para redu√ß√£o de vi√©s na avalia√ß√£o de desfechos."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Estudo 2: 'A randomiza√ß√£o foi estratificada por idade: 12 a 15 anos, 16 a 55 anos, ou 56 anos ou mais, com no m√≠nimo 40% dos participantes no estrato >=56 anos.' Os participantes foram 'randomizados igualmente' para os grupos de vacina ou placebo.",
            "level_description": "Randomiza√ß√£o estratificada documentada com aloca√ß√£o 1:1. Atende ao padr√£o para garantir grupos compar√°veis."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Idades 5-11: O Estudo 3 incluiu 3.109 receptores de COMIRNATY no per√≠odo controlado por placebo Fase 2/3. Idades 12-15: O Estudo 2 incluiu 1.131 receptores de COMIRNATY. O grupo de 5-11 anos atende ao limite de >3.000; o grupo de 12-15 est√° no n√≠vel m√≠nimo aceit√°vel (~1.000).",
            "level_description": "O grupo de 5-11 anos (3.109) atende ao limite ideal para detectar eventos de 1:1.000. O grupo de 12-15 √© menor, mas ainda adequado para avalia√ß√£o prim√°ria de seguran√ßa."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo 2 (16+ anos): 'No momento da an√°lise... havia 25.651 (58,2%) participantes com 16 anos ou mais acompanhados por >=4 meses ap√≥s a segunda dose.' Estudo 3 (5-11 anos): 'mediana de 1,9 meses (varia√ß√£o de 0,1 a 7,5 meses) ap√≥s a segunda dose.' Para adolescentes de 12-15 anos: '69,0% dos adolescentes acompanhados por >=4 meses ap√≥s a segunda dose.'",
            "level_description": "Rea√ß√µes adversas solicitadas foram monitoradas por apenas 7 dias. O acompanhamento cego controlado por placebo foi de 4-6 meses para a maioria dos participantes. Isso √© grosseiramente inadequado para detectar rea√ß√µes autoimunes/neurol√≥gicas que podem emergir meses ou anos depois. O documento reconhece: 'Informa√ß√µes ainda n√£o est√£o dispon√≠veis sobre potenciais sequelas de longo prazo.'"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O documento apresenta an√°lises separadas para: 5-11 anos, 12-15 anos, 16-55 anos e 56+ anos. As Tabelas 3-12 fornecem dados de seguran√ßa separados por faixa et√°ria. A efic√°cia tamb√©m foi analisada separadamente por estratos de idade.",
            "level_description": "Estratifica√ß√£o por idade apropriada com an√°lises separadas de seguran√ßa e efic√°cia para popula√ß√µes pedi√°trica, adolescente, adulta e idosa."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudo 2: 'excluiu participantes que eram imunocomprometidos e aqueles que tinham diagn√≥stico cl√≠nico ou microbiol√≥gico pr√©vio de COVID-19.' Incluiu: 'participantes com doen√ßa est√°vel preexistente... participantes com infec√ß√£o conhecida e est√°vel por HIV, v√≠rus da hepatite C (HCV) ou v√≠rus da hepatite B (HBV).' Participantes HIV-positivos (n=200) foram 'resumidos separadamente nas an√°lises de seguran√ßa.'",
            "level_description": "Embora algumas popula√ß√µes vulner√°veis (HIV est√°vel) tenham sido inclu√≠das, indiv√≠duos imunocomprometidos foram exclu√≠dos do ensaio principal. Discuss√£o limitada sobre a generaliza√ß√£o para popula√ß√µes do mundo real com condi√ß√µes inst√°veis."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes locais solicitadas (dor, vermelhid√£o, incha√ßo) e rea√ß√µes sist√™micas (febre, fadiga, cefaleia, calafrios, v√¥mito, diarreia, dor muscular, dor articular) foram coletadas via di√°rio eletr√¥nico (e-diary) do Dia 1 ao Dia 7. Grada√ß√£o de gravidade definida: Leve/Moderada/Grave/Grau 4 com limites espec√≠ficos (ex.: febre >=38,0¬∞C, vermelhid√£o >2cm). As tabelas fornecem frequ√™ncia detalhada por grau de gravidade.",
            "level_description": "Utiliza categorias padronizadas de eventos adversos solicitados com limites de gravidade definidos. Coleta sistem√°tica via e-diary. Atende ao padr√£o para relato consistente de eventos adversos."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes solicitadas foram ativamente monitoradas via e-diary por 7 dias p√≥s-vacina√ß√£o. Eventos adversos n√£o solicitados foram monitorados 'da Dose 1 at√© 1 m√™s [todos os eventos adversos n√£o solicitados] ou at√© 6 meses [eventos adversos graves] ap√≥s a √∫ltima vacina√ß√£o.' Taxas de eventos adversos graves: Estudo 2 adultos 0,8% vacina vs 0,9% placebo; adolescentes 0,9% vs 0,2%.",
            "level_description": "Solicita√ß√£o ativa limitada a janela de 7 dias para rea√ß√µes comuns. Al√©m disso, dependeu de relato do participante/investigador (semi-passivo). Janela curta de monitoramento ativo pode perder eventos graves tardios."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Paralisia de Bell relatada: 4 COMIRNATY vs 2 placebo (declarado: 'Informa√ß√µes atualmente dispon√≠veis s√£o insuficientes para determinar rela√ß√£o causal'). Miocardite/pericardite identificadas p√≥s-comercializa√ß√£o: '~8 casos por milh√£o de doses em indiv√≠duos de 6 meses a 64 anos e ~27 casos por milh√£o de doses em homens de 12 a 24 anos.' Para crian√ßas de 5-11: convuls√µes febris relatadas p√≥s-comercializa√ß√£o. Nenhum protocolo espec√≠fico de monitoramento neurol√≥gico/autoimune de longo prazo descrito.",
            "level_description": "Alguns eventos neurol√≥gicos rastreados (Paralisia de Bell, s√≠ncope), mas nenhum protocolo sistem√°tico para monitoramento autoimune/neurol√≥gico com avalia√ß√µes programadas. Sinal de miocardite detectado principalmente p√≥s-comercializa√ß√£o, n√£o nos ensaios."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Participantes com HIV est√°vel (n=200) foram inclu√≠dos e analisados separadamente. Comorbidades rastreadas: 46% dos adultos e ~26% das crian√ßas tinham condi√ß√µes que aumentam o risco de COVID-19 grave. No entanto, indiv√≠duos imunocomprometidos foram explicitamente exclu√≠dos. O documento afirma: 'Pessoas imunocomprometidas... podem ter uma resposta imune diminu√≠da.' N√£o h√° prematuros, nem an√°lises de subgrupos de medicamentos concomitantes apresentadas.",
            "level_description": "Inclus√£o limitada de subgrupos vulner√°veis. Imunocomprometidos exclu√≠dos dos ensaios principais. Nenhuma an√°lise separada para crian√ßas prematuras, aquelas com alergias ou medicamentos concomitantes."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "An√°lise de efic√°cia: 95,0% (intervalo de credibilidade de 95%: 90,3, 97,6) atendendo ao 'crit√©rio de sucesso pr√©-especificado.' Intervalos de confian√ßa fornecidos para compara√ß√µes de efic√°cia e imunogenicidade. Crit√©rios de n√£o inferioridade especificados para imunobridging (GMR >0,67). No entanto, n√£o h√° declara√ß√£o expl√≠cita de que o estudo tinha poder estat√≠stico para desfechos de seguran√ßa.",
            "level_description": "An√°lise estat√≠stica adequada para desfechos de efic√°cia. Intervalos de confian√ßa padr√£o e valores p para imunogenicidade. No entanto, os ensaios tinham poder para efic√°cia, n√£o para seguran√ßa - uma limita√ß√£o fundamental para detectar eventos adversos raros."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "M√∫ltiplos estudos registrados no ClinicalTrials.gov (NCT04368728, NCT04816643, NCT04955626, NCT05472038, NCT05543616). Resultados publicados em peri√≥dicos revisados por pares. O documento n√£o menciona Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB) ou disponibilidade de dados de participantes individuais (IPD) para an√°lise independente.",
            "level_description": "Registro de ensaio cl√≠nico e publica√ß√£o revisada por pares presentes. No entanto, n√£o h√° men√ß√£o de supervis√£o por DSMB ou disponibilidade de dados brutos para verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 Experi√™ncia P√≥s-comercializa√ß√£o lista rea√ß√µes adversas identificadas: miocardite, pericardite, rea√ß√µes al√©rgicas graves, convuls√µes febris (em crian√ßas de 5-11). O documento cita fontes de dados p√≥s-comercializa√ß√£o incluindo 'dados de sinistros de seguro de sa√∫de comercial.' Referencia o VAERS para relato de eventos adversos. Menciona estudo de acompanhamento de miocardite em andamento (estudo multic√™ntrico MACiV).",
            "level_description": "Vigil√¢ncia p√≥s-comercializa√ß√£o ativa com identifica√ß√£o de novos sinais de seguran√ßa (miocardite/pericardite). Utiliza m√∫ltiplas fontes de dados. No entanto, o VAERS √© um sistema de notifica√ß√£o passiva com limita√ß√µes conhecidas de subnotifica√ß√£o."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento √© uma bula fabricada pela Pfizer Inc. e BioNTech Manufacturing GmbH. Nenhuma divulga√ß√£o de fontes de financiamento para ensaios cl√≠nicos ou potenciais conflitos de interesse dos investigadores. Nenhuma declara√ß√£o sobre an√°lise independente.",
            "level_description": "Nenhuma divulga√ß√£o de conflito de interesse no documento. Estudos conduzidos pelo fabricante. Sem men√ß√£o de financiamento ou an√°lise independente."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o fornece dados de mortalidade por todas as causas comparando os grupos de vacina e placebo. Morte √© mencionada apenas como componente da defini√ß√£o de COVID-19 grave e como potencial desfecho que requer investiga√ß√£o no monitoramento de eventos adversos. Nenhuma contagem total de mortes apresentada para qualquer grupo.",
            "level_description": "Mortalidade por todas as causas n√£o relatada. O documento foca em desfechos relacionados √† vacina sem fornecer total de mortes nos grupos vacina vs placebo, impedindo avalia√ß√£o do impacto geral na mortalidade."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Os ensaios cl√≠nicos da COMIRNATY demonstram desenho razo√°vel para avalia√ß√£o de efic√°cia, com estudos randomizados, controlados por placebo e cegos em m√∫ltiplas faixas et√°rias. O tamanho da amostra pedi√°trica para idades 5-11 (n=3.109) atende ao limite para detectar eventos adversos de 1:1.000. No entanto, existem limita√ß√µes significativas para avalia√ß√£o de seguran√ßa pedi√°trica: (1) a dura√ß√£o do acompanhamento foi inadequada, com mediana de 1,9 meses para crian√ßas de 5-11 e 4-6 meses para participantes mais velhos, muito aqu√©m dos 6-12 meses m√≠nimos necess√°rios para detectar complica√ß√µes autoimunes/neurol√≥gicas; (2) o sinal cr√≠tico de miocardite foi detectado principalmente atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o em vez de ensaios cl√≠nicos; (3) nenhum dado de mortalidade por todas as causas √© fornecido; (4) crian√ßas imunocomprometidas foram exclu√≠das; (5) nenhuma divulga√ß√£o de conflito de interesse apesar de ensaios conduzidos pelo fabricante. O documento reconhece explicitamente que 'Informa√ß√µes ainda n√£o est√£o dispon√≠veis sobre potenciais sequelas de longo prazo de miocardite ou pericardite.' Embora a vacina tenha demonstrado forte efic√°cia (88,2% em crian√ßas de 5-11), as evid√™ncias de seguran√ßa t√™m lacunas not√°veis que limitam a confian√ßa na seguran√ßa pedi√°trica de longo prazo."
        }
      },
      "safety_en": {
        "vaccine_id": "covid19_comirnaty",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "For children 5-11 years: 3,109 received COMIRNATY in the placebo-controlled Phase 2/3 of Study 3, meeting the >3,000 threshold needed to detect adverse events occurring at 1:1,000 frequency. For adolescents 12-15 years: 1,131 received COMIRNATY in Study 2, which is the minimum acceptable level but may miss rarer events. Combined with post-marketing data from millions of doses, the sample provides reasonable safety signal detection, though very rare events (1:10,000+) would not be detected in clinical trials."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Active solicited adverse event monitoring lasted only 7 days post-vaccination. For children 5-11 years in Study 3, median blinded placebo-controlled follow-up was only 1.9 months (range 0.1 to 7.5 months) after dose 2. For adolescents 12-15 years, 69% had at least 4 months follow-up. This is grossly inadequate for detecting autoimmune, neurological, or developmental effects that may take months or years to manifest. The document explicitly states: 'Information is not yet available about potential long-term sequelae of myocarditis or pericarditis following administration of mRNA COVID-19 vaccines.' A minimum of 12 months with 2-3+ years ideal is needed to assess long-term safety in children."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Study 2 and Study 3 used true saline placebo as comparator with random allocation and double-blinding (Study 2) or observer-blinding (Study 3). This allows proper determination of which adverse events are causally related to the vaccine versus coincidental. Study 3: 3,109 vaccine vs 1,538 placebo for ages 5-11. Study 2: 1,131 vaccine vs 1,129 placebo for ages 12-15. The placebo-controlled design was maintained for the initial safety assessment period."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Solicited adverse reactions (injection site reactions and systemic symptoms) were actively collected via electronic diary for only 7 days after each vaccination - too short to capture delayed reactions. Unsolicited adverse events were monitored through 1 month (non-serious) and 6 months (serious) but relied on participant/investigator reporting rather than scheduled active follow-up. Serious adverse events in children 5-11: 8 (0.3%) vaccine vs 2 (0.1%) placebo, with statement 'No serious adverse events were considered related to vaccination.' The lack of extended active surveillance with scheduled medical examinations limits detection of delayed serious events."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "No specific neurological or developmental monitoring protocol described for pediatric participants. Febrile seizures in children 5-11 were identified only through post-marketing surveillance, not in clinical trials. Bell's palsy (facial paralysis) was tracked in adults (4 vaccine vs 2 placebo) but document states 'Currently available information is insufficient to determine a causal relationship.' Myocarditis risk (~8-27 per million doses) was detected primarily through post-marketing data, not trial surveillance. No scheduled developmental assessments, neurological exams, or systematic surveillance for conditions like Guillain-Barre syndrome in pediatric population."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Children with comorbidities increasing COVID-19 risk were included (25.7% of vaccine group in Study 3). However, immunocompromised children were explicitly excluded from trials. Document states: 'Immunocompromised persons... may have a diminished immune response to COMIRNATY.' No premature infants studied, no separate analysis for children with allergies, autoimmune conditions, or on concurrent medications. Results may not generalize to these vulnerable pediatric populations."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials registered on ClinicalTrials.gov with identification numbers provided (NCT04816643 for pediatric Study 3). Detailed safety tables included with frequency data by severity grade. However, no mention of independent Data Safety Monitoring Board (DSMB) oversight, no individual participant data availability for independent analysis, and no conflict of interest disclosure. All studies were conducted and analyzed by the manufacturer (Pfizer/BioNTech)."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 documents postmarketing adverse reactions identified after widespread use including: myocarditis/pericarditis (highest risk in males 12-24), severe allergic reactions/anaphylaxis, febrile seizures specifically in children 5-11 years. Postmarketing data sources include commercial health insurance claims databases, VAERS passive reporting, and the MACiV multicenter study for myocarditis outcomes. Estimated myocarditis rates provided: ~8 cases per million (ages 6mo-64y) and ~27 per million (males 12-24). CDC guidance referenced for myocarditis management. Active surveillance continues, though VAERS passive system has known underreporting limitations."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This package insert provides PARTIAL evidence of safety for children ages 5-11. Strengths include: adequate sample size (3,109 children), proper placebo-controlled design, standardized adverse event collection, and robust post-marketing surveillance that identified myocarditis and febrile seizures. However, critical limitations undermine confidence in pediatric safety: (1) Follow-up duration was grossly inadequate - median 1.9 months for children 5-11, far short of the 12+ months needed to detect autoimmune or neurological complications; (2) No systematic neurological/developmental monitoring protocol existed; (3) Key safety signals like myocarditis were detected through post-marketing surveillance rather than clinical trials; (4) The document explicitly acknowledges uncertainty about long-term cardiac outcomes: 'Information is not yet available about potential long-term sequelae'; (5) Immunocompromised and other vulnerable children were excluded. While the vaccine shows good short-term tolerability (common reactions being injection site pain 72.9%, fatigue 39.2%, headache 28.4%, fever 6.3% in children 5-11), the document cannot provide confidence about long-term safety in children due to insufficient follow-up duration and the absence of developmental monitoring."
        }
      },
      "safety_pt": {
        "vaccine_id": "covid19_comirnaty",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Para crian√ßas de 5-11 anos: 3.109 receberam COMIRNATY na Fase 2/3 controlada por placebo do Estudo 3, atendendo ao limite de >3.000 necess√°rio para detectar eventos adversos que ocorrem com frequ√™ncia de 1:1.000. Para adolescentes de 12-15 anos: 1.131 receberam COMIRNATY no Estudo 2, que √© o n√≠vel m√≠nimo aceit√°vel, mas pode n√£o detectar eventos mais raros. Combinado com dados p√≥s-comercializa√ß√£o de milh√µes de doses, a amostra fornece detec√ß√£o razo√°vel de sinais de seguran√ßa, embora eventos muito raros (1:10.000+) n√£o seriam detectados em ensaios cl√≠nicos."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O monitoramento ativo de eventos adversos solicitados durou apenas 7 dias p√≥s-vacina√ß√£o. Para crian√ßas de 5-11 anos no Estudo 3, a mediana de acompanhamento cego controlado por placebo foi de apenas 1,9 meses (varia√ß√£o de 0,1 a 7,5 meses) ap√≥s a dose 2. Para adolescentes de 12-15 anos, 69% tiveram pelo menos 4 meses de acompanhamento. Isso √© grosseiramente inadequado para detectar efeitos autoimunes, neurol√≥gicos ou de desenvolvimento que podem levar meses ou anos para se manifestar. O documento afirma explicitamente: 'Informa√ß√µes ainda n√£o est√£o dispon√≠veis sobre potenciais sequelas de longo prazo de miocardite ou pericardite ap√≥s administra√ß√£o de vacinas COVID-19 de mRNA.' Um m√≠nimo de 12 meses com 2-3+ anos ideais √© necess√°rio para avaliar a seguran√ßa de longo prazo em crian√ßas."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo 2 e o Estudo 3 utilizaram placebo salino verdadeiro como comparador com aloca√ß√£o aleat√≥ria e duplo-cegamento (Estudo 2) ou cegamento para o observador (Estudo 3). Isso permite determina√ß√£o adequada de quais eventos adversos s√£o causalmente relacionados √† vacina versus coincidentes. Estudo 3: 3.109 vacina vs 1.538 placebo para idades 5-11. Estudo 2: 1.131 vacina vs 1.129 placebo para idades 12-15. O desenho controlado por placebo foi mantido para o per√≠odo inicial de avalia√ß√£o de seguran√ßa."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Rea√ß√µes adversas solicitadas (rea√ß√µes no local da inje√ß√£o e sintomas sist√™micos) foram ativamente coletadas via di√°rio eletr√¥nico por apenas 7 dias ap√≥s cada vacina√ß√£o - muito curto para capturar rea√ß√µes tardias. Eventos adversos n√£o solicitados foram monitorados at√© 1 m√™s (n√£o graves) e 6 meses (graves), mas dependeram de relato do participante/investigador em vez de acompanhamento ativo programado. Eventos adversos graves em crian√ßas de 5-11: 8 (0,3%) vacina vs 2 (0,1%) placebo, com declara√ß√£o de que 'Nenhum evento adverso grave foi considerado relacionado √† vacina√ß√£o.' A falta de vigil√¢ncia ativa estendida com exames m√©dicos programados limita a detec√ß√£o de eventos graves tardios."
          },
          "neurological_monitoring": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Nenhum protocolo espec√≠fico de monitoramento neurol√≥gico ou de desenvolvimento descrito para participantes pedi√°tricos. Convuls√µes febris em crian√ßas de 5-11 foram identificadas apenas atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o, n√£o em ensaios cl√≠nicos. Paralisia de Bell (paralisia facial) foi rastreada em adultos (4 vacina vs 2 placebo), mas o documento afirma que 'Informa√ß√µes atualmente dispon√≠veis s√£o insuficientes para determinar rela√ß√£o causal.' O risco de miocardite (~8-27 por milh√£o de doses) foi detectado principalmente atrav√©s de dados p√≥s-comercializa√ß√£o, n√£o de vigil√¢ncia em ensaios. Nenhuma avalia√ß√£o de desenvolvimento programada, exames neurol√≥gicos ou vigil√¢ncia sistem√°tica para condi√ß√µes como S√≠ndrome de Guillain-Barre na popula√ß√£o pedi√°trica."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Crian√ßas com comorbidades que aumentam o risco de COVID-19 foram inclu√≠das (25,7% do grupo vacina no Estudo 3). No entanto, crian√ßas imunocomprometidas foram explicitamente exclu√≠das dos ensaios. O documento afirma: 'Pessoas imunocomprometidas... podem ter uma resposta imune diminu√≠da √† COMIRNATY.' Nenhum prematuro estudado, nenhuma an√°lise separada para crian√ßas com alergias, condi√ß√µes autoimunes ou em medicamentos concomitantes. Os resultados podem n√£o se generalizar para essas popula√ß√µes pedi√°tricas vulner√°veis."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Ensaios cl√≠nicos registrados no ClinicalTrials.gov com n√∫meros de identifica√ß√£o fornecidos (NCT04816643 para Estudo pedi√°trico 3). Tabelas de seguran√ßa detalhadas inclu√≠das com dados de frequ√™ncia por grau de gravidade. No entanto, nenhuma men√ß√£o de supervis√£o por Comit√™ Independente de Monitoramento de Seguran√ßa de Dados (DSMB), nenhuma disponibilidade de dados de participantes individuais para an√°lise independente, e nenhuma divulga√ß√£o de conflito de interesse. Todos os estudos foram conduzidos e analisados pelo fabricante (Pfizer/BioNTech)."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A se√ß√£o 6.2 documenta rea√ß√µes adversas p√≥s-comercializa√ß√£o identificadas ap√≥s uso generalizado, incluindo: miocardite/pericardite (maior risco em homens de 12-24), rea√ß√µes al√©rgicas graves/anafilaxia, convuls√µes febris especificamente em crian√ßas de 5-11 anos. Fontes de dados p√≥s-comercializa√ß√£o incluem bancos de dados de sinistros de seguro de sa√∫de comercial, sistema de notifica√ß√£o passiva VAERS e o estudo multic√™ntrico MACiV para desfechos de miocardite. Taxas estimadas de miocardite fornecidas: ~8 casos por milh√£o (idades 6m-64a) e ~27 por milh√£o (homens 12-24). Orienta√ß√µes do CDC referenciadas para manejo de miocardite. A vigil√¢ncia ativa continua, embora o sistema passivo VAERS tenha limita√ß√µes conhecidas de subnotifica√ß√£o."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Esta bula fornece evid√™ncia PARCIAL de seguran√ßa para crian√ßas de 5-11 anos. Os pontos fortes incluem: tamanho de amostra adequado (3.109 crian√ßas), desenho apropriado controlado por placebo, coleta padronizada de eventos adversos e vigil√¢ncia p√≥s-comercializa√ß√£o robusta que identificou miocardite e convuls√µes febris. No entanto, limita√ß√µes cr√≠ticas comprometem a confian√ßa na seguran√ßa pedi√°trica: (1) A dura√ß√£o do acompanhamento foi grosseiramente inadequada - mediana de 1,9 meses para crian√ßas de 5-11, muito aqu√©m dos 12+ meses necess√°rios para detectar complica√ß√µes autoimunes ou neurol√≥gicas; (2) N√£o existia protocolo sistem√°tico de monitoramento neurol√≥gico/de desenvolvimento; (3) Sinais de seguran√ßa importantes como miocardite foram detectados atrav√©s de vigil√¢ncia p√≥s-comercializa√ß√£o em vez de ensaios cl√≠nicos; (4) O documento reconhece explicitamente incerteza sobre desfechos card√≠acos de longo prazo: 'Informa√ß√µes ainda n√£o est√£o dispon√≠veis sobre potenciais sequelas de longo prazo'; (5) Crian√ßas imunocomprometidas e outras vulner√°veis foram exclu√≠das. Embora a vacina mostre boa tolerabilidade de curto prazo (rea√ß√µes comuns sendo dor no local da inje√ß√£o 72,9%, fadiga 39,2%, cefaleia 28,4%, febre 6,3% em crian√ßas de 5-11), o documento n√£o pode fornecer confian√ßa sobre a seguran√ßa de longo prazo em crian√ßas devido √† dura√ß√£o insuficiente do acompanhamento e √† aus√™ncia de monitoramento de desenvolvimento."
        }
      }
    },
    {
      "id": "den_dengvaxia",
      "name": "Dengvaxia",
      "type": "Dengue",
      "manufacturer": "Sanofi Pasteur",
      "description": "Dengue Tetravalent Vaccine, Live for prevention of dengue disease.",
      "sources": [
        "den_dengvaxia_insert.pdf",
        "den_dengvaxia_statistical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "den_dengvaxia",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "The studies used 0.9% sodium chloride (saline) as placebo. Study 1 (NCT01374516) and Study 2 (NCT01373281) were placebo-controlled with saline placebo. A total of 22,924 subjects received DENGVAXIA and 10,668 received placebo (0.9% sodium chloride).",
            "level_description": "Exceeds expected standard - uses true inert saline placebo rather than another vaccine as comparator, allowing accurate identification of adverse events attributable to the vaccine."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Studies were described as 'observer-blind, randomized' trials. The document states: 'In two multi-center, observer-blind, randomized (2:1), placebo-controlled trials...'",
            "level_description": "Meets expectations - observer-blind design prevents bias in outcome assessment, though participant blinding status is less explicitly documented than observer blinding."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Subjects were randomized 2:1 to receive either DENGVAXIA or saline placebo. The studies are described as 'randomized, placebo-controlled, multicenter clinical trials.'",
            "level_description": "Meets expectations with documented random allocation at 2:1 ratio, though specific details on allocation concealment methods are not provided in the package insert."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "A total of 22,924 subjects aged 6 through 16 years received at least one dose of DENGVAXIA across 12 clinical trials. Study 1 enrolled 20,869 subjects (ages 9-16), Study 2 enrolled 10,278 subjects (ages 6-14). The reactogenicity subset included 2,000 subjects in Study 1 and 1,310 subjects in Study 2.",
            "level_description": "Exceeds expected standard with over 22,000 pediatric subjects - far exceeding the 3,000 per age group threshold needed for adequate safety detection."
          },
          "follow_up_duration": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Subjects were monitored for severe dengue from Day 0 to month 72 (6 years) after first vaccination in Studies 1, 2, 3, and 4. Study 4 (NCT01983553) was an extension study to evaluate safety for 72 months. Serious adverse events were monitored for at least 6 months after the last dose.",
            "level_description": "Exceeds expected standard with 6-year (72 months) follow-up for severe dengue outcomes, allowing detection of long-term safety signals including delayed adverse events."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Data presented separately for ages 6-8 years and 9-14 years in Study 2, and for ages 9-16 years in Study 1. Adverse reaction tables provide separate data by age groups (6 through 8 years vs 9 through 14 years, and 9 through 16 years).",
            "level_description": "Meets expectations with age group separation, though groupings are broader than ideal (0-1, 1-5, 6-12 breakdown not provided)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "The vaccine is indicated for individuals 6-16 years with laboratory-confirmed previous dengue infection living in endemic areas. Contraindicated in immunocompromised individuals and those with severe allergic reactions. Studies enrolled subjects irrespective of previous dengue infection status for initial enrollment.",
            "level_description": "Meets expectations - clear criteria documented with explicit discussion of population limitations (endemic areas, prior infection status)."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited adverse reactions recorded daily for 14 days with defined severity grades. Fever defined as ‚â•38.0¬∞C (Grade 3: ‚â•39.0¬∞C). Pain, erythema, swelling graded with specific thresholds (e.g., Grade 3 for swelling: ‚â•50mm for ages 6-11, >100mm for ages 12+). Severe dengue defined by IDMC criteria including specific clinical parameters.",
            "level_description": "Meets expectations with objective thresholds for solicited reactions and standardized severe dengue definition by Independent Data Monitoring Committee."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Subjects monitored for serious adverse events for at least 6 months after last dose across 12 studies. SAEs within 28 days: 0.7% (168/22,924) in DENGVAXIA vs 0.9% (98/10,668) in placebo. Deaths tracked from first dose to month 72: 53 deaths (0.2%) in DENGVAXIA group, 34 deaths (0.3%) in placebo group. Related SAEs identified: asthma attack, urticaria, convulsion, acute disseminated encephalomyelitis.",
            "level_description": "Meets expectations with active monitoring for SAEs and documented causal investigation of serious events."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One case of acute disseminated encephalomyelitis (ADEM) 7 days post Dose 1 was identified and considered related to DENGVAXIA. One convulsion on day of Dose 1 was reported. Severe dengue definition includes encephalopathy. No systematic neurological assessment protocol or predefined list of autoimmune conditions documented.",
            "level_description": "Present but with significant limitations - specific neurological adverse events identified but no evidence of scheduled neurological exams or systematic autoimmune monitoring protocol."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Immunocompromised individuals are contraindicated and excluded. No specific mention of inclusion or separate analysis of premature infants, children with allergies, chronic conditions, or those on concurrent medications. One case of asthma crisis reported. Pregnancy registry established for inadvertent exposures.",
            "level_description": "Present but with flaws - immunocompromised explicitly excluded rather than studied; no evidence of intentional inclusion of other vulnerable subgroups."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Vaccine efficacy calculated as 1 minus ratio of density incidence with 95% confidence intervals provided. Hazard ratios for severe dengue by serostatus presented with 95% CI. Pre-specified efficacy criterion documented (lower bound of 95% CI >25%). Modified Full Analysis Set (mFASE) defined for analysis.",
            "level_description": "Meets expectations with confidence intervals, hazard ratios, and pre-specified analysis criteria documented."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Multiple clinical trial registry numbers provided (NCT01374516, NCT01373281, NCT00842530, NCT01983553, and 8 others). Independent Data Monitoring Committee (IDMC) oversaw the studies. Studies conducted as peer-reviewed trials with registration numbers. Efficacy and safety data presented with sample sizes.",
            "level_description": "Meets expectations with registered trials, IDMC oversight, and detailed data presentation, though raw individual participant data availability not mentioned."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 describes postmarketing experience with spontaneously reported adverse events including allergic/anaphylactic reactions and severe dengue infection (including hospitalization and death) in individuals with unknown prior dengue status. Adverse reaction reporting encouraged via VAERS (1-800-822-7967) and manufacturer pharmacovigilance department.",
            "level_description": "Meets expectations with established passive surveillance system and identified post-marketing safety signals, though reliance on spontaneous reporting has inherent underreporting limitations."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document is a Sanofi Pasteur package insert. Studies were conducted by the manufacturer. No disclosure of independent funding or researcher conflicts of interest. Independent Data Monitoring Committee mentioned but no details on independence from sponsor.",
            "level_description": "Present but with flaws - manufacturer-sponsored studies without explicit disclosure of potential conflicts or evidence of independent analysis."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "From first dose to month 72, 53 deaths (0.2%) reported in DENGVAXIA group vs 34 deaths (0.3%) in placebo group across 9 of 12 studies. Statement: 'None of the deaths were considered related to vaccination. Causes of death among subjects were consistent with those generally reported in children and adolescent populations.'",
            "level_description": "Exceeds expected standard with comprehensive all-cause mortality reporting in both groups with explicit causality assessment and comparison to background rates."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The DENGVAXIA clinical trial program demonstrates robust methodology with exemplary strengths in several areas: large pediatric sample size (over 22,000 children), true saline placebo control, extended 6-year follow-up, and comprehensive all-cause mortality reporting. The trials appropriately identified a critical safety signal - increased risk of severe dengue in seronegative individuals (HR 3.94) - leading to important labeling restrictions. However, the program has partial limitations in systematic neurological/autoimmune monitoring, vulnerable subgroup assessment (immunocompromised excluded rather than studied), and conflict of interest transparency. Overall, this represents an adequate to strong safety evaluation that, while not perfect, successfully identified a major delayed safety concern that fundamentally changed the vaccine's indication."
        }
      },
      "trial_pt": {
        "vaccine_id": "den_dengvaxia",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Os estudos utilizaram cloreto de s√≥dio 0,9% (solu√ß√£o salina) como placebo. O Estudo 1 (NCT01374516) e o Estudo 2 (NCT01373281) foram controlados por placebo com placebo salino. Um total de 22.924 participantes receberam DENGVAXIA e 10.668 receberam placebo (cloreto de s√≥dio 0,9%).",
            "level_description": "Excede o padr√£o esperado - utiliza placebo salino verdadeiramente inerte em vez de outra vacina como comparador, permitindo identifica√ß√£o precisa de eventos adversos atribu√≠veis √† vacina."
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos foram descritos como ensaios 'cegos para o observador, randomizados'. O documento afirma: 'Em dois ensaios multic√™ntricos, cegos para o observador, randomizados (2:1), controlados por placebo...'",
            "level_description": "Atende √†s expectativas - o desenho cego para o observador previne vi√©s na avalia√ß√£o de desfechos, embora o status de cegamento do participante esteja menos explicitamente documentado do que o cegamento do observador."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os participantes foram randomizados 2:1 para receber DENGVAXIA ou placebo salino. Os estudos s√£o descritos como 'ensaios cl√≠nicos randomizados, controlados por placebo, multic√™ntricos'.",
            "level_description": "Atende √†s expectativas com aloca√ß√£o aleat√≥ria documentada na propor√ß√£o 2:1, embora detalhes espec√≠ficos sobre m√©todos de oculta√ß√£o da aloca√ß√£o n√£o sejam fornecidos na bula."
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Um total de 22.924 participantes de 6 a 16 anos recebeu pelo menos uma dose de DENGVAXIA em 12 ensaios cl√≠nicos. O Estudo 1 incluiu 20.869 participantes (idades 9-16), o Estudo 2 incluiu 10.278 participantes (idades 6-14). O subgrupo de reatogenicidade incluiu 2.000 participantes no Estudo 1 e 1.310 participantes no Estudo 2.",
            "level_description": "Excede o padr√£o esperado com mais de 22.000 participantes pedi√°tricos - muito superior ao limite de 3.000 por faixa et√°ria necess√°rio para detec√ß√£o adequada de seguran√ßa."
          },
          "follow_up_duration": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Os participantes foram monitorados para dengue grave do Dia 0 at√© o m√™s 72 (6 anos) ap√≥s a primeira vacina√ß√£o nos Estudos 1, 2, 3 e 4. O Estudo 4 (NCT01983553) foi um estudo de extens√£o para avaliar seguran√ßa por 72 meses. Eventos adversos graves foram monitorados por pelo menos 6 meses ap√≥s a √∫ltima dose.",
            "level_description": "Excede o padr√£o esperado com 6 anos (72 meses) de acompanhamento para desfechos de dengue grave, permitindo detec√ß√£o de sinais de seguran√ßa de longo prazo incluindo eventos adversos tardios."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os dados s√£o apresentados separadamente para idades 6-8 anos e 9-14 anos no Estudo 2, e para idades 9-16 anos no Estudo 1. As tabelas de rea√ß√µes adversas fornecem dados separados por faixas et√°rias (6 a 8 anos vs 9 a 14 anos, e 9 a 16 anos).",
            "level_description": "Atende √†s expectativas com separa√ß√£o por faixa et√°ria, embora os agrupamentos sejam mais amplos do que o ideal (subdivis√£o 0-1, 1-5, 6-12 n√£o fornecida)."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A vacina √© indicada para indiv√≠duos de 6-16 anos com infec√ß√£o pr√©via por dengue confirmada laboratorialmente, vivendo em √°reas end√™micas. Contraindicada em indiv√≠duos imunocomprometidos e naqueles com rea√ß√µes al√©rgicas graves. Os estudos inclu√≠ram participantes independentemente do status de infec√ß√£o pr√©via por dengue na inscri√ß√£o inicial.",
            "level_description": "Atende √†s expectativas - crit√©rios claros documentados com discuss√£o expl√≠cita das limita√ß√µes populacionais (√°reas end√™micas, status de infec√ß√£o pr√©via)."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes adversas solicitadas foram registradas diariamente por 14 dias com graus de gravidade definidos. Febre definida como ‚â•38,0¬∞C (Grau 3: ‚â•39,0¬∞C). Dor, eritema, incha√ßo graduados com limites espec√≠ficos (ex.: Grau 3 para incha√ßo: ‚â•50mm para idades 6-11, >100mm para idades 12+). Dengue grave definida por crit√©rios do IDMC incluindo par√¢metros cl√≠nicos espec√≠ficos.",
            "level_description": "Atende √†s expectativas com limites objetivos para rea√ß√µes solicitadas e defini√ß√£o padronizada de dengue grave pelo Comit√™ Independente de Monitoramento de Dados."
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os participantes foram monitorados para eventos adversos graves por pelo menos 6 meses ap√≥s a √∫ltima dose em 12 estudos. Eventos adversos graves em 28 dias: 0,7% (168/22.924) em DENGVAXIA vs 0,9% (98/10.668) em placebo. Mortes rastreadas da primeira dose at√© o m√™s 72: 53 mortes (0,2%) no grupo DENGVAXIA, 34 mortes (0,3%) no grupo placebo. Eventos adversos graves relacionados identificados: crise asm√°tica, urtic√°ria, convuls√£o, encefalomielite disseminada aguda.",
            "level_description": "Atende √†s expectativas com monitoramento ativo para eventos adversos graves e investiga√ß√£o de causalidade documentada de eventos graves."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um caso de encefalomielite disseminada aguda (ADEM) 7 dias ap√≥s a Dose 1 foi identificado e considerado relacionado √† DENGVAXIA. Uma convuls√£o no dia da Dose 1 foi relatada. A defini√ß√£o de dengue grave inclui encefalopatia. Nenhum protocolo de avalia√ß√£o neurol√≥gica sistem√°tica ou lista predefinida de condi√ß√µes autoimunes documentada.",
            "level_description": "Presente, mas com limita√ß√µes significativas - eventos adversos neurol√≥gicos espec√≠ficos identificados, mas sem evid√™ncia de exames neurol√≥gicos programados ou protocolo de monitoramento autoimune sistem√°tico."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Indiv√≠duos imunocomprometidos s√£o contraindicados e exclu√≠dos. Nenhuma men√ß√£o espec√≠fica de inclus√£o ou an√°lise separada de prematuros, crian√ßas com alergias, condi√ß√µes cr√¥nicas ou aquelas em medicamentos concomitantes. Um caso de crise asm√°tica relatado. Registro de gravidez estabelecido para exposi√ß√µes inadvertidas.",
            "level_description": "Presente, mas com falhas - imunocomprometidos explicitamente exclu√≠dos em vez de estudados; sem evid√™ncia de inclus√£o intencional de outros subgrupos vulner√°veis."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A efic√°cia vacinal foi calculada como 1 menos a raz√£o de incid√™ncia de densidade com intervalos de confian√ßa de 95% fornecidos. Raz√µes de risco para dengue grave por sorostatus apresentadas com IC 95%. Crit√©rio de efic√°cia pr√©-especificado documentado (limite inferior do IC 95% >25%). Conjunto de An√°lise Completo Modificado (mFASE) definido para an√°lise.",
            "level_description": "Atende √†s expectativas com intervalos de confian√ßa, raz√µes de risco e crit√©rios de an√°lise pr√©-especificados documentados."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√∫ltiplos n√∫meros de registro de ensaios cl√≠nicos fornecidos (NCT01374516, NCT01373281, NCT00842530, NCT01983553 e outros 8). Comit√™ Independente de Monitoramento de Dados (IDMC) supervisionou os estudos. Estudos conduzidos como ensaios revisados por pares com n√∫meros de registro. Dados de efic√°cia e seguran√ßa apresentados com tamanhos amostrais.",
            "level_description": "Atende √†s expectativas com ensaios registrados, supervis√£o por IDMC e apresenta√ß√£o detalhada de dados, embora a disponibilidade de dados brutos de participantes individuais n√£o seja mencionada."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 descreve experi√™ncia p√≥s-comercializa√ß√£o com eventos adversos relatados espontaneamente incluindo rea√ß√µes al√©rgicas/anafil√°ticas e infec√ß√£o grave por dengue (incluindo hospitaliza√ß√£o e morte) em indiv√≠duos com status desconhecido de dengue pr√©via. Relato de rea√ß√µes adversas incentivado via VAERS (1-800-822-7967) e departamento de farmacovigil√¢ncia do fabricante.",
            "level_description": "Atende √†s expectativas com sistema de vigil√¢ncia passiva estabelecido e sinais de seguran√ßa p√≥s-comercializa√ß√£o identificados, embora a depend√™ncia de relato espont√¢neo tenha limita√ß√µes inerentes de subnotifica√ß√£o."
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento √© uma bula da Sanofi Pasteur. Os estudos foram conduzidos pelo fabricante. Nenhuma divulga√ß√£o de financiamento independente ou conflitos de interesse dos pesquisadores. Comit√™ Independente de Monitoramento de Dados mencionado, mas sem detalhes sobre independ√™ncia do patrocinador.",
            "level_description": "Presente, mas com falhas - estudos patrocinados pelo fabricante sem divulga√ß√£o expl√≠cita de potenciais conflitos ou evid√™ncia de an√°lise independente."
          },
          "all_cause_mortality": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Da primeira dose at√© o m√™s 72, 53 mortes (0,2%) relatadas no grupo DENGVAXIA vs 34 mortes (0,3%) no grupo placebo em 9 dos 12 estudos. Declara√ß√£o: 'Nenhuma das mortes foi considerada relacionada √† vacina√ß√£o. As causas de morte entre os participantes foram consistentes com aquelas geralmente relatadas em popula√ß√µes de crian√ßas e adolescentes.'",
            "level_description": "Excede o padr√£o esperado com relato abrangente de mortalidade por todas as causas em ambos os grupos com avalia√ß√£o expl√≠cita de causalidade e compara√ß√£o com taxas de base."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "O programa de ensaios cl√≠nicos da DENGVAXIA demonstra metodologia robusta com pontos fortes exemplares em v√°rias √°reas: grande tamanho de amostra pedi√°trica (mais de 22.000 crian√ßas), controle com placebo salino verdadeiro, acompanhamento estendido de 6 anos e relato abrangente de mortalidade por todas as causas. Os ensaios identificaram apropriadamente um sinal de seguran√ßa cr√≠tico - risco aumentado de dengue grave em indiv√≠duos soronegativos (HR 3,94) - levando a importantes restri√ß√µes na indica√ß√£o. No entanto, o programa tem limita√ß√µes parciais em monitoramento sistem√°tico neurol√≥gico/autoimune, avalia√ß√£o de subgrupos vulner√°veis (imunocomprometidos exclu√≠dos em vez de estudados) e transpar√™ncia sobre conflitos de interesse. No geral, isso representa uma avalia√ß√£o de seguran√ßa adequada a forte que, embora n√£o perfeita, identificou com sucesso uma preocupa√ß√£o de seguran√ßa tardia importante que mudou fundamentalmente a indica√ß√£o da vacina."
        }
      },
      "safety_en": {
        "vaccine_id": "den_dengvaxia",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "A total of 22,924 children aged 6-16 years received at least one dose of DENGVAXIA across 12 clinical trials. Study 1 enrolled 20,869 subjects (ages 9-16), Study 2 enrolled 10,278 subjects (ages 6-14). This far exceeds the 3,000 per age group threshold, providing excellent statistical power to detect adverse events occurring at rates of 1:1,000 or more common."
          },
          "follow_up_duration": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Subjects were monitored for severe dengue from Day 0 to month 72 (6 years) after first vaccination. Study 4 (NCT01983553) was specifically an extension study to evaluate safety for 72 months. This extended follow-up period enabled detection of the critical delayed safety signal (increased severe dengue in seronegative individuals), far exceeding the minimum 12-month standard."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "True saline placebo (0.9% sodium chloride) used as comparator with 2:1 randomization in observer-blind studies. A total of 10,668 subjects received placebo, enabling accurate attribution of adverse events. The saline control allows unbiased comparison of reaction rates, confirming which events are truly vaccine-related versus coincidental."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicited adverse reactions recorded daily for 14 days following each vaccination. Serious adverse events actively monitored for at least 6 months after last dose across 12 studies. Deaths and severe dengue cases tracked to month 72. Related SAEs identified and investigated (asthma attack, urticaria, convulsion, acute disseminated encephalomyelitis). However, the reactogenicity subset was limited to 2,000-1,310 subjects rather than the full cohort."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "One case of acute disseminated encephalomyelitis (ADEM) 7 days post Dose 1 identified as vaccine-related. One convulsion on day of Dose 1 reported. Severe dengue definition includes encephalopathy as a criterion. However, no evidence of scheduled developmental assessments, routine neurological examinations, or systematic protocol for detecting conditions like Guillain-Barre syndrome, seizure disorders, or developmental delays over the follow-up period."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Immunocompromised individuals are explicitly contraindicated and excluded from trials rather than studied with appropriate safeguards. No mention of intentional inclusion or separate analysis for premature infants, children with allergies, chronic conditions, or those on concurrent medications. The document identifies that children under 6 years are at increased risk regardless of serostatus, but this was discovered reactively rather than through prospective vulnerable subgroup inclusion."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Twelve clinical trial registry numbers provided (NCT01374516, NCT01373281, NCT00842530, NCT01983553, and 8 others). Independent Data Monitoring Committee (IDMC) oversaw the studies. Detailed tables with adverse event rates, confidence intervals, and hazard ratios published. However, individual participant data not mentioned as publicly available, and raw data access for independent verification is not documented."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Postmarketing section (6.2) describes spontaneously reported adverse events including allergic/anaphylactic reactions and severe dengue infection with hospitalization and death in individuals with unknown prior dengue status. Reporting encouraged via VAERS (1-800-822-7967) and Sanofi Pasteur pharmacovigilance (1-800-822-2463). Pregnancy registry established. However, this is primarily passive surveillance with acknowledged limitations in estimating true event frequency."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "The DENGVAXIA safety documentation provides reasonable confidence in the vaccine's safety profile for the approved population (seropositive individuals aged 6-16 years in endemic areas), but with important caveats. Strengths include an exceptionally large pediatric sample (22,924 children), true saline placebo control, and 6-year follow-up that successfully identified a critical delayed safety signal - seronegative children face nearly 4-fold increased risk of severe dengue after vaccination (HR 3.94). This finding led to appropriate restriction of the indication. However, the documentation falls short in systematic neurological monitoring and vulnerable subgroup assessment. Parents should feel moderately confident about safety in the approved population, but must ensure prior dengue infection is confirmed before vaccination given the serious consequences for seronegative individuals."
        }
      },
      "safety_pt": {
        "vaccine_id": "den_dengvaxia",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Um total de 22.924 crian√ßas de 6-16 anos recebeu pelo menos uma dose de DENGVAXIA em 12 ensaios cl√≠nicos. O Estudo 1 incluiu 20.869 participantes (idades 9-16), o Estudo 2 incluiu 10.278 participantes (idades 6-14). Isso excede em muito o limite de 3.000 por faixa et√°ria, fornecendo excelente poder estat√≠stico para detectar eventos adversos que ocorrem em taxas de 1:1.000 ou mais frequentes."
          },
          "follow_up_duration": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Os participantes foram monitorados para dengue grave do Dia 0 at√© o m√™s 72 (6 anos) ap√≥s a primeira vacina√ß√£o. O Estudo 4 (NCT01983553) foi especificamente um estudo de extens√£o para avaliar seguran√ßa por 72 meses. Este per√≠odo de acompanhamento estendido permitiu a detec√ß√£o do sinal de seguran√ßa cr√≠tico tardio (aumento de dengue grave em indiv√≠duos soronegativos), excedendo em muito o padr√£o m√≠nimo de 12 meses."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Placebo salino verdadeiro (cloreto de s√≥dio 0,9%) utilizado como comparador com randomiza√ß√£o 2:1 em estudos cegos para o observador. Um total de 10.668 participantes recebeu placebo, permitindo atribui√ß√£o precisa de eventos adversos. O controle salino permite compara√ß√£o imparcial das taxas de rea√ß√£o, confirmando quais eventos s√£o verdadeiramente relacionados √† vacina versus coincidentes."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Rea√ß√µes adversas solicitadas foram registradas diariamente por 14 dias ap√≥s cada vacina√ß√£o. Eventos adversos graves foram ativamente monitorados por pelo menos 6 meses ap√≥s a √∫ltima dose em 12 estudos. Mortes e casos de dengue grave foram rastreados at√© o m√™s 72. Eventos adversos graves relacionados foram identificados e investigados (crise asm√°tica, urtic√°ria, convuls√£o, encefalomielite disseminada aguda). No entanto, o subgrupo de reatogenicidade foi limitado a 2.000-1.310 participantes em vez da coorte completa."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Um caso de encefalomielite disseminada aguda (ADEM) 7 dias ap√≥s a Dose 1 foi identificado como relacionado √† vacina. Uma convuls√£o no dia da Dose 1 foi relatada. A defini√ß√£o de dengue grave inclui encefalopatia como crit√©rio. No entanto, n√£o h√° evid√™ncia de avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos de rotina ou protocolo sistem√°tico para detectar condi√ß√µes como S√≠ndrome de Guillain-Barre, dist√∫rbios convulsivos ou atrasos no desenvolvimento durante o per√≠odo de acompanhamento."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Indiv√≠duos imunocomprometidos s√£o explicitamente contraindicados e exclu√≠dos dos ensaios em vez de estudados com salvaguardas apropriadas. Nenhuma men√ß√£o de inclus√£o intencional ou an√°lise separada para prematuros, crian√ßas com alergias, condi√ß√µes cr√¥nicas ou aquelas em medicamentos concomitantes. O documento identifica que crian√ßas menores de 6 anos est√£o em risco aumentado independentemente do sorostatus, mas isso foi descoberto reativamente em vez de atrav√©s de inclus√£o prospectiva de subgrupos vulner√°veis."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Doze n√∫meros de registro de ensaios cl√≠nicos fornecidos (NCT01374516, NCT01373281, NCT00842530, NCT01983553 e outros 8). Comit√™ Independente de Monitoramento de Dados (IDMC) supervisionou os estudos. Tabelas detalhadas com taxas de eventos adversos, intervalos de confian√ßa e raz√µes de risco publicadas. No entanto, dados de participantes individuais n√£o s√£o mencionados como publicamente dispon√≠veis, e acesso a dados brutos para verifica√ß√£o independente n√£o est√° documentado."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A se√ß√£o p√≥s-comercializa√ß√£o (6.2) descreve eventos adversos relatados espontaneamente incluindo rea√ß√µes al√©rgicas/anafil√°ticas e infec√ß√£o grave por dengue com hospitaliza√ß√£o e morte em indiv√≠duos com status desconhecido de dengue pr√©via. Relato incentivado via VAERS (1-800-822-7967) e farmacovigil√¢ncia da Sanofi Pasteur (1-800-822-2463). Registro de gravidez estabelecido. No entanto, esta √© principalmente vigil√¢ncia passiva com limita√ß√µes reconhecidas na estimativa da frequ√™ncia real dos eventos."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "A documenta√ß√£o de seguran√ßa da DENGVAXIA fornece confian√ßa razo√°vel no perfil de seguran√ßa da vacina para a popula√ß√£o aprovada (indiv√≠duos soropositivos de 6-16 anos em √°reas end√™micas), mas com ressalvas importantes. Os pontos fortes incluem uma amostra pedi√°trica excepcionalmente grande (22.924 crian√ßas), controle com placebo salino verdadeiro e acompanhamento de 6 anos que identificou com sucesso um sinal de seguran√ßa cr√≠tico tardio - crian√ßas soronegativas enfrentam risco quase 4 vezes maior de dengue grave ap√≥s vacina√ß√£o (HR 3,94). Esta descoberta levou √† restri√ß√£o apropriada da indica√ß√£o. No entanto, a documenta√ß√£o √© deficiente em monitoramento neurol√≥gico sistem√°tico e avalia√ß√£o de subgrupos vulner√°veis. Os pais devem sentir confian√ßa moderada sobre a seguran√ßa na popula√ß√£o aprovada, mas devem garantir que a infec√ß√£o pr√©via por dengue seja confirmada antes da vacina√ß√£o, dadas as consequ√™ncias graves para indiv√≠duos soronegativos."
        }
      }
    }
  ],
  "criteria_trial": {
    "placebo_control": {
      "id": "placebo_control",
      "name": "Placebo control group",
      "name_pt": "Grupo controle com placebo",
      "why_it_matters": "Allows identification of which reactions are caused by the vaccine vs. coincidental events",
      "why_it_matters_pt": "Permite identificar quais rea√ß√µes s√£o causadas pela vacina vs. eventos coincidentes",
      "what_is_ideal": "Inert placebo (saline). Using another vaccine as comparator obscures true adverse event rates",
      "what_is_ideal_pt": "Placebo inerte (solu√ß√£o salina). Usar outra vacina como comparador obscurece as taxas reais de eventos adversos"
    },
    "double_blind": {
      "id": "double_blind",
      "name": "Double-blind study",
      "name_pt": "Estudo duplo-cego",
      "why_it_matters": "Prevents bias in observation and symptom reporting",
      "why_it_matters_pt": "Previne vi√©s na observa√ß√£o e relato de sintomas",
      "what_is_ideal": "Neither participants nor researchers know who received vaccine/placebo",
      "what_is_ideal_pt": "Nem participantes nem pesquisadores sabem quem recebeu vacina/placebo"
    },
    "randomization": {
      "id": "randomization",
      "name": "Randomization",
      "name_pt": "Randomiza√ß√£o",
      "why_it_matters": "Ensures differences in outcomes are due to the vaccine, not pre-existing characteristics",
      "why_it_matters_pt": "Garante que diferen√ßas nos resultados s√£o devido √† vacina, n√£o caracter√≠sticas pr√©-existentes",
      "what_is_ideal": "Documented random allocation with allocation concealment",
      "what_is_ideal_pt": "Aloca√ß√£o aleat√≥ria documentada com oculta√ß√£o da aloca√ß√£o"
    },
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare reactions. Detecting 1:1,000 events requires ~3,000 participants",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar rea√ß√µes raras. Detectar eventos 1:1.000 requer ~3.000 participantes",
      "what_is_ideal": ">3,000 children per age group for adequate safety detection",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio para detec√ß√£o adequada de seguran√ßa"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune/neurological reactions may emerge weeks or months later",
      "why_it_matters_pt": "Rea√ß√µes autoimunes/neurol√≥gicas podem surgir semanas ou meses depois",
      "what_is_ideal": "Minimum 6-12 months; ideal: several years with scheduled assessments",
      "what_is_ideal_pt": "M√≠nimo 6-12 meses; ideal: v√°rios anos com avalia√ß√µes programadas"
    },
    "separate_age_groups": {
      "id": "separate_age_groups",
      "name": "Separate age groups",
      "name_pt": "Grupos et√°rios separados",
      "why_it_matters": "Infants, toddlers, and older children have different immune systems",
      "why_it_matters_pt": "Beb√™s, crian√ßas pequenas e crian√ßas mais velhas t√™m sistemas imunol√≥gicos diferentes",
      "what_is_ideal": "Separate analysis: 0-1 years, 1-5 years, 6-12 years",
      "what_is_ideal_pt": "An√°lise separada: 0-1 ano, 1-5 anos, 6-12 anos"
    },
    "inclusion_exclusion_criteria": {
      "id": "inclusion_exclusion_criteria",
      "name": "Inclusion/exclusion criteria",
      "name_pt": "Crit√©rios de inclus√£o/exclus√£o",
      "why_it_matters": "Allows understanding of who the results apply to",
      "why_it_matters_pt": "Permite entender a quem os resultados se aplicam",
      "what_is_ideal": "Balanced criteria that include representative population",
      "what_is_ideal_pt": "Crit√©rios equilibrados que incluem popula√ß√£o representativa"
    },
    "standardized_adverse_events": {
      "id": "standardized_adverse_events",
      "name": "Standardized definition of adverse events",
      "name_pt": "Defini√ß√£o padronizada de eventos adversos",
      "why_it_matters": "Enables comparison across studies and prevents under/over-reporting",
      "why_it_matters_pt": "Permite compara√ß√£o entre estudos e previne sub/super-notifica√ß√£o",
      "what_is_ideal": "Brighton Collaboration criteria or MedDRA coding",
      "what_is_ideal_pt": "Crit√©rios Brighton Collaboration ou codifica√ß√£o MedDRA"
    },
    "active_monitoring_serious": {
      "id": "active_monitoring_serious",
      "name": "Active monitoring of serious adverse events",
      "name_pt": "Monitoramento ativo de eventos adversos graves",
      "why_it_matters": "Passive/unsolicited reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva/n√£o solicitada subestima muito os eventos graves",
      "what_is_ideal": "Active solicited surveillance for hospitalization, sequelae, deaths",
      "what_is_ideal_pt": "Vigil√¢ncia ativa solicitada para hospitaliza√ß√£o, sequelas, mortes"
    },
    "autoimmune_neurological": {
      "id": "autoimmune_neurological",
      "name": "Assessment of autoimmune/neurological reactions",
      "name_pt": "Avalia√ß√£o de rea√ß√µes autoimunes/neurol√≥gicas",
      "why_it_matters": "Conditions like Guillain-Barr√©, seizures, myocarditis are rare but serious",
      "why_it_matters_pt": "Condi√ß√µes como Guillain-Barr√©, convuls√µes, miocardite s√£o raras mas graves",
      "what_is_ideal": "Specific long-term monitoring with scheduled exams",
      "what_is_ideal_pt": "Monitoramento espec√≠fico de longo prazo com exames programados"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature, immunocompromised children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras, imunocomprometidas podem reagir diferentemente",
      "what_is_ideal": "Intentional inclusion and separate analysis of these groups",
      "what_is_ideal_pt": "Inclus√£o intencional e an√°lise separada desses grupos"
    },
    "statistical_analysis": {
      "id": "statistical_analysis",
      "name": "Robust statistical analysis",
      "name_pt": "An√°lise estat√≠stica robusta",
      "why_it_matters": "Most vaccine trials are powered for efficacy, not safety",
      "why_it_matters_pt": "A maioria dos ensaios de vacinas tem poder para efic√°cia, n√£o seguran√ßa",
      "what_is_ideal": "Study powered for safety outcomes; confidence intervals documented",
      "what_is_ideal_pt": "Estudo com poder para desfechos de seguran√ßa; intervalos de confian√ßa documentados"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Allows independent verification by other researchers",
      "why_it_matters_pt": "Permite verifica√ß√£o independente por outros pesquisadores",
      "what_is_ideal": "Independent DSMB; raw data available; peer-reviewed publication",
      "what_is_ideal_pt": "DSMB independente; dados brutos dispon√≠veis; publica√ß√£o revisada por pares"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "Detects rare reactions that only appear in millions of doses",
      "why_it_matters_pt": "Detecta rea√ß√µes raras que s√≥ aparecem em milh√µes de doses",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    },
    "conflict_of_interest": {
      "id": "conflict_of_interest",
      "name": "Conflict of interest / funding source",
      "name_pt": "Conflito de interesse / fonte de financiamento",
      "why_it_matters": "Industry-funded studies are more likely to report favorable outcomes",
      "why_it_matters_pt": "Estudos financiados pela ind√∫stria tendem a relatar resultados favor√°veis",
      "what_is_ideal": "Independent funding or full disclosure of all financial ties",
      "what_is_ideal_pt": "Financiamento independente ou divulga√ß√£o completa de todos os v√≠nculos financeiros"
    },
    "all_cause_mortality": {
      "id": "all_cause_mortality",
      "name": "All-cause mortality and morbidity",
      "name_pt": "Mortalidade e morbidade por todas as causas",
      "why_it_matters": "Focusing only on vaccine-related outcomes can miss overall harm",
      "why_it_matters_pt": "Focar apenas em resultados relacionados √† vacina pode perder danos gerais",
      "what_is_ideal": "Report total deaths and hospitalizations in all groups",
      "what_is_ideal_pt": "Relatar total de mortes e hospitaliza√ß√µes em todos os grupos"
    }
  },
  "criteria_safety": {
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare events (1 in 1,000, 1 in 10,000)",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar eventos raros (1 em 1.000, 1 em 10.000)",
      "what_is_ideal": ">3,000 children per age group",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune and neurological problems may take months or years to appear",
      "why_it_matters_pt": "Problemas autoimunes e neurol√≥gicos podem levar meses ou anos para aparecer",
      "what_is_ideal": "Minimum 12 months; 2-3+ years to assess long-term effects",
      "what_is_ideal_pt": "M√≠nimo 12 meses; 2-3+ anos para avaliar efeitos de longo prazo"
    },
    "comparison_group": {
      "id": "comparison_group",
      "name": "Comparison group",
      "name_pt": "Grupo de compara√ß√£o",
      "why_it_matters": "Need a group that did not receive the vaccine for comparison",
      "why_it_matters_pt": "Precisa de um grupo que n√£o recebeu a vacina para compara√ß√£o",
      "what_is_ideal": "True placebo (saline solution), with randomization and double-blind",
      "what_is_ideal_pt": "Placebo verdadeiro (solu√ß√£o salina), com randomiza√ß√£o e duplo-cego"
    },
    "active_surveillance": {
      "id": "active_surveillance",
      "name": "Active surveillance for serious events",
      "name_pt": "Vigil√¢ncia ativa para eventos graves",
      "why_it_matters": "Passive reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva subestima muito eventos graves",
      "what_is_ideal": "Regular contact with families, review of medical records, causality analysis",
      "what_is_ideal_pt": "Contato regular com fam√≠lias, revis√£o de prontu√°rios, an√°lise de causalidade"
    },
    "neurological_monitoring": {
      "id": "neurological_monitoring",
      "name": "Neurological/developmental monitoring",
      "name_pt": "Monitoramento neurol√≥gico/desenvolvimento",
      "why_it_matters": "Check if children developed normally months and years later",
      "why_it_matters_pt": "Verificar se as crian√ßas se desenvolveram normalmente meses e anos depois",
      "what_is_ideal": "Scheduled developmental assessments, follow-up neurological exams",
      "what_is_ideal_pt": "Avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos de acompanhamento"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature and immunosuppressed children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras e imunossuprimidas podem reagir diferentemente",
      "what_is_ideal": "These groups intentionally included with results presented separately",
      "what_is_ideal_pt": "Esses grupos intencionalmente inclu√≠dos com resultados apresentados separadamente"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Is it possible to verify the complete study data?",
      "why_it_matters_pt": "√â poss√≠vel verificar os dados completos do estudo?",
      "what_is_ideal": "Peer-reviewed publication with complete adverse event data",
      "what_is_ideal_pt": "Publica√ß√£o revisada por pares com dados completos de eventos adversos"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "What was discovered after millions of children received it?",
      "why_it_matters_pt": "O que foi descoberto ap√≥s milh√µes de crian√ßas receberem?",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    }
  },
  "metadata": {
    "generated_at": "2026-01-11T13:57:48.732755Z",
    "vaccines_count": 28,
    "verification_status": "all_verified"
  }
}